FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Segal, DM
   Perez, M
   Shapshak, P
AF Segal, DM
   Perez, M
   Shapshak, P
TI Oxandrolone, used for treatment of wasting disease in HIV-1-infected
   patients, does not diminish the antiviral activity of deoxynucleoside
   analogues in lymphocyte and macrophage cell cultures
SO JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY
LA English
DT Article
DE oxandrolone; ZDV; ddC; ddI; HIV-1 replication; AIDS; wasting; weight
   gain; IC50; reverse transcriptase; P24 antigen
ID IMMUNODEFICIENCY-VIRUS TYPE-1; BRAIN-TISSUE; HIV-1; ZIDOVUDINE;
   INFECTION; SENSITIVITY; THERAPY; AIDS
AB Antiviral agents are the primary therapy for patients infected with HIV-1. However, supportive therapies are often necessary in addition to antiviral drugs because of the devastating wasting process associated with HIV-1 infection and AIDS. Oxandrolone, an anabolic steroid, is used in promoting weight gain and, most important lean body mass (LBM), in patients with HIV-1 disease. We investigated whether oxandrolone interferes with the antiviral activity of zidovudine (ZDV), dideoxyinosine (ddI), and dideoxycytidine (ddC) on HIV-1 replication in peripheral blood lymphocytes and macrophage-monocytes. The nucleoside analogues had nanomolar 50% inhibitory concentrations (IC50) in peripheral lymphocytes. Combinations of nucleoside analogues and oxandrolone did not result in increased IC50 values. Oxandrolone used alone exhibited micromolar IC50 values in peripheral blood lymphocytes. Lack of interference was consistent for nucleoside concentrations up to 5 mu M and for oxandrolone concentrations up to 100 mu M in several combinations of drugs, viral strains, and peripheral lymphocytes and macrophages. We conclude that oxandrolone can be used for the promotion of weight gain in patients with AIDS-related wasting without interference with the antiviral effects of ZDV, ddI, or ddC.
C1 Univ Miami, Sch Med, Dept Psychiat & Behav Sci, Miami, FL 33136 USA.
   Univ Miami, Sch Med, Comprehens Drug Res Ctr, Miami, FL 33136 USA.
   Univ Miami, Sch Med, Dept Neurol, Miami, FL 33136 USA.
   Univ Miami, Sch Med, Dept Pathol, Miami, FL 33136 USA.
RP Shapshak, P (reprint author), Univ Miami, Sch Med, Dept Psychiat, Elliott Bldg,2nd floor,1800 NW 10th Ave, Miami, FL 33136 USA.
FU NIDA NIH HHS [DA04787, DA 07909]
CR Berger JR, 1996, AIDS, V10, P1657, DOI 10.1097/00002030-199612000-00010                                                
   ERICE A, 1993, NEW ENGL J MED, V328, P1163, DOI 10.1056/NEJM199304223281605
   Ferrando S, 1998, AIDS, V12, pF65, DOI 10.1097/00002030-199808000-00002                                                
   GENDELMAN HE, 1989, AIDS, V3, P475, DOI 10.1097/00002030-198908000-00001
   Hecht FM, 1998, NEW ENGL J MED, V339, P307, DOI 10.1056/NEJM199807303390504                                                     
   JAPOUR AJ, 1993, ANTIMICROB AGENTS CH, V37, P1095, DOI 10.1128/AAC.37.5.1095                                                           
   KARIM A, 1973, CLIN PHARMACOL THER, V14, P862
   LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383
   MENG TC, 1992, ANN INTERN MED, V116, P13, DOI 10.7326/0003-4819-116-1-13
   PALCA J, 1995, SCIENCE, V252, P372
   PARKS WP, 1988, J ACQ IMMUN DEF SYND, V1, P125
   RICHMAN DD, 1987, J EXP MED, V166, P1144, DOI 10.1084/jem.166.4.1144
   Rolinski B, 1997, J ACQ IMMUN DEF SYND, V15, P192, DOI 10.1097/00042560-199707010-00002                                                
   SHAPSHAK P, 1991, J ACQ IMMUN DEF SYND, V4, P228
   SHAPSHAK P, 1992, AIDS, V6, P915, DOI 10.1097/00002030-199209000-00002
   SHAPSHAK P, 1992, MODERN PATHOL, V5, P649
   STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788                                                         
   Stoneburner R L, 1994, Acta Paediatr Suppl, V400, P1
   WAINBERG MA, 1993, J ACQ IMMUN DEF SYND, V6, P36
   YOSHIOKA M, 1992, ACTA NEUROPATHOL, V84, P297
NR 20
TC 6
Z9 6
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1077-9450
J9 J ACQ IMMUN DEF SYND
JI J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.
PD MAR 1
PY 1999
VL 20
IS 3
BP 215
EP 219
DI 10.1097/00042560-199903010-00001                                        
          
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 175EP
UT WOS:000079080400001
PM 10077168
OA gold
DA 2018-01-05
ER

PT J
AU Siddiqui, AQ
   Ballatore, C
   McGuigan, C
   De Clercq, E
   Balzarini, J
AF Siddiqui, AQ
   Ballatore, C
   McGuigan, C
   De Clercq, E
   Balzarini, J
TI The presence of substituents on the aryl moiety of the aryl
   phosphoramidate derivative of d4T enhances anti-HIV efficacy in cell
   culture: A structure-activity relationship
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN LYMPHOID-CELLS;
   2',3'-DIDEOXYNUCLEOSIDE ANALOGS; INTRACELLULAR METABOLISM;
   REVERSE-TRANSCRIPTASE; HTLV-III/LAV; INVITRO; INHIBITORS; POTENT;
   2',3'-DIDEHYDRO-2',3'-DIDEOXYTHYMIDINE
AB New substituted-aryl phosphoramidate derivatives of the anti-HIV drug d4T were synthesized as membrane-soluble intracellular prodrugs for the free bioactive phosphate to establish relationship(s) between compound structure and in vitro antiviral activity. The majority of compounds demonstrated an elevation of in vitro potency relative to that of the parent nucleoside, and unlike d4T, all retained full activity in thymidine kinase-deficient cells. The compound bearing a p-chloro aryl group (8e) expressed nanomolar activity in vitro, a 14-fold increase in activity relative to that of the unsubstituted phosphoramidate (100-fold compared to d4T). An assay using pig liver esterase was used to establish the stability of the compounds to enzymatic degradation. While there was no apparent correlation between in vitro activity and half-life of enzymatic degradation, there was a close correlation between compound lipophilicity, determined by octanol/water partition coefficient, and in vitro potency. We suggest that substitutions made td the aryl moiety of the aryl phosphoramidate of d4T that result in enhancing lipophilicity may serve to increase the cellular uptake of the prodrug by passive diffusion, leading to the expression of antiviral potency at reduced prodrug concentrations.
C1 Univ Wales Coll Cardiff, Welsh Sch Pharm, Cardiff CF1 3XF, S Glam, Wales.
   Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
RP McGuigan, C (reprint author), Univ Wales Coll Cardiff, Welsh Sch Pharm, King Edward VII Ave, Cardiff CF1 3XF, S Glam, Wales.
EM mcguigan@cardiff.ac.uk
RI Ballatore, Carlo/L-1034-2017; McGuigan, Chris/P-1580-2014
OI Ballatore, Carlo/0000-0002-2718-3850; McGuigan,
   Chris/0000-0001-8409-710X
CR BABA M, 1987, BIOCHEM BIOPH RES CO, V142, P128, DOI 10.1016/0006-291X(87)90460-8
   BALZARINI J, 1989, BIOCHEM BIOPH RES CO, V158, P413, DOI 10.1016/S0006-291X(89)80063-4
   Balzarini J, 1996, MOL PHARMACOL, V50, P1207
   BALZARINI J, 1987, MOL PHARMACOL, V32, P798
   Balzarini J, 1997, FEBS LETT, V410, P324, DOI 10.1016/S0014-5793(97)00616-9
   Balzarini J, 1996, P NATL ACAD SCI USA, V93, P7295, DOI 10.1073/pnas.93.14.7295                                                         
   BALZARINI J, 1989, J BIOL CHEM, V264, P6127
   BALZARINI J, 1988, BIOCHEM PHARMACOL, V37, P2847, DOI 10.1016/0006-2952(88)90049-4
   BALZARINI J, 1987, MOL PHARMACOL, V32, P162
   DeClercq E, 1997, CLIN MICROBIOL REV, V10, P674
   FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333
   HANSCH C, 1979, SUBSTITUTION CONSTAN
   HAO Z, 1990, MOL PHARMACOL, V37, P157
   HERDEWIJN P, 1987, J MED CHEM, V30, P1270, DOI 10.1021/jm00391a003
   HORWITZ JP, 1966, J ORG CHEM, V31, P205, DOI 10.1021/jo01339a045                                                             
   JOHNSON MA, 1989, MOL PHARMACOL, V36, P291
   JOHNSON MA, 1988, J BIOL CHEM, V263, P15354
   JONES RJ, 1995, ANTIVIR RES, V27, P1, DOI 10.1016/0166-3542(95)00011-A                                                    
   JUNGE W, 1974, ARCH BIOCHEM BIOPHYS, V165, P749, DOI 10.1016/0003-9861(74)90304-X
   JUNGE W, 1979, EUR J BIOCHEM, V95, P519, DOI 10.1111/j.1432-1033.1979.tb12992.x
   MANSURI MM, 1990, ANTIMICROB AGENTS CH, V34, P637, DOI 10.1128/AAC.34.4.637                                                            
   MANSURI MM, 1989, J MED CHEM, V32, P462
   McGuigan C, 1997, ANTIVIR RES, V35, P195, DOI 10.1016/S0166-3542(97)00029-6
   McGuigan C, 1996, BIOORG MED CHEM LETT, V6, P1183, DOI 10.1016/0960-894X(96)00195-3                                                    
   MCGUIGAN C, 1993, J MED CHEM, V36, P1048, DOI 10.1021/jm00060a013
   McGuigan C, 1996, J MED CHEM, V39, P1748, DOI 10.1021/jm950605j
   Meier C, 1998, SYNLETT, P233
   MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911
   MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096                                                         
   PERNO CF, 1989, J EXP MED, V169, P933, DOI 10.1084/jem.169.3.933                                                           
   STARNES MG, 1987, J BIOL CHEM, V32, P798
   Valette G, 1996, J MED CHEM, V39, P1981, DOI 10.1021/jm9507338
NR 32
TC 71
Z9 76
U1 0
U2 14
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD FEB 11
PY 1999
VL 42
IS 3
BP 393
EP 399
DI 10.1021/jm9803931                                                       
          
PG 7
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 166XF
UT WOS:000078602600008
PM 9986709
DA 2018-01-05
ER

PT J
AU Kuipers, ME
   Swart, PJ
   Witvrouw, M
   Este, JA
   Reymen, D
   De Clercq, E
   Meijer, DKF
AF Kuipers, ME
   Swart, PJ
   Witvrouw, M
   Este, JA
   Reymen, D
   De Clercq, E
   Meijer, DKF
TI Anti-HIV-1 activity of combinations and covalent conjugates of
   negatively charged human serum albumins (NCAs) and AZT
SO JOURNAL OF DRUG TARGETING
LA English
DT Article
DE Aco-HSA; AZT; HIV; polyanion; Suc-HSA; synergy
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ANTI-HIV ACTIVITY; PROTEASE INHIBITORS;
   REVERSE-TRANSCRIPTASE; SULFATED POLYSACCHARIDES; ENVELOPE GLYCOPROTEIN;
   SELECTIVE-INHIBITION; MEMBRANE-FUSION; ANTIVIRAL DRUGS; DEXTRAN SULFATE
AB Negatively charged albumins (NCAs, with the prototypes Suc-HSA and Aco-HSA), modified proteins with a potent anti-HIV-1 activity in the nanomolar concentration range, were studied for several aspects of their antiviral mechanism. In addition we investigated the antiviral activity of combinations and covalent conjugates of these NCAs and the reverse transcriptase inhibitor AZT.
   Addition of NCAs to HIV-l-infected target cells in time-of-addition experiments could be delayed for 30 min after infection before significant loss of activity occurred. Syncytium formation of HIV-infected and uninfected T-cells was inhibited by the NCAs at concentrations of 1-4 mu g/ml. The gp120-mediated virus/cell binding, however, was only inhibited by the NCAs at a 10-fold higher concentrations. The combined data are compatible with a preferential influence on virus/cell fusion.
   A subsynergistic activity against HIV-I was observed with the non-covalent mixture of Aco-HSA and AZT, When AZT was covalently coupled to the NCAs, and added one hour after infection of the target cells, the anti-HIV-l activity of NCA-AZTMP was diminished by only 2-6-fold, while this was diminished at least 120-fold for the NCAs, Furthermore the addition of NCA-AZTMP could be delayed up to at least 3h after infection without loss of antiviral activity. It is concluded that AZT that was coupled to the NCAs significantly contributes to the overall antiviral activity of the conjugates leading to complementary effects.
   These results highlight the potential of using NCA-AZTMP as dual-targeting preparations against HIV-I in which both the carrier and the coupled drug contribute to the therapeutic efficacy acting at a different level in the replication cycle.
C1 Univ Groningen, Ctr Pharm, GIDS, Sect Pharmacokinet & Drug Delivery, NL-9713 AV Groningen, Netherlands.
   Katholieke Univ Leuven, Rega Inst Med Res, Louvain, Belgium.
RP Swart, PJ (reprint author), Univ Groningen, Ctr Pharm, GIDS, Sect Pharmacokinet & Drug Delivery, Antonius Deusinglaan 1, NL-9713 AV Groningen, Netherlands.
OI Este, Jose/0000-0002-1436-5823
CR AMES GF, 1992, FASEB J, V6, P2660
   ANAND R, 1990, AIDS RES HUM RETROV, V6, P679, DOI 10.1089/aid.1990.6.679
   BABA M, 1990, J ACQ IMMUN DEF SYND, V3, P493
   BABA M, 1984, ANTIMICROB AGENTS CH, V25, P515, DOI 10.1128/AAC.25.4.515                                                            
   BERGERON L, 1992, J VIROL, V66, P2389
   Borman AM, 1996, J GEN VIROL, V77, P419, DOI 10.1099/0022-1317-77-3-419
   BREEN EC, 1990, J IMMUNOL, V144, P480
   BRIGHTY DW, 1991, P NATL ACAD SCI USA, V88, P7802, DOI 10.1073/pnas.88.17.7802
   Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602
   DECLERCO E, 1992, P NATL ACAD SCI USA, V89, P5286, DOI 10.1073/pnas.89.12.5286                                                         
   DECLERCQ E, 1987, ANTICANCER RES, V7, P1023
   DECLERCQ E, 1995, CLIN MICROBIOL REV, V8, P200
   DIMITROV DS, 1994, J VIROL, V68, P1956
   ELION GB, 1954, J BIOL CHEM, V208, P477
   FITZGIBBON JE, 1992, ANTIMICROB AGENTS CH, V36, P153, DOI 10.1128/AAC.36.1.153                                                            
   GORDON LM, 1995, AIDS RES HUM RETROV, V11, P677, DOI 10.1089/aid.1995.11.677
   Groenink M, 1997, AIDS RES HUM RETROV, V13, P179, DOI 10.1089/aid.1997.13.179                                                         
   HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2
   HALLORAN MJ, 1966, J IMMUNOL, V96, P373
   HASELTINE WA, 1988, J ACQ IMMUN DEF SYND, V1, P217
   HAYASHI S, 1990, ANTIMICROB AGENTS CH, V34, P82, DOI 10.1128/AAC.34.1.82                                                             
   JANSEN RW, 1993, PHARM RES-DORDR, V10, P1611, DOI 10.1023/A:1018972603494
   JANSEN RW, 1991, MOL PHARMACOL, V39, P818
   JANSEN RW, 1993, MOL PHARMACOL, V44, P1003
   KATZENSTEIN DA, 1995, AIDS CLIN REV, V96, P277
   KENNEDY CJ, 1987, HIV OTHER HIGHLY PAT, P81
   Kuipers ME, 1997, ANTIVIR RES, V33, P99, DOI 10.1016/S0166-3542(96)01005-4
   Kuipers ME, 1996, J ACQ IMMUN DEF SYND, V11, P419, DOI 10.1097/00042560-199604150-00001                                                
   KUIPERS ME, 1995, J MED CHEM, V38, P883, DOI 10.1021/jm00006a005
   KUIPERS ME, 1996, THESIS U GRONINGEN N
   Lafeuillade A, 1997, J INFECT DIS, V175, P1051, DOI 10.1086/516442                                                                  
   LAMBERT DM, 1993, ANTIVIR RES, V21, P327, DOI 10.1016/0166-3542(93)90011-7
   LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383
   LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983
   LIFSON JD, 1986, NATURE, V323, P725, DOI 10.1038/323725a0
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MACHIDA A, 1984, GASTROENTEROLOGY, V86, P910
   MENG TC, 1992, ANN INTERN MED, V116, P13, DOI 10.7326/0003-4819-116-1-13
   MESHCHERYAKOVA D, 1993, MOL IMMUNOL, V30, P993, DOI 10.1016/0161-5890(93)90124-T                                                    
   MOLEMA G, 1990, BIOCHEM PHARMACOL, V40, P2603, DOI 10.1016/0006-2952(90)90577-8
   MOLEMA G, 1991, J MED CHEM, V34, P1137, DOI 10.1021/jm00107a038
   MOLEMA G, 1992, DELIVERY ANTI HIV DR
   Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760
   Moyle G, 1996, DRUGS, V51, P701, DOI 10.2165/00003495-199651050-00001
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   PINTER A, 1993, J VIROL, V67, P5692
   SCHOLS D, 1990, VIROLOGY, V175, P556, DOI 10.1016/0042-6822(90)90440-3
   STCLAIR MH, 1993, J ACQ IMMUN DEF SYND, V6, P891
   STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788                                                         
   Swart P J, 1996, Drug Deliv, V3, P165, DOI 10.3109/10717549609029446
   Swart PJ, 1996, J DRUG TARGET, V4, P109, DOI 10.3109/10611869609046269                                                       
   SWART PJ, 1994, ANTIVIRAL NEWS, V2, P69
   TISDALE M, 1995, ANTIMICROB AGENTS CH, V39, P1704, DOI 10.1128/AAC.39.8.1704                                                           
   UENO R, 1987, LANCET, V1, P1379
   vantWout AB, 1997, J CLIN INVEST, V100, P2325, DOI 10.1172/JCI119771
   Vella S, 1995, J ACQ IMMUN DEF SYND, V10, pS58
   WILDE MI, 1993, DRUGS, V46, P515, DOI 10.2165/00003495-199346030-00010
   WITVROUW M, 1994, ANTIVIR CHEM CHEMOTH, V5, P345, DOI 10.1177/095632029400500601                                                      
NR 58
TC 11
Z9 11
U1 0
U2 1
PU HARWOOD ACAD PUBL GMBH
PI READING
PA C/O STBS LTD, PO BOX 90, READING, BERKS, ENGLAND RG1 8JL
SN 1061-186X
J9 J DRUG TARGET
JI J. Drug Target.
PY 1999
VL 6
IS 5
BP 323
EP 335
DI 10.3109/10611869908996840                                               
          
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 194QM
UT WOS:000080205100002
PM 10342381
DA 2018-01-05
ER

PT J
AU Kubinyi, H
AF Kubinyi, H
TI Chance favors the prepared mind - From serendipity to rational drug
   design
SO JOURNAL OF RECEPTOR AND SIGNAL TRANSDUCTION RESEARCH
LA English
DT Article; Proceedings Paper
CT 8th Swiss Workshop of Methodology in Receptor Research
CY MAY 03-07, 1998
CL MORSCHACH, SWITZERLAND
SP Astra Draco AB, Carl Zeiss, Kontaktgruppe Forsch Fragen, Novartis Pharma AG
ID PROTEIN-LIGAND COMPLEXES; HIGH-AFFINITY LIGANDS; COMBINATORIAL
   CHEMISTRY; MOLECULAR RECOGNITION; COMPUTATIONAL TOOLS; AUTOMATIC DESIGN;
   DOCKING METHOD; ACTIVE-SITE; POTENT; INHIBITORS
AB Accidental discoveries always played an important role in science, especially in the search for new drugs. Several examples of serendipitous findings, leading to therapeutically useful drugs, are presented and discussed. Captopril, an antihypertensive Angiotensin-converting enzyme inhibitor, was the first drug that could be derived from a structural model of a protein. Dorzolamide, a Carboanhydrase inhibitor for the treatment of glaucoma, and the HIV protease inhibitors Saquinavir, Indinavir, Ritonavir, and Nelfinavir are further examples of therapeutically used drugs from structure-based design. More enzyme inhibitors, e.g. the anti-influenza drugs Zanamivir and GS 4104, are in clinical development. In the absence of a protein 3D structure, the 3D structures of certain ligands may be used for rational design. This approach is exemplified by the design of specifically acting integrin receptor antagonists. In the last years, combinatorial and computational approaches became important methods for rational drug design. SAR by NMR searches for low-affinity ligands that bind to proximal subsites of an enzyme; linkage with an appropriate tether produces nanomolar inhibitors. The de novo design program LUDI and the docking program FlexX are tools for the computer-aided design of protein ligands. Work is in progress to combine such approaches to strategies for combinatorial drug design.
C1 BASF AG, ZHFG A30, Combinatorial Chem & Mol Modelling, D-67056 Ludwigshafen, Germany.
RP Kubinyi, H (reprint author), BASF AG, ZHFG A30, Combinatorial Chem & Mol Modelling, D-67056 Ludwigshafen, Germany.
CR Babine RE, 1997, CHEM REV, V97, P1359, DOI 10.1021/cr960370z                                                               
   Bamborough P, 1996, CURR OPIN STRUC BIOL, V6, P236, DOI 10.1016/S0959-440X(96)80081-9
   Beddell C. R., 1992, DESIGN DRUGS MACROMO
   Bohacek RS, 1996, MED RES REV, V16, P3, DOI 10.1002/(SICI)1098-1128(199601)16:1<3::AID-MED1>3.3.CO;2-D
   Bohm HJ, 1996, ANGEW CHEM INT EDIT, V35, P2589
   Bohm HJ, 1996, J COMPUT AID MOL DES, V10, P265, DOI 10.1007/BF00124496
   Bohm HJ, 1996, CURR OPIN BIOTECH, V7, P433, DOI 10.1016/S0958-1669(96)80120-0
   BOHM HJ, 1992, J COMPUT AID MOL DES, V6, P593, DOI 10.1007/BF00126217
   BOHM HJ, 1992, J COMPUT AID MOL DES, V6, P61, DOI 10.1007/BF00124387
   Bohm HJ, 1996, PROG BIOPHYS MOL BIO, V66, P197, DOI 10.1016/S0079-6107(97)00005-9
   BOHM HJ, 1996, WIRKSTOFFDESIGN
   BOHM HJ, 1993, 3D QSAR DRUG DESIGN, P386
   BOHM HJ, 1997, COMPUTER ASSISTED LE, P123
   BONE R, 1997, STRUCTURE BASED DRUG, P525
   BURGER A, 1983, GUIDE CHEM BASIS DRU
   Caflisch A, 1995, PERSPECT DRUG DISCOV, V3, P51, DOI 10.1007/BF02174467                                                              
   Caflisch A., 1997, STRUCTURE BASED DRUG, P541
   Chand P, 1997, J MED CHEM, V40, P4030, DOI 10.1021/jm970479e                                                               
   Cowley PM, 1997, CURR MED CHEM, V4, P211
   de Stevens G, 1986, Prog Drug Res, V30, P189
   Dixon J S, 1997, Proteins, VSuppl 1, P198
   DOLLE RE, 1996, MOL DIVERS, V2, P223
   Engleman VW, 1996, ANNU REP MED CHEM, V31, P191, DOI 10.1016/S0065-7743(08)60459-5
   EVANS BE, 1986, P NATL ACAD SCI USA, V83, P4918, DOI 10.1073/pnas.83.13.4918
   GANELLIN CR, 1993, MED CHEM ROLE ORGANI
   GOODFORD PJ, 1984, J MED CHEM, V27, P557, DOI 10.1021/jm00371a001
   Graul AI, 1998, DRUG NEWS PERSPECT, V11, P15
   GREER J, 1994, J MED CHEM, V37, P1035, DOI 10.1021/jm00034a001
   Hajduk PJ, 1997, J AM CHEM SOC, V119, P5818, DOI 10.1021/ja9702778                                                               
   Hajduk PJ, 1997, SCIENCE, V278, P497, DOI 10.1126/science.278.5337.497
   HOLTJE HD, 1996, MOL MODELING BASIC P
   Hubbard RE, 1997, CURR OPIN BIOTECH, V8, P696, DOI 10.1016/S0958-1669(97)80122-X                                                   
   Keenan RM, 1997, J MED CHEM, V40, P2289, DOI 10.1021/jm970205r
   Kim CU, 1997, J AM CHEM SOC, V119, P681, DOI 10.1021/ja963036t
   Kubinyi H, 1998, 3D QSAR DRUG DESIGN, V2
   KUBINYI H, 1998, 3D QSAR DRUG DESIGN, V2, P225
   Lemmen C, 1997, J COMPUT AID MOL DES, V11, P357, DOI 10.1023/A:1007959729800
   Lengauer T, 1996, CURR OPIN STRUC BIOL, V6, P402, DOI 10.1016/S0959-440X(96)80061-3
   LEWIS SL, 1937, H WALPOLES CORRES
   Makino S, 1997, J COMPUT CHEM, V18, P1812, DOI 10.1002/(SICI)1096-987X(19971115)18:14<1812::AID-JCC10>3.0.CO;2-H
   Marrone TJ, 1997, ANNU REV PHARMACOL, V37, P71, DOI 10.1146/annurev.pharmtox.37.1.71                                                
   MATTOS C, 1993, 3D QSAR DRUG DESIGN, P226
   Meyer EF, 1995, PERSPECT DRUG DISCOV, V3, P168, DOI 10.1007/BF02174473
   MULLER K, 1995, PERSP DRUG DISCOV DE, V3, P1
   Myers PL, 1997, CURR OPIN BIOTECH, V8, P701, DOI 10.1016/S0958-1669(97)80123-1
   Parrill A, 1997, EXPERT OPIN THER PAT, V7, P937, DOI 10.1517/13543776.7.9.937                                                        
   Rarey M, 1996, J MOL BIOL, V261, P470, DOI 10.1006/jmbi.1996.0477
   Remer T., 1965, SERENDIPITY 3 PRINCE
   Restak R., 1994, RECEPTORS
   Roberts Royston, 1989, SERENDIPITY ACCIDENT
   Samanen J, 1996, ANNU REP MED CHEM, V31, P91, DOI 10.1016/S0065-7743(08)60449-2
   Samanen JM, 1996, J MED CHEM, V39, P4867, DOI 10.1021/jm960558a
   Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531
   Sneader W., 1996, DRUG PROTOTYPES THEI
   SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0
   Sternbach L H, 1978, Prog Drug Res, V22, P229
   STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888
   SWIFT J, 1985, GULLIVERS TRAVELS 3, P223
   VACCA JP, 1997, DRUG DISCOV TODAY, V2, P6
   Veerapandian P., 1997, STRUCTURE BASED DRUG
   vonItzstein M, 1996, J MED CHEM, V39, P388, DOI 10.1021/jm950294c
   VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0
   Wermuth C. G., 1996, PRACTICE MED CHEM
   WESTHEAD DR, 1997, J COMPUT AID MOL DES, V11, P203
   WOLFF ME, 1995, BURGERS MED CHEM DRU, V1
   ZINKERNAGEL RM, 1997, S PHARM WISS ARZN GE
NR 66
TC 62
Z9 62
U1 0
U2 14
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016 USA
SN 1079-9893
J9 J RECEPT SIGNAL TR R
JI J. Recept. Signal Transduct. Res.
PD JAN-JUL
PY 1999
VL 19
IS 1-4
BP 15
EP 39
DI 10.3109/10799899909036635
PG 25
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 170UR
UT WOS:000078825900004
PM 10071748
DA 2018-01-05
ER

PT J
AU Blindauer, CA
   Sjastad, TI
   Holy, A
   Sletten, E
   Sigel, H
AF Blindauer, CA
   Sjastad, TI
   Holy, A
   Sletten, E
   Sigel, H
TI Aspects of the co-ordination chemistry of the antiviral nucleotide
   analogue, 9-[2-(phosphonomethoxy)ethyl]-2,6-diaminopurine (PMEDAP)
SO JOURNAL OF THE CHEMICAL SOCIETY-DALTON TRANSACTIONS
LA English
DT Article
ID METAL-ION COMPLEXES; HUMAN-IMMUNODEFICIENCY-VIRUS; TUBERCIDIN
   5'-MONOPHOSPHATE 7-DEAZA-AMP; N7 DEAZA DERIVATIVES; AQUEOUS-SOLUTION;
   COORDINATING PROPERTIES; ADENOSINE 5'-MONOPHOSPHATE; DNA-POLYMERASE;
   NUCLEOSIDE 5'-TRIPHOSPHATES; MACROCHELATE FORMATION
AB The acidity constants of the twofold protonated, acyclic, antiviral nucleotide analogue 9-[2-(phosphonomethoxy)ethyl]-2,6-diaminopurine, H-2(PMEDAP)(+/-), as well as the stability constants of the M(H;PMEDAP)(+) and M(PMEDAP) complexes with the metal ions M2+=Mg2+, Ca2+, Sr2+, Ba2+, Mn2+, Co2+, Ni2+, Cu2+, Zn2+ or Cd2+, have been determined by potentiometric pH titrations in aqueous solution at I=0.1 M (NaNO3) and 25 degrees C. Application of previously determined straight-line plots of log K-M(R-PO3(M)) versus pK(H(R-PO3)(H)) for simple phosph(on)ate ligands and comparisons with previous results obtained for the nucleobase-free compound (phosphonomethoxy)ethane, PME, and its derivative, PME-R, where R represents a nucleobase residue without an affinity for metal ions, show that the primary binding site of PMEDAP(2-) is the phosphonate group with all the metal ions studied and that also in all instances 5-membered chelates involving the ether oxygen of the -CH2OCH2PO32- chain are formed. The position of the isomeric equilibria between these chelates, M(PMEDAP)(cl/O), and the 'open' complexes, M(PMEDAP)(op), is determined. In the M2+/PMEDAP(2-) systems with Co2+, Ni2+, Cu2+, and most likely also Zn2+, a third isomer is formed which was detected by comparing the stabilities of the M(PMEDAP) and M(PME-R) complexes; this additional stability enhancement has to be attributed to the 2,6-diaminopurine residue. General considerations as well as H-1 NMR line broadening studies with Cu2+ reveal that in this third isomer a macrochelate is formed in which the phosphonate-bound metal ion interacts in addition with N7 of the purine residue, M(PMEDAP)(cl/N7). The equilibria involving the three isomers are described and quantified; e.g. 19 (+/- 3)% of Cu(PMEDAP) exists as an isomer with a sole phosphonate co-ordination, 38 (+/- 11)% as Cu(PMEDAP)(cl/O) and 43 (+/- 11)% as Cu(PMEDAP)(cl/N7). The corresponding numbers of Ni(PMEDAP) are 33 (+/- 6)% (open), 13 (+/- 8)% (cl/O) and 54 (+/- 10)% (cl/N7). The open and the macrochelated isomers resemble in their structure the corresponding complexes formed by the parent nucleotide adenosine 5'-monophosphate (AMP(2-)). The possible interrelation between the structure of the metal ion complexes in solution and the antiviral properties of PMEDAP and related compounds is discussed.
C1 Univ Basel, Inst Inorgan Chem, CH-4056 Basel, Switzerland.
   Univ Bergen, Dept Chem, N-5007 Bergen, Norway.
   Acad Sci Czech Republ, Inst Organ Chem & Biochem, CZ-16610 Prague, Czech Republic.
RP Sigel, H (reprint author), Univ Basel, Inst Inorgan Chem, Spitalstr 51, CH-4056 Basel, Switzerland.
RI Blindauer, Claudia/G-3237-2011
OI Blindauer, Claudia/0000-0001-8396-9332
CR BALZARINI J, 1991, P NATL ACAD SCI USA, V88, P1499, DOI 10.1073/pnas.88.4.1499
   Balzarini J, 1996, BIOCHEM BIOPH RES CO, V219, P337, DOI 10.1006/bbrc.1996.0234
   BANERJEA D, 1981, INORG CHEM, V20, P2586, DOI 10.1021/ic50222a040                                                             
   BarditchCrovo P, 1997, J INFECT DIS, V176, P406, DOI 10.1086/514057                                                                  
   BENOIT RL, 1984, CAN J CHEM, V62, P995, DOI 10.1139/v84-164
   Blindauer CA, 1997, CHEM-EUR J, V3, P1526, DOI 10.1002/chem.19970030922                                                        
   Blindauer CA, 1998, J BIOL INORG CHEM, V3, P423, DOI 10.1007/s007750050252                                                           
   Blindauer CA, 1999, COLLECT CZECH CHEM C, V64, P613, DOI 10.1135/cccc19990613                                                            
   Blindauer CA, 1997, J CHEM SOC PERK T 2, P2353, DOI 10.1039/a702356a                                                                
   Cihlar T, 1996, MOL PHARMACOL, V50, P1502
   De Clercq E, 1998, COLLECT CZECH CHEM C, V63, P480, DOI 10.1135/cccc19980480                                                            
   De Clercq E, 1998, COLLECT CZECH CHEM C, V63, P449, DOI 10.1135/cccc19980449                                                            
   DECLERCQ E, 1991, BIOCHEM PHARMACOL, V42, P963, DOI 10.1016/0006-2952(91)90276-B                                                    
   DECLERCQ E, 1990, DRUG EXP CLIN RES, V16, P319
   DECLERCQ E, 1987, ANTIVIR RES, V8, P261
   FOSTER SA, 1991, J BIOL CHEM, V266, P238
   Franek F, 1999, INT J ONCOL, V14, P745
   HOLY A, 1989, ACS SYM SER, V401, P51
   HOLY A, 1990, ANTIVIR RES, V13, P295, DOI 10.1016/0166-3542(90)90014-X
   HOLY A, 1989, COLLECT CZECH CHEM C, V54, P2190, DOI 10.1135/cccc19892190                                                            
   Holy A, 1999, J MED CHEM, V42, P2064, DOI 10.1021/jm9811256
   IRVING H, 1948, NATURE, V162, P746, DOI 10.1038/162746a0                                                                
   IRVING HM, 1967, ANAL CHIM ACTA, V38, P475, DOI 10.1016/S0003-2670(01)80616-4                                                   
   JI LN, 1991, J CHEM SOC DALTON, P1367, DOI 10.1039/dt9910001367
   Kapinos LE, 1999, CHEM-EUR J, V5, P1794, DOI 10.1002/(SICI)1521-3765(19990604)5:6<1794::AID-CHEM1794>3.0.CO;2-4
   Kapinos LE, 1998, INORG CHIM ACTA, V280, P50, DOI 10.1016/S0020-1693(98)00052-8                                                   
   Kramata P, 1996, MOL PHARMACOL, V49, P1005
   Luth MS, 1999, J CHEM SOC DALTON, P357, DOI 10.1039/a808479c
   LYNCH BM, 1958, J CHEM SOC, P2973, DOI 10.1039/jr9580002973                                                            
   Martin RB, 1996, MET IONS BIOL SYST, V32, P61
   MARTIN RB, 1979, MET IONS BIOL SYST, V8, P57
   Martin RB, 1988, COMMENTS INORG CHEM, V6, P285
   Martin R.B., 1979, MET IONS BIOL SYST, V9, P1
   MASSOUD SS, 1988, INORG CHEM, V27, P1447, DOI 10.1021/ic00281a030                                                             
   MASSOUD SS, 1989, EUR J BIOCHEM, V179, P451, DOI 10.1111/j.1432-1033.1989.tb14574.x                                              
   Meiser C, 1997, CHEM-EUR J, V3, P388
   MERTA A, 1992, BIOCHEM PHARMACOL, V44, P2067, DOI 10.1016/0006-2952(92)90110-5
   MILDVAN AS, 1987, MAGNESIUM, V6, P28
   MILDVAN AS, 1990, MET IONS BIOL SYST, V26, P1
   Murray K., 1996, JOINT EXPERT SPECIAT
   NAESENS L, 1989, EUR J CLIN MICROBIOL, V8, P1043, DOI 10.1007/BF01975167
   Naesens L, 1997, ANTIVIR CHEM CHEMOTH, V8, P1
   NEYTS J, 1993, EUR J CLIN MICROBIOL, V12, P437, DOI 10.1007/BF01967438
   NEYTS J, 1994, BIOCHEM PHARMACOL, V47, P39, DOI 10.1016/0006-2952(94)90435-9
   Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d
   PELLETIER H, 1994, SCIENCE, V266, P2025, DOI 10.1126/science.7801132
   Pettit L. D., 1998, IUPAC STABILITY CONS
   REINERT H, 1969, H-S Z PHYSIOL CHEM, V350, P1310, DOI 10.1515/bchm2.1969.350.2.1310
   ROBBINS BL, 1995, ANTIMICROB AGENTS CH, V39, P2304, DOI 10.1128/AAC.39.10.2304                                                          
   Saha A, 1996, J BIOL INORG CHEM, V1, P231, DOI 10.1007/s007750050048                                                           
   Sigel H., 1996, MET IONS BIOL SYST, V32, P1
   SIGEL H, 1967, BIOCHIM BIOPHYS ACTA, V148, P655, DOI 10.1016/0304-4165(67)90038-4
   SIGEL H, 1970, ACCOUNTS CHEM RES, V3, P201, DOI 10.1021/ar50030a004                                                             
   Sigel H, 1999, CHEM COMMUN, P743, DOI 10.1039/a901233h                                                                
   Sigel H, 1996, MET IONS BIOL SYST, V32, P135
   SIGEL H, 1990, COORDIN CHEM REV, V100, P453, DOI 10.1016/0010-8545(90)85018-N                                                    
   SIGEL H, 1984, J AM CHEM SOC, V106, P7935, DOI 10.1021/ja00337a050
   SIGEL H, 1995, COORDIN CHEM REV, V144, P287, DOI 10.1016/0010-8545(95)01158-L                                                    
   SIGEL H, 1988, J AM CHEM SOC, V110, P6857, DOI 10.1021/ja00228a040                                                             
   SIGEL H, 1992, HELV CHIM ACTA, V75, P2634, DOI 10.1002/hlca.19920750817                                                        
   SIGEL H, 1994, J AM CHEM SOC, V116, P2958, DOI 10.1021/ja00086a028
   SIGEL H, 1991, ANAL CHIM ACTA, V255, P63, DOI 10.1016/0003-2670(91)85088-A                                                    
   SIGEL H, 1993, CHEM SOC REV, V22, P255, DOI 10.1039/cs9932200255                                                            
   SIGEL H, 1989, MET IONS BIOL SYST, V25, P1
   Sigel H., 1992, COMMENTS INORG CHEM, V13, P35
   SIGEL H, 1990, COORDIN CHEM REV, V100, P529
   SIGEL H, IN PRESS PURE APPL C, V72, P2000
   Sigel RKO, 1997, J AM CHEM SOC, V119, P744, DOI 10.1021/ja962970l                                                               
   SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098                                                          
   Smith R. M., 1998, NIST CRITICALLY SELE
   Song B, 1998, INORG CHIM ACTA, V273, P101, DOI 10.1016/S0020-1693(97)05917-3                                                   
   SONG B, 1994, HELV CHIM ACTA, V77, P1738, DOI 10.1002/hlca.19940770706
   SONG B, 1999, IN PRESS METAL BASED, V6
   Steitz TA, 1998, NATURE, V391, P231, DOI 10.1038/34542
   SUN MS, 1967, CAN J CHEMISTRY, V45, P2729, DOI 10.1139/v67-443                                                                 
   TRIBOLET R, 1987, EUR J BIOCHEM, V163, P353, DOI 10.1111/j.1432-1033.1987.tb10807.x
   VESELY J, 1990, NEOPLASMA, V37, P105
   VILLEMIN D, 1993, SYNTHETIC COMMUN, V23, P1053, DOI 10.1080/00397919308018581                                                       
   VOTRUBA I, 1987, MOL PHARMACOL, V32, P524
   Yamauchi O, 1996, MET IONS BIOL SYST, V32, P207
   YOKOTA T, 1991, ANTIMICROB AGENTS CH, V35, P394, DOI 10.1128/AAC.35.2.394                                                            
NR 81
TC 35
Z9 35
U1 0
U2 1
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD,, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0300-9246
J9 J CHEM SOC DALTON
JI J. Chem. Soc.-Dalton Trans.
PY 1999
IS 21
BP 3661
EP 3671
DI 10.1039/a904838c                                                        
          
PG 11
WC Chemistry, Inorganic & Nuclear
SC Chemistry
GA 249ML
UT WOS:000083336800003
DA 2018-01-05
ER

PT J
AU Serizawa, T
AF Serizawa, T
TI Polymeric assemblies with nano-structures
SO KOBUNSHI RONBUNSHU
LA Japanese
DT Article
DE assembly; nano-structure; polymer film; particle; core-corona type
   nanosphere; alternate adsorption; quartz crystal microbalance (QCM)
   macromonomer; radical copolymerization; particle size; metal
   nano-particle; carbohydrate; protein; HIV-1; lectin
ID IMMOBILIZED POLYSTYRENE NANOSPHERES; HYDROPHOBIC BACKBONE; HYDROPHILIC
   BRANCHES; GRAFT-COPOLYMERS; EMULSION COPOLYMERIZATION; POLY(STYRENE)
   NANOSPHERES; NANOPARTICLES; SURFACE; WATER; FILMS
AB Among recent topics which are related to "Polymeric Assemblies with Nano-Structures" of our research group, particle assemblies on ultrathin polymer films, and synthesis and applications of core-corona type polymeric nanospheres were reviewed. Polymeric particles (latex) were electrostatically adsorbed onto the surface of ultrathin polymer films, which had been prepared by an alternate adsorption technique with poly(allylamine hydrochloride) (PAH) and poly(sodium 4-styrenesulfonate) (PSS) in the absence or presence of NaCl. The adsorption processes were quantitatively analyzed by using quartz crystal microbalance (QCM) and scanning electron microscope (SEM) techniques. Charge densities of films, particle concentrations, particle sizes, and surface charges of particles significantly affected adsorption. Ordered mono- or multi-layer particle assemblies were observed. Core-corona type polymeric nanospheres were prepared by the free radical copolymerization of hydrophilic macromonomers and hydrophobic comonomers in polar organic solvents. Polymerization parameters such as molecular weights of macromonomer, monomer concentrations, polymerization temperatures, and solvent species significantly affected particle sizes. Potential applications such as catalytic supports and biomedical uses were also studied. Metal nano-particles were easily deposited on nanospheres due to steric stabilization on nanosphere surfaces. Carbohydrates and proteins were covalently conjugated on nanospheres.
C1 Kagoshima Univ, Fac Engn, Dept Chem Engn & Appl Chem, Kagoshima 8900065, Japan.
RP Serizawa, T (reprint author), Kagoshima Univ, Fac Engn, Dept Chem Engn & Appl Chem, 1-21-40 Korimoto, Kagoshima 8900065, Japan.
CR AKASHI M, 1989, J POLYM SCI POL CHEM, V27, P3521, DOI 10.1002/pola.1989.080271029                                                     
   AKASHI M, 1985, ANGEW MAKROMOL CHEM, V132, P81, DOI 10.1002/apmc.1985.051320107                                                     
   Akashi M, 1998, BIOCONJUGATE CHEM, V9, P50, DOI 10.1021/bc970045y                                                               
   Alivisatos AP, 1996, NATURE, V382, P609, DOI 10.1038/382609a0
   Ariga K, 1997, CHEM LETT, P125, DOI 10.1246/cl.1997.125                                                             
   Baker BE, 1996, J AM CHEM SOC, V118, P8721, DOI 10.1021/ja961327w                                                               
   BLAADEREN A, 1997, NATURE, V385, P321
   Chen CW, 1998, ADV MATER, V10, P1122, DOI 10.1002/(SICI)1521-4095(199810)10:14<1122::AID-ADMA1122>3.3.CO;2-E
   Chen CW, 1999, CHEM MATER, V11, P1381, DOI 10.1021/cm9900047                                                               
   CHEN CW, 1998, J CHEM SOC CHEM COMM, P831
   Chen MQ, 1999, POLYM ADVAN TECHNOL, V10, P120, DOI 10.1002/(SICI)1099-1581(199901/02)10:1/2<120::AID-PAT781>3.3.CO;2-7
   Chen MQ, 1996, J POLYM SCI POL CHEM, V34, P2213
   CHEN MQ, IN PRESS J POLYM S A
   Decher G, 1997, SCIENCE, V277, P1232, DOI 10.1126/science.277.5330.1232                                                   
   DEMITROV AS, 1996, LANGMUIR, V12, P1303
   Fulda KU, 1998, THIN SOLID FILMS, V327, P752, DOI 10.1016/S0040-6090(98)00780-9
   Fulda KU, 1996, PROG COLL POL SCI S, V101, P178
   Fulda KU, 1997, SUPRAMOL SCI, V4, P265, DOI 10.1016/S0968-5677(97)00012-6                                                   
   Hayakawa T, 1998, J MED VIROL, V56, P327, DOI 10.1002/(SICI)1096-9071(199812)56:4<327::AID-JMV7>3.0.CO;2-A
   Horvolgyi Z, 1996, LANGMUIR, V12, P997, DOI 10.1021/la940658o                                                               
   Ishizu K, 1996, POLYMER, V37, P1729, DOI 10.1016/0032-3861(96)83726-8                                                    
   KAWAGUCHI S, 1995, MACROMOLECULES, V28, P1159, DOI 10.1021/ma00108a051                                                             
   Kimizuka N, 1996, J AM CHEM SOC, V118, P5808, DOI 10.1021/ja960707e                                                               
   KOTOV NA, 1995, J PHYS CHEM-US, V99, P13065, DOI 10.1021/j100035a005                                                             
   LVOV Y, 1993, LANGMUIR, V9, P481, DOI 10.1021/la00026a020                                                             
   Lvov Y, 1997, LANGMUIR, V13, P6195, DOI 10.1021/la970517x                                                               
   Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0
   NISHI N, 1988, J AM CHEM SOC, V110, P5246, DOI 10.1021/ja00224a002                                                             
   Pileni MP, 1997, LANGMUIR, V13, P3266, DOI 10.1021/la960319q                                                               
   RAMSDEN JJ, 1995, THIN SOLID FILMS, V254, P246, DOI 10.1016/0040-6090(94)06262-J
   ROBINSON DJ, 1993, LANGMUIR, V9, P1436, DOI 10.1021/la00029a045                                                             
   SAUERBREY G, 1959, Z PHYS, V155, P206, DOI 10.1007/BF01337937                                                              
   Schmitt J, 1997, ADV MATER, V9, P61, DOI 10.1002/adma.19970090114
   Serizawa T, 1999, J BIOMAT SCI-POLYM E, V10, P391, DOI 10.1163/156856299X00441                                                         
   Serizawa T, 1999, LANGMUIR, V15, P4682, DOI 10.1021/la9816398                                                               
   Serizawa T, 1997, CHEM LETT, P809, DOI 10.1246/cl.1997.809
   Serizawa T, 1998, LANGMUIR, V14, P4088, DOI 10.1021/la9713661                                                               
   Serizawa T, 1998, CHEM LETT, P487, DOI 10.1246/cl.1998.487                                                             
   Serizawa T, 1998, LANGMUIR, V14, P1278, DOI 10.1021/la970992v                                                               
   Serizawa T, 1998, J POLYM SCI POL CHEM, V36, P2581, DOI 10.1002/(SICI)1099-0518(199810)36:14<2581::AID-POLA17>3.0.CO;2-E
   SERIZAWA T, IN PRESS J POLYM S A
   SERIZAWA T, IN PRESS LANGMUIR
   SERIZAWA T, 1999, J POLYM SCI A, V36, P801
   SERIZAWA T, UNPUB
   SUN Y, 1996, J CHEM SOC CHEM COMM, P2381
   Sun YP, 1997, LANGMUIR, V13, P5168, DOI 10.1021/la9703510                                                               
   TAKEUCHI S, 1993, MAKROMOL CHEM, V194, P551
   Trau M, 1996, SCIENCE, V272, P706, DOI 10.1126/science.272.5262.706                                                    
   Yeh SR, 1997, NATURE, V386, P57, DOI 10.1038/386057a0
   Yonezawa T, 1998, ADV MATER, V10, P414, DOI 10.1002/(SICI)1521-4095(199803)10:5<414::AID-ADMA414>3.3.CO;2-4
NR 50
TC 1
Z9 1
U1 0
U2 5
PU SOC POLYMER SCIENCE JAPAN
PI TOKYO
PA TSUKIJI DAISAN NAGAOKA BLDG, 2-4-2 TSUKIJI, CHUO-KU, TOKYO, 104, JAPAN
SN 0386-2186
J9 KOBUNSHI RONBUNSHU
JI Kobunshi Ronbunshu
PY 1999
VL 56
IS 8
BP 469
EP 479
DI 10.1295/koron.56.469                                                    
          
PG 11
WC Polymer Science
SC Polymer Science
GA 231BE
UT WOS:000082285500001
OA gold
DA 2018-01-05
ER

PT J
AU Allemann, E
   Leroux, JC
   Gurny, R
AF Allemann, E
   Leroux, JC
   Gurny, R
TI Polymeric nano- and microparticles for the oral delivery of peptides and
   peptidomimetics
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE nanoparticles; microparticles; peptides; peptidomimetics; oral
   administration; in vivo studies
ID HIV-1 PROTEASE INHIBITORS; ALPHA-AMINO-ACIDS; INTESTINAL-ABSORPTION;
   POLYALKYLCYANOACRYLATE NANOCAPSULES; ANTIMETASTATIC ACTIVITY;
   SALMON-CALCITONIN; PERORAL DELIVERY; POTENTIAL ROLE; PARTICLE-SIZE;
   DIABETIC RATS
AB Due to recent advances, numerous bioactive peptides are now available in large quantities. Administering these substances by the oral route appears as a formidable challenge due to their insufficient stability in the gastrointestinal tract and their poor absorption pattern. Several approaches have been investigated to improve their oral bioavailability. Among them, the use of polymeric particulate delivery systems (microparticles and nanoparticles) represents a promising concept. Encapsulating or incorporating peptides in particles should at least protect these substances against degradation and, in some cases, also enhance their absorption. The aim of this paper is to review the principal studies where peptide-loaded particles were administered by the oral route. The preparation methods and in vitro trials are presented and in vivo results are discussed with emphasis placed on the peptide blood levels reached or on the biological effects observed. Whether or not intact particles can be taken up and translocated to the systemic circulation is not the aim of this review. (C) 1998 Published by Elsevier Science B.V. All rights reserved.
C1 Univ Geneva, Sch Pharm, Geneva, Switzerland.
   Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada.
RP Allemann, E (reprint author), Univ Geneva, Sch Pharm, Geneva, Switzerland.
RI Leroux, Jean-Christophe/N-4202-2015
OI Leroux, Jean-Christophe/0000-0001-5601-1292
CR ABDELMEGUID SS, 1994, BIOCHEMISTRY-US, V33, P11671, DOI 10.1021/bi00205a001
   ALKHOURI N, 1986, PHARM ACTA HELV, V61, P274
   ALLEMANN E, 1993, PHARMACEUT RES, V10, P1732, DOI 10.1023/A:1018970030327
   ALLEMANN E, 1993, EUR J PHARM BIOPHARM, V39, P173
   ALTERI E, 1993, ANTIMICROB AGENTS CH, V37, P2087, DOI 10.1128/AAC.37.10.2087                                                          
   Banga A., 1995, THERAPEUTIC PEPTIDES
   BARRATT G, 1994, INT J IMMUNOPHARMACO, V16, P457, DOI 10.1016/0192-0561(94)90036-1
   Barry M, 1997, CLIN PHARMACOKINET, V32, P194, DOI 10.2165/00003088-199732030-00003                                                
   BECK PH, 1994, EUR J PHARM BIOPHARM, V40, P134
   BETEN DB, 1994, INT J PHARMACEUT, V103, P243, DOI 10.1016/0378-5173(94)90174-0
   BIRRENBACH G, 1976, J PHARM SCI, V65, P1763, DOI 10.1002/jps.2600651217                                                          
   Bonduelle S, 1996, EUR J PHARM BIOPHARM, V42, P313
   BONDUELLE S, 1992, J MICROENCAPSUL, V9, P173
   BONDUELLE S, 1995, EUR J PHARM BIOPHARM, V41, P27
   CHOUINARD F, 1991, INT J PHARM, V72, P211, DOI 10.1016/0378-5173(91)90110-A                                                    
   DAMGE C, 1995, DIABETES NUTR METAB, V8, P3
   DAMGE C, 1990, J CONTROL RELEASE, V13, P233, DOI 10.1016/0168-3659(90)90013-J                                                    
   DAMGE C, 1988, DIABETES, V37, P246, DOI 10.2337/diabetes.37.2.246
   DAMGE C, 1987, INT J PHARM, V36, P121, DOI 10.1016/0378-5173(87)90146-3                                                    
   DEBOUCK C, 1992, AIDS RES HUM RETROV, V8, P153, DOI 10.1089/aid.1992.8.153
   Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145
   DEJAEGHERE F, 1997, P COLL DRUG CARR 3 E
   Desai MP, 1996, PHARMACEUT RES, V13, P1838, DOI 10.1023/A:1016085108889
   FALLOUH NA, 1986, INT J PHARM, V28, P125
   FLORENCE AT, 1995, J DRUG TARGET, V3, P65, DOI 10.3109/10611869509015936                                                       
   FLORENCE AT, 1995, J CONTROL RELEASE, V36, P39, DOI 10.1016/0168-3659(95)00059-H                                                    
   Florence AT, 1997, PHARMACEUT RES, V14, P259, DOI 10.1023/A:1012029517394
   Hillery AM, 1996, J CONTROL RELEASE, V41, P271, DOI 10.1016/0168-3659(96)01342-9                                                    
   Hillery AM, 1996, J CONTROL RELEASE, V42, P65, DOI 10.1016/0168-3659(96)01368-5                                                    
   Irache JM, 1996, PHARMACEUT RES, V13, P1716, DOI 10.1023/A:1016405126656
   JANI P, 1990, J PHARM PHARMACOL, V42, P821, DOI 10.1111/j.2042-7158.1990.tb07033.x                                              
   Kai T, 1996, CHEM PHARM BULL, V44, P568
   KONDO N, 1994, J PHARM SCI, V83, P566, DOI 10.1002/jps.2600830425
   Landry FB, 1996, STP PHARMA SCI, V6, P195
   LANG M, 1993, ARCH PHARM, V326, P921, DOI 10.1002/ardp.19933261202                                                        
   LEHR CM, 1990, J CONTROL RELEASE, V13, P51, DOI 10.1016/0168-3659(90)90074-4
   LEHR CM, 1992, J PHARM PHARMACOL, V44, P402, DOI 10.1111/j.2042-7158.1992.tb03633.x                                              
   LEONEBAY A, 1995, J MED CHEM, V38, P4263, DOI 10.1021/jm00021a015                                                             
   LEONEBAY A, 1995, J MED CHEM, V38, P4257, DOI 10.1021/jm00021a014
   LERAY AM, 1994, INT J PHARM, V106, P201, DOI 10.1016/0378-5173(94)90003-5
   LEROUX JC, 1995, J PHARM SCI, V84, P1387, DOI 10.1002/jps.2600841202
   Leroux JC, 1996, PHARMACEUT RES, V13, P485, DOI 10.1023/A:1016073416332                                                         
   LIN KF, 1995, POLYM COMPOSITE, V16, P269, DOI 10.1002/pc.750160402                                                            
   LOWE PJ, 1994, J PHARM PHARMACOL, V46, P547, DOI 10.1111/j.2042-7158.1994.tb03854.x                                              
   MAINCENT P, 1986, J PHARM SCI, V75, P955, DOI 10.1002/jps.2600751009
   MICHEL C, 1991, J PHARM PHARMACOL, V43, P1, DOI 10.1111/j.2042-7158.1991.tb05437.x                                              
   Michel C, 1991, P INT S CONTROL RELE, V18, P97
   Milstein SJ, 1996, J MICROENCAPSUL, V13, P651, DOI 10.3109/02652049609026049
   Molpeceres J, 1996, J PHARM SCI, V85, P206, DOI 10.1021/js950164r
   MORISHITA I, 1993, INT J PHARM, V91, P29, DOI 10.1016/0378-5173(93)90418-F
   Morishita I, 1991, Drug Des Deliv, V7, P309
   MORISHITA I, 1992, INT J PHARM, V78, P9, DOI 10.1016/0378-5173(92)90349-7
   MORISHITA M, 1992, INT J PHARM, V78, P1, DOI 10.1016/0378-5173(92)90348-6                                                    
   OHagan DT, 1996, J ANAT, V189, P477
   OPPENHEIM RC, 1982, DRUG DEV IND PHARM, V8, P531, DOI 10.3109/03639048209022119
   ROBINS T, 1993, J ACQ IMMUN DEF SYND, V6, P162
   ROQUES M, 1995, DIABETOLOGIA, V38, P180
   ROQUES M, 1992, DIABETES, V41, P451, DOI 10.2337/diabetes.41.4.451
   Sarubbi D, 1994, P INT S CONTROL RELE, V21, P288
   SMITH MW, 1995, EXP PHYSIOL, V80, P735, DOI 10.1113/expphysiol.1995.sp003882                                                
   Szentkuti L, 1997, J CONTROL RELEASE, V46, P233, DOI 10.1016/S0168-3659(96)01600-8                                                   
   Vranckx H, 1996, EUR J PHARM BIOPHARM, V42, P345
   YU WP, 1991, INT J IMMUNOPHARMACO, V13, P167, DOI 10.1016/0192-0561(91)90095-O
   VRANCHX H, 1996, Patent No. 5500224
   Fessi H., 1992, Patents, Patent No. [FR 2608988, 2608988]
   Couvreur P, 1982, US patent, Patent No. [4329332 A, 4329332]
NR 66
TC 157
Z9 163
U1 1
U2 30
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD DEC 1
PY 1998
VL 34
IS 2-3
BP 171
EP 189
DI 10.1016/S0169-409X(98)00039-8
PG 19
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 147AE
UT WOS:000077465400005
DA 2018-01-05
ER

PT J
AU Sudbeck, EA
   Mao, C
   Vig, R
   Venkatachalam, TK
   Tuel-Ahlgren, L
   Uckun, FM
AF Sudbeck, EA
   Mao, C
   Vig, R
   Venkatachalam, TK
   Tuel-Ahlgren, L
   Uckun, FM
TI Structure-based design of novel dihydroalkoxybenzyloxopyrimidine
   derivatives as potent nonnucleoside inhibitors of the human
   immunodeficiency virus reverse transcriptase
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID POKEWEED ANTIVIRAL PROTEIN; HIGHLY POTENT;
   1-<(2-HYDROXYETHOXY)METHYL>-6-(PHENYLTHIO)THYMINE HEPT; 3-DIMENSIONAL
   STRUCTURE; SELECTIVE INHIBITORS; RESISTANCE MUTATIONS; ANTI-HIV-1
   ACTIVITY; HIV-1 REPLICATION; PETT COMPOUNDS; TYPE-1
AB Two highly potent dihydroalkoxybenzyloxopyrimidine (DABO) derivatives targeting the nonnucleoside inhibitor (NNI) binding site of human immunodeficiency virus (HIV) reverse transcriptase (RT) have been designed based on the structure of the NNI binding pocket and tested for anti-HIV activity. Our lead DABO derivative, 5-isopropyl-2-[(methylthiomethyl)thio]-6-(benzyl)-pyrimidin-4-(1H)-one, elicited potent inhibitory activity against purified recombinant HIV RT and abrogated HIV replication in peripheral blood mononuclear cells at nanomolar concentrations (50% inhibitory concentration, <1 nM) but showed no detectable cytotoxicity at concentrations as high as 100 mu M.
C1 Hughes Inst, Drug Discovery Program, St Paul, MN 55113 USA.
   Hughes Inst, Dept Chem, St Paul, MN 55113 USA.
   Hughes Inst, Dept Biol Struct, St Paul, MN 55113 USA.
   Hughes Inst, Dept Virol, St Paul, MN 55113 USA.
RP Uckun, FM (reprint author), Hughes Inst, Drug Discovery Program, St Paul, MN 55113 USA.
EM fatih_uckun@mercury.ih.org
CR AHGREN C, 1995, ANTIMICROB AGENTS CH, V39, P1329, DOI 10.1128/AAC.39.6.1329                                                           
   BABA M, 1992, ANTIVIR RES, V17, P245, DOI 10.1016/0166-3542(92)90021-V
   Balzarini J, 1995, Verh K Acad Geneeskd Belg, V57, P575
   BALZARINI J, 1992, P NATL ACAD SCI USA, V89, P4392, DOI 10.1073/pnas.89.10.4392
   BELL FW, 1995, J MED CHEM, V38, P4929, DOI 10.1021/jm00025a010
   BOHM HJ, 1992, J COMPUT AID MOL DES, V6, P593, DOI 10.1007/BF00126217
   BOHM HJ, 1994, J COMPUT AID MOL DES, V8, P243, DOI 10.1007/BF00126743
   BOSWORTH N, 1989, NATURE, V341, P167, DOI 10.1038/341167a0
   Buckheit RW, 1997, ANTIMICROB AGENTS CH, V41, P831
   Buckheit RW, 1997, AIDS RES HUM RETROV, V13, P789, DOI 10.1089/aid.1997.13.789
   BUCKHEIT RW, 1995, ANTIMICROB AGENTS CH, V39, P2718, DOI 10.1128/AAC.39.12.2718                                                          
   Cantrell AS, 1996, J MED CHEM, V39, P4261, DOI 10.1021/jm950639r
   CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170
   Danel K, 1997, ACTA CHEM SCAND, V51, P426, DOI 10.3891/acta.chem.scand.51-0426
   Danel K, 1998, J MED CHEM, V41, P191, DOI 10.1021/jm970443m
   Danel K, 1996, J MED CHEM, V39, P2427, DOI 10.1021/jm9600499
   Das K, 1996, J MOL BIOL, V264, P1085, DOI 10.1006/jmbi.1996.0698
   DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001
   DECLERCQ E, 1992, AIDS RES HUM RETROV, V8, P119, DOI 10.1089/aid.1992.8.119                                                          
   DING J, 1995, STRUCTURE, V3, P365, DOI 10.1016/S0969-2126(01)00168-X
   DING JP, 1995, NAT STRUCT BIOL, V2, P407, DOI 10.1038/nsb0595-407
   ERICE A, 1993, ANTIMICROB AGENTS CH, V37, P835, DOI 10.1128/AAC.37.4.835                                                            
   Esnouf RM, 1997, P NATL ACAD SCI USA, V94, P3984, DOI 10.1073/pnas.94.8.3984
   Font M, 1997, Drug Des Discov, V14, P305
   Fujiwara M, 1997, MICROBIOL IMMUNOL, V41, P301, DOI 10.1111/j.1348-0421.1997.tb01205.x                                              
   GREENE WC, 1991, NEW ENGL J MED, V324, P308
   GROB PM, 1992, AIDS RES HUM RETROV, V8, P145, DOI 10.1089/aid.1992.8.145
   Heinisch G, 1997, ANTIVIR CHEM CHEMOTH, V8, P443, DOI 10.1177/095632029700800507                                                      
   Hopkins AL, 1996, J MED CHEM, V39, P1589, DOI 10.1021/jm960056x
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   Kleim JP, 1996, P NATL ACAD SCI USA, V93, P34, DOI 10.1073/pnas.93.1.34
   KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403
   LUTY BA, 1995, J COMPUT CHEM, V16, P454, DOI 10.1002/jcc.540160409                                                           
   Mai A, 1997, J MED CHEM, V40, P1447, DOI 10.1021/jm960802y
   Mao C, 1998, BIOORG MED CHEM LETT, V8, P2213, DOI 10.1016/S0960-894X(98)00384-9                                                   
   MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273
   *MOL SIM INC, 1996, INS 2
   Nicholls A., 1992, GRASP GRAPHICAL REPR
   Pontikis R, 1997, J MED CHEM, V40, P1845, DOI 10.1021/jm960765a
   REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293
   REN JS, 1995, STRUCTURE, V3, P915, DOI 10.1016/S0969-2126(01)00226-X
   ROMERO DL, 1993, J MED CHEM, V36, P1505, DOI 10.1021/jm00062a027
   Romero DL, 1996, J MED CHEM, V39, P3769, DOI 10.1021/jm960158n
   SMERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911, DOI 10.1073/pnas.91.9.3911
   TANAKA H, 1991, J MED CHEM, V34, P349, DOI 10.1021/jm00105a055
   TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665                                                          
   Uckun FM, 1998, ANTIMICROB AGENTS CH, V42, P383
   VIG R, 1998, BIOORGAN MED CHEM, V6, P1
   ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0
NR 49
TC 50
Z9 53
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD DEC
PY 1998
VL 42
IS 12
BP 3225
EP 3233
PG 9
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 145ER
UT WOS:000077358500029
PM 9835518
DA 2018-01-05
ER

PT J
AU Sacht, G
   Marten, A
   Deiters, U
   Sussmuth, R
   Jung, G
   Wingender, E
   Muhlradt, PF
AF Sacht, G
   Marten, A
   Deiters, U
   Sussmuth, R
   Jung, G
   Wingender, E
   Muhlradt, PF
TI Activation of nuclear factor-chi B in macrophages by mycoplasmal
   lipopeptides
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE lipopeptide; macrophage activation; NF-chi B; mycoplasma
ID TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; IMMUNODEFICIENCY-VIRUS TYPE-1; LONG
   TERMINAL REPEAT; NITRIC-OXIDE; GENE-EXPRESSION; FACTOR BINDING;
   CELL-LINES; TNF-ALPHA; FERMENTANS
AB Mycoplasmas are potent macrophage stimulators. The active principle are lipopeptides or lipoproteins with a characteristic N-terminal S-[dihydroxypropyl]-cysteinyl group bearing two ester-bound fatty acids and lacking the amide-bound one common to other bacterial lipoproteins. Using synthetic analogues of mycoplasmal lipopeptides, we investigated activation of the transcription factor NF-kappa B in the C3H/HeJ mouse-derived DMBM-3 cell line. The lipopeptides activated NF-kappa B at below nanomolar concentrations. Activation in the murine system occurred distinctly earlier than TNF-alpha liberation, excluding autocrine stimulation by TNF-alpha. As determined from a supershift experiment, the active NF-kappa B complex consisted of the heterodimer p50/p65(RelA). The relevance of these findings for the inflammatory response to mycoplasmas and for mycoplasma-mediated effects on HIV-infected macrophages is discussed.
C1 Gesell Biotechnol Forsch GmbH, Immunobiol Res Grp, D-38124 Braunschweig, Germany.
   Univ Tubingen, Inst Organ Chem, D-7400 Tubingen, Germany.
RP Muhlradt, PF (reprint author), Gesell Biotechnol Forsch GmbH, Immunobiol Res Grp, Mascheroder Weg 1, D-38124 Braunschweig, Germany.
OI Sussmuth, Roderich/0000-0001-7027-2069
CR Bauerle PA, 1994, ANNU REV IMMUNOL, V2, P141
   BRAUN V, 1994, BACTERIAL CELL WALL, P319
   BROWN AM, 1994, MOL CELL BIOL, V14, P2926, DOI 10.1128/MCB.14.5.2926                                                           
   CHOWDHURY MIH, 1990, LANCET, V336, P247
   DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974                                                         
   Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0
   FREUDENBERG MA, 1991, INFECT IMMUN, V59, P2110
   Frisch M, 1996, EUR J IMMUNOL, V26, P1050, DOI 10.1002/eji.1830260514                                                          
   GALLILY R, 1992, IMMUNOL LETT, V34, P27, DOI 10.1016/0165-2478(92)90023-H                                                    
   GAYNOR RB, 1988, P NATL ACAD SCI USA, V85, P9406, DOI 10.1073/pnas.85.24.9406
   HOFFMANN P, 1988, IMMUNOBIOLOGY, V177, P158, DOI 10.1016/S0171-2985(88)80036-6                                                   
   HOHMANN HP, 1990, J BIOL CHEM, V265, P22409
   LEMAITRE M, 1992, INFECT IMMUN, V60, P742
   LO SC, 1991, LANCET, V338, P1415, DOI 10.1016/0140-6736(91)92721-D
   LO SC, 1991, SCIENCE, V251, P1074, DOI 10.1126/science.1705362                                                         
   Monner DA, 1997, J LEUKOCYTE BIOL, V61, P469
   MUHLRADT PF, 1991, INFECT IMMUN, V59, P3969
   MUHLRADT PF, 1994, INFECT IMMUN, V62, P3801
   Muhlradt PF, 1997, J EXP MED, V185, P1951, DOI 10.1084/jem.185.11.1951
   Muhlradt PF, 1998, INFECT IMMUN, V66, P4804
   NIRPAZ R, 1995, FEMS MICROBIOL LETT, V128, P63, DOI 10.1111/j.1574-6968.1995.tb07501.x
   Norgard MV, 1996, INFECT IMMUN, V64, P3845
   Rawadi G, 1998, J IMMUNOL, V160, P1330
   ROULSTON A, 1995, MICROBIOL REV, V59, P481
   RUUTH E, 1989, IMMUNOL REV, V112, P133, DOI 10.1111/j.1600-065X.1989.tb00556.x
   SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419
   SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cellbio.10.1.405
   TaylorRobinson D, 1996, CLIN INFECT DIS, V23, P671, DOI 10.1093/clinids/23.4.671                                                        
   XIE QW, 1994, J BIOL CHEM, V269, P4705
   YOGEV D, 1995, J BACTERIOL, V177, P5636, DOI 10.1128/jb.177.19.5636-5643.1995                                                
NR 30
TC 29
Z9 31
U1 0
U2 2
PU WILEY-V C H VERLAG GMBH
PI BERLIN
PA MUHLENSTRASSE 33-34, D-13187 BERLIN, GERMANY
SN 0014-2980
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD DEC
PY 1998
VL 28
IS 12
BP 4207
EP 4212
DI 10.1002/(SICI)1521-4141(199812)28:12<4207::AID-IMMU4207>3.0.CO;2-R
PG 6
WC Immunology
SC Immunology
GA 148QC
UT WOS:000077542500032
PM 9862357
OA gold
DA 2018-01-05
ER

PT J
AU Hayakawa, T
   Kawamura, M
   Okamoto, M
   Baba, M
   Niikawa, T
   Takehara, S
   Serizawa, T
   Akashi, M
AF Hayakawa, T
   Kawamura, M
   Okamoto, M
   Baba, M
   Niikawa, T
   Takehara, S
   Serizawa, T
   Akashi, M
TI Concanavalin A-immobilized polystyrene nanospheres capture HIV-1 virions
   and gp120: Potential approach towards prevention of viral transmission
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE AIDS; lectin; glycoprotein; antiviral
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HYDROPHOBIC BACKBONE; HYDROPHILIC
   BRANCHES; GRAFT-COPOLYMERS; HIGHLY POTENT; REPLICATION; GLYCOPROTEIN;
   TYPE-1; MICROSPHERES; INHIBITORS
AB To establish an effective tool for the prevention of HIV-1 transmission, lectin-immobilized polystyrene nanospheres were synthesized and examined for their HIV-1 capture activity. When concanavalin A (Con A) was immobilized on the surface of polystyrene nanospheres (400 nm in diameter) with poly(methacrylic acid) branches and incubated with HIV-1 suspension at room temperature for 60 min, the nanospheres (Con A-NSs) achieved a >3.3 log and a 2.2 log reduction of viral infectivity in HIV-1 (III, strain) suspension at a concentration of 2 and 0.5 mg/ml, respectively. Meanwhile, Con A-free nanospheres, which were not immobilized with Con A, achieved only a 0.29 log reduction at 0.5 mg/ml. Con A-NSs (2 mg/ml) could also reduce the gp120 level of ill, and HE strains to <7.1% and 5.5% of each control, respectively. The combination of Con A-NS treatment followed by filtration with a microporous membrane efficiently removed virion-free gp120 as well as infectious viral particles from HIV-1 suspension. Electron microscopic examination demonstrated that HIV-1 virions were trapped on the surface of Con ANSs. Thus, Con A-NSs can capture HIV-1 virions and gp120 with high affinity, and may have potential as an effective tool for the prevention of HIV-1 transmission. (C) 1998 Wiley-Liss, Inc.
C1 Kagoshima Univ, Fac Med, Ctr Chron Viral Dis, Div Human Retroviruses, Kagoshima 890, Japan.
   Kagoshima Univ, Fac Engn, Dept Appl Chem & Chem Engn, Kagoshima, Japan.
RP Baba, M (reprint author), Kagoshima Univ, Fac Med, Ctr Chron Viral Dis, Div Human Retroviruses, 8-35-1 Sakuragaoka, Kagoshima 890, Japan.
EM baba@med3.kufm.kagoshima-u.ac.jp
RI Baba, Masanori/G-3867-2011
CR Akashi M, 1998, BIOCONJUGATE CHEM, V9, P50, DOI 10.1021/bc970045y                                                               
   BABA M, 1990, ANTIMICROB AGENTS CH, V34, P134, DOI 10.1128/AAC.34.1.134                                                            
   BABA M, 1994, ANTIMICROB AGENTS CH, V38, P688, DOI 10.1128/AAC.38.4.688                                                            
   BALZARINI J, 1991, ANTIMICROB AGENTS CH, V35, P410, DOI 10.1128/AAC.35.3.410                                                            
   BENTO CA, 1997, AGENTS ACTIONS, V38, P48
   Chackerian B, 1997, J VIROL, V71, P3932
   Chen MQ, 1996, J POLYM SCI POL CHEM, V34, P2213
   Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145
   EVANS LA, 1993, HIV MOL ORG PATHOGEN, P29
   HAMAMOTO Y, 1989, VOX SANG, V56, P230, DOI 10.1111/j.1423-0410.1989.tb02034.x                                              
   LIFSON J, 1986, J EXP MED, V164, P2101, DOI 10.1084/jem.164.6.2101
   MEYLAN PRA, 1994, ANTIMICROB AGENTS CH, V38, P2910, DOI 10.1128/AAC.38.12.2910                                                          
   NEYTS J, 1995, J ACQ IMMUN DEF SYND, V10, P8
   Nishida A, 1996, FOOD CHEM TOXICOL, V34, P701, DOI 10.1016/0278-6915(96)00037-3
   PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0
   PERNO CF, 1988, J EXP MED, V168, P1111, DOI 10.1084/jem.168.3.1111
   POTTS M, 1994, AM J PUBLIC HEALTH, V84, P890, DOI 10.2105/AJPH.84.6.890                                                           
   RIZA M, 1995, J POLYM SCI POL CHEM, V33, P1219, DOI 10.1002/pola.1995.080330804                                                     
   Sakuma S, 1997, INT J PHARM, V149, P93, DOI 10.1016/S0378-5173(96)04861-2
   SCHOLS D, 1990, VIROLOGY, V175, P556, DOI 10.1016/0042-6822(90)90440-3
   TIEGS G, 1992, J CLIN INVEST, V90, P196, DOI 10.1172/JCI115836                                                               
   WEIR SS, 1994, AM J PUBLIC HEALTH, V84, P910, DOI 10.2105/AJPH.84.6.910                                                           
NR 22
TC 43
Z9 43
U1 0
U2 2
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0146-6615
J9 J MED VIROL
JI J. Med. Virol.
PD DEC
PY 1998
VL 56
IS 4
BP 327
EP 331
DI 10.1002/(SICI)1096-9071(199812)56:4<327::AID-JMV7>3.0.CO;2-A
PG 5
WC Virology
SC Virology
GA 136AA
UT WOS:000076834200007
PM 9829637
DA 2018-01-05
ER

PT J
AU Boulme, F
   Freund, F
   Moreau, S
   Nielsen, PE
   Gryaznov, S
   Toulme, JJ
   Litvak, S
AF Boulme, F
   Freund, F
   Moreau, S
   Nielsen, PE
   Gryaznov, S
   Toulme, JJ
   Litvak, S
TI Modified (PNA, 2 '-O-methyl and phosphoramidate) anti-TAR antisense
   oligonucleotides as strong and specific inhibitors of in vitro HIV-1
   reverse transcription
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; PEPTIDE NUCLEIC-ACID; RNASE-H; IN-VITRO;
   GENE-EXPRESSION; INFECTED-CELLS; PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES;
   NUCLEOTIDE-SEQUENCE; AIDS VIRUS; DNA
AB Natural beta-phosphodiester (16)mer and (15)mer antisense oligonucleotides targeted against the HIV-1 and HIV-2 TAR RNAs respectively were previously described as sequence-specific inhibitors of in vitro retroviral reverse transcription. In this work, we tested chemically modified oligonucleotide analogues: alpha-phosphodiester, phosphorothioate, methylphosphonate, peptide nucleic acid or PNA, 2'-O-methyl and (N3'-P5') phosphoramidate versions of the 16mer anti-TAR oligonucleotide. PNA, 2'-O-methyl and (N3'-P5') phosphoramidate oligomers showed a strong inhibitory effect compared with the unmodified 16mer, with reverse transcription inhibition (IC50) values in the nanomolar range. The inhibition was sequence-specific, as scrambled and mismatched control oligonucleotides were not able to inhibit cDNA synthesis. No direct binding of the 2'-O-methyl, PNA or (N3'-P5') phosphoramidate anti-TAR oligonucleotides to the HIV-1 reverse transcriptase was observed. The higher T-m obtained with 2'-O-methyl, (N3'-P5') phosphoramidate and PNA molecules concerning the annealing with the stem-loop structure of the TAR RNA, in comparison with the P-phosphodiester oligonucleotides, is correlated with their high inhibitory effect on reverse transcription.
C1 Univ Bordeaux 2, CNRS, EP630, F-33077 Bordeaux, France.
   Univ Bordeaux 2, INSERM, U386, F-33076 Bordeaux, France.
   Panum Inst, Dept Biochem B, IMBG, Copenhagen, Denmark.
   Geron Corp, Menlo Pk, CA USA.
RP Litvak, S (reprint author), Univ Bordeaux 2, CNRS, EP630, 1 Rue Camille St Saens, F-33077 Bordeaux, France.
EM simon.litvak@ibgc.u-bordeaux2.fr
OI Toulme, Jean-jacques/0000-0002-8432-5034
CR ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555
   AGRAWAL S, 1990, P NATL ACAD SCI USA, V87, P1401, DOI 10.1073/pnas.87.4.1401
   Agrawal S, 1997, P NATL ACAD SCI USA, V94, P2620, DOI 10.1073/pnas.94.6.2620
   AKTHAR S, 1991, LIFE SCI, V24, P1793
   Alama A, 1997, PHARMACOL RES, V36, P171, DOI 10.1006/phrs.1997.0227
   ALIZON M, 1986, CELL, V46, P63, DOI 10.1016/0092-8674(86)90860-3
   ALMARSSON O, 1993, P NATL ACAD SCI USA, V90, P9542, DOI 10.1073/pnas.90.20.9542
   Anderson KP, 1996, ANTIMICROB AGENTS CH, V40, P2004
   ARTS EJ, 1998, PROG NUCL ACID RES M, V58, P335
   BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041
   Bennett CF, 1998, BIOCHEM PHARMACOL, V55, P9, DOI 10.1016/S0006-2952(97)00214-1
   Bohjanen PR, 1996, NUCLEIC ACIDS RES, V24, P3733, DOI 10.1093/nar/24.19.3733
   BOIZIAU C, 1991, NUCLEIC ACIDS RES, V19, P1113, DOI 10.1093/nar/19.5.1113
   Boiziau C, 1996, ANTISENSE NUCLEIC A, V6, P103, DOI 10.1089/oli.1.1996.6.103
   BOIZIAU C, 1992, P NATL ACAD SCI USA, V89, P768, DOI 10.1073/pnas.89.2.768
   BOIZIAU C, 1994, FEBS LETT, V340, P236, DOI 10.1016/0014-5793(94)80145-2
   BOIZIAU C, 1995, NUCLEIC ACIDS RES, V23, P188
   BONHAM MA, 1995, NUCLEIC ACIDS RES, V23, P1197, DOI 10.1093/nar/23.7.1197
   BORDIER B, 1995, P NATL ACAD SCI USA, V92, P9383, DOI 10.1073/pnas.92.20.9383
   BORDIER B, 1992, NUCLEIC ACIDS RES, V20, P5999, DOI 10.1093/nar/20.22.5999                                                          
   Boulme F, 1997, BBA-GENE STRUCT EXPR, V1351, P249, DOI 10.1016/S0167-4781(97)00026-2                                                   
   CHRISTENSEN L, 1995, J PEPT SCI, V1, P175, DOI DOI 10.1002/PSC.310010304
   Crooke ST, 1996, ANNU REV PHARMACOL, V36, P107, DOI 10.1146/annurev.pa.36.040196.000543                                             
   Das AT, 1997, J VIROL, V71, P2346
   DEMICHELIS M, 1994, J ARCHIT EDUC, V48, P131, DOI 10.1080/10464883.1994.10734633                                                  
   DIBHAJJ F, 1993, PROTEIN SCI, V2, P231
   Eckardt S, 1997, BIOCHEMISTRY-US, V36, P12711, DOI 10.1021/bi9707234
   ECKER DJ, 1992, SCIENCE, V257, P985
   Eder P S, 1991, Antisense Res Dev, V1, P141
   ElDiraniDiab R, 1997, ANTIMICROB AGENTS CH, V41, P2141
   GAGNOR C, 1989, NUCLEIC ACIDS RES, V17, P5107, DOI 10.1093/nar/17.13.5107                                                          
   GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001
   Ghosh M K, 1992, Antisense Res Dev, V2, P111
   GILES RV, 1993, ANTI-CANCER DRUG DES, V8, P33
   Giovannangeli C, 1996, J MOL BIOL, V261, P386, DOI 10.1006/jmbi.1996.0471
   Gryaznov S, 1996, NUCLEIC ACIDS RES, V24, P1508, DOI 10.1093/nar/24.8.1508
   GRYAZNOV S, 1994, J AM CHEM SOC, V116, P3143, DOI 10.1021/ja00086a062
   Harrich D, 1996, J VIROL, V70, P4017
   Heidenreich O, 1997, NUCLEIC ACIDS RES, V25, P776, DOI 10.1093/nar/25.4.776
   Helene Claude, 1997, Annales Pharmaceutiques Francaises, V55, P95
   HJALT T, 1992, NUCLEIC ACIDS RES, V20, P6723, DOI 10.1093/nar/20.24.6723
   HOMANN M, 1993, J MOL BIOL, V233, P7, DOI 10.1006/jmbi.1993.1480
   INOUE H, 1987, NUCLEIC ACIDS RES, V15, P6131, DOI 10.1093/nar/15.15.6131
   Knudsen H, 1997, ANTI-CANCER DRUG, V8, P113, DOI 10.1097/00001813-199702000-00002                                                
   Koppelhus U, 1997, NUCLEIC ACIDS RES, V25, P2167, DOI 10.1093/nar/25.11.2167
   LAMOND AI, 1993, FEBS LETT, V325, P123, DOI 10.1016/0014-5793(93)81427-2
   Leeds JM, 1997, DRUG METAB DISPOS, V25, P921
   LIMA WF, 1992, BIOCHEMISTRY-US, V31, P12055, DOI 10.1021/bi00163a013
   LISZIEWICZ J, 1993, P NATL ACAD SCI USA, V90, P3860, DOI 10.1073/pnas.90.9.3860
   Mak J, 1997, J VIROL, V71, P8087
   MATSUKURA M, 1989, P NATL ACAD SCI USA, V86, P4244, DOI 10.1073/pnas.86.11.4244
   Matteucci M, 1997, CIBA F SYMP, V209, P5
   MAURY G, 1993, BIOCHIM BIOPHYS ACTA, V1216, P1, DOI 10.1016/0167-4781(93)90030-H
   McBride MS, 1996, J VIROL, V70, P2963
   McBride MS, 1997, J VIROL, V71, P4544
   MILLER PS, 1986, BIOCHEMISTRY-US, V25, P5092, DOI 10.1021/bi00366a017
   MORVAN F, 1993, J MED CHEM, V36, P280, DOI 10.1021/jm00054a013                                                             
   NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210
   PORTMAN DS, 1994, EMBO J, V13, P213
   QUARTIN RS, 1989, NUCLEIC ACIDS RES, V17, P7253, DOI 10.1093/nar/17.18.7253
   Rigl CT, 1997, BIOCHEMISTRY-US, V36, P650, DOI 10.1021/bi961980w
   RITTNER K, 1993, NUCLEIC ACIDS RES, V21, P1381, DOI 10.1093/nar/21.6.1381
   ROY S, 1990, J VIROL, V64, P1402
   SALLAFRANQUEANDREOLA ML, 1989, EUR J BIOCHEM, V184, P367, DOI 10.1111/j.1432-1033.1989.tb15028.x                                              
   Skorski T, 1997, P NATL ACAD SCI USA, V94, P3966, DOI 10.1073/pnas.94.8.3966
   Stein CA, 1996, CHEM BIOL, V3, P319, DOI 10.1016/S1074-5521(96)90113-1                                                   
   Toulme JJ, 1996, BIOCHIMIE, V78, P663, DOI 10.1016/S0300-9084(96)80012-5
   Uhlmann E, 1996, ANGEW CHEM INT EDIT, V35, P2632, DOI 10.1002/anie.199626321                                                          
   VICKERS T, 1991, NUCLEIC ACIDS RES, V19, P3359, DOI 10.1093/nar/19.12.3359
   WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4
NR 70
TC 50
Z9 51
U1 2
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD DEC 1
PY 1998
VL 26
IS 23
BP 5492
EP 5500
DI 10.1093/nar/26.23.5492
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 147WE
UT WOS:000077487400035
PM 9826777
OA gold
DA 2018-01-05
ER

PT J
AU Venkatachalam, TK
   Tai, HL
   Vig, R
   Chen, CL
   Jan, ST
   Uckun, FM
AF Venkatachalam, TK
   Tai, HL
   Vig, R
   Chen, CL
   Jan, ST
   Uckun, FM
TI Enhancing effects of a mono-bromo substitution at the para position of
   the phenyl moiety on the metabolism and anti-HIV activity of D4T-phenyl
   methoxyalaninyl phosphate derivatives
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
ID POKEWEED ANTIVIRAL PROTEIN; PHOSPHORAMIDATE DERIVATIVES; EFFICACY;
   POTENT; CELLS; D4T; AZT
AB d4T-5'-[p-Bromophenyl methoxyalaninyl phosphate] (d4T-pBPMAP), a novel phenyl phosphate derivative of 2',3'-didehydro-2',3'-dideoxythymidine (d4T) that has an enhanced ability to undergo hydrolysis due to the electron withdrawing properties of its single bromo substituent at the para-position of the phenyl moiety, was found to yield substantially more of the key metabolite alaninyl d4T monophosphate (A-d4T-MP) than the unsubstituted d4T-5'-phenyl methoxyalaninyl phosphate or para-methoxy substituted d4T-5'-phenyl methoxydaninyl phosphate. d4T-pBPMAP was tested for its anti-HIV-1 activity in peripheral blood mononuclear cells (PBMNC) and thymidine kinase (TK)-deficient CEM T-cells. d4T-pBPMAP was 12.6-fold more potent than the parent compound d4T in inhibiting p24 production (IC50 values: 44 nM vs 556 nM) and 41.3-fold more potent than d4T in inhibiting the reverse transcriptase (RT) activity (IC50 values: 57 nM vs 2355 nM) in HIV-1-infected TK-deficient CEM cells. Similarly, d4T-pBPMAP was more potent than the unsubstituted or paramethoxy substituted phenyl methoxyalaninyl phosphate derivatives of d4T. d4T-pBPMAP did not exhibit any detectable cytotoxicity to PBMNC or CEM cells at concentrations as high as 10,000 nM. Notably, d4T-pBPMAP was capable of inhibiting the replication of a zidovudine (ZDV/AZT)-resistant HIV-1 strain as well as HIV-2 in PBMNC at nanomolar concentrations. To our knowledge, this is the first demonstration that the potency of the d4T-aryl-phosphate derivatives can be substantially enhanced by introducing a single para-bromo substituent in the aryl moiety. (C) 1998 Published by Elsevier Science Ltd. All rights reserved.
C1 Hughes Inst, Drug Discovery Program, Dept Chem, Roseville, MN 55113 USA.
   Hughes Inst, Drug Discovery Program, Dept Virol, Roseville, MN 55113 USA.
   Hughes Inst, Drug Discovery Program, Dept Mol Pharmacol, Roseville, MN 55113 USA.
RP Uckun, FM (reprint author), Hughes Inst, Drug Discovery Program, Dept Chem, Roseville, MN 55113 USA.
CR BALZARINI J, 1989, J BIOL CHEM, V264, P6127
   ERICE A, 1993, ANTIMICROB AGENTS CH, V37, P835, DOI 10.1128/AAC.37.4.835                                                            
   FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333
   HAO Z, 1988, MOL PHARMACOL, V34, P431
   JAN ST, 1998, IN PRESS ANTIVIRAL C
   MANSURI MM, 1989, J MED CHEM, V32, P461, DOI 10.1021/jm00122a029
   MCGUIGAN C, 1992, ANTIVIR RES, V17, P311, DOI 10.1016/0166-3542(92)90026-2
   McGuigan C, 1996, BIOORG MED CHEM LETT, V6, P1183, DOI 10.1016/0960-894X(96)00195-3                                                    
   MCGUIGAN C, 1993, J MED CHEM, V36, P1048, DOI 10.1021/jm00060a013
   McGuigan C, 1996, J MED CHEM, V39, P1748, DOI 10.1021/jm950605j
   McIntee EJ, 1997, J MED CHEM, V40, P3323, DOI 10.1021/jm960694f
   Uckun FM, 1998, ANTIMICROB AGENTS CH, V42, P383
   ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0
NR 13
TC 41
Z9 41
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD NOV 17
PY 1998
VL 8
IS 22
BP 3121
EP 3126
DI 10.1016/S0960-894X(98)00547-2
PG 6
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 155HW
UT WOS:000077941800004
PM 9873688
DA 2018-01-05
ER

PT J
AU McCord, M
   Stahl, SJ
   Mueser, TC
   Hyde, CC
   Vora, AC
   Grandgenett, DP
AF McCord, M
   Stahl, SJ
   Mueser, TC
   Hyde, CC
   Vora, AC
   Grandgenett, DP
TI Purification of recombinant Rous sarcoma virus integrase possessing
   physical and catalytic properties similar to virion-derived integrase
SO PROTEIN EXPRESSION AND PURIFICATION
LA English
DT Article
ID MURINE LEUKEMIA-VIRUS; VIRAL-DNA ENDS; IN-VITRO; RETROVIRAL DNA;
   CONCERTED INTEGRATION; HIV-1 INTEGRASE; BINDING PROPERTIES; TYPE-1
   INTEGRASE; PROTEIN; INVITRO
AB Recombinant Rous sarcoma virus integrase cloned from the Prague A (PrA) virus strain was expressed in Escherichia coli. Here we report the detailed purification procedure resulting in an apparently homogeneous integrase. Recombinant PrA integrase was compared at both the protein structural and the catalytic levels to avian myeloblastosis virus integrase purified from virions. Both proteins exist minimally in a dimeric state at low nanomolar concentrations as analyzed by glycerol gradient sedimentation and protein crosslinking studies, Likewise, both proteins have similar specific activities for full-site (concerted integration reaction) and half-site strand transfer activities using linear 480-bp retrovirus-like donor substrates that contain wild-type or mutant termini, They respond similarly to high NaCl concentrations (similar to 350 mM) as well as aprotic solvents for efficient full-site strand transfer. The data suggest that recombinant integrase proteins with physical and catalytic properties similar to the virion counterpart can be purified using these techniques and will faithfully and efficiently promote the full-site integration reaction in vitro, (C) 1998 Academic Press.
C1 St Louis Univ, Hlth Sci Ctr, Inst Mol Virol, St Louis, MO 63110 USA.
   NIAMSD, Bethesda, MD 20892 USA.
RP Grandgenett, DP (reprint author), St Louis Univ, Hlth Sci Ctr, Inst Mol Virol, St Louis, MO 63110 USA.
EM Grandgdp@SLU.EDU
FU NCI NIH HHS [CA16312]
CR Aiyar A, 1996, J VIROL, V70, P3571
   ANDRAKE MD, 1995, J BIOL CHEM, V270, P29299, DOI 10.1074/jbc.270.49.29299                                                        
   Asante-Appiah E, 1998, PROTEIN EXPRES PURIF, V12, P105, DOI 10.1006/prep.1997.0818
   BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X                                                    
   BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556
   BUKRINSKY MI, 1993, P NATL ACAD SCI USA, V90, P6125, DOI 10.1073/pnas.90.13.6125
   BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144
   BUSHMAN FD, 1994, J VIROL, V68, P2215
   Cai ML, 1997, NAT STRUCT BIOL, V4, P567, DOI 10.1038/nsb0797-567
   CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y                                                    
   FARNET CM, 1990, P NATL ACAD SCI USA, V87, P4164, DOI 10.1073/pnas.87.11.4164
   Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7                                                   
   GERARD GF, 1980, MOL BIOL RNA TUMOR V, P345
   GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7
   GOFF SP, 1992, ANNU REV GENET, V26, P527
   GRANDGENETT DP, 1978, VIROLOGY, V89, P119, DOI 10.1016/0042-6822(78)90046-6
   Hazuda DJ, 1997, J VIROL, V71, P7005
   JONES KS, 1992, J BIOL CHEM, V267, P16037
   KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.biochem.63.1.133
   KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U                                                    
   KATZMAN M, 1989, J VIROL, V63, P5319
   KNAUS RJ, 1984, BIOCHEMISTRY-US, V23, P350, DOI 10.1021/bi00297a026
   KUKOLJ G, 1995, GENE DEV, V9, P2556, DOI 10.1101/gad.9.20.2556
   LEE MS, 1994, P NATL ACAD SCI USA, V91, P9823, DOI 10.1073/pnas.91.21.9823
   Lee SP, 1997, BIOCHEMISTRY-US, V36, P173, DOI 10.1021/bi961849o
   LEE YMH, 1991, MOL CELL BIOL, V11, P1419, DOI 10.1128/MCB.11.3.1419                                                           
   Maher JF, 1996, P NATL ACAD SCI USA, V93, P6716, DOI 10.1073/pnas.93.13.6716
   MARCZINOVITIS I, 1992, VIRUS GENES, V3, P301
   MUMM SR, 1991, J VIROL, V65, P1160
   PANET A, 1987, J VIROL, V61, P1756
   Pemberton IK, 1996, J BIOL CHEM, V271, P1498, DOI 10.1074/jbc.271.3.1498                                                          
   SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561
   SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5                                                    
   Singh IR, 1997, P NATL ACAD SCI USA, V94, P1304, DOI 10.1073/pnas.94.4.1304                                                          
   TERRY R, 1988, J VIROL, V62, P2358
   VINK C, 1993, TRENDS GENET, V9, P4333
   VORA AC, 1995, J VIROL, V69, P7483
   Vora AC, 1997, J BIOL CHEM, V272, P23938, DOI 10.1074/jbc.272.38.23938
   VORA AC, 1994, NUCLEIC ACIDS RES, V22, P4454, DOI 10.1093/nar/22.21.4454
   Zheng RL, 1996, P NATL ACAD SCI USA, V93, P13659, DOI 10.1073/pnas.93.24.13659                                                        
NR 40
TC 15
Z9 15
U1 0
U2 0
PU ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1046-5928
J9 PROTEIN EXPRES PURIF
JI Protein Expr. Purif.
PD NOV
PY 1998
VL 14
IS 2
BP 167
EP 177
DI 10.1006/prep.1998.0954
PG 11
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 133RD
UT WOS:000076698800003
PM 9790878
DA 2018-01-05
ER

PT J
AU Kervinen, J
   Lubkowski, J
   Zdanov, A
   Bhatt, D
   Dunn, BM
   Hui, KY
   Powell, DJ
   Kay, J
   Wlodawer, A
   Gustchina, A
AF Kervinen, J
   Lubkowski, J
   Zdanov, A
   Bhatt, D
   Dunn, BM
   Hui, KY
   Powell, DJ
   Kay, J
   Wlodawer, A
   Gustchina, A
TI Toward a universal inhibitor of retroviral proteases: Comparative
   analysis of the interactions of LP-130 complexed with proteases from
   HIV-I, FIV, and EIAV
SO PROTEIN SCIENCE
LA English
DT Article
DE drug design; drug resistance; HIV; proteases; retroviruses
ID FELINE IMMUNODEFICIENCY VIRUS; X-RAY-DIFFRACTION; PROTEINASE; BINDING;
   SUSCEPTIBILITY; SENSITIVITY; RESISTANT; SEQUENCES; VARIANTS; PEPTIDES
AB One of the major problems encountered in antiviral therapy against AIDS is the emergence of viral variants that exhibit drug resistance. The sequences of proteases (PRs) from related retroviruses sometimes include, at structurally equivalent positions, amino acids identical to those found in drug-resistant forms of HIV-1 PR. The statine-based inhibitor LP-130 was found to be a universal, nanomolar-range inhibitor against all tested retroviral PRs. We solved the crystal structures of LP-130 in complex with retroviral PRs from HIV-1. feline immunodeficiency virus, and equine infectious anemia virus and compared the structures to determine the differences in the interactions between the inhibitor and the active-site residues of the enzymes. This comparison shows an extraordinary similarity in the binding modes of the inhibitor molecules. The only exceptions are the different conformations of naphthylalanine side chains at the P3/P3' positions, which might be responsible for the variation in the K-i, values. These findings indicate that successful inhibition of different retroviral PRs by LP-130 is achieved because this compound can be accommodated without serious conformational differences, despite the variations in the type of residues forming the active site region. Although strong, specific interactions between the ligand and the enzyme might improve the potency of the inhibitor, the absence of such interactions seems to favor the universality of the compound. Hence, the ability of potential anti-AIDS drugs to inhibit multiple retroviral PRs might indicate their likelihood of not eliciting drug resistance. These studies may also contribute to the development of a small-animal model for preclinical testing of antiviral compounds.
C1 NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Macromol Struct Lab, Frederick, MD 21702 USA.
   Univ Florida, J Hillis Miller Hlth Ctr, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA.
   Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA.
   Univ Wales Coll Cardiff, Sch Mol & Med Biosci, Cardiff CF1 3US, S Glam, Wales.
RP Gustchina, A (reprint author), NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Macromol Struct Lab, Frederick, MD 21702 USA.
EM alla@orion.ncifcrf.gov
FU NIGMS NIH HHS [P01 GM48870]; NIAID NIH HHS [AI28571]
CR Brunger A. T., 1992, X PLOR VERSION 3 1 S
   CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0
   DUNN BM, 1994, METHOD ENZYMOL, V241, P254
   ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122
   Erickson JW, 1996, ANNU REV PHARMACOL, V36, P545, DOI 10.1146/annurev.pa.36.040196.002553                                             
   GARRY RF, 1995, RETROVIRIDAE, V4, P491
   GULNIK SV, 1995, BIOCHEMISTRY-US, V34, P9282, DOI 10.1021/bi00029a002
   Gustchina A, 1996, PROTEIN SCI, V5, P1453, DOI 10.1002/pro.5560050802                                                          
   GUSTCHINA A, 1991, PROTEINS, V10, P325, DOI 10.1002/prot.340100406
   HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252
   HUI KY, 1993, FEBS LETT, V327, P355, DOI 10.1016/0014-5793(93)81020-Z
   JONES TA, 1985, METHOD ENZYMOL, V115, P157
   KAPLAN AH, 1994, P NATL ACAD SCI USA, V91, P5597, DOI 10.1073/pnas.91.12.5597
   Kervinen J, 1996, PROTEIN PEPTIDE LETT, V3, P399
   Laco GS, 1997, BIOCHEMISTRY-US, V36, P10696, DOI 10.1021/bi9707436
   LangeSavage G, 1997, EUR J BIOCHEM, V248, P313, DOI 10.1111/j.1432-1033.1997.00313.x
   Lee T, 1998, P NATL ACAD SCI USA, V95, P939, DOI 10.1073/pnas.95.3.939                                                           
   McCune JM, 1997, SCIENCE, V278, P2141, DOI 10.1126/science.278.5346.2141
   MULICHAK AM, 1993, J BIOL CHEM, V268, P13103
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   PATICK AK, 1995, J VIROL, V69, P2148
   PAYNE SL, 1994, J GEN VIROL, V75, P425, DOI 10.1099/0022-1317-75-2-425
   Powell DJ, 1997, EUR J BIOCHEM, V246, P258
   RATNER L, 1987, AIDS RES HUM RETROV, V3, P57, DOI 10.1089/aid.1987.3.57
   Roberts NA, 1998, AIDS, V12, P453, DOI 10.1097/00002030-199805000-00005
   ROMINES KR, 1995, J MED CHEM, V38, P1884, DOI 10.1021/jm00011a008
   Rose RB, 1998, BIOCHEMISTRY-US, V37, P2607, DOI 10.1021/bi9716074
   Rosenberg N., 1997, P475
   SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7
   Schinazi R. F., 1997, International Antiviral News, V5, P129
   SLEE DH, 1995, J AM CHEM SOC, V117, P11867, DOI 10.1021/ja00153a008                                                             
   Vandamme AM, 1998, ANTIVIR CHEM CHEMOTH, V9, P187, DOI 10.1177/095632029800900301                                                      
   Willett BJ, 1997, IMMUNOL TODAY, V18, P182, DOI 10.1016/S0167-5699(97)84665-8
   Wilson SI, 1997, BBA-PROTEIN STRUCT M, V1339, P113, DOI 10.1016/S0167-4838(96)00224-5
   WINSLOW DL, 1995, AIDS RES HUM RETROV, V11, P107, DOI 10.1089/aid.1995.11.107
   WLODAWER A, 1995, NAT STRUCT BIOL, V2, P480, DOI 10.1038/nsb0695-480
   Wlodawer A, 1998, ANNU REV BIOPH BIOM, V27, P249, DOI 10.1146/annurev.biophys.27.1.249                                                
   Wu J, 1998, BIOCHEMISTRY-US, V37, P4518, DOI 10.1021/bi972183g
   Zhang L, 1997, PROTEIN PEPTIDE LETT, V4, P225
NR 39
TC 30
Z9 31
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 40 WEST 20TH STREET, NEW YORK, NY 10011-4211 USA
SN 0961-8368
J9 PROTEIN SCI
JI Protein Sci.
PD NOV
PY 1998
VL 7
IS 11
BP 2314
EP 2323
DI 10.1002/pro.5560071108                                                  
          
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 134WE
UT WOS:000076766100008
PM 9827997
OA gold
DA 2018-01-05
ER

PT J
AU Barnes, DA
   Bonnin, A
   Huang, JX
   Gousset, L
   Wu, J
   Gut, J
   Doyle, P
   Dubremetz, JF
   Ward, H
   Petersen, C
AF Barnes, DA
   Bonnin, A
   Huang, JX
   Gousset, L
   Wu, J
   Gut, J
   Doyle, P
   Dubremetz, JF
   Ward, H
   Petersen, C
TI A novel multi-domain mucin-like glycoprotein of Cryptosporidium parvum
   mediates invasion
SO MOLECULAR AND BIOCHEMICAL PARASITOLOGY
LA English
DT Article
DE Cryptosporidium; sporozoite; merozoite; surface antigen; invasion; GP900
ID HYPERIMMUNE BOVINE COLOSTRUM; HUMAN-IMMUNODEFICIENCY-VIRUS;
   PLASMODIUM-FALCIPARUM; MONOCLONAL-ANTIBODIES; ENDOTHELIAL LIGAND;
   SURFACE-ANTIGEN; NEONATAL MICE; IN-VITRO; SPOROZOITES; CELLS
AB Cryptosporidium parvum is a protozoan parasite which produces self-limited disease in immunocompetent hosts and devastating, persistent diarrhea in immunocompromised individuals. There is no effective treatment for cryptosporidiosis and little is known about the basic biology of the organism. Cloning and sequence analysis of the gene encoding GP900, a previously identified >900 kDa glycoprotein, predicts a mucin-like glycoprotein composed of distal cysteine-rich domains separated by polythreonine domains and a large membrane proximal N-glycosylated core region. A trinucleotide repeat composed predominantly of the triplet ACA encodes the threonine domains. GP900 is stored in micronemes prior to appearance on the surface of invasive forms. The concentration of native GP900 which inhibits 50% (IC50) of invasion in vitro is low picomolar; the IC,, for a recombinant cysteine rich-domain is low nanomolar. These observations indicate that GP900 is a parasite ligand for a host receptor involved in attachment/invasion and suggest that immunotherapy or chemotherapy directed against GP900 may be feasible. (C) 1998 Elsevier Science B.V. All rights reserved.
C1 Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA.
   Hop Bocage, Lab Parasitol Mycol, Dijon, France.
   INSERM, U42, F-59650 Villeneuve Dascq, France.
   Tufts Univ, New England Med Ctr, Sch Med, Boston, MA 02111 USA.
RP Petersen, C (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Room 405,Bldg 30, San Francisco, CA 94110 USA.
EM cparvum@itsa.ucsf.edu
FU NIAID NIH HHS [AI33256, AI33817, AI35123]
CR ADAMS JH, 1990, CELL, V63, P141, DOI 10.1016/0092-8674(90)90295-P
   AKIYAMA SK, 1995, CANCER METAST REV, V14, P173, DOI 10.1007/BF00690290
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389                                                          
   ARROWOOD MJ, 1989, INFECT IMMUN, V57, P2283
   BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3
   BERNFIELD M, 1992, ANN REV CELL BIOL, V8, P367
   BJORNEBY JM, 1991, INFECT IMMUN, V59, P1172
   BONNIN A, 1991, INFECT IMMUN, V59, P1703
   BROWN JC, 1994, MATRIX BIOL, V14, P287, DOI 10.1016/0945-053X(94)90194-5
   BUTENHOF KJ, 1993, BIOCHEMISTRY-US, V32, P2650, DOI 10.1021/bi00061a025
   Carraway M, 1997, INFECT IMMUN, V65, P3958
   CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7
   Colford JM, 1996, AM J EPIDEMIOL, V144, P807
   Coulson BS, 1997, P NATL ACAD SCI USA, V94, P5389, DOI 10.1073/pnas.94.10.5389
   DominguezJimenez C, 1996, CELL ADHES COMMUN, V4, P251, DOI 10.3109/15419069609010770
   DOWBENKO D, 1993, J BIOL CHEM, V268, P14399
   DOYLE PS, 1993, INFECT IMMUN, V61, P4079
   DUPONT HL, 1995, NEW ENGL J MED, V332, P855, DOI 10.1056/NEJM199503303321304
   FAYER R, 1990, INFECT IMMUN, V58, P2962
   FAYER R, 1989, J PARASITOL, V75, P151, DOI 10.2307/3282956
   FAYER R, 1989, J PARASITOL, V75, P393, DOI 10.2307/3282595
   Fayer R., 1997, CRYPTOSPORIDIUM CRYP
   GUM JR, 1994, J BIOL CHEM, V269, P2440
   GUT J, 1994, J EUKARYOT MICROBIOL, V41, pS42
   GUT J, 1991, J PROTOZOOL, V38, pS72
   Guyonnet Duperat Veronique, 1995, Biochemical Journal, V305, P211
   HARDING SE, 1989, ADV CARBOHYD CHEM BI, V47, P345
   HAUSER F, 1992, J BIOL CHEM, V267, P24620
   HOLDER AA, 1994, PARASITOLOGY, V108, pS5, DOI 10.1017/S0031182000075673                                                       
   HOLLINGDALE MR, 1984, J IMMUNOL, V132, P909
   JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3
   JOE A, 1994, J EUKARYOT MICROBIOL, V41, pS44
   KIM K, 1992, MOL BIOCHEM PARASIT, V50, P105, DOI 10.1016/0166-6851(92)90248-I
   KIM K, 1994, INFECT IMMUN, V62, P203
   LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G
   MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304
   MILLARD PS, 1994, JAMA-J AM MED ASSOC, V272, P1592, DOI 10.1001/jama.272.20.1592
   NORD J, 1990, AIDS, V4, P581, DOI 10.1097/00002030-199006000-00015
   NUSSENZWEIG V, 1985, CELL, V42, P401, DOI 10.1016/0092-8674(85)90093-5
   PERKINS ME, 1992, PARASITOL TODAY, V8, P28, DOI 10.1016/0169-4758(92)90308-O
   PETERSEN C, 1992, CLIN INFECT DIS, V15, P903, DOI 10.1093/clind/15.6.903                                                          
   PETERSEN C, 1989, MOL BIOCHEM PARASIT, V36, P61, DOI 10.1016/0166-6851(89)90200-4
   PETERSEN C, 1992, INFECT IMMUN, V60, P5132
   PETERSEN C, 1992, INFECT IMMUN, V60, P2343
   PETERSEN C, 1997, J EUKARYOTIC MIC NOV, pS89
   PETRY F, UNPUB CHARACTERIZATI
   POTOCNJAK P, 1980, J EXP MED, V151, P1504, DOI 10.1084/jem.151.6.1504                                                          
   REHG JE, 1987, INFECT IMMUN, V55, P2669
   RIGGS MW, 1989, J IMMUNOL, V143, P1340
   Riggs MW, 1997, J IMMUNOL, V158, P1787
   RUIZ RD, 1993, PARASITE IMMUNOL, V15, P121, DOI 10.1111/j.1365-3024.1993.tb00591.x
   SAMBROOK J, 1989, MOL CLONING LAB MANU, P942
   SCHOFIELD L, 1986, MOL BIOCHEM PARASIT, V18, P183, DOI 10.1016/0166-6851(86)90037-X
   SCHWARTZMAN JD, 1986, INFECT IMMUN, V51, P760
   STEINMETZ M, 1981, CELL, V24, P125, DOI 10.1016/0092-8674(81)90508-0
   SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1                                                    
   TZIPORI S, 1986, BRIT MED J, V293, P1276, DOI 10.1136/bmj.293.6557.1276                                                       
   UNGAR BLP, 1990, GASTROENTEROLOGY, V98, P486, DOI 10.1016/0016-5085(90)90842-O                                                    
   VANKLINKEN JW, 1995, AM J PHYSIOL, V269, pG614
   VOORHEES P, 1995, EMBO J, V14, P4961
   WARD H, 1998, ADV PARASIT, V40, P157
   WHITMIRE WM, 1988, INFECT IMMUN, V56, P2538
   ZU SX, 1992, PARASITOL TODAY, V8, P24, DOI 10.1016/0169-4758(92)90307-N
NR 63
TC 101
Z9 108
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-6851
EI 1872-9428
J9 MOL BIOCHEM PARASIT
JI Mol. Biochem. Parasitol.
PD OCT 30
PY 1998
VL 96
IS 1-2
BP 93
EP 110
DI 10.1016/S0166-6851(98)00119-4
PG 18
WC Biochemistry & Molecular Biology; Parasitology
SC Biochemistry & Molecular Biology; Parasitology
GA 143DR
UT WOS:000077240200009
PM 9851610
DA 2018-01-05
ER

PT J
AU Vo-Dinh, T
AF Vo-Dinh, T
TI Surface-enhanced Raman spectroscopy using metallic nanostructures
SO TRAC-TRENDS IN ANALYTICAL CHEMISTRY
LA English
DT Review
DE surface-enhanced Raman scattering; remote sensor; single molecule; near
   field; in situ analysis; biomedical diagnostics; human immunodeficiency
   virus
ID FLOW-INJECTION ANALYSIS; SILVER-COATED ALUMINA; P-AMINOBENZOIC ACID;
   SCATTERING SPECTROMETRY; ELECTROMAGNETIC THEORY; QUANTITATIVE DETECTION;
   CHARGE-TRANSFER; ISLAND FILMS; GOLD SOLS; PYRIDINE
AB This article provides an overview of the development and application of the surface-enhanced Raman scattering (SERS) techniques using metal-coated nanostructures on solid substrates, An introduction to theoretical principles of the SERS effect and the different SERS-active media is presented. The focus is on nanostructured solid substrates and their practical applications in chemical, environmental and biomedical areas. Specific examples of analytical techniques, instruments and sensors developed in the author's laboratory will be discussed to illustrate the usefulness and potential of the SERS techniques. (C) 1998 Elsevier Science B.V. All rights reserved.
C1 Oak Ridge Natl Lab, Div Life Sci, Adv Monitoring Dev Grp, Oak Ridge, TN 37831 USA.
RP Vo-Dinh, T (reprint author), Oak Ridge Natl Lab, Div Life Sci, Adv Monitoring Dev Grp, Oak Ridge, TN 37831 USA.
CR ADRIAN FJ, 1982, J CHEM PHYS, V77, P5302, DOI 10.1063/1.443800
   AHERN AM, 1987, ANAL CHEM, V59, P2816
   ALAK AM, 1989, ANAL CHEM, V61, P656, DOI 10.1021/ac00182a004
   ALAK AM, 1988, ANAL CHIM ACTA, V206, P333
   ALAK AM, 1987, ANAL CHEM, V59, P2149, DOI 10.1021/ac00144a030
   Alarie JP, 1996, POLYCYCL AROMAT COMP, V8, P45, DOI 10.1080/10406639608048333                                                       
   ALARIE JP, 1992, APPL SPECTROSC, V46, P1608, DOI 10.1366/0003702924926736                                                        
   ALBRECHT MG, 1977, J AM CHEM SOC, V99, P5215, DOI 10.1021/ja00457a071                                                             
   AROCA R, 1986, J RAMAN SPECTROSC, V17, P243, DOI 10.1002/jrs.1250170303
   BARBER PW, 1983, PHYS REV LETT, V50, P997, DOI 10.1103/PhysRevLett.50.997
   BARBER PW, 1983, PHYS REV B, V27, P725
   BEER KD, 1989, J ELECTROANAL CHEM, V258, P313, DOI 10.1016/0022-0728(89)85117-4                                                    
   BELLO JM, 1990, APPL SPECTROSC, V44, P63, DOI 10.1366/0003702904085877                                                        
   BELLO JM, 1989, ANAL CHEM, V61, P1779, DOI 10.1021/ac00190a600                                                             
   BELLO JM, 1989, APPL SPECTROSC, V43, P1325, DOI 10.1366/0003702894204326
   BELLO JM, 1992, SPECTROCHIM ACTA A, V48, P563, DOI 10.1016/0584-8539(92)80047-Z                                                    
   BELLO JM, 1990, ANAL CHEM, V62, P1349
   BERTHOD A, 1987, APPL SPECTROSC, V41, P1137, DOI 10.1366/0003702874447653
   BETZIG E, 1991, SCIENCE, V251, P1468, DOI 10.1126/science.251.5000.1468
   Bohren CF, 1983, ABSORPTION SCATTERIN
   BUNCICK MC, 1984, B AM PHYS SOC, V29, P129
   CARRABBA MM, 1987, ANAL CHEM, V59, P2559, DOI 10.1021/ac00148a006                                                             
   CHANG RK, 1984, CRC CR REV SOL STATE, V12, P1, DOI 10.1080/01611598408244065
   Chang R. K., 1982, SURFACE ENHANCED RAM
   COTTON TM, 1992, PHYSICAL METHODS CHE
   CREIGHTON JA, 1979, J CHEM SOC FARAD T 2, V75, P790, DOI 10.1039/f29797500790                                                            
   DECKERT V, 1998, IN PRESS ANAL CHEM
   EMORY SN, 1998, J PHYS CHEM B, V102, P49
   ENLOW PD, 1986, ANAL CHEM, V58, P1119, DOI 10.1021/ac00297a031
   FLEISCHMANN M, 1974, CHEM PHYS LETT, V26, P163, DOI 10.1016/0009-2614(74)85388-1                                                    
   FLEISCHMANN M, 1985, J ELECTROANAL CHEM, V182, P87, DOI 10.1016/0368-1874(85)85442-3                                                    
   FREEMAN RD, 1988, APPL SPECTROSC, V42, P456, DOI 10.1366/0003702884427997
   Furtak T. E., 1984, ADV LASER SPECTROSCO, V2, P175
   GARRELL RL, 1989, ANAL CHEM, V61, pA401, DOI 10.1021/ac00181a001                                                             
   GAUTNER E, 1985, ANAL CHEM, V57, P1658
   GERSTEN J, 1980, J CHEM PHYS, V73, P3023, DOI 10.1063/1.440560
   GERSTEN JI, 1980, J CHEM PHYS, V72, P5779, DOI 10.1063/1.439002                                                                
   GOLAB JT, 1988, J CHEM PHYS, V88, P7942, DOI 10.1063/1.454251                                                                
   GOUDONNET JP, 1982, CHEM PHYS LETT, V92, P197, DOI 10.1016/0009-2614(82)80105-X
   HALLER KL, 1989, J CHEM PHYS, V90, P1237, DOI 10.1063/1.456129                                                                
   HEARD SM, 1983, CHEM PHYS LETT, V95, P154, DOI 10.1016/0009-2614(83)85086-6                                                    
   HELMENSTINE A, 1993, J TOXICOL ENV HEALTH, V40, P195, DOI 10.1080/15287399309531787                                                       
   HELMENSTINE AM, 1993, VIB SPECTROSC, V4, P359, DOI 10.1016/0924-2031(93)80009-5                                                    
   HILDEBRANDT P, 1984, J PHYS CHEM-US, V88, P5935, DOI 10.1021/j150668a038
   Ibrahim A, 1996, J RAMAN SPECTROSC, V27, P887
   Isola NR, 1998, ANAL CHEM, V70, P1352, DOI 10.1021/ac970901z
   JEANMAIRE DL, 1977, J ELECTROANAL CHEM, V84, P1, DOI 10.1016/S0022-0728(77)80224-6
   JENNINGS C, 1984, ANAL CHEM, V56, P2033, DOI 10.1021/ac00276a012
   JIANG XD, 1987, CHEM PHYS LETT, V140, P95, DOI 10.1016/0009-2614(87)80423-2
   Kambhampati P, 1998, J CHEM PHYS, V108, P5013, DOI 10.1063/1.475909
   KERKER M, 1982, PHYS REV B, V26, P4052, DOI 10.1103/PhysRevB.26.4052
   KERKER M, 1984, ACCOUNTS CHEM RES, V17, P271, DOI 10.1021/ar00104a002                                                             
   KIM UJ, 1995, NUCLEIC ACIDS RES, V23, P1838, DOI 10.1093/nar/23.10.1838
   Kim UJ, 1996, P NATL ACAD SCI USA, V93, P6297, DOI 10.1073/pnas.93.13.6297
   KING DA, 1983, CHEM PHYSICS SOLID S
   Kneipp K, 1998, APPL SPECTROSC, V52, P175, DOI 10.1366/0003702981943275                                                        
   Kneipp K, 1997, PHYS REV LETT, V78, P1667, DOI 10.1103/PhysRevLett.78.1667
   Koglin E., 1983, Journal de Physique Colloque, V44, P487, DOI 10.1051/jphyscol:19831098
   LAOR U, 1981, CHEM PHYS LETT, V82, P566, DOI 10.1016/0009-2614(81)85442-5
   LASERNA JJ, 1990, ANAL CHIM ACTA, V237, P439, DOI 10.1016/S0003-2670(00)83948-3                                                   
   LEE PC, 1983, CHEM PHYS LETT, V99, P262, DOI 10.1016/0009-2614(83)87537-X
   LEE PC, 1982, J PHYS CHEM-US, V86, P3391, DOI 10.1021/j100214a025                                                             
   LI YS, 1992, APPL SPECTROSC, V46, P1354, DOI 10.1366/0003702924123674                                                        
   LIAO PF, 1982, OPT LETT, V7, P483, DOI 10.1364/OL.7.000483
   Liao P. F., 1982, SURFACE ENHANCED RAM, P379
   LOO BH, 1981, J CHEM PHYS, V75, P5955, DOI 10.1063/1.442050                                                                
   LOO BH, 1983, J PHYS CHEM-US, V87, P3003, DOI 10.1021/j100239a005                                                             
   LUND PA, 1982, CHEM PHYS LETT, V89, P508, DOI 10.1016/0009-2614(82)83055-8
   MCCCREERY RL, 1996, MODERN TECHNIQUES RA
   MEIER M, 1985, J PHYS CHEM-US, V89, P1843, DOI 10.1021/j100256a002                                                             
   MEIER M, 1983, OPT LETT, V8, P58
   MILLER SK, 1984, J CHEM SOC FARAD T 1, V80, P1305, DOI 10.1039/f19848001305                                                            
   MOODY RL, 1987, APPL SPECTROSC, V41, P966, DOI 10.1366/0003702874447761
   MOODY RL, 1986, UNPUB
   MOSKOVITS M, 1985, REV MOD PHYS, V57, P783, DOI 10.1103/RevModPhys.57.783
   Moskovits M., 1982, SURFACE ENHANCED RAM, P243
   MULLEN KI, 1991, ANAL CHEM, V63, P2196, DOI 10.1021/ac00019a023
   MYRICK M, 1990, APPL OPTICS, V29, P133
   NARAYANAN VA, 1993, J RAMAN SPECTROSC, V24, P123, DOI 10.1002/jrs.1250240302                                                          
   NARAYANAN VA, 1991, ANALUSIS, V19, P307
   NARAYANAN VA, 1994, J RAMAN SPECTROSC, V25, P415, DOI 10.1002/jrs.1250250607                                                          
   NARAYANAN VA, 1993, ANALUSIS, V21, P107
   NARAYANAN VA, 1991, J RAMAN SPECTROSC, V22, P327, DOI 10.1002/jrs.1250220605                                                          
   NARAYANAN VA, 1993, POLYCYCL AROMAT COMP, V3, P137
   NI F, 1990, ANAL CHEM, V62, P1958, DOI 10.1021/ac00217a012
   NI F, 1986, ANAL CHEM, V58, P3159, DOI 10.1021/ac00127a053
   Nie SM, 1997, SCIENCE, V275, P1102, DOI 10.1126/science.275.5303.1102
   OTTO A, 1980, SURF SCI, V92, pL55, DOI 10.1016/0039-6028(80)90237-X
   OTTO A, 1992, J PHYS-CONDENS MAT, V4, P1143, DOI 10.1088/0953-8984/4/5/001
   OTTO A, 1978, SURF SCI, V75, P1392
   PANDEY PKK, 1984, J CHEM PHYS, V80, P2959, DOI 10.1063/1.447045
   Pemberton J., 1991, ELECTROCHEMICAL INTE
   PEMBERTON JE, 1981, ANAL CHEM, V53, P2263, DOI 10.1021/ac00237a030                                                             
   PERSSON BNJ, 1981, CHEM PHYS LETT, V82, P56
   PETTINGER B, 1980, SURF SCI, V101, P409, DOI 10.1016/0039-6028(80)90637-8                                                    
   POCKRAND I, 1984, SURFACE ENHANCED RAM
   POHL DW, 1984, APPL PHYS LETT, V44, P651, DOI 10.1063/1.94865                                                                 
   RITCHIE RH, 1957, PHYS REV, V106, P879
   RUPEREZ A, 1996, MODERN TECHNIQUES RA
   SANDROFF CJ, 1983, J PHYS CHEM-US, V87, P2127, DOI 10.1021/j100235a020                                                             
   SANDROFF CJ, 1983, CHEM PHYS LETT, V96, P547, DOI 10.1016/0009-2614(83)80445-X                                                    
   SCHATZ GC, 1980, SURF SCI, V101, P425, DOI 10.1016/0039-6028(80)90639-1                                                    
   SCHATZ GC, 1984, ACCOUNTS CHEM RES, V17, P370, DOI 10.1021/ar00106a005                                                             
   SEQUARIS JML, 1987, ANAL CHEM, V59, P525, DOI 10.1021/ac00130a034
   SHENG RS, 1986, ANAL CHEM, V58, P1116, DOI 10.1021/ac00297a030                                                             
   SIMAN O, 1983, J PHYS CHEM-US, V87, P1014
   STEVENSON CL, 1996, MODERN TECHNIQUES RA
   STOKES DL, 1998, 1998 PITTSB C NEW OR
   STOKES DL, 1998, IN PRESS INTEGRATED
   SUTHERLAND WS, 1994, INSTRUM SCI TECHNOL, V22, P231, DOI 10.1080/10739149408000452                                                       
   SUTHERLAND WS, 1991, J RAMAN SPECTROSC, V22, P541, DOI 10.1002/jrs.1250221002                                                          
   SUTHERLAND WS, 1994, SERS TOXIC ANAL DATA
   TAN WH, 1992, SCIENCE, V258, P778, DOI 10.1126/science.1439785
   Taranenko N, 1996, J RAMAN SPECTROSC, V27, P379, DOI 10.1002/(SICI)1097-4555(199605)27:5<379::AID-JRS925>3.0.CO;2-G                  
   THIERRY D, 1985, SURF SCI, V149, P592, DOI 10.1016/0039-6028(85)90083-4                                                    
   TORRES EL, 1987, ANAL CHEM, V59, P1626, DOI 10.1021/ac00140a010
   TRAN CD, 1984, ANAL CHEM, V56, P824, DOI 10.1021/ac00268a057                                                             
   TRAN CD, 1984, J CHROMATOGR, V292, P432, DOI 10.1016/S0021-9673(01)83624-4                                                   
   UDAGAWA M, 1981, PHYS REV B, V23, P6843, DOI 10.1103/PhysRevB.23.6843
   VANDUYNE RP, 1993, J CHEM PHYS, V99, P2101, DOI 10.1063/1.465276
   VO-DINH T, 1986, ANAL CHIM ACTA, V181, P139, DOI 10.1016/S0003-2670(00)85228-9                                                   
   VO-DINH T, 1984, ANAL CHEM, V56, P1667, DOI 10.1021/ac00273a029                                                             
   VO-DINH T, 1987, APPL SPECTROSC, V41, P605, DOI 10.1366/0003702874448616                                                        
   VO-DINH T, 1989, TALANTA, V36, P227, DOI 10.1016/0039-9140(89)80100-6
   VO-DINH T, 1993, APPL SPECTROSC, V47, P1728, DOI 10.1366/0003702934334679                                                        
   VO-DINH T, 1994, ANAL CHEM, V66, P3379, DOI 10.1021/ac00092a014
   VODINH T, 1994, REV SCI INSTRUM, V65, P3766, DOI 10.1063/1.1144504                                                               
   VODINH T, 1988, SPECTROCHIM ACTA B, V415, P605
   VODINH T, 1995, PHOTONIC PROBES SURF
   VODINH T, 1989, CHEM ANAL POLYCYCLIC
   VODINH T, 1994, SPIE, V2338, P148
   VODINH T, 1997, P HUM GEN PROJ DOE C
   WANG DS, 1980, APPL OPTICS, V19, P2256, DOI 10.1364/AO.19.002256
   WOKAUN A, 1982, PHYS REV LETT, V48, P957, DOI 10.1103/PhysRevLett.48.957
   WOKAUN A, 1984, SOLID STATE PHYS, V38, P223
   WOOD TH, 1980, SOLID STATE COMMUN, V35, P263, DOI 10.1016/0038-1098(80)90493-7                                                    
   Zeisel D, 1998, CHEM PHYS LETT, V283, P381, DOI 10.1016/S0009-2614(97)01391-2
   ZEMAN EJ, 1987, J PHYS CHEM-US, V91, P634, DOI 10.1021/j100287a028                                                             
   Carrabba M. M., 1992, U. S. Patent, Patent No. [5,112,127, 5112127]
NR 139
TC 343
Z9 352
U1 6
U2 155
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-9936
J9 TRAC-TREND ANAL CHEM
JI Trac-Trends Anal. Chem.
PD SEP-OCT
PY 1998
VL 17
IS 8-9
BP 557
EP 582
DI 10.1016/S0165-9936(98)00069-7                                           
          
PG 26
WC Chemistry, Analytical
SC Chemistry
GA 121UE
UT WOS:000076031700021
DA 2018-01-05
ER

PT J
AU Mao, C
   Vig, R
   Venkatachalam, TK
   Sudbeck, EA
   Uckun, FM
AF Mao, C
   Vig, R
   Venkatachalam, TK
   Sudbeck, EA
   Uckun, FM
TI Structure-based design of N-[2-(1-piperidinylethyl)]-N
   '-[2-(5-bromopyridyl]-thiourea and N-[2-(1-piperazinylethyl)]-N
   '-[2-(5-bromopyridyl)]-thiourea as potent non-nucleoside inhibitors of
   HIV-1 reverse transcriptase
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; POKEWEED ANTIVIRAL PROTEIN; NONNUCLEOSIDE
   INHIBITORS; ANTI-HIV-1 ACTIVITY; PETT COMPOUNDS; ANALOGS; SERIES;
   DERIVATIVES; HEPT; 1-<(2-HYDROXYETHOXY)METHYL>-6-(PHENYLTHIO)THYMINE
AB A novel computer model of the HIV reverse transcriptase (RT) non-nucleoside inhibitor (NNI) binding pocket, which was generated using high resolution crystal structure information from 9 individual RT/NNI complexes, revealed previously unrecognized ligand derivatization sites for phenethylthiazolylthiourea (PETT) derivatives. Spatial gaps surrounding the pyridyl ring of the active PETT derivative trovirdine were discovered during modeling procedures. Docking studies using the computer-generated model of the binding pocket (composite binding pocket) suggested that the replacement of the planar pyridyl ring of trovirdine with a nonplanar piperidinyl or piperazinyl ring, which occupy larger volumes, would better fill the spacious Wing 2 region of the butterfly-shaped NNI binding pocket. The anti-HIV activity of the synthesized heterocyclic compounds N-[2-(1-piperidinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea and N-[2-(1-piperazinylethyl)]-N'-[2(5-bromopyridyl)]-thiourea was examined in HTLVIIIB-infected peripheral blood mononuclear cells. Both compounds were more potent than trovirdine and abrogated HIV replication at nanomolar concentrations without any evidence of cytotoxicity. (C) 1998 Elsevier Science Ltd. All rights reserved.
C1 Wayne Hughes Inst, Drug Discovery Program, St Paul, MN 55113 USA.
   Wayne Hughes Inst, Dept Biol Struct, St Paul, MN 55113 USA.
   Wayne Hughes Inst, Dept Chem, St Paul, MN 55113 USA.
   Wayne Hughes Inst, Dept Virol, St Paul, MN 55113 USA.
RP Uckun, FM (reprint author), Wayne Hughes Inst, Drug Discovery Program, St Paul, MN 55113 USA.
CR AHGREN C, 1995, ANTIMICROB AGENTS CH, V39, P1329, DOI 10.1128/AAC.39.6.1329                                                           
   BALZARINI J, 1992, P NATL ACAD SCI USA, V89, P4392, DOI 10.1073/pnas.89.10.4392
   BELL FW, 1995, J MED CHEM, V38, P4929, DOI 10.1021/jm00025a010
   Cantrell AS, 1996, J MED CHEM, V39, P4261, DOI 10.1021/jm950639r
   Danel K, 1997, ACTA CHEM SCAND, V51, P426, DOI 10.3891/acta.chem.scand.51-0426
   Danel K, 1996, J MED CHEM, V39, P2427, DOI 10.1021/jm9600499
   DECLERCQ E, 1992, AIDS RES HUM RETROV, V8, P119, DOI 10.1089/aid.1992.8.119                                                          
   DING J, 1995, STRUCTURE, V3, P365, DOI 10.1016/S0969-2126(01)00168-X
   DING JP, 1995, NAT STRUCT BIOL, V2, P407, DOI 10.1038/nsb0595-407
   ERICE A, 1993, ANTIMICROB AGENTS CH, V37, P835, DOI 10.1128/AAC.37.4.835                                                            
   Esnouf RM, 1997, P NATL ACAD SCI USA, V94, P3984, DOI 10.1073/pnas.94.8.3984
   GREENE WC, 1991, NEW ENGL J MED, V324, P308
   Heinisch G, 1997, ANTIVIR CHEM CHEMOTH, V8, P443, DOI 10.1177/095632029700800507                                                      
   Hopkins AL, 1996, J MED CHEM, V39, P1589, DOI 10.1021/jm960056x
   KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403
   Mai A, 1997, J MED CHEM, V40, P1447, DOI 10.1021/jm960802y
   MAO C, UNPUB BIOORG MED CHE
   MAO C, UNPUB ANTIMICROB AGE
   MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273
   Nicholls A., 1992, GRASP GRAPHICAL REPR
   PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0
   REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293
   REN JS, 1995, STRUCTURE, V3, P915, DOI 10.1016/S0969-2126(01)00226-X
   ROMERO DL, 1993, J MED CHEM, V36, P1505, DOI 10.1021/jm00062a027
   SMERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911, DOI 10.1073/pnas.91.9.3911
   SUDBECK EA, UNPUB ANTIMICROB AGE
   TANAKA H, 1991, J MED CHEM, V34, P349, DOI 10.1021/jm00105a055
   TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665                                                          
   Uckun FM, 1998, ANTIMICROB AGENTS CH, V42, P383
   Vig R, 1998, BIOORG MED CHEM LETT, V8, P1461, DOI 10.1016/S0960-894X(98)00250-9
   VIG R, 1998, IN PRESS BIOORG MED
   ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0
NR 32
TC 68
Z9 68
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD AUG 18
PY 1998
VL 8
IS 16
BP 2213
EP 2218
DI 10.1016/S0960-894X(98)00384-9                                           
          
PG 6
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 115XT
UT WOS:000075692200030
PM 9873515
DA 2018-01-05
ER

PT J
AU Kudo, N
   Wolff, B
   Sekimoto, T
   Schreiner, EP
   Yoneda, Y
   Yanagida, M
   Horinouchi, S
   Yoshida, M
AF Kudo, N
   Wolff, B
   Sekimoto, T
   Schreiner, EP
   Yoneda, Y
   Yanagida, M
   Horinouchi, S
   Yoshida, M
TI Leptomycin B inhibition of signal-mediated nuclear export by direct
   binding to CRM1
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ORDER CHROMOSOME STRUCTURE; ANTI-FUNGAL
   ANTIBIOTICS; HIV-1 REV PROTEIN; NUCLEOCYTOPLASMIC TRANSPORT; FISSION
   YEAST; SCHIZOSACCHAROMYCES-POMBE; ACTIVATION DOMAIN; CELL-CYCLE;
   IDENTIFICATION
AB Leptomycin B (LMB) is a Streptomyces metabolite that, inhibits nuclear export of the human immunodeficiency virus type 1 regulatory protein Rev at low nanomolar concentrations. Recently, LMB was shown to inhibit the function of CRM1, a receptor for the nuclear export signal (NES). Here we show evidence that LIMB binds directly to CRMI1 and that CRM1 is essential for NES-dependent nuclear export of proteins in both yeast and mammalian cells. Binding experiments with a biotinylated derivative of LMB and a HeLa cell extract led to identifying CRM1 as a major protein that bound to the LMB derivative. Microinjection of a purified anti-human CRM1 antibody into the mammalian nucleus specifically inhibited nuclear export of NES-containing proteins, as did LMB. Consistent with this, CRM1 was found to interact with NES, when assayed with immobilized NES and HeLa cell extracts. This association was disrupted by adding LMB or purified anti-human CRM1 antibody. The inhibition of CRM1 by LIMB was also observed in fission yeast. The fission yeast crm1 mutant was defective in the nuclear export of NES-fused proteins, but not in the import of nuclear localization signal (NLS)-fused proteins. Interestingly, a protein containing both NES and NLS, which is expected to shuttle between nucleus and cytoplasm, was highly accumulated in the nucleus of the crm1 mutant cells or of cells treated with LMB. These results strongly suggest that CRM1 is the target of LIMB and is an essential factor for nuclear export of proteins in eukaryotes. (C) 1998 Academic Press.
C1 Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 113, Japan.
   Novartis Forschungsinst, A-1235 Vienna, Austria.
   Osaka Univ, Sch Med, Dept Anat & Cell Biol, Suita, Osaka 565, Japan.
   Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 60601, Japan.
RP Yoshida, M (reprint author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 113, Japan.
RI Yoshida, Minoru/C-8049-2014
OI Yoshida, Minoru/0000-0002-4376-5674
CR ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195
   Alfa C., 1993, EXPT FISSION YEAST L
   BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9
   COREY EJ, 1974, J AM CHEM SOC, V96, P5614, DOI 10.1021/ja00824a073                                                             
   DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W
   FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0
   Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2
   Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807
   FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0
   Fukuda M, 1997, NATURE, V390, P308
   Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513
   GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0
   Griffith EC, 1997, CHEM BIOL, V4, P461, DOI 10.1016/S1074-5521(97)90198-8
   HAMAMOTO T, 1983, J ANTIBIOT, V36, P639, DOI 10.7164/antibiotics.36.639                                                      
   HAMAMOTO T, 1983, J ANTIBIOT, V36, P646, DOI 10.7164/antibiotics.36.646                                                      
   HAMAMOTO T, 1985, J ANTIBIOT, V38, P1573, DOI 10.7164/antibiotics.38.1573                                                     
   Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742
   MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D                                                    
   MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532                                                         
   Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6
   Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0
   NISHI K, 1994, J BIOL CHEM, V269, P6320
   OSAREHNAZARI B, 1997, SCIENCE, V278, P141
   Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842
   SCHAUMBERG JP, 1984, J CHEM SOC CHEM COMM, P1450, DOI 10.1039/c39840001450                                                            
   SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0
   Stutz F, 1996, MOL CELL BIOL, V16, P7144
   STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7
   Tachibana T, 1996, FEBS LETT, V397, P177, DOI 10.1016/S0014-5793(96)01180-5
   ULLAH AHJ, 1988, PREP BIOCHEM, V18, P473, DOI 10.1080/00327488808062545
   WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2
   WOLFF B, 1995, EXP CELL RES, V217, P31, DOI 10.1006/excr.1995.1060
   Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X                                                   
   YONEDA Y, 1987, EXP CELL RES, V170, P439, DOI 10.1016/0014-4827(87)90319-3
   YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X
NR 36
TC 607
Z9 615
U1 1
U2 13
PU ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
J9 EXP CELL RES
JI Exp. Cell Res.
PD AUG 1
PY 1998
VL 242
IS 2
BP 540
EP 547
DI 10.1006/excr.1998.4136
PG 8
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 110UT
UT WOS:000075399700016
PM 9683540
DA 2018-01-05
ER

PT J
AU Neamati, N
   Mazumder, A
   Sunder, S
   Owen, JM
   Tandon, M
   Lown, JW
   Pommier, Y
AF Neamati, N
   Mazumder, A
   Sunder, S
   Owen, JM
   Tandon, M
   Lown, JW
   Pommier, Y
TI Highly potent synthetic polyamides, bisdistamycins, and lexitropsins as
   inhibitors of human immunodeficiency virus type 1 integrase
SO MOLECULAR PHARMACOLOGY
LA English
DT Article
ID COMBINATION THERAPY; ANTIVIRAL ACTIVITY; DNA INTEGRATION; AGENTS;
   DISTAMYCIN; BINDING; RESISTANCE; STRATEGIES; INFECTIONS; MECHANISM
AB Alignment of the available human immunodeficiency virus type 1 (HIV-1) viral DNA termini [U5 and U3 long terminal repeats (LTRs)] shows a high degree of conservation and the presence of a stretch of five or six consecutive adenine and thymine (AT) sequences similar to 10 nucleotides away from each LTR end. A series of AT-selective minor-groove binders, including distamycin and bisdistamycins, bisnetropsins, novel lexitropsins, and the classic monomeric DNA binders Hoechst 33258, 4'-diamino-2-phenylindole, pentamidine, berenil, spermine, and spermidine, were tested for their inhibitory activities against HIV-1 integrase (IN). Although netropsin, distamycin, and all other monomeric DNA binders showed weak activities in the range of 50-200 mu M, some of the polyamides, bisdistamycins, and lexitropsins were remarkably active at nanomolar concentrations. Bisdistamycins were 200 times less potent when the conserved AAAAT stretch present in the U5 LTR was replaced with GGGGG, consistent with the preferred binding of these drugs to AT sequences. DNase I footprinting of the U5 LTR further demonstrated the selectivity of these bisdistamycins for the conserved AT sequence. The tested compounds were more potent in Mg+2 than in Mn+2 and inhibited IN50-212 deletion mutant in disintegration assays and the formation of IN/DNA complexes. The lexitropsins also were active against HIV-2 IN. Some of the synthetic polyamides exhibited significant antiviral activity. Taken together, these data suggest that selective targeting of the U5 and U3 ends of the HIV-1 LTRs can inhibit IN function. Polyamides might represent new leads for the development of antiviral agents against acquired immune deficiency syndrome.
C1 NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA.
   Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada.
RP Pommier, Y (reprint author), NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bldg 37,Rm 5D02, Bethesda, MD 20892 USA.
EM pommier@nih.gov
CR Arts EJ, 1996, ANTIMICROB AGENTS CH, V40, P527
   Bouziane M, 1996, J BIOL CHEM, V271, P10359, DOI 10.1074/jbc.271.17.10359                                                        
   BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428
   CARTEAU S, 1993, BIOCHEM BIOPH RES CO, V192, P1409, DOI 10.1006/bbrc.1993.1573
   CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845                                                         
   DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001
   DeClercq E, 1996, MED RES REV, V16, P125, DOI 10.1002/(SICI)1098-1128(199603)16:2<125::AID-MED1>3.0.CO;2-2
   ENGELMAN A, 1995, J VIROL, V69, P5908
   ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C
   Erickson JW, 1996, ANNU REV PHARMACOL, V36, P545, DOI 10.1146/annurev.pa.36.040196.002553                                             
   FESEN MR, 1993, P NATL ACAD SCI USA, V90, P2399, DOI 10.1073/pnas.90.6.2399                                                          
   FESEN MR, 1994, BIOCHEM PHARMACOL, V48, P595, DOI 10.1016/0006-2952(94)90291-7
   Hazuda D, 1997, J VIROL, V71, P807
   Hazuda DJ, 1997, J VIROL, V71, P7005
   Helene C, 1998, NATURE, V391, P436, DOI 10.1038/35026                                                                   
   JOHNSON VA, 1994, AIDS RES HUM RETROV, V10, P907, DOI 10.1089/aid.1994.10.907
   KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.biochem.63.1.133
   KOPKA ML, 1985, P NATL ACAD SCI USA, V82, P1376, DOI 10.1073/pnas.82.5.1376
   Kopka ML, 1992, NUCL ACID TARGETED D, P303
   LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804                                                         
   Lown J. William, 1994, Journal of Molecular Recognition, V7, P79, DOI 10.1002/jmr.300070205
   LOWN JW, 1989, J MED CHEM, V32, P2368, DOI 10.1021/jm00130a024
   LOWN JW, 1988, ANTI-CANCER DRUG DES, V3, P25
   Mazumder A, 1996, J MED CHEM, V39, P2472, DOI 10.1021/jm960074e
   Mazumder A, 1997, J MED CHEM, V40, P3057, DOI 10.1021/jm970190x
   Mazumder A, 1996, J BIOL CHEM, V271, P27330, DOI 10.1074/jbc.271.44.27330                                                        
   Neamati N, 1997, DRUG DISCOV TODAY, V2, P487, DOI 10.1016/S1359-6446(97)01105-7                                                   
   Neamati N, 1997, MOL PHARMACOL, V52, P1041
   NEMATI N, 1997, J MED CHEM, V40, P942
   NISHIWAKI E, 1988, HETEROCYCLES, V27, P1945
   Pommier Y, 1997, ANTIVIR CHEM CHEMOTH, V8, P463, DOI 10.1177/095632029700800601                                                      
   Rice P, 1996, CURR OPIN STRUC BIOL, V6, P76, DOI 10.1016/S0959-440X(96)80098-4                                                   
   SCHINAZI R F, 1991, P109
   VINK C, 1991, NUCLEIC ACIDS RES, V19, P6691, DOI 10.1093/nar/19.24.6691
   WANG WY, 1992, J MED CHEM, V35, P2890, DOI 10.1021/jm00093a023
   WEISLOW OS, 1989, J NATL CANCER I, V81, P577, DOI 10.1093/jnci/81.8.577
   White S, 1998, NATURE, V391, P468
   ZIMMER C, 1983, BIOCHIM BIOPHYS ACTA, V741, P15, DOI 10.1016/0167-4781(83)90004-0                                                    
   ZIMMER C, 1971, EUR J BIOCHEM, V21, P269, DOI 10.1111/j.1432-1033.1971.tb01466.x
NR 39
TC 58
Z9 61
U1 0
U2 3
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0026-895X
J9 MOL PHARMACOL
JI Mol. Pharmacol.
PD AUG
PY 1998
VL 54
IS 2
BP 280
EP 290
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 108CW
UT WOS:000075249300007
PM 9687569
DA 2018-01-05
ER

PT J
AU Filikov, AV
   James, TL
AF Filikov, AV
   James, TL
TI Structure-based design of ligands for protein basic domains: Application
   to the HIV-1 Tat protein
SO JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
LA English
DT Article
DE calorimetry; drug design; molecular docking; molecular mimicry; protein
   structure; thermodynamics
ID VIRUS TYPE-1 TAT; RNA RECOGNITION; BINDING; ENERGY; COMPLEXES; DOCKING;
   PEPTIDE; PREDICTION; PARAMETERS; POTENTIALS
AB A methodology has been developed for designing ligands to bind a flexible basic protein domain where the structure of the domain is essentially known. It is based on an empirical binding free energy function developed for highly charged complexes and on Monte Carlo simulations in internal coordinates with both the ligand and the receptor being flexible. HIV-1 encodes a transactivating regulatory protein called Tat. finding of the basic domain of Tat to TAR RNA is required for efficient transcription of the viral genome. The structure of a biologically active peptide containing the Tat basic RNA-binding domain is available from NMR studies. The goal of the current project is to design a ligand which will bind to that basic domain and potentially inhibit the TAR-Tat interaction. The basic domain contains six arginine and two lysine residues. Our strategy was to design a ligand for arginine first and then a superligand for the basic domain by joining arginine ligands with a linker. Several possible arginine Ligands were obtained by searching the Available Chemicals Directory with DOCK 3.5 software. Phytic acid, which can potentially bind multiple arginines, was chosen as a building block for the superligand. Calorimetric binding studies of several compounds to methylguanidine and Arg-/Lys-containing peptides were performed. The data were used to develop an empirical binding free energy function for prediction of affinity of the ligands for the Tar basic domain. Modeling of the conformations of the complexes with both the superligand and the basic domain being flexible has been carried out via Biased Probability Monte Carlo (BPMC) simulations in internal coordinates (ICM 2.6 suite of programs). The simulations used parameters to ensure correct folding, i.e., consistent with the experimental NMR structure of a 25-residue Tat peptide, from a random starting conformation. Superligands for the basic domain were designed by joining together two molecules of phytic acid with peptidic and peptidomimetic linkers. The Linkers were refined by varying the length and side chains of the linking residues, carrying out BPMC simulations, and evaluation of the binding foe energy for the best energy conformation. The dissociation constant of the best ligand designed is estimated to be in the low- to mid-nanomolar range.
C1 Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.
RP James, TL (reprint author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.
FU NCRR NIH HHS [RR01081]; NIGMS NIH HHS [GM39247]
CR ABAGYAN R, 1994, J MOL BIOL, V235, P983, DOI 10.1006/jmbi.1994.1052                                                          
   ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503                                                           
   ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555
   BELL TW, 1990, ANGEW CHEM INT EDIT, V29, P923, DOI 10.1002/anie.199009231                                                          
   Bohacek RS, 1996, MED RES REV, V16, P3, DOI 10.1002/(SICI)1098-1128(199601)16:1<3::AID-MED1>3.3.CO;2-D
   CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167
   CARROLL R, 1992, J VIROL, V66, P2000
   DERSE D, 1991, J VIROL, V65, P7012
   HAMY F, 1993, J MOL BIOL, V230, P111, DOI 10.1006/jmbi.1993.1129
   HAUBER J, 1989, J VIROL, V63, P1181
   KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0
   KARN J, 1991, BIOCHIMIE, V73, P9, DOI 10.1016/0300-9084(91)90068-C                                                    
   LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472
   LORET EP, 1992, P NATL ACAD SCI USA, V89, P9734, DOI 10.1073/pnas.89.20.9734
   MARCINIAK RA, 1991, EMBO J, V10, P4189
   MENG EC, 1992, J COMPUT CHEM, V13, P505, DOI 10.1002/jcc.540130412                                                           
   MERNISSIARIFI K, 1995, ANAL CHEM, V67, P2567, DOI 10.1021/ac00111a012                                                             
   MOMANY FA, 1975, J PHYS CHEM-US, V79, P2361, DOI 10.1021/j100589a006                                                             
   MUJEEB A, 1994, P NATL ACAD SCI USA, V91, P8248, DOI 10.1073/pnas.91.17.8248
   Mujeeb A, 1996, J BIOMOL STRUCT DYN, V13, P649, DOI 10.1080/07391102.1996.10508877                                                  
   NOVOTNY J, 1989, BIOCHEMISTRY-US, V28, P4735, DOI 10.1021/bi00437a034
   PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678                                                          
   PUGLISI JD, 1993, P NATL ACAD SCI USA, V90, P3680, DOI 10.1073/pnas.90.8.3680
   PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200
   SHOICHET BK, 1992, J COMPUT CHEM, V13, P380, DOI 10.1002/jcc.540130311
   VERKHIVKER G, 1995, PROTEIN ENG, V8, P677, DOI 10.1093/protein/8.7.677                                                         
   VERLINDE CLMJ, 1994, STRUCTURE, V2, P577, DOI 10.1016/S0969-2126(00)00060-5
   WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002
   WESSON L, 1992, PROTEIN SCI, V1, P227
   WILLBOLD D, 1994, SCIENCE, V264, P1584, DOI 10.1126/science.7515512
   WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3
   YE X, 1995, CHEM BIOL, V2, P8237
NR 32
TC 8
Z9 8
U1 0
U2 0
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0920-654X
J9 J COMPUT AID MOL DES
JI J. Comput.-Aided Mol. Des.
PD MAY
PY 1998
VL 12
IS 3
BP 229
EP 240
DI 10.1023/A:1007949625270
PG 12
WC Biochemistry & Molecular Biology; Biophysics; Computer Science,
   Interdisciplinary Applications
SC Biochemistry & Molecular Biology; Biophysics; Computer Science
GA 116PR
UT WOS:000075734200002
PM 9749367
DA 2018-01-05
ER

PT J
AU Roy, S
   Cain, KJ
   Chapin, RB
   Charboneau, RG
   Barke, RA
AF Roy, S
   Cain, KJ
   Chapin, RB
   Charboneau, RG
   Barke, RA
TI Morphine modulates NF kappa B activation in macrophages
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
ID NECROSIS-FACTOR-ALPHA; IN-VITRO; NITRIC-OXIDE; TREATED MICE; INHIBITION;
   TRANSCRIPTION; INVOLVEMENT; METHADONE; ENHANCER; CELLS
AB Chronic use of morphine affects the immune system and predisposes an individual to opportunistic infections. Macrophages play an important role in conferring a first line of defense against invading pathogens. Understanding the mechanisms by Which morphine affects the functioning of macrophages would have significant therapeutic benefit in treatment against infections such as HIV and AIDS related syndromes. Two of the major cytokines secreted by activated macrophages are Interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha). Our studies show that morphine differentially modulates lipopolysaccharide (LPS) induced expression of IL-6 and TNF-alpha. Nanomolar concentrations of morphine synergize with LPS and augment the secretion of both IL-6 and TNF-alpha. However, at micromolar concentrations morphine inhibits LPS induced synthesis of IL-6 and TNF-alpha. Expression of both these cytokine genes is dependent on the activation of a transcription factor, NF kappa B. Interestingly, morphine treatment also modulated the activation of NF kappa B by LPS, Pretreatment with a low dose of morphine (nanomolar) resulted in an increase in NF kappa B activation. In contrast pretreatment with a high dose of morphine (micromolar) led to a significant decrease in NF kappa B activation. Furthermore unlike the augmentation which was naloxone reversible, the inhibition of NF kappa B by morphine was not reversed by naloxone, suggesting the involvement of a nonclassical opioid receptor. (C) 1998 Academic Press.
C1 Vet Adm Med Ctr, Dept Pharmacol, Minneapolis, MN 55417 USA.
   Vet Adm Med Ctr, Dept Surg, Minneapolis, MN 55417 USA.
   Univ Minnesota, Minneapolis, MN 55417 USA.
RP Roy, S (reprint author), Vet Adm Med Ctr, Dept Pharmacol, 1 Vet Dr, Minneapolis, MN 55417 USA.
EM royxx002@gold.tc.umn.edu
FU NIDA NIH HHS [R29-DA08188]
CR Alicea C, 1996, J NEUROIMMUNOL, V64, P83, DOI 10.1016/0165-5728(95)00159-X                                                    
   Ausubel F. M., 1989, CURRENT PROTOCOLS MO, V1
   Ausubel FM, 1989, CURRENT PROTOCOLS MO, V2
   BAUERLE PA, 1988, CELL, V53, P211
   BIAN TH, 1995, ACTA PHARM SINIC, V16, P449
   BURKE RA, 1994, SURGERY, V116, P141
   BUSSIERE JL, 1993, J PHARMACOL EXP THER, V264, P591
   COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498                                                           
   FECHO K, 1994, J IMMUNOL, V152, P5845
   Galien R, 1996, MOL ENDOCRINOL, V10, P713, DOI 10.1210/me.10.6.713                                                             
   HOUSE RV, 1995, IMMUNOL LETT, V46, P117, DOI 10.1016/0165-2478(95)00035-4
   JESSOP JJ, 1991, IMMUNOPHARMACOLOGY, V22, P175, DOI 10.1016/0162-3109(91)90042-W
   KOFF WC, 1985, J IMMUNOL, V135, P350
   KUPRASH DV, 1995, ONCOGENE, V11, P97
   LEVIER DG, 1994, FUND APPL TOXICOL, V22, P525, DOI 10.1006/faat.1994.1060
   PACIFICI R, 1995, INT J IMMUNOPHARMACO, V17, P771, DOI 10.1016/0192-0561(95)00046-5                                                    
   PACIFICI R, 1993, INT J IMMUNOPHARMACO, V15, P711, DOI 10.1016/0192-0561(93)90143-M
   PACIFICI R, 1992, IMMUNOPHARM IMMUNOT, V14, P355, DOI 10.3109/08923979209005399
   POWELL JD, 1993, CLIN EXP IMMUNOL, V91, P473
   ROY S, 1996, NEUROCHEM RES, V21, P1373
   SHARP BM, 1985, ENDOCRINOLOGY, V117, P793, DOI 10.1210/endo-117-2-793                                                          
   Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8
   SWINGLER S, 1994, BIOCHEM BIOPH RES CO, V203, P623, DOI 10.1006/bbrc.1994.2228
   SZABO I, 1993, J PHARMACOL EXP THER, V267, P703
   THOMAS PT, IMMUNOMODULATORY EFF
   Tomei EZ, 1997, J NEUROIMMUNOL, V74, P111, DOI 10.1016/S0165-5728(96)00213-5
   TUBARO E, 1987, INT J IMMUNOPHARMACO, V9, P79, DOI 10.1016/0192-0561(87)90113-5                                                    
NR 27
TC 116
Z9 128
U1 0
U2 3
PU ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD APR 17
PY 1998
VL 245
IS 2
BP 392
EP 396
DI 10.1006/bbrc.1998.8415                                                  
          
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA ZK046
UT WOS:000073279500019
PM 9571161
DA 2018-01-05
ER

PT J
AU Litera, J
   Weber, J
   Krizova, I
   Pichova, I
   Konvalinka, J
   Fusek, M
   Soucek, M
AF Litera, J
   Weber, J
   Krizova, I
   Pichova, I
   Konvalinka, J
   Fusek, M
   Soucek, M
TI Peptide inhibitors of aspartic proteinases with hydroxyethylene isostere
   replacement of peptide bond. II. Preparation of pseudotetrapeptides
   derived from diastereoisomeric
   5-amino-2-benzyl-4-hydroxy-6-phenylhexanoic acids
SO COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS
LA English
DT Article
DE Candida sp. proteinases; HIV-1 proteinase; aspartic proteinase
   inhibitors; pseudopeptides; peptidomimetics
ID CANDIDA-ALBICANS; DIPEPTIDE ISOSTERES; POTENT INHIBITOR; PROTEASE;
   SPECIFICITY
AB Twelve pseudotetrapeptides, Boc-NHCH(CH2Ph)CH(OH)CH2CH(CH2Ph) CO-Xaa-Phe-NH2 9-11, were prepared by [(benzotriazol-1-yl)oxy]tris(dimethylamino)phosphonium hexafluorophosphate-mediated couplings of diastereoisomeric O-silylated (2R or 2S,4R or 4S,5S)-2-benzyl-5-(tert-butoxycarbonyl)amino-4-hydroxy-6-phenylhexanoic acids 1 with dipeptides H-Xaa-Phe-NH2 (Xaa = Gln, Glu(OBzl) or Ile) 3-5, followed by O-deprotection. Pseudotetrapeptides 9-11 were tested for inhibition of aspartic proteinases secreted by Candida albicans and C. tropicalis. The level of inhibition of both yeast proteinases was very low, contrasting with the nanomolar IC50 values obtained for inhibition of HIV-1 proteinase.
C1 Acad Sci Czech Republ, Inst Organ Chem & Biochem, CR-16610 Prague 6, Czech Republic.
RP Soucek, M (reprint author), Acad Sci Czech Republ, Inst Organ Chem & Biochem, CR-16610 Prague 6, Czech Republic.
RI Weber, Jan/B-5405-2013; Pichova, Iva/G-7917-2014; Konvalinka,
   Jan/G-7518-2014; Krizova, Ivana/G-5572-2014
OI Weber, Jan/0000-0002-2799-7352; Konvalinka, Jan/0000-0003-0695-9266
CR AbadZapatero C, 1996, PROTEIN SCI, V5, P640
   ABDELMEGUID SS, 1993, MED RES REV, V13, P731, DOI 10.1002/med.2610130605
   BODANZKY M, 1984, PRACTICE PEPTIDE SYN
   CAPOBIANCO JO, 1992, ANAL BIOCHEM, V204, P96, DOI 10.1016/0003-2697(92)90145-W                                                    
   EVANS BE, 1985, J ORG CHEM, V50, P4615, DOI 10.1021/jo00223a037
   FUSEK M, 1994, BIOCHEMISTRY-US, V33, P9791, DOI 10.1021/bi00198a051
   Konvalinka J, 1997, EUR J BIOCHEM, V250, P559, DOI 10.1111/j.1432-1033.1997.0559a.x                                                
   KONVALINKA J, 1995, EUR J BIOCHEM, V228, P191, DOI 10.1111/j.1432-1033.1995.0191o.x
   Litera J, 1998, COLLECT CZECH CHEM C, V63, P231, DOI 10.1135/cccc19980231                                                            
   PAVLICKOVA L, 1990, MED RES REV, V10, P173
   RICH DH, 1991, J MED CHEM, V34, P1222, DOI 10.1021/jm00107a049                                                             
   SCARBOROUGH PE, 1993, PROTEIN SCI, V2, P264
   URBAN J, 1992, FEBS LETT, V298, P9, DOI 10.1016/0014-5793(92)80010-E
   VACCA JP, 1991, J MED CHEM, V34, P1225, DOI 10.1021/jm00107a050
   Weber J, 1997, ARCH BIOCHEM BIOPHYS, V341, P62, DOI 10.1006/abbi.1997.9945
NR 15
TC 6
Z9 6
U1 0
U2 2
PU INST ORGANIC CHEM AND BIOCHEM
PI PRAGUE 6
PA ACAD SCI CZECH REPUBLIC, FLEMINGOVO NAM 2, PRAGUE 6, CZECH REPUBLIC 166
   10
SN 0010-0765
J9 COLLECT CZECH CHEM C
JI Collect. Czech. Chem. Commun.
PD APR
PY 1998
VL 63
IS 4
BP 541
EP 548
DI 10.1135/cccc19980541                                                    
          
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA ZQ855
UT WOS:000073909800008
DA 2018-01-05
ER

PT J
AU Turpin, JA
   Buckheit, RW
   Derse, D
   Hollingshead, M
   Williamson, K
   Palamone, C
   Osterling, MC
   Hill, SA
   Graham, L
   Schaeffer, CA
   Bu, M
   Huang, MJ
   Cholody, WM
   Michejda, CJ
   Rice, WG
AF Turpin, JA
   Buckheit, RW
   Derse, D
   Hollingshead, M
   Williamson, K
   Palamone, C
   Osterling, MC
   Hill, SA
   Graham, L
   Schaeffer, CA
   Bu, M
   Huang, MJ
   Cholody, WM
   Michejda, CJ
   Rice, WG
TI Inhibition of acute-, latent-, and chronic-phase human immunodeficiency
   virus type 1 (HIV-1) replication by a bistriazoloacridone analog that
   selectively inhibits HIV-1 transcription
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID DYNAMICS IN-VIVO; RNA-POLYMERASE; ZINC FINGERS; PROTEIN; POTENT; CELLS;
   BISIMIDAZOACRIDONES; INTEGRATION; LYMPHOCYTES; GENERATION
AB Nanomolar concentrations of temacrazine (1,4-bis[3-(6-oxo-6H-v-triazolo[4,5,1-de]acridin-5-yl)amino- propyl]piperazine) were discovered to inhibit acute human immunodeficiency virus type 1 (HIV-1) infections and suppress the production of virus from chronically and latently infected cells containing integrated proviral DNA. This bistriazoloacridone derivative exerted its mechanism of antiviral action through selective inhibition of HIV-1 transcription during the postintegrative phase of virus replication. Mechanistic studies revealed that temacrazine blocked HIV-1 RNA formation without interference with the transcription of cellular genes or,vith events associated with the HIV-1 Tat and Rev regulatory proteins. Although temacrazine inhibited the in vitro 3' processing and strand transfer activities of HIV-1 integrase, with a 50% inhibitory concentration of approximately 50 nM, no evidence of an inhibitory effect on the intracellular integration of proviral DNA into the cellular genome during the early phase of infection could be detected. Furthermore, temacrazine did not interfere with virus attachment or fusion to host cells or the enzymatic activities of HIV-1 reverse transcriptase or protease, and the compound was not directly virucidal. Demonstration of in vivo anti-HIV-l activity by temacrazine identifies bistriazoloacridones as a new class of pharmaceuticals that selectively blocks HIV-1 transcription.
C1 NCI, Lab Antiviral Drug Mech, Dev Therapeut Program, Frederick Canc Res & Dev Ctr,SAIC Frederick, Frederick, MD 21702 USA.
   NCI, Lab Leukocyte Biol, Div Basic Sci, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA.
   NCI, Biol Testing Branch,Dev Therapeut Program, Div Canc Treatment Diag & Ctr, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA.
   NCI, Macromol Struct Lab, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA.
   Frederick Res Ctr, Virol Res Grp, So Res Inst, Frederick, MD 21701 USA.
RP Rice, WG (reprint author), NCI, Lab Antiviral Drug Mech, Dev Therapeut Program, Frederick Canc Res & Dev Ctr,SAIC Frederick, Bldg 431T-B,POB B, Frederick, MD 21702 USA.
FU PHS HHS [N01-C0-56000, N01-C0-46000]
CR Andrews JM, 1997, J VIROL, V71, P741
   Baba M, 1997, ANTIMICROB AGENTS CH, V41, P1250
   BADER JP, 1991, P NATL ACAD SCI USA, V88, P6740, DOI 10.1073/pnas.88.15.6740                                                         
   BUCKHEIT RW, 1994, AIDS RES HUM RETROV, V10, P1497, DOI 10.1089/aid.1994.10.1497
   BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339                                                          
   BUTERA ST, 1995, MOL MED, V1, P758
   CARROLL R, 1991, J VIROL, V65, P3460
   CHOLODY WM, 1995, J MED CHEM, V38, P3043, DOI 10.1021/jm00016a007
   CLANTON DJ, 1995, ANTIVIR RES, V27, P335, DOI 10.1016/0166-3542(95)00017-G
   CLOUSE KA, 1989, J IMMUNOL, V142, P431
   COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947
   Cohen J, 1997, SCIENCE, V277, P32, DOI 10.1126/science.277.5322.32
   Cujec TP, 1997, MOL CELL BIOL, V17, P1817, DOI 10.1128/MCB.17.4.1817                                                           
   Farnet CM, 1996, P NATL ACAD SCI USA, V93, P9742, DOI 10.1073/pnas.93.18.9742
   FELBER BK, 1988, SCIENCE, V239, P184, DOI 10.1126/science.3422113
   FOLKS TM, 1988, J IMMUNOL, V140, P1117
   Hamy F, 1997, P NATL ACAD SCI USA, V94, P3548, DOI 10.1073/pnas.94.8.3548
   HERNANDEZ L, 1995, CANCER RES, V55, P2338
   HERRMANN CH, 1995, J VIROL, V69, P1612
   HOLLINGSHEAD M, 1995, ANTIVIR RES, V28, P265, DOI 10.1016/0166-3542(95)00055-Q
   HOPE TJ, 1990, P NATL ACAD SCI USA, V87, P7787, DOI 10.1073/pnas.87.19.7787
   HSU MC, 1993, P NATL ACAD SCI USA, V90, P6395, DOI 10.1073/pnas.90.14.6395
   KAGEYAMA S, 1993, ANTIMICROB AGENTS CH, V37, P810, DOI 10.1128/AAC.37.4.810                                                            
   KAPLAN AH, 1993, J VIROL, V67, P4050
   KARIYA Y, 1987, GENE, V53, P1, DOI 10.1016/0378-1119(87)90087-4
   KINGSTON RE, 1996, CURRENT PROTOCOLS MO
   LAFEMINA RL, 1995, ANTIMICROB AGENTS CH, V39, P320, DOI 10.1128/AAC.39.2.320                                                            
   MICHEJDA CJ, UNPUB
   Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582
   POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7
   RICE WG, 1993, P NATL ACAD SCI USA, V90, P9721, DOI 10.1073/pnas.90.20.9721
   Rice WG, 1997, ANTIMICROB AGENTS CH, V41, P419
   RICE WG, 1995, SCIENCE, V270, P1194, DOI 10.1126/science.270.5239.1194
   Rice WG, 1997, NAT MED, V3, P341, DOI 10.1038/nm0397-341                                                              
   Saltarelli MJ, 1996, AIDS RES HUM RETROV, V12, P1443, DOI 10.1089/aid.1996.12.1443
   Stevens SW, 1996, J VIROL, V70, P6459
   STEVENSON M, 1992, AIDS RES HUM RETROV, V2, P107
   Turpin JA, 1996, J VIROL, V70, P6180
   WUBAER F, 1995, EMBO J, V14, P5995
   ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L
   Zhou QA, 1996, SCIENCE, V274, P605, DOI 10.1126/science.274.5287.605
NR 41
TC 48
Z9 50
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD MAR
PY 1998
VL 42
IS 3
BP 487
EP 494
PG 8
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA YZ945
UT WOS:000072311000001
PM 9517921
DA 2018-01-05
ER

PT J
AU Hartmann, R
   Norby, PL
   Martensen, PM
   Jorgensen, P
   James, MC
   Jacobsen, C
   Moestrup, SK
   Clemens, MJ
   Justesen, J
AF Hartmann, R
   Norby, PL
   Martensen, PM
   Jorgensen, P
   James, MC
   Jacobsen, C
   Moestrup, SK
   Clemens, MJ
   Justesen, J
TI Activation of 2 '-5 ' oligoadenylate synthetase by single-stranded and
   double-stranded RNA aptamers
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID HUMAN IMMUNODEFICIENCY VIRUS-1; TREATED HELA-CELLS; PROTEIN-KINASE;
   2',5'-OLIGO(A) POLYMERASE; RESPONSE ELEMENT; BINDING DOMAIN; VAI RNA;
   INTERFERON; RECOGNITION; LIGANDS
AB A number of small RNA molecules that are high affinity ligands for the 46-kDa form of human 2'-5' oligoadenylate synthetase have been identified by the SELEX method, Surface plasmon resonance analysis indicates that these RNAs bind to the enzyme with dissociation constants in the nanomolar range, Competition experiments indicate that the binding site for the small RNAs on the 2'-5' oligoadenylate synthetase molecule at least partially overlaps that for the synthetic double-stranded RNA, poly(I). poly(C). Several of the RNAs function as potent activators of 2'-5' oligoadenylate synthetase in vitro, although there is no correlation between binding affinity and ability to activate, The RNA aptamers having the strongest activation potential appear to have few base-paired regions. This suggests that 2'-5' oligoadenylate synthetase, which has previously been believed to be activated only by double-stranded RNA, can also be activated by RNA ligands with little secondary structure, Since 2'-5' oligoadenylate synthetase possesses no homology to other known RNA-binding proteins, the development of small specific ligands by SELEX should facilitate studies of RNA-protein interactions and may reveal novel features of the structure-function relationships involving this enzyme.
C1 Aarhus Univ, Dept Mol & Struct Biol, DK-8000 Aarhus C, Denmark.
   Univ London St Georges Hosp, Sch Med, Dept Cellular & Mol Sci, Div Biochem, London SW17 0RE, England.
   Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark.
RP Justesen, J (reprint author), Aarhus Univ, Dept Mol & Struct Biol, CF Mollers Alle,Bldg 130, DK-8000 Aarhus C, Denmark.
RI Martensen, Pia/I-3996-2012; Moestrup, Soren Kragh/A-1403-2014
OI Moestrup, Soren Kragh/0000-0003-3862-2107; Martensen, Pia
   Moller/0000-0002-1259-0226; Hartmann, Rune/0000-0003-1159-066X
CR BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6
   BENECH P, 1985, EMBO J, V4, P2249
   Bevilacqua PC, 1996, BIOCHEMISTRY-US, V35, P9983, DOI 10.1021/bi9607259
   BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511                                                         
   CHEBATH J, 1992, INTERFERON PRINCIPLE, P225
   Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503
   CLEMENS MJ, 1996, TRANSLATIONAL CONTRO, P139
   CLEMENS MJ, 1984, TRANSCRIPTION TRANSL, P270
   DESAI SY, 1995, J BIOL CHEM, V270, P3454, DOI 10.1074/jbc.270.7.3454                                                          
   FERBUS D, 1984, MOL CELL BIOCHEM, V62, P51
   GHOSH SK, 1991, J BIOL CHEM, V266, P15293
   GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478
   GUNNERY S, 1990, P NATL ACAD SCI USA, V87, P8687, DOI 10.1073/pnas.87.22.8687
   Johnston D.S.T., 1992, P NATL ACAD SCI USA, V89, P10979
   JOHNSTON MI, 1984, MECH PRODUCTION ACTI, P189
   JUSTESEN J, 1992, ANAL BIOCHEM, V207, P90, DOI 10.1016/0003-2697(92)90506-3
   JUSTESEN J, 1980, NUCLEIC ACIDS RES, V8, P3073, DOI 10.1093/nar/8.14.3073
   KATZE MG, 1987, EMBO J, V6, P689
   KING CA, 1991, BACULOVIRUS EXPRESSI
   KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683
   LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0                                                   
   Lund AH, 1996, NUCLEIC ACIDS RES, V24, P800, DOI 10.1093/nar/24.4.800
   MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R
   MELLITS KH, 1990, NUCLEIC ACIDS RES, V18, P5401, DOI 10.1093/nar/18.18.5401
   MINKS MA, 1980, J BIOL CHEM, V255, P6403
   MINKS MA, 1979, J BIOL CHEM, V254, P180
   MORDECHAI E, 1995, VIROLOGY, V206, P913, DOI 10.1006/viro.1995.1014
   PATEL RC, 1992, J BIOL CHEM, V267, P7671
   PETERSON ET, 1994, J MOL BIOL, V242, P186, DOI 10.1006/jmbi.1994.1571
   PRATT G, 1988, NUCLEIC ACIDS RES, V16, P3497, DOI 10.1093/nar/16.8.3497
   SAUNDERS ME, 1985, EMBO J, V4, P1761
   SCHNEIDER D, 1992, J MOL BIOL, V228, P862, DOI 10.1016/0022-2836(92)90870-P
   SENGUPTA DN, 1989, NUCLEIC ACIDS RES, V17, P969, DOI 10.1093/nar/17.3.969
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   TUERK C, 1993, GENE, V137, P33, DOI 10.1016/0378-1119(93)90248-2                                                    
   Zuker M, 1994, Methods Mol Biol, V25, P267
NR 36
TC 62
Z9 63
U1 0
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 6
PY 1998
VL 273
IS 6
BP 3236
EP 3246
DI 10.1074/jbc.273.6.3236                                                  
          
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA YV427
UT WOS:000071822300022
PM 9452437
OA gold
DA 2018-01-05
ER

PT J
AU Griffiths, AD
   Duncan, AR
AF Griffiths, AD
   Duncan, AR
TI Strategies for selection of antibodies by phage display
SO CURRENT OPINION IN BIOTECHNOLOGY
LA English
DT Review
ID SINGLE-CHAIN FV; HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN
   MONOCLONAL-ANTIBODIES; BY-PASSING IMMUNIZATION; AFFINITY MATURATION;
   FILAMENTOUS PHAGE; PARSIMONIOUS MUTAGENESIS; SYNTHETIC REPERTOIRES;
   SOMATIC HYPERMUTATION; LIBRARIES
AB Phage antibody-display is rapidly maturing into a very effective tool for antibody generation. The recent development of large primary antibody libraries enables selection of antibodies against most targets in under two weeks and many of these antibodies have relatively high (nanomolar) affinities. Successful strategies have also been developed to affinity mature these antibodies into the picomolar range if required. (C) Current Biology Ltd ISSN 0958-1669.
C1 MRC, Mol Biol Lab, Cambridge CB2 2QH, England.
   Cambridge Antibody Technol Ltd, Melbourn SG8 6JJ, Cambs, England.
RP Griffiths, AD (reprint author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.
RI Griffiths, Andrew/A-1370-2010
OI Griffiths, Andrew/0000-0002-0808-3539
CR BALINT RF, 1993, GENE, V137, P109, DOI 10.1016/0378-1119(93)90258-5                                                    
   Barbas CF, 1996, TRENDS BIOTECHNOL, V14, P230, DOI 10.1016/0167-7799(96)10029-9
   BARBAS CF, 1994, P NATL ACAD SCI USA, V91, P3809, DOI 10.1073/pnas.91.9.3809                                                          
   BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978                                                         
   BREITLING F, 1991, GENE, V104, P147, DOI 10.1016/0378-1119(91)90244-6
   BURTON DR, 1991, P NATL ACAD SCI USA, V88, P10134, DOI 10.1073/pnas.88.22.10134
   CHANG CN, 1991, J IMMUNOL, V147, P3610
   CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0
   CLACKSON T, 1994, TRENDS BIOTECHNOL, V12, P173, DOI 10.1016/0167-7799(94)90079-5
   DAVIES EL, 1995, J IMMUNOL METHODS, V186, P125, DOI 10.1016/0022-1759(95)00143-X
   DEKRUIF J, 1995, J MOL BIOL, V248, P97, DOI 10.1006/jmbi.1995.0204                                                          
   DEKRUIF J, 1995, P NATL ACAD SCI USA, V92, P3938, DOI 10.1073/pnas.92.9.3938
   DeLalla C, 1996, MOL IMMUNOL, V33, P1049, DOI 10.1016/S0161-5890(96)00061-2
   deWildt RMT, 1996, EUR J IMMUNOL, V26, P629, DOI 10.1002/eji.1830260319
   Doorbar J, 1997, VIROLOGY, V238, P40, DOI 10.1006/viro.1997.8768
   Engberg J, 1996, MOL BIOTECHNOL, V6, P287, DOI 10.1007/BF02761708
   Finnern R, 1997, CLIN EXP IMMUNOL, V107, P269, DOI 10.1111/j.1365-2249.1997.254-ce1127.x                                           
   GARRARD LJ, 1991, BIO-TECHNOL, V9, P1373, DOI 10.1038/nbt1291-1373
   GLASER SM, 1992, J IMMUNOL, V149, P3903
   Graus YF, 1997, J IMMUNOL, V158, P1919
   GRIFFITHS AD, 1994, EMBO J, V13, P3245
   GRIFFITHS AD, 1993, EMBO J, V12, P725
   HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2                                                    
   Holliger P, 1996, PROTEIN ENG, V9, P299, DOI 10.1093/protein/9.3.299
   Holliger P, 1997, NAT BIOTECHNOL, V15, P632, DOI 10.1038/nbt0797-632
   HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444
   HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133
   HOOGENBOOM HR, 1992, J MOL BIOL, V227, P381, DOI 10.1016/0022-2836(92)90894-P                                                    
   Hoogenboom HR, 1997, TRENDS BIOTECHNOL, V15, P62, DOI 10.1016/S0167-7799(97)84205-9
   Ignatovich O, 1997, J MOL BIOL, V268, P69, DOI 10.1006/jmbi.1997.0956
   Iliades P, 1997, FEBS LETT, V409, P437, DOI 10.1016/S0014-5793(97)00475-4
   KANG AS, 1991, P NATL ACAD SCI USA, V88, P4363, DOI 10.1073/pnas.88.10.4363
   Kontermann RE, 1997, NAT BIOTECHNOL, V15, P629, DOI 10.1038/nbt0797-629
   Lang IM, 1996, GENE, V172, P295, DOI 10.1016/0378-1119(96)00021-2
   Low NM, 1996, J MOL BIOL, V260, P359, DOI 10.1006/jmbi.1996.0406
   MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U
   MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0
   McGuinness BT, 1996, NAT BIOTECHNOL, V14, P1149, DOI 10.1038/nbt0996-1149
   NISSIM A, 1994, EMBO J, V13, P692
   Ohlin M, 1996, MOL IMMUNOL, V33, P583, DOI 10.1016/0161-5890(96)00018-1                                                    
   Osbourn JK, 1996, IMMUNOTECHNOLOGY, V2, P181, DOI 10.1016/S1380-2933(96)00046-2
   OSBOURN JK, 1998, IN PRESS IMMUNOTECHN
   Parsons HL, 1996, PROTEIN ENG, V9, P1043, DOI 10.1093/protein/9.11.1043
   Pei XY, 1997, P NATL ACAD SCI USA, V94, P9637, DOI 10.1073/pnas.94.18.9637
   Pereira S, 1997, HYBRIDOMA, V16, P11, DOI 10.1089/hyb.1997.16.11
   PERISIC O, 1994, STRUCTURE, V2, P1217, DOI 10.1016/S0969-2126(94)00123-5
   Rakonjac J, 1997, GENE, V198, P99, DOI 10.1016/S0378-1119(97)00298-9
   Roben P, 1996, J CLIN INVEST, V98, P2827, DOI 10.1172/JCI119111
   Schier R, 1996, GENE, V169, P147, DOI 10.1016/0378-1119(95)00821-7
   Schier R, 1996, J MOL BIOL, V263, P551, DOI 10.1006/jmbi.1996.0598
   Schier R, 1996, J MOL BIOL, V255, P28, DOI 10.1006/jmbi.1996.0004
   Schier Robert, 1996, Human Antibodies and Hybridomas, V7, P97
   SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944
   Tomlinson IM, 1996, J MOL BIOL, V256, P813, DOI 10.1006/jmbi.1996.0127
   TOMLINSON IM, 1998, ENCY IMMUNOLOGY
   VanEwijk W, 1997, P NATL ACAD SCI USA, V94, P3903, DOI 10.1073/pnas.94.8.3903
   VAUGHAN TJ, 1996, NAT BIOTECHNOL, V14, P306
   VIEIRA J, 1987, METHOD ENZYMOL, V153, P3
   Vimekas B., 1994, NUCLEIC ACIDS RES, V22, P5600
   WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245
   Yamanaka HI, 1996, J IMMUNOL, V157, P1156
   YANG WP, 1995, J MOL BIOL, V254, P392, DOI 10.1006/jmbi.1995.0626
   Zhu ZP, 1997, PROTEIN SCI, V6, P781
   ZIE MH, 1997, NAT BIOTECHNOL, V15, P768
NR 64
TC 169
Z9 195
U1 2
U2 24
PU CURRENT BIOLOGY LTD
PI LONDON
PA 34-42 CLEVELAND STREET, LONDON W1P 6LB, ENGLAND
SN 0958-1669
J9 CURR OPIN BIOTECH
JI Curr. Opin. Biotechnol.
PD FEB
PY 1998
VL 9
IS 1
BP 102
EP 108
DI 10.1016/S0958-1669(98)80092-X
PG 7
WC Biochemical Research Methods; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA YY066
UT WOS:000072108800016
PM 9503596
DA 2018-01-05
ER

PT J
CA SMR Comm
TI Case histories in drug discovery and design
SO DRUG NEWS & PERSPECTIVES
LA English
DT Article
AB Seven highly informative accounts of drug discovery and design were delivered by members of an international panel of speakers. The evolution of a new drug treatment for schizophrenia commenced with the observation that chlorpromazine possessed "neuroleptic" activity and progressed through studies with various dopamine and serotonin antagonists to ultimately lead to the discovery of risperidone. The 20-amino-acid peptide bivalirudin was rationally derived from hirudin. The alkoxypolyaryl derivative LY-303366 emerged from a second-generation chemical prog ram with the aim of improving the solubility and pharmacokinetic profile of cilofungin. Antiviral activity in the low nanomolar range, combined with oral bioavailability and a clean safety profile, resulted in the development of saquinavir mesylate as the first HIV proteinase inhibitor to become available as a marketed drug. The marimastat drug design program was based on knowledge of the collagenase cleavage site, and molecules incorporated features to allow them to coordinate with the active site zinc atom and side chains that allowed interaction with the enzyme subsites. Initial lead compounds in the anastrozole development program were azoles incorporated onto nonsteroidal estrogen-like scaffolds. Chance synthesis of a nitrile intermediate needed for the naphthalene analogues and further elaboration eventually led to this potent and selective aromatase inhibitor. Rosiglitazone emerged from an SAR program on ciglitazone in which the lipophilic cyclohexyl group was replaced by aromatic and polar groups.
NR 0
TC 0
Z9 0
U1 1
U2 6
PU PROUS SCIENCE, SA
PI BARCELONA
PA PO BOX 540, PROVENZA 388, 08025 BARCELONA, SPAIN
SN 0214-0934
J9 DRUG NEWS PERSPECT
JI Drug News Perspect.
PD FEB
PY 1998
VL 11
IS 1
BP 52
EP 57
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA ZH097
UT WOS:000073071800009
DA 2018-01-05
ER

PT J
AU Lobenberg, R
   Araujo, L
   von Briesen, H
   Rodgers, E
   Kreuter, J
AF Lobenberg, R
   Araujo, L
   von Briesen, H
   Rodgers, E
   Kreuter, J
TI Body distribution of azidothymidine bound to hexyl-cyanoacrylate
   nanoparticles after i.v. injection to rats
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE nanoparticles; drug targeting; macrophages; AZT; AIDS
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN KUPFFER CELLS; TISSUE DISTRIBUTION;
   POLYBUTYLCYANOACRYLATE NANOPARTICLES; PRIMARY CULTURES; IN-VITRO;
   MACROPHAGES; HIV; INFECTION; ZIDOVUDINE
AB Cells of the reticuloendothelial system (RES e.g. macrophages) play an important role in the immunopathogenesis of AIDS. The objective of the present study was to investigate the possibility of specifically targeting antiviral drugs such as azidothymidine (AZT) to macrophages using nanoparticles as colloidal drug carriers. In a first series of experiments the body distribution of C-14-labelled AZT bound to nanoparticles and a similarly prepared control solution with unbound AZT were studied in rats after intravenous injection. In a second series of experiments polysorbate 80-coated nanoparticles and a solution of AZT in saline were tested. C-14-labelled AZT was bound to nanoparticles using the surfactant bis(2-ethylhexyl) sulphosuccinate sodium (DOSS). The radioactivity in several organs, including those containing large numbers of macrophages, was measured after intravenous injection of the AZT-nanoparticles and the AZT-control solutions. AZT concentrations were up to 18 times higher in organs belonging to the RES if the drug was bound to nanoparticles compared with unbound AZT. These results demonstrate that nanoparticles are a potential drug targeting system for anti-AIDS drugs. The increase in drug concentration at the sites containing abundant macrophages may allow a reduction in dosage to reduce systemic toxicity. (C) 1998 Elsevier Science B.V.
C1 Univ Frankfurt, Inst Pharmaceut Technol, D-60439 Frankfurt, Germany.
   Chemotherapeut Res Inst, D-60596 Frankfurt, Germany.
   Queens Univ Belfast, Sch Pharm, Belfast, Antrim, North Ireland.
RP Kreuter, J (reprint author), Univ Frankfurt, Inst Pharmaceut Technol, Marie Curie Str 9, D-60439 Frankfurt, Germany.
OI Lobenberg, Raimar/0000-0002-0919-0213
CR ALYAUTDIN R, 1995, EUR J PHARM BIOPHARM, V41, P44
   Alyautdin RN, 1997, PHARMACEUT RES, V14, P325, DOI 10.1023/A:1012098005098                                                         
   Balter M, 1996, SCIENCE, V274, P1464, DOI 10.1126/science.274.5292.1464
   Benatti U, 1996, BIOCHEM BIOPH RES CO, V220, P20, DOI 10.1006/bbrc.1996.0349
   BENDER A, 1994, RES VIROLOGY, V145, P215, DOI 10.1016/S0923-2516(07)80025-2                                                   
   Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   BORCHARD G, 1994, INT J PHARM, V110, P29, DOI 10.1016/0378-5173(94)90372-7                                                    
   BORCHARD G, 1993, UNTERSUCHUNG INTERAK
   COUVREUR P, 1980, J PHARM SCI, V69, P199, DOI 10.1002/jps.2600690222                                                          
   DOUGLAS SJ, 1984, J COLLOID INTERF SCI, V101, P149, DOI 10.1016/0021-9797(84)90015-8                                                    
   GENDELMAN HE, 1989, AIDS, V3, P475, DOI 10.1097/00002030-198908000-00001
   GRISLAIN L, 1983, INT J PHARM, V15, P335, DOI 10.1016/0378-5173(83)90166-7
   HAASE AT, 1996, SCIENCE, V274
   KANTE B, 1980, INT J PHARM, V7, P45, DOI 10.1016/0378-5173(80)90097-6
   KREUTER J, 1995, BRAIN RES, V674, P171, DOI 10.1016/0006-8993(95)00023-J
   KREUTER J, 1983, ONCOLOGY, V40, P363
   KREUTER J, 1979, J PHARM SCI, V68, P1443, DOI 10.1002/jps.2600681129
   Kreuter J., 1994, COLLOIDAL DRUG DELIV, P219
   LENAERTS V, 1984, J PHARM SCI, V73, P980, DOI 10.1002/jps.2600730730
   Lobenberg R, 1996, AIDS RES HUM RETROV, V12, P1709, DOI 10.1089/aid.1996.12.1709
   MARTINDALE, 1993, ANTIVIRAL AGENTS, V30, P560
   MCLEOD GX, 1992, ANN INTERN MED, V117, P487, DOI 10.7326/0003-4819-117-6-487
   MELTZER MS, 1990, IMMUNOL TODAY, V11, P217, DOI 10.1016/0167-5699(90)90086-O                                                    
   MULLER RH, 1992, INT J PHARM, V84, P1, DOI 10.1016/0378-5173(92)90209-K
   NEFZGER M, 1984, J PHARM SCI, V73, P1309, DOI 10.1002/jps.2600730934
   PHILLIPS NC, 1992, BLOOD, V79, P1137
   ROY S, 1988, J LEUKOCYTE BIOL, V43, P91
   SACHS L, 1984, ANGEWANDTE STAT
   Schafer V, 1994, Clin Diagn Virol, V1, P279, DOI 10.1016/0928-0197(94)90058-2
   SCHAFER V, 1992, PHARMACEUT RES, V9, P541, DOI 10.1023/A:1015852732512
   SCHMITT MP, 1990, AIDS RES HUM RETROV, V6, P987
   SCHMITT MP, 1990, RES VIROLOGY, V141, P143, DOI 10.1016/0923-2516(90)90016-C                                                    
   SCHOLMERICH P, 1996, ARZNEIMITTELTHERAPIE, P58
   SHAFER RW, 1994, J INFECT DIS, V169, P722, DOI 10.1093/infdis/169.4.722                                                        
   SINGER JM, 1969, J RETICULOENDOTH SOC, V6, P561
   TROSTER SD, 1990, INT J PHARM, V61, P85, DOI 10.1016/0378-5173(90)90047-8
   VONBAEYER H, 1993, INT J CLIN PHARM TH, V31, P382
   VONBRIESEN H, 1990, RES VIROLOGY, V141, P225, DOI 10.1016/0923-2516(90)90025-E
   WASER PG, 1987, INT J PHARM, V39, P213, DOI 10.1016/0378-5173(87)90219-5
NR 39
TC 81
Z9 85
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD JAN 2
PY 1998
VL 50
IS 1-3
BP 21
EP 30
DI 10.1016/S0168-3659(97)00105-3
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA YU373
UT WOS:000071710600003
PM 9685869
DA 2018-01-05
ER

PT J
AU Fujiwara, M
   Okamoto, M
   Ijichi, K
   Tokuhisa, K
   Hanasaki, Y
   Katsuura, K
   Uemura, D
   Shigeta, S
   Konno, K
   Yokota, T
   Baba, M
AF Fujiwara, M
   Okamoto, M
   Ijichi, K
   Tokuhisa, K
   Hanasaki, Y
   Katsuura, K
   Uemura, D
   Shigeta, S
   Konno, K
   Yokota, T
   Baba, M
TI Upregulation of HIV-1 replication in chronically infected cells by
   ingenol derivatives
SO ARCHIVES OF VIROLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN-KINASE-C; EUPHORBIA-KANSUI;
   ACTIVATION; EXPRESSION; AGENTS; RECEPTOR; ACETATE; BINDING; ESTERS
AB We have previously reported that ingenol derivatives are highly potent inhibitors of human immunodeficiency virus type I (HIV-I) replication in acutely infected cells. In this study, however, we ha cre found that some ingenol derivatives strongly enhance the replication of HIV-1 in chronically infected cells at nanomolar concentrations. One of the derivatives could activate nuclear factor kappa B(NF-kappa B), a potent inducer of HIV-I replication, through the activation of protein kinase C (PKC). Whereas;another derivative, which affected neither PKC nor NF-kappa B, significantly enhanced HIV-1 replication, suggesting that a PKC-independent mechanism may also exist in ingenol derivative-induced HIV-I up-regulation.
C1 Rat Drug Design Labs, Fukushima 9601242, Japan.
   Kagoshima Univ, Fac Med, Ctr Chron Viral Dis, Div Human Retroviruses, Kagoshima 890, Japan.
   Tosoh Corp, Tokyo Res Lab, Kanagawa, Japan.
   Nagoya Univ, Grad Sch Sci, Dept Chem, Nagoya, Aichi, Japan.
   Sagami Chem Res Ctr, Kanagawa, Japan.
   Fukushima Med Univ, Sch Med, Dept Microbiol, Fukushima, Japan.
RP Fujiwara, M (reprint author), Rat Drug Design Labs, 4-1-1 Misato, Fukushima 9601242, Japan.
RI Baba, Masanori/G-3867-2011
CR ANTONI BA, 1994, VIROLOGY, V202, P684, DOI 10.1006/viro.1994.1390
   BUTERA ST, 1991, J VIROL, V65, P4645
   CASTAGNA M, 1982, J BIOL CHEM, V257, P7847
   CHOWDHURY MIH, 1990, VIROLOGY, V176, P126
   Cohen PS, 1997, MOL MED, V3, P339
   DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405
   FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274                                                         
   FOLKS TM, 1988, J IMMUNOL, V140, P1117
   Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917
   Fujiwara M, 1996, ANTIVIR CHEM CHEMOTH, V7, P230, DOI 10.1177/095632029600700502                                                      
   GOLDING H, 1994, J VIROL, V68, P1962
   HARADA S, 1986, VIROLOGY, V154, P249, DOI 10.1016/0042-6822(86)90451-4
   HASLER CM, 1992, CANCER RES, V52, P202
   HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0
   KIMPTON J, 1992, J VIROL, V66, P2232
   KINTER AL, 1990, J VIROL, V64, P4306
   KUMAR S, 1996, EUR CYTOKINE NETW, V7, P558
   MATSUMOTO T, 1992, PLANTA MED, V58, P255, DOI 10.1055/s-2006-961447
   MUFSON RA, 1979, CANCER RES, V39, P3602
   OBRIEN MC, 1995, BIOCHEM BIOPH RES CO, V207, P903, DOI 10.1006/bbrc.1995.1271                                                          
   POLI G, 1992, AIDS RES HUM RETROV, V8, P191, DOI 10.1089/aid.1992.8.191
   SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419
   SORG B, 1987, CARCINOGENESIS, V8, P1, DOI 10.1093/carcin/8.1.1                                                            
   WU TS, 1991, J NAT PROD, V54, P823, DOI 10.1021/np50075a011
NR 24
TC 20
Z9 23
U1 0
U2 2
PU SPRINGER-VERLAG WIEN
PI VIENNA
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA
SN 0304-8608
J9 ARCH VIROL
JI Arch. Virol.
PY 1998
VL 143
IS 10
BP 2003
EP 2010
DI 10.1007/s007050050436                                                   
          
PG 8
WC Virology
SC Virology
GA 139TT
UT WOS:000077046300012
PM 9856087
DA 2018-01-05
ER

PT J
AU Akashi, M
   Niikawa, T
   Serizawa, T
   Hayakawa, T
   Baba, M
AF Akashi, M
   Niikawa, T
   Serizawa, T
   Hayakawa, T
   Baba, M
TI Graft copolymers having hydrophobic backbone and hydrophilic branches
   part XIV - Capture of HIV-1 gp120 and virions by lectin-immobilized
   polystyrene nanospheres
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; MICROSPHERES; SURFACES
AB A lectin such as concanavalin A (Con A) was immobilized on the surfaces of poly(methacrylic acid) branches covered with polystyrene nanospheres with a diameter of 360 nm, which were obtained by the free radical copolymerization of styrene with the poly(tert-butylmethacrylate) macromonomer, followed by hydrolysis. Using Con A-immobilized (0.3 mu g/cm(2)) nanospheres, the interaction of the nanospheres with HIV-1 was determined by the reduction of the gp120 level and the viral infectivity of the HIV-1 suspensions after a 60 min incubation at room temperatures. Con A-immobilized nanospheres achieved a 95 and a 77% reduction of the gp120 level and the infectivity at a concentration of 0.5 mg/mL, respectively, indicating the effective capture of the gp120 and the virions.
C1 Kagoshima Univ, Fac Engn, Dept Appl Chem & Chem Engn, Kagoshima 890, Japan.
   Kagoshima Univ, Fac Med, Div Human Retroviruses, Ctr Chron Viral Dis, Kagoshima 890, Japan.
RP Akashi, M (reprint author), Kagoshima Univ, Fac Engn, Dept Appl Chem & Chem Engn, 1-21-40 Korimoto, Kagoshima 890, Japan.
RI Baba, Masanori/G-3867-2011
CR AKASHI M, 1992, BIOCONJUGATE CHEM, V3, P363, DOI 10.1021/bc00017a002
   BALZARINI J, 1991, ANTIMICROB AGENTS CH, V35, P410, DOI 10.1128/AAC.35.3.410                                                            
   Chen MQ, 1996, J POLYM SCI POL CHEM, V34, P2213
   EVANS LA, 1993, HIV MOL ORG PATHOGEN, P29
   Kawaguchi H., 1993, BIOMEDICAL APPL POLY, P299
   LIFSON J, 1986, J EXP MED, V164, P2101, DOI 10.1084/jem.164.6.2101
   Mbemba E, 1996, AIDS RES HUM RETROV, V12, P47, DOI 10.1089/aid.1996.12.47
   RIZA M, 1995, J POLYM SCI POL CHEM, V33, P1219, DOI 10.1002/pola.1995.080330804                                                     
   Sakuma S, 1997, INT J PHARM, V149, P93, DOI 10.1016/S0378-5173(96)04861-2
   SINGER JM, 1956, AM J MED, V21, P888, DOI 10.1016/0002-9343(56)90103-6                                                    
NR 10
TC 74
Z9 81
U1 0
U2 6
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD JAN-FEB
PY 1998
VL 9
IS 1
BP 50
EP 53
DI 10.1021/bc970045y                                                       
          
PG 4
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA YR500
UT WOS:000071501500006
PM 9460546
DA 2018-01-05
ER

PT J
AU Lewis, KJ
   Irwin, WJ
   Akhtar, S
AF Lewis, KJ
   Irwin, WJ
   Akhtar, S
TI Development of a sustained-release biodegradable polymer delivery system
   for site-specific delivery of oligonucleotides: Characterization of
   P(LA-GA) copolymer microspheres in vitro
SO JOURNAL OF DRUG TARGETING
LA English
DT Article
DE oligonucleotides; antisense; poly(lactic acid co-glycolic acid);
   delivery; biodegradable; stability
ID ANTISENSE OLIGONUCLEOTIDES; POLYALKYLCYANOACRYLATE NANOPARTICLES;
   SYNTHETIC OLIGONUCLEOTIDES; GELATIN MICROSPHERES; INVITRO DEGRADATION;
   LEUPROLIDE ACETATE; INVIVO DEGRADATION; CELLULAR UPTAKE; PARTICLE-SIZE;
   STABILITY
AB Antisense oligodeoxynucleotides (ODNs) can selectively inhibit individual gene expression provided they gain access to and remain stable at the target site for a sufficient period of time. Biodegradable sustained-release delivery systems may facilitate site-specific delivery and also prevent degradation of ODNs by nucleases whilst delivering the nucleic acid in a controlled manner to the desired site of action. In this study, we have characterized biodegradable poly (lactide-co-glycolide) (P(LA-GA)) 50:50 microspheres for the potential delivery of antisense oligonucleotides in vivo. Phosphodiester (PO) oligonucleotides complementary to either c-myc proto-oncogene or the Inr gene in HIV-RNA were adequately incorporated within P(LA-GA) microspheres with entrapment efficiencies up to 60% depending on particles size. In vitro release profiles of antisense nucleic acids from 10-20 mu m size microspheres over 56 days in physiological buffer were triphasic, Profiles were characterised by an initial burst effect during the first 48 hours (phase 1) of release followed by a more sustained release (phase 2) with an additional increased release (phase 3) being observed after 25 days which corresponded with bulk degradation of the copolymer matrix. The release profiles were influenced by microsphere size, copolymer molecular weight, ODN loading, ODN length and by the pH of release medium used. The serum stability of PO ODNs was significantly improved when entrapped within P(LA-GA) microspheres and the hybridization capability, as assessed by duplex melting (Tm) measurements, of released ODN was not impaired by the double-emulsion microsphere fabrication procedure used. Thus, P(LA-GA) microspheres appear to be promising candidates for improving site-specific delivery profiles for ODNs and are worthy of further evaluation in vivo.
C1 Aston Univ, Inst Pharmaceut Sci, Birmingham B4 7ET, W Midlands, England.
RP Akhtar, S (reprint author), Aston Univ, Inst Pharmaceut Sci, Aston Triangle, Birmingham B4 7ET, W Midlands, England.
EM S.Akhtar@aston.ac.uk
CR AGRAWAL S, 1991, P NATL ACAD SCI USA, V88, P7595, DOI 10.1073/pnas.88.17.7595
   Akhtar S, 1997, INT J PHARM, V151, P57, DOI 10.1016/S0378-5173(97)04887-4                                                   
   Akhtar S, 1992, Trends Cell Biol, V2, P139, DOI 10.1016/0962-8924(92)90100-2
   Akhtar S, 1996, J ANTIMICROB CHEMOTH, V38, P159, DOI 10.1093/jac/38.2.159
   Akhtar S, 1997, TRENDS PHARMACOL SCI, V18, P12, DOI 10.1016/S0165-6147(96)01002-4
   AKHTAR S, 1991, LIFE SCI, V49, P1793, DOI 10.1016/0024-3205(91)90480-Y
   Akhtar S, 1995, DELIVERY STRATEGIES
   ALONSO MJ, 1993, PHARMACEUT RES, V10, P945, DOI 10.1023/A:1018942118148
   BHARDWAJ SB, 1995, J MICROENCAPSUL, V12, P71, DOI 10.3109/02652049509051128
   BOLTON ET, 1962, P NATL ACAD SCI USA, V48, P1390, DOI 10.1073/pnas.48.8.1390
   BREM H, 1990, BIOMATERIALS, V11, P699, DOI 10.1016/0142-9612(90)90030-T
   CHAVANY C, 1994, PHARMACEUT RES, V11, P1370, DOI 10.1023/A:1018923301967
   CHAVANY C, 1992, PHARMACEUT RES, V9, P441, DOI 10.1023/A:1015871809313
   CHU CC, 1982, J BIOMED MATER RES, V16, P117, DOI 10.1002/jbm.820160204
   CHU CC, 1981, J BIOMED MATER RES, V15, P795, DOI 10.1002/jbm.820150604
   COHEN S, 1991, PHARMACEUT RES, V8, P713, DOI 10.1023/A:1015841715384                                                         
   CORTESI R, 1994, INT J PHARM, V105, P181, DOI 10.1016/0378-5173(94)90464-2
   Coulson JM, 1996, MOL PHARMACOL, V50, P314
   DAGLE JM, 1991, NUCLEIC ACIDS RES, V19, P1805, DOI 10.1093/nar/19.8.1805
   DAVIS SS, 1993, J CONTROL RELEASE, V24, P157, DOI 10.1016/0168-3659(93)90175-5
   FOURNIER C, 1991, CANCER RES, V51, P5384
   HOKE GD, 1991, NUCLEIC ACIDS RES, V19, P5743, DOI 10.1093/nar/19.20.5743
   Hudson AJ, 1996, INT J PHARM, V136, P23, DOI 10.1016/0378-5173(96)04474-2
   ILLUM L, 1987, LIFE SCI, V40, P367, DOI 10.1016/0024-3205(87)90138-X
   ITAKURA K, 1984, ANNU REV BIOCHEM, V53, P323
   Juliano R L, 1992, Antisense Res Dev, V2, P165
   KAMEI S, 1995, EUR HOSP PHARM, V1, P113
   LECORRE P, 1994, INT J PHARM, V107, P41, DOI 10.1016/0378-5173(94)90300-X                                                    
   LEWIS KJ, 1995, J CONTROL RELEASE, V37, P173, DOI 10.1016/0168-3659(95)00100-M
   MAHER LJ, 1988, NUCLEIC ACIDS RES, V16, P3341, DOI 10.1093/nar/16.8.3341
   Nakada Y, 1996, PHARMACEUT RES, V13, P38, DOI 10.1023/A:1016017014573
   NARAYANI R, 1994, J MICROENCAPSUL, V11, P69, DOI 10.3109/02652049409040439
   OGAWA Y, 1988, CHEM PHARM BULL, V36, P2576
   OGAWA Y, 1988, CHEM PHARM BULL, V36, P1095
   ROPERT C, 1994, ANTISENSE RES DEV, V4, P207
   Sambrook J, 1989, MOL CLONING LAB MANU
   SCHWAB G, 1994, P NATL ACAD SCI USA, V91, P10460, DOI 10.1073/pnas.91.22.10460                                                        
   STEIN CA, 1988, GENE, V72, P333, DOI 10.1016/0378-1119(88)90160-6
   Tsai D C, 1986, J Microencapsul, V3, P181, DOI 10.3109/02652048609031572
   VISSCHER GE, 1988, J BIOMED MATER RES, V22, P733, DOI 10.1002/jbm.820220806
   WANG HT, 1990, BIOMATERIALS, V11, P679, DOI 10.1016/0142-9612(90)90026-M
   WICKSTROM E, 1986, J BIOCHEM BIOPH METH, V13, P97, DOI 10.1016/0165-022X(86)90021-7
   ZHAO QY, 1995, ANTISENSE RES DEV, V5, P185
NR 43
TC 49
Z9 50
U1 0
U2 7
PU HARWOOD ACAD PUBL GMBH
PI READING
PA C/O STBS LTD, PO BOX 90, READING, BERKS, ENGLAND RG1 8JL
SN 1061-186X
J9 J DRUG TARGET
JI J. Drug Target.
PY 1998
VL 5
IS 4
BP 291
EP 302
DI 10.3109/10611869808995882                                               
          
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 106RL
UT WOS:000075164200006
PM 9713978
DA 2018-01-05
ER

PT S
AU Grimm, MC
   Ben-Baruch, A
   Taub, DD
   Howard, OMZ
   Wang, JM
   Oppenheim, JJ
AF Grimm, MC
   Ben-Baruch, A
   Taub, DD
   Howard, OMZ
   Wang, JM
   Oppenheim, JJ
BE McCann, SM
   Lipton, JM
   Sternberg, EM
   Chrousos, GP
   Gold, PW
   Smith, CC
TI Opiate inhibition of chemokine-induced chemotaxis
SO NEUROIMMUNOMODULATION: MOLECULAR ASPECTS, INTEGRATIVE SYSTEMS, AND
   CLINICAL ADVANCES
SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
LA English
DT Article; Proceedings Paper
CT 3rd Congress of the International-Society-of-Neuroimmunomodulation on
   Neuroimmunomodulation - Molecular Aspects, Integrative Systems, and
   Clinical Advances
CY NOV 13-15, 1996
CL BETHESDA, MARYLAND
SP Int Soc Neuroimmunomodulat, NIH, NCI, Natl Inst Aging, NIAID, Natl Inst Arthritis & Muskuloskeletal & Skin Dis, NICHHD, NIDR, NIMH, Natl Inst Nursing Res, NIH, Off Alternat Med, NIH, Off Behav & Social Sci Res, NIH, Off Rare Dis Res, NIH, Off Res Womens Hlth, Glaxowellcome Inc, TIG Instrumenten Gesell Ag, Vector Lab
ID RECEPTOR GENE-EXPRESSION; NITRIC-OXIDE; MORPHINE; HIV-1; CELLS;
   PROTEINS; INVERTEBRATE; GRANULOCYTES; IMMUNOCYTES; INFECTION
AB Chemokines consist of a family of 8-16-kDa cytokines that are generated very early in a wide variety of inflammatory responses and attract leukocytes to local sites. At nanomolar concentrations chemokines initiate signal transduction and activate leukocytes through seven transmembrane receptors (STM), but higher micromolar doses result in homologous desensitizing effects. On the basis of reports that opiates have anti-inflammatory effects and also use STM, we have investigated the possibility that they may cross-desensitize the response of leukocytes to chemokines. We have confirmed previous observations that met-enkephalin (MET) is chemotactic for human peripheral blood monocytes. Furthermore, we observed that preincubation of monocytes or neutrophils with MET or morphine prevented their subsequent chemotaxis in response to chemokines (MIP1 alpha or IL-8). However, MET did not inhibit the chemotactic response of PMN to NAP-2 a homologous chemokine that is less potent than IL-8 but cannot be desensitized. The inhibitory effect of opiates on chemokine-induced chemotaxis was antagonized by naloxone. Since MIP-1 alpha and IL-8, unlike NAP-2, have the capacity to desensitize leukocytes, it is possible that opiates, by desensitizing some chemokine responses, can suppress inflammatory reactions.
C1 NCI, Frederick Canc Res & Dev Ctr, Div Basic Sci, Intramural Res Support Program,SAIC Frederick, Frederick, MD 21702 USA.
   NCI, Frederick Canc Res & Dev Ctr, Mol Immunoregulat Lab, Div Basic Sci, Frederick, MD 21702 USA.
   NCI, Frederick Canc Res & Dev Ctr, Clin Serv Program, Frederick, MD 21702 USA.
RP Grimm, MC (reprint author), NCI, Frederick Canc Res & Dev Ctr, Div Basic Sci, Intramural Res Support Program,SAIC Frederick, Bldg 560,Rm 21-89A, Frederick, MD 21702 USA.
RI Howard, O M Zack/B-6117-2012
OI Howard, O M Zack/0000-0002-0505-7052
CR Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955
   BenBaruch A, 1997, J IMMUNOL, V158, P5927
   BHARGAVA HN, 1994, BRAIN RES, V642, P1, DOI 10.1016/0006-8993(94)90899-0
   BRYANT HU, 1987, LIFE SCI, V41, P1731, DOI 10.1016/0024-3205(87)90601-1
   Chao CC, 1996, P NATL ACAD SCI USA, V93, P8051, DOI 10.1073/pnas.93.15.8051
   Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6
   CHUANG LF, 1994, BIOCHEM BIOPH RES CO, V202, P1291, DOI 10.1006/bbrc.1994.2071
   CHUANG TK, 1995, BIOCHEM BIOPH RES CO, V216, P922, DOI 10.1006/bbrc.1995.2709
   CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021
   Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0
   Donahoe RM, 1988, PSYCHOL NEUROPSYCHIA, P145
   Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8                                                   
   Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0
   ERWIN RA, 1995, ENDOCRINOLOGY, V136, P3512, DOI 10.1210/en.136.8.3512
   FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/0022-1759(80)90211-2
   Goldstein A, 1973, Adv Biochem Psychopharmacol, V8, P471
   HEAGY W, 1995, J CLIN INVEST, V96, P1366, DOI 10.1172/JCI118171                                                               
   KENNEDY J, 1995, J IMMUNOL, V155, P203
   Magazine HI, 1996, J IMMUNOL, V156, P4845
   MAKMAN MH, 1995, J IMMUNOL, V154, P1323
   MUKAIDA N, 1992, INTERLEUKIN, V8, P41
   Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3
   NOVICK DM, 1989, J PHARMACOL EXP THER, V250, P606
   OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153                                             
   PACIFICI R, 1994, J PHARMACOL EXP THER, V269, P1112
   PELLIS NR, 1986, EXP NEUROL, V93, P92, DOI 10.1016/0014-4886(86)90148-2                                                    
   PETERSON PK, 1997, IN PRESS ADV NEUROIM
   RUFF M, 1985, CLIN IMMUNOL IMMUNOP, V37, P387, DOI 10.1016/0090-1229(85)90108-4
   SHEFFLER LA, 1995, J LEUKOCYTE BIOL, V57, P152
   STEFANO GB, 1993, P NATL ACAD SCI USA, V90, P11099, DOI 10.1073/pnas.90.23.11099
   TUBARO E, 1983, J INFECT DIS, V148, P656, DOI 10.1093/infdis/148.4.656                                                        
   VANEPPS DE, 1984, J IMMUNOL, V132, P3046
NR 32
TC 61
Z9 63
U1 0
U2 4
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA
SN 0077-8923
BN 1-57331-072-7
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 1998
VL 840
BP 9
EP 20
DI 10.1111/j.1749-6632.1998.tb09544.x                                      
          
PG 12
WC Endocrinology & Metabolism; Immunology; Multidisciplinary Sciences;
   Neurosciences
SC Endocrinology & Metabolism; Immunology; Science & Technology - Other
   Topics; Neurosciences & Neurology
GA BL14S
UT WOS:000074444500002
PM 9629232
DA 2018-01-05
ER

PT J
AU Faiman, GA
   Horovitz, A
AF Faiman, GA
   Horovitz, A
TI Thermodynamic analysis of the interaction between the 0.5 beta Fv
   fragment and the RP135 peptide antigen derived from the V3 loop of HIV-1
   gp120
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; NEUTRALIZING ANTIBODY; HEAT-CAPACITY;
   CRYSTAL-STRUCTURE; BINDING; SITE; PROTEINS; DETERMINANT; RECOGNITION;
   ASSOCIATION
AB The Fv fragment of the 0.5 beta monoclonal antibody has recently been constructed, expressed, and purified. It binds with nanomolar affinity to the immunogenic RP135 peptide that is derived from the principal neutralizing determinant of HIV-1 in the third hypervariable region of gp120. Here, we analyzed the temperature-dependence of binding of the 0.5 beta Fv fragment to the RP135 peptide and a series of mutants thereof. Our results show that there is almost complete enthalpy-entropy compensation in the effects of mutations in the peptide on binding to the Fv, indicating that the mutations do not change the binding mechanism. There is good correlation, for residues within the antigenic epitope, between mutational effects on Delta C-p and calculated values of Delta Delta C-p, based on the extent of burial of polar and non-polar surface areas of amino acids. The value of Delta C-p for the binding of the 0.5 beta Fv fragment to the wild-type RP135 peptide is found to be -5.0 (+/- 0.9) heal K-1 mol(-1) in the presence of 0.1% Tween-20 but only -0.1 (+/- 0.9) kcal K-1 mol(-1) in its absence. This result has important implications for the successful application of the structural parameterization approach to predicting changes in heat capacity that accompany binding reactions carried out in the presence of detergent or protein-stabilizing agents.
C1 WEIZMANN INST SCI, DEPT BIOL STRUCT, IL-76100 REHOVOT, ISRAEL.
CR AYALA YM, 1995, J MOL BIOL, V253, P787, DOI 10.1006/jmbi.1995.0591
   DECRISTOFARO R, 1994, J MOL BIOL, V239, P569, DOI 10.1006/jmbi.1994.1396
   Faiman GA, 1996, J BIOL CHEM, V271, P13829, DOI 10.1074/jbc.271.23.13829                                                        
   Frisch C, 1997, J MOL BIOL, V267, P696, DOI 10.1006/jmbi.1997.0892
   GHIARA JB, 1994, SCIENCE, V264, P82, DOI 10.1126/science.7511253                                                         
   GOMEZ J, 1995, PROTEINS, V22, P404, DOI 10.1002/prot.340220410
   GOMEZ J, 1995, J MOL BIOL, V252, P337, DOI 10.1006/jmbi.1995.0501                                                          
   Guinto ER, 1996, BIOCHEMISTRY-US, V35, P8800, DOI 10.1021/bi9608828
   HIBBITS KA, 1994, BIOCHEMISTRY-US, V33, P3584, DOI 10.1021/bi00178a015                                                             
   Hurle Mark R., 1994, Current Opinion in Biotechnology, V5, P428, DOI 10.1016/0958-1669(94)90053-1
   LADBURY JE, 1994, J MOL BIOL, V238, P669, DOI 10.1006/jmbi.1994.1328
   LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X
   LEFFLER JE, 1963, RATES EQUILIBRIA ORG, P315
   Mandiyan V, 1996, J BIOL CHEM, V271, P4770
   MATSUSHITA S, 1988, J VIROL, V62, P2107
   MURPHY KP, 1993, PROTEINS, V15, P113, DOI 10.1002/prot.340150203
   MURPHY KP, 1995, PROTEINS, V21, P83, DOI 10.1002/prot.340210202
   MURPHY KP, 1992, J MOL BIOL, V227, P293, DOI 10.1016/0022-2836(92)90699-K
   MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2
   NILSSON B, 1995, CURR OPIN STRUC BIOL, V5, P450, DOI 10.1016/0959-440X(95)80028-X                                                    
   PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932
   PLUCKTHUN A, 1992, IMMUNOL REV, V130, P151, DOI 10.1111/j.1600-065X.1992.tb01525.x
   REES AR, 1994, TRENDS BIOTECHNOL, V12, P199, DOI 10.1016/0167-7799(94)90083-3                                                    
   RINI JM, 1993, P NATL ACAD SCI USA, V90, P6325, DOI 10.1073/pnas.90.13.6325                                                         
   SNYDER SL, 1975, ANAL BIOCHEM, V64, P284, DOI 10.1016/0003-2697(75)90431-5
   SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294
   STANFIELD RL, 1995, CURR OPIN STRUC BIOL, V5, P103, DOI 10.1016/0959-440X(95)80015-S
   STOLL VS, 1990, METHOD ENZYMOL, V182, P24
   TIMASHEFF SN, 1993, ANNU REV BIOPH BIOM, V22, P67, DOI 10.1146/annurev.bb.22.060193.000435                                             
   VARADARAJAN R, 1992, BIOCHEMISTRY-US, V31, P1421, DOI 10.1021/bi00120a019
   WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0
   ZVI A, 1992, BIOCHEMISTRY-US, V31, P6972, DOI 10.1021/bi00145a015
   ZVI A, 1995, EUR J BIOCHEM, V229, P178, DOI 10.1111/j.1432-1033.1995.tb20453.x
   Zvi A, 1997, BIOCHEMISTRY-US, V36, P8619, DOI 10.1021/bi970520f
NR 34
TC 5
Z9 5
U1 0
U2 0
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 12
PY 1997
VL 272
IS 50
BP 31407
EP 31411
DI 10.1074/jbc.272.50.31407                                                
          
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA YL419
UT WOS:A1997YL41900031
PM 9395472
OA gold
DA 2018-01-05
ER

PT J
AU Bloom, J
   Ortiz, J
   Rodriguez, JF
AF Bloom, J
   Ortiz, J
   Rodriguez, JF
TI Azidothymidine triphosphate determination using micellar electrokinetic
   capillary chromatography
SO CELLULAR AND MOLECULAR BIOLOGY
LA English
DT Article; Proceedings Paper
CT 5th RCMI International AIDS Symposium
CY NOV 10-12, 1996
CL SAN JUAN, PR
SP NIH, Natl Ctr Res Resources, Res Ctr Minority Inst, Morehouse Sch Med, Atlanta GA, Ponce Sch Med, PR, Univ Cent Caribe, PR, Univ PR, Rio Piedras, Univ PR, Med Sci, FL A & M Univ, TX So Univ, Tuskegee Univ, Charles Drew Sch Med, Howard Univ, Maharry Med Coll
DE capillary electrophoresis; nucleotides; azidothymidine;
   azidothymidine-triphosphate
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PERFORMANCE LIQUID-CHROMATOGRAPHY;
   AIDS-RELATED COMPLEX; ZONE ELECTROPHORESIS; CELLULAR PHARMACOLOGY; ORAL
   ZIDOVUDINE; NUCLEOTIDES; SEPARATION; TRIAL; 2',3'-DIDEOXYINOSINE
AB There is a need to perform pharmacokinetic studies in the pediatric population utilizing antiretroviral drugs, which have shown effectiveness for the treatment of human immunodeficiency virus (HN). In order to establish a relationship between efficacy and toxicity, we need to detect and quantitate these antiretroviral nucleosides and their metabolites at the intracellular level. Micellar electrokinetic capillary chromatography (MECC) was used for the separation of five nucleotides: cytidine triphosphate (CTP), adenosine triphosphate (ATP), thymidine triphosphate (TTP), guanosine triphosphate (GTP) and azidothymidine triphosphate (AZT-TP). Attomoles of these nucleotides were satisfactorily resolved in short run times with hi,oh peak efficiencies. In addition, nanoliters of sample volume were used to perform the analysis using ultraviolet (UV) detection at 254 nm.
C1 UNIV PUERTO RICO,SCH MED,DEPT BIOCHEM,SAN JUAN,PR 00936.
   UNIV PUERTO RICO,SCH PHARM,DEPT PHARMACEUT SCI,SAN JUAN,PR 00936.
FU NCRR NIH HHS [RR-03051, RR11126]; NIGMS NIH HHS [S06GM08224]
CR AHLUWALIA G, 1987, BIOCHEM PHARMACOL, V36, P3797, DOI 10.1016/0006-2952(87)90440-0
   BLANCHE S, 1988, AM J MED, V317, P203
   COBB KA, 1989, ANAL CHEM, V61, P2226, DOI 10.1021/ac00195a003
   DEYL Z, 1994, J CHROMATOGR B, V656, P3, DOI 10.1016/0378-4347(94)00035-2
   ETTRE LS, 1967, PRACTICE GAS CHROMAT, P125
   FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333
   GROSS L, 1990, ANAL CHEM, V62, P427, DOI 10.1021/ac00204a002                                                             
   GROSSMAN PD, 1988, ANAL BIOCHEM, V173, P265, DOI 10.1016/0003-2697(88)90188-1
   GUTTMAN A, 1990, ANAL CHEM, V62, P137, DOI 10.1021/ac00201a010                                                             
   HAMMER DF, 1988, ANAL BIOCHEM, V169, P300, DOI 10.1016/0003-2697(88)90288-6                                                    
   HO HT, 1989, ANTIMICROB AGENTS CH, V33, P844, DOI 10.1128/AAC.33.6.844                                                            
   HUANG MX, 1992, ANAL BIOCHEM, V207, P231, DOI 10.1016/0003-2697(92)90005-R                                                    
   LAMBERT JS, 1990, NEW ENGL J MED, V322, P1333, DOI 10.1056/NEJM199005103221901
   LOREGIAN A, 1994, ANAL CHEM, V66, P2981, DOI 10.1021/ac00090a028                                                             
   MAESSEN JG, 1988, CLIN CHEM, V34, P1087
   MCKINNEY RE, 1990, J PEDIATR-US, V116, P640, DOI 10.1016/S0022-3476(05)81619-1
   MCKINNEY RE, 1991, NEW ENGL J MED, V324, P1018, DOI 10.1056/NEJM199104113241503
   NG CL, 1994, J CHROMATOGR A, V680, P579, DOI 10.1016/0021-9673(94)85157-3
   NG M, 1992, ANAL CHEM, V64, P1682, DOI 10.1021/ac00039a010
   NGUYEN AL, 1990, ANAL CHEM, V62, P2490, DOI 10.1021/ac00221a015
   PIZZO PA, 1988, NEW ENGL J MED, V319, P889, DOI 10.1056/NEJM198810063191401
   RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402
   SHAO XW, 1994, J CHROMATOGR A, V680, P463, DOI 10.1016/0021-9673(94)85144-1
   STOCCHI V, 1987, ANAL BIOCHEM, V167, P181, DOI 10.1016/0003-2697(87)90150-3
   TADEPALLI SM, 1990, J ACQ IMMUN DEF SYND, V3, P19
   TADEPALLI SM, 1990, CLIN CHEM, V36, P897
   TSENG HC, 1994, ANAL BIOCHEM, V222, P55, DOI 10.1006/abio.1994.1453                                                          
   Uhrova M, 1996, J CHROMATOGR B, V681, P99, DOI 10.1016/0378-4347(95)00535-8
NR 28
TC 5
Z9 5
U1 0
U2 0
PU CELLULAR & MOLECULAR BIOLOGY
PI NOISY-LE-GRAND
PA PROF R WEGMANN RESIDENCE HAUSSMANN 1 AVENUE DU PAVE NEUF, 93160
   NOISY-LE-GRAND, FRANCE
SN 0145-5680
J9 CELL MOL BIOL
JI Cell. Mol. Biol.
PD NOV
PY 1997
VL 43
IS 7
BP 1051
EP 1055
PG 5
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA YK970
UT WOS:A1997YK97000017
PM 9449538
DA 2018-01-05
ER

PT J
AU Lobenberg, R
   Araujo, L
   Kreuter, J
AF Lobenberg, R
   Araujo, L
   Kreuter, J
TI Body distribution of azidothymidine bound to nanoparticles after oral
   administration
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article
DE AZT; body distribution; drug targeting; nanoparticles; macrophages
ID HUMAN-IMMUNODEFICIENCY-VIRUS; POLYBUTYLCYANOACRYLATE NANOPARTICLES;
   GASTROINTESTINAL MUCOSA; IN-VITRO; RATS; TRANSLOCATION; MICROSPHERES;
   DELIVERY; PATCHES; DRUG
AB Reticuloendothelial cells play an important role in the immunopathogenesis of AIDS. For this reason, a targeted delivery of antiviral drugs to these cells should significantly improve therapy of AIDS. The objective of the present study was to investigate the possibility of specific drug targeting of antiviral drugs to the reticuloendothelial cells by the oral route. Hexylcyanoacrylate nanoparticles were used as colloidal drug carriers for azidothymidine (AZT). C-14-labelled AZT was bound to nanoparticles using bis(2-ethylhexyl) sulfosuccinate sodium as surfactant. The radioactivity in several organs including those containing large numbers of macrophages was measured after peroral administration of the nanoparticle preparation and compared to a [C-14]AZT control solution containing the same components without the nanoparticles. In the liver the area under the curve (AUG) of [C-14]AZT was 30% higher when the drug was bound to nanoparticles than after administration of the solution. In addition, higher [C-14]AZT concentrations were observed after I hour and at later time points in blood and brain when nanoparticles were used compared to the control solution. These results indicate that nanoparticles are a promising drug targeting system for nucleoside analogues. Furthermore, the increase in drug availability at sites containing abundant macrophages, e.g. in the blood and in the brain, may allow a reduction in dosage and a decrease in systemic toxicity. (C) 1997 Elsevier Science B.V.
C1 UNIV FRANKFURT,INST PHARMACEUT TECHNOL,D-60439 FRANKFURT,GERMANY.
OI Lobenberg, Raimar/0000-0002-0919-0213
CR BECK PH, 1994, EUR J PHARM BIOPHARM, V40, P134
   BENDER A, 1994, RES VIROLOGY, V145, P215, DOI 10.1016/S0923-2516(07)80025-2                                                   
   Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   CHRISTOFINIS G, 1987, AIDS, V1, P229
   DAMGE C, 1987, INT J PHARM, V36, P121, DOI 10.1016/0378-5173(87)90146-3                                                    
   DYKSTRA K, 1993, J PHARMACOL EXP THER, V27, P1227
   ELDRIDGE JH, 1990, J CONTROL RELEASE, V11, P205, DOI 10.1016/0168-3659(90)90133-E
   FLORENCE AT, 1995, J DRUG TARGET, V3, P65, DOI 10.3109/10611869509015936                                                       
   HILLERY AM, 1994, J DRUG TARGET, V2, P151, DOI 10.3109/10611869409015904                                                       
   HODGES GM, 1995, J DRUG TARGET, V3, P57, DOI 10.3109/10611869509015934                                                       
   ILLUM L, 1982, INT J PHARM, V12, P135
   JANI P, 1990, J PHARM PHARMACOL, V42, P821, DOI 10.1111/j.2042-7158.1990.tb07033.x                                              
   JANI P, 1989, J PHARM PHARMACOL, V41, P809, DOI 10.1111/j.2042-7158.1989.tb06377.x                                              
   JANI PU, 1992, INT J PHARM, V86, P239, DOI 10.1016/0378-5173(92)90202-D
   KREUTER J, 1983, INT J PHARM, V16, P105, DOI 10.1016/0378-5173(83)90133-3
   KREUTER J, 1979, J PHARM SCI, V68, P1443, DOI 10.1002/jps.2600681129
   KREUTER J, 1989, INT J PHARM, V55, P39, DOI 10.1016/0378-5173(89)90274-3
   LERAY AM, 1994, INT J PHARM, V106, P201, DOI 10.1016/0378-5173(94)90003-5
   LEROUX JC, 1995, J PHARM SCI, V84, P1387, DOI 10.1002/jps.2600841202
   Lobenberg R, 1996, AIDS RES HUM RETROV, V12, P1709, DOI 10.1089/aid.1996.12.1709
   MAINCENT P, 1986, J PHARM SCI, V75, P955, DOI 10.1002/jps.2600751009
   MAINCENT P, 1992, PHARMACEUT RES, V9, P1534, DOI 10.1023/A:1015895804597
   MCCULLOUGH JS, 1995, J SUBMICR CYTOL PATH, V27, P119
   MCLEOD GX, 1992, ANN INTERN MED, V117, P487, DOI 10.7326/0003-4819-117-6-487
   MELTZER MS, 1990, IMMUNOL TODAY, V11, P217, DOI 10.1016/0167-5699(90)90086-O                                                    
   NEFZGER M, 1984, J PHARM SCI, V73, P1309, DOI 10.1002/jps.2600730934
   O'HAGAN D T, 1990, Advanced Drug Delivery Reviews, V5, P265, DOI 10.1016/0169-409X(90)90020-S
   PIMIENTA C, 1990, PHARMACEUT RES, V7, P49, DOI 10.1023/A:1015883525263                                                         
   REYNOLDS JEF, 1993, ANTIVIRAL AGENTS, V30, P560
   ROY S, 1988, J LEUKOCYTE BIOL, V43, P91
   SCHERER D, 1994, INT J PHARM, V101, P165, DOI 10.1016/0378-5173(94)90086-8
   SCHOLMERICH P, 1996, ARZNEIMITTELTHERAPIE, V14, P58
NR 32
TC 48
Z9 54
U1 1
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0939-6411
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD SEP
PY 1997
VL 44
IS 2
BP 127
EP 132
DI 10.1016/S0939-6411(97)00078-7
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA XZ930
UT WOS:A1997XZ93000003
DA 2018-01-05
ER

PT J
AU Seppala, M
   Jiang, S
   Strick, N
   Lin, K
   Li, YY
   Koistinen, H
   Koistinen, R
   Neurath, AR
AF Seppala, M
   Jiang, S
   Strick, N
   Lin, K
   Li, YY
   Koistinen, H
   Koistinen, R
   Neurath, AR
TI Glycodelins GdA and GdS modified by 3-hydroxyphthalic anhydride inhibit
   gp120-CD4 binding and HIV-1 infection in vitro
SO LABORATORY INVESTIGATION
LA English
DT Article
ID HUMAN PLACENTAL PROTEIN-14; AMINO-ACID SEQUENCE; BETA-LACTOGLOBULINS;
   ANTIBODIES
AB Bovine beta-lactoglobulin chemically modified with 3-hydroxyphthalic anhydride (3HP) was recently shown, at nanomolar concentrations, to block the binding site on CD4 for the HIV surface glycoprotein (gp120), potentially inhibiting HIV transmission. Human glycodelin has sequence homology with bovine beta-lactoglobulin and appears as different glycoforms in endometrium (GdA) and seminal plasma (GdS). We studied the anti-HIV effects of chemically modified GdA and GdS on both the infection of MT-2 cells by HIV-1(IIB), and the infection of peripheral blood mononuclear cells by the primary HIV isolate THA/93/051 belonging to subtype E. Whereas the native proteins were inactive when tested at physiologic concentrations, nanomolar concentrations of either 3HP-GdA or 3HP-GdS inhibited the production of HIV nucleocapsid p24, cytopathic effects of HIV-1(IIIB), and infection of peripheral brood mononuclear cells by the primary HIV isolate THA/93/051. Moreover, both modified proteins inhibited gp120-GD4 binding, 3HP-GdS being more potent than 3HP-GdA (p = 0.0042). Because GdA and GdS have the same major protein core, the observed difference in gp120-CD4 binding must depend on the specific glycoform. In view of the previously reported contraceptive activity of GdA, the observed anti-HIV activity induced by its chemical modification should be of special interest in the development of antiviral strategies that may also have contraceptive effects.
C1 NEW YORK BLOOD CTR,LINDSLEY F KIMBALL RES INST,LAB BIOCHEM VIROL,NEW YORK,NY 10021.
RP Seppala, M (reprint author), UNIV HELSINKI,DEPT OBSTET & GYNECOL,CENT HOSP,HAARTMANINKATU 2,FIN-00290 HELSINKI,FINLAND.
RI Jiang, Shibo/L-4500-2014
FU NCI NIH HHS [CA 43315]
CR DELL A, 1995, J BIOL CHEM, V270, P24116, DOI 10.1074/jbc.270.41.24116                                                        
   Gartner S, 1990, TECHNIQUES HIV RES, P53
   HUHTALA ML, 1987, ENDOCRINOLOGY, V120, P2620, DOI 10.1210/endo-120-6-2620                                                         
   JIANG S, 1992, AIDS, V6, P331, DOI 10.1097/00002030-199203000-00012
   JIANG S, 1991, J EXP MED, V174, P1557, DOI 10.1084/jem.174.6.1557
   Julkunen M, 1984, Arch Androl, V12 Suppl, P59
   JULKUNEN M, 1988, P NATL ACAD SCI USA, V85, P8845, DOI 10.1073/pnas.85.23.8845
   JULKUNEN M, 1985, BRIT J OBSTET GYNAEC, V92, P1145, DOI 10.1111/j.1471-0528.1985.tb03027.x                                              
   KASHIWAGI N, 1994, TOHOKU J EXP MED, V173, P115, DOI 10.1620/tjem.173.115                                                            
   Koistinen H, 1996, Mol Hum Reprod, V2, P759, DOI 10.1093/molehr/2.10.759
   Koistinen H, 1997, LAB INVEST, V76, P683
   KREISS J, 1992, JAMA-J AM MED ASSOC, V268, P477, DOI 10.1001/jama.268.4.477                                                          
   Mann Jonathan, 1992, AIDS WORLD
   Miller C. J., 1992, Laboratory Investigation, V68, P129
   Morris HR, 1996, J BIOL CHEM, V271, P32159, DOI 10.1074/jbc.271.50.32159                                                        
   Neurath AR, 1996, NAT MED, V2, P230, DOI 10.1038/nm0296-230                                                              
   OEHNINGER S, 1995, FERTIL STERIL, V63, P377
   OKAMOTO N, 1991, AM J REPROD IMMUNOL, V26, P137, DOI 10.1111/j.1600-0897.1991.tb00713.x                                              
   RIITTINEN L, 1991, J IMMUNOL METHODS, V136, P85, DOI 10.1016/0022-1759(91)90253-C                                                    
   RITCHIE DG, 1983, METHOD ENZYMOL, V92, P577
   SotoRamirez LE, 1996, SCIENCE, V271, P1291, DOI 10.1126/science.271.5253.1291
NR 21
TC 9
Z9 10
U1 0
U2 1
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD AUG
PY 1997
VL 77
IS 2
BP 127
EP 130
PG 4
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA XR748
UT WOS:A1997XR74800002
PM 9274854
DA 2018-01-05
ER

PT J
AU Morris, MC
   Vidal, P
   Chaloin, L
   Heitz, F
   Divita, G
AF Morris, MC
   Vidal, P
   Chaloin, L
   Heitz, F
   Divita, G
TI A new peptide vector for efficient delivery of oligonucleotides into
   mammalian cells
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE; GENE-TRANSFER;
   ANTISENSE OLIGONUCLEOTIDES; SEQUENCE; INHIBITION; KINETICS; THERAPY;
   HIV-1; DNA
AB The development of antisense and gene therapy has focused mainly on improving methods for oligonucleotide and gene delivery into cells, In the present work, we describe a potent new strategy for oligonucleotide delivery based on the use of a short peptide vector, termed MPG (27 residues), which contains a hydrophobic domain derived from the fusion sequence of HIV gp41 and a hydrophilic domain derived from the nuclear localization sequence of SV40 T-antigen, The formation of peptide vector/oligonucleotide complexes was investigated by measuring changes in intrinsic tryptophan fluorescence of peptide and of mansyl-labelled oligonucleotides, MPG exhibits relatively high affinity for bath single- and double-stranded DNA in a nanomolar range. Based an both intrinsic and extrinsic fluorescence titrations, it appears that the main binding between MPG; and oligonucleotides occurs through electrostatic interactions, which involve the basic-residues of the peptide vector, Further peptide/peptide Interactions also occur, leading to a higher MPG/oligonucleotide ratio (in the region of 20/1), which suggests that oligonucleotides are most likely coated with several molecules of MPG, Premixed complexes of peptide vector with single or double stranded oligonucleotides are delivered into cultured mammalian cells in less than 1 h with relatively high efficiency (90%), This new strategy of oligonucleotide delivery into cultured cells based on a peptide vector offers several advantages compared to other commonly used approaches of delivery including efficiency, stability and absence of cytotoxicity, The interaction with MPG strongly increases both the stability of the oligonucleotide to nuclease and crossing of the plasma membrane, The mechanism of cell delivery of oligonucleotides by MPG does not follow the endosomal pathway, which explains the rapid and efficient delivery of oligonucleotides in the nucleus, As such, we propose this peptide vector as a powerful fool for potential development in gene and antisense therapy.
C1 CRBM,URS 155 CNRS,F-34033 MONTPELLIER 1,FRANCE.
RI MORRIS, May/J-5940-2016
OI MORRIS, May/0000-0001-8106-9728; Chaloin, Laurent/0000-0002-5757-5804
CR Agrawal S, 1996, TRENDS BIOTECHNOL, V14, P376, DOI 10.1016/0167-7799(96)10053-6
   AUDUBEL FM, 1988, CURRENT PROTOCOLS MO
   BALTIMORE D, 1988, NATURE, V335, P395, DOI 10.1038/335395a0                                                                
   BEHR JP, 1994, BIOCONJUGATE CHEM, V5, P382, DOI 10.1021/bc00029a002
   BEHR JP, 1989, P NATL ACAD SCI USA, V86, P6982, DOI 10.1073/pnas.86.18.6982
   BORDIER B, 1995, P NATL ACAD SCI USA, V92, P9383, DOI 10.1073/pnas.92.20.9383
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Delahunty MD, 1996, VIROLOGY, V218, P94, DOI 10.1006/viro.1996.0169
   DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805
   DIVITA G, 1993, BIOCHEMISTRY-US, V32, P7966, DOI 10.1021/bi00082a018
   DIVITA G, 1995, J MOL BIOL, V245, P508, DOI 10.1006/jmbi.1994.0042
   FELGNER JH, 1994, J BIOL CHEM, V269, P2550
   Flegner P. L., 1987, P NATL ACAD SCI USA, V84, P7413
   FREED EO, 1990, P NATL ACAD SCI USA, V87, P4650, DOI 10.1073/pnas.87.12.4650
   GALLAHER WR, 1987, CELL, V50, P327, DOI 10.1016/0092-8674(87)90485-5                                                    
   GauthierRouviere C, 1996, MOL BIOL CELL, V7, P719
   GIBSON KJ, 1987, NUCLEIC ACIDS RES, V15, P604
   GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8
   Gottschalk S, 1996, GENE THER, V3, P448
   Harris JD, 1996, TRENDS GENET, V12, P400, DOI 10.1016/0168-9525(96)40031-2
   KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0
   Lewis JG, 1996, P NATL ACAD SCI USA, V93, P3176, DOI 10.1073/pnas.93.8.3176
   MARTIN L, 1996, J VIROL, V70, P298
   MERY J, 1993, INT J PEPT PROT RES, V42, P44
   MICHAEL SI, 1994, GENE THER, V1, P223
   MULLER B, 1991, BIOCHEMISTRY-US, V30, P3709, DOI 10.1021/bi00229a017                                                             
   PLANK C, 1994, J BIOL CHEM, V269, P12918
   SOUKCHAREUN S, 1995, BIOCONJUGATE CHEM, V6, P43, DOI 10.1021/bc00031a004
   STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515                                                         
   Vidal P, 1996, J PEPT SCI, V2, P125, DOI 10.1002/psc.58
   WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0
   WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4
NR 32
TC 359
Z9 380
U1 3
U2 38
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD, ENGLAND OX2 6DP
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD JUL 15
PY 1997
VL 25
IS 14
BP 2730
EP 2736
DI 10.1093/nar/25.14.2730
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA XL841
UT WOS:A1997XL84100007
PM 9207018
OA gold
DA 2018-01-05
ER

PT J
AU Beaulieu, PL
   Wernic, D
   Abraham, A
   Anderson, PC
   Bogri, T
   Bousquet, Y
   Croteau, G
   Guse, I
   Lamarre, D
   Liard, F
   Paris, W
   Thibeault, D
   Pav, S
   Tong, L
AF Beaulieu, PL
   Wernic, D
   Abraham, A
   Anderson, PC
   Bogri, T
   Bousquet, Y
   Croteau, G
   Guse, I
   Lamarre, D
   Liard, F
   Paris, W
   Thibeault, D
   Pav, S
   Tong, L
TI Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide
   isostere
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID PROTEINASE-INHIBITORS; BINDING; DESIGN; ENZYME; AIDS; CLEAVAGE; LIGANDS;
   COMPLEX; TARGET; SERIES
AB A series of HIV protease inhibitors containing a novel (hydroxyethyl)amidosuccinoyl core has been synthesized. These peptidomimetic structures inhibit viral protease activity at low nanomolar concentrations (IC50 < 10 nM for HIV-1 protease). The inhibition constant (K-i) for inhibitor 19 was determined to be 7.5 pM against HIV-1 and 1.2 nM against HIV-2 proteases, respectively. Several compounds (19-24) inhibited HIV-1 replication in cell culture assays with 50% effective concentrations (Ec(50)) = 3.7-35 nM. This series of inhibitors was found to exhibit poor bioavailability (< 10%) in the rat, following oral administration. The synthesis and biological properties of these compounds are discussed. In addition, an X-ray structure of one of these inhibitors (23) in complex with HIV-2 protease provides insight into the binding mode of this novel class of HN protease inhibitors.
C1 BOEHRINGER INGELHEIM PHARMACEUT INC,RIDGEFIELD,CT 06877.
RP Beaulieu, PL (reprint author), BOEHRINGER INGELHEIM CANADA LTD,BIOMEGA RES DIV,2100 CUNARD ST,LAVAL,PQ H7S 2G5,CANADA.
CR Appelt Krzysztof, 1993, Perspectives in Drug Discovery and Design, V1, P23, DOI 10.1007/BF02171654
   BARRISH JC, 1994, J MED CHEM, V37, P1758, DOI 10.1021/jm00038a005
   Beaulieu PL, 1996, J ORG CHEM, V61, P3635, DOI 10.1021/jo960109i                                                               
   BEAULIEU PL, 1995, TETRAHEDRON LETT, V36, P3317, DOI 10.1016/0040-4039(95)00533-I
   BETAGERI R, 1993, J BIOCHEM BIOPH METH, V27, P191, DOI 10.1016/0165-022X(93)90003-7
   BOEHME RE, 1995, ANNU REP MED CHEM, V30, P139
   BOYD GV, 1978, J CHEM SOC PERK T 1, P1338, DOI 10.1039/p19780001338                                                            
   BRUNGER AT, 1992, XPLOR MANUAL VERSION
   BRYANT M, 1995, ANTIMICROB AGENTS CH, V39, P2229, DOI 10.1128/AAC.39.10.2229                                                          
   Cohen J, 1996, SCIENCE, V272, P1880, DOI 10.1126/science.272.5270.1880
   Cohen J, 1996, SCIENCE, V272, P1882, DOI 10.1126/science.272.5270.1882                                                   
   DAquila RT, 1996, ANN INTERN MED, V124, P1019, DOI 10.7326/0003-4819-124-12-199606150-00001
   Darke P L, 1994, Adv Pharmacol, V25, P399, DOI 10.1016/S1054-3589(08)60438-X
   DARKE PL, 1988, BIOCHEM BIOPH RES CO, V156, P297, DOI 10.1016/S0006-291X(88)80839-8                                                   
   DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001
   DELFRAISSY JF, 1995, BIOTECHNOLOGY, V13, P940
   GHOSH AK, 1994, J MED CHEM, V37, P2506, DOI 10.1021/jm00042a002                                                             
   GHOSH AK, 1994, J MED CHEM, V37, P1177, DOI 10.1021/jm00034a016
   Gillard J, 1996, J ORG CHEM, V61, P2226, DOI 10.1021/jo9519874                                                               
   GODT HC, 1968, J CHEM ENG DATA, V13, P138, DOI 10.1021/je60036a043                                                             
   HOLMES DS, 1993, J MED CHEM, V36, P3129, DOI 10.1021/jm00073a012
   HUFF JR, 1991, J MED CHEM, V34, P2305, DOI 10.1021/jm00112a001
   Kempf DJ, 1996, CURR PHARM DESIGN, V2, P225
   KHOL NE, 1988, P NATL ACAD SCI USA, V85, P4686
   KIM BM, 1995, BIOORG MED CHEM LETT, V5, P185
   KIM EE, 1995, J AM CHEM SOC, V117, P1181, DOI 10.1021/ja00108a056                                                             
   KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3
   KRAMER RA, 1986, SCIENCE, V231, P1580, DOI 10.1126/science.2420008
   KROHN A, 1991, J MED CHEM, V34, P3340, DOI 10.1021/jm00115a028
   LAMARRE D, 1997, ANTIMICROB AGENTS CH, V5, P965
   Liard F, 1995, J PHARMACEUT BIOMED, V14, P151, DOI 10.1016/0731-7085(95)01625-2
   MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201
   MOSS N, 1995, J MED CHEM, V38, P3617, DOI 10.1021/jm00018a022
   Noble S, 1996, DRUGS, V52, P93, DOI 10.2165/00003495-199652010-00007                                                
   PARGELLIS CA, 1994, BIOCHEMISTRY-US, V33, P12527, DOI 10.1021/bi00207a021
   PAV S, 1994, PROTEINS, V20, P98, DOI 10.1002/prot.340200110
   POLONSKI T, 1988, J CHEM SOC PERK T 1, P629, DOI 10.1039/p19880000629
   RICH DH, 1990, J MED CHEM, V33, P1285, DOI 10.1021/jm00167a003
   RICH DH, 1991, J MED CHEM, V34, P1222, DOI 10.1021/jm00107a049                                                             
   Richman DD, 1996, SCIENCE, V272, P1886, DOI 10.1126/science.272.5270.1886
   ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354
   ROMERO DL, 1994, ANNU REP MED CHEM, V29, P123
   SARIN PS, 1995, IMMUNOPHARM IMMUNOT, V17, P217, DOI 10.3109/08923979509019748
   SCHREIBER K, 1961, J ORG CHEM, V26, P1744, DOI 10.1021/jo01065a012                                                             
   THAISRIVONGS S, 1994, ANNU REP MED CHEM, V29, P133
   TONG L, 1995, STRUCTURE, V3, P33, DOI 10.1016/S0969-2126(01)00133-2
   TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124
   TUCKER TJ, 1992, J MED CHEM, V35, P2525, DOI 10.1021/jm00092a002                                                             
   VAZQUEZ ML, 1995, J MED CHEM, V38, P581, DOI 10.1021/jm00004a001
   *WHO, 1996, B WORLD HEALTH ORGAN, V71, P205
   WIDEQVIST S, 1950, ARK KEMI, V2, P321
   WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551                                             
   Anderson P. C., 1997, US Patent, Patent No. [5614533, 5 614 533]
   Gorys V., 1996, U. S. Patent, Patent No. [5 552 405, 5552405]
   Anderson P.C., 1996, US Patent, Patent No. [5545640, 5.545.640]
   REED KL, 1992, Patent No. 8700
NR 56
TC 19
Z9 22
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD JUL 4
PY 1997
VL 40
IS 14
BP 2164
EP 2176
DI 10.1021/jm9606608
PG 13
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA XH835
UT WOS:A1997XH83500010
PM 9216835
DA 2018-01-05
ER

PT J
AU Boyd, MR
   Gustafson, KR
   McMahon, JB
   Shoemaker, RH
   OKeefe, BR
   Mori, T
   Gulakowski, RJ
   Wu, L
   Rivera, MI
   Laurencot, CM
   Currens, MJ
   Cardellina, JH
   Buckheit, RW
   Nara, PL
   Pannell, LK
   Sowder, RC
   Henderson, LE
AF Boyd, MR
   Gustafson, KR
   McMahon, JB
   Shoemaker, RH
   OKeefe, BR
   Mori, T
   Gulakowski, RJ
   Wu, L
   Rivera, MI
   Laurencot, CM
   Currens, MJ
   Cardellina, JH
   Buckheit, RW
   Nara, PL
   Pannell, LK
   Sowder, RC
   Henderson, LE
TI Discovery of cyanovirin-N, a novel human immunodeficiency
   virus-inactivating protein that binds viral surface envelope
   glycoprotein gp120: Potential applications to microbicide development
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID HUMAN MONOCLONAL-ANTIBODIES; 3RD VARIABLE DOMAIN; BLUE-GREEN-ALGAE;
   LACTOBACILLUS-PLANTARUM; ANTIVIRAL ACTIVITY; NATURAL-PRODUCTS; FAB
   FRAGMENTS; HIV-INFECTION; CELL-LINE; TYPE-1
AB We have isolated and sequenced a novel 11-kDa virucidal protein, named cyanovirin-N (CV-N), from cultures of the cyanobacterium (blue-green alga) Nostoc ellipsosporum. We also have produced CV-N recombinantly by expression of a corresponding DNA sequence in Escherichia coli. Low nanomolar concentrations of either natural or recombinant CV-N irreversibly inactivate diverse laboratory strains and primary isolates of human immunodeficiency virus (HIV) type 1 as well as strains of HIV type 2 and simian immunodeficiency virus. In addition, CV-N aborts cell-to-cell fusion and transmission of HIV-1 infection. Continuous, 2-day exposures of uninfected CEM-SS cells or peripheral blood lymphocytes to high concentrations (e.g., 9,000 nM) of CV-N were not lethal to these representative host cell types. The antiviral activity of CV-N is due, at least in part, to unique, high-affinity interactions of CV-N with the viral surface envelope glycoprotein gp120. The biological activity of CV-N is highly resistant to physicochemical denaturation, further enhancing its potential as an anti-HIV microbicide.
C1 NCI,DIV BASIC SCI,TUMOR CELL BIOL LAB,FREDERICK,MD 21702.
   FREDERICK CANC RES & DEV CTR,SO RES INST,VIROL RES GRP,FREDERICK,MD 21702.
   NIDDKD,BIOORGAN CHEM LAB,BETHESDA,MD 20892.
   FREDERICK CANC RES & DEV CTR,SCI APPLICAT INT CORP,AIDS VACCINE PROGRAM,FREDERICK,MD 21702.
RP Boyd, MR (reprint author), NCI,FREDERICK CANC RES & DEV CTR,DCTDC,DTP,LAB DRUG DISCOVERY RES & DEV,BLDG 1052,RM 121,FREDERICK,MD 21702, USA.
CR ANDREU A, 1995, J INFECT DIS, V171, P1237, DOI 10.1093/infdis/171.5.1237                                                       
   BALTER M, 1994, SCIENCE, V266, P1312, DOI 10.1126/science.7973714
   BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P9339, DOI 10.1073/pnas.89.19.9339                                                         
   Bates P, 1996, CELL, V86, P1, DOI 10.1016/S0092-8674(00)80070-7
   BEUTLER JA, 1993, ANTIVIR CHEM CHEMOTH, V4, P167, DOI 10.1177/095632029300400306                                                      
   BOYD MR, 1988, AIDS ETIOLOGY DIAGNO, P305
   BRYAN RA, 1989, J VIROL, V63, P4370
   BUCKHEIT RW, 1994, AIDS RES HUM RETROV, V10, P1497, DOI 10.1089/aid.1994.10.1497
   BUCKHEIT RW, 1994, ANTIVIR RES, V25, P43, DOI 10.1016/0166-3542(94)90092-2
   BUCKHEIT RW, UNPUB
   BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652
   BURTON DR, 1991, P NATL ACAD SCI USA, V88, P10134, DOI 10.1073/pnas.88.22.10134
   CARDELLINA JH, 1993, J NAT PROD, V56, P1123, DOI 10.1021/np50097a016
   Chackerian B, 1997, J VIROL, V71, P3932
   Chang H, 1996, NAT BIOTECHNOL, V14, P444, DOI 10.1038/nbt0496-444                                                             
   Chen ZW, 1997, J VIROL, V71, P2705
   CIMINALE V, 1990, AIDS RES HUM RETROV, V6, P1281
   Cohen J, 1997, SCIENCE, V275, P1261, DOI 10.1126/science.275.5304.1261
   COLLMAN R, 1992, J VIROL, V66, P7517
   Currens MJ, 1996, J PHARMACOL EXP THER, V279, P652
   Currens MJ, 1996, J PHARMACOL EXP THER, V279, P645
   Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856
   DSOUZA MP, 1991, AIDS, V5, P1061, DOI 10.1097/00002030-199109000-00001                                                
   ELIAS C, 1996, AIDS, V10, P543
   Elmer GW, 1996, JAMA-J AM MED ASSOC, V275, P870, DOI 10.1001/jama.275.11.870
   Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8
   Essex M, 1996, AIDS RES HUM RETROV, V12, P361, DOI 10.1089/aid.1996.12.361
   GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648
   GARTNER S, 1990, TECHNIQUES HIV RES
   GENDELMAN HE, 1989, AIDS, V3, P475, DOI 10.1097/00002030-198908000-00001
   GORNY MK, 1993, J IMMUNOL, V150, P635
   GORNY MK, 1991, P NATL ACAD SCI USA, V88, P3238, DOI 10.1073/pnas.88.8.3238
   GULAKOWSKI RJ, 1991, J VIROL METHODS, V33, P87, DOI 10.1016/0166-0934(91)90010-W
   GUSTAFSON KR, 1989, J NATL CANCER I, V81, P1254, DOI 10.1093/jnci/81.16.1254                                                         
   HILL CM, 1996, NATURE, V4382, P688
   HILLIER SL, 1996, NIAID C ADV AIDS VAC, P56
   HOLS P, 1994, APPL ENVIRON MICROB, V60, P1401
   *INT WORK GROUP VA, 1996, AIDS, V10
   Kelley KJ, 1996, NAT BIOTECHNOL, V14, P587, DOI 10.1038/nbt0596-587                                                             
   Killington RA, 1985, VIROLOGY PRACTICAL A, P207
   KIMPTON J, 1992, J VIROL, V66, P2232
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LAMAN JD, 1992, J VIROL, V66, P1823
   LAMAN JD, 1993, AIDS RES HUM RETROV, V9, P605, DOI 10.1089/aid.1993.9.605                                                          
   LANGE JMA, 1993, LANCET, V341, P1356
   LAYNE SP, 1991, J VIROL, V65, P3293
   LEEDER JS, 1989, ANAL BIOCHEM, V177, P364, DOI 10.1016/0003-2697(89)90067-5
   LEER RJ, 1992, MOL GEN GENET, V234, P265, DOI 10.1007/BF00283847                                                              
   Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5
   Marcon L, 1997, J VIROL, V71, P2522
   MATSUSHITA S, 1988, J VIROL, V62, P2107
   MCGROARTY JA, 1993, FEMS IMMUNOL MED MIC, V6, P251, DOI 10.1111/j.1574-695X.1993.tb00337.x
   Mercenier A., 1994, Genetics and biotechnology of lactic acid bacteria., P252
   MERSON MH, 1993, SCIENCE, V260, P1266, DOI 10.1126/science.8493570
   MOORE JP, 1995, J VIROL, V69, P101
   Moore JP, 1997, SCIENCE, V276, P51, DOI 10.1126/science.276.5309.51
   MOORE JP, 1994, J VIROL, V68, P469
   MOORE JP, 1995, NATURE, V376, P115, DOI 10.1038/376115a0                                                                
   Moore J.P., 1993, VIRAL FUSION MECH, P233
   NARA PL, 1988, NATURE, V332, P469, DOI 10.1038/332469a0
   PAINTER K, 1996, USA TODAY       0710
   PATTERSON GML, 1993, J PHYCOL, V29, P125, DOI 10.1111/j.1529-8817.1993.tb00290.x
   Pauwels R, 1996, J ACQ IMMUN DEF SYND, V11, P211, DOI 10.1097/00042560-199603010-00001                                                
   Paxton WA, 1996, AIDS RES HUM RETROV, V12, P1203, DOI 10.1089/aid.1996.12.1203
   PIOT P, 1994, TXB AIDS MED, P109
   PRECIOUS B, 1985, VIROLOGY PRACTICAL A, P193
   ROBEN P, 1994, J VIROL, V68, P4821
   ROSENBERG MJ, 1993, SEX TRANSM DIS, V20, P41, DOI 10.1097/00007435-199301000-00008                                                
   Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0
   SATTENTAU QJ, 1993, PHILOS T ROY SOC B, V342, P59, DOI 10.1098/rstb.1993.0136
   SotoRamirez LE, 1996, SCIENCE, V271, P1291, DOI 10.1126/science.271.5253.1291
   STEIMER KS, 1988, VACCINES 88, P347
   SULLIVAN N, 1995, J VIROL, V69, P4413
   TAYLOR R, 1994, J NIH RES, V6, P26
   *US DEP HHS, 1996, AIDS RES REF REAG PR
   VONBRUNN A, 1993, VACCINE, V11, P817, DOI 10.1016/0264-410X(93)90356-3
   VONBRUNN A, 1993, VACCINES93 : MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P159
   WEISLOW OS, 1989, J NATL CANCER I, V81, P577, DOI 10.1093/jnci/81.8.577
   Weiss RA, 1996, NATURE, V381, P647, DOI 10.1038/381647a0                                                                
   WHITESCHARF ME, 1993, VIROLOGY, V192, P197, DOI 10.1006/viro.1993.1022
   Zhang LQ, 1996, NATURE, V383, P768, DOI 10.1038/383768a0                                                                
NR 81
TC 389
Z9 420
U1 2
U2 15
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JUL
PY 1997
VL 41
IS 7
BP 1521
EP 1530
PG 10
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA XJ131
UT WOS:A1997XJ13100021
PM 9210678
DA 2018-01-05
ER

PT J
AU Kim, JC
   Kim, YH
   Park, JI
   Kim, SH
   Choi, SK
AF Kim, JC
   Kim, YH
   Park, JI
   Kim, SH
   Choi, SK
TI Synthesis and antitumor evaluation of acyclic
   1-[omega-(N'-2-chloroethyl-N'-nitrosoureido)alkyl]thymidine nucleoside
   analogues
SO ARCHIVES OF PHARMACAL RESEARCH
LA English
DT Article
DE acyclic thymidine nucleoside analogues;
   1-[4-(N'-2-chloroethyl-N'-nitrosoureido)butyl]thymine; regioisomeric
   nitrosoureas; in vitro cytotoxicity; human chronic myelogenous leukemia
   cell; mouse lymphoid neoplasma cell; mouse mammary caruisoma cell; IC50
ID COLORIMETRIC ASSAY; INVITRO; HIV; INFECTIVITY; AZT
AB In the preparation of acyclic thymidine nucleoside analogues, K2CO3 (or NaH) treated thymine in DMSO was alkylated with omega-chloroalkyl nitrite (Cl-(CH2)(n)-CN; n=1, 2, 3, 4) to provide an isomeric mixture of 1-(omega-cyanoalkyl)thymine (2a-d) and 1,3-bis(omega-cyanoalkyl)thymine in approximately 5:1 ratios. Reduction of the cyano function 2a-d with NaBH4/CoCl2 . 6H(2)O gave the corresponding 1-(omega-aminoalkyl)thymine (3a-d). The newly formed primary amino function in 3a-d was directly reacted with 2-chloroethylisocyanate to afford the 1-[omega-(N'2-chloroethylureido) alkyl]thymine (4a-d) in good yields. Nitrosation of 1-[5-(N'-2-chloroethylureido)pentyl]thymine (4d) with glacial acetic acid and dry NaNO2 powder in anhydrous CH2Cl2 gave two types of regioisomeric nitrosoureas, 1 -[5-(N'-2-chloroethyl-N'-nitrosoureido)penty]thymine (5d) and 1-[5-(N'-2-chloroethyl-N-nitrosoureido)pentyl]thymine in approximately 5:1 ratios. The in vitro cytotoxicity of the synthesized compounds (2a-d, 3a-d, 4a-d and 5a-d) against three cell lines (K-562, P-388 and FM-3A) are measured as IC50 values. Compounds 3b and 4c showed moderate activities against all three cell lines, and all other compounds were found to be not active.
C1 PUSAN NATL UNIV,COLL MED,DEPT BIOCHEM,PUSAN 609735,SOUTH KOREA.
   DONG A UNIV,DEPT CHEM,PUSAN,SOUTH KOREA.
RP Kim, JC (reprint author), PUSAN NATL UNIV,DEPT CHEM,COLL NAT SCI,PUSAN 609735,SOUTH KOREA.
CR CARMICHAEL J, 1987, CANCER RES, V47, P936
   CHU CK, 1986, J HETEROCYCLIC CHEM, V23, P289, DOI 10.1002/jhet.5570230201                                                         
   COATES JAV, 1992, ANTIMICROB AGENTS CH, V36, P202, DOI 10.1128/AAC.36.1.202                                                            
   DECLERCQ E, 1986, PROGR MED CHEM, V23, pCH5
   FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401                                                     
   KAMETANI T, 1982, J MED CHEM, V25, P1219, DOI 10.1021/jm00352a024
   KELLEY JL, 1981, J MED CHEM, V24, P753, DOI 10.1021/jm00138a022                                                             
   KIM JC, 1994, B KOR CHEM SOC, V15, P173
   KIM JC, 1994, ARCH PHARM RES, P420
   KIM JC, 1994, J MED CHEM, V4, P111
   LAMBERT JS, 1990, NEW ENGL J MED, V322, P1333, DOI 10.1056/NEJM199005103221901
   LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383
   MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911
   MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096                                                         
   MONTGOMERIE J, 1961, J AM CHEM SOC, V83, P630, DOI 10.1021/ja01464a031                                                             
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   NASR M, 1990, ANTIVIR RES, V14, P125, DOI 10.1016/0166-3542(90)90030-B
   NORBECK DW, 1989, TETRAHEDRON LETT, V30, P6263, DOI 10.1016/S0040-4039(01)93868-7                                                   
   SCHAEFFER HJ, 1978, NATURE, V272, P583, DOI 10.1038/272583a0
   SCHINAZI RF, 1992, AIDS RES HUM RETROV, V8, P553
   URBINA JA, 1991, ANTIMICROB AGENTS CH, V35, P730, DOI 10.1128/AAC.35.4.730                                                            
   YARCHOAN R, 1988, LANCET, V1, P76
NR 22
TC 0
Z9 0
U1 0
U2 1
PU PHARMACEUTICAL SOCIETY KOREA
PI SEOUL
PA 1489-3 SUHCHO-DONG, SUHCHO-KU, SEOUL 137-071, SOUTH KOREA
SN 0253-6269
J9 ARCH PHARM RES
JI Arch. Pharm. Res.
PD JUN
PY 1997
VL 20
IS 3
BP 259
EP 263
DI 10.1007/BF02976154
PG 5
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA XG355
UT WOS:A1997XG35500010
PM 18975161
DA 2018-01-05
ER

PT J
AU Fong, SE
   Smanik, P
   Smith, MC
   Jaskunas, SR
AF Fong, SE
   Smanik, P
   Smith, MC
   Jaskunas, SR
TI Cationic liposome-mediated uptake of human immunodeficiency virus type 1
   Tat protein into cells
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE HIV-1; Tat; cationic; liposome; cellular; uptake
ID TRANS-ACTIVATOR GENE; PRESENTATION PATHWAY; HIV-1; TRANSACTIVATION;
   RECOGNITION; REPLICATION; INTEGRIN; SEQUENCE; INVITRO; ANTIGEN
AB The human immunodeficiency virus type 1 (HIV-1) Tar protein strongly transactivates gene expression from the viral long terminal repeat (LTR) and is required for virus efficient replication. Previous studies have shown that cells scrape-loaded in the presence of purified recombinant Tat can absorb,the protein in a receptor-independent fashion. Using recombinant Tat in which cysteine residues were blocked by sulfitolysis to prevent disulfide aggregation (S-Tat) we were unable to observe this phenomenon, possibly because of improper protein folding. In this study we report that the block to cellular uptake could be overcome by mixing S-Tat with a cationic liposome, Lipofectin. When mixed with Lipofectin, S-Tat effected a specific, concentration-dependent transactivation of HIV-1 LTR-directed reporter gene activity in Hela cells. Cellular uptake was confirmed by Western blot analysis with an anti-Tat antibody. The method described utilizes cells plated in a 96-well format, requires only nanogram quantities of S-Tat protein and is much less labor-intensive than assays involving scrape-loading, making it suitable for use as a high-throughput screen for detecting Tat inhibitors. The method may have applications for the analysis of other recombinant proteins that require uptake into intact cells for determination of functionality and presents a general technique for introducing exogenous proteins into cells. (C) 1997 Elsevier Science B.V.
C1 LILLY CORP CTR,LILLY RES LABS,INFECT DIS RES,INDIANAPOLIS,IN 46285.
CR BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941
   BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5
   CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167
   CHEN WS, 1993, J IMMUNOL METHODS, V160, P49, DOI 10.1016/0022-1759(93)90007-T
   CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985
   DANG CV, 1989, J BIOL CHEM, V264, P18019
   DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6                                                    
   DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725                                                             
   DIMITROV DS, 1993, J VIROL, V67, P2182
   Endo S, 1989, Virus Genes, V3, P99
   ENSOLI B, 1993, J VIROL, V67, P277
   Felgner Jiin, 1993, Journal of Tissue Culture Methods, V15, P63, DOI 10.1007/BF01667363
   FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413
   FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0
   Fong SE, 1997, J VIROL METHODS, V66, P91, DOI 10.1016/S0166-0934(97)00039-6
   Frankel A D, 1992, Curr Opin Genet Dev, V2, P293, DOI 10.1016/S0959-437X(05)80287-4
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   GENTZ R, 1989, P NATL ACAD SCI USA, V86, P821, DOI 10.1073/pnas.86.3.821
   KUPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V17, P3551, DOI 10.1093/nar/17.9.3551                                                           
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   MANN DA, 1991, EMBO J, V10, P1733
   RUBEN S, 1989, J VIROL, V63, P1
   SCHWARTZ O, 1990, GENE, V88, P197, DOI 10.1016/0378-1119(90)90032-M
   SIOMI H, 1990, J VIROL, V64, P1803
   VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461
   WALKER C, 1992, P NATL ACAD SCI USA, V89, P7915, DOI 10.1073/pnas.89.17.7915
   ZAULI G, 1995, J ACQ IMMUN DEF SYND, V10, P306
NR 27
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
J9 J VIROL METHODS
JI J. Virol. Methods
PD JUN
PY 1997
VL 66
IS 1
BP 149
EP 157
DI 10.1016/S0166-0934(97)00070-0
PG 9
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA XH947
UT WOS:A1997XH94700018
PM 9220401
DA 2018-01-05
ER

PT J
AU Grzesiek, S
   Bax, A
   Hu, JS
   Kaufman, J
   Palmer, I
   Stahl, SJ
   Tjandra, N
   Wingfield, PT
AF Grzesiek, S
   Bax, A
   Hu, JS
   Kaufman, J
   Palmer, I
   Stahl, SJ
   Tjandra, N
   Wingfield, PT
TI Refined solution structure and backbone dynamics of HIV-1 Nef
SO PROTEIN SCIENCE
LA English
DT Article
DE heteronuclear NMR; HIV-1; multi-dimensional NMR; Nef; protein dynamics;
   protein structure
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CELL-SURFACE CD4; PROTEIN-STRUCTURE
   DETERMINATION; ISOTOPICALLY ENRICHED PROTEINS; MAGNETIC-RESONANCE
   RELAXATION; CALCIUM-FREE CALMODULIN; MODEL-FREE APPROACH;
   DOWN-REGULATION; TYPE-1 NEF; CYTOPLASMIC DOMAIN
AB The tendency of HTV-1 Nef to form aggregates in solution, particularly at pH values below 8, together with its large fraction of highly mobile residues seriously complicated determination of its three-dimensional structure, both for heteronuclear solution NMR (Grzesiek et al., 1996a, Nat Struct Biol 3:340-345) and for X-ray crystallography (Lee et al., 1996, Cell 85:931-932). Methods used to determine the Nef structure by NMR at pH 8 and 0.6 mM concentration are presented, together with a detailed description of Nef's secondary and tertiary structure. The described techniques have general applicability for the NMR structure determination of proteins that are aggregating and/or have limited stability at low pH values. Extensive chemical shift assignments are reported for backbone and side chain H-1, C-13, and N-15 resonances of the HIV-1 Nef deletion mutants NEFDelta Z2-39, NEFDelta 2-39,Delta 159-173, and of NEFDelta 2-39,Delta 159-173 complex with the SH3 domain of the Hck tyrosine protein kinase. Besides a type II polyproline helix, Nef's structure consists of three alpha-helices, a 310 helix, and a five-stranded anti-parallel beta-sheet. The analysis of N-15 relaxation parameters of the backbone amide sites reveals that all the secondary structure elements are non-mobile on the picosecond to nanosecond and on the millisecond time scale. A large number of slowly exchanging amide protons provides evidence for the stability of the Nef core even on the time scale of hours. Significant internal motions on the ps to us time scale are detected for residues 60 to 71 and for residues 149 to 180, which form solvent-exposed loops. The residues of the HIV-1 protease cleavage site (W57/L58) do not exhibit large amplitude motions on the sub-nanosecond time scale, and their side chains insert themselves into a hydrophobic crevice formed between the C-terminus of helix 1 and the N-terminus of helix 2. A refined structure has been determined based on additional constraints for side-chain and backbone dihedral angles derived from a large number of three-bond J-couplings and ROE data.
C1 NIAMSD,PROT EXPRESS LAB,NIH,BETHESDA,MD 20892.
RP Grzesiek, S (reprint author), NIDDKD,PHYS CHEM LAB,NIH,BLDG 5,BETHESDA,MD 20892, USA.
OI Grzesiek, Stephan/0000-0003-1998-4225
CR ADZUBEI AA, 1993, J MOL BIOL, V229, P472
   AHMAD N, 1988, SCIENCE, V241, P1481, DOI 10.1126/science.3262235
   AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3
   Aiken C, 1996, VIROLOGY, V217, P293, DOI 10.1006/viro.1996.0116
   ANDERSON SJ, 1994, J VIROL, V68, P3092
   ANGLISTER J, 1994, BIOCHEMISTRY-US, V33, P3540, DOI 10.1021/bi00178a010
   BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110
   BAX A, 1994, J MAGN RESON SER A, V106, P269, DOI 10.1006/jmra.1994.1038                                                          
   BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K
   BAX A, 1990, J MAGN RESON, V87, P620, DOI 10.1016/0022-2364(90)90320-9                                                    
   BENSON RE, 1993, J EXP MED, V177, P1561, DOI 10.1084/jem.177.6.1561
   BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069                                                             
   BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211
   Brunger A. T., 1992, X PLOR VERSION 3 1 S
   CHENGMAYER C, 1989, SCIENCE, V246, P1629, DOI 10.1126/science.2531920
   CHOWERS MY, 1995, VIROLOGY, V212, P451, DOI 10.1006/viro.1995.1502
   CHOWERS MY, 1994, J VIROL, V68, P2906
   CULLEN BR, 1994, VIROLOGY, V205, P1, DOI 10.1006/viro.1994.1613
   DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917                                                         
   DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809                                                              
   DERONDE A, 1992, VIROLOGY, V188, P391, DOI 10.1016/0042-6822(92)90772-H                                                    
   FOSTER JL, 1994, VIROLOGY, V201, P373, DOI 10.1006/viro.1994.1303
   FREUND J, 1994, EUR J BIOCHEM, V223, P589, DOI 10.1111/j.1432-1033.1994.tb19029.x
   FREUND J, 1994, EUR J BIOCHEM, V221, P811, DOI 10.1111/j.1432-1033.1994.tb18795.x                                              
   GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0
   GARCIA JV, 1993, J VIROL, V67, P1511
   GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P                                                    
   GARRETT DS, 1994, J MAGN RESON SER B, V104, P99, DOI 10.1006/jmrb.1994.1061
   GOLDSMITH MA, 1995, J VIROL, V69, P4112
   GRONENBORN AM, 1994, J BIOMOL NMR, V4, P455
   Grzesiek S, 1996, BIOCHEMISTRY-US, V35, P10256, DOI 10.1021/bi9611164
   GRZESIEK S, 1993, J BIOMOL NMR, V3, P487
   Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340
   GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003
   GRZESIEK S, 1995, J AM CHEM SOC, V117, P5312, DOI 10.1021/ja00124a014                                                             
   GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S                                                    
   GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052
   GRZESIEK S, 1995, J AM CHEM SOC, V117, P9594, DOI 10.1021/ja00142a040                                                             
   GRZESIEK S, 1993, J BIOMOL NMR, V3, P185
   Grzesiek S, 1997, J BIOMOL NMR, V9, P207, DOI 10.1023/A:1018614505948
   GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0
   HARPER ET, 1993, BIOCHEMISTRY-US, V32, P7605, DOI 10.1021/bi00081a001
   Hiroaki H, 1996, J BIOMOL NMR, V8, P105
   Hu JS, 1996, J AM CHEM SOC, V118, P8170, DOI 10.1021/ja9616239                                                               
   Hu JS, 1997, J AM CHEM SOC, V119, P1803, DOI 10.1021/ja963625z                                                               
   IKURA M, 1990, J MAGN RESON, V86, P204, DOI 10.1016/0022-2364(90)90227-Z                                                    
   KAY LE, 1992, J MAGN RESON, V97, P359, DOI 10.1016/0022-2364(92)90320-7                                                    
   KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003
   KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145                                                          
   KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I                                                    
   KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405
   Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4
   KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416
   KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768
   KUSZEWSKI J, 1995, J MAGN RESON SER B, V106, P92, DOI 10.1006/jmrb.1995.1017
   Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148
   LEE CH, 1995, EMBO J, V14, P5006
   Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3
   LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010
   LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009
   LIPPENS G, 1995, J BIOMOL NMR, V5, P327, DOI 10.1007/BF00211762
   LUCIW PA, 1987, P NATL ACAD SCI USA, V84, P1434, DOI 10.1073/pnas.84.5.1434
   Mariani R, 1996, J VIROL, V70, P7752
   MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004
   MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101
   NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003
   NICHOLSON LK, 1995, NAT STRUCT BIOL, V2, P274, DOI 10.1038/nsb0495-274
   NIEDERMAN TMJ, 1989, P NATL ACAD SCI USA, V86, P1128, DOI 10.1073/pnas.86.4.1128
   NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7
   PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855
   PREKUMAR DRD, 1996, AIDS RES HUM RETROV, V12, P337
   SAKSELA K, 1995, EMBO J, V14, P484
   SALGHETTI S, 1995, P NATL ACAD SCI USA, V92, P349, DOI 10.1073/pnas.92.2.349
   SANTORO J, 1992, J MAGN RESON, V97, P202, DOI 10.1016/0022-2364(92)90250-B                                                    
   SHUGARS DC, 1993, J VIROL, V67, P4639
   SKOWRONSKI J, 1993, EMBO J, V12, P703
   SPERA S, 1991, J AM CHEM SOC, V113, P5490, DOI 10.1021/ja00014a071
   SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115                                                           
   VANDEVEN FJM, 1992, J MAGN RESON, V97, P637, DOI 10.1016/0022-2364(92)90045-9                                                    
   VUISTER GW, 1993, J AM CHEM SOC, V115, P5334, DOI 10.1021/ja00065a071                                                             
   VUISTER GW, 1992, J MAGN RESON, V98, P428, DOI 10.1016/0022-2364(92)90144-V                                                    
   VUISTER GW, 1994, J AM CHEM SOC, V166, P9206
   Welker R, 1996, VIROLOGY, V219, P228, DOI 10.1006/viro.1996.0240
   WHATMORE AM, 1995, J VIROL, V69, P5117
   WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9                                                    
   WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q
   WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033
   Wuthrich K., 1986, NMR PROTEINS NUCL AC
   ZUIDERWEG ERP, 1990, J MAGN RESON, V86, P210, DOI 10.1016/0022-2364(90)90228-2
NR 90
TC 134
Z9 136
U1 0
U2 3
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 40 WEST 20TH STREET, NEW YORK, NY 10011-4211
SN 0961-8368
J9 PROTEIN SCI
JI Protein Sci.
PD JUN
PY 1997
VL 6
IS 6
BP 1248
EP 1263
DI 10.1002/pro.5560060613                                                  
          
PG 16
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA XE145
UT WOS:A1997XE14500013
PM 9194185
OA gold
DA 2018-01-05
ER

PT J
AU Akhtar, S
   Lewis, KJ
AF Akhtar, S
   Lewis, KJ
TI Antisense oligonucleotide delivery to cultured macrophages is improved
   by incorporation into sustained-release biodegradable polymer
   microspheres
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE cell uptake; microspheres; nucleic acid delivery; oligodeoxynucleotides;
   poly(lactide-co-glycolide) copolymer
ID CELLULAR UPTAKE; POLYALKYLCYANOACRYLATE NANOPARTICLES; MODIFIED
   OLIGODEOXYNUCLEOTIDES; IN-VITRO; PHAGOCYTOSIS; STABILITY; CARRIERS;
   CELLS; EXTRACTS; ANALOGS
AB Macrophages are important reservoirs of infection including the human immunodeficiency virus (HIV) virus and strategies which target therapeutic agents to these cells appear worthwhile. In this study, we have evaluated the use of biodegradable poly(lactide-co-glycolide) (P(LA-GA)) microspheres for the improved delivery of anti-HIV oligonucleotides (ODNs) to macrophage cells in culture. Phosphodiester (PO) or phosphorothioate (PS) sequences, including those antisense to the rat gene in HIV, were incorporated into biodegradable P(LA-GA) microspheres (1-2 mu m) using a double-emulsion solvent evaporation procedure. For a given polymer molecular weight and ODN chemistry, entrapment efficiencies and in vitro release rates were dependent on microsphere size. Smaller microspheres (1-2 mu m) released 70% of the entrapped ODN within 4 days compared with 40 days for larger microspheres (10-20 mu m), suggesting that this delivery system also offers the potential for sustained release of ODNs. The cellular association of ODNs entrapped within small microspheres was improved 10-fold in murine macrophages compared with free ODNs. Uptake was enhanced when macrophages were activated with interferon-gamma (INF-gamma) and lipopolysaccharide (LPS) treatment but decreased significantly in the presence of metabolic and phagocytosis inhibitors. Fluorescence microscopy studies with macrophages showed that a more diffuse subcellular distribution of ODNs was observed when delivered as a microsphere formulation compared with free ODNs, which exhibited the characteristic punctate periplasmic distribution. These results indicate that polymer microspheres represent an attractive strategy for the improved cellular delivery of ODNs. (C) 1997 Elsevier Science B.V.
RP Akhtar, S (reprint author), ASTON UNIV,INST PHARMACEUT SCI,ASTON TRIANGLE,BIRMINGHAM B4 7ET,W MIDLANDS,ENGLAND.
CR AGRAWAL S, 1991, P NATL ACAD SCI USA, V88, P7595, DOI 10.1073/pnas.88.17.7595
   AGRAWAL S, 1995, BIOCHEM PHARMACOL, V50, P571, DOI 10.1016/0006-2952(95)00160-2                                                    
   Akhtar S, 1996, ANTISENSE NUCLEIC A, V6, P197, DOI 10.1089/oli.1.1996.6.197
   Akhtar S, 1992, Trends Cell Biol, V2, P139, DOI 10.1016/0962-8924(92)90100-2
   AKHTAR S, 1995, TETRAHEDRON LETT, V36, P7333, DOI 10.1016/0040-4039(95)01512-G
   Akhtar S, 1996, J ANTIMICROB CHEMOTH, V38, P159, DOI 10.1093/jac/38.2.159
   Akhtar S, 1997, TRENDS PHARMACOL SCI, V18, P12, DOI 10.1016/S0165-6147(96)01002-4
   AKHTAR S, 1991, LIFE SCI, V49, P1793, DOI 10.1016/0024-3205(91)90480-Y
   Akhtar S, 1995, DELIVERY STRATEGIES
   AUGER MJ, 1992, MACROPHAGE NATURAL I
   BAZILE DV, 1992, BIOMATERIALS, V13, P1093, DOI 10.1016/0142-9612(92)90142-B
   Beck GF, 1996, PHARMACEUT RES, V13, P1028, DOI 10.1023/A:1016002606705
   BELTINGER C, 1995, J CLIN INVEST, V95, P1814, DOI 10.1172/JCI117860
   BENDER A, 1994, RES VIROLOGY, V145, P215, DOI 10.1016/S0923-2516(07)80025-2                                                   
   CHAVANY C, 1994, PHARMACEUT RES, V11, P1370, DOI 10.1023/A:1018923301967
   CHAVANY C, 1992, PHARMACEUT RES, V9, P441, DOI 10.1023/A:1015871809313
   CORTESI R, 1994, INT J PHARM, V105, P181, DOI 10.1016/0378-5173(94)90464-2
   Coulson JM, 1996, MOL PHARMACOL, V50, P314
   DAVIS SS, 1993, J CONTROL RELEASE, V24, P157, DOI 10.1016/0168-3659(93)90175-5
   ELDRIDGE JH, 1990, J CONTROL RELEASE, V11, P205, DOI 10.1016/0168-3659(90)90133-E
   FENANDEZURRUSUN.R, 1995, TOXICOL APPL PHARM, V130, P272
   FOURNIER C, 1991, CANCER RES, V51, P5384
   GODARD G, 1995, EUR J BIOCHEM, V232, P404, DOI 10.1111/j.1432-1033.1995.404zz.x
   Hudson AJ, 1996, INT J PHARM, V133, P257, DOI 10.1016/0378-5173(95)04390-X                                                    
   HUDSON AJ, 1986, INT J PHARM, V136, P23
   ILLUM L, 1987, LIFE SCI, V40, P367, DOI 10.1016/0024-3205(87)90138-X
   Iversen P L, 1992, Antisense Res Dev, V2, P211
   JOHNSON GD, 1982, J IMMUNOL METHODS, V55, P231, DOI 10.1016/0022-1759(82)90035-7
   KHAN IM, 1993, NUCLEIC ACIDS RES, V21, P2957, DOI 10.1093/nar/21.12.2957                                                          
   KIMURA H, 1994, CURR EYE RES, V13, P353, DOI 10.3109/02713689409167299                                                       
   LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494
   LERAY AM, 1994, INT J PHARM, V106, P201, DOI 10.1016/0378-5173(94)90003-5
   LEWIS KJ, 1995, J CONTROL RELEASE, V37, P173, DOI 10.1016/0168-3659(95)00100-M
   LHERM C, 1992, INT J PHARM, V84, P13, DOI 10.1016/0378-5173(92)90210-S
   LISIEWICZ J, 1993, P NATL ACAD SCI USA, V90, P3860
   MELTZER MS, 1990, IMMUNOL TODAY, V11, P217, DOI 10.1016/0167-5699(90)90086-O                                                    
   MOORE V, 1997, IN PRESS BIOCH PHARM
   Nakada Y, 1996, PHARMACEUT RES, V13, P38, DOI 10.1023/A:1016017014573
   Narayanan Ramaswamy, 1996, Current Opinion in Oncology, V8, P509
   Pouton CW, 1996, ADV DRUG DELIVER REV, V18, P133, DOI 10.1016/0169-409X(95)00092-L                                                    
   ROY S, 1988, J LEUKOCYTE BIOL, V43, P91
   Sambrook J, 1989, MOL CLONING LAB MANU
   SCHWAB G, 1994, P NATL ACAD SCI USA, V91, P10460, DOI 10.1073/pnas.91.22.10460                                                        
   SHOJI Y, 1991, NUCLEIC ACIDS RES, V19, P5543, DOI 10.1093/nar/19.20.5543
   SPILLER DG, 1992, ANTI-CANCER DRUG DES, V7, P115
   TABATA Y, 1988, J BIOMED MATER RES, V22, P837, DOI 10.1002/jbm.820221002
   TABATA Y, 1988, BIOMATERIALS, V9, P356, DOI 10.1016/0142-9612(88)90033-6
   WICKSTROM E, 1986, J BIOCHEM BIOPH METH, V13, P97, DOI 10.1016/0165-022X(86)90021-7
   YAMAGUCHI K, 1993, J CONTROL RELEASE, V24, P81, DOI 10.1016/0168-3659(93)90169-6
NR 49
TC 49
Z9 50
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARM
JI Int. J. Pharm.
PD MAY 12
PY 1997
VL 151
IS 1
BP 57
EP 67
DI 10.1016/S0378-5173(97)04887-4                                           
          
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA XD088
UT WOS:A1997XD08800007
DA 2018-01-05
ER

PT J
AU Frey, A
   Neutra, MR
   Robey, FA
AF Frey, A
   Neutra, MR
   Robey, FA
TI Peptomer aluminum oxide nanoparticle conjugates as systemic and mucosal
   vaccine candidates: Synthesis and characterization of a conjugate
   derived from the C4 domain of HIV-1(MN) gp120
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; MONOCLONAL-ANTIBODIES;
   AFFINITY-CHROMATOGRAPHY; CONTAINING PEPTIDES; CYCLIC-PEPTIDES;
   AMINO-ACID; IDENTIFICATION; GLYCOPROTEIN; RECEPTOR; ADJUVANT
AB Peptomers are polymers composed of peptides that are specifically cross-linked in a head-to-tail fashion. Recently, a peptomer composed of an amphipathic peptide from the C4 domain of HIV-1(MN) gp120 was shown to display a prominent alpha-helical conformation that, as an immunogen, elicited rabbit antibodies recognizing native and recombinant gp120 [Robey et al. (1995) J. Biol. Chem. 270, 23918-23921]. For the present study, we synthesized a conjugate composed of the C4 peptomer covalently linked to calcinated aluminum oxide nanoparticles. The nanoparticles were first reacted with (3-aminopropyl)-triethoxysilane to provide an amine load of 15.9 mmol of R-NH2/g of solid. The amine-modified aluminum oxide nanoparticles then were reacted with N-acetylhomocysteine thiolactone at pH 10 to place a reactive thiol on the nanoparticles. A bromoacetylated C4 peptomer, modified at the E-amines of lysine residues, then was reacted with the thiolated nanoparticles to give the peptomer covalently linked to aluminum oxide via a thioether bond. The peptomer load was determined to be 16 mg of peptomer/g of particles, a 55% theoretical yield. Particle shape and size of the peptomer-conjugated alumina were analyzed by electron microscopy and displayed a mean maximum diameter of 355 nm and a mean minimum diameter of 113 nm, well within the desired size range of 300 nm believed to be optimal for mucosal immunization purposes. Experimentally determined values of mean particle diameters, specific surface area, and specific peptomer load provided the information necessary to calculate the mean antigen load, which was determined to be 53 000 +/- 42 000 peptomer epitopes per particle. Peptomer-alumina conjugates, such as that described here, could form the basis of a new class of biomaterial that combines a chemically defined organic immunogen with a nontoxic chemically defined inorganic adjuvant.
C1 NIDR,ORAL & PHARYNGEAL CANC BRANCH,NIH,BETHESDA,MD 20892.
   HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115.
   CHILDRENS HOSP,GI CELL BIOL RES LAB,BOSTON,MA 02115.
FU NIDDK NIH HHS [DK-34854]; NIAID NIH HHS [AI34757]; NICHD NIH HHS
   [HD17557]
CR AMERONGEN HM, 1991, J ACQ IMMUN DEF SYND, V4, P760
   ANSPACH B, 1988, J CHROMATOGR, V457, P195, DOI 10.1016/S0021-9673(01)82067-7
   BERNATOWICZ MS, 1986, ANAL BIOCHEM, V155, P107
   BJORK RL, 1991, IMMUNOL LETT, V28, P91, DOI 10.1016/0165-2478(91)90104-I
   BLAND PW, 1986, IMMUNOLOGY, V58, P9
   BORRASCUESTA F, 1988, EUR J IMMUNOL, V18, P199, DOI 10.1002/eji.1830180203
   Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023
   CHRISTEL PS, 1992, CLIN ORTHOPAEDICS, V282, P10
   CORDONNIER A, 1989, NATURE, V340, P571, DOI 10.1038/340571a0
   DELGIUDICE G, 1986, J IMMUNOL, V137, P2952
   DESCHRYVER A, 1990, B WORLD HEALTH ORGAN, V68, P639
   EARL PL, 1990, P NATL ACAD SCI USA, V87, P648, DOI 10.1073/pnas.87.2.648
   ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6                                                    
   Fairhurst C W, 1992, Adv Dent Res, V6, P78
   FORREST BD, 1992, VACCINE RES, V1, P137
   FRANCIS MJ, 1991, IMMUNOLOGY, V73, P249
   Frey A, 1996, J EXP MED, V184, P1045, DOI 10.1084/jem.184.3.1045
   GOLDING H, 1988, J EXP MED, V167, P914, DOI 10.1084/jem.167.3.914
   Gupta R K, 1995, Pharm Biotechnol, V6, P229
   GURGO C, 1988, VIROLOGY, V164, P531, DOI 10.1016/0042-6822(88)90568-5
   Hem S L, 1995, Pharm Biotechnol, V6, P249
   HILLMAN K, 1991, CELL IMMUNOL, V134, P1, DOI 10.1016/0008-8749(91)90326-7
   HUISDEN RE, 1990, J CHROMATOGR, V508, P289, DOI 10.1016/S0021-9673(00)91271-8
   IVANOV B, 1995, BIOCONJUGATE CHEM, V6, P269, DOI 10.1021/bc00033a006
   JAKOBY WB, 1984, REV BIOCHEM TOXICOL, V6, P97
   KOSSOVSKY N, 1995, BIOCONJUGATE CHEM, V6, P507, DOI 10.1021/bc00035a001                                                             
   LARSSON PO, 1983, ADV CHROMATOGR, V21, P41
   LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1
   LINDENSCHMIDT RC, 1990, TOXICOL APPL PHARM, V102, P268, DOI 10.1016/0041-008X(90)90026-Q
   LYNN M, 1975, IMMOBILIZED ENZYMES
   MARX PA, 1993, SCIENCE, V260, P1323, DOI 10.1126/science.8493576
   MASSIA SP, 1990, ANAL BIOCHEM, V187, P292, DOI 10.1016/0003-2697(90)90459-M
   MOORE JP, 1994, J VIROL, V68, P469
   NAKAMURA GR, 1993, J VIROL, V67, P6179
   Neutra Marian R., 1994, P685
   Neutra MR, 1996, CELL, V86, P345, DOI 10.1016/S0092-8674(00)80106-3
   Neutra MR, 1996, ANNU REV IMMUNOL, V14, P275, DOI 10.1146/annurev.immunol.14.1.275
   OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4
   Robey F A, 1994, Methods Mol Biol, V35, P73
   ROBEY FA, 1989, ANAL BIOCHEM, V177, P373, DOI 10.1016/0003-2697(89)90068-7
   Robey FA, 1996, J BIOL CHEM, V271, P17990, DOI 10.1074/jbc.271.30.17990                                                        
   ROBEY FA, 1995, J BIOL CHEM, V270, P23918, DOI 10.1074/jbc.270.41.23918                                                        
   SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1
   SASTRY KJ, 1991, AIDS, V5, P699, DOI 10.1097/00002030-199106000-00009                                                
   SCIBIENS.RJ, 1973, J IMMUNOL, V111, P114
   SKEA DL, 1993, VACCINE, V11, P1018, DOI 10.1016/0264-410X(93)90127-J
   SPORTSMAN JR, 1980, ANAL CHEM, V52, P2013, DOI 10.1021/ac50063a006                                                             
   STARCICH BR, 1986, CELL, V45, P637, DOI 10.1016/0092-8674(86)90778-6
   SUN NC, 1989, J VIROL, V63, P3579
   TAKEDA A, 1988, SCIENCE, V242, P580, DOI 10.1126/science.2972065                                                         
   TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409
   Washburn EW, 1921, P NATL ACAD SCI USA, V7, P115, DOI 10.1073/pnas.7.4.115                                                            
   Weetall H H, 1976, Methods Enzymol, V44, P134
   YOKEL RA, 1994, J TOXICOL ENV HEALTH, V41, P131, DOI 10.1080/15287399409531834                                                       
NR 54
TC 37
Z9 37
U1 0
U2 11
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD MAY-JUN
PY 1997
VL 8
IS 3
BP 424
EP 433
DI 10.1021/bc970036p
PG 10
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA XB627
UT WOS:A1997XB62700022
PM 9177850
DA 2018-01-05
ER

PT J
AU Bettelheim, FA
   Churchill, AC
   Siew, EL
   Tumminia, SJ
   Russell, P
AF Bettelheim, FA
   Churchill, AC
   Siew, EL
   Tumminia, SJ
   Russell, P
TI Light scattering and morphology of cataract formation in transgenic mice
   containing the HIV-1 protease linked to the lens alpha A-crystallin
   promoter
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE birefringence; cataract; HIV-1 protease; mouse lens; polarized light
   scattering; protein aggregates; scanning electron microscopy
ID OPTICAL ANISOTROPY; FLUCTUATION THEORY; EYE
AB Two constructs of transgenic mice, TG(61) and TG(72), containing the HIV-1 protease linked to the lens alpha A-crystallin promoter develop cataract. The TG(61) construct develop cataract in utero. while the TG(72) construct exhibit frank opacities on the 24th day (homozygotes) and 26th day (hemizygotes) post natum. Polarized light scattering measurements were performed on cortical and nuclear sections of TG(72) lenses from day 19 to day 26 as a function of scattering angle. The parallel components of the scattered light intensity increase gradually during opacification, the perpendicular components show very low values from day 19 to day 22 after which they increase exponentially. Analysis of the scattered light intensities yielded parameters describing the size of the protein aggregates. the size of the domains exhibiting optical anisotropy/birefringence, the difference in refractive index between (a) the protein aggregates and their surroundings and (b) the birefringent units and their surroundings. The last parameter accounts for the major portion of the increase in lens turbidity.
   The TG(72) construct shows normal lens development on day 16. By day 21 the posterior cortex shows some disintegration, while the lens is still clear. By day 26 the lens nucleus migrates toward the posterior pole and there is a major alteration in the cortical fibers. Scanning electron microscopic studies reveal normal fiber cell organizations in control animals. In the TG(72) construct the fiber cells are well organized at 16 days after birth but already develop some slight separation in the posterior cortical part of the lens. By post-natal day 21, the nucleus and the anterior cortex still exhibit well aligned fiber cell organization, but the posterior cortex shows disalignment. By day 26 in the TG(72) construct, all areas of the lens show complete disintegration of the fiber cells and amorphous masses are present throughout. The light scattering parameters describing changes on the nanometer scale can be correlated with the changes in lens morphology during cataractogenesis that occur on the micrometer scale. In comparison, the light and scanning electron microscopic examinations of the postnatal TG(61) construct show that the lens is severely disrupted and contains completely disintegrated fiber cell remnants at an early age. (C) 1997 Academic Press Limited.
C1 ADELPHI UNIV, DEPT BIOL, GARDEN CITY, NY 11530 USA.
   SUNY, HVCC, DEPT CHEM, TROY, NY 12180 USA.
   NEI, LAB OCULAR DIS, NIH, BETHESDA, MD 20892 USA.
RP Bettelheim, FA (reprint author), ADELPHI UNIV, DEPT CHEM, GARDEN CITY, NY 11530 USA.
FU NEI NIH HHS [EY-02571]
CR BENEDEK GB, 1971, APPL OPTICS, V10, P459, DOI 10.1364/AO.10.000459
   BETELHEIM FA, 1995, ARCH BIOCHEM BIOPHYS, V324, P223
   BETTELHEIM FA, 1979, EXP EYE RES, V28, P189, DOI 10.1016/0014-4835(79)90130-1
   BETTELHEIM FA, 1983, BIOPHYS J, V41, P29, DOI 10.1016/S0006-3495(83)84402-6                                                   
   BETTELHEIM FA, 1974, EXP EYE RES, V18, P351, DOI 10.1016/0014-4835(74)90111-0
   BETTELHEIM FA, 1986, CURR EYE RES, V5, P925, DOI 10.3109/02713688608995173
   BETTELHEIM FA, 1995, EXP EYE RES, V60, P153, DOI 10.1016/S0014-4835(95)80005-0
   BETTELHEIM FA, 1979, BIOPHYS J, V26, P85, DOI 10.1016/S0006-3495(79)85237-6                                                   
   BETTELHEIM FA, 1975, EXP EYE RES, V21, P231, DOI 10.1016/0014-4835(75)90093-7
   BETTELHEIM FA, 1978, J COLLOID INTERF SCI, V63, P251, DOI 10.1016/0021-9797(78)90132-7
   Bettelheim FA, 1985, OCULAR LENS STRUCTUR, P265
   CLARK JI, 1982, CURR EYE RES, V1, P695
   DAVID LL, 1993, J BIOL CHEM, V268, P1937
   DAVID LL, 1984, INVEST OPHTH VIS SCI, V25, P1275
   DAVID LL, 1992, BIOCHIM BIOPHYS ACTA, P1139
   DEBYE P, 1949, J APPL PHYS, V20, P518, DOI 10.1063/1.1698419
   EGELSTAFF P, 1966, INTRO LIQUID STATE, P121
   JONAK G, COMMUNICATION
   KAKAR SK, 1991, BIOPOLYMERS, V31, P1283, DOI 10.1002/bip.360311106
   Siew EL, 1996, EXP EYE RES, V62, P265, DOI 10.1006/exer.1996.0032
   SIEW EL, 1981, EXP EYE RES, V33, P603, DOI 10.1016/S0014-4835(81)80100-5
   SIEW EL, 1981, INVEST OPHTH VIS SCI, V20, P333
   Tumminia SJ, 1996, J BIOL CHEM, V271, P425, DOI 10.1074/jbc.271.1.425                                                           
   Wiener O., 1912, ABH SACHS GES AKAD W, V32, P509
   ZIMM BH, 1948, J CHEM PHYS, V16, P1099, DOI 10.1063/1.1746740                                                               
NR 25
TC 5
Z9 5
U1 0
U2 0
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
J9 EXP EYE RES
JI Exp. Eye Res.
PD MAY
PY 1997
VL 64
IS 5
BP 667
EP 674
DI 10.1006/exer.1996.0233
PG 8
WC Ophthalmology
SC Ophthalmology
GA XD248
UT WOS:A1997XD24800002
PM 9245895
DA 2018-01-05
ER

PT J
AU Hamy, F
   Felder, ER
   Heizmann, G
   Lazdins, J
   AboulEla, F
   Varani, G
   Karn, J
   Klimkait, T
AF Hamy, F
   Felder, ER
   Heizmann, G
   Lazdins, J
   AboulEla, F
   Varani, G
   Karn, J
   Klimkait, T
TI An inhibitor of the Tat/TAR RNA interaction that effectively suppresses
   HIV-1 replication
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE peptoid; RNA-protein interactions; TAR RNA structure
ID SOLID-PHASE SYNTHESIS; TAT-DERIVED PEPTIDES; PROTEIN RECOGNITION; DRUG
   DISCOVERY; MAJOR GROOVE; IMMUNODEFICIENCY; BINDING; TRANSCRIPTION;
   INITIATION; ELONGATION
AB One of the first steps in HIV gene expression is the recruitment of Tat protein to the transcription machinery after its binding to the RNA response element TAR. Starting from a pool of 3.2 x 10(6) individual chemical entities, we were able to select a hybrid peptoid/peptide oligomer of 9 residues (CGP64222) that was able to block the formation of the Tat/TAR RNA complex in vitro at nanomolar concentrations. NMR studies demonstrated that the compound binds similarly to polypeptides derived from the Tat protein and induces a conformational change in TAR RNA at the Tat-binding site. In addition, 10-30 mu M CGP64222 specifically inhibited Tat activity in a cellular Tat-dependent transactivation assay [fusion-induced gene stimulation (FIGS) assay] and blocked HIV-1 replication in primary human lymphocytes. By contrast, peptides of a comparable size and side-chain composition inhibited cell fusion in the FIGS assay and only partially inhibited HIV-1 replication in primary human lymphocytes. Thus, we have discovered a compound, CGP64222, that specifically inhibits the Tat/TAR RNA interaction, both in vitro and in vivo.
C1 MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND.
RP Hamy, F (reprint author), NOVARTIS LTD,PHARMAECUT,PHARMA RES,CH-4002 BASEL,SWITZERLAND.
RI Hamy, Francois/A-1048-2008; Klimkait, Thomas/A-1057-2008
CR AboulEla F, 1996, NUCLEIC ACIDS RES, V24, P3974, DOI 10.1093/nar/24.20.3974
   ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555
   ALTERI E, 1993, ANTIMICROB AGENTS CH, V37, P2087, DOI 10.1128/AAC.37.10.2087                                                          
   BRUNGER AT, 1990, XPLOR MANUAL
   CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201
   CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128
   CUPELLI LA, 1995, J VIROL, V69, P2640
   DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925                                                         
   HAMY F, 1993, J MOL BIOL, V230, P111, DOI 10.1006/jmbi.1993.1129
   HEIZMANN G, 1994, PEPTIDE RES, V7, P328
   HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0
   KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0
   Keen NJ, 1996, P NATL ACAD SCI USA, V93, P2505, DOI 10.1073/pnas.93.6.2505
   LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0
   LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0
   LAZDINS JK, 1991, J IMMUNOL, V147, P1201
   MARCINIAK RA, 1991, EMBO J, V10, P4189
   MICHNE WF, 1995, J MED CHEM, V38, P3197, DOI 10.1021/jm00017a003
   PRITCHARD CE, 1994, NUCLEIC ACIDS RES, V22, P2592, DOI 10.1093/nar/22.13.2592
   PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097
   RINK H, 1987, TETRAHEDRON LETT, V28, P3787, DOI 10.1016/S0040-4039(00)96384-6
   SIMON RJ, 1992, P NATL ACAD SCI USA, V89, P9367, DOI 10.1073/pnas.89.20.9367
   WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9
   WEEKS KM, 1992, BIOCHEMISTRY-US, V31, P10281, DOI 10.1021/bi00157a015                                                             
   WYATT JR, 1994, P NATL ACAD SCI USA, V91, P1356, DOI 10.1073/pnas.91.4.1356
   ZUCKERMANN RN, 1992, J AM CHEM SOC, V114, P10646, DOI 10.1021/ja00052a076
NR 26
TC 221
Z9 230
U1 1
U2 14
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 15
PY 1997
VL 94
IS 8
BP 3548
EP 3553
DI 10.1073/pnas.94.8.3548
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA WW810
UT WOS:A1997WW81000014
PM 9108013
OA gold
DA 2018-01-05
ER

PT J
AU Simmons, G
   Clapham, PR
   Picard, L
   Offord, RE
   Rosenkilde, MM
   Schwartz, TW
   Buser, R
   Wells, TNC
   Proudfoot, AEI
AF Simmons, G
   Clapham, PR
   Picard, L
   Offord, RE
   Rosenkilde, MM
   Schwartz, TW
   Buser, R
   Wells, TNC
   Proudfoot, AEI
TI Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by
   a novel CCR5 antagonist
SO SCIENCE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; TROPIC HIV-1; FUSION; CELLS; ENTRY;
   RECEPTOR; RANTES; IDENTIFICATION; MIP-1-ALPHA; MIP-1-BETA
AB The chemokine receptors CXCR4 and CCR5 have recently been shown to act as coreceptors, in concert with CD4, for human immunodeficiency virus-type 1 (HIV-1) infection. RANTES and other chemokines that interact with CCR5 and block infection of peripheral blood mononuclear cell cultures inhibit infection of primary macrophages inefficiently at best. If used to treat HIV-1-infected individuals, these chemokines could fail to influence HIV replication in nonlymphocyte compartments while promoting unwanted inflammatory side effects. A derivative of RANTES that was created by chemical modification of the amino terminus, aminooxypentane (AOP)-RANTES, did not induce chemotaxis and was a subnanomolar antagonist of CCR5 function in monocytes. It potently inhibited infection of diverse cell types (including macrophages and lymphocytes) by nonsyncytium-inducing, macrophage-tropic HIV-1 strains. Thus, activation of cells by chemokines is not a prerequisite for the inhibition of viral uptake and replication. Chemokine receptor antagonists like AOP-RANTES that achieve full receptor occupancy at nanomolar concentrations are strong candidates for the therapy of HIV-1-infected individuals.
C1 INST CANC RES,CHESTER BEATTY LABS,VIROL GRP,LONDON SW3 6JB,ENGLAND.
   CTR MED UNIV GENEVA,DEPT BIOCHIM MED,CH-1211 GENEVA 4,SWITZERLAND.
   GRYPHON SCI,S SAN FRANCISCO,CA 94080.
   RIGSHOSP 6321,MOL PHARMACOL LAB,DK-2100 COPENHAGEN,DENMARK.
   GLAXOWELLCOME RES & DEV SA,GENEVA BIOMED RES INST,CH-1228 PLAN LES OUATES,GENEVA,SWITZERLAND.
RI Simmons, Graham/G-3523-2012
OI Simmons, Graham/0000-0002-9615-7023; Wells, Timothy/0000-0001-9796-847X
CR Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955
   ArenzanaSeisdedos F, 1996, NATURE, V383, P400, DOI 10.1038/383400a0
   CLAPHAM PR, 1992, J VIROL, V66, P3531
   CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P
   COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811
   Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0
   Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0
   DRAGIC T, 1992, J VIROL, V66, P4794
   ENDRES MJ, 1996, CELL, V87, P1
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   GAERTNER HF, 1992, BIOCONJUGATE CHEM, V3, P262, DOI 10.1021/bc00015a010
   LUSTINARASIMHAN M, 1995, J BIOL CHEM, V270, P2716, DOI 10.1074/jbc.270.6.2716                                                          
   McKnight A, 1997, J VIROL, V71, P1692
   MCKNIGHT A, 1995, J VIROL, V69, P3167
   Moriuchi H, 1996, P NATL ACAD SCI USA, V93, P15341, DOI 10.1073/pnas.93.26.15341
   Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412
   Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599                                                          
   Schmidtmayerova H, 1996, NATURE, V382, P767, DOI 10.1038/382767a0
   SIMMONS G, 1995, VIROLOGY, V209, P696, DOI 10.1006/viro.1995.1307
   Simmons G, 1996, J VIROL, V70, P8355
NR 20
TC 536
Z9 560
U1 0
U2 25
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005
SN 0036-8075
J9 SCIENCE
JI Science
PD APR 11
PY 1997
VL 276
IS 5310
BP 276
EP 279
DI 10.1126/science.276.5310.276
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA WT925
UT WOS:A1997WT92500052
PM 9092481
DA 2018-01-05
ER

PT J
AU Buckheit, RW
   Snow, MJ
   FliakasBoltz, V
   Kinjerski, TL
   Russell, JD
   Pallansch, LA
   Brouwer, WG
   Yang, SS
AF Buckheit, RW
   Snow, MJ
   FliakasBoltz, V
   Kinjerski, TL
   Russell, JD
   Pallansch, LA
   Brouwer, WG
   Yang, SS
TI Highly potent oxathiin carboxanilide derivatives with efficacy against
   nonnucleoside reverse transcriptase inhibitor-resistant human
   immunodeficiency virus isolates
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID HIV-1 REPLICATION; TIBO DERIVATIVES; BINDING-SITE; NEVIRAPINE; DRUG;
   INVITRO; SERIES; ENZYME
AB The structure-activity relationships of a series of compounds related to the nonnucleoside reverse transcriptase (RT) inhibitor (NNRTI) oxathiin carboxanilide have been described (R. W. Buckheit, Jr., T. L. Kinjerski, V. Fliakas-Boltz, J. D. Russell, T. L. Stup, L. A. Pallansch, W. G. Brouwer, D. C. Dao, W. A. Harrison, R. J. Schultz, J. P. Bader, and S. S. Yang, Antimicrob, Agents Chemother, 39:2718-2727, 1996). From these studies, the furanyl-containing analog UC10 was identified as the most potent inhibitor of human immunodeficiency virus type 1 (HIV-1) replication and a promising candidate for further development. Three new UC analogs (UC040, UC82, and UC781) have been determined to inhibit laboratory-derived and low-passage-number, primary virus isolates at low nanomolar concentrations in both established and fresh human cells. Each of the compounds synergistically interacted with the nucleoside analogs zidovudine, dideoxyinosine, dideoxycytosine, and lamivudine to inhibit HIV-1 replication. As a group, the UC compounds were found to be less active against viruses with the L100I, K103N, and Y181C amino acid changes in the RT and, upon in vitro selection, yielded resistant virus with the Y181C mutation in the RT. The most potent of the three new compounds, UC781, contains a furanyl side chain, similar to UC10, but differs in having an extended ether side chain instead of an oxime chain. The broad therapeutic index of UC781 (>62,000) resulted in effective inhibition of NNRTI-resistant virus isolates at high nanomolar concentrations. Furthermore, UC781 and the NNRTI costatolide were able to synergistically inhibit HIV-1 replication when used in combination, suggesting that UC781 may interact with the RT differently than the other UC analogs. The favorable anti-HIV properties of the UC compounds suggest they should be considered for further clinical development.
C1 FREDERICK RES CTR,SO RES INST,VIROL RES GRP,FREDERICK,MD 21701.
   UNIROYAL CHEM LTD,RES LABS,GUELPH,ON,CANADA.
   NCI,DIV CANC TREATMENT DIAGNOSIS & CTR,DEV THERAPEUT PROGRAM,BETHESDA,MD 20892.
FU NCI NIH HHS [N01 CM-37818]
CR BADER JP, 1991, P NATL ACAD SCI USA, V88, P6740, DOI 10.1073/pnas.88.15.6740                                                         
   BALZARINI J, 1995, ANTIVIR CHEM CHEMOTH, V6, P169, DOI 10.1177/095632029500600306                                                      
   BOYER PL, 1993, J VIROL, V67, P2412
   BUCKHEIT RW, 1995, ANTIMICROB AGENTS CH, V39, P2718, DOI 10.1128/AAC.39.12.2718                                                          
   BUCKHEIT RW, 1993, AIDS RES HUM RETROV, V9, P1097, DOI 10.1089/aid.1993.9.1097
   BUCKHEIT RW, 1995, ANTIVIR RES, V26, P117, DOI 10.1016/0166-3542(94)00069-K
   BUCKHEIT RW, 1994, ANTIVIR RES, V25, P43, DOI 10.1016/0166-3542(94)90092-2
   BUCKHELT RW, IN PRESS HUM RETROVI
   BYRNES VW, 1993, ANTIMICROB AGENTS CH, V37, P1576, DOI 10.1128/AAC.37.8.1576                                                           
   CLANTON DJ, 1995, ANTIVIR RES, V27, P1
   COHEN KA, 1991, J BIOL CHEM, V266, P14670
   CONDRA JH, 1992, ANTIMICROB AGENTS CH, V36, P1441, DOI 10.1128/AAC.36.7.1441                                                           
   FLETCHER RS, 1995, BIOCHEMISTRY-US, V34, P4346, DOI 10.1021/bi00013a025
   FLETCHER RS, 1995, BIOCHEMISTRY-US, V34, P10106, DOI 10.1021/bi00032a002
   GROB PM, 1992, AIDS RES HUM RETROV, V8, P145, DOI 10.1089/aid.1992.8.145
   HARRISON WA, 1991, TREATMENT HIV INFECT
   KAGEYAMA S, 1994, ANTIMICROB AGENTS CH, V38, P15107
   KASHMAN Y, 1992, J MED CHEM, V35, P2735, DOI 10.1021/jm00093a004
   Kinjerski TL, 1996, ANTIVIR CHEM CHEMOTH, V7, P261, DOI 10.1177/095632029600700506                                                      
   KLUNDER JM, 1992, J MED CHEM, V35, P1887, DOI 10.1021/jm00088a027                                                             
   MAASS G, 1993, ANTIMICROB AGENTS CH, V37, P2612, DOI 10.1128/AAC.37.12.2612                                                          
   MCMAHON JB, 1995, J PHARMACOL EXP THER, V276, P298
   MELLORS JW, 1992, MOL PHARMACOL, V41, P446
   MERLUZZI VJ, 1991, SCIENCE, V251, P362
   MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568                                                         
   PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0
   PRICHARD MN, 1990, ANTIVIR RES, V14, P181, DOI 10.1016/0166-3542(90)90001-N                                                    
   RICHMAN DD, 1994, J VIROL, V68, P1660
   SAAG MS, 1993, NEW ENGL J MED, V329, P1065, DOI 10.1056/NEJM199310073291502
   WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003
NR 30
TC 38
Z9 39
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD APR
PY 1997
VL 41
IS 4
BP 831
EP 837
PG 7
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA WR166
UT WOS:A1997WR16600023
PM 9087499
DA 2018-01-05
ER

PT J
AU Daubendiek, SL
   Kool, ET
AF Daubendiek, SL
   Kool, ET
TI Generation of catalytic RNAs by rolling transcription of synthetic DNA
   nanocircles
SO NATURE BIOTECHNOLOGY
LA English
DT Article
DE convergent synthesis; rolling circle; hammerhead ribozyme; ASBV viroid
ID POLYMERASE; INVITRO; OLIGORIBONUCLEOTIDE; BACTERIOPHAGE-T7; RIBOZYMES;
   CLEAVAGE
AB Small catalytic RNAs are commonly produced either by transcription of promoter-driven linear DNA templates or by stepwise chemical synthesis on solid supports. We describe a different approach, in which very small chemically synthesized circular DNAs serve as efficient templates for generation of catalytic RNAs in vitro. The circles are 83 nucleotides in size, are single stranded, and contain no canonical RNA polymerase promoters. Despite this, T7 and Escherichia coli RNA polymerases transcribe the circles by a rolling mechanism, producing long concatemeric RNAs (similar to 7,500 nt). During the transcription reaction, the repeating RNAs self-cleave, ultimately reaching monomer length. Despite having self-complementary sequences at their substrate-binding domains, these monomeric 83-nt RNAs are shown to be catalytically active ribozymes that sequence-specifically cleave RNA targets in trans. In addition, a circular vector encoding a repeating (non-self-processing) ribozyme is described; the resulting multimeric ribozyme, targeted to a sequence in the HIV-1 genome, is also catalytically active in trans. This novel approach to the synthesis of catalytic RNAs offers a number of differences and potential advantages over current approaches to RNA synthesis.
C1 UNIV ROCHESTER,DEPT CHEM,ROCHESTER,NY 14627.
   UNIV ROCHESTER,DEPT BIOCHEM & BIOPHYS,ROCHESTER,NY 14627.
CR ALYAR SE, 1994, J BIOL CHEM, V269, P13179
   CHAMBERL.M, 1970, NATURE, V228, P227, DOI 10.1038/228227a0
   CHAMBERL.M, 1973, J BIOL CHEM, V248, P2245
   DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0
   DAUBE SS, 1992, SCIENCE, V258, P1320, DOI 10.1126/science.1280856
   DAUBENDIEK SL, 1995, J AM CHEM SOC, V117, P7818, DOI 10.1021/ja00134a032
   DAUBENDIEK SL, 1996, UNPUB
   DZIANOTT AM, 1989, P NATL ACAD SCI USA, V86, P4823, DOI 10.1073/pnas.86.13.4823
   GROSSHANS CA, 1991, NUCLEIC ACIDS RES, V19, P3875, DOI 10.1093/nar/19.14.3875
   HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0
   HUTCHINS CJ, 1986, NUCLEIC ACIDS RES, V14, P3627, DOI 10.1093/nar/14.9.3627                                                           
   KADESCH TR, 1982, J BIOL CHEM, V257, P5286
   KRUPP G, 1988, GENE, V72, P75, DOI 10.1016/0378-1119(88)90129-1
   LONG DM, 1993, FASEB J, V7, P25
   MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783
   MOLLEGAARD NE, 1994, P NATL ACAD SCI USA, V91, P3892, DOI 10.1073/pnas.91.9.3892
   OHKAWA J, 1993, P NATL ACAD SCI USA, V90, P11302, DOI 10.1073/pnas.90.23.11302
   RUBIN E, 1995, NUCLEIC ACIDS RES, V23, P3547, DOI 10.1093/nar/23.17.3547
   SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573                                                         
   SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0                                                                
   SYMONS RH, 1981, NUCLEIC ACIDS RES, V9, P6527, DOI 10.1093/nar/9.23.6527                                                           
   SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641
   TAIRA K, 1991, NUCLEIC ACIDS RES, V19, P5125, DOI 10.1093/nar/19.19.5125
   UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0
NR 24
TC 46
Z9 49
U1 0
U2 16
PU NATURE PUBLISHING CO
PI NEW YORK
PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707
SN 1087-0156
J9 NAT BIOTECHNOL
JI Nat. Biotechnol.
PD MAR
PY 1997
VL 15
IS 3
BP 273
EP 277
DI 10.1038/nbt0397-273
PG 5
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA WM050
UT WOS:A1997WM05000033
PM 9062929
OA gold
DA 2018-01-05
ER

PT J
AU Eugster, C
   Rivara, G
   Biglino, A
   Cavallo, R
   Gioannini, P
   Forno, B
   Macario, M
   Pollono, AM
AF Eugster, C
   Rivara, G
   Biglino, A
   Cavallo, R
   Gioannini, P
   Forno, B
   Macario, M
   Pollono, AM
TI Phytosterol compounds having antiviral efficacy
SO PANMINERVA MEDICA
LA English
DT Article
DE phytosterol esters; microemulsion; solubilization system
ID ASSAY
AB The present study is focused on the antiviral action patterns obtained in vitro with synthetic sterolester comprising compositions on virus-bearing host cell-lines, Appropriate cell-lines were infected with HIV-1, human Cytomegalovirus (HCMV) and Herpes simplex virus (HSV). There appears to exist a clear anti-infective efficacy for a selected number of such ester compounds, provided they are formulated into spontaneously dispersible concentrates, which in aqueous dilution engender ultramicro-emulsions having micelles in the lowest nanosize region, A significant protection against HIV-induced cytopathogenic effect was demonstrated employing a methyltetrazolium salt reduction assay on HIV-infected MT4 cells when they were incubated with such concentrates, A similar effect was evidenced with the same concentrates, when preincubating concentrated virus, but not the target cells, Antiviral activity appeared to be remarkable also on HCMV infections in vitro, where a blocking effect on immediate-early antigen expression in fibroblast monolayers could be observed, Similarly, HSV-associated glycoprotein antigen in VERO cells also suggests that virus-cell interaction and/or virus multiplication could have been blocked at a very early point of time, This would be quite different from antiviral action-patterns studied so far and imputed into the current models of explanation, Proper solubilization of the employed phytosterol compounds is essential for achieving the described activity modes, The often recommended liposome formulations would not be well suited for such compounds and such purpose, since after dilution they produce aqueous macro-emulsions, only, Furthermore, liposome formulations tend to coalesce and exhibit Marangoni effects.
C1 CIRIE,ASN 6,TURIN,ITALY.
OI CAVALLO, Rossana/0000-0001-8655-8707
CR ASZALOS A, 1980, ANTITUMOR COMPOUNDS, V2, P221
   BERGAMINI A, 1992, J VIROL METHODS, V40, P275, DOI 10.1016/0166-0934(92)90086-S
   DARNELL J, 1990, MOL CELL BIOL SCI, P177
   Eugster C, 1995, PANMINERVA MED, V37, P228
   GLUCK R, 1995, EPAXAL BERNA VIROSOM
   GREGORIADIS G, 1995, ENG LIPOSOMES DRUG D, V13
   LEVY JA, 1995, LANCET, V345, P1619, DOI 10.1016/S0140-6736(95)90121-3
   PAUWELS R, 1987, J VIROL METHODS, V16, P171, DOI 10.1016/0166-0934(87)90002-4
   STEINEGGER E, 1988, LEHRBUCH PHARMAKOGNO, P195
   ZUBAY GL, 1983, BIOCHEMISTRY-US, P1079
NR 10
TC 2
Z9 3
U1 0
U2 2
PU EDIZIONI MINERVA MEDICA
PI TURIN
PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY
SN 0031-0808
J9 PANMINERVA MED
JI Panminerva Medica
PD MAR
PY 1997
VL 39
IS 1
BP 12
EP 20
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA WU970
UT WOS:A1997WU97000003
PM 9175415
DA 2018-01-05
ER

PT J
AU Wolff, B
   Sanglier, JJ
   Wang, Y
AF Wolff, B
   Sanglier, JJ
   Wang, Y
TI Leptomycin B is an inhibitor of nuclear export: Inhibition of
   nucleo-cytoplasmic translocation of the human immunodeficiency virus
   type 1 (HIV-1) Rev protein and Rev-dependent mRNA
SO CHEMISTRY & BIOLOGY
LA English
DT Article
DE HIV-1 Rev; leptomycin B; nuclear export
ID NF-KAPPA-B; ANTI-FUNGAL ANTIBIOTICS; VIRAL MESSENGER-RNA; ACTIVATION
   DOMAIN; SCHIZOSACCHAROMYCES-POMBE; GENE-EXPRESSION; KAZUSAMYCIN-B;
   DNA-BINDING; CELL-CYCLE; HTLV-III
AB Background: The human immunodeficiency virus type 1 (HIV-1) regulatory protein Rev is required for unspliced and incompletely spliced viral mRNAs to appear in the cytoplasm and thus for viral replication. Translocation of Rev from the nucleus to the cytoplasm is essential if Rev is to function. We wanted to identify inhibitors of this transport process because they would be potential antiviral agents.
   Results: The Streptomyces metabolite, leptomycin B, and other antibiotics of the leptomycin/kazusamycin family were identified as inhibitors of the nucleo-cytoplasmic translocation of Rev at nanomolar concentrations. Rev-dependent export of mRNA into the cytoplasm is also blocked by leptomycin B, which inhibits Rev-dependent, but not Rev-independent gene expression in a short-term transfection assay, In primary human monocytes, leptomycin B suppresses HIV-1 replication.
   Conclusions: Leptomycin B is the first low molecular weight inhibitor of nuclear export to be identified. Although it cannot be used therapeutically, it should serve as a valuable tool for dissecting nuclear export pathways.
C1 NOVARTIS PRECLIN RES,BASEL,SWITZERLAND.
RP Wolff, B (reprint author), SANDOZ INST MED RES,BRUNNER STR 59,A-1230 VIENNA,AUSTRIA.
CR ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689
   ARRIGO SJ, 1991, GENE DEV, V5, P808, DOI 10.1101/gad.5.5.808
   ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040
   BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0
   BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899
   Bevec D, 1996, SCIENCE, V271, P1858, DOI 10.1126/science.271.5257.1858
   BEVEC D, 1992, P NATL ACAD SCI USA, V89, P9870, DOI 10.1073/pnas.89.20.9870
   BOHNLEIN E, 1991, J VIROL, V65, P7051
   CICCARELLI RB, 1994, ANTIVIR CHEM CHEMOTH, V5, P169, DOI 10.1177/095632029400500305                                                      
   CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0
   CULLEN BR, 1987, METHOD ENZYMOL, V152, P684
   DUAN LX, 1994, P NATL ACAD SCI USA, V91, P5075, DOI 10.1073/pnas.91.11.5075
   FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495
   FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0
   Fridell RA, 1996, P NATL ACAD SCI USA, V93, P2936, DOI 10.1073/pnas.93.7.2936
   Fritz CC, 1996, CURR BIOL, V6, P848, DOI 10.1016/S0960-9822(02)00608-5
   Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024                                                        
   GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0                                                                
   HAMAMOTO T, 1983, J ANTIBIOT, V36, P639, DOI 10.7164/antibiotics.36.639                                                      
   HAMAMOTO T, 1983, J ANTIBIOT, V36, P646, DOI 10.7164/antibiotics.36.646                                                      
   HAMAMOTO T, 1985, J ANTIBIOT, V38, P1573, DOI 10.7164/antibiotics.38.1573                                                     
   HAMMARSKJOLD ML, 1989, J VIROL, V63, P1959
   HOPE TJ, 1990, P NATL ACAD SCI USA, V87, P7787, DOI 10.1073/pnas.87.19.7787
   KOMIYAMA K, 1985, J ANTIBIOT, V38, P220, DOI 10.7164/antibiotics.38.220                                                      
   KOMIYAMA K, 1985, J ANTIBIOT, V38, P224, DOI 10.7164/antibiotics.38.224                                                      
   LEE TC, 1992, NEW BIOL, V4, P66
   MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0                                                                
   MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0
   MATSUKURA M, 1989, P NATL ACAD SCI USA, V86, P4244, DOI 10.1073/pnas.86.11.4244
   MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649                                                          
   MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538
   NISHI K, 1994, J BIOL CHEM, V269, P6320
   NISHI K, 1992, MOL MICROBIOL, V6, P761, DOI 10.1111/j.1365-2958.1992.tb01526.x
   Palmeri D, 1996, J VIROL, V70, P6442
   PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   PERNO CF, 1989, J EXP MED, V169, P933, DOI 10.1084/jem.169.3.933                                                           
   POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935
   ROBERTS BJ, 1986, CANCER CHEMOTH PHARM, V16, P95
   ROUET P, 1992, BIOTECHNIQUES, V13, P700
   RUHL M, 1993, J CELL BIOL, V123, P1309, DOI 10.1083/jcb.123.6.1309
   SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   SZILVAY AM, 1995, J VIROL, V69, P3315
   TAKAMIYA K, 1988, J ANTIBIOT, V41, P1854, DOI 10.7164/antibiotics.41.1854                                                     
   TERWILLIGER E, 1988, J VIROL, V62, P655
   VARMUS H, 1988, GENE DEV, V2, P1055, DOI 10.1101/gad.2.9.1055
   WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2
   WOLFF B, 1995, EXP CELL RES, V217, P31, DOI 10.1006/excr.1995.1060
   YOSHIDA E, 1987, J ANTIBIOT, V40, P1596, DOI 10.7164/antibiotics.40.1596                                                     
   YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X
   ZABEL U, 1993, EMBO J, V12, P201
   ZAPP ML, 1993, CELL, V74, P969, DOI 10.1016/0092-8674(93)90720-B
NR 52
TC 465
Z9 470
U1 2
U2 9
PU CURRENT BIOLOGY LTD
PI LONDON
PA 34-42 CLEVELAND STREET, LONDON, ENGLAND W1P 6LB
SN 1074-5521
J9 CHEM BIOL
JI Chem. Biol.
PD FEB
PY 1997
VL 4
IS 2
BP 139
EP 147
DI 10.1016/S1074-5521(97)90257-X                                           
          
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA WP129
UT WOS:A1997WP12900007
PM 9190288
OA gold
DA 2018-01-05
ER

PT J
AU Lowell, GH
   Kaminski, RW
   VanCott, TC
   Slike, B
   Kersey, K
   Zawoznik, E
   LoomisPrice, L
   Smith, G
   Redfield, RR
   Amselem, S
   Birx, DL
AF Lowell, GH
   Kaminski, RW
   VanCott, TC
   Slike, B
   Kersey, K
   Zawoznik, E
   LoomisPrice, L
   Smith, G
   Redfield, RR
   Amselem, S
   Birx, DL
TI Proteosomes, emulsomes, and cholera toxin B improve nasal Immunogenicity
   of human immunodeficiency virus gp160 in mice: Induction of serum,
   intestinal, vaginal, and lung IgA and IgG
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 2nd National Conference on Human Retroviruses and Related Infections
CY JAN 29-FEB 02, 1995
CL WASHINGTON, DC
ID MUCOSAL IMMUNE-SYSTEM; INTRANASAL IMMUNIZATION; ANTIBODY-RESPONSES;
   PROTEIN ANTIGEN; LIPOPOLYSACCHARIDE VACCINES; INFLUENZA VACCINE;
   CELL-SURFACE; SUBUNIT; ENHANCEMENT; LIPOSOMES
AB Intranasal immunization of mice with human immunodeficiency virus (HIV) rgp160 complexed to proteosomes improved anti-gp160 serum IgA and IgG titers, increased the number of gp160 peptides recognized, and stimulated anti-gp160 intestinal IgA compared with immunization with uncomplexed rgp160 in saline, These enhanced responses were especially evident when either a bioadhesive nanoemulsion (emulsomes) or cholera toxin B subunit (CTB) was added to the proteosome-rgp160 vaccine, Furthermore, anti-gp160 Ige and IgA in vaginal secretions and fecal extracts were induced after intranasal immunization with proteosome-rgp160 delivered either in saline or with emulsomes, Formulation of uncomplexed rgp160 with emulsomes or CTB also enhanced serum and selected mucosal IgA responses, Induction of serum, vaginal, bronchial, intestinal, and fecal IgA and IgG by intranasal proteosome-rgp160 vaccines delivered in saline or with emulsomes or CTB is encouraging for mucosal vaccine development to help control the spread of HIV transmission and AIDS.
C1 WALTER REED ARMY MED CTR,WALTER REED ARMY INST RES,DIV PATHOL,WASHINGTON,DC 20307.
   WALTER REED ARMY INST RES,DEPT RETROVIRAL RES,ROCKVILLE,MD.
   HENRY M JACKSON FDN,ROCKVILLE,MD.
   PHARMOS CORP,ALACHUA,FL.
   PHARMOS CORP,REHOVOT,ISRAEL.
   MICROGENESYS INC,MERIDEN,CT.
RP Lowell, GH (reprint author), INTELLIVAX INC,6303 WESTERN RUN DR,BALTIMORE,MD 21215, USA.
CR ABRAHAM E, 1992, VACCINE, V10, P461, DOI 10.1016/0264-410X(92)90395-Z
   ALPAR HO, 1992, INT J PHARM, V88, P335, DOI 10.1016/0378-5173(92)90332-V
   ALVING CR, 1995, HANDB NAT T, V8, P47
   AMSELEM S, 1994, P INT S CONTR REL BI, P21
   ANASTASSIOU ED, 1990, J IMMUNOL, V145, P2375
   BURNETT PR, 1994, J IMMUNOL, V152, P4642
   CARDENAS L, 1992, CLIN MICROBIOL REV, V5, P328
   CHELEN CJ, 1995, J CLIN INVEST, V95, P1415, DOI 10.1172/JCI117796                                                               
   DICKINSON BL, 1995, INFECT IMMUN, V63, P1617
   ELDRIDGE JH, 1989, CURR TOP MICROBIOL I, V146, P58
   ELGUINK N, 1989, VACCINE, V7, P147, DOI 10.1016/0264-410X(89)90055-8
   FANTINI J, 1991, P NATL ACAD SCI USA, V88, P9297, DOI 10.1073/pnas.88.20.9297
   FORREST BD, 1991, LANCET, V337, P835, DOI 10.1016/0140-6736(91)92527-9
   FURATA Y, 1994, P NATL AAD SCI US, V91, P12559
   GIZURARSON S, 1992, VACCINE, V10, P101, DOI 10.1016/0264-410X(92)90025-F
   GOULDFOGERITE S, 1994, AIDS RES HUM RETROV, V10, pS99
   GRAHAM BS, 1995, NEW ENGL J MED, V333, P1331, DOI 10.1056/NEJM199511163332007                                                     
   HAJISHENGALLIS G, 1995, J IMMUNOL, V154, P4322
   HANEBERG B, 1994, INFECT IMMUN, V62, P15
   Hashigucci K, 1996, VACCINE, V14, P113, DOI 10.1016/0264-410X(95)00174-Y                                                    
   HIRABAYASHI Y, 1990, VACCINE, V8, P243, DOI 10.1016/0264-410X(90)90053-O
   HIRABAYASHI Y, 1992, IMMUNOLOGY, V75, P493
   HOLMGREN J, 1993, VACCINE, V11, P1179, DOI 10.1016/0264-410X(93)90039-Z
   HUNT RE, 1993, ARMY SCI NEW FRONTIE, P71
   Kahn James O., 1994, V5, P213
   KAMINSKI RW, 1996, VACCINE RES, V4, P189
   LANGERMANN S, 1994, NATURE, V372, P552, DOI 10.1038/372552a0                                                                
   LEHNER T, 1993, P NATL ACAD SCI USA, V90, P8638, DOI 10.1073/pnas.90.18.8638
   LEHNER T, 1992, SCIENCE, V258, P1365, DOI 10.1126/science.1360702
   LEHNER T, 1992, VACCINE RES, V1, P319
   LEVI R, 1995, VACCINE, V13, P1353, DOI 10.1016/0264-410X(94)00083-Y
   LEVINE MM, 1983, MICROBIOL REV, V47, P510
   LOOMIS LD, 1995, J ACQ IMMUN DEF SYND, V10, P13
   LOWELL GH, 1988, SCIENCE, V240, P800, DOI 10.1126/science.2452484
   LOWELL GH, 1988, J EXP MED, V167, P658, DOI 10.1084/jem.167.2.658
   Lowell GH, 1996, INFECT IMMUN, V64, P4686
   LOWELL GH, 1990, NEW GENERATION VACCI, P141
   LOWELL GH, 1995, INFECT IMMUN, V64, P1706
   LOWELL GH, 1995, P 7 USA IDF C INF DI
   LOWELL GH, 1995, P 95 GEN M AM SOC MI
   LYCKE N, 1989, J IMMUNOL, V142, P3781
   MALLETT CP, 1995, INFECT IMMUN, V63, P2382
   MARX PA, 1993, SCIENCE, V260, P1323, DOI 10.1126/science.8493576
   MAYER KH, 1986, AM J MED, V80, P357, DOI 10.1016/0002-9343(86)90706-0
   MAZANEC MB, 1993, IMMUNOL TODAY, V14, P430, DOI 10.1016/0167-5699(93)90245-G
   MCGHEE JR, 1992, VACCINE, V10, P75, DOI 10.1016/0264-410X(92)90021-B
   MESTECKY J, 1987, J CLIN IMMUNOL, V7, P265, DOI 10.1007/BF00915547                                                              
   MUSTER T, 1995, J VIROL, V69, P6678
   NATUK RJ, 1993, AIDS RES HUM RETROV, V9, P395, DOI 10.1089/aid.1993.9.395
   Neutra M R, 1992, Trends Cell Biol, V2, P134, DOI 10.1016/0962-8924(92)90099-9
   ORR N, 1993, INFECT IMMUN, V61, P2390
   ORR N, 1994, INFECT IMMUN, V62, P5198
   REDFIELD RR, 1991, NEW ENGL J MED, V324, P1678
   RUEGG CL, 1990, J IMMUNOL METHODS, V135, P101, DOI 10.1016/0022-1759(90)90262-T
   RUSSELL MW, 1991, INFECT IMMUN, V59, P4061
   SHAHIN R, 1995, INFECT IMMUN, V63, P1195
   TAMURA S, 1989, VACCINE, V7, P257, DOI 10.1016/0264-410X(89)90240-5
   TAMURA S, 1994, VACCINE, V12, P419, DOI 10.1016/0264-410X(94)90118-X
   THIBODEAU L, 1992, AIDS RES HUM RETROV, V8, P1379
   VANCOTT TC, 1995, J IMMUNOL METHODS, V183, P103, DOI 10.1016/0022-1759(95)00038-C                                                    
   WALKER RI, 1994, VACCINE, V12, P387, DOI 10.1016/0264-410X(94)90112-0
   Wetzler LW, 1996, J EXP MED, V183, P1151, DOI 10.1084/jem.183.3.1151
   WU HY, 1993, INFECT IMMUN, V61, P314
   Zollinger WD, 1990, NEW GENERATION VACCI, P325
NR 64
TC 57
Z9 59
U1 0
U2 2
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD FEB
PY 1997
VL 175
IS 2
BP 292
EP 301
DI 10.1093/infdis/175.2.292                                                
          
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA WF063
UT WOS:A1997WF06300008
PM 9203649
OA gold
DA 2018-01-05
ER

PT J
AU Jadhav, PK
   Ala, P
   Woerner, FJ
   Chang, CH
   Garber, SS
   Anton, ED
   Bacheler, LT
AF Jadhav, PK
   Ala, P
   Woerner, FJ
   Chang, CH
   Garber, SS
   Anton, ED
   Bacheler, LT
TI Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency
   against both wild type and protease inhibitor resistant mutants of HIV
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE; IN-VIVO; DECREASED
   SENSITIVITY; REDUCED SENSITIVITY; CRYSTAL-STRUCTURE; RATIONAL DESIGN;
   VARIANTS; RNA; PROTEINASE
AB Cyclic urea amides, a novel series of HIV-1 protease (HIV PR) inhibitors, have increased activity against drug-resistant mutants of the HIV PR. The design strategy for these inhibitors is based on the hypotheses that (i) the hydrogen-bonding interactions between the inhibitor and the protease backbone will remain constant for wild-type and mutant enzymes and (ii) inhibitors which are capable of forming many nonbonded interactions, distributed throughout the active site, will experience a lower percent change in binding energy as a result of mutation in the target enzyme than those that form fewer interactions by partial occupation of the active site. The cyclic urea amide, SD146, forms 14 hydrogen bonds and 191 van der Waals contacts to HIV PR. SD146 is a very potent antiviral agent (IC90 = 5.1 nM) against wild-type HIV and potency against a range of mutant strains of HIV with resistance to a wide variety of HIV protease inhibitors.
RP Jadhav, PK (reprint author), DUPONT MERCK PHARMACEUT CO,DUPONT MERCK RES LABS,WILMINGTON,DE 19880, USA.
CR ANTON ED, 1995, 4 INT WORKSH DRUG RE
   BACHELER LT, 1994, ANTIVIR CHEM CHEMOTH, V5, P111, DOI 10.1177/095632029400500208                                                      
   BALDWIN ET, 1995, NAT STRUCT BIOL, V2, P244, DOI 10.1038/nsb0395-244
   BODANSZKY M, 1986, PEPTIDE CHEM PRACTIC, P63
   BOYER JC, 1992, P NATL ACAD SCI USA, V89, P6919, DOI 10.1073/pnas.89.15.6919
   BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458
   COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947
   CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0
   DEBOUCK C, 1992, AIDS RES HUM RETROV, V8, P153, DOI 10.1089/aid.1992.8.153
   DORSEY BD, 1994, J MED CHEM, V37, P3443, DOI 10.1021/jm00047a001                                                             
   ELFARRASH MA, 1994, J VIROL, V68, P233
   ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122
   ERICKSON JW, 1995, NAT STRUCT BIOL, V2, P523, DOI 10.1038/nsb0795-523
   ERICKSONVIITANEN S, 1994, ANTIMICROB AGENTS CH, V38, P1628, DOI 10.1128/AAC.38.7.1628                                                           
   GENG XD, 1992, J CHROMATOGR, V599, P185, DOI 10.1016/0021-9673(92)85472-6
   HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0
   HO DD, 1994, J VIROL, V68, P2016
   Hodge CN, 1996, CHEM BIOL, V3, P301, DOI 10.1016/S1074-5521(96)90110-6
   HUBNER A, 1992, J MOL BIOL, V223, P595, DOI 10.1016/0022-2836(92)90975-P
   JACOBSEN H, 1995, VIROLOGY, V206, P527, DOI 10.1016/S0042-6822(95)80069-7                                                   
   JADHAV PK, 1992, BIOORG MED CHEM LETT, V2, P353, DOI 10.1016/S0960-894X(01)80218-3
   JI JP, 1992, BIOCHEMISTRY-US, V31, P954, DOI 10.1021/bi00119a002                                                             
   KAPLAN AH, 1994, P NATL ACAD SCI USA, V91, P5597, DOI 10.1073/pnas.91.12.5597
   KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.biochem.63.1.133
   KEMPF DJ, 1995, P NATL ACAD SCI USA, V92, P2484, DOI 10.1073/pnas.92.7.2484
   KIM EE, 1995, J AM CHEM SOC, V117, P1181, DOI 10.1021/ja00108a056                                                             
   KING RW, 1995, ANTIVIR CHEM CHEMOTH, V6, P80, DOI 10.1177/095632029500600202                                                      
   KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686
   KOZAL MJ, 1995, 4 INT WORKSH DRUG RE
   Lam PYS, 1996, J MED CHEM, V39, P3514, DOI 10.1021/jm9602571
   LAM PYS, 1994, SCIENCE, V263, P380, DOI 10.1126/science.8278812
   LOEB DD, 1989, NATURE, V340, P397, DOI 10.1038/340397a0
   MANCHESTER M, 1994, J BIOL CHEM, V269, P7689
   MANSKY LM, 1995, J VIROL, V69, P5087
   MARKOWITZ M, 1995, J VIROL, V69, P701
   NORBECK D, 1995, 4 INT WORKSH DRUG RE
   Nugiel DA, 1996, J MED CHEM, V39, P2156, DOI 10.1021/jm960083n
   OTTO MJ, 1993, P NATL ACAD SCI USA, V90, P7543, DOI 10.1073/pnas.90.16.7543
   PARTALEDIS JA, 1995, J VIROL, V69, P5228
   PATICK AK, 1996, 5 INT WORKSH DRUG RE
   Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582
   ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925
   ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354
   Rose RE, 1996, P NATL ACAD SCI USA, V93, P1648, DOI 10.1073/pnas.93.4.1648
   TISDALE M, 1995, 4 INT WORKSH DRUG RE
   WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0
   WINSLOW DL, 1994, BIOCHEM BIOPH RES CO, V205, P1651, DOI 10.1006/bbrc.1994.2857
   WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551                                             
   WONG YN, 1994, BIOPHARM DRUG DISPOS, V15, P535, DOI 10.1002/bdd.2510150702                                                          
   JADHAV PK, 1994, Patent No. 5294720
NR 50
TC 100
Z9 102
U1 1
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD JAN 17
PY 1997
VL 40
IS 2
BP 181
EP 191
DI 10.1021/jm960586t
PG 11
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA WC980
UT WOS:A1997WC98000004
PM 9003516
DA 2018-01-05
ER

PT J
AU Wang, Y
   Ponelle, M
   Sanglier, JJ
   Wolff, B
AF Wang, Y
   Ponelle, M
   Sanglier, JJ
   Wolff, B
TI Novel leptomycins from a Streptomyces strain A92-308902: Inhibitors of
   the nucleo-cytoplasmic translocation of the HIV-1 regulatory protein Rev
SO HELVETICA CHIMICA ACTA
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PHASE-SPECIFIC INHIBITOR; ANTI-FUNGAL
   ANTIBIOTICS; MAMMALIAN-CELL CYCLE; VIRAL MESSENGER-RNA; ANTITUMOR
   ANTIBIOTICS; PHYSICOCHEMICAL PROPERTIES; STRUCTURE ELUCIDATION;
   BIOLOGICAL-ACTIVITIES; ACTIVATION DOMAIN
AB As one of the regulatory gene products in the HIV-1 genome, Rev protein must be translocated from the nucleus to the cytoplasm to exert its function. Therefore, inhibition of Rev protein translocation could be a useful target for HIV therapy. An extract from the Streptomyces strain A92-308902 with very potent inhibitory activity was found in the course of a high throughput screening with a Rev translocation assay (RTA). Bioassay-guided fractionation with gel filtration, normal-phase and reversed-phase chromatography yielded six RTA-active metabolites belonging to the leptomycin family, the known leptomycin A (1), leptomycin B (2), kazusamycin B (3), and kazusamycin A (4), and the hitherto unknown dilactonmycin (5) and delactonmycin (6), together with an inactive cyclic hexadepsipeptide L-156,620 (7). The structures were established mainly by spectroscopic methods (UV, FT-IR, FAB-MS,H-1-NMR,C-13-NMR(JMOD),DQ-COSY, ROESY, HSQC, and HMBC). The configuration of all C = C bonds of 1-6 was unambiguously established by analysis of coupling constants and ROESY spectra. All isolated leptomycins 1-6 inhibit Rev translocation at nanomolar concentrations. Six derivatives (2a-c and 4a-c) of leptomycin B (2) and kazusamycin A (4) were also prepared and tested in the RTA for preliminary investigations on structure-activity relationships.
C1 NOVARTIS RES INST,A-1230 VIENNA,AUSTRIA.
RP Wang, Y (reprint author), NOVARTIS PHARMA INC,RES,CORE TECHNOL AREA,CH-4002 BASEL,SWITZERLAND.
CR ABE K, 1993, J ANTIBIOT, V46, P728, DOI 10.7164/antibiotics.46.728                                                      
   ABE K, 1993, J ANTIBIOT, V46, P735, DOI 10.7164/antibiotics.46.735                                                      
   ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040
   CALDWELL CG, 1990, J ORG CHEM, V55, P2355, DOI 10.1021/jo00295a023
   DURETTE PL, 1992, BIOORG MED CHEM LETT, V2, P1033, DOI 10.1016/S0960-894X(00)80613-7
   DURETTE PL, 1990, TETRAHEDRON LETT, V31, P1237, DOI 10.1016/S0040-4039(00)88774-2                                                   
   FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495
   FUNAISHI K, 1987, J ANTIBIOT, V40, P778, DOI 10.7164/antibiotics.40.778                                                      
   HAMAMOTO T, 1983, J ANTIBIOT, V36, P639, DOI 10.7164/antibiotics.36.639                                                      
   HAMAMOTO T, 1983, J ANTIBIOT, V36, P646, DOI 10.7164/antibiotics.36.646                                                      
   HAMMARSKJOLD ML, 1989, J VIROL, V63, P1959
   Hayakawa Y, 1996, J ANTIBIOT, V49, P974, DOI 10.7164/antibiotics.49.974                                                      
   HAYAKAWA Y, 1995, J ANTIBIOT, V48, P954, DOI 10.7164/antibiotics.48.954                                                      
   Hayakawa Y, 1996, J ANTIBIOT, V49, P980, DOI 10.7164/antibiotics.49.980                                                      
   HENSENS OD, 1991, J ANTIBIOT, V44, P249, DOI 10.7164/antibiotics.44.249                                                      
   HOSOKAWA N, 1993, J ANTIBIOT, V46, P676, DOI 10.7164/antibiotics.46.676                                                      
   KOMIYAMA K, 1985, J ANTIBIOT, V38, P220, DOI 10.7164/antibiotics.38.220                                                      
   KOMIYAMA K, 1985, J ANTIBIOT, V38, P224, DOI 10.7164/antibiotics.38.224                                                      
   KUHNT M, UNPUB
   MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0
   MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538
   O'Donnell A.G., 1985, CHEM METHODS BACTERI, P131
   POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935
   ROBERTS BJ, 1986, CANCER CHEMOTH PHARM, V16, P95
   SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   STANECK JL, 1974, APPL MICROBIOL, V28, P226
   SZILVAY AM, 1995, J VIROL, V69, P3315
   TAKAMIYA K, 1988, J ANTIBIOT, V41, P1854, DOI 10.7164/antibiotics.41.1854                                                     
   TERWILLIGER E, 1988, J VIROL, V62, P655
   TSUJI RF, 1995, IMMUNOPHARMACOLOGY, V29, P79, DOI 10.1016/0162-3109(95)00047-W
   TSUJI RF, 1992, BIOSCI BIOTECH BIOCH, V56, P1686, DOI 10.1271/bbb.56.1686                                                             
   UMEZAWA I, 1984, J ANTIBIOT, V37, P706, DOI 10.7164/antibiotics.37.706                                                      
   WOLFF B, 1995, EXP CELL RES, V217, P31, DOI 10.1006/excr.1995.1060
   Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X                                                   
   YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X
NR 35
TC 6
Z9 6
U1 0
U2 2
PU NEW SWISS CHEMICAL SOC
PI BASEL
PA C/O NOVARTIS AG, K-25 1 45, CH-4002 BASEL, SWITZERLAND
SN 0018-019X
J9 HELV CHIM ACTA
JI Helv. Chim. Acta
PY 1997
VL 80
IS 7
BP 2157
EP 2167
DI 10.1002/hlca.19970800715                                                
          
PG 11
WC Chemistry, Multidisciplinary
SC Chemistry
GA YF391
UT WOS:A1997YF39100014
DA 2018-01-05
ER

PT J
AU Cogliati, M
   Roverselli, A
   Boelaert, JR
   Taramelli, D
   Lombardi, L
   Viviani, MA
AF Cogliati, M
   Roverselli, A
   Boelaert, JR
   Taramelli, D
   Lombardi, L
   Viviani, MA
TI Development of an in vitro macrophage system to assess Penicillium
   marneffei growth and susceptibility to nitric oxide
SO INFECTION AND IMMUNITY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION; THAILAND
AB We investigated the effect of nitric oxide (NO) and reactive nitrogen intermediates on the in vitro growth of Penicillium marnffei both in a cell-free system and in a novel macrophage culture system. In the cell-free system, NO that was chemically generated from NaNO2 in acid media (pH 4 and 5) markedly inhibited the growth of P. marneffei, On the contrary, inhibition of growth did not occur in neutral medium (pH 7.4) in which NO was not produced, P, marneffei conidia were phagocytized by nonstimulated murine J774 macrophages after 2 h of incubation, During the following 24 h, P, marneffei grew as yeast-like cells replicating by fission in the J774 macrophages, The intracellular growth of P. marneffei damaged nonstimulated J774 macrophages, as confirmed by electron microscopy. When 5774 cells were stimulated by gamma interferon and lipopolysaccharide, which led to enhanced production of reactive nitrogen intermediates, the percentage of yeast-like cells was significantly reduced and P. marneffei conidia were damaged in the J774 macrophages. The inhibition of NO synthesis by N-monomethyl-L-arginine restored the intracellular growth of P, marneffei. The inverse correlation between intramacrophage growth and the amount of nitrite detected in culture supernatants supports the hypothesis that the L-arginine-dependent NO pathway plays an important role in the murine macrophage immune response against P. marneffei.
C1 UNIV MILAN,IRCCS,OSPED MAGGIORE,IST IGIENE & MED PREVENT,I-20122 MILAN,ITALY.
   UNIV MILAN,IST MICROBIOL,I-20133 MILAN,ITALY.
   IST NAZL TUMORI,DIV ONCOL SPERIMENTALE A,I-20133 MILAN,ITALY.
   ALGEMEEN ZIEKENHUIS ST JAN,UNIT RENAL & INFECT DIS,BRUGGE,BELGIUM.
RI Roverselli, Annamaria/D-7504-2013
OI Roverselli, Annamaria/0000-0002-2143-3054
CR ALSPAUGH JA, 1991, INFECT IMMUN, V59, P2291
   BLASI E, 1995, INFECT IMMUN, V63, P1806
   CHAN YF, 1990, ULTRASTRUCT PATHOL, V14, P439, DOI 10.3109/01913129009007223                                                       
   DEGROOTE MA, 1995, CLIN INFECT DIS, V21, pS162, DOI 10.1093/clinids/21.Supplement_2.S162                                            
   DING AH, 1988, J IMMUNOL, V141, P2407
   DROUHET E, 1988, Bulletin de la Societe Francaise de Mycologie Medicale, V17, P77
   DROUHET E, 1993, J MYCOL MED, V4, P195
   GARRISON RG, 1973, CAN J MICROBIOL, V19, P1305, DOI 10.1139/m73-209                                                                 
   GRANGER DL, 1988, J CLIN INVEST, V81, P1129, DOI 10.1172/JCI113427
   IMWIDTHAYA P, 1994, MYCOPATHOLOGIA, V127, P135, DOI 10.1007/BF01102912
   ISHIMINE T, 1995, MICROBIOL IMMUNOL, V39, P49, DOI 10.1111/j.1348-0421.1995.tb02167.x                                              
   JORENS PG, 1995, INFECT IMMUN, V63, P4489
   KWONCHUNG KJ, 1992, MED MYCOLOGY, P825
   LANE TE, 1994, INFECT IMMUN, V62, P1478
   MICHALISZYN E, 1995, INFECT IMMUN, V63, P2075
   MONCADA S, 1993, NEW ENGL J MED, V329, P2002
   NAKAMURA LT, 1994, INFECT IMMUN, V62, P680
   PETO TEA, 1988, J INFECTION, V16, P285, DOI 10.1016/S0163-4453(88)97700-6
   ROMAGNOLI MJ, 1994, 94 GEN M AM SOC MICR
   SCHOEDON G, 1995, CLIN INFECT DIS, V21, pS152, DOI 10.1093/clinids/21.Supplement_2.S152                                            
   THOUGCHAROEN P, 1992, THAI AIDS J, V4, P117
   VIVIANI MA, 1993, DIMORPHIC FUNGI IN BIOLOGY AND MEDICINE, P413
   VIVIANI MA, 1993, EUR J EPIDEMIOL, V9, P79, DOI 10.1007/BF00463094
NR 23
TC 23
Z9 25
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD JAN
PY 1997
VL 65
IS 1
BP 279
EP 284
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA WA609
UT WOS:A1997WA60900040
PM 8975924
DA 2018-01-05
ER

PT B
AU Gourley, MF
   Gourley, PL
AF Gourley, MF
   Gourley, PL
BE Gourley, PL
   Katzir, A
TI Integration of electro-optical mechanical systems and medicine: Where
   are we and where can we go?
SO MICRO- AND NANOFABRICATED ELECTRO-OPTICAL MECHANICAL SYSTEMS FOR
   BIOMEDICAL AND ENVIRONMENTAL APPLICATIONS, PROCEEDINGS OF
SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
   (SPIE)
LA English
DT Proceedings Paper
CT 1st SPIE Conference on Microfabricated and Nanofabricated
   Electro-Optical Mechanical Systems for Biomedical and Environmental
   Applications
CY FEB 10-11, 1997
CL SAN JOSE, CA
SP Soc Photo Opt Instrumentat Engineers
DE biomedical; analysis; DNA; flow cytometry; microelectromechanical
   systems; Microchip; DNA amplification; fluorescent activated cell
   sorting; diagnosis; medicine
AB The marriage of microfabricated materials with microbiological systems will allow advances in medicine to proceed at an unprecedented pace. Biomedical research is placing new demands on speed and limits of detection to assay body tissues and fluids. Emerging microfabricated chip technologies from the engineering community offer researchers novel types of analysis of human samples. In guiding these developments, the ability to swiftly and accurately gain useful information for identification and establish a diagnosis, is of utmost importance. Current examples of such technology include DNA amplification and analysis, and fluorescent cell analysis by flow cytometry. Potential applications include the development of rapid techniques for examining large number of cells in tissue or in blood. These could serve as screening tools for the detection and quantification of abnormal cell types; for example malignant or HIV infected cells. Micro/Nanofabrication methods will make these devices compact, providing access of this technology to point of care providers; in a clinic, ambulance, or on a battlefield. Currently, these tools are in the construction phase. Upon delivery to researchers, validation of these instruments will lead to clinical demand that requires approval from the Food and Drug Administration. This paper will outline criteria that successful devices must satisfy.
RP Gourley, MF (reprint author), WASHINGTON HOSP CTR,WASHINGTON,DC 20010, USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU SPIE - INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA PO BOX 10, BELLINGHAM, WA 98227-0010
BN 0-8194-2389-0
J9 P SOC PHOTO-OPT INS
PY 1997
VL 2978
BP 197
EP 204
DI 10.1117/12.269969
PG 4
WC Engineering, Biomedical; Engineering, Electrical & Electronic; Optics
SC Engineering; Optics
GA BH52D
UT WOS:A1997BH52D00024
DA 2018-01-05
ER

PT J
AU Lobenberg, R
   Kreuter, J
AF Lobenberg, R
   Kreuter, J
TI Macrophage targeting of azidothymidine: A promising strategy for AIDS
   therapy
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; NANOPARTICLES; DRUG; INFECTION; MONOCYTES;
   LIPOSOMES; DELIVERY
AB Macrophages play an important role in the immunopathogenesis of AIDS, The objective of this study was to investigate the possibility of specific targeting of antivirals such as azidothymidine (AZT) to macrophages, using nanoparticles as a colloidal drug carrier, The body distribution of AZT bound to nanoparticles and as a control solution was studied in rats after intravenous and peroral administration, C-14-Labeled AZT was bound to nanoparticles in the presence of bis(2-ethylhexyl)sulfosuccinate sodium, The radioactivity was measured in different organs including those containing large numbers of macrophages. After intravenous injection, the concentrations of AZT were up to 18 times higher in organs belonging to the reticuloendothelial system (RES) when the drug was bound to nanoparticles than after injection of an aqueous AZT solution, Likewise, after oral administration the nanoparticle formulation delivered AZT more efficiently to the RES than the aqueous solution, In addition, the blood concentration was significantly higher after oral administration of nanoparticles. These results demonstrate that nanoparticles are a promising drug-targeting system for AZT to the RES organs. The increase in drug availability at the sites containing abundant macrophages may allow a reduction in dosage to avoid systemic toxicity.
C1 UNIV FRANKFURT,INST PHARMAZEUT TECHNOL,D-60439 FRANKFURT,GERMANY.
OI Lobenberg, Raimar/0000-0002-0919-0213
CR ADACHI N, 1994, J BIOMAT SCI-POLYM E, V6, P463
   BECK PH, 1994, EUR J PHARM BIOPHARM, V40, P134
   BENDER A, 1994, RES VIROLOGY, V145, P215, DOI 10.1016/S0923-2516(07)80025-2                                                   
   Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   BORCHARD G, 1994, INT J PHARM, V110, P29, DOI 10.1016/0378-5173(94)90372-7                                                    
   DAMGE C, 1987, INT J PHARM, V36, P121, DOI 10.1016/0378-5173(87)90146-3                                                    
   GENDELMAN HE, 1989, AIDS, V3, P475, DOI 10.1097/00002030-198908000-00001
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   ILLUM L, 1982, INT J PHARM, V12, P135
   ILLUM L, 1987, LIFE SCI, V40, P367, DOI 10.1016/0024-3205(87)90138-X
   KREUTER J, 1983, PHARM ACTA HELV, V58, P217
   Kreuter J., 1994, COLLOIDAL DRUG DELIV, P219
   KREUTER J, 1985, DRUG TARGETING, P51
   KUHNEL H, 1989, P NATL ACAD SCI USA, V86, P2383, DOI 10.1073/pnas.86.7.2383                                                          
   MAINCENT P, 1986, J PHARM SCI, V75, P955, DOI 10.1002/jps.2600751009
   MCLEOD GX, 1992, ANN INTERN MED, V117, P487, DOI 10.7326/0003-4819-117-6-487
   MELTZER MS, 1990, IMMUNOL TODAY, V11, P217, DOI 10.1016/0167-5699(90)90086-O                                                    
   NEFZGER M, 1984, J PHARM SCI, V73, P1309, DOI 10.1002/jps.2600730934
   ROY S, 1988, J LEUKOCYTE BIOL, V43, P91
   Schafer V, 1994, Clin Diagn Virol, V1, P279, DOI 10.1016/0928-0197(94)90058-2
   SCHAFER V, 1992, PHARMACEUT RES, V9, P541, DOI 10.1023/A:1015852732512
   TROSTER SD, 1990, INT J PHARM, V61, P61
   VONBRIESEN H, 1990, RES VIROLOGY, V141, P225, DOI 10.1016/0923-2516(90)90025-E
   WASER PG, 1987, INT J PHARM, V39, P213, DOI 10.1016/0378-5173(87)90219-5
NR 24
TC 47
Z9 53
U1 0
U2 2
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD DEC 10
PY 1996
VL 12
IS 18
BP 1709
EP 1715
DI 10.1089/aid.1996.12.1709
PG 7
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA VY708
UT WOS:A1996VY70800009
PM 8959248
DA 2018-01-05
ER

PT J
AU vonderHelm, K
AF vonderHelm, K
TI Retroviral proteases: Structure, function and inhibition from a
   non-anticipated viral enzyme to the target of a most promising HIV
   therapy
SO BIOLOGICAL CHEMISTRY
LA English
DT Review
DE HIV; HIV-protease-inhibitor; HIV therapy; protease; proteinase;
   retrovirus
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ESCHERICHIA-COLI; PROTEINASE-INHIBITOR;
   TYPE-1 PROTEASE; IN-VITRO; REVERSE-TRANSCRIPTASE; ASPARTIC PROTEASE;
   CRYSTAL-STRUCTURE; RATIONAL DESIGN; CELL-CULTURE
AB Retrovirally encoded proteases are responsible for the maturation of immature viral particles yielding mature, infectious virus, This is done by apparent (auto)-processing and self-activation of the protease (PR) from a larger viral gag-PR-(pol) protein (zymogen) precursor and subsequent processing of the viral reverse transcriptase (RT) and integrase (IN), and the gag protein precursor into mature gag proteins. Only the matured components are capable of forming capsids for intact, infectious viruses. Blocking this proteolytic process results in production of immature, non-infective virions,
   All retroviral proteases are aspartic-type proteases. Determination of the three-dimensional structure revealed retroviral proteases as small, nearly symmetric homodimers. This prompted de novo design of inhibitors for the HIV protease taking advantage of the unique symmetric structure of the active center, unparalleled by cellular proteases. The novel substances inhibit in vitro the HIV protease at nanomolar/subnanomolar concentrations and exhibit very low toxicity, They are inactive against human proteases such as renin or pepsin, The HIV protease inhibitors (PI) represent a promising alternative to the reverse transcriptase (RT) inhibitors (AZT,ddC,ddl) hitherto used with limited success for HIV chemotherapy. Clinical studies confirmed the low toxicity but revealed a pharmacological pattern typical for these hydrophobic compounds, such as low water solubility, poor oral bioavailibility, and short plasma half-life, Typical for antimicrobial agents, also a resistance phenomenon became evident, Latest clinical results show, however, promisingly that both problems might be overcome by application of the PI in combination with RT inhibitors (such as AZT, ddl or ddC) exerting a remarkable synergistic antiviral effect with lasting restoration of the CD4 T-cell level.
RP vonderHelm, K (reprint author), UNIV MUNICH, MAX VON PETTENKOFER INST, PETTENKOFERSTR 9A, D-80336 MUNICH, GERMANY.
CR ALIPERTI G, 1978, VIROLOGY, V90, P366, DOI 10.1016/0042-6822(78)90321-5
   ARGOS P, 1984, NUCLEIC ACIDS RES, V12, P7251, DOI 10.1093/nar/12.18.7251                                                          
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   BAZAN JF, 1989, FEBS LETT, V249, P5, DOI 10.1016/0014-5793(89)80003-1                                                    
   BRENNAN TM, 1995, ANTIVIR RES, V26, P173, DOI 10.1016/0166-3542(94)00074-I
   CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913
   Chiba M, 1996, DRUG METAB DISPOS, V24, P307
   Chou KC, 1996, PROTEINS, V24, P51, DOI 10.1002/(SICI)1097-0134(199601)24:1<51::AID-PROT4>3.0.CO;2-R
   CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0
   CRAIG JC, 1994, ANTIVIR CHEM CHEMOTH, V5, P380, DOI 10.1177/095632029400500605                                                      
   CRAIG JC, 1991, ANTIVIR RES, V16, P295, DOI 10.1016/0166-3542(91)90045-S
   CRAIG JC, 1992, ANTIVRIAL CHEM CHEMO, V2, P181
   DEBOUCK C, 1992, AIDS RES HUM RETROV, V8, P153, DOI 10.1089/aid.1992.8.153
   DEBOUCK C, 1992, STRUCTURE FUNCTION A, P407
   DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001
   DITTMAR KJ, 1978, J VIROL, V28, P106
   DREYER GB, 1989, P NATL ACAD SCI USA, V86, P9752, DOI 10.1073/pnas.86.24.9752
   DUNN JG, 1986, BIOCHEM BIOPH RES CO, V134, P71
   EBERLE J, 1995, AIDS RES HUM RETROV, V11, P671, DOI 10.1089/aid.1995.11.671                                                         
   ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122
   ERICKSONVIITANEN S, 1994, ANTIMICROB AGENTS CH, V38, P1628, DOI 10.1128/AAC.38.7.1628                                                           
   FARMERIE WG, 1987, SCIENCE, V236, P305, DOI 10.1126/science.2436298
   GIAM CZ, 1988, J BIOL CHEM, V263, P14617
   GRAVES MC, 1988, P NATL ACAD SCI USA, V85, P2449, DOI 10.1073/pnas.85.8.2449
   GRAVES MC, 1990, BIOCHEM BIOPH RES CO, V168, P30, DOI 10.1016/0006-291X(90)91670-N
   GREENLEE WJ, 1990, MED RES REV, V10, P173, DOI 10.1002/med.2610100203
   GROBELNY D, 1990, BIOCHEM BIOPH RES CO, V169, P1111, DOI 10.1016/0006-291X(90)92010-W
   HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0
   Hodge CN, 1996, CHEM BIOL, V3, P301, DOI 10.1016/S1074-5521(96)90110-6
   HOMMA M, 1971, J VIROL, V8, P619
   IVANOFF LA, 1986, P NATL ACAD SCI USA, V83, P5392, DOI 10.1073/pnas.83.15.5392
   JACOBSON MA, 1995, AIDS, V9, P727, DOI 10.1097/00002030-199507000-00010                                                
   KAPLAN AH, 1994, J VIROL, V68, P6782
   KATOH I, 1987, NATURE, V329, P654, DOI 10.1038/329654a0
   KEMPF DJ, 1995, P NATL ACAD SCI USA, V92, P2484, DOI 10.1073/pnas.92.7.2484
   KEMPF DJ, 1990, J MED CHEM, V33, P2687, DOI 10.1021/jm00172a002
   KEMPF DJ, 1993, J MED CHEM, V36, P320, DOI 10.1021/jm00055a003
   KIDO H, 1993, J BIOL CHEM, V268, P13406
   KISSELEV A, 1995, THESIS U MOSCOW
   KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686
   KORANT B, 1979, P NATL ACAD SCI USA, V76, P2992, DOI 10.1073/pnas.76.6.2992
   KORANT BD, 1972, J VIROL, V10, P751
   KOTLER M, 1992, J VIROL, V66, P6781
   KRAMER RA, 1986, SCIENCE, V231, P1580, DOI 10.1126/science.2420008
   KRAUSSLICH H, 1988, ANNU REV BIOCHEM, V57, P710
   KRAUSSLICH HG, 1991, P NATL ACAD SCI USA, V88, P3213, DOI 10.1073/pnas.88.8.3213                                                          
   KUO LC, 1994, METHOD ENZYMOL, P241
   LAM PYS, 1994, SCIENCE, V263, P380, DOI 10.1126/science.8278812
   Lindhofer H, 1995, VIROLOGY, V214, P624, DOI 10.1006/viro.1995.0074                                                          
   LINDHOFER H, 1993, PORTL PR P, P219
   LOEB DD, 1989, J VIROL, V63, P111
   MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486
   MEEK TD, 1989, P NATL ACAD SCI USA, V86, P1841, DOI 10.1073/pnas.86.6.1841
   MEEK TD, 1990, NATURE, V343, P90, DOI 10.1038/343090a0
   Mellors JW, 1996, NAT MED, V2, P274, DOI 10.1038/nm0396-274
   Merrill DP, 1996, J INFECT DIS, V173, P355, DOI 10.1093/infdis/173.2.355                                                        
   MILLER M, 1989, NATURE, V337, P576, DOI 10.1038/337576a0
   NITSCHKO H, 1994, ANTIVIR CHEM CHEMOTH, V5, P236, DOI 10.1177/095632029400500405                                                      
   Noble S, 1996, DRUGS, V52, P93, DOI 10.2165/00003495-199652010-00007                                                
   OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153
   OSWALD M, 1991, FEBS LETT, V292, P298, DOI 10.1016/0014-5793(91)80888-A
   PALMENBERG AC, 1979, J VIROL, V32, P770
   PARTALEDIS JA, 1995, J VIROL, V69, P5228
   PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0
   PELHAM HRB, 1979, VIROLOGY, V96, P463, DOI 10.1016/0042-6822(79)90104-1
   Pennisi E, 1996, SCIENCE, V272, P1884, DOI 10.1126/science.272.5270.1884
   PHYLIP LH, 1992, FEBS LETT, V314, P449, DOI 10.1016/0014-5793(92)81524-P                                                    
   POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935
   RICHMAN DD, 1996, SCIENCE, V272, P1876
   Roberts NA, 1995, AIDS, V9, pS27
   ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354
   SCHATZL H, 1991, ARCH VIROL, V120, P71, DOI 10.1007/BF01310950
   SCHEID A, 1974, VIROLOGY, V57, P475, DOI 10.1016/0042-6822(74)90187-1
   SCHNEIDER J, 1988, CELL, V54, P363, DOI 10.1016/0092-8674(88)90199-7
   SEELMEIER S, 1988, P NATL ACAD SCI USA, V85, P6612, DOI 10.1073/pnas.85.18.6612
   SHOEMAN RL, 1992, MED HYPOTHESES, V37, P137, DOI 10.1016/0306-9877(92)90071-J
   SHOEMAN RL, 1991, FEBS LETT, V278, P199, DOI 10.1016/0014-5793(91)80116-K
   SHOEMAN RL, 1990, P NATL ACAD SCI USA, V87, P6336, DOI 10.1073/pnas.87.16.6336
   STRICKLER JE, 1989, PROTEINS, V6, P139, DOI 10.1002/prot.340060205
   THAISRIVONGS S, 1991, J MED CHEM, V34, P2344, DOI 10.1021/jm00112a005                                                             
   THAISRIVONGS S, 1994, J MED CHEM, V37, P3200, DOI 10.1021/jm00046a002
   TOH H, 1985, NATURE, V315, P691, DOI 10.1038/315691a0                                                                
   TOMASSELLI AG, 1990, J VIROL, V64, P3157
   VACCA JP, 1994, P NATL ACAD SCI USA, V91, P4096, DOI 10.1073/pnas.91.9.4096
   VACCA JP, 1991, J MED CHEM, V34, P1228
   Vella S, 1995, AIDS, V9, pS21
   Vella S, 1995, J ACQ IMMUN DEF SYND, V10, pS58
   VONDERHELM K, 1989, FEBS LETT, V247, P349, DOI 10.1016/0014-5793(89)81368-7                                                    
   VONDERHELM K, 1994, METHOD ENZYMOL, V241, P89
   VONDERHELM K, 1977, P NATL ACAD SCI USA, V74, P911
   VONDERHELM K, 1981, ANTIVIRAL CHEMOTHERA, P49
   WEBER IT, 1989, GENE, V85, P565, DOI 10.1016/0378-1119(89)90453-8
   Weiss RA, 1996, SCIENCE, V272, P1885, DOI 10.1126/science.272.5270.1885                                                   
   WEST ML, 1995, TRENDS PHARMACOL SCI, V16, P67, DOI 10.1016/S0165-6147(00)88980-4
   WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279
   YOSHINAKA Y, 1977, CELL, V12, P709, DOI 10.1016/0092-8674(77)90271-9
   ZYBARTH G, 1995, J VIROL, V69, P3878
NR 97
TC 30
Z9 30
U1 0
U2 4
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 1431-6730
EI 1437-4315
J9 BIOL CHEM
JI Biol. Chem.
PD DEC
PY 1996
VL 377
IS 12
BP 765
EP 774
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA WB062
UT WOS:A1996WB06200002
PM 8997487
DA 2018-01-05
ER

PT J
AU Das, K
   English, DS
   Fehr, MJ
   Smirnov, AV
   Petrich, JW
AF Das, K
   English, DS
   Fehr, MJ
   Smirnov, AV
   Petrich, JW
TI Excited-state processes in polycyclic quinones: The light-induced
   antiviral agent, hypocrellin, and a comparison with hypericin
SO JOURNAL OF PHYSICAL CHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HYDROGEN-ATOM TRANSFER; PROTON-TRANSFER;
   ANTIRETROVIRAL ACTIVITY; PHOTODYNAMIC-ACTION; ANTICANCER AGENTS; OXYGEN;
   3-HYDROXYFLAVONE; SOLVENT; PHOTOSENSITIZATION
AB Hypocrellin is a naturally occurring perylene quinone that possesses light-induced antiviral activity, most notably against the human immunodeficiency virus (HIV), as does the related molecule, hypericin. White-light continuum is employed to examine the excited-state processes in hypocrellin from the picosecond to the nanosecond time scales. These processes are assigned to intramolecular proton transfer, intersystem crossing, and interconversion between different conformations of hypocrellin, which is constrained to be nonplanar in its ground-state owing to its bulky side chains. The ground state of hypocrellin is suggested to be heterogeneous and to be comprised of an equilibrium between at least two tautomeric forms. The results are discussed in terms of the properties of hypericin, which bears marked similarities and differences with respect to hypocrellin, both in terms of its excited-state properties as well as its mode of induced antiviral activity.
C1 IOWA STATE UNIV,DEPT CHEM,AMES,IA 50011.
RI English, Douglas/B-9382-2009; Petrich, Jacob/L-1005-2015
CR BARBARA PF, 1989, J PHYS CHEM-US, V93, P29, DOI 10.1021/j100338a011                                                             
   BRUCKER GA, 1991, J PHYS CHEM-US, V95, P3190, DOI 10.1021/j100161a043                                                             
   BRUCKER GA, 1987, J PHYS CHEM-US, V91, P2856, DOI 10.1021/j100295a040                                                             
   BUCHSCHACHER GL, 1993, JAMA-J AM MED ASSOC, V269, P2880, DOI 10.1001/jama.269.22.2880
   CARPENTER S, 1994, P NATL ACAD SCI USA, V91, P12273, DOI 10.1073/pnas.91.25.12273
   CARPENTER S, 1991, PHOTOCHEM PHOTOBIOL, V53, P169, DOI 10.1111/j.1751-1097.1991.tb03919.x                                              
   CARRINGTON T, 1986, J CHEM PHYS, V84, P4364, DOI 10.1063/1.450058                                                                
   COOPER WC, 1990, INT C AIDS, V6, P369
   DAHL TA, 1993, PHOTOCHEM PHOTOBIOL, V57, P248, DOI 10.1111/j.1751-1097.1993.tb02283.x
   DEGAR S, 1992, AIDS RES HUM RETROV, V8, P1929, DOI 10.1089/aid.1992.8.1929
   DIWU Z, 1995, PHOTOCHEM PHOTOBIOL, V61, P529, DOI 10.1111/j.1751-1097.1995.tb09903.x                                              
   DIWU ZJ, 1992, J PHOTOCH PHOTOBIO A, V64, P273, DOI 10.1016/1010-6030(92)85002-C                                                    
   DIWU ZJ, 1993, FREE RADICAL BIO MED, V14, P209, DOI 10.1016/0891-5849(93)90012-J
   DURAN N, 1986, PHOTOCHEM PHOTOBIOL, V43, P677, DOI 10.1111/j.1751-1097.1986.tb05646.x
   ENSMINGER FA, 1993, J CHEM PHYS, V99, P8341, DOI 10.1063/1.465607                                                                
   ETZLSTORFER C, 1993, MONATSH CHEM, V124, P751, DOI 10.1007/BF00817311                                                              
   FALK H, 1994, J CHEM SOC CHEM COMM, P891
   FEHR MJ, 1994, BIOORG MED CHEM LETT, V4, P1339, DOI 10.1016/S0960-894X(01)80357-7
   FEHR MJ, 1995, BIOCHEMISTRY-US, V34, P15845, DOI 10.1021/bi00048a030                                                             
   FEHR MJ, 1995, J AM CHEM SOC, V117, P1833, DOI 10.1021/ja00111a024                                                             
   FREY W, 1991, J PHYS CHEM-US, V95, P10391, DOI 10.1021/j100178a028                                                             
   GAI F, 1994, J AM CHEM SOC, V116, P735, DOI 10.1021/ja00081a039
   GAI F, 1993, J AM CHEM SOC, V115, P3384, DOI 10.1021/ja00061a069
   GAI F, 1994, J PHYS CHEM-US, V98, P8352, DOI 10.1021/j100085a015                                                             
   GAI F, 1994, J PHYS CHEM-US, V98, P5784, DOI 10.1021/j100073a036                                                             
   HUDSON JB, 1994, PHOTOCHEM PHOTOBIOL, V60, P253, DOI 10.1111/j.1751-1097.1994.tb05100.x                                              
   JOHNSTON MI, 1993, SCIENCE, V260, P1286, DOI 10.1126/science.7684163
   KRAUS GA, 1990, BIOCHEM BIOPH RES CO, V172, P149, DOI 10.1016/S0006-291X(05)80185-8
   Kraus GA, 1996, CHEM REV, V96, P523, DOI 10.1021/cr9500139                                                               
   KREITMAIR H, 1950, Pharmazie, V5, P556
   LAERMER F, 1988, CHEM PHYS LETT, V148, P119, DOI 10.1016/0009-2614(88)80286-0
   LENARD J, 1993, P NATL ACAD SCI USA, V90, P158, DOI 10.1073/pnas.90.1.158
   MALKIN J, 1993, PHOTOCHEM PHOTOBIOL, V57, P929, DOI 10.1111/j.1751-1097.1993.tb02951.x
   MCMORROW D, 1984, J PHYS CHEM-US, V88, P2235, DOI 10.1021/j150655a012
   MERUELO D, 1988, P NATL ACAD SCI USA, V85, P5230, DOI 10.1073/pnas.85.14.5230
   MERUELO D, NATURAL PRODUCTS ANT, P91
   RACINET H, 1988, J CHIM PHYS PCB, V85, P971, DOI 10.1051/jcp/1988850971                                                          
   SCHWARTZ BJ, 1992, J PHYS CHEM-US, V96, P3591, DOI 10.1021/j100188a009                                                             
   STEINBECKKLOSE A, 1993, INT C AIDS, V9, P470
   STRANDJORD AJG, 1985, J PHYS CHEM-US, V89, P2355, DOI 10.1021/j100257a041                                                             
   THOMAS C, 1992, PHOTOCHEM PHOTOBIOL, V55, P831, DOI 10.1111/j.1751-1097.1992.tb08531.x
   VALENTINE FT, 1991, INT C AIDS JUN 16 21, V7, P97
   Wei-shin C, 1981, LIEBIGS ANN CHEM, P1880
   1991, SCIENCE, V254, P522
   1991, AIDS TREAT NEWS, V125, P4
   1992, AIDS TREAT NEWS, V146, P1
NR 46
TC 56
Z9 56
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0022-3654
J9 J PHYS CHEM-US
JI J. Phys. Chem.
PD NOV 14
PY 1996
VL 100
IS 46
BP 18275
EP 18281
DI 10.1021/jp961156h                                                       
          
PG 7
WC Chemistry, Physical
SC Chemistry
GA VT708
UT WOS:A1996VT70800039
DA 2018-01-05
ER

PT J
AU Oehlenschlager, F
   Schwille, P
   Eigen, M
AF Oehlenschlager, F
   Schwille, P
   Eigen, M
TI Detection of HIV-1 RNA by nucleic acid sequence-based amplification
   combined with fluorescence correlation spectroscopy
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; HTLV-III;
   INFECTION; NASBA; AIDS; IDENTIFICATION; HYBRIDIZATION; BIOTECHNOLOGY;
   ANTIBODIES
AB Nucleic acid sequence-based amplification (NASBA) has proved to be an ultrasensitive method for HIV-1 diagnosis in plasma even in the primary HIV infection stage. This technique was combined with fluorescence correlation spectroscopy (FCS) which enables online detection of the HIV-1 RNA molecules amplified by NASBA. A fluorescently labeled DNA probe at nanomolar concentration was introduced into the NASBA reaction mixture and hybridizing to a distinct sequence of the amplified RNA molecule. The specific hybridization and extension of this probe during amplification reaction, resulting in an increase of its diffusion time, was monitored online by FCS. As a consequence, after having reached a critical concentration of 0.1-1 nM (threshold for unaided FCS detection), the number of amplified RNA molecules in the further course of reaction could be determined. Evaluation of the hybridization/extension kinetics allowed an estimation of the initial HIV-1 RNA concentration that was present at the beginning of amplification. The value of initial HIV-1 RNA number enables discrimination between positive and false-positive samples (caused for instance by carryover contamination)-this possibility of discrimination is an essential necessity for all diagnostic methods using amplification systems (PCR as well as NASBA). Quantitation of HIV-1 RNA in plasma by combination of NASBA with FCS may also be useful in assessing the efficacy of anti-HIV agents, especially in the early infection stage when standard ELISA antibody tests often display negative results.
C1 MAX PLANCK INST BIOPHYS CHEM,DEPT BIOCHEM KINET,D-37077 GOTTINGEN,GERMANY.
RI Schwille, Petra/A-4983-2010
CR BOOM R, 1990, J CLIN MICROBIOL, V28, P495
   COMPTON J, 1991, NATURE, V350, P91, DOI 10.1038/350091a0
   EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740
   Gebinoga M, 1996, EUR J BIOCHEM, V235, P256, DOI 10.1111/j.1432-1033.1996.00256.x                                                
   HASELTINE WA, 1989, NEW ENGL J MED, V320, P1487, DOI 10.1056/NEJM198906013202210                                                     
   KIEVITS T, 1991, J VIROL METHODS, V35, P273, DOI 10.1016/0166-0934(91)90069-C
   KINJO M, 1995, NUCLEIC ACIDS RES, V23, P1795, DOI 10.1093/nar/23.10.1795
   LOCHE M, 1988, LANCET, V2, P418
   MAYER KH, 1986, ANN INTERN MED, V104, P194, DOI 10.7326/0003-4819-104-2-194
   OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784                                                         
   PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089
   PURCELL RH, 1994, P NATL ACAD SCI USA, V91, P2401, DOI 10.1073/pnas.91.7.2401                                                          
   QIAN H, 1991, APPL OPTICS, V30, P1185, DOI 10.1364/AO.30.001185
   RANKI A, 1987, LANCET, V2, P589
   RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0                                                                
   Rauer B, 1996, BIOPHYS CHEM, V58, P3, DOI 10.1016/0301-4622(95)00080-1                                                    
   RIGLER R, 1995, J BIOTECHNOL, V41, P177, DOI 10.1016/0168-1656(95)00054-T
   RIGLER R, 1993, EUR BIOPHYS J BIOPHY, V22, P169
   Rigler R., 1992, FLUORESCENCE SPECTRO, P13
   ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503
   SALAHUDDIN SZ, 1984, LANCET, V2, P1418
   SARNGADHARAN MG, 1984, SCIENCE, V224, P506, DOI 10.1126/science.6324345                                                         
   Schwille P, 1996, BIOCHEMISTRY-US, V35, P10182, DOI 10.1021/bi960517g
   Thompson N. L., 1991, TOPICS FLUORESCENCE, V1, P337
   TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0
   VANDERVLIET GME, 1993, J GEN MICROBIOL, V139, P2423
   VANGEMEN B, 1993, J VIROL METHODS, V43, P177, DOI 10.1016/0166-0934(93)90075-3
   VANGEMEN B, 1994, J VIROL METHODS, V49, P157, DOI 10.1016/0166-0934(94)90040-X                                                    
   VANGEMEN B, 1995, PCR METH APPL, V4, P177
   VANGEMEN B, 1993, AIDS S2, V7, P107
   VYAS GN, 1994, TRANSFUS MED REV, V8, P253, DOI 10.1016/S0887-7963(94)70117-6                                                   
   WEISS SH, 1985, JAMA-J AM MED ASSOC, V253, P221, DOI 10.1001/jama.253.2.221
NR 32
TC 62
Z9 62
U1 1
U2 16
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 12
PY 1996
VL 93
IS 23
BP 12811
EP 12816
DI 10.1073/pnas.93.23.12811
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA VT054
UT WOS:A1996VT05400027
PM 8917501
OA gold
DA 2018-01-05
ER

PT J
AU Gargano, N
   Biocca, S
   Bradbury, A
   Cattaneo, A
AF Gargano, N
   Biocca, S
   Bradbury, A
   Cattaneo, A
TI Human recombinant antibody fragments neutralizing human immunodeficiency
   virus type 1 reverse transcriptase provide an experimental basis for the
   structural classification of the DNA polymerase family
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID SINGLE-CHAIN ANTIBODY; CRYSTAL-STRUCTURE; INTRACELLULAR ANTIBODIES;
   MONOCLONAL-ANTIBODIES; ANGSTROM RESOLUTION; DRUG-BINDING; INHIBITION;
   RESISTANCE; DESIGN; EXPRESSION
AB We describe in this paper the binding and biochemical properties of two human antibody fragments directed against the human immunodeficiency virus type 1 reverse transcriptase (RT). These fragments were isolated from a synthetic combinatorial library of human Fab antibody fragments displayed on the surface of filamentous phage. The antibody fragments were selected by using recombinant heterodimeric human immunodeficiency virus type 1 RT purified from insect cells as a solid-phase selector. This procedure led to the isolation of two antibody fragments that completely neutralize the RNA-dependent DNA polymerase activity of RT at nanomolar concentrations. Both antibody fragments bind only to the enzymatically active form of the RT. The inhibitory activity of the anti-RT antibody fragments is competitive with respect to the template primer. The antibody fragments also neutralize the activities of RTs from avian and murine retroviruses and of DNA polymerases of prokaryotic origin as well as human DNA polymerase alpha. Thus, the antibody fragments selected and characterized in this study appear to recognize a structural fold that is common to the different DNA polymerases and necessary for their activity. The results provide an immunological experimental basis for a purely structural and evolutionary classification of the polymerase family.
C1 MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND.
   SCUOLA INT SUPER STUDI AVANZATI,TRIESTE,ITALY.
   CNR,INST NEUROBIOL,ROME,ITALY.
RI Cattaneo, Antonino/K-4471-2016
OI Cattaneo, Antonino/0000-0002-6975-8923
CR BEARD WA, 1995, HIV PRACTICAL APPROA, P15
   Beard William A., 1994, Current Opinion in Biotechnology, V5, P414, DOI 10.1016/0958-1669(94)90051-5
   BIOCCA S, 1990, EMBO J, V9, P101
   BIOCCA S, 1995, TRENDS CELL BIOL, V5, P245
   DAVIES JF, 1994, CELL, V76, P1123, DOI 10.1016/0092-8674(94)90388-3                                                    
   DECLERCQ E, 1994, BIOCHEM PHARMACOL, V47, P155, DOI 10.1016/0006-2952(94)90001-9                                                    
   DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461
   DUAN LX, 1994, P NATL ACAD SCI USA, V91, P5075, DOI 10.1073/pnas.91.11.5075
   ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303
   FERNS RB, 1991, AIDS RES HUM RETROV, V6, P307
   FERRIS AL, 1990, VIROLOGY, V175, P456, DOI 10.1016/0042-6822(90)90430-Y                                                    
   GAIT MJ, 1995, TRENDS BIOTECHNOL, V13, P430, DOI 10.1016/S0167-7799(00)88998-2
   GARGANO N, UNPUB
   GEORGIADIS MM, 1995, STRUCTURE, V3, P879, DOI 10.1016/S0969-2126(01)00223-4
   GRIFFITHS AD, 1994, EMBO J, V13, P3245
   HIZI A, 1991, J BIOL CHEM, V266, P6230
   Hughes SH, 1996, J VIROL, V70, P2679
   JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320                                                         
   KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0
   KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403
   Larder B A, 1993, REVERSE TRANSCRIPTAS, P205
   MAEIEJESKI JP, 1995, NATURE LONDON MED, V1, P667
   MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889
   MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U
   MHASHILKAR AM, 1995, EMBO J, V14, P1542
   PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006
   REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293
   REN JS, 1995, STRUCTURE, V3, P915, DOI 10.1016/S0969-2126(01)00226-X
   RESTLE T, 1992, J BIOL CHEM, V267, P14654
   RICHARDSON JH, 1995, TRENDS BIOTECHNOL, V13, P306, DOI 10.1016/S0167-7799(00)88970-2                                                   
   RICHMAN DD, 1993, ANNU REV PHARMACOL, V33, P149, DOI 10.1146/annurev.pa.33.040193.001053
   Sambrook J, 1989, MOL CLONING LAB MANU
   SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581
   SUMMERS MD, 1987, MANUAL METHODS BACUL
   TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665                                                          
   TISDALE M, 1988, J VIROL, V62, P3662
   TOMLINSON IM, 1992, J MOL BIOL, V227, P776, DOI 10.1016/0022-2836(92)90223-7
   WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245
   WU J, 1993, J BIOL CHEM, V268, P9980
   YU M, 1994, GENE THER, V1, P13
NR 40
TC 20
Z9 21
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD NOV
PY 1996
VL 70
IS 11
BP 7706
EP 7712
PG 7
WC Virology
SC Virology
GA VL792
UT WOS:A1996VL79200039
PM 8892891
DA 2018-01-05
ER

PT J
AU Mazumder, A
   Neamati, N
   Ojwang, JO
   Sunder, S
   Rando, RF
   Pommier, Y
AF Mazumder, A
   Neamati, N
   Ojwang, JO
   Sunder, S
   Rando, RF
   Pommier, Y
TI Inhibition of the human immunodeficiency virus type I integrase by
   guanosine quartet structures
SO BIOCHEMISTRY
LA English
DT Article
ID OXYTRICHA TELOMERIC DNA; HIV-1 INTEGRASE; VIRAL-DNA; ESCHERICHIA-COLI;
   CRYSTAL-STRUCTURE; POTENT INHIBITOR; STABLE COMPLEX; GENOMIC RNA;
   PROTEIN; BINDING
AB An oligonucleotide (T30177) composed entirely of deoxyguanosine and thymidine has previously been shown to fold upon itself in the presence of potassium into a highly stable four-stranded DNA structure containing two stacked deoxyguanosine quarters (G4s). T30177 also protects host cells from the cytopathic effects of human immunodeficiency virus type 1 (HIV-1). We report that this G4 oligonucleotide is the most potent inhibitor of HIV-1 integrase identified to date, with IC50 values in the nanomolar range. Both the number of quarters formed and the sequence of the loops between the quartets are important for optimal activity. T30177 binds to HIV-1 integrase without being processed and blocks the binding of the normal viral DNA substrate to the enzyme. The normal DNA substrate was not able to compete off T30177 binding to HIV-1 integrase, indicating a tight binding of G4s to the enzyme. Experiments with truncated HIV-1 integrases indicate that the N-terminal region containing a putative zinc finger is required for inhibition by T30177 and that T30177 binds better to full-length or deletion mutant integrases containing the zinc finger region than to a deletion mutant consisting of only the central catalytic domain. The N-terminal region of integrase alone is able to bind efficiently to T30177, but not the linear viral DNA substrate, in the presence of zinc. Hence, G4s represent the first class of compounds that inhibit HIV-1 integrase by interacting with the enzyme N-terminal domain, The greater inhibitory potency of T30177 in buffer containing magnesium versus manganese suggests that divalent metal ion coordination along the phosphodiester backbone may play a role in the inhibitory activity. T30177 inhibited HIV-2 integrase with similar potency as HIV-1 but inhibited feline and simian immunodeficiency virus integrases at higher concentrations, suggesting selectivity can be achieved. We propose that novel AIDS therapies could be based upon guanosine quartets as inhibitors of HIV-I integrase.
C1 NCI,MOL PHARMACOL LAB,DIV BASIC SCI,BETHESDA,MD 20892.
   ARONEX PHARMACEUT INC,THE WOODLANDS,TX 77381.
CR ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1
   AWANG G, 1993, BIOCHEMISTRY-US, V32, P11453, DOI 10.1021/bi00093a024
   Bishop JS, 1996, J BIOL CHEM, V271, P5698, DOI 10.1074/jbc.271.10.5698                                                         
   BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0
   BURKE CJ, 1992, J BIOL CHEM, V267, P9639
   BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428
   CHOW SA, 1994, J VIROL, V68, P3896
   CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845                                                         
   CHUNG IK, 1992, NUCLEIC ACIDS RES, V20, P1973, DOI 10.1093/nar/20.8.1973
   CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y                                                    
   DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124
   ELLISON V, 1994, P NATL ACAD SCI USA, V91, P7316, DOI 10.1073/pnas.91.15.7316
   ELLISON V, 1995, J BIOL CHEM, V270, P3320, DOI 10.1074/jbc.270.7.3320                                                          
   ENGELMAN A, 1995, J VIROL, V69, P2729
   ENGELMAN A, 1994, J VIROL, V68, P5911
   ENGELMAN A, 1995, J VIROL, V69, P5908
   ENGELMAN A, 1992, J VIROL, V66, P6361
   ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C
   ENGLUND G, 1995, J VIROL, V69, P3216
   FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5
   FESEN MR, 1994, BIOCHEM PHARMACOL, V48, P595, DOI 10.1016/0006-2952(94)90291-7
   FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950
   GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013                                                         
   KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0
   KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.biochem.63.1.133
   KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U                                                    
   Leavitt AD, 1996, J VIROL, V70, P721
   LIU ZP, 1994, CELL, V77, P1083, DOI 10.1016/0092-8674(94)90447-2
   MAZUMDER A, 1994, P NATL ACAD SCI USA, V91, P5771, DOI 10.1073/pnas.91.13.5771                                                         
   Mazumder A, 1996, MOL PHARMACOL, V49, P621
   MAZUMDER A, 1995, AIDS RES HUM RETROV, V11, P115, DOI 10.1089/aid.1995.11.115
   MAZUMDER A, 1995, BIOCHEMISTRY-US, V34, P15111, DOI 10.1021/bi00046a018
   MURCHIE AIH, 1992, NUCLEIC ACIDS RES, V20, P49, DOI 10.1093/nar/20.1.49
   OJWANG JO, 1995, ANTIMICROB AGENTS CH, V39, P2426, DOI 10.1128/AAC.39.11.2426                                                          
   PEARSON AM, 1993, J BIOL CHEM, V268, P3546
   PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026
   RANDO RF, 1995, J BIOL CHEM, V270, P1754, DOI 10.1074/jbc.270.4.1754                                                          
   RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9
   SCHIERER T, 1994, BIOCHEMISTRY-US, V33, P2240, DOI 10.1021/bi00174a034
   SCHULTZE P, 1994, J MOL BIOL, V235, P1532, DOI 10.1006/jmbi.1994.1105
   SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0                                                                
   SMITH FW, 1992, NATURE, V356, P164, DOI 10.1038/356164a0                                                                
   SUNDQUIST WI, 1993, P NATL ACAD SCI USA, V90, P3393, DOI 10.1073/pnas.90.8.3393
   SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0                                                                
   TSUCHIHASHI Z, 1994, J VIROL, V68, P5863
   VANGENT DC, 1992, P NATL ACAD SCI USA, V89, P9598, DOI 10.1073/pnas.89.20.9598
   VARMUS H, 1989, MOBILE DNA, P53
   VINCENT KA, 1993, J VIROL, V67, P425
   VINK C, 1994, NUCLEIC ACIDS RES, V22, P4103, DOI 10.1093/nar/22.20.4103
   VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419
   VINK C, 1991, NUCLEIC ACIDS RES, V19, P6691, DOI 10.1093/nar/19.24.6691
   VINK C, 1994, J VIROL, V68, P1468
   VINK C, 1993, TRENDS GENET, V9, P433, DOI 10.1016/0168-9525(93)90107-S
   WALSH K, 1992, J BIOL CHEM, V267, P13714
   WEISMANSHOMER P, 1993, J BIOL CHEM, V268, P3306
   WYATT JR, 1994, P NATL ACAD SCI USA, V91, P1356, DOI 10.1073/pnas.91.4.1356
   YOSHINAGA T, 1994, J VIROL, V68, P5690
   ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0
NR 58
TC 117
Z9 118
U1 0
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD OCT 29
PY 1996
VL 35
IS 43
BP 13762
EP 13771
DI 10.1021/bi960541u
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA VP990
UT WOS:A1996VP99000008
PM 8901518
DA 2018-01-05
ER

PT J
AU Tjandra, N
   Wingfield, P
   Stahl, S
   Bax, A
AF Tjandra, N
   Wingfield, P
   Stahl, S
   Bax, A
TI Anisotropic rotational diffusion of perdeuterated HIV protease from N-15
   NMR relaxation measurements at two magnetic
SO JOURNAL OF BIOMOLECULAR NMR
LA English
DT Article
DE N-15 NMR; rotational diffusion; chemical shift anisotropy; dynamics;
   magnetic field dependence; deuteration
ID MODEL-FREE APPROACH; BACKBONE DYNAMICS; STAPHYLOCOCCAL NUCLEASE;
   RESONANCE RELAXATION; CROSS-CORRELATION; SPECTROSCOPY; MACROMOLECULES;
   PROTEINS; DIPOLAR; RANGE
AB N-15 NMR relaxation times in perdeuterated HIV-1 protease, complexed with the sub-nanomolar inhibitor DMP323, have been measured at 600 and 360 MHz H-1 frequency. The relative magnitudes of the principal components of the inertia tensor, calculated from the X-ray coordinates of the protein-drug complex, are 1.0:0.85:0.44. The relation between the T-1/T-2 ratios observed for the individual backbone amides and their N-H orientation within the 3D structure of the protease dimer yields a rotational diffusion tensor oriented nearly collinear to the inertia tenser. The relative magnitudes of its principal components (1.00:1.11:1.42) are also in good agreement with hydrodynamic modeling results. The orientation and magnitude of the diffusion tensors derived from relaxation data obtained at 360 and 600 MHz are nearly identical. The anisotropic nature of the rotational diffusion has little influence on the order parameters derived from the N-15 T-1 and T-2 relaxation times; however, if anisotropy is ignored, this can result in erroneous identification of either exchange broadening or internal motions on a nanosecond time scale. The average ratio of the T-1 values measured at 360 and 600 MHz is 0.50+/-0.015, which is slightly larger than the value of 0.466 expected for an isotropic rigid rotor with tau(c)=10.7 ns. The average ratio of the T-2 values measured at 360 and 600 MHz is 1.14+/-0.04, which is also slightly larger than the expected ratio of 1.11, This magnetic field dependence of the T-1 and T-2 relaxation times suggests that the spectral density contribution from fast internal motions is not negligible, and that the chemical shift anisotropy of peptide backbone amides, on average, is larger than the 160 ppm value commonly used in N-15 relaxation studies of proteins.
C1 NIAMSD,PROT EXPRESS LAB,NIH,BETHESDA,MD 20892.
RP Tjandra, N (reprint author), NIDDKD,CHEM PHYS LAB,NIH,BLDG 2,BETHESDA,MD 20892, USA.
CR ALLERHAN.A, 1971, J AM CHEM SOC, V93, P544, DOI 10.1021/ja00731a053                                                             
   BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005
   BEVINGTON PR, 1992, DATA REDUCTION ERROR, P205
   BOYD J, 1990, CHEM PHYS LETT, V175, P477, DOI 10.1016/0009-2614(90)85567-V                                                    
   BRUSCHWEILER R, 1995, SCIENCE, V268, P886, DOI 10.1126/science.7754375                                                         
   CLORE GM, 1990, BIOCHEMISTRY-US, V29, P7387, DOI 10.1021/bi00484a006                                                             
   CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070
   COLE HBR, 1991, CHEM PHYS, V158, P271, DOI 10.1016/0301-0104(91)87071-3
   DAVIS DG, 1994, J MAGN RESON SER B, V104, P266, DOI 10.1006/jmrb.1994.1084                                                          
   DELATORRE JG, 1981, Q REV BIOPHYS, V14, P81, DOI 10.1017/S0033583500002080                                                       
   DELLWO MJ, 1989, J AM CHEM SOC, V111, P4571, DOI 10.1021/ja00195a007
   GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052
   HANSEN AP, 1994, BIOCHEMISTRY-US, V33, P15418, DOI 10.1021/bi00255a023
   HIYAMA Y, 1988, J AM CHEM SOC, V110, P2378, DOI 10.1021/ja00216a006
   KAY LE, 1992, J MAGN RESON, V97, P359, DOI 10.1016/0022-2364(92)90320-7                                                    
   KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003
   KING R, 1978, BIOPHYS J, V6, P103
   KORDEL J, 1992, BIOCHEMISTRY-US, V31, P4856
   LAM PYS, 1994, SCIENCE, V263, P380, DOI 10.1126/science.8278812
   LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010
   LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009
   LONDON RE, 1980, MAGNETIC RESONANCE B, P1
   NICHOLSON LK, 1995, NAT STRUCT BIOL, V2, P274, DOI 10.1038/nsb0495-274
   NIRMALA NR, 1988, J AM CHEM SOC, V110, P7557, DOI 10.1021/ja00230a057
   OAS TG, 1987, J AM CHEM SOC, V109, P5962, DOI 10.1021/ja00254a011
   Palmer Arthur G. Iii, 1993, Current Opinion in Biotechnology, V4, P385, DOI 10.1016/0958-1669(93)90002-E
   PENG JW, 1991, J MAGN RESON, V95, P421, DOI 10.1016/0022-2364(91)90233-J
   Peng JW, 1995, BIOCHEMISTRY-US, V34, P16733, DOI 10.1021/bi00051a023
   PENG JW, 1992, BIOCHEMISTRY-US, V31, P8571, DOI 10.1021/bi00151a027
   PHAN I, 1996, IN PRESS J BIOMOL NM
   SCHNEIDER DM, 1992, BIOCHEMISTRY-US, V31, P3645, DOI 10.1021/bi00129a013                                                             
   SCHURR JM, 1994, J MAGN RESON SER B, V105, P211, DOI 10.1006/jmrb.1994.1127
   Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020                                                             
   TJANDRA N, 1995, EUR J BIOCHEM, V230, P1014, DOI 10.1111/j.1432-1033.1995.tb20650.x
   TJANDRA N, 1996, IN PRESS J AM CHEM S
   TORCHIA DA, 1993, NMR PROTEINS, P190
   WAGNER G, 1993, CURR OPIN STRUC BIOL, V3, P748, DOI 10.1016/0959-440X(93)90059-T
   WOESSNER DE, 1962, J CHEM PHYS, V37, P647, DOI 10.1063/1.1701390                                                               
   WUTHRICH K, 1978, TRENDS BIOCHEM SCI, V3, P227, DOI 10.1016/S0968-0004(78)94607-8
NR 39
TC 204
Z9 204
U1 0
U2 6
PU ESCOM SCI PUBL BV
PI LEIDEN
PA PO BOX 214, 2300 AE LEIDEN, NETHERLANDS
SN 0925-2738
J9 J BIOMOL NMR
JI J. Biomol. NMR
PD OCT
PY 1996
VL 8
IS 3
BP 273
EP 284
DI 10.1007/BF00410326                                                      
          
PG 12
WC Biochemistry & Molecular Biology; Spectroscopy
SC Biochemistry & Molecular Biology; Spectroscopy
GA VW192
UT WOS:A1996VW19200005
PM 8953218
DA 2018-01-05
ER

PT J
AU Schofield, DJ
   Dimmock, NJ
AF Schofield, DJ
   Dimmock, NJ
TI Determination of affinities of a panel of IgGs and Fabs for whole
   enveloped (influenza A) virions using surface plasmon resonance
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE influenza A virus; IgG; Fab; affinity; surface plasmon resonance
ID IMMUNODEFICIENCY-VIRUS TYPE-1; BIOSPECIFIC INTERACTION ANALYSIS; HUMAN
   MONOCLONAL-ANTIBODY; BIOSENSOR TECHNOLOGY; VIRAL NEUTRALIZATION;
   CROSS-REACTIVITY; MOSAIC-VIRUS; HIV-1; BINDING; FRAGMENTS
AB The affinity of a panel of neutralizing monoclonal IgGs and their Fab fragments has been measured for the first time with an enveloped type A influenza virus, by surface plasmon resonance (SPR) and the BIAlite(TM) instrument. Equilibrium constants could be calculated for four of the five mAbs tested. These were in the nanomolar range. The ranking order was very similar to that obtained with an affinity ELISA, (an equilibrium system) but as others have found, affinities were 2-10-fold lower as measured by SPR (a flow system). No data were obtained with mAb HC58 although it had one of the highest affinities using an ELISA format, and was 28-fold higher than another mAb (HC10) which gave good data by SPR. This may relate to the orientation of its binding on the virion surface. The K-dissoc. of the Fabs was only 3-10-fold higher compared to their IgGs. Fab from the lowest affinity IgG (HC10) could not be measured, possibly because it fell below the threshold for detection.
C1 UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND.
CR BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P10164, DOI 10.1073/pnas.89.21.10164                                                        
   BARBAS CF, 1994, P NATL ACAD SCI USA, V91, P3809, DOI 10.1073/pnas.91.9.3809                                                          
   BLANK SE, 1972, J IMMUNOL, V108, P665
   BRIGHAMBURKE M, 1992, ANAL BIOCHEM, V205, P125, DOI 10.1016/0003-2697(92)90588-X
   BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652
   CASASNOVAS JM, 1995, J BIOL CHEM, V270, P13216, DOI 10.1074/jbc.270.22.13216                                                        
   CAVACINI LA, 1994, J IMMUNOL, V152, P2538
   CONLEY AJ, 1994, P NATL ACAD SCI USA, V91, P3348, DOI 10.1073/pnas.91.8.3348                                                          
   DITZEL HJ, 1995, J IMMUNOL, V154, P895
   DUBS MC, 1992, J CHROMATOGR, V597, P391, DOI 10.1016/0021-9673(92)80136-I
   DUBS MC, 1991, IMMUNOL LETT, V31, P59
   GODET M, 1994, J VIROL, V68, P8008
   GRIFFITHS AD, 1993, EMBO J, V12, P725
   GRUEN LC, 1993, EUR J BIOCHEM, V217, P319, DOI 10.1111/j.1432-1033.1993.tb18249.x
   HORNICK CL, 1972, IMMUNOCHEMISTRY, V9, P325, DOI 10.1016/0019-2791(72)90096-1
   KANTRONG S, 1995, ARCH VIROL, V140, P453, DOI 10.1007/BF01718423
   KELLY DC, 1974, VIROLOGY, V61, P210, DOI 10.1016/0042-6822(74)90255-4
   KOVACS GJ, 1982, ELECTROMAGNETIC SURF, P143
   LAMARRE A, 1995, J IMMUNOL, V154, P3975
   LOUNSBACH GR, 1994, J GEN VIROL, V74, P2559
   LUCEY DR, 1993, J AIDS, V6
   MALMBORG AC, 1992, SCAND J IMMUNOL, V35, P643, DOI 10.1111/j.1365-3083.1992.tb02970.x
   MANI JC, 1994, MOL IMMUNOL, V31, P439, DOI 10.1016/0161-5890(94)90063-9                                                    
   MOORE JP, 1995, J VIROL, V69, P101
   NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603                                                         
   Nisonoff A, 1975, ANTIBODY MOL
   PARHAM P, 1983, J IMMUNOL, V131, P2895
   PELLEQUER JL, 1993, J IMMUNOL METHODS, V166, P133, DOI 10.1016/0022-1759(93)90337-7
   PORTA C, 1994, VIROLOGY, V202, P949, DOI 10.1006/viro.1994.1417
   RAMSDALE TE, 1993, FEBS LETT, V333, P217, DOI 10.1016/0014-5793(93)80657-G
   RICHALETSECORDEL PM, 1994, J IMMUNOL METHODS, V176, P221, DOI 10.1016/0022-1759(94)90316-6
   ROBEN P, 1994, J VIROL, V68, P4821
   SATTENTAU QJ, 1995, J EXP MED, V182, P185, DOI 10.1084/jem.182.1.185
   SCHOFIELD DJ, 1996, IN PRESS P NATL ACAD
   SUGRUE RJ, 1990, EMBO J, V9, P3469
   TARRAB E, 1995, J GEN VIROL, V76, P551, DOI 10.1099/0022-1317-76-3-551
   TAYLOR HP, 1987, VIROLOGY, V159, P288, DOI 10.1016/0042-6822(87)90466-1
   TOSSER G, 1994, VIROLOGY, V204, P8, DOI 10.1006/viro.1994.1505
   VANCOTT TC, 1992, J IMMUNOL METHODS, V146, P163, DOI 10.1016/0022-1759(92)90225-I                                                    
   VANCOTT TC, 1994, J IMMUNOL, V153, P449
   WELFORD K, 1991, OPT QUANT ELECTRON, V23, P1, DOI 10.1007/BF00619516                                                              
NR 41
TC 43
Z9 44
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
J9 J VIROL METHODS
JI J. Virol. Methods
PD OCT
PY 1996
VL 62
IS 1
BP 33
EP 42
DI 10.1016/0166-0934(96)02086-1                                            
          
PG 10
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA VR096
UT WOS:A1996VR09600004
PM 8910646
DA 2018-01-05
ER

PT J
AU Reid, RC
   March, DR
   Dooley, MJ
   Bergman, DA
   Abbenante, G
   Fairlie, DP
AF Reid, RC
   March, DR
   Dooley, MJ
   Bergman, DA
   Abbenante, G
   Fairlie, DP
TI A novel bicyclic enzyme inhibitor as a consensus peptidomimetic for the
   receptor-bound conformations of 12 peptidic inhibitors of HIV-1 protease
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID HUMAN IMMUNODEFICIENCY VIRUS-1; CRYSTAL-STRUCTURE; BINDING MODES;
   DESIGN; COMPLEX; RESOLUTION; SYMMETRY
AB The X-ray crystal structures of 12 substrate-based peptidic inhibitors bound in the active site of the aspartyl protease, HIV-1 protease, have been compared. The inhibitor-binding modes of these inhibitors are remarkably similar despite their structural diversity and conformational flexibility, This prompted the design of a bicyclic peptidomimetic inhibitor 13 with macrocyclic components in constrained conformations that are preorganized for receptor-binding. This inhibitor is a consensus conformational mimic of the protease-bound inhibitor structures with superior properties to peptides, including stability to acid and peptidases as well as antiviral activity. Each of its 15- and 16-membered rings, formed through side-chain to backbone condensation, contains two proteolytically resistant amide bonds and either isoleucine or valine linked via a short aliphatic spacer to tyrosine, The two cycles are connected by a hydroxyethylamine transition state isostere. Molecular modeling and NMR studies indicate that each macrocycle is a highly constrained structural mimic of tripeptide components of linear peptide substrates/inhibitors of HIV-1 protease. Thus the bicyclic peptidomimetic superimposes upon and structurally mimics acyclic hexapeptide inhibitors and their analogues. This results in functional mimicry, as demonstrated by comparable inhibition of HIV-1 protease by acyclic and cyclic molecules at nanomolar concentrations. The rational design of cycles which fix receptor-bound conformations of these bioactive peptides has potential applications for the structural mimicry of other bioactive peptides and may facilitate rational drug design.
C1 UNIV QUEENSLAND,CTR DRUG DESIGN & DEV,BRISBANE,QLD 4072,AUSTRALIA.
RI Reid, Robert/D-8041-2012; Fairlie, David/F-8865-2014
OI Reid, Robert/0000-0002-0829-239X; Fairlie, David/0000-0002-7856-8566
CR ABBENANTE G, 1995, J AM CHEM SOC, V117, P10220, DOI 10.1021/ja00146a007                                                             
   ASHORN P, 1990, P NATL ACAD SCI USA, V87, P7472, DOI 10.1073/pnas.87.19.7472
   BERGMAN DA, 1995, LETT PEPT SCI, V2, P99, DOI 10.1007/BF00128504
   BONE R, 1991, J AM CHEM SOC, V113, P9382, DOI 10.1021/ja00024a061
   Darke P L, 1994, Adv Pharmacol, V25, P399, DOI 10.1016/S1054-3589(08)60438-X
   DREYER GB, 1992, BIOCHEMISTRY-US, V31, P6646, DOI 10.1021/bi00144a004
   ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122
   Fairlie D. P., 1995, CURR MED CHEM, V2, P672
   HOSUR MV, 1994, J AM CHEM SOC, V116, P847, DOI 10.1021/ja00082a004
   JASKOLSKI M, 1991, BIOCHEMISTRY-US, V30, P1600, DOI 10.1021/bi00220a023
   KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686
   KRISHNO HM, 1992, J BIOL CHEM, V267, P22770
   LAM PYS, 1994, SCIENCE, V263, P380, DOI 10.1126/science.8278812
   March DR, 1996, J AM CHEM SOC, V118, P3375, DOI 10.1021/ja953790z
   MARCH DR, 1996, DESIGNING NEW ANTIVI, P1
   MEGUID SSA, IN PRESS
   MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029
   PASSMORE M, UNPUB
   REID RL, UNPUB
   RICH DH, 1991, J MED CHEM, V34, P1222, DOI 10.1021/jm00107a049                                                             
   SCHNEIDER J, 1988, CELL, V54, P363, DOI 10.1016/0092-8674(88)90199-7
   SWAIN AL, 1990, P NATL ACAD SCI USA, V87, P8805, DOI 10.1073/pnas.87.22.8805
   THOMPSON SJ, IN PRESS
   THONKI N, IN PRESS
   TOMASSELLI AG, 1992, CHIM OGGI, P6
   WEST ML, 1995, TRENDS PHARMACOL SCI, V16, P67, DOI 10.1016/S0165-6147(00)88980-4
   WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551                                             
   WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279
NR 28
TC 43
Z9 43
U1 0
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD SEP 11
PY 1996
VL 118
IS 36
BP 8511
EP 8517
DI 10.1021/ja960433v                                                       
          
PG 7
WC Chemistry, Multidisciplinary
SC Chemistry
GA VG351
UT WOS:A1996VG35100001
DA 2018-01-05
ER

PT J
AU Anderson, KP
   Fox, MC
   BrownDriver, V
   Martin, MJ
   Azad, RF
AF Anderson, KP
   Fox, MC
   BrownDriver, V
   Martin, MJ
   Azad, RF
TI Inhibition of human cytomegalovirus immediate-early gene expression by
   an antisense oligonucleotide complementary to immediate-early RNA
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; GUANOSINE-QUARTET STRUCTURE; MEDIATED
   CELL-FUSION; ANTIVIRAL ACTIVITY; TYPE-2 GROWTH; OLIGODEOXYNUCLEOTIDES;
   MECHANISMS; ACTIVATION; ENVELOPE; ANALOGS
AB ISIS 2922 is a phosphorothioate oligonucleotide that is complementary to human cytomegalovirus (CMV) immediate-early (IE) RNA and that exhibits potent and specific antiviral activity against CMV in cell culture assays, Specific assay systems were developed to separately characterize the antisense and nonantisense components of the antiviral activity mediated by ISIS 2922, In U373 cells transformed with cDNA encoding the CMV IE 55-kDa (IE55) protein, expression was inhibited at nanomolar concentrations comparable to effective concentrations in antiviral assays. The specificity of inhibition was demonstrated by using control oligonucleotides incorporating progressive base changes to destabilize oligonucleotide-RNA base pairing and by showing a lack of inhibition of the CMV IE72 product expressed from the same promoter, Inhibition of IE55 protein expression correlated with a reduction in mRNA levels consistent with an RNase II-mediated termination event, Studies with virus-infected cells demonstrated that antisense and nonantisense mechanisms contribute to the antiviral activity of ISIS 2922, Base complementarity to target RNA was important for optimal activity in antiviral assays, but base changes affecting parameters other than hybridization affinity also influenced antiviral activity, Sequence-independent inhibition of virus adsorption to host cells by phosphorothioate oligonucleotides was also observed at high concentrations. Therefore, at least three different mechanisms may contribute to the antiviral activity of ISIS 2922 in cell culture: antisense-mediated inhibition of target gene expression; nonantisense, sequence-dependent inhibition of virus replication; and sequence-independent inhibition of virus adsorption to host cells.
RP Anderson, KP (reprint author), ISIS PHARMACEUT,2292 FARADAY AVE,CARLSBAD,CA 92008, USA.
CR ANDERSON KP, 2922 ISIS
   AZAD RF, 1993, ANTIMICROB AGENTS CH, V37, P1945, DOI 10.1128/AAC.37.9.1945                                                           
   AZAD RF, 1995, ANTIVIR RES, V28, P101, DOI 10.1016/0166-3542(95)00035-K
   BARACCHINI E, 1992, VIROLOGY, V188, P518, DOI 10.1016/0042-6822(92)90506-K
   BENNETT CF, 1992, MOL PHARMACOL, V41, P1023
   BENNETT CF, 1994, J IMMUNOL, V152, P3530
   CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125
   CHIANG MY, 1991, J BIOL CHEM, V266, P18162
   CUMMINS LL, 1995, NUCLEIC ACIDS RES, V23, P2019, DOI 10.1093/nar/23.11.2019                                                          
   DEAN NM, 1994, J BIOL CHEM, V269, P16416
   ECKER DJ, 1995, NUCLEOS NUCLEOT, V14, P1117, DOI 10.1080/15257779508012547
   GAO W, 1989, J BIOL CHEM, V264, P11521
   GAO WY, 1990, J BIOL CHEM, V265, P20172
   GAO WY, 1990, ANTIMICROB AGENTS CH, V34, P808, DOI 10.1128/AAC.34.5.808                                                            
   Hanecak R, 1996, J VIROL, V70, P5203
   KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0
   MARGOLIS MJ, 1995, J VIROL, V69, P7759
   MATSUKURA M, 1989, P NATL ACAD SCI USA, V86, P4244, DOI 10.1073/pnas.86.11.4244
   MATSUKURA M, 1987, P NATL ACAD SCI USA, V84, P7706, DOI 10.1073/pnas.84.21.7706
   MIRAGLIA L, IN PRESS J BIOL CHEM
   MONIA BP, 1992, J BIOL CHEM, V267, P19954
   RANDO RF, 1995, J BIOL CHEM, V270, P1754, DOI 10.1074/jbc.270.4.1754                                                          
   STENBERG RM, 1985, J VIROL, V56, P665
   VICKERS T, 1991, NUCLEIC ACIDS RES, V19, P3359, DOI 10.1093/nar/19.12.3359
   VICKERS TA, 1992, NUCLEIC ACIDS RES, V20, P3945, DOI 10.1093/nar/20.15.3945
   WYATT JR, 1994, P NATL ACAD SCI USA, V91, P1356, DOI 10.1073/pnas.91.4.1356
NR 26
TC 108
Z9 113
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD SEP
PY 1996
VL 40
IS 9
BP 2004
EP 2011
PG 8
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA VF645
UT WOS:A1996VF64500007
PM 8878571
DA 2018-01-05
ER

PT J
AU Tossi, A
   Furian, M
   Antcheva, N
   Romeo, D
   Miertus, S
AF Tossi, A
   Furian, M
   Antcheva, N
   Romeo, D
   Miertus, S
TI Efficient inhibition of HIV-1 aspartic protease by synthetic, computer
   designed peptide mimetics
SO MINERVA BIOTECNOLOGICA
LA English
DT Article; Proceedings Paper
CT 6th Workshop on Synthetic Oligonucleotides in Molecular Biology and
   Biotechnology
CY FEB 08-09, 1996
CL FERRARA, ITALY
SP Ferrara Univ, Biotechnol Ctr, Ferrara Univ, Dept Biochem & Molec Biol
DE HIV-1; aspartic protease; peptides, chemical synthesis; drug design
ID HUMAN-IMMUNODEFICIENCY-VIRUS; MECHANISMS
AB Inhibitors of HIV-1 aspartic protease, an enzyme which is essential for viral processing and maturation, represent an important new type of anti-AIDS drug. To be effective, these must be potent and selec tive, must present a suitable pharmacological profile with respect to drug uptake and clearance, and should also be synthesizeable in good yields. We have developed a design method based on computer aided modification of a reference compound for which the crystal structure of the complex with the enzyme is known. After relaxation of the new structures to an optimized geometry, the complexation energy is calculated, relative to that of the reference inhibitor, taking into account all aspects of the interaction, including solvation. This affords a numerical prediction of the putative effectiveness of the new structure as an inhibitor, relative to that of the reference structure, and thus allows us to rapidly evaluate modifications that could result in increased potency and reduce the number of compounds that it is actually necessary to synthesize so as to obtain useful lead compounds for drug development. In an initial study, we have determined the role of flanking residues in modulating inhibition, for hexapeptide mimetics with a central, reduced amide non-cleavable bond. The structure was based on that of the reference inhibitor MVT-101. We have found that by tuning the residues flanking the central bond, the complexation energy could be markedly improved, and have determined that the putatively optimal structure should contain an aromatic residue (Phe or Tyr) at positions p1 and p1', immediately flanking the central bond, a hydrophobic residue at P2, a glutamic acid residue at P2', and an aromatic residue (Phe, Tyr or Trp) at positions P3 and P3', most distant from the central bond. Synthesis of a series of inhibitors containing these modifications was carried out entirely in the solid phase, using Fmoc type chemistry, on a polyethylene glycol/polystyrene resin, and in vitro enzyme inhibition assays have confirmed the computer-based predictions. In particular, it was possible to obtain several inhibitors with potency in the low nanomolar range, an improvement of several orders of magnitude with respect to the parent compound.
C1 UNIV TRIESTE,DIPARTIMENTO BIOCHIM BIOFIS & CHIM MACROMOL,I-34127 TRIESTE,ITALY.
OI Tossi, Alessandro/0000-0001-9087-5764; Miertus,
   Stanislav/0000-0001-6766-4571
CR CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0
   DUNN BM, 1994, METHOD ENZYMOL, V241, P255
   FEHRENTZ JA, 1983, SYNTHESIS-STUTTGART, P676
   MEEK TD, 1994, METHOD ENZYMOL, V241, P127
   MIERTUS S, 1993, BIOORG MED CHEM LETT, V3, P2105, DOI 10.1016/S0960-894X(01)81026-X                                                   
   MIERTUS S, 1992, J MATH CHEM, V10, P183, DOI 10.1007/BF01169174                                                              
   MIERTUS S, IN PRESS JR PROUS BA
   MIERTUS S, IN PRESS CHEM PHYS
   MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029
   Pennington M W, 1994, Methods Mol Biol, V35, P241
   RICHMAN DD, 1995, NATURE, V374, P494, DOI 10.1038/374494a0                                                                
   STONE D, 1995, BIOTECHNOL, V13, P941
   VACCA JP, 1994, METHOD ENZYMOL, V241, P311
   WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551                                             
NR 14
TC 2
Z9 2
U1 0
U2 1
PU EDIZIONI MINERVA MEDICA
PI TURIN
PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY
SN 1120-4826
J9 MINERVA BIOTECNOL
JI Minerva Biotechnol.
PD SEP
PY 1996
VL 8
IS 3
BP 165
EP 171
PG 7
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA VN044
UT WOS:A1996VN04400011
DA 2018-01-05
ER

PT J
AU Coburn, CA
   Young, MB
   Hungate, RW
   Isaacs, RCA
   Vacca, JP
   Huff, JR
AF Coburn, CA
   Young, MB
   Hungate, RW
   Isaacs, RCA
   Vacca, JP
   Huff, JR
TI Aromatic P-1 replacements for the highly potent HIV-1 protease inhibitor
   CRIXIVAN(R)
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
ID L-735,524; TARGET; DESIGN; AIDS
AB A series of analogs of CRIXIVAN(R) containing various aromatic P-1 ligands were prepared and evaluated for inhibition of the HIV-1 protease enzyme. These new compounds were found to be effective inhibitors at nanomolar concentrations in the in vitro enzyme inhibition assay as well as the whole cell assay. Copyright (C) 1996 Elsevier Science Ltd
RP Coburn, CA (reprint author), MERCK RES LABS,DEPT MED CHEM,W POINT,PA 19486, USA.
CR ASKIN D, 1994, TETRAHEDRON LETT, V35, P673, DOI 10.1016/S0040-4039(00)75787-X
   Darke P L, 1994, Adv Pharmacol, V25, P399, DOI 10.1016/S1054-3589(08)60438-X
   DEBOUCK C, 1992, AIDS RES HUM RETROV, V8, P153, DOI 10.1089/aid.1992.8.153
   DORSEY BD, 1994, J MED CHEM, V37, P3443, DOI 10.1021/jm00047a001                                                             
   EIS MJ, 1984, J AM CHEM SOC, V106, P3693, DOI 10.1021/ja00324a060                                                             
   FAIRLIE DP, 1995, TRENDS PHARMACOL SCI, V16, P67
   HEIMBACH JC, 1989, BIOCHEM BIOPH RES CO, V164, P955, DOI 10.1016/0006-291X(89)91762-2
   KALDOR SW, 1995, BIOORG MED CHEM LETT, V5, P715, DOI 10.1016/0960-894X(95)00101-X
   KALDOR SW, 1994, BIOORG MED CHEM LETT, V4, P1385, DOI 10.1016/S0960-894X(01)80367-X
   KALISH VJ, 1995, BIOORG MED CHEM LETT, V5, P727, DOI 10.1016/0960-894X(95)00103-Z
   KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686
NR 11
TC 5
Z9 5
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD AUG 20
PY 1996
VL 6
IS 16
BP 1937
EP 1940
DI 10.1016/0960-894X(96)00345-9
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA VD937
UT WOS:A1996VD93700013
DA 2018-01-05
ER

PT J
AU Fassler, A
   Bold, G
   Capraro, HG
   Cozens, R
   Mestan, J
   Poncioni, B
   Rosel, J
   TintelnotBlomley, M
   Lang, M
AF Fassler, A
   Bold, G
   Capraro, HG
   Cozens, R
   Mestan, J
   Poncioni, B
   Rosel, J
   TintelnotBlomley, M
   Lang, M
TI Aza-peptide analogs as potent human immunodeficiency virus type-1
   protease inhibitors with oral bioavailability
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID HIV-PROTEINASE-INHIBITORS; RAY CRYSTAL-STRUCTURE; ANTIVIRAL ACTIVITY;
   RATIONAL DESIGN; DIPEPTIDE ISOSTERE; SERIES; AIDS; SYMMETRY; TARGET;
   HYDRAZINO
AB A series of aza-peptide analogs with a (hydroxyethyl)hydrazine isostere has been synthesized as HIV-1 protease inhibitors using a simple synthetic scheme. Structure-activity studies based on the X-ray of a previously described inhibitor-enzyme complex led to potent inhibitors with antiviral activity in the low-nanomolar range. The S-configuration of the transition-state hydroxyl group was preferred in this series. Small modifications of the P2P3 and P-2'P-3' substituents had little effect on enzyme inhibition but greatly influenced the pharmacokinetic profile. As a result of these studies, the symmetrically acylated compound 8a and its close analog 24a bearing a methyl carbamate in P-3 and an ethyl carbamate in P-3' position were identified as potent inhibitors with plasma concentrations exceeding antiviral ED(50) values 150-fold following oral application in mice.
C1 CIBA GEIGY AG,DIV PHARMACEUT,RES LABS CANC & INFECT DIS,CH-4002 BASEL,SWITZERLAND.
CR ABDELMEGUID SS, 1993, MED RES REV, V13, P731, DOI 10.1002/med.2610130605
   ABDELMEGUID SS, 1993, BIOCHEMISTRY-US, V32, P7972, DOI 10.1021/bi00082a019
   AHMAD S, 1995, BIOORG MED CHEM LETT, V5, P1729, DOI 10.1016/0960-894X(95)00293-3                                                    
   ALTERI E, 1993, ANTIMICROB AGENTS CH, V37, P2087, DOI 10.1128/AAC.37.10.2087                                                          
   ASKIN D, 1992, J ORG CHEM, V57, P2771, DOI 10.1021/jo00036a004
   BABINE RE, 1992, BIOORG MED CHEM LETT, V2, P541, DOI 10.1016/S0960-894X(01)81194-X                                                   
   BARRISH JC, 1994, J MED CHEM, V37, P1758, DOI 10.1021/jm00038a005
   BILLICH S, 1988, J BIOL CHEM, V263, P17905
   BOEHME RE, 1995, ANNU REP MED CHEM, V30, P139
   BONE R, 1991, J AM CHEM SOC, V113, P9382, DOI 10.1021/ja00024a061
   BUDT KH, 1995, BIOORGAN MED CHEM, V3, P559, DOI 10.1016/0968-0896(95)00069-S
   CHENERA B, 1991, BIOORG MED CHEM LETT, V1, P219, DOI 10.1016/S0960-894X(00)80256-5
   Darke P L, 1994, Adv Pharmacol, V25, P399, DOI 10.1016/S1054-3589(08)60438-X
   DEBOUCK C, 1992, AIDS RES HUM RETROV, V8, P153, DOI 10.1089/aid.1992.8.153
   DECAMP AE, 1991, TETRAHEDRON LETT, V32, P1867, DOI 10.1016/S0040-4039(00)85983-3
   DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001
   DUTTA AS, 1975, J CHEM SOC PERK T 1, P1712, DOI 10.1039/p19750001712
   ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122
   ETTMAYER P, 1994, BIOORG MED CHEM LETT, V4, P2851, DOI 10.1016/S0960-894X(01)80827-1                                                   
   FASSLER A, 1993, BIOORG MED CHEM LETT, V3, P2837, DOI 10.1016/S0960-894X(01)80775-7
   FASSLER A, 1995, 210 ACS M CHIC IL
   GANTE J, 1989, SYNTHESIS-STUTTGART, P405
   GETMAN DP, 1993, J MED CHEM, V36, P288, DOI 10.1021/jm00054a014
   Girijavallabhan V M, 1994, Bioorg Med Chem, V2, P1075, DOI 10.1016/S0968-0896(00)82057-X
   HUFF JR, 1991, J MED CHEM, V34, P2305, DOI 10.1021/jm00112a001
   KALDOR SW, 1994, BIOORG MED CHEM LETT, V4, P1385, DOI 10.1016/S0960-894X(01)80367-X
   KAY J, 1990, BIOCHIM BIOPHYS ACTA, V1048, P1, DOI 10.1016/0167-4781(90)90015-T
   KEMPF DJ, 1991, ANTIMICROB AGENTS CH, V35, P2209, DOI 10.1128/AAC.35.11.2209                                                          
   KEMPF DJ, 1990, J MED CHEM, V33, P2687, DOI 10.1021/jm00172a002
   KEMPF DJ, 1993, J MED CHEM, V36, P320, DOI 10.1021/jm00055a003
   KROHN A, 1991, J MED CHEM, V34, P3340, DOI 10.1021/jm00115a028
   LAM PYS, 1994, SCIENCE, V263, P380, DOI 10.1126/science.8278812
   LANG M, 1993, ARCH PHARM, V326, P921, DOI 10.1002/ardp.19933261202                                                        
   LECOQ A, 1991, TETRAHEDRON LETT, V32, P2765, DOI 10.1016/0040-4039(91)85080-O                                                    
   LULY JR, 1987, J ORG CHEM, V52, P1487, DOI 10.1021/jo00384a020                                                             
   MARTIN JA, 1992, ANTIVIR RES, V17, P265, DOI 10.1016/0166-3542(92)90022-W
   MEEK TD, 1992, J ENZYM INHIB, V6, P65, DOI 10.3109/14756369209041357                                                       
   NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0
   PEYMAN A, 1992, TETRAHEDRON LETT, V33, P4549, DOI 10.1016/S0040-4039(00)61309-6                                                   
   PEYMAN A, 1994, BIOORG MED CHEM LETT, V4, P1191, DOI 10.1016/S0960-894X(01)80327-9
   PRIESTLE JP, 1995, STRUCTURE, V33, P381
   RANDAD RS, 1995, BIOORG MED CHEM LETT, V5, P1707, DOI 10.1016/0960-894X(95)00289-6
   RICHARDS AD, 1990, J BIOL CHEM, V265, P7733
   ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354
   RUTJES FPJT, 1993, TETRAHEDRON, V49, P8605, DOI 10.1016/S0040-4020(01)96267-2
   Sham HL, 1996, J MED CHEM, V39, P392, DOI 10.1021/jm9507183
   SHAM HL, 1995, BIOCHEM BIOPH RES CO, V211, P159, DOI 10.1006/bbrc.1995.1791
   SHAM HL, 1993, J CHEM SOC CHEM COMM, P1052, DOI 10.1039/c39930001052                                                            
   SMITH AB, 1994, J MED CHEM, V37, P215, DOI 10.1021/jm00028a001
   SPALTENSTEIN A, 1993, TETRAHEDRON LETT, V34, P1457, DOI 10.1016/S0040-4039(00)60317-9
   THOMPSON WJ, 1992, J MED CHEM, V35, P1685, DOI 10.1021/jm00088a003                                                             
   TUCKER TJ, 1992, J MED CHEM, V35, P2525, DOI 10.1021/jm00092a002                                                             
   VAZQUEZ ML, 1995, J MED CHEM, V38, P581, DOI 10.1021/jm00004a001
   WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279
   WONACOTT A, 1993, J MED CHEM, V36, P3113, DOI 10.1021/jm00073a010                                                             
   FASSLER A, 1993, Patent No. 521827
   HOFFMANNLAROCHE INC, 1991, Patent No. 0432695
   HAEBISCH DD, 1993, Patent No. 528242
   THOMPSON WJ, 1990, Patent No. 434365
   BOLD G, 1995, Patent No. 2582
NR 60
TC 58
Z9 59
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD AUG 2
PY 1996
VL 39
IS 16
BP 3203
EP 3216
DI 10.1021/jm960022p
PG 14
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA VA564
UT WOS:A1996VA56400022
PM 8759643
DA 2018-01-05
ER

PT J
AU Bender, AR
   vonBriesen, H
   Kreuter, J
   Duncan, IB
   RubsamenWaigmann, H
AF Bender, AR
   vonBriesen, H
   Kreuter, J
   Duncan, IB
   RubsamenWaigmann, H
TI Efficiency of nanoparticles as a carrier system for antiviral agents in
   human immunodeficiency virus-infected human monocytes/macrophages in
   vitro
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID HIV PROTEINASE-INHIBITORS; MONOCYTES MACROPHAGES; INVITRO; REPLICATION;
   TOXICITY; PROTEASE; THERAPY; DISEASE; FUTURE; DESIGN
AB Polyhexylcyanoacrylate nanoparticles loaded with either the human immunodeficiency virus (HIV) protease inhibitor saquinavir (Ro 31-8959) or the nucleoside analog zalcitabine (2',3'-dideoxycytidine) were prepared by emulsion polymerization and tested for antiviral activity in primary human monocytes/macrophages in vitro. Both nanoparticulate formulations led to a dose-dependent reduction of HIV type 1 antigen production, While nanoparticle-bound zalcitabine showed no superiority to an aqueous solution of the drug, a significantly higher efficacy was observed with saquinavir-loaded nanoparticles. In acutely infected cells, an aqueous solution of saquinavir showed little antiviral activity at concentrations below 10 nM, whereas the nanoparticulate formulation exhibited a good antiviral effect at a concentration of 1 nM and a still-significant antigen reduction at 0.1 nM (50% inhibitory concentrations = 4.23 nM for the free drug and 0.39 nM for the nanoparticle-bound drug). At a concentration of 100 nM, saquinavir was completely inactive in chronically HIV-infected macrophages, but when bound to nanoparticles it caused a 35% decrease in antigen production. Using nanoparticles as a drug carrier system could improve the delivery of antiviral agents to the mononuclear phagocyte system in vivo, overcoming pharmacokinetic problems and enhancing the activities of drugs for the treatment of HN infection and AIDS.
C1 INST GEORG SPEYER HAUS,CHEMOTHERAPEUT RES INST,D-60596 FRANKFURT,GERMANY.
   UNIV FRANKFURT,INST PHARMACEUT TECHNOL,D-60439 FRANKFURT,GERMANY.
   BAYER AG,INST VIROL,D-42096 WUPPERTAL,GERMANY.
   ROCHE PROD LTD,WELWYN GARDEN CIT AL7 3AY,HERTS,ENGLAND.
CR ALLEMANN E, 1993, EUR J PHARM BIOPHARM, V39, P173
   BECK PH, 1994, EUR J PHARM BIOPHARM, V40, P134
   BENDER A, 1994, RES VIROLOGY, V145, P215, DOI 10.1016/S0923-2516(07)80025-2                                                   
   CLERICI M, 1994, IMMUNOL TODAY, V15, P575, DOI 10.1016/0167-5699(94)90220-8                                                    
   COONEY DA, 1986, BIOCHEM PHARMACOL, V35, P1065
   CRAIG JC, 1991, ANTIVIR RES, V16, P295, DOI 10.1016/0166-3542(91)90045-S
   DECLERCQ E, 1992, AIDS RES HUM RETROV, V8, P119, DOI 10.1089/aid.1992.8.119                                                          
   DOMIN BA, 1993, BIOCHEM PHARMACOL, V46, P725, DOI 10.1016/0006-2952(93)90560-J
   ESSER R, 1991, PATHOBIOLOGY, V59, P219, DOI 10.1159/000163649
   GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648
   GENDELMAN HE, 1994, J LEUKOCYTE BIOL, V56, P389
   HAO Z, 1988, MOL PHARMACOL, V34, P431
   HARVIE P, 1995, AIDS, V9, P701, DOI 10.1097/00002030-199507000-00006
   HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0
   JOHNSTON MI, 1993, SCIENCE, V260, P1286, DOI 10.1126/science.7684163
   KHOO SH, 1995, J ANTIMICROB CHEMOTH, V35, P245, DOI 10.1093/jac/35.2.245
   KITCHEN VS, 1995, LANCET, V345, P952, DOI 10.1016/S0140-6736(95)90699-1
   KREUTER J, 1995, BRAIN RES, V674, P171, DOI 10.1016/0006-8993(95)00023-J
   KREUTER J, 1983, PHARM ACTA HELV, V58, P196
   KREUTER J, 1979, J PHARM SCI, V68, P1443, DOI 10.1002/jps.2600681129
   Kreuter J., 1994, COLLOIDAL DRUG DELIV, P219
   KUHNEL H, 1989, P NATL ACAD SCI USA, V86, P2383, DOI 10.1073/pnas.86.7.2383                                                          
   LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383
   LEVY JA, 1993, MICROBIOL REV, V57, P183
   MARTIN JA, 1992, ANTIVIR RES, V17, P265, DOI 10.1016/0166-3542(92)90022-W
   MATSUYAMA T, 1991, AIDS, V5, P1405, DOI 10.1097/00002030-199112000-00001                                                
   MCGANN KA, 1994, J INFECT DIS, V169, P746, DOI 10.1093/infdis/169.4.746                                                        
   MILMAN G, 1994, AIDS RES HUM RETROV, V10, P1305, DOI 10.1089/aid.1994.10.1305
   MITSUYA H, 1990, SCIENCE, V249, P2533
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   NICHOLSON JKA, 1986, J IMMUNOL, V137, P323
   PERNO CF, 1992, ANTIVIR RES, V17, P289, DOI 10.1016/0166-3542(92)90024-Y
   PERNO CF, 1993, J INFECT DIS, V168, P1148, DOI 10.1093/infdis/168.5.1148                                                       
   PERNO CF, 1994, J LEUKOCYTE BIOL, V56, P381
   PHILLIPS NC, 1992, BLOOD, V79, P1137
   ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354
   Roberts Noel A., 1993, P129
   ROBINS T, 1993, J ACQ IMMUN DEF SYND, V6, P162
   ROSSI JJ, 1992, AIDS RES HUM RETROV, V8, P183, DOI 10.1089/aid.1992.8.183
   RUBSAMENWAIGMANN H, 1989, LANCET, V2, P1155
   RUBSAMENWAIGMANN H, 1991, INFECTION, V19, pS77, DOI 10.1007/BF01644472
   Schafer V, 1994, Clin Diagn Virol, V1, P279, DOI 10.1016/0928-0197(94)90058-2
   SCHAFER V, 1992, PHARMACEUT RES, V9, P541, DOI 10.1023/A:1015852732512
   SCHAFER V, 1994, J MICROENCAPSUL, V11, P261, DOI 10.3109/02652049409040455
   SCHINAZI RF, 1992, AIDS RES HUM RETROV, V8, P963, DOI 10.1089/aid.1992.8.963                                                          
   VANTWOUT AB, 1994, J CLIN INVEST, V94, P2060, DOI 10.1172/JCI117560
   VELLA S, 1994, AIDS, V8, pS25, DOI 10.1097/00002030-199409001-00006
   VONBRIESEN H, 1990, RES VIROLOGY, V141, P225, DOI 10.1016/0923-2516(90)90025-E
   WASER PG, 1987, INT J PHARM, V39, P213, DOI 10.1016/0378-5173(87)90219-5
   WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0
   WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571                                                         
   Winslow D L, 1995, AIDS, V9 Suppl A, pS183
   YARCHOAN R, 1991, BLOOD, V78, P859
NR 53
TC 94
Z9 99
U1 1
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JUN
PY 1996
VL 40
IS 6
BP 1467
EP 1471
PG 5
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA UP107
UT WOS:A1996UP10700026
PM 8726020
DA 2018-01-05
ER

PT J
AU Ijichi, K
   Fujiwara, M
   Nagano, H
   Matsumoto, Y
   Hanasaki, Y
   Ide, T
   Katsuura, K
   Takayama, H
   Shirakawa, S
   Aimi, N
   Shigeta, S
   Konno, K
   Matsushima, M
   Yokota, T
   Baba, M
AF Ijichi, K
   Fujiwara, M
   Nagano, H
   Matsumoto, Y
   Hanasaki, Y
   Ide, T
   Katsuura, K
   Takayama, H
   Shirakawa, S
   Aimi, N
   Shigeta, S
   Konno, K
   Matsushima, M
   Yokota, T
   Baba, M
TI Anti-HIV-1 activity of thiadiazole derivatives: Structure-activity
   relationship, reverse transcriptase inhibition, and lipophilicity
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE NNRTI; HIV-1-specific reverse transcriptase inhibitor; lipophilicity;
   structure-activity relationship; TDA derivatives
ID IMMUNODEFICIENCY-VIRUS TYPE-1; NONNUCLEOSIDE INHIBITORS;
   SELECTIVE-INHIBITION; HIV-1 REPLICATION; POTENT; RESISTANT; INFECTION;
   SERIES; ASSAY; DRUG
AB The structure-activity relationship of the non-nucleoside HIV-1-specific reverse transcriptase (RT) inhibitors 4-phenyl-1,2,5-thiadiazol-3-yl N,N-dialkylcarbamate (TDA) derivatives was investigated with respect to their anti-HIV-1 activity, RT inhibition, and lipophilicity. 4-Phenyl-1,2,5-thiadiazol-3-yl N,N-dimethylcarbamate inhibited HIV-1-induced cytopathic effect (CPE) by 50% at a concentration of 28.8 mu M in MT-4 cells. The activity increased more than 100-fold when the hydrogens at the 2-position and the 6-position in phenyl moiety were substituted by chlorines. However, the derivative with a chlorine at the it-position of phenyl moiety did not show any inhibition of HIV-1 replication at its non-toxic concentrations. All of the 4-(2,6-dichlorophenyl)-1,2,5-thiadiazol-3-yl N-methyl-N-alkylcarbamates proved inhibitory to HIV-1 replication in the nanomolar concentration range. The TDA derivatives that showed anti-HIV-1 activity also inhibited RT activity in an enzymatic assay. However, the TDA derivatives did not show any specific inhibition of a non-nucleoside RT inhibitor (NNRTI)-resistant mutant and its RT activity. When the TDA derivatives were examined for their inhibitory effect on HIV-1 replication in the presence of 50% human serum, the activity significantly decreased depending on their lipophilicity.
C1 TOSOH CO LTD,TOKYO RES LAB,KANAGAWA 252,JAPAN.
   CHIBA UNIV,FAC PHARMACEUT SCI,CHIBA 263,JAPAN.
   FUKUSHIMA MED COLL,DEPT MICROBIOL,FUKUSHIMA 96012,JAPAN.
   KAGOSHIMA UNIV,FAC MED,DIV HUMAN RETROVIRUSES,CTR CHRON VIRAL DIS,KAGOSHIMA 890,JAPAN.
RP Ijichi, K (reprint author), RAT DRUG DESIGN LABS,FUKUSHIMA 96012,JAPAN.
RI Takayama, Hiromitsu/H-6829-2015; Baba, Masanori/G-3867-2011
CR BABA M, 1993, BIOCHEM PHARMACOL, V45, P2507
   BABA M, 1994, ANTIMICROB AGENTS CH, V38, P688, DOI 10.1128/AAC.38.4.688                                                            
   BABA M, 1991, P NATL ACAD SCI USA, V88, P2356, DOI 10.1073/pnas.88.6.2356
   BOYER PL, 1993, J VIROL, V67, P2412
   COHEN KA, 1991, J BIOL CHEM, V266, P14671
   DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001
   DECLERCQ E, 1993, MED RES REV, V13, P229, DOI 10.1002/med.2610130303                                                          
   GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863
   GROB PM, 1992, AIDS RES HUM RETROV, V8, P145, DOI 10.1089/aid.1992.8.145
   HANASAKI Y, 1995, J MED CHEM, V38, P2038, DOI 10.1021/jm00012a002
   HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081                                                         
   IJICHI K, 1995, ANTIMICROB AGENTS CH, V39, P2337, DOI 10.1128/AAC.39.10.2337                                                          
   JANSSEN RS, 1989, NEUROLOGY, V39, P119, DOI 10.1212/WNL.39.1.119                                                            
   KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403
   MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568                                                         
   NUNBERG JH, 1991, J VIROL, V65, P4887
   PAUWELS R, 1993, P NATL ACAD SCI USA, V90, P1711, DOI 10.1073/pnas.90.5.1711                                                          
   PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   REN JS, 1995, STRUCTURE, V3, P915, DOI 10.1016/S0969-2126(01)00226-X
   RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241
   SMITH MBK, 1995, PROTEIN SCI, V4, P2203
   TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665                                                          
   VISWANADHAN VN, 1989, J CHEM INF COMP SCI, V29, P163, DOI 10.1021/ci00063a006
NR 24
TC 21
Z9 22
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-3542
J9 ANTIVIR RES
JI Antiviral Res.
PD JUN
PY 1996
VL 31
IS 1-2
BP 87
EP 94
DI 10.1016/0166-3542(96)00950-3
PG 8
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA UT712
UT WOS:A1996UT71200008
PM 8793012
DA 2018-01-05
ER

PT J
AU Chen, H
   McBroom, DG
   Zhu, YQ
   Gold, L
   North, TW
AF Chen, H
   McBroom, DG
   Zhu, YQ
   Gold, L
   North, TW
TI Inhibitory RNA ligand to reverse transcriptase from feline
   immunodeficiency virus
SO BIOCHEMISTRY
LA English
DT Article
ID BACTERIOPHAGE-T4 DNA-POLYMERASE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE;
   INFECTION; CATS; THERAPY; MODEL
AB High-affinity, high-specificity RNA ligands for reverse transcriptase from feline immunode ficiency virus (FIV) were isolated from an RNA library by the SELEX (Systematic Evolution of Ligands by EXponential enrichment) procedure, The selected RNA ligands bound to FIV reverse transcriptase with dissociation constants in the nanomolar range, One of the ligands was a potent inhibitor of the RNA-dependent DNA polymerase activity of both the recombinant and the virion-derived FN reverse transcriptase, It also inhibited the reverse transcriptase from an FIV mutant that is resistant to 3'-azido-3'-deoxythymidine (AZT). The inhibition of FIV reverse transcriptase was competitive with respect to template-primer and noncompetitive with respect to deoxyribonucleoside 5'-triphosphates. This ligand was specific for the FIV enzyme and did not inhibit other reverse transcriptases tested (avian myeloblastosis virus, Moloney murine leukemia virus, and human immunodeficiency virus type 1).
C1 UNIV MONTANA,DIV BIOL SCI,MISSOULA,MT 59812.
   UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309.
FU NIGMS NIH HHS [GM19963, GM28685]; NIAID NIH HHS [AI28189]
CR BARLOUGH JE, 1993, ANTIVIR RES, V22, P259, DOI 10.1016/0166-3542(93)90036-I
   CHEN H, 1994, BIOCHEMISTRY-US, V33, P8746, DOI 10.1021/bi00195a016                                                             
   CRONN RC, 1992, BIOCHEM PHARMACOL, V44, P1375, DOI 10.1016/0006-2952(92)90539-U
   GOBERT JM, 1994, ANTIMICROB AGENTS CH, V38, P861, DOI 10.1128/AAC.38.4.861                                                            
   GOLD L, 1995, J BIOL CHEM, V270, P13581, DOI 10.1074/jbc.270.23.13581                                                        
   GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555
   ISHIDA T, 1990, JPN J VET SCI, V52, P645
   JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320                                                         
   JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706
   KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403
   LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383
   LIM WA, 1991, METHOD ENZYMOL, V208, P196
   NORTH TW, 1990, J BIOL CHEM, V265, P5121
   NORTH TW, 1989, ANTIMICROB AGENTS CH, V33, P915, DOI 10.1128/AAC.33.6.915                                                            
   NORTH TW, 1994, ANTIMICROB AGENTS CH, V38, P388, DOI 10.1128/AAC.38.2.388                                                            
   NORTH TW, 1995, NAT MED, V1, P410, DOI 10.1038/nm0595-410
   NORTH TW, 1990, ANTIMICROB AGENTS CH, V34, P1505, DOI 10.1128/AAC.34.8.1505                                                           
   PEDERSEN NC, 1987, SCIENCE, V235, P790, DOI 10.1126/science.3643650
   PEDERSEN N. C., 1993, RETROVIRIDAE, V2, P181
   REMINGTON KM, 1991, J VIROL, V65, P308
   REMINGTON KM, 1994, J VIROL, V68, P632
   RICHMAN DD, 1993, ANTIMICROB AGENTS CH, V37, P1207, DOI 10.1128/AAC.37.6.1207                                                           
   TALBOTT RL, 1989, P NATL ACAD SCI USA, V86, P5743, DOI 10.1073/pnas.86.15.5743
   TORTEN M, 1991, J VIROL, V65, P2225
   TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988, DOI 10.1073/pnas.89.15.6988                                                         
   TUERK C, 1990, J MOL BIOL, V213, P749, DOI 10.1016/S0022-2836(05)80261-X
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   YARCHOAN R, 1989, AM J MED, V87, P191
   ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181
NR 29
TC 23
Z9 24
U1 0
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD MAY 28
PY 1996
VL 35
IS 21
BP 6923
EP 6930
DI 10.1021/bi9600106                                                       
          
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA UN288
UT WOS:A1996UN28800046
PM 8639644
DA 2018-01-05
ER

PT J
AU Meijer, DKF
   Molema, G
   Moolenaar, F
   deZeeuw, D
   Swart, PJ
AF Meijer, DKF
   Molema, G
   Moolenaar, F
   deZeeuw, D
   Swart, PJ
TI (Glyco)-protein drug carriers with an intrinsic therapeutic activity:
   The concept of dual targeting
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article; Proceedings Paper
CT 7th International Symposium on Recent Advances in Drug Delivery Systems
CY FEB 27-MAR 02, 1995
CL SALT LAKE CITY, UT
SP Baxter Healthcare Corp, Becton Dickinson & Co, Ciba Geigy Corp, Hoffmann La Roche Inc, MacroMed Inc, Marion Merrell Dow Inc, Pacific Corp, JAGO Pharma AG, Sam Yang Co Ltd, TheraTech Inc, Shiseido Res Ctr, 3M Pharm, Drug Delivery Syst, Jpjohn Co, Yamanouchi Pharm Co Ltd
DE antiviral protein; negatively charged albumin; drug targeting; anti-HIV
   agent; renal targeting; hepatic targeting; AZT; naproxen; lysozyme;
   glycoprotein
ID MOLECULAR-WEIGHT PROTEINS; HUMAN SERUM ALBUMINS; LYSOZYME; RAT;
   DERIVATIVES; DELIVERY; POTENT; LIVER; ACID
AB Dual targeting can in principle be achieved by using intrinsically active carriers that not only deliver the conjugated drug but also otherwise influence the pathological process. Potential carriers of this kind are monoclonal antibodies, certain interferons and interleukins, as well as certain enzymes, peptide hormones and antivirally active (glyco)-proteins. The low molecular weight protein lysozyme, that is easily filtered and reabsorbed in kidney tubular cells, was used as a carrier for renal delivery of various drugs including anti-bacterial agents. The carrier itself can add to the anti-infective effect through its lysing effect on bacterial cell walls. Albumins derivatized with various sugars were used for delivery of the anti-inflammatory drug naproxen to hepatocytes, endothelial cells and Kupffer cells. Naproxen-albumin exhibited a potent hepatoprotective effect if delivered to sinusoidal cell types. Negatively charged and enzymatically active protein carriers can contribute to therapeutic effects, among others, through receptor antagonism and detoxification of endotoxins. Some (glyco)-proteins, designed as a drug carrier for anti-HIV agents, exhibited an intrinsic antiviral activity even without coupling of antiviral drugs. This activity was caused by an increased negative charge of the particular (glyco)-proteins. The in vitro IC50 values of some of these polyanionic proteins were in the nanomolar concentration range. The mechanism of action was found to be inhibition of a post binding virus/cell fusion event. The particular negatively charged albumins (NCAs) showed, in the therapeutic dose range, favorable pharmacokinetics with regard to lymphatic distribution and residence time in the blood stream. They have little acute toxicity and, in contrast to other polyanionic compounds, such as dextran sulfate are readily biodegradable. The NCAs lack an anticoagulant activity and exhibit low immunogenicity. Importantly, a high activity against primary clinical HIV isolates was observed. We detected a high affinity binding to the V3 loop of the envelope glycoprotein gp120, explaining the potent effect on virus/cell fusion and HIV-1 replication as well as the significant activity on syncytium-inducing HIV variants. The particular antiviral proteins can in principle be applied as intrinsically active drug carriers for the targeting of nucleoside analogues such as AZT, protease inhibitors and glycosidase inhibitors. A major advantage would be the concomitant blocking of sequential steps in the viral replication process with the aims to obtain synergism and prevention of drug resistance.
C1 GRONINGEN UTRECHT INST DRUG EXPLORAT,DEPT PHARMACOKINET & DRUG DELIVERY,GRONINGEN,NETHERLANDS.
RI de Zeeuw, Dick/E-9080-2014
OI de Zeeuw, Dick/0000-0003-3434-7777
CR FRANSSEN EJF, 1992, INT J PHARM, V80, pR15, DOI 10.1016/0378-5173(92)90293-B
   FRANSSEN EJF, 1993, BIOCHEM PHARMACOL, V45, P1215, DOI 10.1016/0006-2952(93)90273-Y
   FRANSSEN EJF, 1993, PHARMACEUT RES, V10, P963, DOI 10.1023/A:1018946219057
   FRANSSEN EJF, 1991, PHARMACEUT RES, V8, P1223, DOI 10.1023/A:1015835325321
   FRANSSEN EJF, 1992, J MED CHEM, V35, P1246, DOI 10.1021/jm00085a012
   FRANSSEN EJF, 1994, ADV DRUG DELIVER REV, V14, P67, DOI 10.1016/0169-409X(94)90006-X                                                    
   JANSEN RW, 1993, PHARM RES-DORDR, V10, P1611, DOI 10.1023/A:1018972603494
   JANSEN RW, 1991, J BIOL CHEM, V266, P3343
   JANSEN RW, 1991, MOL PHARMACOL, V39, P818
   JANSEN RW, 1993, MOL PHARMACOL, V44, P1003
   JANSEN RW, 1993, HEPATOLOGY, V18, P146, DOI 10.1002/hep.1840180122
   JANSEN RW, 1991, BIOCHEM BIOPH RES CO, V180, P3343
   Meijer D K, 1981, Methods Enzymol, V77, P81
   MEIJER DKF, 1992, ANTIVIR RES, V18, P215, DOI 10.1016/0166-3542(92)90058-D
   MEIJER DKF, 1989, PHARMACEUT RES, V6, P105, DOI 10.1023/A:1015961424122
   MEIJER DKF, 1990, CURRENT TOPICS GASTR, P374
   MEIJER DKF, 1990, TRENDS DRUG RES, V13, P303
   Meijer DKF, 1993, BIOL BARRIERS PROTEI, P339
   MEIJER DKF, 1991, OXFORD TXB CLIN HEPA, P40
   MOLEMA G, 1994, ADV DRUG DELIVER REV, V14, P25, DOI 10.1016/0169-409X(94)90004-3
   MOLEMA G, 1992, J CHROMATOGR-BIOMED, V579, P107, DOI 10.1016/0378-4347(92)80368-Z
   MOLEMA G, 1991, J MED CHEM, V43, P1137
   MOLEMA G, 1990, BIOCHEM PHARMACOL, V39, P2603
   VANDERSLUIJS P, 1986, HEPATOLOGY, V6, P723, DOI 10.1002/hep.1840060431
   VANDERSLUIJS P, 1991, LIVER DISEASES TARGE, P235
   WITVROUW M, 1994, ANTIVIR CHEM CHEMOTH, V5, P345, DOI 10.1177/095632029400500601                                                      
NR 26
TC 20
Z9 20
U1 2
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD MAY
PY 1996
VL 39
IS 2-3
BP 163
EP 172
DI 10.1016/0168-3659(95)00150-6
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA UT432
UT WOS:A1996UT43200007
DA 2018-01-05
ER

PT J
AU Ishikawa, T
   Watanabe, T
   Tanigawa, H
   Saito, T
   Kotake, KI
   Ohashi, Y
   Ishii, H
AF Ishikawa, T
   Watanabe, T
   Tanigawa, H
   Saito, T
   Kotake, KI
   Ohashi, Y
   Ishii, H
TI Nitrosation of phenolic substrates under mildly basic conditions:
   Selective preparation of p-quinone monooximes and their antiviral
   activities
SO JOURNAL OF ORGANIC CHEMISTRY
LA English
DT Article
ID INFECTIVITY; INHIBITION; OXETANOCIN
AB Nitrosation of 3-methoxyphenol and 1-naphthol were examined under both acidic (NaNO2-EtCO(2)H-H2O) and basic (i-AmNO2-K2CO3-DMF) conditions, Acidic nitrosations afforded ortho-directed products, whereas para-directed nitrosations were observed under basic conditions to yield p-quinone monooximes. The basic para-directed nitrosation was further examined using 15 phenols, two naphthols, and four phenolic heterocyclics, A one-pot operation of the basic nitrosation followed by methylation with dimethyl sulfate gave the corresponding methyl ethers in high yield, Two p-quinone monooximes derived from 3-methoxyphenol and 8-hydroxyquinoline showed a moderate activity against HSV-1, and the latter oxime was also effective against HSV-2, On the other hand, p-quinone monooximes derived from methyl salicylate, 1-naphthol, 7-hydroxy-2-methylbenzo[b]-furan, and 8-hydroxycoumarin showed the comparable activity to that of DDI against HIV-1.
RP Ishikawa, T (reprint author), CHIBA UNIV,FAC PHARMACEUT SCI,1-33 YAYOI CHO,CHIBA 263,JAPAN.
CR BENSON WR, 1966, J ORG CHEM, V31, P2498, DOI 10.1021/jo01346a016                                                             
   CONE MC, 1995, TETRAHEDRON, V51, P3095, DOI 10.1016/0040-4020(95)00071-F
   COOMBES RG, 1979, COMPREHENSIVE ORGANI, V2, P305
   CRONHEIM G, 1947, J ORG CHEM, V12, P7, DOI 10.1021/jo01165a002                                                             
   DAHN H, 1994, HELV CHIM ACTA, V77, P306, DOI 10.1002/hlca.19940770130                                                        
   DEMONCHAUX P, 1994, BIOORG MED CHEM LETT, V4, P2383, DOI 10.1016/S0960-894X(01)80395-4
   GERALDES CFG, 1988, OPT PURA APL, V21, P71
   HALFPENNY E, 1952, J CHEM SOC, P939, DOI 10.1039/jr9520000939                                                            
   HARAYAMA T, 1994, HETEROCYCLES, V39, P613, DOI 10.3987/COM-94-S(B)54                                                           
   HOSHINO H, 1987, J ANTIBIOT, V40, P1077, DOI 10.7164/antibiotics.40.1077                                                     
   HOUBEN J, 1920, BER, V53, P2352
   ISHII H, 1993, J CHEM SOC PERK T 1, P1019, DOI 10.1039/p19930001019                                                            
   ISHII H, 1992, CHEM PHARM BULL, V40, P1123
   ISHIKAWA T, 1995, CHEM PHARM BULL, V43, P1039
   ISHIKAWA T, 1995, TETRAHEDRON, V51, P8447, DOI 10.1016/0040-4020(95)00460-P
   ISHIKAWA T, UNPUB, P65307
   KLOPMAN G, 1974, CHEM REACTIVITY REAC, P81
   MALESKI RJ, 1993, SYNTHETIC COMMUN, V23, P343, DOI 10.1080/00397919308009786                                                       
   NISHIYAMA Y, 1989, J ANTIBIOT, V42, P1854, DOI 10.7164/antibiotics.42.1854                                                     
   NORRIS RK, 1969, AUST J CHEM, V22, P935, DOI 10.1071/CH9690935                                                               
   RICE WG, 1993, NATURE, V361, P473, DOI 10.1038/361473a0                                                                
   UFFMANN H, 1967, Z NATURFORSCH PT B, VB 22, P491
NR 22
TC 23
Z9 23
U1 1
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0022-3263
J9 J ORG CHEM
JI J. Org. Chem.
PD APR 19
PY 1996
VL 61
IS 8
BP 2774
EP 2779
DI 10.1021/jo951873s                                                       
          
PG 6
WC Chemistry, Organic
SC Chemistry
GA UG483
UT WOS:A1996UG48300036
DA 2018-01-05
ER

PT J
AU Dax, SL
   Cook, SC
AF Dax, SL
   Cook, SC
TI Cyclic urea HIV protease inhibitors containing alkynyl- and
   alkenyl-tethered heterocycles in the P2 region
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
AB A series of cyclic urea HIV protease inhibitors containing alkynyl- and allrenyl-tethered heterocycles in the P2 region were synthesized The alkynyl compounds exhibited poor activity against the HN protease enzyme. However, reduction of the triple bond afforded trans-alkenyl derivatives (XU348 and XU430) which displayed superb potency (sub-nanomolar K-i). Copyright (C) 1996 Elsevier Science Ltd
RP Dax, SL (reprint author), DUPONT MERCK PHARMACEUT CO,DEPT CHEM & PHYS SCI,WILMINGTON,DE 19880, USA.
CR DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001
   ERICKSONVIITANEN S, 1989, AIDS RES HUM RETROV, V5, P577, DOI 10.1089/aid.1989.5.577
   LAM PYS, 1994, SCIENCE, V263, P380, DOI 10.1126/science.8278812
   1995, SCRIP           1227, P21
NR 4
TC 16
Z9 16
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD APR 9
PY 1996
VL 6
IS 7
BP 797
EP 802
DI 10.1016/0960-894X(96)00108-4
PG 6
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA UG180
UT WOS:A1996UG18000013
DA 2018-01-05
ER

PT J
AU Kawczynski, W
   Czochralska, B
   Lindqvist, L
   Torrence, PF
AF Kawczynski, W
   Czochralska, B
   Lindqvist, L
   Torrence, PF
TI Reaction intermediates of a dihydropyridine derivative of
   2',3'-dideoxycytidine related to AIDS dementia studied by laser flash
   photolysis
SO BIOELECTROCHEMISTRY AND BIOENERGETICS
LA English
DT Article
DE cytidine derivative; flash photolysis; AIDS dementia; radical
   intermediate
ID HUMAN IMMUNODEFICIENCY VIRUS; CHEMICAL DELIVERY SYSTEM;
   AQUEOUS-SOLUTION; ZIDOVUDINE; EXCITATION; INVITRO; METABOLISM;
   MECHANISM; NADH; NM
AB A derivative of 2',3'-dideoxycytidine (ddC), carrying one 1,4-dihydro-1-methyl-3-pyridinyl-carbonyl group at the cytidine exocyclic amino group and one at the ribose 5-hydroxyl group, was exposed in water-ethanol solution to high-power pulsed laser emission at a wavelength of 354.7 nm. Measurement of the transient absorption spectra. with nanosecond time resolution shows that the photoejection of an electron occurs due to stepwise two-photon absorption by the dihydropyridine via its fluorescent state. The spectrum of the cation radical formed in this reaction was determined, together with that of the neutral radical appearing following deprotonation of the cation. The electron is apparently abstracted only from the pyridine group attached to the ribose, since a comparative study on ddC carrying a dihydropyridine only at the exocyclic amino group showed no evidence for photoionization in the same experimental conditions.
C1 UNIV WARSAW,INST EXPTL PHYS,DEPT BIOPHYS,PL-02089 WARSAW,POLAND.
   UNIV PARIS 11,CNRS,PHOTOPHYS MOLEC LAB,F-91405 ORSAY,FRANCE.
   NIDDKD,SECT BIOMED CHEM,MED CHEM LAB,NIH,BETHESDA,MD 20892.
CR AGGARWAL SK, 1990, J MED CHEM, V33, P1505, DOI 10.1021/jm00167a034
   BALZARINI J, 1987, MOL PHARMACOL, V32, P798
   BREWSTER ME, 1991, J PHARM SCI, V80, P843, DOI 10.1002/jps.2600800908                                                          
   BRODER S, 1990, MED RES REV, V4, P419
   CZOCHRALSKA B, 1983, CHEM PHYS LETT, V101, P297, DOI 10.1016/0009-2614(83)87016-X
   GANSER A, 1989, EXP HEMATOL, V17, P321
   GOGU SR, 1989, BIOCHEM BIOPH RES CO, V160, P656, DOI 10.1016/0006-291X(89)92483-2
   HART EJ, 1970, HYDRATED ELECTRON
   KELLMANN A, 1986, J PHOTOCHEM, V35, P155, DOI 10.1016/0047-2670(86)85025-0                                                    
   LINDQVIST L, 1994, J PHOTOCH PHOTOBIO B, V23, P207, DOI 10.1016/1011-1344(94)06999-9
   LINDQVIST L, 1985, CHEM PHYS LETT, V119, P494, DOI 10.1016/0009-2614(85)85375-6
   Little R, 1990, J BIOPHARM SCI, V1, P1
   MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911
   PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272
   STARNES MC, 1987, J BIOL CHEM, V262, P988
   TORRENCE PF, 1993, J MED CHEM, V36, P529, DOI 10.1021/jm00057a002                                                             
   TORRENCE PF, 1988, FEBS LETT, V234, P135, DOI 10.1016/0014-5793(88)81319-X
   VISSER AJWG, 1981, PHOTOCHEM PHOTOBIOL, V33, P35, DOI 10.1111/j.1751-1097.1981.tb04293.x
NR 18
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE SA LAUSANNE
PI LAUSANNE 1
PA PO BOX 564, 1001 LAUSANNE 1, SWITZERLAND
SN 0302-4598
J9 BIOELECTROCH BIOENER
JI Bioelectrochem. Bioenerg.
PD MAR
PY 1996
VL 39
IS 2
BP 263
EP 266
DI 10.1016/0302-4598(95)01889-1                                            
          
PG 4
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA UG704
UT WOS:A1996UG70400017
DA 2018-01-05
ER

PT J
AU Soler, F
   Poujade, C
   Evers, M
   Carry, JC
   Henin, Y
   Bousseau, A
   Huet, T
   Pauwels, R
   DeClercq, E
   Mayaux, JF
   LePecq, JB
   Dereu, N
AF Soler, F
   Poujade, C
   Evers, M
   Carry, JC
   Henin, Y
   Bousseau, A
   Huet, T
   Pauwels, R
   DeClercq, E
   Mayaux, JF
   LePecq, JB
   Dereu, N
TI Betulinic acid derivatives: A new class of specific inhibitors of human
   immunodeficiency virus type 1 entry
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID ANTI-HIV PRINCIPLE; AIDS AGENTS; GLYCYRRHIZIN; REPLICATION; INVITRO
AB A novel series of omega-aminoalkanoic acid derivatives of betulinic acid were synthesized and evaluated for their activity against human immunodeficiency virus (HIV). The anti-HIV-1 activity of several members of this new series was found to be in the nanomolar range in CEM 4 and MT-4 cell cultures. The optimization of the omega-aminoalkanoic acid side chain is described. The presence of an amide function within the side chain was found important for optimal activity. RPR 103611 (14g), a statine derivative, was found to be inactive against HIV-1 protease, reverse transcriptase, and integrase as well as on gp120/CD4 binding. ''Time of addition'' experiments suggested interaction with an early step of HIV-1 replication. As syncytium formation, but not virus-cell binding, seems to be affected, betulinic acid derivatives are assumed to interact with the postbinding virus-cell fusion process.
C1 RHONE POULENC RORER,CTR RECH VITRY ALFORTVILLE,DEPT BIOL,F-14403 VITRY,FRANCE.
   RHONE POULENC RORER,CTR RECH VITRY ALFORTVILLE,DEPT BIOTECHNOL,F-14403 VITRY,FRANCE.
   KATHOLIEKE UNIV LEUVEN,REGA INST MED RES,B-3000 LOUVAIN,BELGIUM.
RP Soler, F (reprint author), RHONE POULENC RORER,CTR RECH VITRY ALFORTVILLE,DEPT CHIM PHARMACEUT,13 QUAI JULES GUESDE,BP 14,F-14403 VITRY,FRANCE.
CR BABA M, 1989, J ACQ IMMUN DEF SYND, V2, P264
   BECKETT AH, 1962, J CHEM SOC, P1386, DOI 10.1039/jr9620001386                                                            
   CHEN K, 1992, J NAT PROD, V55, P340, DOI 10.1021/np50081a010
   COFFMAN DD, 1948, J POLYM SCI, V3, P85, DOI 10.1002/pol.1948.120030110                                                      
   CRAVEN AP, 1989, TETRAHEDRON, V45, P2417, DOI 10.1016/S0040-4020(01)83439-6
   DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001
   DEREU N, 1993, 9 INT C AIDS BERL
   DREY CNC, 1982, J CHEM SOC P1, V7, P1587
   Evers M, 1996, J MED CHEM, V39, P1056, DOI 10.1021/jm950670t
   Franchimont APN, 1908, RECL TRAV CH PAYS-BA, V27, P192
   FREIFELDER M, 1962, J ORG CHEM, V27, P284, DOI 10.1021/jo01048a505                                                             
   ISHIDA S, 1989, CHEM PHARM BULL, V37, P2509
   ITO M, 1988, ANTIVIR RES, V10, P289, DOI 10.1016/0166-3542(88)90047-2                                                    
   ITO M, 1987, ANTIVIR RES, V7, P127, DOI 10.1016/0166-3542(87)90001-5
   LI HY, 1993, J NAT PROD, V56, P1130, DOI 10.1021/np50097a017
   MAGIDSON OY, 1967, KHIM FARM ZH, V1, P9
   MAYAUX JF, 1993, 9 INT C AIDS BERL
   MAYAUX JF, 1994, IN PRESS P NATL ACAD
   MULLER A, 1932, CHEM BER, V65, P1354
   NAYLOR RF, 1947, J CHEM SOC, P1106, DOI 10.1039/jr9470001106                                                            
   PANIZO FM, 1950, AN R SOC ESP FIS Q B, V46, P727
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   POMPEI R, 1979, NATURE, V281, P689, DOI 10.1038/281689a0
   PROVITA J, 1976, COLLECT CZECH CHEM C, V41, P1200
   SHCHAVLINSKII AN, 1976, IZV VYSSH UCHEBN ZAV, V19, P237
   SOFUKU S, 1973, B CHEM SOC JPN, V46, P968, DOI 10.1246/bcsj.46.968                                                             
   STEULMANN R, 1975, LIEBIGS ANN CHEM, V12, P2245
   ZHAN H, 1961, CHEM BER, V41, P2470
   ZHAN H, 1965, CHEM BER, V98, P3251
NR 29
TC 108
Z9 117
U1 0
U2 7
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD MAR 1
PY 1996
VL 39
IS 5
BP 1069
EP 1083
DI 10.1021/jm950669u
PG 15
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA TY544
UT WOS:A1996TY54400010
PM 8676342
DA 2018-01-05
ER

PT J
AU Leroux, JC
   Cozens, RM
   Roesel, JL
   Galli, B
   Doelker, E
   Gurny, R
AF Leroux, JC
   Cozens, RM
   Roesel, JL
   Galli, B
   Doelker, E
   Gurny, R
TI pH-sensitive nanoparticles: An effective means to improve the oral
   delivery of HIV-1 protease inhibitors in dogs
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE nanoparticle; methacrylic acid copolymer; HIV protease inhibitor; dog
   AIDS treatment; solid dispersion
ID PURIFICATION
C1 UNIV GENEVA,SCH PHARM,GENEVA,SWITZERLAND.
   CIBA GEIGY AG,DIV PHARMACEUT,CH-4002 BASEL,SWITZERLAND.
RI Leroux, Jean-Christophe/N-4202-2015
OI Leroux, Jean-Christophe/0000-0001-5601-1292
CR ABDELMEGUID SS, 1994, BIOCHEMISTRY-US, V33, P11671, DOI 10.1021/bi00205a001
   ALLEMANN E, 1993, EUR J PHARM BIOPHARM, V39, P13
   ALTERI E, 1993, ANTIMICROB AGENTS CH, V37, P2087, DOI 10.1128/AAC.37.10.2087                                                          
   CHOUINARD F, 1991, INT J PHARM, V72, P211, DOI 10.1016/0378-5173(91)90110-A                                                    
   DELABOURET A, 1995, DRUG DEV IND PHARM, V21, P229, DOI 10.3109/03639049509048106                                                       
   GABLER FR, 1987, FILTRATION PHARM IND, P453
   LANG M, 1993, ARCH PHARM, V326, P921, DOI 10.1002/ardp.19933261202                                                        
   LEROUX JC, 1995, J PHARM SCI, V84, P1387, DOI 10.1002/jps.2600841202
   LEROUX JC, 1995, LIFE SCI, V57, P695, DOI 10.1016/0024-3205(95)00321-V                                                    
   VERDUN C, 1986, Journal of Controlled Release, V3, P205, DOI 10.1016/0168-3659(86)90081-7
   Fessi H., 1992, Patents, Patent No. [5118528, FR 2608988]
NR 11
TC 47
Z9 48
U1 4
U2 10
PU PLENUM PUBL CORP
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013
SN 0724-8741
J9 PHARMACEUT RES
JI Pharm. Res.
PD MAR
PY 1996
VL 13
IS 3
BP 485
EP 487
DI 10.1023/A:1016073416332                                                 
          
PG 3
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA UB418
UT WOS:A1996UB41800025
PM 8692747
DA 2018-01-05
ER

PT J
AU Celeghini, C
   Marchisio, M
   Mischiati, C
   Bertolaso, L
   Capitani, S
   Zauli, G
AF Celeghini, C
   Marchisio, M
   Mischiati, C
   Bertolaso, L
   Capitani, S
   Zauli, G
TI In vivo and in vitro modulatory effect of human immunodeficiency virus
   type-1 (HIV-1) Tat protein on protein kinase C activity
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE Tat; HIV-1; PKC activity; Jurkat; lipid cofactors
ID EXPRESSION; GROWTH; CELLS; SUPPRESSION; INHIBITION; MECHANISM
AB Extracellular HIV-1 Tat protein shows a pleiotropic activity on the survival/proliferation of different cell types, which may be relevant to the pathogenesis of the immune suppression as well as of the frequent neoplastic disorders observed during the course of HIV-1 disease. Therefore, we investigated the effect of recombinant Tat on the protein kinase C (PKC) activity in Jurkat CD4(+) T lymphoma cells by using a serine substituted specific PKC peptide substrate, which allowed the evaluation of the whole catalytic activity of both Ca++-dependent and Ca++-independent PKC isoforms. High concentrations of recombinant Tat (1 mu g/ml) induced an early (5 min) stimulation followed by a secondary (30-60 min) inhibition of PKC in whole Jurkat cell homogenates. Immuno-localization experiments showed that recombinant Tat protein was rapidly taken up by Jurkat cells within the first 5 min from the addition in culture, thus suggesting the possibility that the secondary inhibitory phase of Tat on PKC activity in Jurkat cells could be due to a direct interaction between the two proteins. Consistently, PKC immunoprecipitated from Jurkat cells or purified from rat brain was significantly inhibited by the addition of high (0.1-1 mu g) but not low (1-10 ng) doses of Tat in a cell-free in vitro assay. The inhibition of PKC catalytic activity mediated by 1 mu g of Tat was at least partially due to competition among substrates. The present data may help in understanding the opposite effects on the survival/proliferation of different cell types observed in the presence of picomolar (stimulation) vs nanomolar (inhibition) concentrations of recombinant Tat.
C1 UNIV FERRARA,INST HUMAN ANAT,I-40100 FERRARA,ITALY.
OI Marchisio, Marco/0000-0003-3058-3422; CAPITANI,
   Silvano/0000-0003-2795-6814; Zauli, Giorgio/0000-0002-3750-8698
CR BUONAGURO L, 1992, J VIROL, V66, P7159
   CHIRMULE N, 1995, J VIROL, V69, P492
   CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045
   DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8
   ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0
   ENSOLI B, 1993, J VIROL, V67, P277
   FLORES SC, 1993, P NATL ACAD SCI USA, V90, P7632, DOI 10.1073/pnas.90.16.7632
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   GIBELLINI D, 1994, BRIT J HAEMATOL, V88, P261, DOI 10.1111/j.1365-2141.1994.tb05016.x
   HAUBER J, 1988, J VIROL, V62, P4801
   HERNDIER BG, 1994, AIDS, V8, P1025, DOI 10.1097/00002030-199408000-00003
   HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329                                                               
   JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441
   LI CJ, 1995, SCIENCE, V268, P229
   MADORE SJ, 1993, J VIROL, V67, P3703
   MARTELLI AM, 1991, EXP CELL RES, V195, P255, DOI 10.1016/0014-4827(91)90525-Y
   MILANI D, 1993, J GEN VIROL, V74, P2587, DOI 10.1099/0022-1317-74-12-2587
   PURI RK, 1995, AIDS RES HUM RETROV, V11, P31, DOI 10.1089/aid.1995.11.31
   PURVIS SF, 1992, CELL IMMUNOL, V144, P32, DOI 10.1016/0008-8749(92)90223-C                                                    
   SCALA G, 1994, J EXP MED, V179, P961, DOI 10.1084/jem.179.3.961
   SHARMA V, 1995, BIOCHEM BIOPH RES CO, V208, P704, DOI 10.1006/bbrc.1995.1395                                                          
   SUBRAMANYAM M, 1993, J IMMUNOL, V150, P2544
   VANDENBERGHE PA, 1990, J IMMUNOL METHODS, V127, P197, DOI 10.1016/0022-1759(90)90069-8
   VELLUTINI C, 1995, AIDS RES HUM RETROV, V11, P21, DOI 10.1089/aid.1995.11.21
   VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795
   WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0
   WESTENDORP MO, 1994, J VIROL, V68, P4177
   ZAULI G, 1993, CANCER RES, V53, P4481
   ZAULI G, 1995, BLOOD, V86, P3823
   ZAULI G, 1992, BLOOD, V80, P3036
   ZAULI G, 1994, ONCOL REP, V1, P773
NR 31
TC 2
Z9 2
U1 0
U2 1
PU INT JOURNAL ONCOLOGY
PI ATHENS
PA C/O PROFESSOR D A SPANDIDOS, EDITORIAL OFFICE, 1, S MERKOURI ST, ATHENS
   116 35, GREECE
SN 1019-6439
J9 INT J ONCOL
JI Int. J. Oncol.
PD FEB
PY 1996
VL 8
IS 2
BP 349
EP 354
PG 6
WC Oncology
SC Oncology
GA TR618
UT WOS:A1996TR61800018
PM 21544367
DA 2018-01-05
ER

PT J
AU Neurath, AR
   Jiang, SB
   Strick, N
   Lin, K
   Li, YY
   Debnath, AK
AF Neurath, AR
   Jiang, SB
   Strick, N
   Lin, K
   Li, YY
   Debnath, AK
TI Bovine beta-lactoglobulin modified by 3-hydroxyphthalic anhydride blocks
   the CD4 cell receptor for HIV
SO NATURE MEDICINE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN; BINDING; INFECTION; COMPLEX;
   DOCKING
AB Sexual transmission is the most frequent (86%) route of adult HIV-1 transmission worldwide(1). In the absence of a prophylactic anti-HIV vaccine, other methods of preventing infection should be implemented. Virucidal spermicides have been considered for this purpose, but their application is contraindicated by adverse effects(2). Anti-HIV drugs(3) or virus-neutralizing monoclonal antibodies(4) are expensive, suggesting that their wide use in topical chemoprophylaxis is unlikely. This emphasizes the importance of developing other methods for preventing HIV transmission. The target cells for sexual and mucosal HIV transmission include T lymphocytes, monocytes/macrophages and dendritic cells(5). Therefore, compounds blocking HIV-CD4 binding are expected to inhibit virus transmission. In exploring the possibility that chemical modification of food proteins might lead to compounds with anti-HIV-1 activity, we found that bovine beta-lactoglobulin (P-LG) modified by 3-hydroxyphthalic anhydride (3HP-beta-LG) (1) blocked at nanomolar concentrations the binding to CD4 of human (HIV) and simian (SIV) immunodeficiency virus surface glycoproteins and monoclonal antibodies specific for the HIV binding site on CD4 and (2) inhibited infection by HIV-1, including primary virus isolates, by HIV-2 and by SIV. The inexpensive and widely available source (whey) for production of 3HP-beta-LG suggests its potential application (nonparenteral) for diminishing the frequency of HIV transmission.
RP Neurath, AR (reprint author), NEW YORK BLOOD CTR,LINDSLEY F KIMBALL RES INST,LAB BIOCHEM VIROL,NEW YORK,NY 10021, USA.
RI Jiang, Shibo/L-4500-2014
FU NIAID NIH HHS [AI 29373]; NCI NIH HHS [CA 43315]
CR ALLAWAY GP, 1995, AIDS RES HUM RETROV, V11, P533, DOI 10.1089/aid.1995.11.533
   BIRD KD, 1991, AIDS, V5, P791, DOI 10.1097/00002030-199107000-00001                                                
   DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574                                                         
   FORTHAL DN, 1995, AIDS RES HUM RETROV, V11, P1095, DOI 10.1089/aid.1995.11.1095                                                        
   GARRETT TPJ, 1993, J MOL BIOL, V234, P763, DOI 10.1006/jmbi.1993.1625
   Gartner S, 1990, TECHNIQUES HIV RES, P53
   GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302                                                          
   HEALEY D, 1990, J EXP MED, V172, P1233, DOI 10.1084/jem.172.4.1233
   JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0                                                                
   KIMPTON J, 1992, J VIROL, V66, P2232
   KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399
   Mann Jonathan, 1992, AIDS WORLD
   Miller C. J., 1992, Laboratory Investigation, V68, P129
   MONACO HL, 1987, J MOL BIOL, V197, P695, DOI 10.1016/0022-2836(87)90476-1
   MORR CV, 1993, CRIT REV FOOD SCI, V33, P431, DOI 10.1080/10408399309527643                                                       
   MULLER R, 1983, METHOD ENZYMOL, V92, P589
   NEURATH AR, 1992, ANTIVIR CHEM CHEMOTH, V3, P55, DOI 10.1177/095632029200300108                                                      
   NEURATH AR, 1992, J EXP MED, V175, P461, DOI 10.1084/jem.175.2.461
   SATO H, 1992, VIROLOGY, V186, P712, DOI 10.1016/0042-6822(92)90038-Q                                                    
   SATTENTAU QJ, 1988, AIDS, V2, P101, DOI 10.1097/00002030-198804000-00005                                                
   SATTENTAU QJ, 1989, J EXP MED, V170, P1319, DOI 10.1084/jem.170.4.1319
   STEELE F, 1995, NAT MED, V1, P285, DOI 10.1038/nm0495-285                                                              
   STODDARD BL, 1992, NATURE, V358, P774, DOI 10.1038/358774a0
NR 23
TC 65
Z9 68
U1 0
U2 3
PU NATURE PUBLISHING CO
PI NEW YORK
PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707
SN 1078-8956
J9 NAT MED
JI Nat. Med.
PD FEB
PY 1996
VL 2
IS 2
BP 230
EP 234
DI 10.1038/nm0296-230                                                      
          
PG 5
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA TU060
UT WOS:A1996TU06000045
PM 8574970
DA 2018-01-05
ER

PT J
AU Putnam, DA
AF Putnam, DA
TI Antisense strategies and therapeutic applications
SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
LA English
DT Article
DE allergies; arthritis; gene therapy; genetic engineering; hepatitis B
   infections; Herpes simplex infections; HIV infections; neoplasms;
   oligonucleotides; papillomavirus infections; restenosis
ID HUMAN-IMMUNODEFICIENCY-VIRUS; MUSCLE CELL-PROLIFERATION; RNA INHIBITS
   PROLIFERATION; HEPATITIS-B VIRUS; MYC MESSENGER-RNA; GENE-EXPRESSION;
   CULTURED-CELLS; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; OLIGOMER
   COMPLEMENTARY; OLIGODEOXYNUCLEOTIDES
AB The concepts underlying the antisense approach to disease therapy are discussed, and potential applications are examined.
   Antisense therapeutic agents bind to DNA or RNA sequences, blocking the synthesis of cellular proteins with unparalleled specificity. Transcription and translation are the two processes with which the agents interfere. There are three major classes of antisense agents: antisense sequences, commonly called antisense oligonucleotides; antigene sequences; and ribozymes. Antisense sequences are derivatives of nucleic acids that hybridize cytosolic messenger RNA (mRNA) sense strands through hydrogen bonding to complementary nucleic acid bases.
   Antigene sequences hybridize double-stranded DNA in the nucleus, forming triple helixes. Ribozymes, rather than inhibiting protein synthesis simply by binding to a single targeted mRNA, combine enzymatic processes with the specificity of antisense base pairing, creating a molecule that can incapacitate multiple targeted mRNAs. Antisense therapeutic agents are being investigated in vitro and in vivo for use in treating human immunodeficiency virus infection, hepatitis B virus infection, herpes simplex virus infection, papillomavirus infection, cancer, restenosis, rheumatoid arthritis, and allergic disorders. Although many results are preliminary, some are promising and have led to clinical trials. A major goal in developing methods of delivering antisense agents is to reduce their susceptibility to nucleases while retaining their ability to bind to targeted sites. Modification of the phosphodiester linkages in oligonucleotides can lend the sequences enzymatic stability without affecting their binding capacities. Carrier systems designed to protect the antisense structure and improve passage through the cell membrane include liposomes, water-soluble polymers, and nanoparticles. The pharmacokinetics of antisense agents are under investigation.
   Antisense therapeutic agents have the potential to become an integral part of medicinal regimens.
RP Putnam, DA (reprint author), UNIV UTAH,COLL PHARM,CTR CONTROLLED CHEM DELIVERY,DEPT PHARMACEUT & PHARMACEUT CHEM,SALT LAKE CITY,UT 84112, USA.
OI Putnam, David/0000-0002-0794-4915
FU NIGMS NIH HHS [GM08393]
CR AGRAWAL S, 1988, P NATL ACAD SCI USA, V85, P7079, DOI 10.1073/pnas.85.19.7079
   AGRAWAL S, 1995, CLIN PHARMACOKINET, V28, P7, DOI 10.2165/00003088-199528010-00002                                                
   AKHTAR S, 1991, LIFE SCI, V49, P1793, DOI 10.1016/0024-3205(91)90480-Y
   ALLEN TM, 1991, BIOCHIM BIOPHYS ACTA, V1066, P29, DOI 10.1016/0005-2736(91)90246-5
   ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379                                                          
   BAUM R, 1994, CHEM ENG NEWS, V18, P21
   Bayever E, 1993, Antisense Res Dev, V3, P383
   BENNETT MR, 1994, J CLIN INVEST, V93, P820, DOI 10.1172/JCI117036
   BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654
   CALABRETTA B, 1991, CANCER RES, V51, P4505
   CALABRETTA B, 1991, P NATL ACAD SCI USA, V88, P2351, DOI 10.1073/pnas.88.6.2351
   CARTER G, 1993, BRIT J CANCER, V67, P869, DOI 10.1038/bjc.1993.164                                                            
   Chang PS, 1990, CLIN BIOTECHNOL, V2, P23
   CHEM TL, 1990, DRUG METAB DISPOS, V18, P815
   CLARENC JP, 1993, ANTI-CANCER DRUG DES, V8, P81
   COHEN JS, 1991, PHARMACOL THERAPEUT, V52, P221
   COWSERT LM, 1993, ANTIMICROB AGENTS CH, V37, P171, DOI 10.1128/AAC.37.2.171                                                            
   EDE NJ, 1994, BIOCONJUGATE CHEM, V5, P373, DOI 10.1021/bc00028a016
   EPSTEIN SE, 1994, J AM COLL CARDIOL, V23, P1278, DOI 10.1016/0735-1097(94)90368-9                                                    
   GEISER T, 1990, ANN NY ACAD SCI, V616, P173
   GENTRY C, 1994, THESIS U UTAH
   GEWIRTZ AM, 1994, BONE MARROW TRANSPL, V14, pS57
   GOODCHILD J, 1991, ARCH BIOCHEM BIOPHYS, V284, P386, DOI 10.1016/0003-9861(91)90313-8
   HALL TJ, 1992, IMMUNOLOGY, V77, P462
   HAMPEL A, 1990, NUCLEIC ACIDS RES, V18, P299, DOI 10.1093/nar/18.2.299
   HANVEY JC, 1990, NUCLEIC ACIDS RES, V18, P157, DOI 10.1093/nar/18.1.157
   HELENE C, 1991, ANTI-CANCER DRUG DES, V6, P569
   HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963                                                             
   Iversen P L, 1992, Antisense Res Dev, V2, P211
   JAROSZEWSKI JW, 1991, ADV DRUG DELIVER REV, V6, P235, DOI 10.1016/0169-409X(91)90019-9
   KARIKO K, 1994, FEBS LETT, V352, P41, DOI 10.1016/0014-5793(94)00914-7
   KIMURA S, 1995, CANCER RES, V55, P1379
   KLIBANOV AL, 1990, FEBS LETT, V268, P235, DOI 10.1016/0014-5793(90)81016-H
   KOPECEK J, 1990, J CONTROL RELEASE, V11, P279, DOI 10.1016/0168-3659(90)90140-O                                                    
   KULKA M, 1989, P NATL ACAD SCI USA, V86, P6868, DOI 10.1073/pnas.86.18.6868
   Leonetti JP, 1990, BIOCONJUGATE CHEM, V1, P149, DOI 10.1021/bc00002a010
   LIEBHABER SA, 1984, J BIOL CHEM, V259, P5597
   LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474
   LUGER SM, 1994, BLOOD S1, V84, P151
   MATSUKURA M, 1989, P NATL ACAD SCI USA, V86, P4244, DOI 10.1073/pnas.86.11.4244
   MATSUKURA M, 1987, P NATL ACAD SCI USA, V84, P7706, DOI 10.1073/pnas.84.21.7706
   MCMANAWAY ME, 1990, LANCET, V335, P808, DOI 10.1016/0140-6736(90)90934-W
   MORISHITA R, 1994, J CLIN INVEST, V93, P1458, DOI 10.1172/JCI117123
   NECKERS L, 1993, AM J PHYSIOL, V265, pL1
   NIETFELD JJ, 1990, ARTHRITIS RHEUM, V33, P1695, DOI 10.1002/art.1780331113                                                          
   NIETFELD JJ, 1994, ARTHRITIS RHEUM, V37, P1357, DOI 10.1002/art.1780370914
   OFFENSPERGER WB, 1993, EMBO J, V12, P1257
   PAGANO JS, 1992, ANN NY ACAD SCI, V660, P107, DOI 10.1111/j.1749-6632.1992.tb21063.x
   PERILLO RP, 1990, NEW ENGL J MED, V323, P295
   PICKERING G, 1992, J AM COLL CARDIOL, V19, P165
   Putnam D, 1995, ADV POLYM SCI, V122, P55
   ROSOLEN A, 1990, CANCER RES, V50, P6316
   ROSSI JJ, 1991, PHARMACOL THERAPEUT, V50, P245, DOI 10.1016/0163-7258(91)90016-F
   ROSSI JJ, 1992, AIDS RES HUM RETROV, V8, P183, DOI 10.1089/aid.1992.8.183
   RYSER HJP, 1978, P NATL ACAD SCI USA, V75, P3867, DOI 10.1073/pnas.75.8.3867                                                          
   SARIN PS, 1988, P NATL ACAD SCI USA, V85, P7448, DOI 10.1073/pnas.85.20.7448
   SAXENA SK, 1990, J BIOL CHEM, V265, P17106
   SCHWAB G, 1994, P NATL ACAD SCI USA, V91, P10460, DOI 10.1073/pnas.91.22.10460                                                        
   SCHWARTZ RS, 1992, J AM COLL CARDIOL, V20, P1284, DOI 10.1016/0735-1097(92)90389-5                                                    
   SHI Y, 1993, CIRCULATION, V88, P1190
   SIMONS M, 1992, CIRC RES, V70, P835
   SPEIR E, 1992, CIRCULATION, V86, P538
   STEIN CA, 1991, PHARMACOL THERAPEUT, V52, P365, DOI 10.1016/0163-7258(91)90032-H                                                    
   TARI AM, 1994, BLOOD, V84, P601
   Taylor N R, 1991, Antisense Res Dev, V1, P173
   TIDD DM, 1990, ANTICANCER RES, V10, P1169
   TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0
   UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0
   UHLMANN E, 1990, CHEM REV, V90, P543, DOI 10.1021/cr00102a001                                                             
   WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856
   WALDER RY, 1988, P NATL ACAD SCI USA, V85, P5011, DOI 10.1073/pnas.85.14.5011                                                         
   WHITESELL L, 1991, MOL CELL BIOL, V11, P1360, DOI 10.1128/MCB.11.3.1360                                                           
   WICKSTROM E, 1986, J BIOCHEM BIOPH METH, V13, P97, DOI 10.1016/0165-022X(86)90021-7
   WU GY, 1992, J BIOL CHEM, V267, P12436
   ZAMECNIK PC, 1986, P NATL ACAD SCI USA, V83, P4143, DOI 10.1073/pnas.83.12.4143
   ZON G, 1990, ANN NY ACAD SCI, V616, P161
NR 76
TC 32
Z9 34
U1 0
U2 4
PU AMER SOC HEALTH-SYSTEM PHARMACISTS
PI BETHESDA
PA 7272 WISCONSIN AVE, BETHESDA, MD 20814
SN 1079-2082
J9 AM J HEALTH-SYST PH
JI Am. J. Health-Syst. Pharm.
PD JAN 15
PY 1996
VL 53
IS 2
BP 151
EP 160
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA TQ252
UT WOS:A1996TQ25200005
PM 8653480
DA 2018-01-05
ER

PT S
AU Leroux, JC
   Cozens, R
   Roesel, JL
   Galli, B
   Doelker, E
   Gurny, R
AF Leroux, JC
   Cozens, R
   Roesel, JL
   Galli, B
   Doelker, E
   Gurny, R
GP CONTROLLED RELEASE SOC
TI pH-sensitive nanoparticles: A new vehicle to improve the oral delivery
   of HIV-1 protease inhibitors
SO 23RD INTERNATIONAL SYMPOSIUM ON CONTROLLED RELEASE OF BIOACTIVE
   MATERIALS, 1996 PROCEEDINGS
SE CONTROLLED RELEASE SOCIETY. INTERNATIONAL SYMPOSIUM ON CONTROLLED
   RELEASE OF BIOACTIVE MATERIALS
LA English
DT Proceedings Paper
CT 23rd International Symposium on Controlled Release of Bioactive
   Materials
CY JUL 07-10, 1996
CL KYOTO, JAPAN
SP Controlled Release Soc Inc, Japan Soc Drug Delivery Syst
RP Leroux, JC (reprint author), UNIV GENEVA,SCH PHARM,CH-1211 GENEVA 4,SWITZERLAND.
RI Leroux, Jean-Christophe/N-4202-2015
OI Leroux, Jean-Christophe/0000-0001-5601-1292
NR 0
TC 0
Z9 0
U1 0
U2 0
PU CONTROLLED RELEASE SOCIETY INC
PI DEERFIELD
PA 1020 MILWAUKEE AVE SUITE 235, DEERFIELD, IL 60015
SN 1022-0178
J9 CRS BUI NAT
PY 1996
BP 141
EP 142
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA BH42C
UT WOS:A1996BH42C00073
DA 2018-01-05
ER

PT J
AU Rusconi, S
   Moonis, M
   Merrill, DP
   Pallai, PV
   Neidhardt, EA
   Singh, SK
   Willis, KJ
   Osburne, MS
   Profy, AT
   Jenson, JC
   Hirsch, MS
AF Rusconi, S
   Moonis, M
   Merrill, DP
   Pallai, PV
   Neidhardt, EA
   Singh, SK
   Willis, KJ
   Osburne, MS
   Profy, AT
   Jenson, JC
   Hirsch, MS
TI Naphthalene sulfonate polymers with CD4-blocking and anti-human
   immunodeficiency virus type 1 activities
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID MOLECULAR-WEIGHT; DEXTRAN SULFATE; HIV ACTIVITIES; HTLV-III; AIDS;
   INHIBITORS; RETROVIRUS; INFECTION; RECEPTOR; BINDING
AB PIC 024-4 and PRO 2000 are naphthalene sulfonate polymers that bind to CD4 with nanomolar affinity and block binding of gp120. Both have activity against human immunodeficiency virus type 1 in 1-19 cells, peripheral blood mononuclear cells, and primary monocyte/macrophages, are synergistic with zidovudine, and do not inhibit tetanus toxoid-stimulated T-cell proliferation at anti-human immunodeficiency virus type 1 concentrations.
C1 MASSACHUSETTS GEN HOSP,INFECT DIS UNIT,BOSTON,MA 02114.
   HARVARD UNIV,SCH MED,BOSTON,MA 02114.
   PROCEPT INC,CAMBRIDGE,MA 02139.
RI Rusconi, Stefano/H-9263-2012
OI Rusconi, Stefano/0000-0002-0375-9990
FU FIC NIH HHS [D42 TW00004]
CR ARULANANDAM ARN, 1993, J EXP MED, V177, P1439, DOI 10.1084/jem.177.5.1439
   CALLAHAN LN, 1991, J VIROL, V65, P1543
   CHOU JH, 1989, DOSE EFFECT ANAL MIC
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4                                                    
   CHOU TC, 1991, SYNERGISM ANTAGONISM, P61
   CONNOR RI, 1993, AIDS RES HUM RETROV, V9, P541, DOI 10.1089/aid.1993.9.541
   CUSHMAN M, 1991, J MED CHEM, V34, P329, DOI 10.1021/jm00105a052
   CUSHMAN M, 1991, J MED CHEM, V34, P337, DOI 10.1021/jm00105a053
   DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0
   DECLERCQ F, 1995, CLIN MICROBIOL REV, V8, P200
   FLEXNER C, 1991, ANTIMICROB AGENTS CH, V35, P2544, DOI 10.1128/AAC.35.12.2544                                                          
   GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648
   JOHNSON VA, 1991, J INFECT DIS, V164, P646, DOI 10.1093/infdis/164.4.646                                                        
   JOHNSTON VA, 1990, TECHNIQUES HIV RES, P95
   KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0
   LEDERMAN S, 1992, AIDS RES HUM RETROV, V8, P1599, DOI 10.1089/aid.1992.8.1599
   MEYLAN PRA, 1994, ANTIMICROB AGENTS CH, V38, P2910, DOI 10.1128/AAC.38.12.2910                                                          
   MOHAN P, 1992, ANTIVIR RES, V18, P139, DOI 10.1016/0166-3542(92)90034-3
   MOHAN P, 1991, J MED CHEM, V34, P212, DOI 10.1021/jm00105a033
   POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935
   WARD LD, 1985, METHOD ENZYMOL, V117, P400
NR 21
TC 121
Z9 127
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JAN
PY 1996
VL 40
IS 1
BP 234
EP 236
PG 3
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA TN213
UT WOS:A1996TN21300046
PM 8787913
DA 2018-01-05
ER

PT J
AU Swart, PJ
   Beljaars, E
   Smit, C
   Pasma, A
   Schuitemaker, H
   Meijer, DKF
AF Swart, PJ
   Beljaars, E
   Smit, C
   Pasma, A
   Schuitemaker, H
   Meijer, DKF
TI Comparative pharmacokinetic, immunologic and hematologic studies on the
   anti-HIV-1/2 compounds aconitylated and succinylated HSA
SO JOURNAL OF DRUG TARGETING
LA English
DT Article
DE pharmacokinetics; Suc-HSA; Aco-HSA; AIDS; HIV; polyanions; toxicity;
   immunogenicity
ID HUMAN SERUM ALBUMINS; MONOCLONAL-ANTIBODIES; RECEPTORS; POTENT
AB Charge modification by succinylation or cis-aconitylation of the terminal epsilon NH2 functions of the amino acid lysine in human serum albumin, resulted in polyanionic compounds with an anti-HIV-1 activity in the low nanomolar concentration range. After iv injections in rats of the negatively charged albumins (NCAs), a dose dependent elimination pattern was observed indicating a saturable eliminations pathway. The Michaelis-Menten parameters V-max and K-m were 62 +/- 8 mu g.min(-1).k(-1) and 16 +/- 4 mu g.ml(-1) (Cl-intr 3.9 +/- 1.1 ml.min(-1).kg(-1)) and 74 +/- 6 mu g.min(-1).kg(-1) and 11 +/- 2 mu g.ml(-1) (Cl-intr 6.7 +/- 1.2 ml.min(-1).kg(-1)) for aconitylated-HSA (Aco-HSA) and succinylated-HSA (Suc-HSA) respectively, using I-125-labelled proteins. The volume of distribution (V) of both compounds was approximately 60 ml.kg(-1). Coadministration of poly-inosinic acid and formaldehyde treated albumin showed a marked inhibition of blood clearance indicating that the compounds are mainly cleared from the bloodstream by scavenger receptors on liver and spleen endothelial cells and macrophages.
   The Michaelis-Menten constant K-m was remarkably higher when the hydrophobic fluorophore fluorescein was covalently linked to the protein, indicating that the affinity for the scavenger receptors is largely decreased by FiTC conjugation. The latter observation may have implications for the kinetic behavior of drug-carrier preparations if antiviral drugs like AZT or PMEA are linked to these intrinsic active carriers.
   In contrast to other polyanionic compounds like heparins and dextran sulfate, these NCAs did not exhibit acute toxicity and had no effect on blood coagulation. They neither had an effect on the lymphocyte proliferation. Studies on immunogenicity of the homologous derivatized albumins in rats did not show a significant response.
   The present pharmacokinetic and toxicologic data of Suc-HSA and Aco-HSA show that both compounds are interesting preparations for studies in SIV infected monkeys and AIDS patients.
C1 NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,DEPT CLIN VIROIMMUNOL,NL-1066 CX AMSTERDAM,NETHERLANDS.
   UNIV AMSTERDAM,CLIN & EXPT IMMUNOL LAB,NL-1066 CX AMSTERDAM,NETHERLANDS.
RP Swart, PJ (reprint author), UNIV GRONINGEN,CTR PHARM,GRONINGEN INST DRUG STUDIES,SECT PHARMACOKINET & DRUG DELIVERY,NL-9713 AW GRONINGEN,NETHERLANDS.
CR ABRAHAM R, 1995, J IMMUNOL, V154, P1
   ALLEN T M, 1988, Advanced Drug Delivery Reviews, V2, P55, DOI 10.1016/0169-409X(88)90005-1
   GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114                                                               
   GROENINK M, 1996, UNPUB AIDS RES HUMAN
   HARMS G, 1990, CELL TISSUE RES, V262, P35, DOI 10.1007/BF00327742
   JANSEN RW, 1993, PHARM RES-DORDR, V10, P1611, DOI 10.1023/A:1018972603494
   JANSEN RW, 1991, MOL PHARMACOL, V39, P818
   JANSEN RW, 1993, MOL PHARMACOL, V44, P1003
   JOBBAGY A, 1966, BIOCHIM BIOPHYS ACTA, V124, P166
   KUIPERS ME, 1996, IN PRESS J ACQ IMMUN
   MAEDA H, 1969, J BIOCHEM-TOKYO, V65, P777, DOI 10.1093/oxfordjournals.jbchem.a129077                                           
   PROOST JH, 1992, COMPUT BIOL MED, V22, P155, DOI 10.1016/0010-4825(92)90011-B
   SWART PJ, 1996, UNPUB AIDS RES HUMAN
   TAKAKURA Y, 1992, LYMPHATIC TRANSPORT, P255
   VANLIER RAW, 1989, IMMUNOLOGY, V68, P45
   VANLIER RAW, 1987, J IMMUNOL, V139, P2873
NR 16
TC 19
Z9 19
U1 0
U2 0
PU HARWOOD ACAD PUBL GMBH
PI READING
PA C/O STBS LTD, PO BOX 90, READING, BERKS, ENGLAND RG1 8JL
SN 1061-186X
J9 J DRUG TARGET
JI J. Drug Target.
PY 1996
VL 4
IS 2
BP 109
EP &
DI 10.3109/10611869609046269                                               
          
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA VP912
UT WOS:A1996VP91200007
PM 8894971
DA 2018-01-05
ER

PT J
AU BUCKHEIT, RW
   KINJERSKI, TL
   FLIAKASBOLTZ, V
   RUSSELL, JD
   STUP, TL
   PALLANSCH, LA
   BROUWER, WG
   DAO, DC
   HARRISON, WA
   SCHULTZ, RJ
   BADER, JP
   YANG, SS
AF BUCKHEIT, RW
   KINJERSKI, TL
   FLIAKASBOLTZ, V
   RUSSELL, JD
   STUP, TL
   PALLANSCH, LA
   BROUWER, WG
   DAO, DC
   HARRISON, WA
   SCHULTZ, RJ
   BADER, JP
   YANG, SS
TI STRUCTURE-ACTIVITY AND CROSS-RESISTANCE EVALUATIONS OF A SERIES OF
   HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1-SPECIFIC COMPOUNDS RELATED TO
   OXATHIIN CARBOXANILIDE
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID HIV-1 REVERSE-TRANSCRIPTASE; NONNUCLEOSIDE INHIBITORS; ANTIVIRAL
   ACTIVITY; TIBO DERIVATIVES; HIV-1-SPECIFIC INHIBITORS; ANGSTROM
   RESOLUTION; CRYSTAL-STRUCTURE; NATURAL-PRODUCTS; VIRAL RESISTANCE;
   BINDING-SITE
AB A series of compounds related to the nonnucleoside reverse transcriptase (RT) inhibitor (NNRTI) oxathiin carboxanilide (UC84) were evaluated for activity against the human immunodeficiency virus (HIV) to determine structural requirements for anti-HN activity, Twenty-seven compounds representative of the more than 400 Uniroyal Chemical Company (UC) compounds were evaluated for structure-activity relationships. Several of the compounds evaluated were highly active, with 50% effective concentrations in the nanomolar range and therapeutic indices of > 1,000. Highly synergistic anti-HIV activity was observed for each compound when used in combination with 3'-azido-3'-deoxythymidine; additive to slightly synergistic interactions were observed with the compounds used in combination with dideoxycytidine. In combination with the NNRTI costatolide, only UC38 synergistically inhibited HIV type 1. Residues in the RT which, when mutated, impart resistance to the carboxanilide compounds were defined by evaluation of the UC compounds against a panel of NNRTI-resistant virus isolates selected in cell culture, against virus variants with site-directed mutations, and against RTs containing defined single amino acid changes. The mutations included changes in RT amino acids 100, 101, 103, 106, 108, and 181. The results with isolates selected in cell culture indicate that the carboxanilide compounds interact with the RT at two vulnerable sites, selecting UC resistant virus isolates,vith the Y-to-C mutation at position 181 (Y181C) or the L100I substitution. A resistant virus isolate containing both Y181C and K101E amino acid changes and another with both Y181C and V106A mutations were isolated. In combination with calanolide A, an NNRTI which retains activity against virus isolates with the single Y181C mutation, UC10 rapidly selected a virus isolate,vith the K103N mutation. The merits of selecting potential candidate anti-HIV agents to be used in rational combination drug design as part of an armamentarium of highly active anti-HIV compounds are discussed.
C1 UNIROYAL CHEM CO LTD,GUELPH,ON,CANADA.
   NCI,ANTIVIRAL EVALUAT BRANCH,BETHESDA,MD 20892.
   NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,BETHESDA,MD 20892.
   NCI,ANTIVIRAL EVALUAT BRANCH,BETHESDA,MD 20892.
RP BUCKHEIT, RW (reprint author), FREDERICK RES CTR,SO RES INST,VIROL RES GRP,431 AVIAT WAY,FREDERICK,MD 21701, USA.
FU NCI NIH HHS [N01-CM-37818]
CR BADER JP, 1991, P NATL ACAD SCI USA, V88, P6740, DOI 10.1073/pnas.88.15.6740                                                         
   BALZARINI J, 1993, J VIROL, V67, P5353
   BALZARINI J, 1995, P NATL ACAD SCI USA, V92, P5470, DOI 10.1073/pnas.92.12.5470
   BALZARINI J, 1993, VIROLOGY, V196, P576, DOI 10.1006/viro.1993.1513
   BALZARINI J, 1993, MOL PHARMACOL, V44, P694
   BALZARINI J, 1995, ANTIVIR CHEM CHEMOTH, V6, P169, DOI 10.1177/095632029500600306                                                      
   BOYD MR, 1988, AIDS ETIOLOGY DIAGNO, P305
   BOYER PL, 1993, J VIROL, V67, P2412
   BUCKHEIT RW, 1993, AIDS RES HUM RETROV, V9, P1097, DOI 10.1089/aid.1993.9.1097
   BUCKHEIT RW, 1995, ANTIVIR RES, V26, P117, DOI 10.1016/0166-3542(94)00069-K
   BUCKHEIT RW, 1992, P NATL ACAD SCI USA, V89, P8361, DOI 10.1073/pnas.89.17.8361                                                         
   BUCKHEIT RW, 1994, ANTIVIR RES, V25, P43, DOI 10.1016/0166-3542(94)90092-2
   BUCKHEIT RW, 1994, ANTIVIR CHEM CHEMOTH, V5, P35, DOI 10.1177/095632029400500105                                                      
   BUCKHEIT RW, 1995, 4TH WORKSH VIR RES, P72
   BYRNES VW, 1993, ANTIMICROB AGENTS CH, V37, P1576, DOI 10.1128/AAC.37.8.1576                                                           
   BYRNES VW, 1994, ANTIMICROB AGENTS CH, V38, P1404, DOI 10.1128/AAC.38.6.1404                                                           
   COHEN KA, 1991, J BIOL CHEM, V266, P14670
   CONDRA JH, 1992, ANTIMICROB AGENTS CH, V36, P1441, DOI 10.1128/AAC.36.7.1441                                                           
   CURRENS MJ, UNPUB KINETIC ANAL I
   DEVREESE K, 1992, VIROLOGY, V188, P900, DOI 10.1016/0042-6822(92)90550-9
   FLETCHER RS, 1995, BIOCHEMISTRY-US, V34, P4346, DOI 10.1021/bi00013a025
   FLETCHER RS, 1995, BIOCHEMISTRY-US, V34, P10106, DOI 10.1021/bi00032a002
   GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863
   GROB PM, 1992, AIDS RES HUM RETROV, V8, P145, DOI 10.1089/aid.1992.8.145
   HARRISON WA, 1991, CHEM ABSTR, V115, P904
   JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320                                                         
   KASHMAN Y, 1992, J MED CHEM, V35, P2735, DOI 10.1021/jm00093a004
   KLUNDER JM, 1992, J MED CHEM, V35, P1887, DOI 10.1021/jm00088a027                                                             
   KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403
   LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803
   MAASS G, 1993, ANTIMICROB AGENTS CH, V37, P2612, DOI 10.1128/AAC.37.12.2612                                                          
   MCMAHON JB, 1993, ANTIMICROB AGENTS CH, V37, P754, DOI 10.1128/AAC.37.4.754                                                            
   MCMAHON JB, UNPUB BIOL BIOCH ANT
   MELLORS JW, 1992, MOL PHARMACOL, V41, P446
   Mellors J., 1995, INT ANTIVIRAL NEWS, V3, P8
   MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568                                                         
   NUNBERG JH, 1991, J VIROL, V65, P4887
   PATTABIRAMAN N, 1995, BIANNUAL M AM CHEM S
   PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0
   PRICHARD MN, 1990, ANTIVIR RES, V14, P181, DOI 10.1016/0166-3542(90)90001-N                                                    
   RICHMAN D, 1991, ANTIMICROB AGENTS CH, V35, P305, DOI 10.1128/AAC.35.2.305                                                            
   RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241
   RICHMAN DD, 1994, J VIROL, V68, P1660
   RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402
   ROMERO DL, 1991, P NATL ACAD SCI USA, V88, P8806, DOI 10.1073/pnas.88.19.8806                                                         
   SAAG MS, 1993, NEW ENGL J MED, V329, P1065, DOI 10.1056/NEJM199310073291502
   SMERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911, DOI 10.1073/pnas.91.9.3911
   STCLAIR MH, 1991, SCIENCE, V245, P1557
   STRAIR RK, 1993, NUCLEIC ACIDS RES, V21, P4836, DOI 10.1093/nar/21.20.4836
   TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665                                                          
   WEISLOW OS, 1989, J NATL CANCER I, V81, P577, DOI 10.1093/jnci/81.8.577
   WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003
   YANG SS, 1995, LEUKEMIA, V9, P75
   YARCHOAN R, 1988, LANCET, V1, P76
NR 54
TC 71
Z9 71
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD DEC
PY 1995
VL 39
IS 12
BP 2718
EP 2727
DI 10.1128/AAC.39.12.2718                                                  
          
PG 10
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA TH293
UT WOS:A1995TH29300024
PM 8593008
OA gold
DA 2018-01-05
ER

PT J
AU LEROUX, JC
   COZENS, R
   ROESEL, JL
   GALLI, B
   KUBEL, F
   DOELKER, E
   GURNY, R
AF LEROUX, JC
   COZENS, R
   ROESEL, JL
   GALLI, B
   KUBEL, F
   DOELKER, E
   GURNY, R
TI PHARMACOKINETICS OF A NOVEL HIV-1 PROTEASE INHIBITOR INCORPORATED INTO
   BIODEGRADABLE OR ENTERIC NANOPARTICLES FOLLOWING INTRAVENOUS AND
   ORAL-ADMINISTRATION TO MICE
SO JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
ID VIRUS TYPE-1 PROTEASE; SALTING-OUT PROCESS; DRUG; NANOCAPSULES;
   ABSORPTION
AB CGP 57813 is a peptidomimetic inhibitor of human immunodeficiency virus type 1 (HIV-1) protease. This lipophilic compound was successfully entrapped into poly(D,L-lactic acid) (PLA) and pH sensitive methacrylic acid copolymers nanoparticles. The intravenous administration to mice of PLA nanoparticles loaded with CGP 57813 resulted in a 2-fold increase of the area under the plasma concentration-time curve, compared to a control solution. An increase in the elimination half-life (from 13 to 61 min) and in the apparent volume of distribution (1.7-3.6 L/kg) was observed for the nanoparticle incorporated compound vs control solution. Following oral administration, only nanoparticles made of the methacrylic acid copolymer soluble at low pH provided sufficient plasma levels of CGP 57813. in vitro, these nanoparticles dissolved completely within 5 min at pH 5.8. PLA nanoparticles, which are insoluble in the gastrointestinal tract, did not provide significant plasma concentrations of CGP 57813. From these observations, one can conclude that the passage of intact PLA nanoparticles across the gastrointestinal mucosa appears to be very low.
C1 UNIV GENEVA,SCH PHARM,CH-1211 GENEVA 4,SWITZERLAND.
   UNIV GENEVA,APPL CHEM LAB,CH-1211 GENEVA 4,SWITZERLAND.
   CIBA GEIGY AG,DIV PHARMACEUT,CH-4002 BASEL,SWITZERLAND.
RI Leroux, Jean-Christophe/N-4202-2015
OI Leroux, Jean-Christophe/0000-0001-5601-1292
CR ALLEMANN E, 1994, J CONTROL RELEASE, V29, P97, DOI 10.1016/0168-3659(94)90125-2                                                    
   ALLEMANN E, 1993, EUR J PHARM BIOPHARM, V39, P173
   ALLEMANN E, 1993, EUR J PHARM BIOPHARM, V39, P13
   ALLEMANN E, 1992, INT J PHARM, V87, P247, DOI 10.1016/0378-5173(92)90249-2                                                    
   ALTERI E, 1993, ANTIMICROB AGENTS CH, V37, P2087, DOI 10.1128/AAC.37.10.2087                                                          
   AMMOURY N, 1991, PHARMACEUT RES, V8, P101, DOI 10.1023/A:1015846810474
   BECK PH, 1994, EUR J PHARM BIOPHARM, V40, P134
   BENDER A, 1995, 1ST P WORLD M APGI A, V1, P529
   BETEN DB, 1994, INT J PHARMACEUT, V103, P243, DOI 10.1016/0378-5173(94)90174-0
   BUGELSKI PJ, 1994, J LEUKOCYTE BIOL, V56, P374
   COUVREUR P, 1992, J CONTROL RELEASE, V19, P259, DOI 10.1016/0168-3659(92)90081-2
   DAMGE C, 1990, J CONTROL RELEASE, V13, P233, DOI 10.1016/0168-3659(90)90013-J                                                    
   DAMGE C, 1987, INT J PHARM, V36, P121, DOI 10.1016/0378-5173(87)90146-3                                                    
   JENKINS PG, 1994, J CONTROL RELEASE, V29, P339, DOI 10.1016/0168-3659(94)90079-5                                                    
   KEMPF DJ, 1991, ANTIMICROB AGENTS CH, V35, P2209, DOI 10.1128/AAC.35.11.2209                                                          
   KONDO N, 1994, J PHARM SCI, V83, P566, DOI 10.1002/jps.2600830425
   KRAMER RA, 1986, SCIENCE, V231, P1580, DOI 10.1126/science.2420008
   LANG M, 1993, ARCH PHARM, V326, P921, DOI 10.1002/ardp.19933261202                                                        
   LERAY AM, 1994, INT J PHARM, V106, P201, DOI 10.1016/0378-5173(94)90003-5
   LEROUX JC, 1994, J BIOMED MATER RES, V28, P471, DOI 10.1002/jbm.820280410
   LEROUX JC, 1995, EUR J PHARM BIOPHARM, V41, P14
   LUSSO P, 1992, J PHARM PHARMACOL, V44, P160
   MAINCENT P, 1986, J PHARM SCI, V75, P955, DOI 10.1002/jps.2600751009
   MONTAGUTI P, 1994, ARZNEIMITTEL-FORSCH, V44-1, P566
   ROLLAND A, 1988, INT J PHARM, V42, P145, DOI 10.1016/0378-5173(88)90170-6                                                    
   SCHAFER V, 1992, PHARMACEUT RES, V9, P541, DOI 10.1023/A:1015852732512
NR 26
TC 55
Z9 58
U1 1
U2 6
PU AMER PHARMACEUTICAL ASSN
PI WASHINGTON
PA 2215 CONSTITUTION AVE NW, WASHINGTON, DC 20037
SN 0022-3549
J9 J PHARM SCI
JI J. Pharm. Sci.
PD DEC
PY 1995
VL 84
IS 12
BP 1387
EP 1391
DI 10.1002/jps.2600841202
PG 5
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA TJ653
UT WOS:A1995TJ65300001
PM 8748318
DA 2018-01-05
ER

PT J
AU DeClercq, E
   Balzarini, J
AF DeClercq, E
   Balzarini, J
TI Knocking out human immunodeficiency virus through non-nucleoside reverse
   transcriptase inhibitors used, as single agents or in combinations: A
   paradigm for the cure of aids?
SO FARMACO
LA English
DT Article
ID NONNUCLEOSIDE INHIBITORS; HIV-1-SPECIFIC INHIBITORS; POTENT INHIBITOR;
   HIV-1 INFECTION; TYPE-1; RESISTANCE; SENSITIVITY; DERIVATIVES;
   REPLICATION; LYMPHOCYTES
AB A large variety of compounds have been reported to inhibit the replication of human immunodeficiency virus (HIV). The compounds that have been most intensively pursued for the treatment of HN infection belong to three classes: nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs). Within each of these classes, a number of compounds have been identified that inhibit HIV replication at nanomolar concentrations which are 10(4) - to 10(5)-fold lower than the cytotoxic concentrations. Yet, the potential usefulness of these compounds seems to be compromised by the rapid emergence of virus drug resistance. Here, we describe a strategy that, at least in cell culture, prevents the development of resistance. This-strategy is based on the use, from the beginning, of sufficiently high drug concentrations. When added at such concentrations, that for some of the NNRTIs did not have to be higher than 10-100 times their 50% effective concentration (EC(50)), these compounds completely suppressed (''knocked out'') HIV-1 replication in cell culture, and thus prevented drug-resistant virus strains from emerging. This ''knock out'' effect could be achieved for longer times and at lower drug concentrations when the compounds were combined (i.e. NNRTIs with one another or with NRTIs) than when used individually. Thus, when used at the appropriate doses, as such or in combination, NNRTIs proved able to completely clear (''cure'') HIV-1-infected cell cultures from the virus.
RP DeClercq, E (reprint author), CATHOLIC UNIV LEUVEN,REGA INST MED RES,MINDERBROEDERSSTR 10,B-3000 LOUVAIN,BELGIUM.
CR BABA M, 1994, ANTIMICROB AGENTS CH, V38, P688, DOI 10.1128/AAC.38.4.688                                                            
   BADER JP, 1991, P NATL ACAD SCI USA, V88, P6740, DOI 10.1073/pnas.88.15.6740                                                         
   BALZARINI J, 1994, P NATL ACAD SCI USA, V91, P6599, DOI 10.1073/pnas.91.14.6599
   BALZARINI J, 1993, J VIROL, V67, P5353
   BALZARINI J, 1995, ANTIVIR RES, V27, P219, DOI 10.1016/0166-3542(95)00006-8
   BALZARINI J, 1995, P NATL ACAD SCI USA, V92, P5470, DOI 10.1073/pnas.92.12.5470
   BALZARINI J, 1993, VIROLOGY, V196, P576, DOI 10.1006/viro.1993.1513
   BALZARINI J, 1995, ANTIMICROB AGENTS CH, V39, P998, DOI 10.1128/AAC.39.4.998                                                            
   BALZARINI J, 1993, MOL PHARMACOL, V43, P109
   BALZARINI J, 1993, P NATL ACAD SCI USA, V90, P6952, DOI 10.1073/pnas.90.15.6952
   BALZARINI J, 1993, VIROLOGY, V192, P246, DOI 10.1006/viro.1993.1027
   BALZARINI J, 1994, J VIROL, V68, P7986
   BALZARINI J, 1993, MOL PHARMACOL, V44, P694
   BALZARINI J, 1995, ANTIVIR CHEM CHEMOTH, V6, P169, DOI 10.1177/095632029500600306                                                      
   BALZARINI J, 1995, UNPUB VIROLOGY
   BOYER PL, 1994, ANTIMICROB AGENTS CH, V38, P1909, DOI 10.1128/AAC.38.9.1909                                                           
   BRYSON YJ, 1995, NEW ENGL J MED, V332, P833, DOI 10.1056/NEJM199503303321301
   BYRNES VW, 1993, ANTIMICROB AGENTS CH, V37, P1576, DOI 10.1128/AAC.37.8.1576                                                           
   CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401
   COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947
   CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0
   DECLERCQ E, 1994, INT J IMMUNOTHER, V10, P145
   DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001
   DECLERCQ E, 1994, BIOCHEM PHARMACOL, V47, P155, DOI 10.1016/0006-2952(94)90001-9                                                    
   DECLERCQ E, 1995, CLIN MICROBIOL REV, V8, P200
   DECLERCQ E, 1993, MED RES REV, V13, P229, DOI 10.1002/med.2610130303                                                          
   DECLERCQ E, 1995, IN PRESS 4TH P C ADV
   De Clercq E, 1994, EXPERT OPIN INV DRUG, V3, P253
   DUEWEKE TJ, 1993, ANTIMICROB AGENTS CH, V37, P1127, DOI 10.1128/AAC.37.5.1127                                                           
   DUEWEKE TJ, 1993, P NATL ACAD SCI USA, V90, P4713, DOI 10.1073/pnas.90.10.4713
   EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0
   HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0
   JONCKHEERE H, 1994, J BIOL CHEM, V269, P25255
   KLEIM JP, 1994, VIROLOGY, V200, P696, DOI 10.1006/viro.1994.1233
   KLEIM JP, 1993, ANTIMICROB AGENTS CH, V37, P1659, DOI 10.1128/AAC.37.8.1659                                                           
   Mellors J., 1995, INT ANTIVIRAL NEWS, V3, P8
   NAJERA I, 1995, J VIROL, V69, P23
   NITSCHKO H, 1994, ANTIVIR CHEM CHEMOTH, V5, P236, DOI 10.1177/095632029400500405                                                      
   PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402                                                     
   PAUWELS R, 1994, ANTIMICROB AGENTS CH, V38, P2863, DOI 10.1128/AAC.38.12.2863                                                          
   PAUWELS R, 1993, P NATL ACAD SCI USA, V90, P1711, DOI 10.1073/pnas.90.5.1711                                                          
   SHIRASAKA T, 1995, P NATL ACAD SCI USA, V92, P2398, DOI 10.1073/pnas.92.6.2398                                                          
   SMITH MS, 1987, J VIROL, V61, P3769
   TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665                                                          
   TOMASSELLI AG, 1995, ADV ANTIVIRAL DRUG D, V2
   UENO T, 1995, IN PRESS CLIN IMMUNO
   VASUDEVACHARI MB, 1992, VIROLOGY, V190, P269, DOI 10.1016/0042-6822(92)91213-E                                                    
   WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0
NR 48
TC 26
Z9 26
U1 0
U2 1
PU SOC CHIMICA ITALIANA
PI ROME
PA VIALE LIEGI 48, I-00198 ROME, ITALY
SN 0014-827X
J9 FARMACO
JI Farmaco
PD NOV
PY 1995
VL 50
IS 11
BP 735
EP 747
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA TL893
UT WOS:A1995TL89300001
PM 8593170
DA 2018-01-05
ER

PT J
AU Tossi, A
   Antcheva, N
   Romeo, D
   Miertus, S
AF Tossi, A
   Antcheva, N
   Romeo, D
   Miertus, S
TI Development of pseudopeptide inhibitors of HIV-1 aspartic protease:
   Analysis and tuning of the subsite specificity
SO PEPTIDE RESEARCH
LA English
DT Article
ID COMPLEXES
AB HIV-1 aspartic protease (PR) is a promising target for acquired immunodeficiency syndrome (AIDS) therapy and the development of PR inhibitors can be accelerated by computer-aided design methods. We describe an approach for the design of new inhibitors, based on the modification of a known reference inhibitor, and the calculation of relative binding energies, taking into account contributions from all species in the binding equilibrium (inhibitor PR and inhibitor/PR complex), as well as their solvation. This allows for a rational selection of new structures that are likely to have increased inhibition potency. We have analyzed reduced amide bond hexapeptides (Ac-P-3-P-2-P-1-Psi[CH2-NH]-P-1'-P-2-P-3'-NH2), based on the structure of the known inhibitor MVT-101. A maximum gain in binding energy (approximate to -55 kcal/mol) is observed when Phe or Tyr are present in positions P-1 and P-1', Glu in position P-2' and aromatic residues (Phe, Trp or Tyr) in positions P-3 and P-3', while, in general, the presence of positively charged residues is destabilizing. This specificity is explained in terms of the interaction of individual inhibitor residues with proximal and distal PR residues. The validity of this computational approach has been confirmed by solid-phase synthesis of several of the designed pseudopeptides, followed by in vitro enzyme inhibition assaying. The best candidate structures show IC50 values in the low nanomolar range.
C1 POLYBIOS,TRIESTE,ITALY.
RP Tossi, A (reprint author), UNIV TRIESTE,DEPT BIOCHEM BIOPHYS & MACROMOLEC CHEM,TRIESTE,ITALY.
OI Tossi, Alessandro/0000-0001-9087-5764; Miertus,
   Stanislav/0000-0001-6766-4571
CR CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0
   DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106
   DUNN BM, 1994, METHOD ENZYMOL, V241, P255
   FEHRENTZ JA, 1983, SYNTHESIS-STUTTGART, P676
   FITZGERALD PMD, 1993, CURR OPIN STRUC BIOL, V3, P868, DOI 10.1016/0959-440X(93)90150-J
   HARTE WE, 1993, J AM CHEM SOC, V115, P3883, DOI 10.1021/ja00063a005
   HOLLOWAY MK, 1995, J MED CHEM, V38, P305, DOI 10.1021/jm00002a012
   KEMPF DJ, 1994, METHOD ENZYMOL, V241, P334
   MAJER P, 1993, ARCH BIOCHEM BIOPHYS, V304, P1, DOI 10.1006/abbi.1993.1314                                                          
   MEEK TD, 1994, METHOD ENZYMOL, V241, P127
   MIERTUS S, 1993, BIOORG MED CHEM LETT, V3, P2105, DOI 10.1016/S0960-894X(01)81026-X                                                   
   MIERTUS S, 1992, J MATH CHEM, V10, P183, DOI 10.1007/BF01169174                                                              
   MIERTUS S, 1995, IN PRESSS QSAR MOL M
   MIERTUS S, IN PRESS CHEM PHYS
   MIERTUS S, 1981, J CHEM PHYS, V65, P117
   MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029
   MILLER MD, 1994, METHOD ENZYMOL, V241, P354
   NAUCHITEL V, 1995, PROTEIN SCI, V4, P1356, DOI 10.1002/pro.5560040711                                                          
   NOVOTNY J, 1989, BIOCHEMISTRY-US, V28, P4735, DOI 10.1021/bi00437a034
   Pennington M W, 1994, Methods Mol Biol, V35, P241
   RINGE D, 1994, METHOD ENZYMOL, V241, P157
   TOMASSELLI AG, 1994, METHOD ENZYMOL, V241, P279
   Tomasselli A. G., 1991, CHIM OGGI, V9, P6
   VACCA JP, 1994, METHOD ENZYMOL, V241, P311
   WEST ML, 1995, TRENDS PHARMACOL SCI, V16, P67, DOI 10.1016/S0165-6147(00)88980-4
   WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551                                             
NR 26
TC 13
Z9 13
U1 0
U2 1
PU EATON PUBLISHING CO
PI NATICK
PA 154 E. CENTRAL ST, NATICK, MA 01760
SN 1040-5704
J9 PEPTIDE RES
JI Peptide Res.
PD NOV-DEC
PY 1995
VL 8
IS 6
BP 328
EP 334
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA TR839
UT WOS:A1995TR83900004
PM 8838416
DA 2018-01-05
ER

PT J
AU DALY, TJ
   DOTEN, RC
   RUSCHE, JR
   AUER, M
AF DALY, TJ
   DOTEN, RC
   RUSCHE, JR
   AUER, M
TI THE AMINO-TERMINAL DOMAIN OF HIV-1 REV IS REQUIRED FOR DISCRIMINATION OF
   THE RRE FROM NONSPECIFIC RNA
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE HIV; RNA BINDING PROTEINS; REV-RESPONSIVE ELEMENT; SPECIFICITY; REV
ID HUMAN-IMMUNODEFICIENCY-VIRUS; DEPENDENT ADENOSINE-TRIPHOSPHATASE;
   GENE-EXPRESSION REQUIRES; HIGH-AFFINITY BINDING; VIRAL MESSENGER-RNA;
   RESPONSIVE ELEMENT; TRANS-ACTIVATOR; CIRCULAR-DICHROISM; TARGET
   SEQUENCE; SECONDARY STRUCTURE
AB The ability of HIV-1 Rev to successfully discriminate between specific Rev-responsive elements (RRE) and nonspecific binding sites in the presence of excess nonspecific RNA was examined using filter binding, gel shift, and gel filtration techniques, using purified M4 Rev mutant protein and endoproteinase Lys-C cleaved wild-type Rev. The M4 Rev displayed a slightly reduced binding affinity to the RRE, as well as a tenfold decrease in its ability to discriminate the RRE from non-specific RNA compared to the wild-type Rev. Gel shift and gel filtration chromotography data also showed decreased ability of the mutant to multimerize in the absence or presence of the RRE. The Lys-C cleaved Rev, which lacks the amino-terminal 20 amino acids of the protein, displayed less ability to discriminate the RRE from nonspecific RNA compared to either the wild-type or the M4 mutant Rev and appeared unable to form protein-protein interactions, yet still bound sense and antisense RNA species with high affinity (Kd was in the nanomolar concentration range). A 40 amino acid peptide containing the arginine-rich RRE binding domain of Rev was also observed to interact with both the RRE and antisense RNA fragments with a binding constant of about 1 x 10(-9) M. However, the peptide displayed almost no ability to discriminate between the RRE and a comparably sized antisense RRE. The loss in ability to discriminate correct from incorrect binding sites correlates with overall decreases in the a-helical character of the protein and perturbations within the amino terminus. The amino terminus of Rev is likely to maintain the conformational integrity of the arginine rich RRE binding domain which is required for specific RNA binding site discrimination or stabilization of specific Rev-RRE interactions. (C) 1995 Academic Press Limited
C1 SANDOZ GMBH,FORSCHUNGSINST,A-1235 VIENNA,AUSTRIA.
   REPLIGEN CORP,CAMBRIDGE,MA 02139.
CR AUER M, 1994, BIOCHEMISTRY-US, V33, P2988, DOI 10.1021/bi00176a031
   BAGSHAW CR, 1974, BIOCHEM J, V141, P351, DOI 10.1042/bj1410351                                                               
   BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331                                                               
   BOEHNLEIN E, 1991, Journal of Virology, V65, P7051
   Bronstein IN, 1991, TASCHENBUCH MATH
   CAINAN BJ, 1991, GENE DEV, V5, P201
   CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167
   CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128
   COCHRANE AW, 1990, J VIROL, V64, P881
   COOK KS, 1991, NUCLEIC ACIDS RES, V19, P1577, DOI 10.1093/nar/19.7.1577
   DALY TJ, 1993, BIOCHEMISTRY-US, V32, P10497, DOI 10.1021/bi00090a028
   DALY TJ, 1990, BIOCHEMISTRY-US, V29, P9791, DOI 10.1021/bi00494a005
   DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0
   DALY TJ, 1993, BIOCHEMISTRY-US, V32, P8945, DOI 10.1021/bi00085a028
   DILLON PJ, 1990, J VIROL, V64, P4428
   EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6                                                    
   FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0
   FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505                                                           
   HADZOPOULOUCLAD.M, 1989, J VIROL, V63, P1265
   HAMMARSKJOLD ML, 1989, J VIROL, V63, P1959
   HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z
   HEAPHY S, 1991, P NATL ACAD SCI USA, V88, P7366, DOI 10.1073/pnas.88.16.7366                                                         
   HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5
   HOLLAND SM, 1990, J VIROL, V64, P5966
   IWAI S, 1992, NUCLEIC ACIDS RES, V20, P6465, DOI 10.1093/nar/20.24.6465
   KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683
   KNIGHT DM, 1987, SCIENCE, V236, P837, DOI 10.1126/science.3033827                                                         
   Kowalczykowski SC, 1981, ENZYMES, V14, P373
   Leatherbarrow RJ, 1992, GRAFIT VERSION 3 0
   LORET EP, 1992, P NATL ACAD SCI USA, V89, P9734, DOI 10.1073/pnas.89.20.9734
   MADORE SJ, 1994, VIROLOGY, V202, P186, DOI 10.1006/viro.1994.1334
   MALIM MH, 1991, J VIROL, V65, P4248
   MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U                                                    
   MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A
   MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0
   MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9                                                    
   MANN DA, 1994, J MOL BIOL, V241, P193, DOI 10.1006/jmbi.1994.1488
   MERMER B, 1990, NUCLEIC ACIDS RES, V18, P2037, DOI 10.1093/nar/18.8.2037                                                           
   MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025                                                             
   ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071
   SAKAKIBARA S, 1965, B CHEM SOC JPN, V38, P1412, DOI 10.1246/bcsj.38.1412
   SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0
   SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079
   TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4
   WEEKS KM, 1992, BIOCHEMISTRY-US, V31, P10281, DOI 10.1021/bi00157a015                                                             
   ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734
   ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0
   ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P134
NR 48
TC 32
Z9 32
U1 0
U2 3
PU ACADEMIC PRESS (LONDON) LTD
PI LONDON
PA 24-28 OVAL RD, LONDON, ENGLAND NW1 7DX
SN 0022-2836
J9 J MOL BIOL
JI J. Mol. Biol.
PD OCT 20
PY 1995
VL 253
IS 2
BP 243
EP 258
DI 10.1006/jmbi.1995.0549
PG 16
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA TA708
UT WOS:A1995TA70800003
PM 7563086
DA 2018-01-05
ER

PT J
AU CLARIA, J
   SERHAN, CN
AF CLARIA, J
   SERHAN, CN
TI ASPIRIN TRIGGERS PREVIOUSLY UNDESCRIBED BIOACTIVE EICOSANOIDS BY HUMAN
   ENDOTHELIAL CELL-LEUKOCYTE INTERACTIONS
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID HUMAN-NEUTROPHILS; INHIBITION; SYNTHASE; LEUKOTRIENE-B4; BIOSYNTHESIS;
   LIPOXIN-A(4); EXPRESSION; DRUGS; ACID
AB Aspirin [acetylsalicylic acid (ASA)], along with its analgesic-antipyretic uses, is now also being considered for cardiovascular protection and treatments in cancer and human immunodeficiency virus infection, Although many of ASA's pharmacological actions are related to its ability to inhibit prostaglandin and thromboxane biosynthesis, some of its beneficial therapeutic effects are not completely understood, Here, ASA triggered transcellular biosynthesis of a previously unrecognized class of eicosanoids during coincubations of human umbilical vein endothelial cells (HUVEC) and neutrophils [polymorphonuclear leukocytes (PMN)]. These eicosanoids were generated with ASA but not by indomethacin, salicylate, or dexamethasone, Formation nas enhanced by cytokines (interleukin 1 beta) that induced the appearance of prostaglandin G/H synthase 2 (PGHS-2) but not 15-lipoxygenase, which initiates their biosynthesis from arachidonic acid in HUVEC, Costimulation of HUVEC/PMN by either thrombin plus the chemotactic peptide fMet-Leu-Phe or phorbol 12-myristate 13-acetate or ionophore A(23187) leads to the production of these eicosanoids from endogenous sources. Four of these eicosanoids were also produced when PMN were exposed to 15R-HETE [(15R)-15-hydroxy-5,8,11-cis-13-trans-eicosatetraenoic acid] and an agonist, Physical methods showed that the class consists of four tetraene-containing products from arachidonic acid that proved to be 15R-epimers of lipoxins. Two of these compounds (III and IV) were potent inhibitors of leukotriene B-4-mediated PMN adhesion to HUVEC, with compound IV [(5S,6R,15R)-5,6,15-trihydroxy-7,9,13- trans-11-cis-eicosatetraenoic acid; 15-epilipoxin A(4)] active in the nanomolar range, These results demonstrate that ASA evokes a unique class of eicosanoids formed by acetylated PGHS-2 and 5-lipoxygenase interactions, which may contribute to the therapeutic impact of this drug, Moreover, they provide an example of a drug's ability to pirate endogenous biosynthetic mechanisms to trigger new mediators.
C1 BRIGHAM & WOMENS HOSP,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115.
   HARVARD UNIV,SCH MED,BOSTON,MA 02115.
OI Claria, Joan/0000-0003-4333-7749
FU NIGMS NIH HHS [GM38765]
CR BRADY HR, 1992, BIOCHEM BIOPH RES CO, V186, P1307, DOI 10.1016/S0006-291X(05)81548-7                                                   
   BREZINSKI DA, 1992, CIRCULATION, V86, P56
   CAPDEVILA J, 1986, BIOCHEM BIOPH RES CO, V141, P1007, DOI 10.1016/S0006-291X(86)80144-9
   CARLOS TM, 1994, BLOOD, V84, P2068
   CLAESSON HE, 1988, EUR J BIOCHEM, V173, P93, DOI 10.1111/j.1432-1033.1988.tb13971.x
   COLGAN SP, 1993, J CLIN INVEST, V92, P75, DOI 10.1172/JCI116601
   EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1153
   Flower R. J., 1985, PROSTAGLANDINS LEUKO, P583
   HEMPEL SL, 1994, J CLIN INVEST, V93, P391, DOI 10.1172/JCI116971
   HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384
   HOLTZMAN MJ, 1992, J BIOL CHEM, V267, P21438
   JAKOBSSON PJ, 1992, P NATL ACAD SCI USA, V89, P3521, DOI 10.1073/pnas.89.8.3521
   JONES DA, 1993, J BIOL CHEM, V268, P9049
   KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854
   LECOMTE M, 1994, J BIOL CHEM, V269, P13207
   LEE TH, 1989, CLIN SCI, V77, P195, DOI 10.1042/cs0770195                                                               
   LEVY BD, 1993, J CLIN INVEST, V92, P1572, DOI 10.1172/JCI116738                                                               
   LEVY BD, 1993, LIPIDS, V28, P1047, DOI 10.1007/BF02537069
   MANCINI JA, 1994, FEBS LETT, V342, P33, DOI 10.1016/0014-5793(94)80579-2                                                    
   MARCUS AJ, 1993, J LIPID RES, V34, P20017
   MEADE EA, 1993, J BIOL CHEM, V268, P6610
   NASSAR GM, 1994, J BIOL CHEM, V269, P27631
   NICOLAOU KC, 1991, ANGEW CHEM INT EDIT, V30, P1100, DOI 10.1002/anie.199111001
   ONEILL GP, 1994, MOL PHARMACOL, V45, P245
   PAPAYIANNI A, 1994, J AM SOC NEPHROL, V5, P792
   RAUD J, 1991, ADV EXP MED BIOL, V314, P185
   RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769
   Samuelsson B, 1982, PRIX NOBEL NOBEL PRI, P153
   SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138, DOI 10.1097/00001648-199403000-00003
   SERHAN CN, 1993, BIOCHEMISTRY-US, V32, P6313, DOI 10.1021/bi00076a002
   SERHAN CN, 1994, BBA-LIPID LIPID MET, V1212, P1, DOI 10.1016/0005-2760(94)90185-6
   SERHAN CN, 1985, FASEB J, V9, pA853
   SOYOMBO O, 1994, ALLERGY, V49, P230, DOI 10.1111/j.1398-9995.1994.tb02654.x
   VANE JR, 1971, NATURE-NEW BIOL, V231, P232
   Vane JR, 1982, PRIX NOBEL NOBEL PRI, P181
   WEISSMANN G, 1991, SCI AM, V264, P84, DOI 10.1038/scientificamerican0191-84                                               
   [Anonymous], 1989, NEW ENGL J MED, V321, P129
NR 37
TC 463
Z9 477
U1 0
U2 15
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 10
PY 1995
VL 92
IS 21
BP 9475
EP 9479
DI 10.1073/pnas.92.21.9475                                                 
          
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA RZ072
UT WOS:A1995RZ07200010
PM 7568157
OA gold
DA 2018-01-05
ER

PT J
AU BECKER, W
AF BECKER, W
TI THE CONTRIBUTION OF NUCLEAR-MEDICINE TO THE PATIENT WITH INFECTION
SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE
LA English
DT Review
DE INFECTION; GA-67 CITRATE; TC-99M NANOCOLLOIDS; LABELED WHITE BLOOD
   CELLS; TC-99M ANTIGRANULOCYTE ANTIBODIES; LABELED UNSPECIFIC HUMAN
   IMMUNOGLOBULIN
ID POLYCLONAL HUMAN-IMMUNOGLOBULIN; INFLAMMATORY BOWEL-DISEASE;
   HUMAN-IMMUNODEFICIENCY-VIRUS; WHITE BLOOD-CELLS; RHEUMATOID-ARTHRITIS;
   UNKNOWN ORIGIN; IN-111 OXINE; MONOCLONAL-ANTIBODIES; LABELED
   GRANULOCYTES; RADIOACTIVE AGENTS
AB Nuclear medicine imaging of infection has two major indications: (a) the localization of a focus of infection in patients with fever of unknown origin; in this context the radio-pharmaceutical should be highly sensitive whereas specificity is not so important because subsequent biopsy or morphologically based imaging can be performed; (b) the diagnosis of an infection in patients with localized symptoms, for example after surgery, when normal anatomy is absent or when metal implants prevent computed tomography or magnetic resonance imaging. In these latter cases high sensitivity and to an even greater extent high specificity are mandatory to guide further clinical management (conservative or surgical). All radiopharmaceuticals available to date, such as technetium-99m nanocolloids, gallium-67 citrate, indium-111- and Tc-99m-labelled white blood cells, Tc-99m-antigranulocyte antibodies, and Tc-99m-or In-111-labelled unspecific human immunoglobulin, have different biodistributions and different physical characteristics. The absence of physiological uptake in an organ and the radiation exposure of a patient are reasons to use different radiopharmaceuticals in different clinical situations, adapted to the inidividual carcumstances of the patient.
RP BECKER, W (reprint author), UNIV GOTTINGEN,DEPT NUCL MED,ROBERT KOCH STR 40,D-37075 GOTTINGEN,GERMANY.
CR ALLAN RA, 1993, EUR J NUCL MED, V20, P195
   ARNDT JW, 1991, J NUCL MED, V32, P2029
   ATHENS JW, 1961, J CLIN INVEST, V40, P989, DOI 10.1172/JCI104338
   BASSANO DA, 1979, J NUCL MED, V20, P255
   BECKER EL, 1987, AM J PATHOL, V129, P16
   BECKER W, 1987, EUR HEART J, V8, P307, DOI 10.1093/eurheartj/8.suppl_J.307                                                 
   BECKER W, 1986, J NUCL MED, V27, P1109
   BECKER W, 1986, KLIN WOCHENSCHR, V64, P141, DOI 10.1007/BF01732640
   BECKER W, 1994, J NUCL MED, V35, P1436
   BECKER W, 1988, NUCL MED COMMUN, V9, P435, DOI 10.1097/00006231-198806000-00008
   BECKER W, 1987, EUR J NUCL MED, V13, P225
   BECKER W, 1988, NUCL MED COMMUN, V9, P693, DOI 10.1097/00006231-198810000-00004
   BECKER W, 1994, SEMIN NUCL MED, V24, P142, DOI 10.1016/S0001-2998(05)80228-4
   BECKER W, 1986, RADIONUCLIDES NEPHRO, P191
   BECKER W, 1994, SEMIN NUCL MED, V24, P1
   BECKER W, 1990, NUKLEARMED, V229, P47
   BERNA L, 1992, EUR J NUCL MED, V19, P173
   Bomanji J, 1993, EUR J NUCL MED, V20, P834
   BORST U, 1993, CLIN NUCL MED, V18, P35, DOI 10.1097/00003072-199301000-00008
   BREEDVELD FC, 1989, J NUCL MED, V30, P2017
   BUIIJS WCA, 1990, EUR J NUCL MED, V16, P433
   BUSCOMBE JR, 1991, NUCL MED COMMUN, V12, P583, DOI 10.1097/00006231-199107000-00003
   BUSCOMBE JR, 1993, J NUCL MED, V34, P1621
   CALAME W, 1991, EUR J NUCL MED, V18, P396, DOI 10.1007/BF02258430
   CLAESSENS RAMJ, 1995, EUR J NUCL MED, V22, P212, DOI 10.1007/BF01081515
   COOK PS, 1984, RADIOLOGY, V150, P557, DOI 10.1148/radiology.150.2.6691116                                                 
   CORDES M, 1991, NUKLEARMED, V30, P173
   CORSTENS FHM, 1993, SEMIN NUCL MED, V23, P148, DOI 10.1016/S0001-2998(05)80095-9
   CORSTENS FHM, 1992, EUR J NUCL MED, V19, P155
   CURRIE DC, 1990, THORAX, V45, P541, DOI 10.1136/thx.45.7.541                                                            
   CURRIE DC, 1987, LANCET, V1, P1335
   DATZ FL, 1994, SEMIN NUCL MED, V24, P92, DOI 10.1016/S0001-2998(05)80225-9
   DEBOIS MHW, 1993, NUCL MED COMMUN, V14, P883, DOI 10.1097/00006231-199310000-00009
   DEBOIS MHW, 1994, BRIT J RHEUMATOL, V33, P67
   DEBOIS MHW, 1992, J RHEUMATOL, V19, P1371
   DEKLEIJN EMH, 1992, NUCL MED COMMUN, V13, P626
   DESCHRIJVER M, 1987, NUCL MED COMMUN, V8, P895, DOI 10.1097/00006231-198711000-00007                                                
   FISCHBACH W, 1991, DIGESTION, V50, P149, DOI 10.1159/000200755                                                               
   FISCHMAN AJ, 1994, SEMIN NUCL MED, V24, P154, DOI 10.1016/S0001-2998(05)80229-6
   FLIVIK G, 1993, J NUCL MED, V34, P1646
   FRAYHA R, 1973, LAB MED J, V26, P49
   GOLDE DW, 1977, HEMATOLOGY, P699
   GOLDENBERG DM, 1994, J NUCL MED, V35, P1028
   HAWKER RJ, 1985, EUR J NUCL MED, V10, P172
   HOFFER P, 1980, J NUCL MED, V21, P282
   HOTZE A, 1988, NUKLEARMED, V27, P63
   HOTZE A, 1984, KNOCHENMARKSSZINTIGR
   HOTZE AL, 1992, J NUCL MED, V33, P526
   HOWARD P, 1977, TEX MED, V73, P56
   JONKER ND, 1992, J NUCL MED, V33, P491
   JOSEPH K, 1988, EUR J NUCL MED, V14, P367
   JOSEPH K, 1987, NUC COMPACT, V18, P223
   JUWEID M, 1992, EUR J NUCL MED, V19, P159
   KEELAN ETM, 1994, J NUCL MED, V35, P276
   KNOCKAERT DC, 1992, ARCH INTERN MED, V152, P51, DOI 10.1001/archinte.152.1.51                                                       
   LARSON EB, 1982, MEDICINE, V61, P269, DOI 10.1097/00005792-198209000-00001                                                
   LIBERATORE M, 1992, EUR J NUCL MED, V19, P853, DOI 10.1007/BF00168160                                                              
   LIND P, 1990, J NUCL MED, V31, P417
   LOCHER JT, 1986, NUCL MED COMMUN, V7, P659
   MACSWEENEY JE, 1990, CLIN RADIOL, V42, P414, DOI 10.1016/S0009-9260(05)80897-9
   MCAFEE JG, 1991, J NUCL MED, V32, P2126
   MCAFEE JG, 1976, J NUCL MED, V17, P480
   MCAFEE JG, 1980, J NUCL MED, V21, P1059
   MCAFEE JG, 1976, J NUCL MED, V17, P488
   MCCARTHY K, 1988, J NUCL MED, V29, P1015
   MUNZ DL, 1991, EUR J NUCL MED, V18, P977
   MYRON I, 1988, CELLULAR MOL ASPECTS
   OSWALD SG, 1989, J NUCL MED, V30, P1321
   OYEN WJG, 1992, RADIOLOGY, V182, P195, DOI 10.1148/radiology.182.1.1727281                                                 
   OYEN WJG, 1991, J NUCL MED, V32, P2195
   OYEN WJG, 1992, J NUCL MED, V33, P651
   PALESTRO CJ, 1991, J NUCL MED, V32, P1861
   PALESTRO CJ, 1994, SEMIN NUCL MED, V24, P128, DOI 10.1016/S0001-2998(05)80227-2
   PETERS AM, 1994, SEMIN NUCL MED, V24, P110, DOI 10.1016/S0001-2998(05)80226-0
   PETERS AM, 1983, J NUCL MED, V24, P39
   PETERSDORF R, 1961, MEDICINE, V40, P1, DOI 10.1097/00005792-196102000-00001
   PRING DJ, 1991, RADIOLOGY, V179, P645
   PRVULOVICH EM, 1995, UNPUB AIDS
   REULAND P, 1991, J NUCL MED, V32, P526
   RUBIN RH, 1989, NEW ENGL J MED, V321, P935, DOI 10.1056/NEJM198910053211404                                                     
   RUBIN RH, 1988, J NUCL MED, V29, P651
   SAPTOGINO A, 1991, NUKLEARMED, V30, P18
   SAVERYMUTTU SH, 1985, BMJ-BRIT MED J, V290, P23, DOI 10.1136/bmj.290.6461.23                                                         
   SAVERYMUTTU SH, 1983, CLIN RADIOL, V34, P593, DOI 10.1016/S0009-9260(83)80176-7
   SAVERYMUTTU SH, 1986, GASTROENTEROLOGY, V90, P1121, DOI 10.1016/0016-5085(86)90376-8                                                    
   SAVERYMUTTU SH, 1985, THORAX, V40, P925, DOI 10.1136/thx.40.12.925
   SAVERYMUTU S, 1981, British Journal of Radiology, V54, P707
   SCHIFFMANN E, 1972, P NATL ACAD SCI USA, V72, P1059
   SCIUK J, 1991, EUR J NUCL MED, V18, P401, DOI 10.1007/BF02258431                                                              
   SEGARRA I, 1991, EUR J NUCL MED, V18, P715, DOI 10.1007/BF00956711
   SERAFINI AN, 1991, J NUCL MED, V32, P2227
   SHOEN RP, 1963, AM J MED, V34, P486
   SIGNORE A, 1987, LANCET, V2, P537
   SIGNORE A, 1994, EUR J ENDOCRINOL, V131, P431, DOI 10.1530/eje.0.1310431                                                           
   SINN H, 1979, BRIT J RADIOL, V52, P758, DOI 10.1259/0007-1285-52-621-758                                                    
   SPECTOR WG, 1967, J PATHOL BACTERIOL, V93, P101, DOI 10.1002/path.1700930109                                                         
   SPINELLI F, 1990, European Journal of Nuclear Medicine, V16, P436
   STREULE K, 1988, NUCL MED COMMUN, V9, P59
   THAKUR ML, 1984, J NUCL MED, V25, P922
   Thakur ML, 1977, J NUCL MED, V18, P1012
   VANDALEN H, 1989, 3 PHASE SCINTIGRAPHY, P474
   VANDERLAKEN J, 1994, EUR J NUCL MED, V21, P790
   VANROYEN EA, 1984, BLOOD CELLS NUCLEA 1, P341
   VORNE M, 1989, ACTA RADIOL, V30, P633
   WEIBLEN BJ, 1979, J LAB CLIN MED, V94, P246
   WHEELER JG, 1990, NUCL MED COMMUN, V11, P127, DOI 10.1097/00006231-199002000-00007
   Woods G, 1993, DIAGNOSTIC PATHOLOGY
   1987, ANN ICRP, V18, P141
   1987, ANN ICRP, V18, P255
   1987, ANN ICRP, V18, P231
NR 110
TC 78
Z9 82
U1 0
U2 2
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010
SN 0340-6997
J9 EUR J NUCL MED
JI Eur. J. Nucl. Med.
PD OCT
PY 1995
VL 22
IS 10
BP 1195
EP 1211
DI 10.1007/BF00800606                                                      
          
PG 17
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA RZ673
UT WOS:A1995RZ67300017
PM 8542906
DA 2018-01-05
ER

PT J
AU ANGLIKER, H
AF ANGLIKER, H
TI SYNTHESIS OF TIGHT-BINDING INHIBITORS AND THEIR ACTION ON THE
   PROPROTEIN-PROCESSING ENZYME FURIN
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID INFLUENZA-VIRUS HEMAGGLUTININ; CLEAVAGE; ACTIVATION; ENDOPROTEASE; ARG
AB Furin is a subtilisin-like eukaryotic serine endoprotease which processes proproteins to biologically active proteins and peptides. Also, the envelope proteins of viruses, such as influenza and HIV viruses, need to be processed by furin for infectivity. This enzyme has a consensus substrate specificity for Arg-Xxx-Lys/Arg-Arg at the cleavage site. Two kinds of transition state analog peptides were designed and tested in vitro with furin. The ketomethylene series, Psi(COCH2), have K-i's in the submicromolar range; the aminomethyl ketone series, Psi(COCH2NH), have Ki's in the nanomolar range. The best inhibitor is Dec-Arg-Val-Lys-Arg-CH2-Ala-Val-Gly-NH2(2c) with a K-i of 3.4 nM.
RP ANGLIKER, H (reprint author), FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND.
CR ANGLIKER H, 1995, ANAL BIOCHEM, V224, P409, DOI 10.1006/abio.1995.1058                                                          
   ANGLIKER H, 1993, BIOCHEM J, V293, P75, DOI 10.1042/bj2930075                                                               
   BASAK A, 1994, INT J PEPT PROT RES, V44, P253
   CHENG LF, 1992, J MED CHEM, V35, P3364, DOI 10.1021/jm00096a010
   DEVROLY E, 1994, J BIOL CHEM, V269, P12240
   GARTEN W, 1989, VIROLOGY, V172, P25, DOI 10.1016/0042-6822(89)90103-7                                                    
   GARTEN W, 1993, OPTIONS CONTROL INFL, V2, P311
   HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0
   HOSAKA M, 1991, J BIOL CHEM, V266, P12127
   MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4
   MELDAL M, 1991, ANAL BIOCHEM, V195, P141, DOI 10.1016/0003-2697(91)90309-H
   MOLLOY SS, 1992, J BIOL CHEM, V267, P16396
   SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X                                                   
   STBRENNAN O, 1994, FEBS LETT, V347, P80
   STBRENNAN O, 1994, FEBS LETT, V338, P147
   STIENEKEGROBER A, 1992, EMBO J, V11, P2407
   YARON A, 1979, ANAL BIOCHEM, V95, P228, DOI 10.1016/0003-2697(79)90210-0
NR 17
TC 39
Z9 39
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA PO BOX 57136, WASHINGTON, DC 20037-0136
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD SEP 29
PY 1995
VL 38
IS 20
BP 4014
EP 4018
DI 10.1021/jm00020a016
PG 5
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA RY255
UT WOS:A1995RY25500016
PM 7562936
DA 2018-01-05
ER

PT J
AU HUNENBERGER, PH
   MARK, AE
   VANGUNSTEREN, WF
AF HUNENBERGER, PH
   MARK, AE
   VANGUNSTEREN, WF
TI FLUCTUATION AND CROSS-CORRELATION ANALYSIS OF PROTEIN MOTIONS OBSERVED
   IN NANOSECOND MOLECULAR-DYNAMICS SIMULATIONS
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE COMPUTER SIMULATION; MOLECULAR DYNAMICS; PROTEIN DYNAMICS; ATOMIC
   FLUCTUATIONS; B-FACTORS
ID PANCREATIC TRYPSIN-INHIBITOR; NORMAL MODE REFINEMENT; COLLECTIVE
   MOTIONS; CRYSTALLOGRAPHIC REFINEMENT; ATOMIC FLUCTUATIONS; HIV-1
   PROTEASE; LYSOZYME; MACROMOLECULES; RIBONUCLEASE; DIFFRACTION
AB Nanosecond molecular dynamics simulations of bovine pancreatic trypsin inhibitor and lysozyme in water are analyzed in terms of backbone atomic positional fluctuations and dynamical cross-correlations. It is found that although the molecular systems are stable, B-factors calculated over a time period as long as 500 ps are not representative for the motions within the proteins. This is especially true for the most mobile residues. On a nanosecond time-scale, the B-factors calculated from the simulations of the proteins in solution are considerably larger than. those obtained by structure refinement of the proteins in crystals, based on X-ray data. The time evolution of the atomic fluctuations shows that for large portions of the proteins under study atomic positional fluctuations are not yet converged after a nanosecond. Cross-correlations do not converge faster than the fluctuations themselves. Most display very erratic behavior if the sampling covers less than about 200 ps. It is also shown that inclusion of mobile atoms into the procedure used to remove rigid-body motion from the simulation can lead to spurious correlations between the motions of the atoms at the surface of the protein. (C) 1995 Academic Press Limited
C1 ETH ZENTRUM,PHYS CHEM LAB,CH-8092 ZURICH,SWITZERLAND.
RI Mark, Alan/A-8799-2011
OI Mark, Alan/0000-0001-5880-4798
CR AMADEI A, 1993, PROTEINS, V17, P412, DOI 10.1002/prot.340170408
   BERENDSEN HJC, 1987, J PHYS CHEM-US, V91, P6269, DOI 10.1021/j100308a038
   BERENDSEN HJC, 1994, J CHEM PHYS, V81, P3684
   BERENDSEN HJC, 1981, INTERMOLECULAR FORCE, P331
   BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3                                                   
   BROOKS CL, 1988, ADV CHEM PHYS, V71, P1
   BRUNGER AT, 1985, P NATL ACAD SCI USA, V82, P8458, DOI 10.1073/pnas.82.24.8458
   CASE DA, 1994, CURR OPIN STRUC BIOL, V4, P285, DOI 10.1016/S0959-440X(94)90321-2
   CASPAR DLD, 1988, NATURE, V332, P659, DOI 10.1038/332659a0
   CASPAR DLD, 1991, CURR OPIN STRUC BIOL, V1, P877
   CAVES LS, 1990, MOL DYNAMICS APPL MO, P27
   CLARAGE JB, 1992, PROTEINS, V12, P145, DOI 10.1002/prot.340120208
   DAGGETT V, 1993, J MOL BIOL, V232, P600, DOI 10.1006/jmbi.1993.1414
   DELACRUZ X, 1994, J MOL BIOL, V236, P1186, DOI 10.1016/0022-2836(94)90020-5
   EDWARDS C, 1990, ACTA CRYSTALLOGR A, V46, P315, DOI 10.1107/S0108767389012912                                                       
   ELOFSSON A, 1993, J MOL BIOL, V233, P766, DOI 10.1006/jmbi.1993.1551                                                          
   FRAUENFELDER H, 1979, NATURE, V280, P558, DOI 10.1038/280558a0
   HARTE WE, 1992, PROTEINS, V13, P175, DOI 10.1002/prot.340130302
   HARTE WE, 1990, P NATL ACAD SCI USA, V87, P8864, DOI 10.1073/pnas.87.22.8864
   HAYWARD S, 1993, J MOL BIOL, V234, P1207, DOI 10.1006/jmbi.1993.1671                                                          
   HUBER R, 1983, BIOPOLYMERS, V22, P261, DOI 10.1002/bip.360220136
   ICHIYE T, 1991, PROTEINS, V11, P205, DOI 10.1002/prot.340110305
   KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211
   KARPLUS M, 1981, MACROMOLECULES, V14, P325, DOI 10.1021/ma50003a019                                                             
   KIDERA A, 1992, J MOL BIOL, V225, P477, DOI 10.1016/0022-2836(92)90933-B
   KIDERA A, 1992, J MOL BIOL, V225, P457, DOI 10.1016/0022-2836(92)90932-A                                                    
   KOMEIJI Y, 1991, PROTEIN ENG, V4, P871, DOI 10.1093/protein/4.8.871
   KOMEIJI Y, 1994, PROTEINS, V20, P248, DOI 10.1002/prot.340200305
   LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X
   LEVITT M, 1988, P NATL ACAD SCI USA, V85, P7557, DOI 10.1073/pnas.85.20.7557                                                         
   LEVITT M, 1985, J MOL BIOL, V181, P423, DOI 10.1016/0022-2836(85)90230-X                                                    
   MARK AE, 1994, J AM CHEM SOC, V116, P6293, DOI 10.1021/ja00093a032                                                             
   MCCAMMON JA, 1984, REP PROG PHYS, V47, P1, DOI 10.1088/0034-4885/47/1/001
   McCammon J. A., 1987, DYNAMICS PROTEINS NU
   MURPHY KP, 1992, J MOL BIOL, V227, P293, DOI 10.1016/0022-2836(92)90699-K
   PTASZEK LM, 1994, BIOPOLYMERS, V34, P1145, DOI 10.1002/bip.360340904
   RAMANADHAM M, 1987, ACTA CRYSTALLOGR A, V43, P13
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5                                                    
   SCHIFFER CA, 1995, ACTA CRYSTALLOGR D, V51, P85, DOI 10.1107/S0907444994007158                                                       
   SCHLITTER J, 1993, CHEM PHYS LETT, V215, P617, DOI 10.1016/0009-2614(93)89366-P
   SMITH LJ, 1995, IN PRESS BIOCHEMISTR
   SWAMINATHAN S, 1991, J AM CHEM SOC, V113, P2717, DOI 10.1021/ja00007a054
   SWAMINATHAN S, 1982, BIOCHEMISTRY-US, V21, P5230, DOI 10.1021/bi00264a019
   TRUEBLOOD KN, 1992, ACCURATE MOL STRUCTU, P199
   VANGUNSTEREN WF, 1990, ANGEW CHEM INT EDIT, V29, P992, DOI 10.1002/anie.199009921                                                          
   VANGUNSTEREN WF, 1995, IN PRESS COMP PHYS C
   van Gunsteren W.F., 1987, GRONINGEN MOL SIMULA
   WLODAWER A, 1987, J MOL BIOL, V193, P145, DOI 10.1016/0022-2836(87)90633-4                                                    
NR 48
TC 205
Z9 208
U1 2
U2 14
PU ACADEMIC PRESS (LONDON) LTD
PI LONDON
PA 24-28 OVAL RD, LONDON, ENGLAND NW1 7DX
SN 0022-2836
J9 J MOL BIOL
JI J. Mol. Biol.
PD SEP 29
PY 1995
VL 252
IS 4
BP 492
EP 503
DI 10.1006/jmbi.1995.0514
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA RX458
UT WOS:A1995RX45800011
PM 7563068
DA 2018-01-05
ER

PT J
AU BROOM, AD
   AGRAWAL, VK
   TUTONDA, MG
   FAIN, HD
   BUCKHEIT, RW
AF BROOM, AD
   AGRAWAL, VK
   TUTONDA, MG
   FAIN, HD
   BUCKHEIT, RW
TI UNUSUAL SINGLE-STRANDED POLYRIBONUCLEOTIDES AS POTENT ANTI-HIV AGENTS
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID THIOPURINE NUCLEOSIDES; TRANSCRIPTASE; NUCLEOTIDES; RESOLUTION;
   INHIBITOR; COMPLEX; AIDS
AB Polyribonucleotides (PMTG and PMTI) containing 1-methyl-6-thioguanosine or 1-methyl-6-thioinosine, respectively, as the sole nucleoside component are shown to be potent inhibitors of various strains of HTV-1 and HTV-2 in a number of human lymphocyte and macrophage cell lines in tissue culture as well as in fresh human peripheral blood lymphocytes and macrophages. PMTI and PMTG exhibit potencies in the range of 10(-7)-10(-8) M in these systems. The polynucleotides are active against virus strains resistant to AZT and pyridinone derivatives. Both PMTI and PMTG are synergistic with AZT and with ddI, and both inhibit HIV reverse transcriptase at nanomolar concentrations. The polymers show little or no toxicity in human cell lines at the highest doses tested (100 mu g/mL, or about 0.2-1 mu M). This class of compounds represents a new lead in AIDS therapeutic drug discovery.
C1 SO RES INST,FREDERICK RES CTR,DIV VIROL RES,FREDERICK,MD 21701.
RP BROOM, AD (reprint author), UNIV UTAH,COLL PHARM,DEPT MED CHEM,SALT LAKE CITY,UT 84112, USA.
FU PHS HHS [R01 27692]
CR AMARNATH V, 1977, BIOCHIM BIOPHYS ACTA, V479, P16, DOI 10.1016/0005-2787(77)90121-6
   ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0
   BARDOS TJ, 1992, ANTIMICROB AGENTS CH, V36, P108, DOI 10.1128/AAC.36.1.108                                                            
   BROOM AD, 1976, BIOCHEM BIOPH RES CO, V70, P1029, DOI 10.1016/0006-291X(76)91005-6
   BUCKHEIT RW, 1992, P NATL ACAD SCI USA, V89, P8361, DOI 10.1073/pnas.89.17.8361                                                         
   BUCKHEIT RW, 1993, ANTIVIR RES, V21, P247, DOI 10.1016/0166-3542(93)90031-D                                                    
   BUCKHEIT RW, 1991, AIDS RES HUM RETROV, V7, P295, DOI 10.1089/aid.1991.7.295
   CARTER WA, 1987, LANCET, V1, P1286
   CHOU JY, 1975, J BIOL CHEM, V250, P508
   CLOYD MW, 1990, VIROLOGY, V174, P103, DOI 10.1016/0042-6822(90)90059-Z                                                    
   GAO Q, 1994, ARCH VIROL, V136, P111, DOI 10.1007/BF01538821                                                              
   Gartner S, 1990, TECHNIQUES HIV RES, P53
   HOARD DE, 1965, J AM CHEM SOC, V87, P1785, DOI 10.1021/ja01086a031                                                             
   JOHNSTON MI, 1993, SCIENCE, V260, P1286, DOI 10.1126/science.7684163
   KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403
   LAURENTCRAWFORD AG, 1992, AIDS RES HUM RETROV, V8, P285, DOI 10.1089/aid.1992.8.285
   MANN JM, 1992, J INFECT DIS, V165, P245, DOI 10.1093/infdis/165.2.245                                                        
   MIURA K, 1975, CHEM PHARM BULL, V23, P2064
   MOSES RE, 1970, J BIOL CHEM, V245, P2414
   NARA PL, 1988, NATURE, V332, P469, DOI 10.1038/332469a0
   PRICHARD MN, 1990, ANTIVIR RES, V14, P181, DOI 10.1016/0166-3542(90)90001-N                                                    
   RATSEP PC, 1991, NUCLEOS NUCLEOT, V10, P1641, DOI 10.1080/15257779108043051
   SULEWSKI M, 1989, BIOCHEMISTRY-US, V28, P5855, DOI 10.1021/bi00440a023
   YOSHIKAWA M, 1969, B CHEM SOC JPN, V42, P3505, DOI 10.1246/bcsj.42.3505                                                            
NR 24
TC 13
Z9 13
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA PO BOX 57136, WASHINGTON, DC 20037-0136
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD AUG 18
PY 1995
VL 38
IS 17
BP 3253
EP 3257
DI 10.1021/jm00017a009
PG 5
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA RQ576
UT WOS:A1995RQ57600009
PM 7650678
DA 2018-01-05
ER

PT J
AU BUSSOLINO, F
   ARESE, M
   MONTRUCCHIO, G
   BARRA, L
   PRINO, L
   BENELLI, R
   SANAVIO, F
   AGLIETTA, M
   GHIGO, D
   ROLAPLESZCZYNSKI, M
   BOSIA, A
   ALBINI, A
   CAMUSSI, G
AF BUSSOLINO, F
   ARESE, M
   MONTRUCCHIO, G
   BARRA, L
   PRINO, L
   BENELLI, R
   SANAVIO, F
   AGLIETTA, M
   GHIGO, D
   ROLAPLESZCZYNSKI, M
   BOSIA, A
   ALBINI, A
   CAMUSSI, G
TI PLATELET-ACTIVATING-FACTOR PRODUCED IN-VITRO BY KAPOSIS-SARCOMA CELLS
   INDUCES AND SUSTAINS IN-VIVO ANGIOGENESIS
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
DE HIV; PLATELET ACTIVATING FACTOR ANTAGONIST; CHEMOKINE; GROWTH FACTOR;
   ANGIOGENESIS
ID ENDOTHELIAL GROWTH-FACTOR; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; TUMOR
   NECROSIS FACTOR; LONG-TERM CULTURE; VASCULAR-PERMEABILITY FACTOR;
   SMOOTH-MUSCLE CELLS; ONCOSTATIN-M; AIDS; EXPRESSION; GENE
AB Imbalance in the network of soluble mediators may play a pivotal role in the pathogenesis of Kaposi's sarcoma (KS), fn this study, we demonstrated that KS cells grown in vitro produced and in part released platelet activating factor (PAF), a powerful Lipid mediator of inflammation and cell-to-cell communication, IL-1, TNF, and thrombin enhanced the synthesis of PAF. PAF receptor mRNA and specific, high affinity binding site for PAF were present in KS cells. Nanomolar concentration of PAF stimulated the chemotaxis and chemokinesis of KS cells, endothelial cells, and vascular smooth muscle cells, The migration response to PAF was inhibited by WEB 2170, a hetrazepinoic PAF receptor antagonist, Because neoangiogenesis is essential for the growth and progression of KS and since PAF can activate vascular endothelial cells, we examined the potential role of PAF as an instrumental mediator of angiogenesis associated with KS, Conditioned medium (CM) from KS cells (KS-CM) or KS cells themselves induced angiogenesis and macrophage recruitment in a murine model in which Matrigel was injected subcutaneously, These effects were inhibited by treating mice with WEB 2170, Synthetic PAF or natural PAF extracted from plasma of patients with classical RS also induced angiogenesis, which in turn was inhibited by WEB 2170, The action of PAF was amplified by expression of other angiogenic factors and chemokines: these included basic and acidic fibroblast growth factor, placental growth factor, vascular endothelial growth factor and ifs specific receptor flk-1, hepatocyte growth factor, KC, and macrophage inflammatory protein-2 Tre;atment with WEB 2170 abolished the expression of the transcripts of these molecules within Matrigel containing KS-CM. These results indicate that PAF may cooperate with other angiogenic molecules and chemokines in inducing vascular development in KS.
C1 UNIV TURIN,DIPARTIMENTO FISIOPATOL CLIN,I-10126 TURIN,ITALY.
   IST NAZL RIC CANC,I-16100 GENOA,ITALY.
   UNIV TURIN,DIPARTIMENTO SCI BIOMED & ONCOL UMANA,I-10126 TURIN,ITALY.
   UNIV SHERBROOKE,FAC MED,DEPT PEDIAT,DIV IMMUNOL,SHERBROOKE,PQ J1K 2R1,CANADA.
   UNIV PAVIA,FAC MED 2,CATTEDRA NEFROL,I-21100 VARESE,ITALY.
RP BUSSOLINO, F (reprint author), UNIV TURIN,DIPARTIMENTO GENET BIOL & CHIM MED,VIA SANTENA 5 BIS,I-10126 TURIN,ITALY.
RI arese, marco/J-6119-2013; Camussi, Giovanni/J-7624-2016
OI arese, marco/0000-0002-7384-9406; Camussi, Giovanni/0000-0003-2795-232X;
   Bussolino, Federico/0000-0002-5348-1341; Ghigo,
   Dario/0000-0001-6050-1577
FU Telethon [582]
CR ABOULAFIA D, 1989, J ACQ IMMUN DEF SYND, V2, P54
   ALBINI A, 1992, INT J ONCOL, V1, P723
   ALBINI A, 1988, J CELL BIOCHEM, V36, P369, DOI 10.1002/jcb.240360406
   ALBINI A, 1994, AIDS, V8, P1237, DOI 10.1097/00002030-199409000-00004
   ARMES J, 1989, ADV CANCER RES, V53, P73, DOI 10.1016/S0065-230X(08)60279-1
   BAIRD A, 1985, BIOCHEM BIOPH RES CO, V126, P358, DOI 10.1016/0006-291X(85)90614-X
   BARILLARI G, 1992, J IMMUNOL, V149, P3727
   BAZAN NG, 1994, P NATL ACAD SCI USA, V91, P5252, DOI 10.1073/pnas.91.12.5252
   BERAL V, 1992, LANCET, V339, P632, DOI 10.1016/0140-6736(92)90793-3                                                    
   BERSE B, 1992, MOL BIOL CELL, V3, P211
   BORCK TA, 1986, AM J PHYSIOL, V250, pH1086
   BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X                                                    
   BREIER G, 1992, DEVELOPMENT, V114, P521
   BUSSOLINO F, 1994, J BIOL CHEM, V269, P2877
   BUSSOLINO F, 1988, J BIOL CHEM, V263, P11856
   BUSSOLINO F, 1987, J IMMUNOL, V139, P2439
   BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629
   CAMUSSI G, 1983, J IMMUNOL, V131, P2397
   CAMUSSI G, 1987, J EXP MED, V166, P1390, DOI 10.1084/jem.166.5.1390
   CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005
   COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5
   CORBEIL J, 1991, J IMMUNOL, V146, P2972
   DEGEN SJF, 1991, BIOCHEMISTRY-US, V30, P9781, DOI 10.1021/bi00104a030                                                             
   DELAPEYRIERE O, 1990, ONCOGENE, V5, P823
   ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0
   ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x
   ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161
   FOLKMAN J, 1992, J BIOL CHEM, V267, P10931
   FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277                                                         
   GILL P, 1990, AM J CLIN ONCOL-CANC, V13, P315, DOI 10.1097/00000421-199008000-00010
   Giraldo G, 1989, APMIS Suppl, V8, P62
   GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198
   HARRISON AC, 1978, J PATHOL, V124, P157, DOI 10.1002/path.1711240305
   HAVERKOS HW, 1985, NEW ENGL J MED, V312, P1518
   HEBERT JM, 1990, DEV BIOL, V138, P456
   HEUER HO, 1990, J PHARMACOL EXP THER, V255, P962
   HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0
   HUANG YQ, 1993, J CLIN INVEST, V91, P1191, DOI 10.1172/JCI116279                                                               
   HUANG YQ, 1992, LANCET, V339, P515, DOI 10.1016/0140-6736(92)90338-4
   IKEGAMI K, 1992, J LIPID MEDIATOR, V5, P177
   KAAYA EE, 1992, EUR J CANCER, V28A, P1890, DOI 10.1016/0959-8049(92)90030-6
   KHAN JO, 1992, AIDS CLIN REV, V4, P261
   KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554                                                         
   KUIJPERS TW, 1992, J CELL BIOL, V117, P565, DOI 10.1083/jcb.117.3.565
   LACASSE C, 1990, J LEUKOCYTE BIOL, V49, P245
   LEGOUVELLO S, 1992, J IMMUNOL, V149, P1289
   LI JJ, 1993, CANCER, V72, P2253, DOI 10.1002/1097-0142(19931001)72:7<2253::AID-CNCR2820720732>3.0.CO;2-4             
   LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223
   MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267
   MANTOVANI A, 1992, IMMUNOL TODAY, V13, P265, DOI 10.1016/0167-5699(92)90008-U
   MCMANUS LM, 1993, LAB INVEST, V69, P639
   MCNUTT NS, 1983, AM J PATHOL, V111, P62
   MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793
   MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068
   MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9
   MONTRUCCHIO G, 1994, J EXP MED, V180, P377, DOI 10.1084/jem.180.1.377
   MONTRUCCHIO G, 1993, CIRCULATION, V88, P1476
   MORE R, 1986, EMBO J, V5, P919
   MULLER E, 1993, P NATL ACAD SCI USA, V90, P5818, DOI 10.1073/pnas.90.12.5818                                                         
   NAIDU YM, 1994, P NATL ACAD SCI USA, V91, P5281, DOI 10.1073/pnas.91.12.5281
   NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792
   NAKAMURA S, 1992, SCIENCE, V255, P1437, DOI 10.1126/science.1371891
   NAKAMURA S, 1988, SCIENCE, V242, P426, DOI 10.1126/science.3262925
   PASSANITI A, 1992, LAB INVEST, V67, P519
   PRESCOTT SM, 1984, P NATL ACAD SCI USA, V81, P3934
   PRESCOTT SM, 1990, J BIOL CHEM, V268, P17381
   QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533
   ROLAPLESZCZYNSKI M, 1992, J LEUKOCYTE BIOL, V51, P609
   ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738
   RUTGERS JL, 1986, AM J PATHOL, V122, P493
   SAFAI B, 1985, ANN INTERN MED, V103, P744, DOI 10.7326/0003-4819-103-5-744
   SALAHUDDIN SZ, 1988, SCIENCE, V242, P430, DOI 10.1126/science.2459779                                                         
   SCHWERTSCHLAG US, 1988, J BIOL CHEM, V263, P13791
   SCIACCA FL, 1994, J IMMUNOL, V153, P4816
   SEEDS EAM, 1991, J LIPID MEDIATOR, V4, P111
   SMITH CS, 1994, CELL IMMUNOL, V155, P292, DOI 10.1006/cimm.1994.1123
   SMITH CS, 1994, J IMMUNOL, V153, P3997
   SNYDER F, 1987, PLATELET ACTIVATING
   STURZL M, 1992, P NATL ACAD SCI USA, V89, P7046, DOI 10.1073/pnas.89.15.7046                                                         
   TAPPERO JW, 1993, J AM ACAD DERMATOL, V28, P371, DOI 10.1016/0190-9622(93)70057-Z                                                    
   TAYLOR JF, 1972, BRIT J CANCER, V26, P483, DOI 10.1038/bjc.1972.66                                                             
   TEKAMPOLSON P, 1990, J EXP MED, V172, P911, DOI 10.1084/jem.172.3.911                                                           
   TESSNER TG, 1989, J BIOL CHEM, V264, P4794
   THOMPSON EW, 1991, CANCER RES, V51, P2670
   VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0
   WEICH HA, 1991, AM J PATHOL, V139, P1251
   WEINDEL K, 1992, BIOCHEM BIOPH RES CO, V183, P1167, DOI 10.1016/S0006-291X(05)80313-4
   WERNER S, 1989, INT J CANCER, V43, P1137, DOI 10.1002/ijc.2910430629
   WICK M R, 1991, Current Opinion in Oncology, V3, P377, DOI 10.1097/00001622-199104000-00021
   WITTEK AE, 1991, AIDS, V5, P1485, DOI 10.1097/00002030-199112000-00011
   XERRI L, 1991, AM J PATHOL, V38, P9
   YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6
   ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387
   1982, NEW ENGL J MED, V103, P248
NR 94
TC 87
Z9 88
U1 0
U2 5
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 222 E 70TH STREET, NEW YORK, NY 10021
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD AUG
PY 1995
VL 96
IS 2
BP 940
EP 952
DI 10.1172/JCI118142
PG 13
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA RM466
UT WOS:A1995RM46600036
PM 7543496
OA gold
DA 2018-01-05
ER

PT J
AU KNEBEL, NG
   SHARP, SR
   MADIGAN, MJ
AF KNEBEL, NG
   SHARP, SR
   MADIGAN, MJ
TI QUANTIFICATION OF THE ANTI-HIV DRUG SAQUINAVIR BY HIGH-SPEED ONLINE
   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY TANDEM MASS-SPECTROMETRY
SO JOURNAL OF MASS SPECTROMETRY
LA English
DT Article
AB A method is described for the fast routine determination of the anti-HIV drug saquinavir and its pentadeuterated analogue [H-2(5)] saquinavir in the plasma of healthy volunteers. The method is based an high-performance liquid chromatography (HPLC)/atmospheric pressure positive-ion chemical ionization (APCI) mass spectrometry, with a stable labelled form of saquinavir (C-13(6)-H-2(3)-N-15) as internal standard. Automated solid-phase extraction in combination with short-column HPLC and multiple reaction monitoring is employed for high selectivity and sensitivity, and this also permits rapid quantification (the run time per sample is 1.5 min) over the range of 0.4-200 ng ml(-1) with excellent accuracy and precision. Up to 200 samples per analyst per day can be analysed. This assay methodology illustrates the versatility of APCI tandem mass spectrometry, in conjunction with high-speed HPLC, for the fast routine quantification of drugs in the nanograms per millilitre range, which is essential for clinical pharmacokinetic studies.
RP KNEBEL, NG (reprint author), ROCHE PROD LTD,DEPT METAB & PHARMACOKINET,40 BROADWATER RD,WELWYN GARDEN CIT AL7 3AY,HERTS,ENGLAND.
CR AVERY MJ, 1992, BIOL MASS SPECTROM, V21, P353, DOI 10.1002/bms.1200210706
   COVEY TR, 1986, ANAL CHEM, V58, P2453, DOI 10.1021/ac00125a022
   EICHELBAUM M, 1986, J CLIN PHARMACOL, V26, P419
   EVANS KA, 1994, ANAL CHEM, V66, P699, DOI 10.1021/ac00077a019
   GILBERT JD, 1992, BIOL MASS SPECTROM, V21, P341, DOI 10.1002/bms.1200210704                                                          
   GILBERT JD, 1992, BIOL MASS SPECTROM, V31, P63
   KAYE B, 1992, BIOL MASS SPECTROM, V21, P585, DOI 10.1002/bms.1200211110
   MALCOLM SL, 1990, 9 INT ROCH RES REP
   MARTIN J A, 1991, Drugs of the Future, V16, P210
   MURPHY AT, 1994, BIOL MASS SPECTROM, V23, P621, DOI 10.1002/bms.1200231004
   Niessen W.M.A., 1992, LIQUID CHROMATOGRAPH
   PROCTOR CJ, 1983, ORG MASS SPECTROM, V18, P509, DOI 10.1002/oms.1210181204                                                          
   QIN XZ, 1994, J PHARMACEUT BIOMED, V12, P221, DOI 10.1016/0731-7085(94)90033-7
   ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354
   STRAUB KM, 1988, PROG DRUG METAB, V11, P267
NR 15
TC 34
Z9 34
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI W SUSSEX
PA BAFFINS LANE CHICHESTER, W SUSSEX, ENGLAND PO19 1UD
SN 1076-5174
J9 J MASS SPECTROM
JI J. Mass Spectrom.
PD AUG
PY 1995
VL 30
IS 8
BP 1149
EP 1156
DI 10.1002/jms.1190300812                                                  
          
PG 8
WC Biochemical Research Methods; Chemistry, Analytical; Spectroscopy
SC Biochemistry & Molecular Biology; Chemistry; Spectroscopy
GA RN313
UT WOS:A1995RN31300011
DA 2018-01-05
ER

PT J
AU BOADO, RJ
AF BOADO, RJ
TI ANTISENSE DRUG-DELIVERY THROUGH THE BLOOD-BRAIN-BARRIER
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE ENDOTHELIUM; BLOOD-BRAIN BARRIER; DRUG DELIVERY; ANTISENSE
   OLIGODEOXYNUCLEOTIDE; RNASE H; PHARMACOKINETICS; PHOSPHOROTHIOATE;
   PEPTIDE NUCLEIC ACID
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PEPTIDE NUCLEIC-ACIDS; ANTI-SENSE
   OLIGODEOXYNUCLEOTIDES; DOXORUBICIN-LOADED NANOPARTICLES;
   THYMINE-SUBSTITUTED POLYAMIDE; SEQUENCE-SPECIFIC INHIBITION; AIDS
   DEMENTIA COMPLEX; HA-RAS ONCOGENE; GENE-EXPRESSION; CELLULAR UPTAKE
AB The blood-brain barrier evolved to protect the brain against peripheral neurotransmitters, cytotoxins and microorganisms. This barrier prevents the delivery to brain of antisense oligomers and other potential therapeutics for the treatment of viral infections, tumors, and other brain disorders. The brain represents a shelter for the human immunodeficiency virus (HIV), for low grade gliomas, and early stages of metastatic tumors to the brain. Non-invasive delivery systems for antisense oligodeoxynucleotide (ODN) therapeutics have been developed that include transcellular avidin-based delivery systems, such as conjugates of avidin analogues and the monoclonal antibody directed to the transferrin receptor (OX26), which targets all tissues expressing these receptors including the blood-brain barrier and liver. Although 3'-biotinylation of phosphodies ter oligodeoxynucleotides provides complete protection against serum and cellular exonuclease-mediated degradation, the in vivo administration of unconjugated or vector-conjugated biotinylated PO-ODN results in a rapid degradation through an endonuclease-mediated mechanism, thus limiting the efficacy of this potential therapeutic for the brain. This rapid in vivo degradation also occurs with phosphorothioate-ODN containing a single internal phosphodiester bond. Alternatively, a biotinylated peptide nucleic acid (PNA) conjugated to the OX,26-streptavidin delivery system is metabolically stable in vivo and is transported to brain through the blood-brain barrier at a rate 28-fold higher than the oligomer alone. This results in a brain uptake comparable to that of morphine, a molecule well known for its pharmacological brain effects. In summary, this review discusses different approaches for delivery of antisense oligonucleotides to the brain and suggests that biotinylated PNA conjugated to avidin-based transcellular delivery system represents a model for the delivery of antisense therapeutics through the blood-brain barrier.
C1 UNIV CALIF LOS ANGELES,SCH MED,BRAIN RES INST,LOS ANGELES,CA 90095.
RP BOADO, RJ (reprint author), UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90095, USA.
CR ADELMAN JP, 1987, SCIENCE, V235, P1514, DOI 10.1126/science.3547652
   AGARWAL S, 1991, PROSPECTS ANTISENSE, P143
   AGRAWAL S, 1991, P NATL ACAD SCI USA, V88, P7595, DOI 10.1073/pnas.88.17.7595
   ATWOOD WJ, 1993, CLIN MICROBIOL REV, V6, P339
   BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222
   Been MD, 1993, NUCLEASES, P407
   BEHL C, 1993, NEUROSURGERY, V33, P679, DOI 10.1227/00006123-199310000-00018                                                
   BENNETT CF, 1992, MOL PHARMACOL, V41, P1023
   BICKEL U, 1993, P NATL ACAD SCI USA, V90, P2618, DOI 10.1073/pnas.90.7.2618
   BOADO R J, 1990, Molecular and Cellular Neuroscience, V1, P224, DOI 10.1016/1044-7431(90)90005-O
   BOADO RJ, 1992, BIOCONJUGATE CHEM, V3, P519, DOI 10.1021/bc00018a010
   BOADO RJ, 1994, BIOCONJUGATE CHEM, V5, P406, DOI 10.1021/bc00029a005
   BOADO RJ, 1995, IN PRESS DRUG METAB
   BOYD MT, 1991, AIDS, V5, P225, DOI 10.1097/00002030-199102000-00016
   BRIGHTMAN MW, 1977, EXP EYE RES, V25, P1, DOI 10.1016/S0014-4835(77)80008-0                                                   
   BROWN DA, 1994, J BIOL CHEM, V269, P26801
   BUCHARDT O, 1993, TRENDS BIOTECHNOL, V11, P384, DOI 10.1016/0167-7799(93)90097-S
   BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511                                                         
   CAZENAVE C, 1993, BIOCHIMIE, V75, P113, DOI 10.1016/0300-9084(93)90032-N
   CAZENAVE C, 1989, NUCLEIC ACIDS RES, V17, P4255, DOI 10.1093/nar/17.11.4255
   CHERNY DY, 1993, P NATL ACAD SCI USA, V90, P1667, DOI 10.1073/pnas.90.5.1667
   CHIANG MY, 1991, J BIOL CHEM, V266, P18162
   CHIANNILKULACHAI N, 1990, CANCER CHEMOTH PHARM, V26, P122, DOI 10.1007/BF02897257                                                              
   CHIANNILKULCHAI N, 1989, SELECT CANCER THER, V5, P1, DOI 10.1089/sct.1989.5.1
   CHIASSON BJ, 1992, EUR J PHARM-MOLEC PH, V227, P451, DOI 10.1016/0922-4106(92)90167-T
   CITRO G, 1992, P NATL ACAD SCI USA, V89, P7031, DOI 10.1073/pnas.89.15.7031
   COHEN JS, 1991, ANTIVIR RES, V16, P121, DOI 10.1016/0166-3542(91)90019-N
   COSSUM PA, 1993, J PHARMACOL EXP THER, V267, P1818
   COTTER FE, 1994, ONCOGENE, V9, P3049
   CROOKE RM, 1991, ANTI-CANCER DRUG DES, V6, P609
   CROOKE ST, 1992, ANNU REV PHARMACOL, V32, P329
   Crouch R. J., 1982, NUCLEASES, P211
   DALLAIRE L, 1992, BIOCHIM BIOPHYS ACTA, V1110, P59, DOI 10.1016/0005-2736(92)90294-V
   DAUMASDUPORT C, 1988, CANCER, V62, P2152, DOI 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T
   Degols G, 1992, Antisense Res Dev, V2, P293
   DEMIDOV VV, 1994, BIOCHEM PHARMACOL, V48, P1310, DOI 10.1016/0006-2952(94)90171-6
   DESMIDT PC, 1991, NUCLEIC ACIDS RES, V19, P4695, DOI 10.1093/nar/19.17.4695                                                          
   DOLNICK BJ, 1991, CANCER INVEST, V9, P185, DOI 10.3109/07357909109044229
   ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055
   EDER PS, 1993, BIOCHIMIE, V75, P123, DOI 10.1016/0300-9084(93)90033-O
   EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0
   EHRLICH G, 1994, ANTISENSE RES DEV, V4, P173
   ELSENHANS B, 1989, BIOCHEM PHARMACOL, V38, P3423, DOI 10.1016/0006-2952(89)90110-X
   FEDOROFF OY, 1993, J MOL BIOL, V233, P509, DOI 10.1006/jmbi.1993.1528
   FRANCOIS JC, 1994, NUCLEIC ACIDS RES, V22, P3943, DOI 10.1093/nar/22.19.3943
   GAGNOR C, 1987, NUCLEIC ACIDS RES, V15, P10419, DOI 10.1093/nar/15.24.10419
   GALBRAITH WM, 1994, ANTISENSE RES DEV, V4, P201
   GAMPER HB, 1993, NUCLEIC ACIDS RES, V21, P145, DOI 10.1093/nar/21.1.145
   GAO WY, 1992, MOL PHARMACOL, V41, P223
   Ghosh M K, 1992, Antisense Res Dev, V2, P111
   GILES RV, 1993, ANTI-CANCER DRUG DES, V8, P33
   GRAY GD, 1993, CANCER RES, V53, P577
   Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8
   GREEN NM, 1990, METHOD ENZYMOL, V184, P51
   HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811                                                         
   HELENE C, 1992, ANN NY ACAD SCI, V660, P27, DOI 10.1111/j.1749-6632.1992.tb21054.x                                              
   HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901
   Ho P T, 1991, Antisense Res Dev, V1, P329
   HOKE GD, 1991, NUCLEIC ACIDS RES, V19, P5743, DOI 10.1093/nar/19.20.5743
   IRIE S, 1988, J CLIN INVEST, V82, P508, DOI 10.1172/JCI113625
   IVERSEN P, 1991, ANTI-CANCER DRUG DES, V6, P531
   IVERSEN PL, 1994, ANTISENSE RES DEV, V4, P43
   IZANT JG, 1984, CELL, V36, P1007, DOI 10.1016/0092-8674(84)90050-3
   JACHIMCZAK P, 1993, J NEUROSURG, V78, P944, DOI 10.3171/jns.1993.78.6.0944
   JEFFERIES WA, 1984, NATURE, V312, P162, DOI 10.1038/312162a0
   JIRIKOWSKI GF, 1992, SCIENCE, V255, P996, DOI 10.1126/science.1546298
   KANG YS, 1995, DRUG METAB DISPOS, V23, P55
   KANG YS, 1994, PHARMACEUT RES, V11, P1257, DOI 10.1023/A:1018982125649                                                         
   KAPLAN I. I., 1944, American Journal of Medical Sciences, V207, P733, DOI 10.1097/00000441-194406000-00004
   KIM TS, 1991, J NEUROSURG, V74, P27, DOI 10.3171/jns.1991.74.1.0027                                                      
   KUMAGAI AK, 1987, J BIOL CHEM, V262, P15214
   LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128                                                            
   LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545                                                           
   LEONETTI JP, 1990, P NATL ACAD SCI USA, V87, P2448, DOI 10.1073/pnas.87.7.2448
   LETSINGER RL, 1989, P NATL ACAD SCI USA, V86, P6553, DOI 10.1073/pnas.86.17.6553
   LISZIEWICZ J, 1994, P NATL ACAD SCI USA, V91, P7942, DOI 10.1073/pnas.91.17.7942
   LISZIEWICZ J, 1992, P NATL ACAD SCI USA, V89, P11209, DOI 10.1073/pnas.89.23.11209
   LIU PK, 1994, ANN NEUROL, V36, P566, DOI 10.1002/ana.410360405                                                           
   LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474
   MAHALEY MS, 1989, J NEUROSURG, V71, P826, DOI 10.3171/jns.1989.71.6.0826                                                      
   MAHER LJ, 1988, NUCLEIC ACIDS RES, V16, P3341, DOI 10.1093/nar/16.8.3341
   MAJUMDAR C, 1989, BIOCHEMISTRY-US, V28, P1340, DOI 10.1021/bi00429a060                                                             
   MARCUSSEKURA CJ, 1987, NUCLEIC ACIDS RES, V15, P5749, DOI 10.1093/nar/15.14.5749
   MATSUKURA M, 1991, PROSPECTS ANTISENSE, P159
   MCCARTHY MM, 1994, BRAIN RES, V636, P209, DOI 10.1016/0006-8993(94)91019-7                                                    
   MERCOLA D, 1988, GENE, V72, P253, DOI 10.1016/0378-1119(88)90151-5
   MERGNY JL, 1992, SCIENCE, V256, P1681, DOI 10.1126/science.256.5064.1681                                                   
   Miller P. S., 1992, Antisense RNA and DNA., P241
   MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136                                                         
   MIYAJIMA N, 1989, CELL, V57, P31, DOI 10.1016/0092-8674(89)90169-4
   MONA BP, 1993, J BIOL CHEM, V268, P14514
   MORGAN DML, 1988, J CELL SCI, V91, P231
   MORRISON RS, 1991, J BIOL CHEM, V266, P728
   MURPHY PR, 1992, MOL ENDOCRINOL, V6, P877, DOI 10.1210/me.6.6.877
   NAVIA BA, 1986, ANN NEUROL, V19, P525, DOI 10.1002/ana.410190603
   NAVIA BA, 1986, ANN NEUROL, V19, P517, DOI 10.1002/ana.410190602
   NECKERS L, 1992, CRIT REV ONCOGENESIS, V3, P175
   NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210
   NIELSEN PE, 1993, ANTI-CANCER DRUG DES, V8, P53
   NITTA T, 1994, NEUROSURGERY, V34, P309, DOI 10.1227/00006123-199402000-00014                                                
   OLDENDORF WH, 1972, SCIENCE, V178, P984, DOI 10.1126/science.178.4064.984                                                    
   Ortigao J F, 1992, Antisense Res Dev, V2, P129
   PAGANELLI G, 1994, J NUCL MED, V35, pP55
   PARDRIDGE WM, 1991, FEBS LETT, V288, P30, DOI 10.1016/0014-5793(91)80996-G
   PARDRIDGE WM, 1987, METABOLISM, V36, P892, DOI 10.1016/0026-0495(87)90099-0
   PARDRIDGE WM, 1995, P NATL ACAD SCI USA, V92, P5592, DOI 10.1073/pnas.92.12.5592
   PARDRIDGE WM, 1995, ADV DRUG DELIVER REV, V15, P5, DOI 10.1016/0169-409X(95)00003-P
   Pardridge WM, 1993, DRUG DELIV, V1, P43, DOI 10.3109/10717549309031340
   Pardridge W. M., 1991, PEPTIDE DRUG DELIVER, P123
   Pardridge WM, 1993, DRUG DELIV, V1, P83
   PERRY VH, 1987, J EXP MED, V166, P1138, DOI 10.1084/jem.166.4.1138                                                          
   PODDEVIN B, 1994, ANTISENSE RES DEV, V4, P147
   QUARTIN RS, 1989, NUCLEIC ACIDS RES, V17, P7253, DOI 10.1093/nar/17.18.7253
   RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P11823, DOI 10.1073/pnas.89.24.11823
   REED JC, 1990, P NATL ACAD SCI USA, V87, P3660, DOI 10.1073/pnas.87.10.3660
   REED JC, 1990, CANCER RES, V50, P6565
   RESNICK L, 1988, NEUROLOGY, V38, P9, DOI 10.1212/WNL.38.1.9                                                              
   RIVERA RT, 1989, J CELL BIOL, V108, P2423, DOI 10.1083/jcb.108.6.2423
   ROBERTS RW, 1992, SCIENCE, V258, P1463, DOI 10.1126/science.1279808
   ROPERT C, 1992, ANN NY ACAD SCI, V660, P334, DOI 10.1111/j.1749-6632.1992.tb21105.x
   ROPERT C, 1994, ANTISENSE RES DEV, V4, P207
   SARIN PS, 1988, P NATL ACAD SCI USA, V85, P7448, DOI 10.1073/pnas.85.20.7448
   SCHOENBERG BS, 1983, ONCOLOGY NERVOUS SYS
   SCHWAB G, 1994, P NATL ACAD SCI USA, V91, P10460, DOI 10.1073/pnas.91.22.10460                                                        
   SCHWAB G, 1994, ANN ONCOL, V5, pS55, DOI 10.1093/annonc/5.suppl_4.S55                                                    
   SMITH CC, 1986, P NATL ACAD SCI USA, V83, P2787, DOI 10.1073/pnas.83.9.2787
   STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515                                                         
   STEIN CA, 1990, ANAL BIOCHEM, V188, P11
   STEVENSON M, 1989, J GEN VIROL, V70, P2673, DOI 10.1099/0022-1317-70-10-2673
   Stull R A, 1993, Antisense Res Dev, V3, P295
   Sullivan S M, 1992, Antisense Res Dev, V2, P187
   TEMSAMANI J, 1994, ANTISENSE RES DEV, V4, P35
   TEMSAMANI J, 1992, ANN NY ACAD SCI, V660, P318, DOI 10.1111/j.1749-6632.1992.tb21099.x
   TERASAKI T, 1988, J INFECT DIS, V158, P630, DOI 10.1093/infdis/158.3.630                                                        
   TIDD DM, 1989, BRIT J CANCER, V60, P343, DOI 10.1038/bjc.1989.283                                                            
   TIDD DM, 1992, ANTISENSE RNA DNA, P227
   VICKERS T, 1991, NUCLEIC ACIDS RES, V19, P3359, DOI 10.1093/nar/19.12.3359
   VONKNEBEL M, 1992, INT J CANCER, V51, P831, DOI 10.1002/ijc.2910510527                                                          
   WAHLESTEDT C, 1993, SCIENCE, V259, P528, DOI 10.1126/science.8380941
   WEI RD, 1970, EXPERIENTIA, V27, P366
   WEINTRAUB H, 1985, TRENDS GENET, V1, P22, DOI 10.1016/0168-9525(85)90010-1
   WESTPHAL M, 1989, NEUROSURGERY, V25, P681, DOI 10.1227/00006123-198911000-00001                                                
   WHITESELL L, 1993, P NATL ACAD SCI USA, V90, P4665, DOI 10.1073/pnas.90.10.4665
   WHITESIDE C, 1983, AM J PHYSIOL, V245, P496
   WICKSTROM E, 1986, J BIOCHEM BIOPH METH, V13, P97, DOI 10.1016/0165-022X(86)90021-7
   WUPONG S, 1992, PHARMACEUT RES, V9, P1010, DOI 10.1023/A:1015846209681                                                         
   WUPONG S, 1994, ANTISENSE RES DEV, V4, P155
   YAKUBOV LA, 1989, P NATL ACAD SCI USA, V86, P6454, DOI 10.1073/pnas.86.17.6454
   Yaswen P, 1993, Antisense Res Dev, V3, P67
   ZENDEGUI JG, 1992, NUCLEIC ACIDS RES, V20, P307, DOI 10.1093/nar/20.2.307
   ZHANG M, 1993, NEUROSCI LETT, V161, P223, DOI 10.1016/0304-3940(93)90299-Z
   Zhao Q, 1993, Antisense Res Dev, V3, P53
NR 152
TC 22
Z9 23
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD JUL
PY 1995
VL 15
IS 1-3
BP 73
EP 107
DI 10.1016/0169-409X(95)00006-S                                            
          
PG 35
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA RM376
UT WOS:A1995RM37600005
DA 2018-01-05
ER

PT J
AU SCHWARTZ, O
   MARECHAL, V
   DANOS, O
   HEARD, JM
AF SCHWARTZ, O
   MARECHAL, V
   DANOS, O
   HEARD, JM
TI HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 NEF INCREASES THE EFFICIENCY OF
   REVERSE TRANSCRIPTION IN THE INFECTED CELL
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID INVITRO; GENE; REPLICATION; PROTEIN
AB We have analyzed the replication of Nef(+) and Nef(-) isogenic human immunodeficiency virus in CEM, HUT78, MT4 lymphoid, and U937 monocytic cell lines, At each passage of infected cells, we have assessed the relative infectivity of the virus particles released in culture media by measuring the number of infectious units per nanogram of p24 protein. Values appeared to be 3- to 10-fold higher for the Nef(+) virus than for the Nef(-) virus. The positive effect of Nef was observed regardless of the cell line, the multiplicity of infection, and the number of virus replication cycles achieved. We showed, by using cells expressing glycosylphosphatidylinositol-linked CD4, that the enhancement of virion infectivity could be dissociated from the down-regulation of cell surface CD4 also induced by Nef. The gp120-to-p24 ratio and the RNA content of virus particles produced in the presence or in the absence of Nef were equivalent. Virions bound to cell surface CD4 receptors with equal efficiencies. Equivalent reverse transcriptase activities were measured both on exogenous substrate and on particle genomic RNAs. In contrast, reverse transcription in infected cells generated 5- to 10-fold less DNA when the virions were produced in the absence of Nef, indicating that these particles performed reverse transcription in a suboptimal environment. These data suggest that the expression of Nef in virus-producing cells is required for efficient processing of the early stages of virus replication in target cells, including the internalization in an appropriate cell compartment and the uncoating of the particle.
RP SCHWARTZ, O (reprint author), INST PASTEUR,CNRS,URA 1157,RETROVIRUS & TRANSFERT GENET LAB,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.
CR ADACHI A, 1986, J VIROL, V59, P284
   AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3
   ANDERSON SJ, 1994, J VIROL, V68, P3092
   ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916                                                         
   BORROTOESODA K, 1991, J VIROL, V65, P1952
   BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X                                                    
   CHOWERS MY, 1994, J VIROL, V68, P2906
   CLAVEL F, 1994, J VIROL, V68, P1179
   CLAVEL F, 1990, J VIROL, V64, P5230
   CULLEN BR, 1994, VIROLOGY, V205, P1, DOI 10.1006/viro.1994.1613
   DERONDE A, 1992, VIROLOGY, V188, P391, DOI 10.1016/0042-6822(92)90772-H                                                    
   FRANCHINI G, 1986, VIROLOGY, V155, P593, DOI 10.1016/0042-6822(86)90219-9
   FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0
   GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0
   GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X
   GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0
   HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5
   KAMINCHIK J, 1991, J VIROL, V65, P583
   KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I                                                    
   KIM SY, 1989, P NATL ACAD SCI USA, V86, P9544, DOI 10.1073/pnas.86.23.9544
   MARSHALL WL, 1994, J VIROL, V68, P4039
   MILLER MD, 1995, J VIROL, V69, P579
   MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101
   Miller Michael D., 1994, Trends in Microbiology, V2, P294, DOI 10.1016/0966-842X(94)90007-8
   SCHWARTZ O, 1995, J VIROL, V69, P528
   SCHWARTZ O, 1993, J VIROL, V67, P3274
   SCHWARTZ O, 1994, VIROLOGY, V198, P360, DOI 10.1006/viro.1994.1042                                                          
   SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115                                                           
   TERWILLIGER E, 1986, J VIROL, V60, P754
   THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0
   TRONO D, 1992, J VIROL, V66, P4893
   ZAZOPOULOS E, 1992, P NATL ACAD SCI USA, V89, P6634, DOI 10.1073/pnas.89.14.6634                                                         
NR 32
TC 230
Z9 230
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD JUL
PY 1995
VL 69
IS 7
BP 4053
EP 4059
PG 7
WC Virology
SC Virology
GA RC226
UT WOS:A1995RC22600013
PM 7539505
DA 2018-01-05
ER

PT J
AU AHGREN, C
   BACKRO, K
   BELL, FW
   CANTRELL, AS
   CLEMENS, M
   COLACINO, JM
   DEETER, JB
   ENGELHARDT, JA
   HOGBERG, M
   JASKUNAS, SR
   JOHANSSON, NG
   JORDAN, CL
   KASHER, JS
   KINNICK, MD
   LIND, P
   LOPEZ, C
   MORIN, JM
   MUESING, MA
   NOREEN, R
   OBERG, B
   PAGET, CJ
   PALKOWITZ, JA
   PARRISH, CA
   PRANC, P
   RIPPY, MK
   RYDERGARD, C
   SAHLBERG, C
   SWANSON, S
   TERNANSKY, RJ
   UNGE, T
   VASILEFF, RT
   VRANG, L
   WEST, SJ
   ZHANG, H
   XHOU, XX
AF AHGREN, C
   BACKRO, K
   BELL, FW
   CANTRELL, AS
   CLEMENS, M
   COLACINO, JM
   DEETER, JB
   ENGELHARDT, JA
   HOGBERG, M
   JASKUNAS, SR
   JOHANSSON, NG
   JORDAN, CL
   KASHER, JS
   KINNICK, MD
   LIND, P
   LOPEZ, C
   MORIN, JM
   MUESING, MA
   NOREEN, R
   OBERG, B
   PAGET, CJ
   PALKOWITZ, JA
   PARRISH, CA
   PRANC, P
   RIPPY, MK
   RYDERGARD, C
   SAHLBERG, C
   SWANSON, S
   TERNANSKY, RJ
   UNGE, T
   VASILEFF, RT
   VRANG, L
   WEST, SJ
   ZHANG, H
   XHOU, XX
TI THE PETT SERIES, A NEW CLASS OF POTENT NONNUCLEOSIDE INHIBITORS OF
   HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID HIV-1 REPLICATION; DERIVATIVES; TISSUE; ALPHA
AB To identify the minimal structural elements necessary for biological activity, the rigid tricyclic nucleus of the known human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) inhibitor tetrahydroimidazobenzodiazepinthione was subjected to systematic bond disconnection to obtain simpler structures. A rational selection and testing of modeled analogs containing these potential pharmacophoric moieties led to the discovery of a new series of nonnucleoside inhibitors of RT. The lead compound of this new PETT series of nonnucleoside RT inhibitors, N-(2-phenylethyl)-N'-(2-thiazolyl)thiourea (LY73497), was found to inhibit HIV-1 but not HIV-2 or simian immunodeficiency virus in cell culture at micromolar concentrations. This derivative was also found to inhibit HIV-1 RT. Through an integrated effort involving synthesis and molecular modeling, compounds with nanomolar potency against HIV-1 in cell culture were developed. In these studies, LY300046-HCl was identified as a potent nonnucleoside inhibitor of HIV-1 RT possessing favorable pharmacokinetic properties.
C1 MEDIVIR AB,HUDDINGE,SWEDEN.
   ELI LILLY & CO,LILLY RES LABS,INDIANAPOLIS,IN 46285.
   UNIV UPPSALA,CTR BIOMED,DEPT MOLEC BIOL,S-75123 UPPSALA,SWEDEN.
   KAROLINSKA INST,MTC,STOCKHOLM,SWEDEN.
FU NCRR NIH HHS [RR-00165]
CR BALZARINI J, 1993, VIROLOGY, V192, P246, DOI 10.1006/viro.1993.1027
   GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863
   HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081                                                         
   HARGRAVE KD, 1991, J MED CHEM, V34, P2231, DOI 10.1021/jm00111a045
   KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903
   MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568                                                         
   Nanni Raymond G., 1993, Perspectives in Drug Discovery and Design, V1, P129, DOI 10.1007/BF02171659
   NUNBERG JH, 1991, J VIROL, V65, P4887
   PARKER WB, 1991, J BIOL CHEM, V266, P1754
   PAUWELS R, 1993, P NATL ACAD SCI USA, V90, P1711, DOI 10.1073/pnas.90.5.1711                                                          
   PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0
   RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241
   ROMERO DL, 1991, P NATL ACAD SCI USA, V88, P8806, DOI 10.1073/pnas.88.19.8806                                                         
   SAARI WS, 1991, J MED CHEM, V34, P2922, DOI 10.1021/jm00113a036
   SHIH CK, 1991, P NATL ACAD SCI USA, V88, P9878, DOI 10.1073/pnas.88.21.9878
   SWAYZE EE, 1993, BIOORG MED CHEM LETT, V3, P543, DOI 10.1016/S0960-894X(01)81224-5                                                   
   VREESE KD, 1992, VIROLOGY, V188, P900
   ZHANG H, 1993, ANTIVIR CHEM CHEMOTH, V4, P301, DOI 10.1177/095632029300400506                                                      
   ZHANG H, IN PRESS ANTIVIRAL R
NR 19
TC 90
Z9 94
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JUN
PY 1995
VL 39
IS 6
BP 1329
EP 1335
DI 10.1128/AAC.39.6.1329                                                   
          
PG 7
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA RB370
UT WOS:A1995RB37000020
PM 7574525
OA gold
DA 2018-01-05
ER

PT J
AU AGOSTINIS, P
   VANDENBOGAERDE, A
   DONELLADEANA, A
   PINNA, LA
   LEE, KT
   GORIS, J
   MERLEVEDE, W
   VANDENHEEDE, JR
   DEWITTE, P
AF AGOSTINIS, P
   VANDENBOGAERDE, A
   DONELLADEANA, A
   PINNA, LA
   LEE, KT
   GORIS, J
   MERLEVEDE, W
   VANDENHEEDE, JR
   DEWITTE, P
TI PHOTOSENSITIZED INHIBITION OF GROWTH FACTOR-REGULATED PROTEIN-KINASES BY
   HYPERICIN
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE HYPERICIN; TYROSINE KINASE; MAP KINASE; CASEIN KINASE 2; INHIBITION;
   SIGNAL TRANSDUCTION
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL ACTIVITY; VIRUCIDAL
   ACTIVITY; CASEIN KINASE-2; AGENTS; PSEUDOHYPERICIN; PEPTIDES;
   PHOSPHORYLATION; ANTHRAQUINONES; INACTIVATION
AB The naphthodianthrone hypericin causes a photosensitized inhibition of protein kinases involved in growth factor signalling pathways. Nanomolar concentrations of hypericin inhibit the protein tyrosine kinase activities (PTR) of the epidermal growth factor receptor and the insulin receptor, while being ineffective towards the cytosolic protein tyrosine kinases Lyn, Fgr, TPK-IIB and CSK. Photosensitized inhibition by hypericin is not restricted to receptor-PTKs since the Ser/Thr protein kinases (protein kinase CK-2, protein kinase C and mitogen-activated kinase) are also extremely sensitive to inhibition (IC50 value for protein kinase CK-2 = 6 nM). A comparison of the hypericin-mediated inhibition of the epidermal growth factor-receptor PTK and protein kinase CK-2 revealed that the inhibition is irreversible, strictly dependent upon irradiation of the enzyme-inhibitor complex with fluorescent light and likely mediated by the formation of radical intermediates (type I mechanism). Although the exact molecular basis for the selectivity of enzyme inhibition by hypericin remains unknown, our results suggest that distantly related protein kinases could still share common reactive domains for the interaction with hypericin.
C1 KATHOLIEKE UNIV LEUVEN,FAC GENEESKUNDE,AFDELING BIOCHEM,B-3001 LOUVAIN,BELGIUM.
   KATHOLIEKE UNIV LEUVEN,FAC FARMACEUT WETENSCHAPPEN,FARMACEUT BIOL LAB,B-3001 LOUVAIN,BELGIUM.
   UNIV PADUA,DIPARTIMENTO CHIM BIOL,PADUA,ITALY.
   UNIV PADUA,CNR,CTR STUDIO FISIOL MITOCONDRIALE,PADUA,ITALY.
OI Agostinis, Patrizia/0000-0003-1314-2115; de Witte,
   Peter/0000-0002-9989-9567
CR AGOSTINIS P, 1992, EUR J BIOCHEM, V205, P241, DOI 10.1111/j.1432-1033.1992.tb16774.x                                              
   ANDERSEN DO, 1991, ANTIVIR RES, V16, P185, DOI 10.1016/0166-3542(91)90024-L
   BRUNATI AM, 1993, EUR J BIOCHEM, V216, P323, DOI 10.1111/j.1432-1033.1993.tb18149.x
   CARPENTER S, 1991, PHOTOCHEM PHOTOBIOL, V53, P169, DOI 10.1111/j.1751-1097.1991.tb03919.x                                              
   COLA C, 1989, BIOCHIM BIOPHYS ACTA, V1012, P191, DOI 10.1016/0167-4889(89)90095-5
   COOPER JA, 1983, METHOD ENZYMOL, V99, P387
   DEGAR S, 1992, AIDS RES HUM RETROV, V8, P1929, DOI 10.1089/aid.1992.8.1929
   DEWITTE P, 1993, BIOCHEM PHARMACOL, V46, P1929, DOI 10.1016/0006-2952(93)90633-8
   DIWU ZJ, 1994, PHARMACOL THERAPEUT, V63, P1, DOI 10.1016/0163-7258(94)90054-X                                                    
   DIWU ZJ, 1993, FREE RADICAL BIO MED, V14, P209, DOI 10.1016/0891-5849(93)90012-J
   DOBROWOLSKA G, 1991, BIOCHIM BIOPHYS ACTA, V1129, P139, DOI 10.1016/0167-4781(91)90230-J
   DONELLADEANA A, 1992, EUR J BIOCHEM, V204, P1159, DOI 10.1111/j.1432-1033.1992.tb16742.x
   DVIR A, 1991, J CELL BIOL, V113, P857, DOI 10.1083/jcb.113.4.857
   GEISSLER JF, 1990, J BIOL CHEM, V265, P22255
   Giese A.C., 1980, PHOTOCHEMICAL AND PHOTOBIOLOGICAL REVIEWS, V5, P229
   HACCARD O, 1993, MOL REPROD DEV, V36, P96, DOI 10.1002/mrd.1080360114
   HONMA Y, 1992, CANCER RES, V48, P1587
   HUDSON JB, 1991, ANTIVIR RES, V15, P101, DOI 10.1016/0166-3542(91)90028-P
   HUNTER T, 1989, ONCOGENES MOL ORIGIN, P147
   LAVIE G, 1989, P NATL ACAD SCI USA, V86, P5963, DOI 10.1073/pnas.86.15.5963
   LOPEZBAZZOCCHI I, 1991, PHOTOCHEM PHOTOBIOL, V54, P95, DOI 10.1111/j.1751-1097.1991.tb01990.x
   MARIN O, 1991, J BIOL CHEM, V266, P17798
   MEGGIO F, 1994, BIOCHEMISTRY-US, V33, P4336, DOI 10.1021/bi00180a030
   MERCIER JC, 1968, B SOC CHIM BIOL, V50, P521
   MERUELO D, 1988, P NATL ACAD SCI USA, V85, P5230, DOI 10.1073/pnas.85.14.5230
   MURAKAMI Y, 1988, CANCER RES, V48, P1587
   SCHINAZI RF, 1990, ANTIVIR RES, V13, P265, DOI 10.1016/0166-3542(90)90071-E
   TAKAHASHI I, 1989, BIOCHEM BIOPH RES CO, V165, P1207, DOI 10.1016/0006-291X(89)92730-7
   TANG J, 1990, ANTIVIR RES, V13, P313, DOI 10.1016/0166-3542(90)90015-Y
   TAYLOR A, 1987, FEBS LETT, V226, P109, DOI 10.1016/0014-5793(87)80561-6
   THOM D, 1977, BIOCHEM J, V168, P187, DOI 10.1042/bj1680187                                                               
   TRAXLER PM, 1991, J MED CHEM, V34, P2328, DOI 10.1021/jm00112a003
   YANG SD, 1981, FEBS LETT, V132, P293, DOI 10.1016/0014-5793(81)81182-9                                                    
NR 33
TC 65
Z9 66
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0006-2952
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD MAY 26
PY 1995
VL 49
IS 11
BP 1615
EP 1622
DI 10.1016/0006-2952(95)00097-J                                            
          
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA RB853
UT WOS:A1995RB85300010
PM 7786302
DA 2018-01-05
ER

PT J
AU YAMASAKI, K
   SAITO, M
   OOBATAKE, M
   KANAYA, S
AF YAMASAKI, K
   SAITO, M
   OOBATAKE, M
   KANAYA, S
TI CHARACTERIZATION OF THE INTERNAL MOTIONS OF ESCHERICHIA-COLI
   RIBONUCLEASE HI BY A COMBINATION OF N-15-NMR RELAXATION ANALYSIS AND
   MOLECULAR-DYNAMICS SIMULATION - EXAMINATION OF DYNAMIC-MODELS
SO BIOCHEMISTRY
LA English
DT Article
ID HETERONUCLEAR NMR-SPECTROSCOPY; MAGNETIC-RESONANCE RELAXATION;
   DNA-BINDING DOMAIN; BACKBONE DYNAMICS; NUCLEIC-ACIDS; FORCE-FIELD;
   PROTEINS; MACROMOLECULES; C-13; INTERLEUKIN-1-BETA
AB The backbone dynamics of Escherichia coli ribonuclease HI (RNase HI) in the picosecond to nanosecond time scale were characterized by a combination of measurements of N-15-NMR relaxation (T-1, T-2, and NOE), analyzed by a model-free approach, and molecular dynamics (MD) simulation in water. The MD simulations in water were carried out with long-range Coulomb interactions to avoid the artificial fluctuation caused by the cutoff approximation. The model-free analysis of the N-15-NMR relaxation indicated that RNase HI has a rotational correlation time of 10.9 ns at 27 degrees C. The generalized order parameter (S-2) for the internal motions varied from 0.15 to 1.0, with an average value of 0.85, which is much larger than that of the RNase H domain of HIV-1 reverse transcriptase (0.78). Large internal motions (small order parameters) were observed in the N-terminal region (Leu2-Lys3), the loop between beta-strands A and B (Cys13-Gly15), the turn between alpha-helix I and beta-strand D (Glu61, His62), the loop between beta-strand D and alpha-helix II (Asp70-Tyr71), the loop between alpha-helices III and IV (Ala93-Lys96), the loop between beta-strand E and alpha-helix V (Gly123-His127), and the C-terminal region (Gln152-Val155). The effective correlation time observed in these regions varied from 0.45 ns (Glu61, Lys96) to 2.2 ns (Leu14). The order parameters calculated from the MD agreed well with those from the NMR experiment, with a few exceptions. The distributions of most of the backbone N-H vectors obtained by MD are approximately consistent with the diffusion-in-a-cone model. These distributions, however, were elliptic, with a long axis perpendicular to the plane defined by the N-H and N-C-alpha vectors. Distributions supporting the axial fluctuation model or the jump-between-two-cones model were also observed in the MD simulation.
RP YAMASAKI, K (reprint author), PROT ENGN RES INST,6-2-3 FURUEDAI,SUITA,OSAKA 565,JAPAN.
CR Abragam A., 1961, PRINCIPLES NUCLEAR M, P264
   BALASUBRAMANIAN S, 1994, J MAGN RESON SER B, V104, P240, DOI 10.1006/jmrb.1994.1081
   BERENDSEN HJC, 1981, INTERMOLECULAR FORCE, P331
   BROOKS CL, 1988, PROTEINS THEORETICAL, P194
   BROWN D, 1984, MOL PHYS, V51, P1243, DOI 10.1080/00268978400100801                                                       
   BRUSCHWEILER R, 1994, J AM CHEM SOC, V116, P8426
   CHANDRASEKHAR I, 1992, J MOL BIOL, V226, P239, DOI 10.1016/0022-2836(92)90136-8
   CLORE GM, 1990, BIOCHEMISTRY-US, V29, P7387, DOI 10.1021/bi00484a006                                                             
   CONNOLLY ML, 1993, J MOL GRAPHICS, V11, P139, DOI 10.1016/0263-7855(93)87010-3
   CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170
   Crouch R. J., 1982, NUCLEASES, P211
   ERIKSSON MAL, 1993, PROTEINS, V17, P375, DOI 10.1002/prot.340170406
   FUSHMAN D, 1994, J BIOMOL NMR, V4, P61, DOI 10.1007/BF00178336
   FUSHMAN D, 1994, J BIOMOL STRUCT DYN, V11, P1377, DOI 10.1080/07391102.1994.10508074                                                  
   HARUKI M, 1994, J BIOL CHEM, V269, P26904
   HIYAMA Y, 1988, J AM CHEM SOC, V110, P237
   HOEL PG, 1971, INTRO MATH STATISTIC
   HUBBARD SJ, 1994, PROTEIN ENG, V7, P613, DOI 10.1093/protein/7.5.613
   JONES DNM, 1994, STRUCTURE, V15, P609
   JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001
   KANAYA S, 1993, J BIOTECHNOL, V28, P117, DOI 10.1016/0168-1656(93)90129-B                                                    
   KANAYA S, 1983, J BIOL CHEM, V258, P1276
   KANAYA S, 1991, J BIOL CHEM, V266, P11621
   KANAYA S, 1990, J BIOL CHEM, V264, P4615
   KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q                                                    
   KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0
   KAY LE, 1992, J MAGN RESON, V97, P359, DOI 10.1016/0022-2364(92)90320-7                                                    
   KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003
   KINOSITA K, 1977, BIOPHYS J, V20, P289, DOI 10.1016/S0006-3495(77)85550-1                                                   
   Levenberg K., 1944, Quarterly of Applied Mathematics, V2, P164
   LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009
   LIPARI G, 1980, BIOPHYS J, V30, P489, DOI 10.1016/S0006-3495(80)85109-5                                                   
   LIPARI G, 1982, NATURE, V300, P197, DOI 10.1038/300197a0
   Maniatis T., 1982, MOL CLONING
   MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2
   MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030                                                                 
   MORIKAMI K, 1992, COMPUT CHEM, V16, P243, DOI 10.1016/0097-8485(92)80010-W
   NIRMALA NR, 1989, J MAGN RESON, V82, P659, DOI 10.1016/0022-2364(89)90232-1
   NIRMALA NR, 1988, J AM CHEM SOC, V110, P7557, DOI 10.1021/ja00230a057
   ODA Y, 1993, J BIOL CHEM, V268, P88
   PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001                                                             
   POWERS R, 1992, BIOCHEMISTRY-US, V31, P9150, DOI 10.1021/bi00153a006
   SAITO M, 1992, MOL SIMULAT, V8, P321, DOI 10.1080/08927029208022487                                                       
   SAITO M, 1994, J CHEM PHYS, V101, P4055, DOI 10.1063/1.468411                                                                
   SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2
   SHARP KA, 1994, TRENDS BIOCHEM SCI, V19, P526, DOI 10.1016/0968-0004(94)90051-5
   Singh U.C., 1986, AMBER UCSF VERSION 3
   Wagner G, 1986, Methods Enzymol, V131, P307
   WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216
   WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051                                                             
   WITTEBORT RJ, 1978, J CHEM PHYS, V69, P1722, DOI 10.1063/1.436748                                                                
   WOESSNER DE, 1962, J CHEM PHYS, V36, P1, DOI 10.1063/1.1732274
   YAMAZAKI T, 1993, BIOCHEMISTRY-US, V32, P5656, DOI 10.1021/bi00072a023                                                             
   YAMAZAKI T, 1991, BIOCHEMISTRY-US, V30, P6036, DOI 10.1021/bi00238a030
   YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648
NR 55
TC 66
Z9 66
U1 0
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA PO BOX 57136, WASHINGTON, DC 20037-0136
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD MAY 23
PY 1995
VL 34
IS 20
BP 6587
EP 6601
DI 10.1021/bi00020a003
PG 15
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA QZ902
UT WOS:A1995QZ90200003
PM 7756290
DA 2018-01-05
ER

PT J
AU ALLAWAY, GP
   DAVISBRUNO, KL
   BEAUDRY, GA
   GARCIA, EB
   WONG, EL
   RYDER, AM
   HASEL, KW
   GAUDUIN, MC
   KOUP, RA
   MCDOUGAL, JS
   MADDON, PJ
AF ALLAWAY, GP
   DAVISBRUNO, KL
   BEAUDRY, GA
   GARCIA, EB
   WONG, EL
   RYDER, AM
   HASEL, KW
   GAUDUIN, MC
   KOUP, RA
   MCDOUGAL, JS
   MADDON, PJ
TI EXPRESSION AND CHARACTERIZATION OF CD4-IGG(2), A NOVEL HETEROTETRAMER
   THAT NEUTRALIZES PRIMARY HIV TYPE-1 ISOLATES
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID RECOMBINANT SOLUBLE CD4; INFECTION; VIRUS; MOLECULES; GP120;
   DISSOCIATION; INHIBITION; ANTIBODIES; VIRIONS; FUSION
AB CD4-IgG(2) is a novel fusion protein comprising human IgG(2) in which the Fv portions of both heavy and light chains have been replaced by the V1 and V2 domains of human CD4. This tetrameric protein is being developed as an immunoprophylactic agent to reduce the probability of infection following HIV-1 exposure, in settings such as occupational or perinatal exposure to the virus. CD4-IgG(2) has been expressed in Chinese hamster ovary cells and is secreted as a fully assembled heterotetramer. The protein binds with nanomolar affinity to purified gp120 from both a laboratory-adapted strain and a primary isolate of HIV-1. Pharmacokinetic studies in rabbits demonstrated that CD4-IgG(2) has a plasma terminal half-life greater than 1 day, compared with 15 min for soluble CD4 (sCD4), CD4-IgG(2) does not bind to Fc receptors on the surface of U937 monocyte/macrophage cells, Compared to molecules that incorporate the Fc portion of IgG(1), CD4-IgG(2) has less potential to mediate functions such as antibody-dependent enhancement of infection or transplacental transmission of HIV-1. When tested in a virus-free HIV-1 envelope glycoprotein-mediated cell fusion assay, the tetrameric CD4-IgG(2) molecule inhibited syncytium formation more effectively than monomeric sCD4 or a dimeric CD4-gamma 2 fusion protein, This suggests the protein will block cell-to-cell transmission of HIV-1, Moreover, CD4-IgG(2) effectively neutralized a panel of laboratory-adapted strains and primary isolates of HIV-1, including strains with different tropisms and isolated from different stages of the disease, at concentrations that should be readily achieved in vivo.
C1 AARON DIAMOND AIDS RES CTR,NEW YORK,NY 10016.
   CTR DIS CONTROL & PREVENT,ATLANTA,GA 30333.
RP ALLAWAY, GP (reprint author), PROGEN PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.
CR ALLAWAY GP, 1993, AIDS RES HUM RETROV, V9, P581, DOI 10.1089/aid.1993.9.581
   CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0
   DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574                                                         
   DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0
   DSOUZA MP, 1994, AIDS, V8, P169
   FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0
   GERBERDING JL, 1994, TXB AIDS MED, P841
   GOMATOS PJ, 1992, AIDS ETIOLOGY DIAGNO, P406
   HAY FC, 1971, CLIN EXP IMMUNOL, V9, P355
   KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751
   MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7
   Mofenson L M, 1994, PEDIATRIC AIDS CHALL, P841
   MOFENSON LM, 1994, PEDIATRIC AIDS CHALL, P179
   MOORE JP, 1994, J VIROL, V68, P5142
   MOORE JP, 1991, J VIROL, V65, P1133
   MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501
   MORRISON SL, 1989, ADV IMMUNOL, V44, P65, DOI 10.1016/S0065-2776(08)60640-9                                                   
   ORLOFF SL, 1993, J VIROL, V67, P1461
   OXTOBY MJ, 1994, PEDIAT AIDS CHALLENG, P3
   POUND JD, 1990, HUMAN IGG SUBCLASSES, P111
   SCHACKER T, 1994, J INFECT DIS, V169, P37, DOI 10.1093/infdis/169.1.37                                                         
   SCHLESINGER JJ, 1981, J IMMUNOL, V127, P659
   TOKARS JI, 1993, ANN INTERN MED, V118, P913, DOI 10.7326/0003-4819-118-12-199306150-00001
   TOTH FD, 1994, CLIN EXP IMMUNOL, V96, P389
   TRAUNECKER A, 1989, NATURE, V339, P68, DOI 10.1038/339068a0                                                                
   URLAUB G, 1983, CELL, V33, P405, DOI 10.1016/0092-8674(83)90422-1
   WARD RHR, 1991, NATURE, V352, P434, DOI 10.1038/352434a0
   WHITESCHARF ME, 1993, VIROLOGY, V192, P197, DOI 10.1006/viro.1993.1022
   1994, FETUS ADOLESCENT, V5, P265
NR 29
TC 177
Z9 180
U1 0
U2 4
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD MAY
PY 1995
VL 11
IS 5
BP 533
EP 539
DI 10.1089/aid.1995.11.533
PG 7
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA RA347
UT WOS:A1995RA34700001
PM 7576908
DA 2018-01-05
ER

PT J
AU KOSSOVSKY, N
   GELMAN, A
   SPONSLER, E
   RAJGURU, S
   TORRES, M
   MENA, E
   LY, K
   FESTEKJIAN, A
AF KOSSOVSKY, N
   GELMAN, A
   SPONSLER, E
   RAJGURU, S
   TORRES, M
   MENA, E
   LY, K
   FESTEKJIAN, A
TI PRESERVATION OF SURFACE-DEPENDENT PROPERTIES OF VIRAL-ANTIGENS FOLLOWING
   IMMOBILIZATION ON PARTICULATE CERAMIC DELIVERY VEHICLES
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
ID INDUCTION; IMMUNIZATION; PARTICLES; PROTEINS; PEPTIDE; CHARGE
AB B-cell stimulation for the purpose of evoking an effective neutralizing humoral immune response is a surface phenomenon that is exquisitely specific to antigen conformation. Consequently, successful delivery of antigen, such as would be desired in a vaccine, entails preservation of an antigen's apparent native surface (conformational) properties. Prior to testing the actual vaccinating efficacy of delivered antigens, the surface properties could be assessed through a variety of in vitro and in vivo assays in which the measurement standard would be the properties of the antigens in their native state (whole virus). Using surface modified nanocrystalline carbon and calcium-phosphate ceramic particulates (carbon ceramics and brushite), we evaluated the surface activity of immobilized non-nuclear material extracted from HIV-1. Physical characterization showed that the particles with immobilized antigen (''HIV decoys'') measured 50 nm in diameter (HN = 50-100 nm) and exhibited the same zeta potentials as whole (live) HIV. In vitro testing showed that the HN decoys were recognized by both conformationally nonspecific and specific monoclonal antibodies, were recognized by human IgG from HIV antibody-positive patients, and could promote surface agglomeration among malignant T-cells similar to live HIV. Last, in vivo testing in three vaccinated animal species showed that the HIV decoys elicited humoral and cellular immune responses similar to that evoked by whole (live) HIV. (C) 1995 John Wiley and Sons, Inc.
RP KOSSOVSKY, N (reprint author), UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL & LAB MED,BIOMAT BIOREACT CHARACTERIZAT LAB,LOS ANGELES,CA 90024, USA.
CR ADA G, 1992, ENCY IMMUNOLOGY, P1540
   ALLISON AC, 1992, VACCINES NEW APPROAC, P431
   ALSHAKHSHIR R, 1994, VACCINE, V12, P472, DOI 10.1016/0264-410X(94)90127-9                                                    
   ARAKAWA T, 1992, BIOCHEMISTRY-US, V21, P6536
   CALLAHAN PM, 1991, PHARMACEUT RES, V8, P851, DOI 10.1023/A:1015843210358                                                         
   CHEDID L, 1987, SYNTHETIC VACCINES, P93
   CROWE JH, 1988, BIOCHIM BIOPHYS ACTA, V947, P367, DOI 10.1016/0304-4157(88)90015-9                                                    
   CROWE JH, 1971, AM NAT, V105, P563, DOI 10.1086/282745                                                                  
   FRANKS F, 1994, BIO-TECHNOL, V12, P253, DOI 10.1038/nbt0394-253
   FRIEDE M, 1993, MOL IMMUNOL, V30, P539, DOI 10.1016/0161-5890(93)90028-A
   Germain Ronald N., 1993, P629
   GOODLICK L, 1984, AM J PATHOL, V144, P623
   HARRIS SJ, 1992, IMMUNOLOGY, V77, P315
   Hunter R. J., 1981, ZETA POTENTIAL COLLO
   KOSSOVSKY N, 1993, BIO-TECHNOL, V11, P1534, DOI 10.1038/nbt1293-1534                                                            
   KOSSOVSKY N, 1990, J APPL BIOMATER, V1, P289, DOI 10.1002/jab.770010404
   KOSSOVSKY N, 1993, J APPL BIOMATER, V4, P281, DOI 10.1002/jab.770040402                                                           
   KOSSOVSKY N, 1991, J APPL BIOMATER, V2, P251, DOI 10.1002/jab.770020406
   KOSSOVSKY N, 1994, ARCH PATHOL LAB MED, V118, P686
   KOSSOVSKY N, 1993, TRENDS POLYM SCI, V1, P190
   KOSSOVSKY N, UNPUB POLYHYDROXYOLI
   KOSSOVSKY N, 1993, MAT TECHNOL, V8, P3
   KOSSOVSKY N, IN PRESS J COLLOID I
   KOSSOVSKY N, IN PRESS PROTEINS IN
   LANKFORD SP, 1993, J BIOL CHEM, V268, P4814
   LAYTON GT, 1993, J IMMUNOL, V151, P1097
   LEVINE H, 1992, BIOPHARM         MAY, P36
   LEWIS RW, 1948, J AM PHARM ASSOC SCI, V37, P511, DOI 10.1002/jps.3030371212                                                          
   LOO YH, 1955, SCIENCE, V121, P367, DOI 10.1126/science.121.3141.367
   MOREIN B, 1984, NATURE, V308, P457, DOI 10.1038/308457a0
   NAIM JO, 1993, IMMUNOL INVEST, V22, P151, DOI 10.3109/08820139309063397
   ROITT I, 1991, ESSENTIAL IMMUNOLOGY, P30
   SHEARER GM, 1993, SCIENCE, V262, P161, DOI 10.1126/science.8211133                                                         
   TAKAHASHI H, 1990, NATURE, V344, P873, DOI 10.1038/344873a0
   TATSUMI N, 1992, THROMB RES, V65, P585, DOI 10.1016/0049-3848(92)90208-R                                                    
   WARREN HS, 1992, ENCY IMMUNOLOGY, P28
   WOODLE MC, 1992, BIOPHYS J, V61, P1
   1993, Patent No. 5178882
   1993, Patent No. 5219577
   LEWIS RW, 1946, Patent No. 2402902
   1988, COULTER DELSA 440 RE
NR 41
TC 10
Z9 10
U1 0
U2 3
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD MAY
PY 1995
VL 29
IS 5
BP 561
EP 573
DI 10.1002/jbm.820290503
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA QV982
UT WOS:A1995QV98200002
PM 7622541
DA 2018-01-05
ER

PT J
AU HADIDA, F
   HAAS, G
   ZIMMERMANN, N
   HOSMALIN, A
   SPOHN, R
   SAMRI, A
   JUNG, G
   DEBRE, P
   AUTRAN, B
AF HADIDA, F
   HAAS, G
   ZIMMERMANN, N
   HOSMALIN, A
   SPOHN, R
   SAMRI, A
   JUNG, G
   DEBRE, P
   AUTRAN, B
TI CTLS FROM LYMPHOID ORGANS RECOGNIZE AN OPTIMAL HLA-A2-RESTRICTED AND
   HLA-B52-RESTRICTED NONAPEPTIDE AND SEVERAL EPITOPES IN THE C-TERMINAL
   REGION OF HIV-1 NEF
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID TOXIC LYMPHOCYTES-T; IMMUNODEFICIENCY-VIRUS TYPE-1; HISTOCOMPATIBILITY
   ANTIGEN HLA-A2; INFLUENZA-VIRUS; SEROPOSITIVE INDIVIDUALS;
   PERIPHERAL-BLOOD; FINE SPECIFICITY; CELL RECOGNITION; MATRIX PROTEIN;
   VIRAL PEPTIDES
AB In a previous analysis of HIV-1-specific CTLs in lymphoid organs from HIV-seropositive patients, we reported high frequencies of in vivo differentiated CTLs directed against two immunodominant regions in the central and in the C-terminal part of the HIV-1 Nef protein. The present study analyzes the epitopes recognized by CTLs in the carboxyl terminus of Nef (amino acids 182-205). In addition to several epitopes that are recognized in association with different HLA molecules (A1, A2, A25(10), B35, B52), we defined an optimal nonapeptide (190-198). This nonapeptide was recognized by CTLs down to nanomolar concentrations in the context of at least two HLA molecules, HLA-B52 and HLA-A2, including three HLA-A2 subtypes: HLA-A2.1, -A2.2, and -A2.4. We also determined the relative frequencies of effector CTLs directed against peptide 190-198 to be as high as 10(-4), as opposed to lower frequencies ranging between 5 x 10(-5) and 5 x 10(-6) observed for the other peptides recognized in the same region, thus confirming the optimal presentation of this nonapeptide in vivo. Molecular modeling of the interactions between HLA-A2.1 and Nef peptide 190-198 suggests the formation of a stable complex and allowed us to study sequence motifs that are important for the binding of the HIV-1 peptide in the pockets of the HLA-A2.1 molecule.
C1 UNIV HOSP CTR PITIE SALPETRIERE,NATL CTR SCI RES,COMBINED RES UNIT,PARIS,FRANCE.
   UNIV TUBINGEN,INST ORGAN CHEM,W-7400 TUBINGEN,GERMANY.
CR BAHARAOUI E, 1990, AIDS RES HUM RETROV, V6, P1087
   BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3                                                   
   BINDER D, 1991, J IMMUNOL, V146, P4301
   BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0
   BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0                                                                
   BOURGAULT I, 1992, J VIROL, V66, P750
   CHEYNIER R, 1992, EUR J IMMUNOL, V22, P2211, DOI 10.1002/eji.1830220905                                                          
   CHEYNIER R, CELL, V78, P373
   CULMANN B, 1991, J IMMUNOL, V146, P1560
   CULMANN B, 1989, EUR J IMMUNOL, V19, P2383, DOI 10.1002/eji.1830191231
   DELASSUS S, 1992, J VIROL, V66, P5642
   DELVAL M, 1991, CELL, V66, P1145, DOI 10.1016/0092-8674(91)90037-Y
   EISENLOHR LC, 1992, J EXP MED, V175, P481, DOI 10.1084/jem.175.2.481
   EMINI EA, 1992, NATURE, V355, P728, DOI 10.1038/355728a0
   ENGELHARD VH, 1994, CURR OPIN IMMUNOL, V6, P13, DOI 10.1016/0952-7915(94)90028-0
   FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0
   GOMEZ A, 1989, CELL IMMUNOL, V118, P312, DOI 10.1016/0008-8749(89)90380-8                                                    
   GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0
   HADIDA F, 1992, J CLIN INVEST, V89, P53, DOI 10.1172/JCI115585
   HAHN YS, 1992, J EXP MED, V176, P1335, DOI 10.1084/jem.176.5.1335                                                          
   HOGAN KT, 1988, J IMMUNOL, V141, P4005
   HU SL, 1992, SCIENCE, V255, P456, DOI 10.1126/science.1531159
   HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328
   JOLY P, 1989, J IMMUNOL, V143, P2193
   JORGENSEN WL, 1983, J CHEM PHYS, V70, P926
   KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8                                                    
   KOENIG S, 1990, J IMMUNOL, V145, P127
   KOENIG S, 1988, P NATL ACAD SCI USA, V85, P8638, DOI 10.1073/pnas.85.22.8638
   LATRON F, 1991, P NATL ACAD SCI USA, V88, P11325, DOI 10.1073/pnas.88.24.11325
   LUCCHIARI M, 1994, INT IMMUNOL, V6
   MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H                                                    
   MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0
   NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0                                                                
   PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0
   PARKER KC, 1992, J IMMUNOL, V149, P2580
   PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0                                                                
   RIVIERE Y, 1989, J VIROL, V63, P2277
   ROBBINS PA, 1989, J IMMUNOL, V143, P4098
   ROBERTGUROFF M, 1990, J VIROL, V64, P3391
   ROGNAN D, 1992, PROTEINS, V13, P70, DOI 10.1002/prot.340130107
   ROGNAN D, 1992, EUR J BIOCHEM, V208, P101, DOI 10.1111/j.1432-1033.1992.tb17163.x
   RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3
   SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P
   SCHNORRENBERG G, 1991, PEPTIDES 1990, P202
   SHIRAI M, 1992, J IMMUNOL, V148, P1657
   SPIEGEL H, 1992, AM J PATHOL, V140, P15
   TAHTINEN M, 1992, VIROLOGY, V187, P156, DOI 10.1016/0042-6822(92)90304-8
   TASWELL C, 1981, J IMMUNOL, V126, P1614
   TENNERRACZ K, 1986, AM J PATHOL, V123, P9
   TSOMIDES TJ, 1991, P NATL ACAD SCI USA, V88, P11276, DOI 10.1073/pnas.88.24.11276                                                        
   UTZ U, 1992, J IMMUNOL, V149, P214
   VANGUNSTEREN WF, 1977, MOL PHYS, V34, P1311, DOI 10.1080/00268977700102571
   WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0                                                                
   WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051                                                             
   YAP KL, 1978, NATURE, V273, P238, DOI 10.1038/273238a0
   ZIMMERMANN N, 1992, ANGEW CHEM INT EDIT, V31, P886, DOI 10.1002/anie.199208861                                                          
NR 56
TC 34
Z9 34
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD APR 15
PY 1995
VL 154
IS 8
BP 4174
EP 4186
PG 13
WC Immunology
SC Immunology
GA QR070
UT WOS:A1995QR07000061
PM 7535824
DA 2018-01-05
ER

PT J
AU HAMMAR, L
   HIRSCH, I
   MACHADO, AA
   DEMAREUIL, J
   BAILLON, JG
   BOLMONT, C
   CHERMANN, JC
AF HAMMAR, L
   HIRSCH, I
   MACHADO, AA
   DEMAREUIL, J
   BAILLON, JG
   BOLMONT, C
   CHERMANN, JC
TI LECTIN-MEDIATED EFFECTS ON HIV TYPE-1 INFECTION IN-VITRO
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; MANNOSE-SPECIFIC LECTIN; ENVELOPE
   GLYCOPROTEIN GP120; HIGHLY CYTOPATHIC STRAIN; DEFICIENCY SYNDROME AIDS;
   HAMSTER OVARY CELLS; NEUTRALIZING ANTIBODIES; BINDING-PROPERTIES;
   GERARDIA-SAVAGLIA; SNOWDROP LECTIN
AB Lectins with specificity for terminal mannose residues and anti-mannan antibodies neutralize HIV-1 infection in vitro. This is assumed to be caused by binding of the agents to the viral glycoproteins. In this study we show that one such agent, the Galanthus nivalis lectin (GNA), also blocks infection at the target cell level. To explore the effect of GNA on HIV infection we used the two HIV-1 isolates LAV and NDK, representing in the first case a prototype virus and in the latter case a highly cytopathic virus, which spreads preferentially via cell-to-cell contact. MT-4 cells were used as target cells and infection was determined from the occurrence of syncytia. Cell-to-cell infection was studied with CEM cells persistently infected with the two virus isolates. GNA, at concentrations in the nanogram per milliliter range, neutralized the HIV-1 isolates LAV, NDK, and MN as well as HIV-2(RoD). Pretreatment of cells with the lectin, before addition of virus, or of infected cells, also blocked infection. This effect was more pronounced with HIV-1(NDK) than with HIV-1(LAV). Mannosidase treatment of the target cells abolished the GNA effect on HIV-1(NDK) infection. It is concluded that GNA inhibits infection of several HIV isolates. It neutralizes infection by binding to the virion but also blocks infection at the target cell level. The latter effect may be different for different virus isolates. Mannosyl residuals at the cell surface are targets for GNA modulation of infection with the cytopathic HIV-1(NDK). These do not represent essential virus receptors.
C1 KAROLINSKA INST, DEPT DERMATOL, STOCKHOLM, SWEDEN.
   INSERM, U322, UNITE RECH RETROVIRUS & MALADIES ASSOCIEES, F-13273 MARSEILLE, FRANCE.
   UNIV SAO PAULO, FAC MED RIBEIRAO PRETO, DEPT CLIN MED, SAO PAULO, BRAZIL.
RI Hirsch, Ivan/J-7726-2015
OI Machado, Alcyone/0000-0002-5677-7332; Hirsch, Ivan/0000-0003-1701-1438
CR ADACHI M, 1988, J EXP MED, V167, P323, DOI 10.1084/jem.167.2.323
   BAHRAOUI E, 1992, AIDS RES HUM RETROV, V8, P565, DOI 10.1089/aid.1992.8.565
   BALZARINI J, 1991, ANTIMICROB AGENTS CH, V35, P410, DOI 10.1128/AAC.35.3.410                                                            
   BALZARINI J, 1992, ANTIVIR RES, V18, P191, DOI 10.1016/0166-3542(92)90038-7                                                    
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   BUSSO M, 1991, AIDS, V5, P1425, DOI 10.1097/00002030-199112000-00003
   CURTIS BM, 1992, P NATL ACAD SCI USA, V89, P8356, DOI 10.1073/pnas.89.17.8356                                                         
   DEMAREUIL J, 1992, J VIROL, V66, P6797
   ELLRODT A, 1984, LANCET, V1, P1383
   EZEKOWITZ RAB, 1989, J EXP MED, V169, P185, DOI 10.1084/jem.169.1.185
   FENOUILLET E, 1994, TRENDS BIOCHEM SCI, V19, P65, DOI 10.1016/0968-0004(94)90034-5                                                    
   FENOUILLET E, 1993, 12TH GLYC INT S GLYC
   FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J
   GATTEGNO L, 1992, AIDS RES HUM RETROV, V8, P27, DOI 10.1089/aid.1992.8.27
   GEYER H, 1988, J BIOL CHEM, V263, P11760
   GILBERT M, 1993, J VIROL METHODS, V42, P1, DOI 10.1016/0166-0934(93)90171-M
   GILLJAM G, 1994, J CHROMATOGR A, V675, P89, DOI 10.1016/0021-9673(94)85263-4
   GILLJAM G, 1993, AIDS RES HUM RETROV, V9, P431, DOI 10.1089/aid.1993.9.431
   HAMMAR L, 1989, AIDS RES HUM RETROV, V5, P495, DOI 10.1089/aid.1989.5.495
   HAMMAR L, 1994, ANN NY ACAD SCI, V724, P89
   HANSEN JES, 1990, J VIROL, V64, P2833
   HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081                                                         
   HIRSCH I, 1992, VIROLOGY, V186, P647, DOI 10.1016/0042-6822(92)90031-J
   HOLSCHBACH C, 1990, BIOCHEM J, V267, P759, DOI 10.1042/bj2670759                                                               
   KAKU H, 1989, METHOD ENZYMOL, V179, P327
   KLJAJIC Z, 1987, EUR J BIOCHEM, V169, P97, DOI 10.1111/j.1432-1033.1987.tb13585.x                                              
   LARKIN M, 1989, AIDS, V3, P793, DOI 10.1097/00002030-198912000-00003
   LEONARD CK, 1990, J BIOL CHEM, V265, P10373
   LI Y, 1993, J VIROL, V67, P584
   LIFSON J, 1986, J EXP MED, V164, P2101, DOI 10.1084/jem.164.6.2101
   MAHMOOD N, 1992, J IMMUNOL METHODS, V151, P9, DOI 10.1016/0022-1759(92)90101-X                                                    
   MIZUOCHI T, 1990, J BIOL CHEM, V265, P8519
   MIZUOCHI T, 1988, BIOCHEM J, V254, P599, DOI 10.1042/bj2540599                                                               
   MULLER WEG, 1988, J ACQ IMMUN DEF SYND, V1, P453
   MULLER WEG, 1990, AIDS, V4, P159
   MULLER WEG, 1989, AIDS FORSCH, V4, P465
   MYERS G, 1992, AIDS RES HUM RETROV, V8, P1459
   REY F, 1987, J VIROL METHODS, V16, P239, DOI 10.1016/0166-0934(87)90008-5
   ROSEN SD, 1993, IMMUNOLOGY, V5, P237
   SATO H, 1992, VIROLOGY, V186, P712, DOI 10.1016/0042-6822(92)90038-Q                                                    
   SHIBUYA N, 1988, J BIOL CHEM, V263, P728
   SPEAR GT, 1993, AIDS, V7, P1149, DOI 10.1097/00002030-199309000-00001
   SPIRE B, 1989, GENE, V81, P275, DOI 10.1016/0378-1119(89)90188-1
   SPIRE B, 1990, VIROLOGY, V177, P756, DOI 10.1016/0042-6822(90)90543-Z
   TETALI SK, 1993, AIDS RES HUM RETROV, V9, P77, DOI 10.1089/aid.1993.9.77                                                           
   USHIJIMA H, 1992, JPN J CANCER RES, V83, P458, DOI 10.1111/j.1349-7006.1992.tb01950.x                                              
   VANDAMME EJM, 1988, PHYSIOL PLANTARUM, V73, P52
   VANDAMME EJM, 1987, PLANT PHYSIOL, V85, P566, DOI 10.1104/pp.85.2.566                                                             
   WEILER BE, 1991, J VIROL METHODS, V32, P287, DOI 10.1016/0166-0934(91)90059-9
   YAHI N, 1992, ARCH VIROL, V125, P287, DOI 10.1007/BF01309645                                                              
NR 50
TC 17
Z9 20
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD JAN
PY 1995
VL 11
IS 1
BP 87
EP 95
DI 10.1089/aid.1995.11.87
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA QE701
UT WOS:A1995QE70100011
PM 7734200
DA 2018-01-05
ER

PT J
AU STIENEKER, F
   KERSTEN, G
   VANBLOOIS, L
   CROMMELIN, DJA
   HEM, SL
   LOWER, J
   KREUTER, J
AF STIENEKER, F
   KERSTEN, G
   VANBLOOIS, L
   CROMMELIN, DJA
   HEM, SL
   LOWER, J
   KREUTER, J
TI COMPARISON OF 24 DIFFERENT ADJUVANTS FOR INACTIVATED HIV-2 SPLIT WHOLE
   VIRUS AS ANTIGEN IN MICE - INDUCTION OF TITERS OF BINDING-ANTIBODIES AND
   TOXICITY OF THE FORMULATIONS
SO VACCINE
LA English
DT Article
DE AIDS; HIV VACCINE; NANOPARTICLES AS ADJUVANT; ADJUVANT;
   POLYMETHYLMETHACRYLATE
ID HUMAN IMMUNODEFICIENCY VIRUS; DOXORUBICIN-CONTAINING LIPOSOMES;
   PARTICULATE POLYMERIC ADJUVANTS; IMMUNE-RESPONSE; COMPLEXES ISCOMS;
   QUIL-A; IMMUNOLOGICAL ADJUVANTS; BILAYER LIPOSOMES; DETERGENT REMOVAL;
   LOADING CAPACITY
AB The objective of this study was the comparison of the quantity and quality of the humoral immune response against inactivated whole human immunodeficiency virus type 2. Twenty-four different adjuvants were tested. The toxicity of these preparations was determined. Due to the large number of experiments, the animal model used was the NMRI mouse. Sera were assayed for the presence of antibodies by ELISA and Western blot, The toxicity of the adjuvants was determined by observing lethal side-effects occurring within two days after injection of the immunogenic preparations, The results show that polymethylmethacrylate nanoparticles were the best overall adjuvant, inducing the highest titres of antibodies compared with other adjuvants as well as producing a significantly better immune response against a number of individual HIV-2 antigens without any observable toxic side-effects, However, this adjuvant did not induce antibodies against the outer envelope protein gp120, whereas such antibodies were induced by aluminium compounds, Freund's complete and incomplete adjuvants, and fumed silica (Aerosil). This result suggests the necessity of using vaccines with two or more different adjuvants in order to induce the required immune response against physically different antigens.
C1 UNIV FRANKFURT,INST PHARMAZEUT TECHNOL,D-60053 FRANKFURT,GERMANY.
   NATL INST PUBL HLTH & ENVIRONM PROTECT,3720 BA BILTHOVEN,NETHERLANDS.
   UNIV UTRECHT,DEPT PHARMACEUT,3508 TB UTRECHT,NETHERLANDS.
   PURDUE UNIV,DEPT IND & PHYS PHARM,W LAFAYETTE,IN 47907.
   PAUL EHRLICH INST,BUNDESAMT SERA & IMPFSTOFFE,W-6070 LANGEN,GERMANY.
CR ALLISON AC, 1991, MOL IMMUNOL, V28, P279, DOI 10.1016/0161-5890(91)90074-T
   BARR M, 1955, BRIT MED J, V2, P635, DOI 10.1136/bmj.2.4940.635                                                          
   BERG UE, 1986, PHARM IND, V48, P75
   BYARS NE, 1990, VACCINE, V8, P49, DOI 10.1016/0264-410X(90)90177-N
   BYARS NE, 1987, VACCINE, V5, P223, DOI 10.1016/0264-410X(87)90105-8
   CABANELA ME, 1972, J BONE JOINT SURG AM, VA 54, P278, DOI 10.2106/00004623-197254020-00005                                                
   Charnley J., 1970, ACRYLIC CEMENT ORTHO
   COOK RF, 1990, VACCINE, V8, P491, DOI 10.1016/0264-410X(90)90252-H
   CROMMELIN DJA, 1983, INT J PHARM, V17, P135, DOI 10.1016/0378-5173(83)90027-3
   CROMMELIN DJA, 1983, INT J PHARMACEUT, V16, P79, DOI 10.1016/0378-5173(83)90130-8
   DALSGAARD K, 1984, ZBL VET MED B, V31, P718
   DAVIES II, 1986, ADVERSE DRUG REACT, V1, P1
   DEDIEU JF, 1992, J VIROL, V66, P3161
   EISLER M, 1959, Z Immun exp ther, V117, P294
   EISLER M, 1949, Klin Med Osterr Z Wiss Prakt Med, V4, P441
   FALK W, 1975, KUNSTSTOFFHANDBUCH P, P851
   FLEBBE LM, 1986, CELL IMMUNOL, V99, P119, DOI 10.1016/0008-8749(86)90221-2
   FOHLMAN J, 1990, VACCINE, V8, P381, DOI 10.1016/0264-410X(90)90098-7
   FREEMAN MJ, 1968, IMMUNOLOGY, V15, P481
   Freund J., 1956, ADV TUBERC RES, V7, P130
   GALLO RC, 1988, J ACQ IMMUN DEF SYND, V1, P521
   GIRARD M P, 1990, AIDS (London), V4, pS143
   GOUDSMIT J, 1989, J ACQ IMMUN DEF SYND, V2, P297
   GRAFE A, 1971, ARZNEI-FORSCHUNG, V21, P903
   JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768                                                         
   JISKOOT W, 1986, PHARM WEEKBLAD, V8, P259, DOI 10.1007/BF01960070                                                              
   KERSTEN GFA, 1988, INFECT IMMUN, V56, P432
   KERSTEN GFA, 1990, THESIS RIJKSUNIVERSI
   KIKUKAWA R, 1986, J VIROL, V57, P1159
   KREUTER J, 1976, EXP CELL BIOL, V44, P12
   KREUTER J, 1976, J PHARM SCI, V65, P1624, DOI 10.1002/jps.2600651115                                                          
   KREUTER J, 1991, J CONTROL RELEASE, V16, P169, DOI 10.1016/0168-3659(91)90040-K
   KREUTER J, 1976, INFECT IMMUN, V13, P204
   KREUTER J, 1988, VACCINE, V6, P253, DOI 10.1016/0264-410X(88)90220-4                                                    
   KREUTER J, 1981, J PHARM SCI, V70, P367, DOI 10.1002/jps.2600700406                                                          
   KREUTER J, 1988, J MICROENCAPSUL, V5, P115, DOI 10.3109/02652048809056475
   KREUTER J, 1978, INFECT IMMUN, V19, P667
   KREUTER J, 1986, VACCINE, V4, P125, DOI 10.1016/0264-410X(86)90051-4
   KREUTER J, 1979, J PHARM SCI, V68, P1443, DOI 10.1002/jps.2600681129
   KREUTER J, 1983, J PHARM SCI, V72, P1146, DOI 10.1002/jps.2600721009                                                          
   KURTH R, 1984, MUNCHEN MED WOCHEN, V126, P1363
   KURTH R, 1985, BEDEUTUNG MENSCHLICH, P23
   LIDGATE DM, 1989, PHARMACEUT RES, V6, P748, DOI 10.1023/A:1015915212195                                                         
   MARX PA, 1986, J VIROL, V60, P431
   MILSMANN MHW, 1978, BIOCHIM BIOPHYS ACTA, V512, P147, DOI 10.1016/0005-2736(78)90225-0
   MOREIN B, 1984, NATURE, V308, P457, DOI 10.1038/308457a0
   NOTHDURFT H, 1955, NATURWISSENSCHAFTEN, V42, P106, DOI 10.1007/BF00617260                                                              
   OSTERHAUS A, 1985, J IMMUNOL, V135, P591
   OTTEL H, 1963, ULLMANS ENCY TECHNIS, V14, P302
   PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932
   PYL G., 1953, Arch. exp. VetMed., V7, P9
   PYLE SW, 1989, VACCINE, V7, P465, DOI 10.1016/0264-410X(89)90164-3
   RASKOVA H, 1967, INT S ADJUVANTS IMMU, V6, P115
   RHODEN V, 1979, BIOCHEMISTRY-US, V18, P4173, DOI 10.1021/bi00586a020
   RIDDLE EH, 1954, MONOMERIC ACRYLIC ES, P15
   RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198
   SALK J, 1987, NATURE, V327, P473, DOI 10.1038/327473a0                                                                
   SCHWENDENER RA, 1981, BIOCHEM BIOPH RES CO, V100, P1055, DOI 10.1016/0006-291X(81)91930-6
   SHEK PN, 1986, IMMUNOLOGY, V57, P153
   SHEK PN, 1984, IMMUNOTOXICOLOGY, V2, P103
   STIENEKER F, 1991, AIDS, V5, P431, DOI 10.1097/00002030-199104000-00012                                                
   STIENEKER F, 1993, VACCINE RES, V2, P111
   STIENEKER F, 1992, ENTWICKLUNG PRUFUNG, P92
   STINSON NE, 1965, BRIT J EXP PATHOL, V46, P135
   SZOKA F, 1980, ANNU REV BIOPHYS BIO, V9, P467, DOI 10.1146/annurev.bb.09.060180.002343
   TESSMAR K, 1961, METHODEN ORGANISCHEN, V14, P1037
   THERIEN HM, 1990, VACCINE, V8, P558, DOI 10.1016/0264-410X(90)90008-A
   TORRIGIANI G, 1965, J EXP MED, V122, P181, DOI 10.1084/jem.122.1.181                                                           
   TRUDEL M, 1987, VACCINE, V5, P239, DOI 10.1016/0264-410X(87)90108-3
   TURK JL, 1977, J INVEST DERMATOL, V68, P336, DOI 10.1111/1523-1747.ep12496358
   Gillman CF, 1975, PHAGOCYTIC ENGULFMEN
   VANROOIJEN N, 1982, TARGETING DRUGS, P301
   VERHEUL AFM, 1989, INFECT IMMUN, V57, P1078
   WOODARD LF, 1985, VACCINE, V3, P137, DOI 10.1016/0264-410X(85)90063-5
   ZUMBUEHL O, 1981, BIOCHIM BIOPHYS ACTA, V640, P252, DOI 10.1016/0005-2736(81)90550-2
   1982, NEW ENGL J MED, V306, P248
   1981, MMWR-MORBID MORTAL W, V30, P305
   1981, MMWR-MORBID MORTAL W, V30, P250
NR 78
TC 34
Z9 38
U1 0
U2 4
PU BUTTERWORTH-HEINEMANN LTD
PI OXFORD
PA LINACRE HOUSE JORDAN HILL, OXFORD, OXON, ENGLAND OX2 8DP
SN 0264-410X
J9 VACCINE
JI Vaccine
PD JAN
PY 1995
VL 13
IS 1
BP 45
EP 53
DI 10.1016/0264-410X(95)80010-B
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA QF019
UT WOS:A1995QF01900009
PM 7762277
DA 2018-01-05
ER

PT J
AU CHIAPPELLI, F
   FROST, P
   MANFRINI, E
   LEE, P
   PHAM, L
   GARCIA, C
   DALEY, S
   KUNG, M
   VILLANUEVA, P
AF CHIAPPELLI, F
   FROST, P
   MANFRINI, E
   LEE, P
   PHAM, L
   GARCIA, C
   DALEY, S
   KUNG, M
   VILLANUEVA, P
TI COCAINE BLUNTS HUMAN CD4(+) CELL ACTIVATION
SO IMMUNOPHARMACOLOGY
LA English
DT Article
DE COCAINE; HUMAN T LYMPHOCYTE; CD4(+) CELL ACTIVATION
ID BLOOD T-LYMPHOCYTES; BETA-ENDORPHIN; PROLIFERATION; INVITRO; EXPRESSION;
   MOLECULE; SURFACE; MICE
AB Cocaine is reported to be immunotoxic. The biochemical mechanisms responsible for the immunopharmacological outcomes of cocaine in vivo and in vitro remain, however, to be fully elucidated. Our experimental data confirm that exposure of normal human T cells to micromolar concentrations of cocaine modulates T-cell responses to stimulation by a variety of stimuli, and indicate that cocaine impairs early activation events during CD4(+) but not CD4(-) T-cell stimulation. Pre-incubation of enriched CD4(+) T-cell subpopulations that express the homing receptor CD62L with nanomolar concentrations of the endogenous opioid peptide beta-endorphin leads to a more severe impairment of activation than that noted following pre-incubation with micromolar concentrations of cocaine alone. These findings begin to elucidate the molecular and cellular mechanisms of the immunopathology of cocaine. Our data support the proposition that cocaine abuse may place cocaine-abuser HIV-seropositive individuals at increased risk of opportunistic infections.
C1 UNIV CALIF LOS ANGELES,SCH MED,DEPT ANAT & CELL BIOL,LOS ANGELES,CA 90024.
   W LOS ANGELES VET AFFAIRS MED CTR,HUMAN IMMUNOL & PSYCHONEUROIMMUNOL LAB,LOS ANGELES,CA 90073.
   UNIV ANCONA,ANCONA,ITALY.
   UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024.
RP CHIAPPELLI, F (reprint author), UNIV CALIF LOS ANGELES,SCH DENT,HUMAN ORAL & MOLEC IMMUNOL LAB,LOS ANGELES,CA 90024, USA.
OI Frost, Patrick/0000-0003-3348-5983
FU PHS HHS [GR 6773-01]; NIDA NIH HHS [NIDA-07683]
CR Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7
   ASHMAN RF, 1990, J LAB CLIN MED, V116, P759
   BISELLI R, 1992, SCAND J IMMUNOL, V35, P439, DOI 10.1111/j.1365-3083.1992.tb02879.x
   BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745                                                        
   CHEN GJ, 1993, LIFE SCI, V52, P1641, DOI 10.1016/0024-3205(93)90046-6
   CHIAPPELLI F, 1992, ALCOHOL, V9, P481, DOI 10.1016/0741-8329(92)90084-N                                                    
   CHIAPPELLI F, 1992, BRAIN BEHAV IMMUN, V6, P1, DOI 10.1016/0889-1591(92)90054-R
   CHIAPPELLI F, 1991, INT J IMMUNOPHARMACO, V13, P291, DOI 10.1016/0192-0561(91)90110-S
   CHIAPPELLI F, 1992, ANN NY ACAD SCI, V650, P211
   CHIAPPELLI F, 1993, ADV BIOSCI, V90, P185
   CHIAPPELLI F, 1994, RES SOC ALCOHOLISM
   CHIAPPELLI F, 1993, ALCOLOGIA, V5, P221
   CHIAPPELLI F, 1993, IN PRESS 14TH P INT
   CHIAPPELLI F, 1993, IN PRESS ANN NY ACAD
   CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497
   CUPPS TR, 1982, IMMUNOL REV, V65, P133, DOI 10.1111/j.1600-065X.1982.tb00431.x
   DIFRANCESCO P, 1992, IMMUNOL RES, V11, P74, DOI 10.1007/BF02918610                                                              
   DIFRANCESCO P, 1993, IMMUNOPHARM IMMUNOT, V15, P69, DOI 10.3109/08923979309066934
   HADDEN JW, 1988, IMMUNOL TODAY, V9, P235, DOI 10.1016/0167-5699(88)91222-4
   HADDEN JW, 1990, IMMUNOPHARMACOL REV, V1, P273
   HEIJNEN CJ, 1991, IMMUNOL REV, V119, P41, DOI 10.1111/j.1600-065X.1991.tb00577.x
   KLEIN TW, 1988, ADV BIOCHEM PSYCHOPH, V44, P139
   KLEIN TW, 1993, INT J IMMUNOPHARMACO, V15, P77, DOI 10.1016/0192-0561(93)90033-U
   LEFKOWITZ SS, 1993, INT J IMMUNOPHARMACO, V15, P717, DOI 10.1016/0192-0561(93)90144-N
   MATSUI K, 1992, INT J IMMUNOPHARMACO, V14, P1213
   MENDELSON JH, 1992, J PHARMACOL EXP THER, V263, P505
   MORIYA N, 1987, J IMMUNOL, V139, P3281
   PACIFICI R, 1992, INT J IMMUNOTHER, V8, P91
   PRABHALA RH, 1989, J LEUKOCYTE BIOL, V45, P249
   RIVIER C, 1987, BRAIN RES, V422, P403, DOI 10.1016/0006-8993(87)90953-X
   Roszman T., 1991, PROG NEUROENDOCRINIM, V4, P69
   RUDD CE, 1989, IMMUNOL REV, V111, P225, DOI 10.1111/j.1600-065X.1989.tb00548.x                                              
   RUIZ P, 1994, CLIN IMMUNOL IMMUNOP, V70, P245, DOI 10.1006/clin.1994.1036
   VANDYKE C, 1986, J CLIN INVEST, V77, P1387, DOI 10.1172/JCI112445
   WALTZ B, 1990, LIFE SCI, V46, P1319
NR 35
TC 12
Z9 12
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0162-3109
J9 IMMUNOPHARMACOLOGY
JI Immunopharmacology
PD NOV-DEC
PY 1994
VL 28
IS 3
BP 233
EP 240
DI 10.1016/0162-3109(94)90059-0                                            
          
PG 8
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA PN500
UT WOS:A1994PN50000008
PM 7852054
DA 2018-01-05
ER

PT J
AU CONRAD, AJ
   CHIANG, EY
   ANDEEN, LE
   AVOLIO, C
   WALKER, SM
   BAUMHEFNER, RW
   MIRZAYAN, R
   TOURTELLOTTE, WW
AF CONRAD, AJ
   CHIANG, EY
   ANDEEN, LE
   AVOLIO, C
   WALKER, SM
   BAUMHEFNER, RW
   MIRZAYAN, R
   TOURTELLOTTE, WW
TI QUANTITATION OF INTRATHECAL MEASLES-VIRUS IGG ANTIBODY-SYNTHESIS RATE -
   SUBACUTE SCLEROSING PANENCEPHALITIS AND MULTIPLE-SCLEROSIS
SO JOURNAL OF NEUROIMMUNOLOGY
LA English
DT Article
DE MEASLES; SUBACUTE SCLEROSING PANENCEPHALITIS; MULTIPLE SCLEROSIS;
   INTRATHECAL SYNTHESIS RATE; ANTIBODY INDEX; ENZYME-LINKED IMMUNOSORBENT
   ASSAY; QUANTITATION; IMMUNOGLOBULIN G
ID CENTRAL NERVOUS-SYSTEM; BLOOD-BRAIN-BARRIER; CEREBROSPINAL-FLUID; HIV
   ANTIBODIES; AIDS; QUANTIFICATION; ENCEPHALITIS; MENINGITIS; INFECTION;
   DIAGNOSIS
AB A method for quantitating specific anti-viral antibodies in serum and cerebrospinal fluid (CSF) is established using enzyme-linked immunosorbent assay (ELISA). Quantitated antibody levels are used to determine intrathecal specific IgG synthesis rate for the particular antibody. Measles virus was used as a model for validating this quantitative technique: a mutated form of measles virus is a cause of subacute sclerosing panencephalitis (SSPE) and there is a possibility that measles virus is related to the cause of multiple sclerosis (MS). Matched serum and CSF samples were assayed. Concentration of anti-measles IgG was determined and intrathecal measles-specific IgG synthesis rate was calculated. For the SSPE samples, measles-specific IgG synthesis rate was elevated and comprised > 20% of the total intrathecal IgG synthesis rate; these results are consistent with the literature. The ELISA method can be performed routinely, providing a quick, simple, reproducible means of quantitating specific antibody concentrations, with sensitivity greater than 1 nanogram per milliliter. With this method, quantitation of IgG antibodies to any other viral antigen can be reliably and precisely determined.
C1 W LOS ANGELES VET AFFAIRS MED CTR,NEUROL SERV,LOS ANGELES,CA 90073.
   W LOS ANGELES VET AFFAIRS MED CTR,RES SERV,LOS ANGELES,CA 90073.
   UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROL,LOS ANGELES,CA 90024.
   CHILDRENS HOSP LOS ANGELES,DEPT PEDIAT,LOS ANGELES,CA 90027.
   UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90027.
   UNIV CALIF LOS ANGELES,SCH MED,BRAIN RES INST,LOS ANGELES,CA 90024.
CR BINIEK R, 1988, J NEUROL, V235, P131, DOI 10.1007/BF00314301                                                              
   BROOKS BR, 1979, ANNU REV NEUROSCI, V2, P309, DOI 10.1146/annurev.ne.02.030179.001521                                             
   CHIODI F, 1988, J NEUROL SCI, V85, P245, DOI 10.1016/0022-510X(88)90184-0
   CHOU MJ, 1988, J INFECT DIS, V157, P805, DOI 10.1093/infdis/157.4.805                                                        
   DELMOTTE P, 1990, NOV INT M NEPH BEHR, P77
   DHIBJALBUT S, 1990, NEUROLOGY, V40, P430, DOI 10.1212/WNL.40.3_Part_1.430                                                     
   KAISER R, 1993, J NEUROL SCI, V118, P64, DOI 10.1016/0022-510X(93)90247-V
   KLAPPER PE, 1981, LANCET, V2, P607
   LINK H, 1973, ARCH NEUROL-CHICAGO, V28, P23, DOI 10.1001/archneur.1973.00490190041004                                            
   LOLLI F, 1990, J NEUROL SCI, V99, P281, DOI 10.1016/0022-510X(90)90162-G                                                    
   LUXTON RW, 1990, J IMMUNOL METHODS, V131, P277, DOI 10.1016/0022-1759(90)90199-6
   MATHIESEN T, 1989, J NEUROL, V236, P238, DOI 10.1007/BF00314506
   MEHTA PD, 1989, J CLIN MICROBIOL, V27, P62
   MEHTA PD, 1977, J IMMUNOL, V118, P2254
   PERSSON MAA, 1989, J NEUROIMMUNOL, V22, P135, DOI 10.1016/0165-5728(89)90044-1                                                    
   PETER JB, 1991, J CLIN LAB ANAL, V5, P317, DOI 10.1002/jcla.1860050504
   PETER JB, 1993, USE INTERPRETATION L, P179
   REIBER H, 1991, CLIN CHEM, V37, P1153
   RESNICK L, 1988, NEUROLOGY, V38, P9, DOI 10.1212/WNL.38.1.9                                                              
   RESNICK L, 1985, NEW ENGL J MED, V313, P1498, DOI 10.1056/NEJM198512123132402
   SHARIEF MK, 1990, J IMMUNOL METHODS, V1330, P19
   STIERNSTEDT GT, 1985, J CLIN MICROBIOL, V21, P819
   TOURTELLOTTE WW, 1980, NEUROLOGY, V30, P240, DOI 10.1212/WNL.30.3.240                                                            
   TOURTELLOTTE WW, 1981, ANN NEUROL, V9, P551, DOI 10.1002/ana.410090607
   TOURTELLOTTE WW, 1985, HDB CLIN NEUROLOGY, V3, P107
   UKKONEN P, 1981, J MED VIROL, V8, P257, DOI 10.1002/jmv.1890080406
   VANDVIK B, 1976, SCAND J IMMUNOL, V5, P979, DOI 10.1111/j.1365-3083.1976.tb03050.x
NR 27
TC 30
Z9 32
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-5728
J9 J NEUROIMMUNOL
JI J. Neuroimmunol.
PD OCT
PY 1994
VL 54
IS 1-2
BP 99
EP 108
DI 10.1016/0165-5728(94)90236-4
PG 10
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA PL703
UT WOS:A1994PL70300012
PM 7929807
DA 2018-01-05
ER

PT J
AU SCHOLZ, D
   BILLICH, A
   CHARPIOT, B
   ETTMAYER, P
   LEHR, P
   ROSENWIRTH, B
   SCHREINER, E
   GSTACH, H
AF SCHOLZ, D
   BILLICH, A
   CHARPIOT, B
   ETTMAYER, P
   LEHR, P
   ROSENWIRTH, B
   SCHREINER, E
   GSTACH, H
TI INHIBITORS OF HIV-1 PROTEINASE CONTAINING 2-HETEROSUBSTITUTED
   4-AMINO-3-HYDROXY-5-PHENYLPENTANOIC ACID - SYNTHESIS, ENZYME-INHIBITION,
   AND ANTIVIRAL ACTIVITY
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; BETA-HYDROXY ACIDS; TYPE-1 PROTEASE;
   AMINO-ACIDS; POTENT INHIBITORS; MATURATION; STATINE; ASSAY; DERIVATIVES;
   RESOLUTION
AB A convenient procedure for the synthesis of 2-heterosubstituted statine derivatives as novel building blocks in HN-protease inhibitors has been developed. The synthesis starts with protected L-phenylalaninols, which were converted to gamma-amino alpha,beta-unsaturated esters in a one-pot procedure. A highly diastereoseletive epoxidation of the N-protected (E)-enoates, followed by regioselective ring opening of the corresponding 2,3-epoxy esters with a variety of heteronucleophiles, resulted in 2-heterosubstituted statine derivatives. The overall stereochemical outcome of the transformations meets the required configuration of HIV-protease inhibitors. The short, synthetically flexible, and highly diastereoselective synthesis of 2-heterosubstituted statines has enabled a broad derivation, covering the S3, S2, and S1'-S3' sites of the enzyme. In a series of 46 derivatives, several potent inhibitors were obtained with K-i values as low as 3.4 nM and antiviral activity in the lower nanomolar-range. The structural parameters of the compounds which determine the potency of inhibition and selectivity for the viral enzyme are discussed.
RP SCHOLZ, D (reprint author), SANDOZ GMBH,FORSCHUNGSINST,DEPT ANTIRETROVIRAL THERAPY,BRUNNER STR 59,A-1235 VIENNA,AUSTRIA.
CR ASHORN P, 1990, P NATL ACAD SCI USA, V87, P7472, DOI 10.1073/pnas.87.19.7472
   BEHRENS CH, 1985, J ORG CHEM, V50, P5696, DOI 10.1021/jo00350a051                                                             
   BILLICH A, 1991, ARCH BIOCHEM BIOPHYS, V290, P186, DOI 10.1016/0003-9861(91)90606-J
   BILLICH A, 1993, J ENZYM INHIB, V7, P213, DOI 10.3109/14756369309040764                                                       
   BILLICH A, 1990, BIOL CHEM H-S, V371, P265, DOI 10.1515/bchm3.1990.371.1.265
   BILLICH A, IN PRESS ANTIVIRAL R
   BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2
   CARDANI S, 1988, TETRAHEDRON, V44, P5563, DOI 10.1016/S0040-4020(01)86061-0
   CHA S, 1975, BIOCHEM PHARMACOL, V24, P2187, DOI 10.1016/0006-2952(75)90051-9
   CHONG JM, 1985, J ORG CHEM, V50, P1560, DOI 10.1021/jo00209a048                                                             
   CRAIG J C, 1991, Antiviral Chemistry and Chemotherapy, V2, P181
   DEBOUCK C, 1992, AIDS RES HUM RETROV, V8, P153, DOI 10.1089/aid.1992.8.153
   DELFRAISSY JF, PHASE 1 2 DOSE RANGI
   DESOLMS SJ, 1991, J MED CHEM, V34, P2852, DOI 10.1021/jm00113a025
   DREYER GB, 1992, BIOCHEMISTRY-US, V31, P6646, DOI 10.1021/bi00144a004
   DUNN B M, 1990, Antiviral Chemistry and Chemotherapy, V1, P3
   ELKER A, 1979, ARCH PHARM, V312, P26, DOI 10.1002/ardp.19793120106                                                        
   FEHRENTZ JA, 1992, BIOCHEM BIOPH RES CO, V188, P873, DOI 10.1016/0006-291X(92)91137-F
   FOURNIEZALUSKI MC, 1992, J MED CHEM, V35, P1259, DOI 10.1021/jm00085a013
   FUTAGAWA S, 1973, B CHEM SOC JPN, V46, P3308, DOI 10.1246/bcsj.46.3308                                                            
   HAGIHARA M, 1992, J AM CHEM SOC, V114, P6570, DOI 10.1021/ja00042a053                                                             
   HOLZMAN TF, 1990, J PROTEIN CHEM, P633
   HUFF JR, 1991, J MED CHEM, V34, P2305, DOI 10.1021/jm00112a001
   HUI KY, 1993, FEBS LETT, V327, P355, DOI 10.1016/0014-5793(93)81020-Z
   HUI KY, 1991, FASEB J, V5, P2606
   IKEDA K, 1989, INT J BIOCHEM, V27, P317
   JASKOLSKI M, 1991, BIOCHEMISTRY-US, V30, P1600, DOI 10.1021/bi00220a023
   KAMANDI E, 1974, ARCH PHARM, V307, P871, DOI 10.1002/ardp.19743071111
   KAMANDI E, 1975, ARCH PHARM, V308, P135, DOI 10.1002/ardp.19753080210                                                        
   KAPLAN AH, 1993, J VIROL, V67, P4050
   KATO K, 1980, J CHEM SOC PERK T 1, P1618, DOI 10.1039/p19800001618
   KEMPF DJ, 1991, ANTIMICROB AGENTS CH, V35, P2209, DOI 10.1128/AAC.35.11.2209                                                          
   KITCHEN V, 1993, 9TH INT C AIDS BERL
   LAMBERT DM, 1992, ANTIMICROB AGENTS CH, V36, P982, DOI 10.1128/AAC.36.5.982                                                            
   LIWSCHITZ Y, 1962, J CHEM SOC, P116
   MANCUSO AJ, 1981, SYNTHESIS-STUTTGART, P165
   MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486
   MEEK TD, 1992, J ENZYM INHIB, V6, P65, DOI 10.3109/14756369209041357                                                       
   MEEK TD, 1990, NATURE, V343, P90, DOI 10.1038/343090a0
   MURTHY KHM, 1992, J BIOL CHEM, V267, P22770
   OVERTON HA, 1990, VIROLOGY, V179, P508, DOI 10.1016/0042-6822(90)90326-M
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   REETZ MT, 1991, TETRAHEDRON LETT, V32, P4477, DOI 10.1016/0040-4039(91)80016-Y
   REETZ MT, 1991, TETRAHEDRON LETT, V32, P4481, DOI 10.1016/0040-4039(91)80017-Z
   REETZ MT, 1991, ANGEW CHEM INT EDIT, V30, P1531, DOI 10.1002/anie.199115313                                                          
   REETZ MT, 1989, ANGEW CHEM INT EDIT, V28, P1706, DOI 10.1002/anie.198917061                                                          
   Reetz M. T., 1989, ANGEW CHEM, V101, P1732
   Reetz M. T., 1991, ANGEW CHEM, V103, P1559
   RICHARDS AD, 1990, J BIOL CHEM, V265, P7733
   ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354
   ROBINS T, 1993, J ACQ IMMUN DEF SYND, V6, P162
   SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X                                                   
   SCOLASTICO C, 1985, SYNTHESIS-STUTTGART, P850
   SEELMEIER S, 1988, P NATL ACAD SCI USA, V85, P6612, DOI 10.1073/pnas.85.18.6612
   TACK JW, 1979, ARCH PHARM, V312, P138, DOI 10.1002/ardp.19793120211                                                        
   TOMASSELLI AG, 1991, CHEM TODAY       MAY, P6
   VEBER DF, 1984, BIOCHEM SOC T, V12, P956, DOI 10.1042/bst0120956                                                              
   WALBORSKY HM, 1958, J AM CHEM SOC, V80, P187, DOI 10.1021/ja01534a047                                                             
   WEBER HP, IN PRESS ACTA CRYS C
   KEMPF DJ, 1990, Patent No. 402646
NR 60
TC 56
Z9 57
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD SEP 16
PY 1994
VL 37
IS 19
BP 3079
EP 3089
DI 10.1021/jm00045a013
PG 11
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA PH073
UT WOS:A1994PH07300013
PM 7932531
DA 2018-01-05
ER

PT J
AU CHEN, H
   GOLD, L
AF CHEN, H
   GOLD, L
TI SELECTION OF HIGH-AFFINITY RNA LIGANDS TO REVERSE-TRANSCRIPTASE -
   INHIBITION OF CDNA SYNTHESIS AND RNASE-H ACTIVITY
SO BIOCHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; BACTERIOPHAGE-T4 DNA-POLYMERASE; PRIMER
   EXTENSION; CHAIN-REACTION; VIRAL-RNA; HIV-1; AMPLIFICATION;
   RETROVIRUSES; RESOLUTION; MOLECULES
AB Specific, high-affinity RNA ligands to avian myeloblastosis virus and Moloney murine leukemia virus reverse transcriptases were isolated from a combinatorial RNA library using the SELEX (systematic evolution of ligands by exponential enrichment) procedure. The selected RNA ligands bound their respective reverse transcriptases with approximately nanomolar dissociation constants. The ligands did not exhibit primary sequence conservation from selections against different target enzymes. Moreover, the selected ligands competed with the binding of template/primer complex and inhibited both the RNA-dependent DNA polymerase and the RNase H activities of the cognate reverse transcriptase. SELEX can yield both high-affinity and high-specificity oligonucleotide antagonists against specific members of a protein family.
C1 UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309.
FU NIGMS NIH HHS [GM-19963, GM-28685]
CR Baltimore D, 1970, NATURE, V226, P209
   BARTA A, 1984, P NATL ACAD SCI-BIOL, V81, P3607, DOI 10.1073/pnas.81.12.3607
   BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6
   BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946
   BISHOP JM, 1978, ANNU REV BIOCHEM, V47, P35, DOI 10.1146/annurev.bi.47.070178.000343
   BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0
   CHEN J, 1991, MUTAT RES, V249, P169, DOI 10.1016/0027-5107(91)90143-C                                                    
   CONNELL GJ, 1993, BIOCHEMISTRY-US, V32, P5497, DOI 10.1021/bi00072a002
   COREY J, 1983, NUCLEIC ACIDS RES, V19, P2601
   DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128                                                                  
   Eckert K A, 1991, PCR Methods Appl, V1, P17
   ELLINGTON A, 1992, NATURE, V355, P818
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   ENNIS PD, 1990, P NATL ACAD SCI USA, V87, P2833, DOI 10.1073/pnas.87.7.2833
   FURFINE ES, 1991, J BIOL CHEM, V266, P406
   GARRET M, 1985, NUCLEIC ACIDS RES, V12, P2259
   GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817
   GOLD L, 1993, RNA WORLD RNA SHAPE
   JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001
   JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706
   JELLINEK D, 1993, P NATL ACAD SCI USA, V90, P11227, DOI 10.1073/pnas.90.23.11227
   JENISON RD, 1994, SCIENCE, V263, P1425, DOI 10.1126/science.7510417
   JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648                                                         
   JOHNSON MS, 1988, P NATL ACAD SCI USA, V85, P2469
   KLOTZ IM, 1985, Q REV BIOPHYS, V18, P227, DOI 10.1017/S0033583500000354                                                       
   KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403
   KRUG MS, 1991, BIOCHEMISTRY-US, V30, P10614, DOI 10.1021/bi00108a003
   KUBIK MF, 1993, UNPUB J BIOL CHEM
   MIZRAHI V, 1989, BIOCHEMISTRY-US, V28, P9088, DOI 10.1021/bi00449a020
   OYAMA F, 1989, J BIOL CHEM, V264, P18808
   ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925
   SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0                                                                
   SCHNEIDER D, 1992, J MOL BIOL, V228, P862, DOI 10.1016/0022-2836(92)90870-P
   SHELNESS GS, 1985, J BIOL CHEM, V260, P8637
   STERN S, 1988, METHOD ENZYMOL, V164, P481
   TAKEUCHI Y, 1988, J VIROL, V62, P3900
   TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0
   TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027
   TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988, DOI 10.1073/pnas.89.15.6988                                                         
   TUERK C, 1990, J MOL BIOL, V213, P749, DOI 10.1016/S0022-2836(05)80261-X
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   TUERK C, 1993, IN PRESS POLYM CHAIN
   VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045
   VARMUS H, 1988, SCIENCE, V240, P1427, DOI 10.1126/science.3287617
   VARMUS H, 1984, RNA TUMOR VIRUSES, P369
   VARMUS H, 1987, SCI AM, V3, P56
   WEISS R, 1985, MOL BIOL TUMOR VIRUS, V2
   WEISS R, 1982, MOL BIOL TUMOR VIRUS, V1
   ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181
NR 49
TC 62
Z9 65
U1 0
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD JUL 26
PY 1994
VL 33
IS 29
BP 8746
EP 8756
DI 10.1021/bi00195a016                                                     
          
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA NY820
UT WOS:A1994NY82000016
PM 7518691
DA 2018-01-05
ER

PT J
AU KALYAN, NK
   LEE, SG
   WILHELM, J
   PISANO, MR
   HUM, WT
   HSIAO, CL
   DAVIS, AR
   EICHBERG, JW
   ROBERTGUROFF, M
   HUNG, PP
AF KALYAN, NK
   LEE, SG
   WILHELM, J
   PISANO, MR
   HUM, WT
   HSIAO, CL
   DAVIS, AR
   EICHBERG, JW
   ROBERTGUROFF, M
   HUNG, PP
TI IMMUNOGENICITY OF RECOMBINANT INFLUENZA-VIRUS HEMAGGLUTININ CARRYING
   PEPTIDES FROM THE ENVELOPE PROTEIN OF HUMAN-IMMUNODEFICIENCY-VIRUS
   TYPE-1
SO VACCINE
LA English
DT Article
DE HA ANTIGENIC SITES; HIV-1 EPITOPES; VACCINE DEVELOPMENT
ID B SURFACE-ANTIGEN; NEUTRALIZING ANTIBODIES; HIV-1; HEMAGGLUTININ;
   CHIMPANZEES; EXPRESSION; GP120; GLYCOPROTEIN; VACCINATION; PROTECTION
AB Haemagglutinin (HA), the major surface glycoprotein of influenza virus, is a potent immunogen against which viral neutralizing antibodies are directed. Studies of the three-dimensional structure of HA have identified major antigenic sites on the molecule. We have exploited HA as a carrier for small antigenic regions (epitopes) of the HIV-1 envelope (env) glycoprotein. Using recombinant DNA techniques, the epitopes were inserted in-frame into a known antigenic site of HA to produce HA-epitope chimeras. Guinea-pigs and mice immunized with these chimeras in combination with adjuvant generated significant immune responses against the carrier HA and also produced epitope-specific antibodies that recognized the native whole HIV-1 env. One of the chimeras which contained a V3-loop sequence of HIV-1 env elicited neutralizing antibodies against the homologous strain of HIV-1. The antibodies against HA and the inserted epitopes remained at high levels for up to 72 weeks. Remarkably, these responses were generated with low doses of immunogens containing only nanogram quantities of the inserted epitopes. These results suggest the utility of HA as a carrier to allow selective antibody induction against foreign epitopes, and offer a new approach for vaccine development as well as for the production of monospecific antibodies useful in diagnostics and research.
C1 NCI,TUMOR CELL BIOL LAB,BETHESDA,MD 20892.
RP KALYAN, NK (reprint author), WYETH AYERST RES,DIV BIOTECHNOL & MICROBIOL,POB 8299,PHILADELPHIA,PA 19101, USA.
CR BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0
   BERZOFSKY JA, 1991, J ACQ IMMUN DEF SYND, V4, P451
   BOLOGNESI DP, 1990, J ACQ IMMUN DEF SYND, V3, P390
   BRYARS NE, 1990, VACCINE, V8, P49
   CHAHN TL, 1986, EMBO J, V5, P3065
   COLBEREGARAPIN F, 1988, P NATL ACAD SCI USA, V85, P8668, DOI 10.1073/pnas.85.22.8668
   EVANS DJ, 1989, NATURE, V339, P385, DOI 10.1038/339385a0
   GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542
   GORNY MK, 1993, J IMMUNOL, V150, P635
   GURGO C, 1988, VIROLOGY, V164, P531, DOI 10.1016/0042-6822(88)90568-5
   HARTMAN JR, 1982, P NATL ACAD SCI-BIOL, V79, P233, DOI 10.1073/pnas.79.2.233
   HITI AL, 1981, VIROLOGY, V111, P113, DOI 10.1016/0042-6822(81)90658-9
   HO DD, 1988, SCIENCE, V239, P1021, DOI 10.1126/science.2830667                                                         
   HURWITZ JL, 1984, J IMMUNOL, V133, P3371
   JAVAHERIAN K, 1990, SCIENCE, V250, P1590, DOI 10.1126/science.1703322
   KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488                                                           
   LI S, 1992, P NATL ACAD SCI USA, V90, P5214
   LI SQ, 1992, J VIROL, V66, P399
   LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47
   LUO LZ, 1992, P NATL ACAD SCI USA, V89, P10527, DOI 10.1073/pnas.89.21.10527
   MATSUSHITA S, 1988, J VIROL, V62, P2107
   POSSEE RD, 1986, VIRUS RES, V5, P43, DOI 10.1016/0168-1702(86)90064-X
   QUINNAN GV, 1983, REV INFECT DIS, V5, P748
   ROBERTGUROFF M, 1990, TECHNIQUES HIV RES, P179
   ROBINSON WE, 1989, P NATL ACAD SCI USA, V86, P4710, DOI 10.1073/pnas.86.12.4710
   RUTGERS T, 1988, BIO-TECHNOL, V6, P1065, DOI 10.1038/nbt0988-1065
   SUMMERS MD, 1987, TEXAS A M U B, V1555
   TOKIYOSHI SD, 1992, NATURE, V355, P728
   WALTER G, 1980, P NATL ACAD SCI-BIOL, V77, P5197, DOI 10.1073/pnas.77.9.5197
   WANG CY, 1991, SCIENCE, V254, P285, DOI 10.1126/science.1925584
   WILEY DC, 1981, NATURE, V289, P373, DOI 10.1038/289373a0
   WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0
   WU JY, 1989, P NATL ACAD SCI USA, V86, P4726, DOI 10.1073/pnas.86.12.4726
NR 33
TC 22
Z9 22
U1 0
U2 0
PU BUTTERWORTH-HEINEMANN LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0264-410X
J9 VACCINE
JI Vaccine
PD JUN
PY 1994
VL 12
IS 8
BP 753
EP 760
DI 10.1016/0264-410X(94)90228-3
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA NN325
UT WOS:A1994NN32500014
PM 7522383
DA 2018-01-05
ER

PT J
AU BENDER, A
   SCHAFER, V
   STEFFAN, AM
   ROYER, C
   KREUTER, J
   RUBSAMENWAIGMANN, H
   VONBRIESEN, H
AF BENDER, A
   SCHAFER, V
   STEFFAN, AM
   ROYER, C
   KREUTER, J
   RUBSAMENWAIGMANN, H
   VONBRIESEN, H
TI INHIBITION OF HIV IN-VITRO BY ANTIVIRAL DRUG-TARGETING USING
   NANOPARTICLES
SO RESEARCH IN VIROLOGY
LA English
DT Article; Proceedings Paper
CT Symposium on Functions of Macrophages and Accessory Cells in HIV and
   Other Lentivirus Infections
CY OCT 13-15, 1993
CL BISCHENBERG, FRANCE
SP FRANCO GERMAN AGREEMENT COOP AGREEMENT COOPERAT AIDS RES
DE HIV, NANOPARTICLE, MICROSPHERE, ANTIVIRAL AGENT, MACROPHAGE;
   DRUG-TARGETING
ID MACROPHAGES; INFECTION; INVITRO; SYSTEM; AIDS
AB Nanoparticles are known to accumulate in the phagocytic cells of the mononuclear phagocyte system. Therefore, the use of this carrier system for the targeting of antiviral drugs to monocytes/macrophages (MO/MAC) is an attractive concept in the treatment of diseases involving MO/MAC, e.g. infection with HIV. In this study, the ability of macrophages isolated from peripheral blood of healthy blood donors to phagocytose and metabolize human serum albumin microspheres was investigated by transmission electron microscopy. Furthermore, nanoparticles manufactured using human serum albumin or polyhexylcyanoacrylate were loaded with nucleoside analogues (AZT and ddC) and tested for their ability to prevent HIV infection in MO/MAC cultures. Our results demonstrate the effectiveness of this drug-targeting system to one of the major target cells for HIV.
C1 UNIV FRANKFURT,INST PHARMAZEUT TECHNOL,D-60053 FRANKFURT,GERMANY.
   GEORG SPEYER HAUS,CHEMOTHERAPEUT FORSCHUNGSINST,D-60596 FRANKFURT,GERMANY.
   UNIV STRASBOURG 1,VIROL LAB,F-67000 STRASBOURG,FRANCE.
CR ANDREESEN R, 1983, J IMMUNOL METHODS, V56, P295, DOI 10.1016/S0022-1759(83)80019-2                                                   
   GASPAR R, 1992, ANN TROP MED PARASIT, V86, P41, DOI 10.1080/00034983.1992.11812629                                                  
   KREUTER J, 1983, PHARM ACTA HELV, V58, P196
   KREUTER J, 1979, J PHARM SCI, V68, P1444
   LEVY JA, 1993, MICROBIOL REV, V57, P183
   MARTY JJ, 1978, PHARM ACTA HELV, V53, P17
   MELTZER MS, 1990, IMMUNOL TODAY, V11, P217, DOI 10.1016/0167-5699(90)90086-O                                                    
   PHILLIPS NC, 1991, J ACQ IMMUN DEF SYND, V4, P959
   ROBINS T, 1993, J ACQ IMMUN DEF SYND, V6, P162
   ROSSI JJ, 1992, AIDS RES HUM RETROV, V8, P183, DOI 10.1089/aid.1992.8.183
   ROY S, 1988, J LEUKOCYTE BIOL, V43, P91
   RUBSAMENWAIGMANN H, 1989, LANCET, V2, P1155
   Schafer V, 1994, Clin Diagn Virol, V1, P279, DOI 10.1016/0928-0197(94)90058-2
   SCHAFER V, 1992, PHARMACEUT RES, V9, P541, DOI 10.1023/A:1015852732512
   SCHAFER V, 1993, PARTIKULARE ARZNEIST
   VONBRIESEN H, 1990, RES VIROLOGY, V141, P225, DOI 10.1016/0923-2516(90)90025-E
   WASER PG, 1987, INT J PHARM, V39, P213, DOI 10.1016/0378-5173(87)90219-5
   WIDDER K, 1979, J PHARM SCI, V68, P79, DOI 10.1002/jps.2600680124
   Couvreur P, 1982, US patent, Patent No. [4329332 A, 4329332]
NR 19
TC 43
Z9 45
U1 1
U2 3
PU EDITIONS SCIENTIFIQUES ELSEVIER
PI PARIS CEDEX 15
PA 141 RUE JAVEL, 75747 PARIS CEDEX 15, FRANCE
SN 0923-2516
J9 RES VIROLOGY
JI Res. Virol.
PD MAY-AUG
PY 1994
VL 145
IS 3-4
BP 215
EP 220
DI 10.1016/S0923-2516(07)80025-2                                           
          
PG 6
WC Virology
SC Virology
GA NZ543
UT WOS:A1994NZ54300012
PM 7800948
DA 2018-01-05
ER

PT J
AU BENNETT, NT
   HOWARD, RJ
AF BENNETT, NT
   HOWARD, RJ
TI QUANTITY OF BLOOD INOCULATED IN A NEEDLESTICK INJURY FROM SUTURE NEEDLES
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Article
ID HIV; CHIMPANZEES; INFECTION; HEPATITIS; EXPOSURE; ANTIGEN; SURGERY;
   RISKS
AB We wanted to quantify the amount of blood inoculum present on several commonly used surgical and phlebotomy needles and to determine the effect of single or double gloving, the depth of needle penetration and needle size on inoculum volume. Nineteen, 22 gauge and 25 gauge phlebotomy needles, as well as the tapered suture needles from zero, 3-0 and 5-0 sutures and a cutting needle from a 4-0 suture were assessed. The needles were dipped into blood labeled with I-125-epidermal growth factor and then embedded 2 or 5 millimeters into an agarose gel. The volume of blood inoculum ranged from 133 to 683 nanoliters for the phlebotomy needles and from 35 to 366 nanoliters for the suture needles. Needles were then passed through none, one or two layers of surgical glove material before embedding the needles 5 millimeters into agarose gel. The use of one layer of surgical glove resulted in a significant (p<0.001) decrease in inoculum from tapered suture needles, but not from the cutting needles. Two gloves were even more efficient (p<0.001) than one glove at removing blood from all suture needles, including the cutting needle. However, surgical glove material did not significantly reduce the volume of blood inoculum transferred by the phlebotomy needles. The size of the needle and depth of penetration were found to have a significant influence on inoculum.
C1 UNIV FLORIDA,DEPT SURG,GAINESVILLE,FL 32610.
CR ARTHUR LO, 1989, J VIROL, V63, P5046
   BENNETT B, 1991, OBSTET GYNECOL, V78, P1019
   COHN GM, 1990, AM J OBSTET GYNECOL, V162, P715, DOI 10.1016/0002-9378(90)90992-G                                                    
   COLE RP, 1989, BRIT J PLAST SURG, V42, P481, DOI 10.1016/0007-1226(89)90019-2                                                    
   COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402
   DOODS RD, 1990, BRIT J SURG, V77, P219
   FEINSTONE SM, 1981, J INFECT DIS, V144, P588, DOI 10.1093/infdis/144.6.588                                                        
   GANI JS, 1990, AM J OBSTET GYNECOL, V62, P771
   Graves EJ, 1992, VITAL HLTH STAT, V13, P1
   HAGEN MD, 1988, JAMA-J AM MED ASSOC, V259, P1359
   HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401
   HOFFMAN PN, 1989, J INFECT DIS, V160, P545, DOI 10.1093/infdis/160.3.545                                                        
   HOWARD RJ, 1990, SURG GYNECOL OBSTET, V171, P22
   KIM CY, 1973, J CLIN INVEST, V52, P1176, DOI 10.1172/JCI107284
   MAST ST, 1991, CLIN RES, V39, pA58
   MATTA H, 1988, BRIT MED J, V297, P597, DOI 10.1136/bmj.297.6648.597                                                        
   MCKINNEY WP, 1990, INFECT CONT HOSP EP, V11, P243
   NAPOLI VM, 1987, J INFECT DIS, V155, P828, DOI 10.1093/infdis/155.4.828                                                        
   SCHIFF SJ, 1990, J NEUROSURG, V73, P615
   SHIRAZIAN D, 1990, INFECT CONT HOSP EP, V11, P180
   WILSON SE, 1990, POSTGRAD MED, V88, P193
NR 21
TC 77
Z9 82
U1 0
U2 0
PU AMER COLL SURGEONS
PI CHICAGO
PA 54 EAST ERIE ST, CHICAGO, IL 60611
SN 1072-7515
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD FEB
PY 1994
VL 178
IS 2
BP 107
EP 110
PG 4
WC Surgery
SC Surgery
GA MX663
UT WOS:A1994MX66300001
PM 8173718
DA 2018-01-05
ER

PT J
AU CLOAD, ST
   SCHEPARTZ, A
AF CLOAD, ST
   SCHEPARTZ, A
TI SELECTION OF STRUCTURE-SPECIFIC INHIBITORS OF THE HIV REV-REV RESPONSE
   ELEMENT COMPLEX
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID VIRAL MESSENGER-RNA; TETHERED OLIGONUCLEOTIDE PROBES; VIRUS TYPE-1
   AFFECTS; SMALL NUCLEAR-RNA; ANTISENSE OLIGONUCLEOTIDES; TRANS-ACTIVATOR;
   HTLV-III; TARGET SEQUENCE; CATALYTIC RNA; RIBOSOMAL-RNA
AB We devised a single-step selection method to identify short sequences within the folded Rev response element (RRE) of the human immunodeficiency virus (HIV) RNA genome that are proximal and able to bind short oligonucleotides. The method employed a library of partially randomized tethered oligonucleotide probes (TOPs) complementary to all regions of the RRE and an RNase H cleavage assay which identified those RRE regions preferred by the TOPs. Six short sequences were identified. Two TOPs synthesized on the basis of this selection, S1-5-S2 and S1-1-S2, were potent, concentration-dependent inhibitors of a RRE function in vitro and abolished interaction of the RRE with the HIV regulatory protein Rev at nanomolar concentration (25-degrees-C, 0.8 nM RRE, 45 nM Rev). TOPs S1-5-S2 and S1-1-S2 exhibited greater potency and faster association kinetics than traditional oligonucleotides targeted to the same regions. The random TOP selection procedure described here allows rational design of oligonucleotide-based ligands for RNA that exploit (rather than avoid) the complex structure of the RNA target.
C1 YALE UNIV,DEPT CHEM,225 PROSPECT ST,NEW HAVEN,CT 06511.
CR BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6
   BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7                                                   
   BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503
   CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8
   CHIN DJ, 1992, J VIROL, V66, P600
   CLOAD ST, 1991, J AM CHEM SOC, V113, P6324, DOI 10.1021/ja00016a089                                                             
   CLOAD ST, 1993, J AM CHEM SOC, V115, P5005, DOI 10.1021/ja00065a008
   CROOKE ST, 1992, BIO-TECHNOL, V10, P882, DOI 10.1038/nbt0892-882
   DALY TJ, 1990, BIOCHEMISTRY-US, V29, P9791, DOI 10.1021/bi00494a005
   DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0
   DAYTON ET, 1989, SCIENCE, V246, P1628
   DONISKELLER H, 1979, NUCLEIC ACIDS RES, V7, P179, DOI 10.1093/nar/7.1.179
   DRAPER DE, 1992, ACCOUNTS CHEM RES, V25, P201, DOI 10.1021/ar00016a005                                                             
   ECKER DJ, 1992, SCIENCE, V257, P958, DOI 10.1126/science.1502560
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6                                                    
   FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0
   FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495
   FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505                                                           
   HADZOPOULOUCLADARAS M, 1989, J VIROL, V63, P1265
   HAMMARSKJOLD ML, 1989, CELL, V63, P1969
   HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V
   HOLLAND SM, 1990, J VIROL, V64, P5966
   JOYCE GF, 1989, GENE, V82, P83, DOI 10.1016/0378-1119(89)90033-4
   KJEMS J, 1992, EMBO J, V11, P1119
   KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683
   KROL A, 1989, METHOD ENZYMOL, V180, P212
   LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870
   LIMA WF, 1992, BIOCHEMISTRY-US, V31, P12055, DOI 10.1021/bi00163a013
   LISZIEWICZ J, 1992, P NATL ACAD SCI USA, V89, P11209, DOI 10.1073/pnas.89.23.11209
   LU XB, 1990, P NATL ACAD SCI USA, V87, P7598, DOI 10.1073/pnas.87.19.7598                                                         
   MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0
   MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9                                                    
   MANIATIS T, 1987, MOL CLONING
   MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783
   RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0                                                                
   RICHARDSON PL, 1991, J AM CHEM SOC, V113, P5109, DOI 10.1021/ja00013a083                                                             
   ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0
   ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2017
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561
   SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0
   THIESEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3203, DOI 10.1093/nar/18.11.3203                                                          
   TINOCO I, 1987, COLD SPRING HARB SYM, V52, P135, DOI 10.1101/SQB.1987.052.01.018                                                     
   Tinoco I. Jr., 1990, Nucleic Acids and Molecular Biology, V4, P205
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   UHLMANN E, 1990, CHEM REV, V90, P543, DOI 10.1021/cr00102a001                                                             
   Vournakis J N, 1981, Gene Amplif Anal, V2, P267
   WEINTRAUB HM, 1990, SCI AM, V262, P40, DOI 10.1038/scientificamerican0190-40                                               
   WEITZMANN CJ, 1990, NUCLEIC ACIDS RES, V18, P3515, DOI 10.1093/nar/18.12.3515
   WELLER JW, 1992, BIOCHEMISTRY-US, V31, P2748, DOI 10.1021/bi00125a015
   WOOLF TM, 1992, P NATL ACAD SCI USA, V89, P7305, DOI 10.1073/pnas.89.16.7305
   WYATT JR, 1989, BIOESSAYS, V11, P100, DOI 10.1002/bies.950110406
   ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0
NR 54
TC 27
Z9 27
U1 0
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD JAN 26
PY 1994
VL 116
IS 2
BP 437
EP 442
DI 10.1021/ja00081a002                                                     
          
PG 6
WC Chemistry, Multidisciplinary
SC Chemistry
GA MV283
UT WOS:A1994MV28300002
DA 2018-01-05
ER

PT S
AU STIENEKER, F
   KREUTER, J
AF STIENEKER, F
   KREUTER, J
BE Cleland, JL
   Langer, R
TI NANOPARTICLES AS A POTENTIAL ANTIGEN DELIVERY SYSTEM
SO FORMULATION AND DELIVERY OF PROTEINS AND PEPTIDES
SE ACS SYMPOSIUM SERIES
LA English
DT Article; Proceedings Paper
CT Symposium on Formulation and Delivery of Proteins and Peptides, at the
   205th National Meeting of the American-Chemical-Society
CY MAR 28-APR 02, 1993
CL DENVER, CO
SP AMER CHEM SOC, DIV BIOCHEM TECHNOL
ID ALUMINUM HYDROXIDE GEL; IMMUNOLOGICAL ADJUVANTS; VACCINE
AB PMMA nanoparticles showed a significant improvement in the induction of the immune response against different antigens such as influenza and inactivated split whole HIV-1 or HIV-2 when compared to other adjuvants. PMMA induced higher titres, which were stable at consistently high levels over prolonged periods of time. The immunization with PMMA was substantially more reproducible and non-responders were not observed. PMMA was biocompatible without any observable side effects or toxic reactions. The titres showed a clear dependence on the hydrophobicity and on the particle size of the respective adjuvant. Comparison of different adjuvants with HIV-2 as the antigen demonstrated that the specificity of the induced antibodies was dependent on the interaction between the various viral proteins and the adjuvant.
RP STIENEKER, F (reprint author), UNIV FRANKFURT,INST PHARMAZEUT TECHNOL,MARIE CURIE STR 9,D-60053 FRANKFURT,GERMANY.
CR ADA G, 1991, MOL IMMUNOL, V28, P225, DOI 10.1016/0161-5890(91)90065-R
   BARR M, 1955, BRIT MED J, V2, P635, DOI 10.1136/bmj.2.4940.635                                                          
   BENTELE V, 1983, International Journal of Pharmaceutics (Kidlington), V13, P109
   BERG UE, 1986, PHARM IND, V48, P75
   EDELMAN R, 1980, REV INFECT DIS, V2, P370
   FREEMAN MJ, 1968, IMMUNOLOGY, V15, P481
   GRAFE A, 1971, ARZNEI-FORSCHUNG, V21, P903
   GREGORIADIS G, 1987, VACCINE, V5, P145, DOI 10.1016/0264-410X(87)90063-6
   KERKHOF NJ, 1975, J PHARM SCI, V64, P940, DOI 10.1002/jps.2600640608
   KREUTER J, 1976, EXP CELL BIOL, V44, P12
   KREUTER J, 1976, INFECT IMMUN, V13, P204
   KREUTER J, 1988, VACCINE, V6, P253, DOI 10.1016/0264-410X(88)90220-4                                                    
   KREUTER J, 1981, J PHARM SCI, V70, P367, DOI 10.1002/jps.2600700406                                                          
   KREUTER J, 1983, INT J PHARM, V14, P43, DOI 10.1016/0378-5173(83)90113-8                                                    
   KREUTER J, 1983, PHARM ACTA HELV, V58, P196
   KREUTER J, 1978, INFECT IMMUN, V19, P667
   KREUTER J, 1979, J PHARM SCI, V68, P1443, DOI 10.1002/jps.2600681129
   KREUTER J, 1983, J PHARM SCI, V72, P1146, DOI 10.1002/jps.2600721009                                                          
   KREUTER J, 1978, RADIAT EFF DEFECT S, V35, P161, DOI 10.1080/00337577808240836
   KREUTER J, 1985, VACCINE, V4, P125
   KREUTER J, 1978, J PHARM SCI, V65, P1624
   KRUG M, 1989, BIOPOLYMERS, V28, P499, DOI 10.1002/bip.360280144
   NAIL SL, 1976, J PHARM SCI, V65, P1192, DOI 10.1002/jps.2600650815
   NAIL SL, 1976, J PHARM SCI, V65, P1188, DOI 10.1002/jps.2600650814
   NAIL SL, 1976, J PHARM SCI, V65, P1195, DOI 10.1002/jps.2600650816                                                          
   PYL G., 1953, Arch. exp. VetMed., V7, P9
   SEEBER SJ, 1991, VACCINE, V9, P201, DOI 10.1016/0264-410X(91)90154-X                                                    
   STIENEKER F, 1991, AIDS, V5, P431, DOI 10.1097/00002030-199104000-00012                                                
   STIENEKER F, 1993, VACCINE RES, V2, P111
   STIENEKER F, 1992, ENTWICKLUNG PRUFUNG, P808
   THERIEN HM, 1990, VACCINE, V8, P558, DOI 10.1016/0264-410X(90)90008-A
   TORRIGIANI G, 1965, J EXP MED, V122, P181, DOI 10.1084/jem.122.1.181                                                           
   TURK JL, 1977, J INVEST DERMATOL, V68, P336, DOI 10.1111/1523-1747.ep12496358
   Gillman CF, 1975, PHAGOCYTIC ENGULFMEN
   VANROOIJEN N, 1982, TARGETING DRUGS, P301
   WIESMULLER KH, 1989, VACCINE, V7, P29, DOI 10.1016/0264-410X(89)90007-8
NR 36
TC 5
Z9 5
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 SIXTEENTH ST NW, WASHINGTON, DC 20036
SN 0097-6156
BN 0-8412-2959-7
J9 ACS SYM SER
PY 1994
VL 567
BP 306
EP 321
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary;
   Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy
GA BB32M
UT WOS:A1994BB32M00018
DA 2018-01-05
ER

PT J
AU DECLERCQ, E
AF DECLERCQ, E
TI RESISTANCE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) TO
   NONNUCLEOSIDE HIV-1-SPECIFIC REVERSE-TRANSCRIPTASE INHIBITORS
SO INTERNATIONAL JOURNAL OF IMMUNOTHERAPY
LA English
DT Article
ID NONNUCLEOSIDE INHIBITORS; SELECTIVE-INHIBITION; POTENT INHIBITOR;
   MULTIDRUG-RESISTANCE; ANTI-HIV-1 ACTIVITY; ANTIVIRAL ACTIVITY; TIBO
   DERIVATIVES; IN-VITRO; REPLICATION; ANALOGS
AB Various non-nucleoside reverse transcriptase inhibitors (NNRTIs) have been reported to specifically inhibit HIV-1: viz. tetrahydroimidazobenzodiazepinone (TIBO), hydroxyethoxymethylphenylthiothymine (HEPT), dipyridodiazepinone (i.e. nevirapine), pyridinone, bis(heteroaryl)piperazine (BHAP), tert-butyidimethyisiiyispiroaminooxathiole-dioxide (TSAO), alpha-anilinophenylacetamide (alpha-APA) and quin oxaline derivatives. The most potent among the TIBO, HEPT and (alpha-APA derivatives have been found to inhibit HIV-1 replication at nanomolar concentrations that are 100,000-fold lower than the cytotoxic concentrations. These compounds therefore offer great potential for the treatment of HIV-1 infections. Yet, the virus may rapidly develop resistance to these drugs. The mutations conferring resistance have been, mapped at the reverse transcriptase positions 100 (Leu --> lie), 103 (Lys --> Asn), 106 (Val --> Aia), 108 (Val --> IIe), 138 (Glu --> Lys), 179 (Val --> Asp), 181 (Tyr --> Cys --> IIe), 188 (Tyr --> Cys/His), 190 (Gly --> Glu), 230 (Met --> IIe) and 236 (Pro --> Leu). However, these mutations do not necessarily lead to cross-resistance among the various NNRTls and, in some cases, they have proved to be mutually suppressive. Several strategies can be envisaged to circumvent or prevent the resistance problem. (i) switching from one NNRTI (to which the virus has developed resistance) to another (to which it has not developed resistance); (iii combination of different NNRTIs that do not confer cross-resistance, or even counteract development of resistance to one another; (iii) using from the start sufficiently high (''knocking out'') concentrations so as to completely shut off virus replication and prevent resistance from emerging; and (iv) by combining strategies (ii) and (iii), using from the start combinations of different drugs so as to achieve virus ''knock out'' at even lower concentrations.
RP DECLERCQ, E (reprint author), KATHOLIEKE UNIV LEUVEN,REGA INST MED RES,B-3000 LOUVAIN,BELGIUM.
CR ALAM M, 1993, ANTIVIR RES, V22, P131, DOI 10.1016/0166-3542(93)90091-V
   ARTICO M, 1993, ANTIVIR CHEM CHEMOTH, V4, P361, DOI 10.1177/095632029300400608                                                      
   BABA M, 1991, MOL PHARMACOL, V39, P805
   BABA M, 1993, BIOCHEM PHARMACOL, V45, P2507
   BABA M, 1991, P NATL ACAD SCI USA, V88, P2356, DOI 10.1073/pnas.88.6.2356
   BADER JP, 1991, P NATL ACAD SCI USA, V88, P6740, DOI 10.1073/pnas.88.15.6740                                                         
   BALZARINI J, 1993, J VIROL, V67, P5353
   BALZARINI J, 1993, VIROLOGY, V196, P576, DOI 10.1006/viro.1993.1513
   BALZARINI J, 1993, MOL PHARMACOL, V43, P109
   BALZARINI J, 1992, ANTIMICROB AGENTS CH, V36, P1073, DOI 10.1128/AAC.36.5.1073                                                           
   BALZARINI J, 1992, P NATL ACAD SCI USA, V89, P4392, DOI 10.1073/pnas.89.10.4392
   BALZARINI J, 1992, J BIOL CHEM, V267, P11831
   BALZARINI J, 1993, P NATL ACAD SCI USA, V90, P6952, DOI 10.1073/pnas.90.15.6952
   BALZARINI J, 1993, VIROLOGY, V192, P246, DOI 10.1006/viro.1993.1027
   BALZARINI J, 1993, MOL PHARMACOL, V44, P694
   BALZARINI J, 1994, UNPUB J VIROL
   BALZARINI J, 1994, IN PRESS BIOCH BIOPH
   BALZARINI J, 1993, INT ANTIVIRAL NEWS, V1, P66
   BALZARINI J, 1994, IN PRESS P NATL ACAD
   BUCKHEIT RW, 1993, ANTIVIR RES, V21, P247, DOI 10.1016/0166-3542(93)90031-D                                                    
   BYRNES VW, 1993, ANTIMICROB AGENTS CH, V37, P1576, DOI 10.1128/AAC.37.8.1576                                                           
   CHOW YK, 1993, NATURE, V361, P650, DOI 10.1038/361650a0                                                                
   CHOW YK, 1993, NATURE, V364, P679, DOI 10.1038/364679a0
   DEBYSER Z, 1991, P NATL ACAD SCI USA, V88, P1451, DOI 10.1073/pnas.88.4.1451
   DECLERCQ E, 1994, BIOCHEM PHARMACOL, V47, P155, DOI 10.1016/0006-2952(94)90001-9                                                    
   DELUCCA GV, 1992, BIOORG MED CHEM LETT, V2, P1639, DOI 10.1016/S0960-894X(00)80447-3
   DEVREESE K, 1992, VIROLOGY, V188, P900, DOI 10.1016/0042-6822(92)90550-9
   DUEWEKE TJ, 1993, ANTIMICROB AGENTS CH, V37, P1127, DOI 10.1128/AAC.37.5.1127                                                           
   DUEWEKE TJ, 1993, P NATL ACAD SCI USA, V90, P4713, DOI 10.1073/pnas.90.10.4713
   EMINI EA, 1993, NATURE, V364, P679, DOI 10.1038/364679b0                                                                
   GOLDMAN ME, 1992, ANTIMICROB AGENTS CH, V36, P1019, DOI 10.1128/AAC.36.5.1019                                                           
   GOLDMAN ME, 1993, ANTIMICROB AGENTS CH, V37, P947, DOI 10.1128/AAC.37.5.947                                                            
   GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863
   KASHMAN Y, 1992, J MED CHEM, V35, P2735, DOI 10.1021/jm00093a004
   KLEIM JP, 1994, VIROLOGY, V200, P696, DOI 10.1006/viro.1994.1233
   KLEIM JP, 1993, ANTIMICROB AGENTS CH, V37, P1659, DOI 10.1128/AAC.37.8.1659                                                           
   KOUP RA, 1991, J INFECT DIS, V163, P966, DOI 10.1093/infdis/163.5.966                                                        
   LARDER BA, 1993, NATURE, V365, P451, DOI 10.1038/365451a0
   LARDER BA, 1992, ANTIMICROB AGENTS CH, V36, P2664, DOI 10.1128/AAC.36.12.2664                                                          
   MCMAHON JB, 1993, ANTIMICROB AGENTS CH, V37, P754, DOI 10.1128/AAC.37.4.754                                                            
   MELLORS JW, 1992, MOL PHARMACOL, V41, P446
   MELLORS JW, 1993, MOL PHARMACOL, V43, P11
   MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568                                                         
   MERTENS A, 1993, J MED CHEM, V36, P2526, DOI 10.1021/jm00069a011
   Nanni Raymond G., 1993, Perspectives in Drug Discovery and Design, V1, P129, DOI 10.1007/BF02171659
   NUNBERG JH, 1991, J VIROL, V65, P4887
   PAUWELS R, 1993, P NATL ACAD SCI USA, V90, P1711, DOI 10.1073/pnas.90.5.1711                                                          
   PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0
   Pauwels R., 1994, Antiviral Research, V23, P109
   PAUWELS R, 1994, UNPUB ANTIMICROB AGE
   RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241
   ROMERO DL, 1993, J MED CHEM, V36, P1505, DOI 10.1021/jm00062a027
   ROMERO DL, 1991, P NATL ACAD SCI USA, V88, P8806, DOI 10.1073/pnas.88.19.8806                                                         
   SARDANA VV, 1992, J BIOL CHEM, V267, P17526
   SMITH MS, 1987, J VIROL, V61, P3769
   Ternansky R. J., 1993, Antiviral Research, V20, P68
   TERRETT NK, 1992, BIOORG MED CHEM LETT, V2, P1745, DOI 10.1016/S0960-894X(00)80468-0
   VANDAMME AM, 1994, AIDS RES HUM RETROV, V10, P39, DOI 10.1089/aid.1994.10.39
   VASUDEVACHARI MB, 1992, VIROLOGY, V190, P269, DOI 10.1016/0042-6822(92)91213-E                                                    
   WHITE EL, 1991, ANTIVIR RES, V16, P257
   WILLIAMS TM, 1993, J MED CHEM, V36, P1291, DOI 10.1021/jm00061a022
   YUASA S, 1993, MOL PHARMACOL, V44, P895
   ZHANG H, 1993, ANTIVIR CHEM CHEMOTH, V4, P301, DOI 10.1177/095632029300400506                                                      
NR 63
TC 19
Z9 19
U1 0
U2 0
PU BIOSCIENCE EDIPRINT INC
PI CAROUGE
PA RUE ALEXANDRE-GAVARD 16, 1227 CAROUGE, SWITZERLAND
SN 0255-9625
J9 INT J IMMUNOTHER
JI Int. J. Immunother.
PY 1994
VL 10
IS 4
BP 145
EP 158
PG 14
WC Immunology
SC Immunology
GA QA711
UT WOS:A1994QA71100002
DA 2018-01-05
ER

PT J
AU PAN, BC
   CHEN, HC
   PIRAS, G
   DUTSCHMAN, GE
   ROWE, EC
   CHENG, YC
   CHU, SH
AF PAN, BC
   CHEN, HC
   PIRAS, G
   DUTSCHMAN, GE
   ROWE, EC
   CHENG, YC
   CHU, SH
TI SYNTHESIS AND ANTI-HIV-1 ACTIVITIES OF 6-ARYLTHIO AND
   6-ARYLSELENOACYCLONUCLEOSIDES
SO JOURNAL OF HETEROCYCLIC CHEMISTRY
LA English
DT Article
ID HIV-1 REVERSE-TRANSCRIPTASE;
   1-<(2-HYDROXYETHOXY)METHYL>-6-(PHENYLTHIO)THYMINE; INHIBITOR; ANALOGS;
   DERIVATIVES; REPLICATION; AGENTS
AB 6-Arylthio and 6-arylselenoacyclonucleosides was synthesized and tested for the ability to inhibit replication of HIV-1. Lithiation of acyclonucleosides with LDA followed by reaction with the electrophiles phenyl disulfide, diphenyl diselenide, 2,2'-dipyrdyl disulfide or 2,2'-dipyridyl diselenide afforded 6-(arylthio or arylseleno)acyclonucleosides 5a-c, 6, 7, 9, 15a-c, 17a-c. Compounds 19a-c and 20a-c were obtained by deprotection of corresponding TBDMS derivatives. Dehydrated products 16a, and 18a-c were also formed during the reactions. 5-Ethyl-6-(alpha-pyridylthio or alpha-pyridylseleno) disubstituted acyclouracils 6 and 7 were more active against HIV-1 in both MT-2 and CEM-IW cell lines than AZT, DDC, DDI or D4T. The EC50 of 6 against HIV-1 in CEM-IW cell was in the nanomolar range with a therapeutic index of 1100.
C1 YALE UNIV,SCH MED,NEW HAVEN,CT 06510.
RP PAN, BC (reprint author), BROWN UNIV,DIV BIOL & MED,PROVIDENCE,RI 02912, USA.
OI Piras, Giovanna/0000-0003-4550-6606
CR CHENG YC, 1987, J BIOL CHEM, V262, P2187
   DAQUILA RT, 1989, J ACQ IMMUN DEF SYND, V2, P579
   GOUDGAON NM, 1991, J MED CHEM, V34, P3305, DOI 10.1021/jm00115a022                                                             
   KUKLA MJ, 1991, J MED CHEM, V34, P3187, DOI 10.1021/jm00115a007
   LARDER BA, 1990, ANTIMICROB AGENTS CH, V34, P436, DOI 10.1128/AAC.34.3.436                                                            
   LEMAITRE M, 1990, 5TH INT C ANT RES, P60
   MAUTNER HG, 1962, J ORG CHEM, V27, P3671, DOI 10.1021/jo01057a065                                                             
   MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568                                                         
   MIYASAKA T, 1989, J MED CHEM, V32, P2507, DOI 10.1021/jm00132a002                                                             
   MUI PW, 1992, J MED CHEM, V35, P201, DOI 10.1021/jm00079a029
   ROMERO DL, 1991, P NATL ACAD SCI USA, V88, P8806, DOI 10.1073/pnas.88.19.8806                                                         
   TANAKA H, 1991, J MED CHEM, V34, P1508, DOI 10.1021/jm00108a041
   TANAKA H, 1991, J MED CHEM, V34, P349, DOI 10.1021/jm00105a055
   WHITE EL, 1991, ANTIVIR RES, V16, P257
NR 14
TC 29
Z9 29
U1 1
U2 1
PU HETERO CORPORATION
PI TAMPA
PA BOX 20285, TAMPA, FL 33622-0285
SN 0022-152X
J9 J HETEROCYCLIC CHEM
JI J. Heterocycl. Chem.
PD JAN-FEB
PY 1994
VL 31
IS 1
BP 177
EP 185
DI 10.1002/jhet.5570310130                                                 
          
PG 9
WC Chemistry, Organic
SC Chemistry
GA MZ758
UT WOS:A1994MZ75800030
DA 2018-01-05
ER

PT J
AU BURNOUFRADOSEVICH, M
   APPOURCHAUX, P
   HUART, JJ
   BURNOUF, T
AF BURNOUFRADOSEVICH, M
   APPOURCHAUX, P
   HUART, JJ
   BURNOUF, T
TI NANOFILTRATION, A NEW SPECIFIC VIRUS ELIMINATION METHOD APPLIED TO
   HIGH-PURITY FACTOR-IX AND FACTOR-XI CONCENTRATES
SO VOX SANGUINIS
LA English
DT Article
ID CELLULOSE HOLLOW FIBER; HUMAN-PLASMA; HEPATITIS-A; REMOVAL; BMM;
   INACTIVATION; HEMOPHILIA; SAFETY
AB We have validated the use of two new regenerated multilayered structured cellulose membranes (BMM), Planova 15 N and Planova 35 N, with respective mean pore sizes of 15 and 35 nm, as a new filtration system to eliminate viruses in highly purified factor IX and fat tor XI concentrates. Virus spiking experiments indicated that single dead-end filtration on the membranes could remove more than 5.7-7.8 log(10) of human immunodeficiency virus, bovine viral diarrhoea virus, porcine pseudorabies virus, reovirus type 3, and simian virus 40, as well as the small non-enveloped viruses, poliovirus Sabin type 1 and bovine parvovirus. In vitro control tests and animal studies (Wessler stasis model, rat hypotension model) of the two concentrates did not reveal any significant differences with the non-nanofiltered material. Viral filtration of plasma derivatives on porous polymeric membranes might be an essential step in the improvement of their viral safety.
C1 CTR REG TRANSFUS SANGUINE,SERV FRACTIONNEMENT,F-59012 LILLE,FRANCE.
CR BURNOUF T, 1992, BIOLOGICALS, V20, P91, DOI 10.1016/S1045-1056(05)80056-9
   BURNOUF T, 1989, VOX SANG, V57, P225, DOI 10.1111/j.1423-0410.1989.tb00832.x                                              
   BURNOUF T, 1993, DEV BIOL STAND, V81, P199
   BURNOUF T, 1992, PLASMA RECOMBINANT B, P67
   BURNOUFRADOSEVICH M, 1992, TRANSFUSION, V32, P861, DOI 10.1046/j.1537-2995.1992.32993110761.x                                          
   CORSI OB, 1988, J MED VIROL, V25, P151
   DILEO AJ, 1992, BIO-TECHNOL, V10, P182, DOI 10.1038/nbt0292-182                                                             
   GERRITZEN A, 1992, LANCET, V340, P1231, DOI 10.1016/0140-6736(92)92937-B                                                    
   HAMAMOTO Y, 1989, VOX SANG, V56, P230, DOI 10.1111/j.1423-0410.1989.tb02034.x                                              
   HEIMBURGER N, 1989, CURR STUD HEMATOL BL, V56, P23
   HOROWITZ B, 1985, TRANSFUSION, V25, P516, DOI 10.1046/j.1537-2995.1985.25686071422.x
   HOROWITZ MS, 1988, LANCET, V2, P186
   IKEDA H, 1990, Artificial Organs, V14, P259
   KLEIN R, 1993, LANCET, V341, P768, DOI 10.1016/0140-6736(93)90549-V
   MANNUCCI PM, 1988, LANCET, V2, P782
   MANNUCCI PM, 1992, LANCET, V339, P819, DOI 10.1016/0140-6736(92)91955-8
   MICHALSKI C, 1993, COLLOQ INSE, V227, P91
   MORGENTHALER JJ, 1993, COLLOQ INSE, V227, P221
   NOEL L, 1989, LANCET, V2, P560
   PEERLINCK K, 1993, LANCET, V341, P179, DOI 10.1016/0140-6736(93)90044-H                                                    
   RUBINSTEIN AI, 1989, VOX SANG, V57, P272, DOI 10.1111/j.1423-0410.1989.tb00841.x                                              
   SEKIGUCHI S, 1990, TRANSFUS SCI, V11, P211, DOI 10.1016/0955-3886(90)90097-3
   TATEISHI J, 1993, MEMBRANE, V18, P101
   TSURUMI T, 1990, POLYM J, V22, P304, DOI 10.1295/polymj.22.304                                                           
   TSURUMI T, 1990, POLYM J, V22, P751, DOI 10.1295/polymj.22.751                                                           
   YAMAGUCHI K, 1989, J ELECTRON MICROSC, V38, P259
   1991, CPMP GUIDELINES AD H
NR 27
TC 78
Z9 79
U1 1
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0042-9007
J9 VOX SANG
JI Vox Sang.
PY 1994
VL 67
IS 2
BP 132
EP 138
DI 10.1111/j.1423-0410.1994.tb01647.x                                      
          
PG 7
WC Hematology
SC Hematology
GA PD016
UT WOS:A1994PD01600003
PM 7801601
DA 2018-01-05
ER

PT J
AU NEHETE, PN
   ARLINGHAUS, RB
   SASTRY, KJ
AF NEHETE, PN
   ARLINGHAUS, RB
   SASTRY, KJ
TI INHIBITION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION AND
   SYNCYTIUM FORMATION IN HUMAN-CELLS BY V3 LOOP SYNTHETIC PEPTIDES FROM
   GP120
SO JOURNAL OF VIROLOGY
LA English
DT Note
ID PRINCIPAL NEUTRALIZING DOMAIN; HTLV-III/LAV ENVELOPE; FUSION DOMAIN;
   GLYCOPROTEIN; ANTIBODIES; AIDS; DETERMINANT; MECHANISM; INDUCTION;
   SEQUENCE
AB Because V3 loop-specific antibodies have been shown to inhibit human immunodeficiency virus type 1 (HIV-1) infection of human cells and because specific mutations in the V3 loop render the virus ineffective for infection and syncytium formation, we tested the anti-HIV effects of V3 loop peptides from different HIV-1 strains.  We obtained evidence that V3 loop synthetic peptides of 8 to 15 amino acids at nanogram concentrations efficiently blocked HIV-1 IIIB infection of several human T-cell lines and of freshly prepared normal human T cells. More importantly, syncytium formation by three different primary clinical HIV isolates was inhibited by the V3 loop peptide from HIV-1 IIIB at a concentration Of 1 mug/ml. Concentrations of V3 peptides up to 50 mug/ml were not toxic to any of the human cells studied.  Additionally, V3 peptides incubated in normal human serum or plasma exhibited biological and physical stability for up to 24 h. Taken together, these results suggest that the V3 loop peptides have medical utility as therapeutic reagents to either prevent HIV-1 infection in humans or reduce the spread of virus infection in HIV-infected individuals.  These findings are especially significant because a number of reports in the literature indicate that the V3 loop region in gp120 Plays an important role in the initial stages of HIV-1 infection of cells.
C1 UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030.
OI Sastry, Jagannadha/0000-0002-6987-4422
FU NIAID NIH HHS [AI 29308]; NCI NIH HHS [CA 16672]
CR BABA M, 1988, P NATL ACAD SCI USA, V85, P6132, DOI 10.1073/pnas.85.16.6132                                                         
   DEROSSI A, 1991, VIROLOGY, V184, P187
   FREED EO, 1990, P NATL ACAD SCI USA, V87, P4650, DOI 10.1073/pnas.87.12.4650
   FREED EO, 1991, J VIROL, V65, P190
   HARDA S, 1985, SCIENCE, V229, P563
   HATTORI T, 1989, FEBS LETT, V248, P48, DOI 10.1016/0014-5793(89)80429-6
   HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131                                                         
   HU SL, 1986, NATURE, V320, P537, DOI 10.1038/320537a0
   IVANOFF LA, 1991, AIDS RES HUM RETROV, V7, P595, DOI 10.1089/aid.1991.7.595                                                          
   JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768                                                         
   Koito A, 1989, Int Immunol, V1, P613, DOI 10.1093/intimm/1.6.613
   LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685                                                         
   LEONARD CK, 1990, J BIOL CHEM, V265, P10373
   LIFSON JD, 1986, NATURE, V323, P725, DOI 10.1038/323725a0
   LINSLEY PS, 1988, J VIROL, V62, P3695
   MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8
   MANNHALTER JW, 1986, J IMMUNOL, V136, P2792
   MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4
   MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025                                                             
   MURAKAMI T, 1991, BIOCHIM BIOPHYS ACTA, V1079, P279, DOI 10.1016/0167-4838(91)90070-G
   PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932
   POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935
   RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198
   SASTRY KJ, 1992, VIROLOGY, V188, P502, DOI 10.1016/0042-6822(92)90504-I
   SODROSKI J, 1986, NATURE, V322, P470, DOI 10.1038/322470a0
   STEIN BS, 1987, CELL, V49, P659, DOI 10.1016/0092-8674(87)90542-3
   TRAVIS BM, 1992, VIROLOGY, V186, P313, DOI 10.1016/0042-6822(92)90088-7
NR 27
TC 39
Z9 39
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD NOV
PY 1993
VL 67
IS 11
BP 6841
EP 6846
PG 6
WC Virology
SC Virology
GA MC016
UT WOS:A1993MC01600062
PM 7692087
DA 2018-01-05
ER

PT J
AU FILION, LG
   LOGAN, D
   GAUDREAULT, R
   IZAGUIRRE, CA
AF FILION, LG
   LOGAN, D
   GAUDREAULT, R
   IZAGUIRRE, CA
TI INHIBITION OF HIV-1 REPLICATION BY DAUNORUBICIN
SO CLINICAL AND INVESTIGATIVE MEDICINE-MEDECINE CLINIQUE ET EXPERIMENTALE
LA English
DT Article
DE ANTHRACYCLINE ANTIBIOTICS; DAUNORUBICIN; HIV; MONOCYTES; T-CELLS
ID HUMAN-IMMUNODEFICIENCY-VIRUS; KAPOSIS SARCOMA; REVERSE-TRANSCRIPTASE;
   DOXORUBICIN; VINBLASTINE; MACROPHAGES; INVITRO
AB Members of the anthracycline family of drugs such as daunorubicin (DNR) are currently being employed in cancer therapy, treatment of Kaposi's sarcoma and lymphomas in HIV-1 infected patients. These drugs may have an antiviral activity against HIV-1. Experiments conducted on U937 (a promonocytic cell line), peripheral blood monocytes (without T cells) and infected with HIV-1 showed anti-viral activity at nanogram/ml concentrations, without affecting cell proliferation and cell viability. Treatment of Hut 78 cells (a T cell line) with DNR was not as effective in inhibiting HIV-1 replication when compared to the anti-HIV activity in cells of the monocyte lineage.
C1 UNIV OTTAWA,ONTARIO CANC TREATMENT & RES FDN,DEPT MED,DIV MED ONCOL,OTTAWA K1H 8M5,ONTARIO,CANADA.
   UNIV LAVAL,FAC MED,ST FOY,PQ,CANADA.
   HLTH & WELF CANADA,DIS CONTROL LAB,OTTAWA K1A 0L2,ONTARIO,CANADA.
RP FILION, LG (reprint author), UNIV OTTAWA,FAC MED,DEPT MICROBIOL & IMMUNOL,AIDS STUDY GRP,OTTAWA K1H 8M5,ONTARIO,CANADA.
CR AJITO K, 1989, J ANTIBIOT, V42, P611, DOI 10.7164/antibiotics.42.611                                                      
   BERGAMINI A, 1991, 7TH INT C AIDS
   BODLEY A, 1989, CANCER RES, V49, P5969
   DAVIES KJA, 1986, J BIOL CHEM, V261, P3060
   DORFMAN RF, 1988, KAPOSIS SARCOMA PATH, P72
   EKSBORG S, 1985, EUR J CLIN PHARMACOL, V28, P205, DOI 10.1007/BF00609693                                                              
   GALLO RC, 1990, J ACQ IMMUNODEF SYND, V3, P1380
   Giraldo G, 1983, Antibiot Chemother (1971), V32, P1
   GREGERSEN JP, 1988, J VIROL METHODS, V19, P161, DOI 10.1016/0166-0934(88)90159-0
   KOYANAGI Y, 1988, SCIENCE, V241, P1673, DOI 10.1126/science.3047875
   LAUBENSTEIN LJ, 1984, J CLIN ONCOL, V2, P1115, DOI 10.1200/JCO.1984.2.10.1115                                                      
   LOGAN DM, 1991, 7TH INT C AIDS
   MELTZER MS, 1990, IMMUNOL TODAY, V11, P217, DOI 10.1016/0167-5699(90)90086-O                                                    
   NAKASHIMA H, 1987, J ANTIBIOT, V40, P396, DOI 10.7164/antibiotics.40.396                                                      
   ODAJNYK C, 1985, J CLIN ONCOL, V3, P1277, DOI 10.1200/JCO.1985.3.9.1277                                                       
   PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0
   PERNO CF, 1990, AIDS RES HUM RETROV, V6, P1051
   SALAHUDDIN SZ, 1985, SCIENCE, V247, P430
   SCHIELDS PG, 1990, J ACQ IMMUNODEF SYND, V3, P695
   VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0
   VOLBERDING PA, 1985, ANN INTERN MED, V103, P335, DOI 10.7326/0003-4819-103-3-335
NR 21
TC 3
Z9 3
U1 0
U2 1
PU CANADIAN MEDICAL ASSOCIATION
PI OTTAWA
PA 1867 ALTA VISTA DR, OTTAWA ON K1G 3Y6, CANADA
SN 0147-958X
J9 CLIN INVEST MED
JI Clin. Invest. Med.-Med. Clin. Exp.
PD OCT
PY 1993
VL 16
IS 5
BP 339
EP 347
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA ME703
UT WOS:A1993ME70300004
PM 8261687
DA 2018-01-05
ER

PT J
AU DIVITA, G
   MULLER, B
   IMMENDORFER, U
   GAUTEL, M
   RITTINGER, K
   RESTLE, T
   GOODY, RS
AF DIVITA, G
   MULLER, B
   IMMENDORFER, U
   GAUTEL, M
   RITTINGER, K
   RESTLE, T
   GOODY, RS
TI KINETICS OF INTERACTION OF HIV REVERSE-TRANSCRIPTASE WITH PRIMER
   TEMPLATE
SO BIOCHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; STEADY-STATE KINETICS; ESCHERICHIA-COLI;
   NONNUCLEOSIDE INHIBITORS; BINDING-SITE; EXPRESSION; REPLICATION;
   MECHANISM; PROCESSIVITY; DERIVATIVES
AB Intrinsic protein fluorescence of reverse transcriptases from HIV-1 and HIV-2 provides a sensitive signal for monitoring the interaction of the enzymes with primer/template duplex molecules. K(d) values for 18/36-mer DNA/DNA duplexes were found to be in the range of a few nanomolar (about 3 times higher for the enzyme from HIV-2 than for that from HIV-1). The quenching of protein fluorescence induced on binding primer/template, together with an increase in extrinsic fluorescence on interaction with primer/template containing a fluorescent nucleotide at the 3'-end of the primer, was used to investigate the kinetics of interaction with reverse transcriptase from HIV-1. The results can be explained in terms of a two-step binding model, with a rapid diffusion-limited initial association (k(ass) = ca. 5 X 10(8) M-1 s-1) followed by a slow isomerization step (k = ca. 0.5 s-1). These (forward) rate constants are increased in the presence of a non-nucleoside inhibitor (S-TIBO) of HIV-1 reverse transcriptase, while the reverse rate constant for the second step is decreased, leading to an increase in affinity between the enzyme and primer/template by a factor of at least 10 when S-TIBO is bound. The results are discussed in terms of present knowledge of the structure of reverse transcriptase.
C1 MAX PLANCK INST MED RES,BIOPHYS ABT,JAHNSTR 29,W-6900 HEIDELBERG 1,GERMANY.
   EMBL,W-6900 HEIDELBERG,GERMANY.
RI Rittinger, Katrin/D-2586-2014; Goody, Roger/J-8845-2014
OI Rittinger, Katrin/0000-0002-7698-4435; Goody, Roger/0000-0002-0772-0444
CR ARGOS P, 1988, NUCLEIC ACIDS RES, V16, P9909, DOI 10.1093/nar/16.21.9909
   BARAT C, 1991, NUCLEIC ACIDS RES, V19, P751, DOI 10.1093/nar/19.4.751
   BARAT C, 1989, EMBO J, V8, P3279
   BASU A, 1992, BIOCHEMISTRY-US, V31, P616, DOI 10.1021/bi00117a045
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   COHEN KA, 1991, J BIOL CHEM, V266, P14670
   DOBYSER Z, 1992, J BIOL CHEM, V267, P11769
   DUEWEKE TJ, 1992, J BIOL CHEM, V267, P27
   FRANK KB, 1991, J BIOL CHEM, V266, P14232
   GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863
   GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763                                                        
   GROB PM, 1992, AIDS RES HUM RETROV, V8, P145, DOI 10.1089/aid.1992.8.145
   HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218
   HUBER HE, 1989, J BIOL CHEM, V264, P4669
   JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648                                                         
   KATI WM, 1992, J BIOL CHEM, V267, P25988
   KOHLSTAEDT LA, 1992, P NATL ACAD SCI USA, V89, P9652, DOI 10.1073/pnas.89.20.9652
   KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403
   LARDER B, 1987, EMBO J, V6, P3133
   LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0
   LEGRICE SFJ, 1988, J VIROL, V62, P2525
   MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657
   MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568                                                         
   MULLER B, 1989, J BIOL CHEM, V264, P13975
   MULLER B, 1991, BIOCHEMISTRY-US, V30, P3709, DOI 10.1021/bi00229a017                                                             
   MULLER B, 1991, J BIOL CHEM, V266, P14709
   PAINTER GR, 1991, J BIOL CHEM, V266, P19362
   PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0
   PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806                                                         
   REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013
   RESTLE T, 1993, UNPUB BIOCHEMISTRY
   SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980
   SARDANA VV, 1992, J BIOL CHEM, V267, P17526
   SARIHCOTTIN L, 1992, J MOL BIOL, V226, P1, DOI 10.1016/0022-2836(92)90117-3
   SHIH CK, 1991, P NATL ACAD SCI USA, V88, P9878, DOI 10.1073/pnas.88.21.9878
   TANESE N, 1986, J VIROL, V59, P743
   WEISS S, 1992, GENE, V111, P183, DOI 10.1016/0378-1119(92)90686-J
   WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003
NR 38
TC 44
Z9 44
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD AUG 10
PY 1993
VL 32
IS 31
BP 7966
EP 7971
DI 10.1021/bi00082a018
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA LV436
UT WOS:A1993LV43600018
PM 7688571
DA 2018-01-05
ER

PT J
AU VAILLANCOURT, M
   VANASSE, B
   COHEN, E
   SAUVE, G
AF VAILLANCOURT, M
   VANASSE, B
   COHEN, E
   SAUVE, G
TI DIFUNCTIONAL ENOLS OF N-PROTECTED AMINO-ACIDS AS LOW-MOLECULAR-WEIGHT
   AND NOVEL INHIBITORS OF HIV-1 PROTEASE
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
ID IMMUNODEFICIENCY VIRUS-1 PROTEASE; ANTIVIRAL ACTIVITY; PROTEINASE;
   DESIGN; INFECTIVITY; CLEAVAGE; INVITRO; SITE
AB The synthesis of difunctional enols of simple amino acids and their novel inhibitory activity against human immunodeficiency virus type 1 protease (HIV-PR) are described. By modifying the substituents on these enols, we were able to achieve mid-nanomolar range in activity against HIV-1 protease which is, to our knowledge, the best reported activity for molecules that do not contain at least one peptide linkage.
C1 UNIV QUEBEC, INST ARMAND FRAPPIER, 531 BOUL PRAIRIES, LAVAL H7N 4Z3, QUEBEC, CANADA.
   UNIV MONTREAL, DEPT MICROBIOL & IMMUNOL, MONTREAL H3C 3J7, QUEBEC, CANADA.
CR BLUMENSTEIN JJ, 1989, BIOCHEM BIOPH RES CO, V163, P980, DOI 10.1016/0006-291X(89)92318-8
   BRINKWORTH RI, 1991, BIOCHEM BIOPH RES CO, V176, P241, DOI 10.1016/0006-291X(91)90915-T
   DARKE PL, 1988, BIOCHEM BIOPH RES CO, V156, P297, DOI 10.1016/S0006-291X(88)80839-8                                                   
   DESJARLAIS RL, 1990, P NATL ACAD SCI USA, V87, P6644, DOI 10.1073/pnas.87.17.6644                                                         
   DESOLMS SJ, 1991, J MED CHEM, V34, P2852, DOI 10.1021/jm00113a025
   DREYER GB, 1989, P NATL ACAD SCI USA, V86, P9752, DOI 10.1073/pnas.86.24.9752
   GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781
   GRIFFITHS JT, 1992, BIOCHEMISTRY-US, V31, P5193, DOI 10.1021/bi00137a015
   KEMPF DJ, 1990, J MED CHEM, V33, P2687, DOI 10.1021/jm00172a002
   KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686
   LAPATTO R, 1989, NATURE, V342, P299, DOI 10.1038/342299a0                                                                
   MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486
   MEEK TD, 1989, P NATL ACAD SCI USA, V86, P1841, DOI 10.1073/pnas.86.6.1841
   MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273
   MOELLING K, 1990, FEBS LETT, V261, P373, DOI 10.1016/0014-5793(90)80595-A
   NORBECK DW, 1991, ANNU REP MED CHEM, V26, P141
   RICH DH, 1990, J MED CHEM, V33, P1285, DOI 10.1021/jm00167a003
   RICHARDS AD, 1989, FEBS LETT, V247, P113, DOI 10.1016/0014-5793(89)81251-7
   SAUVE G, 1990, J ORG CHEM, V55, P3002, DOI 10.1021/jo00297a008
   SHAM HL, 1991, J CHEM SOC CHEM COMM, P110, DOI 10.1039/c39910000110                                                            
   THAISRIVONGS S, 1991, J MED CHEM, V34, P2344, DOI 10.1021/jm00112a005                                                             
   TOMASSELLI AG, 1990, BIOCHEMISTRY-US, V29, P264, DOI 10.1021/bi00453a036                                                             
   WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279
NR 23
TC 14
Z9 14
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD JUN
PY 1993
VL 3
IS 6
BP 1169
EP 1174
DI 10.1016/S0960-894X(00)80308-X
PG 6
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA LH321
UT WOS:A1993LH32100037
DA 2018-01-05
ER

PT J
AU MOHAN, P
AF MOHAN, P
TI PROBLEMS AND PERSPECTIVES IN THE DESIGN OF ANTI-HIV-1 AGENTS
SO DRUG DEVELOPMENT RESEARCH
LA English
DT Review
DE HIV; ENZYME INHIBITORS AND DERIVATIVES; VIRAL BINDING
ID HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE INHIBITORS; INDUCED
   SYNCYTIUM FORMATION; RECOMBINANT SOLUBLE CD4; GIANT-CELL FORMATION;
   AIDS-RELATED COMPLEX; DEXTRAN SULFATE; HIV REPLICATION;
   ACID-DERIVATIVES; ANTIRETROVIRUS ACTIVITY
AB The human immunodeficiency virus (HIV) that produces the acquired immune deficiency syndrome (AIDS) continues to evade all strategies for potential therapeutic intervention. Global efforts in the search for potential anti-HIV-1 agents have mainly centered around the design of enzyme inhibitors and derivatives that inhibit viral binding or gene expression. Both nucleoside and non-nucleoside reverse transcriptase inhibitors have demonstrated potent anti-HIV-1 activity. However, toxicity considerations and the emergence of resistant strains will require further structural manipulations to diminish these undesirable properties. Protease inhibitors also exhibit activities at nanomolar concentrations, but many of these agents may suffer from problems of absorption and biodegradation. These apparent shortcomings have been circumvented by the preparation of peptidomimetic molecules. Similarly, smaller CD4 mimetics have emerged as alternatives to the larger soluble CD4 derivatives as inhibitors of viral binding. Other viral binding inhibitors, the anionic molecules, suffer from an inherent inability to enter cells and potential anticoagulant activity. These properties may be remedied by rational analog design and synthesis. Oligonucleotides can be constructed to inhibit specific segments of selected regulatory genes of the virus. These agents have been critiqued on the basis of stability, cellular uptake, and assurance of hybridization. Once again, structure activity relationship studies have revealed that many of these apparent problems can be overcome. The more recently discovered agents belong to the unique classes of tat antagonists or viral uncoating inhibitors.
RP MOHAN, P (reprint author), UNIV ILLINOIS, COLL PHARM, DEPT MED CHEM & PHARMACOGNOSY M-C 781, BOX 6998, CHICAGO, IL 60680 USA.
CR ADAMS LD, 1992, AIDS RES HUM RETROV, V8, P291, DOI 10.1089/aid.1992.8.291
   ANDERSON BD, 1992, J CONTROL RELEASE, V19, P219, DOI 10.1016/0168-3659(92)90078-6
   ARNOLD E, 1991, ADV VIRUS RES, V39, P1, DOI 10.1016/S0065-3527(08)60792-7
   BABA M, 1990, J ACQ IMMUN DEF SYND, V3, P493
   BABA M, 1988, BIOCHEM BIOPH RES CO, V155, P1404, DOI 10.1016/S0006-291X(88)81297-X
   BABA M, 1992, ANTIVIR RES, V17, P245, DOI 10.1016/0166-3542(92)90021-V
   BABA M, 1990, ANTIMICROB AGENTS CH, V34, P134, DOI 10.1128/AAC.34.1.134                                                            
   BABA M, 1988, ANTIMICROB AGENTS CH, V32, P1742, DOI 10.1128/AAC.32.11.1742                                                          
   BABA M, 1990, J INFECT DIS, V161, P208, DOI 10.1093/infdis/161.2.208                                                        
   BABA M, 1993, IN PRESS ANTIVIRAL C
   BABOONIAN C, 1991, BIOCHEM BIOPH RES CO, V179, P17, DOI 10.1016/0006-291X(91)91327-9
   BAGASRA O, 1991, J INFECT DIS, V164, P1082, DOI 10.1093/infdis/164.6.1082                                                       
   BAIRD LG, 1980, ANIONIC POLYM DRUGS, P185
   BALZARINI J, 1989, P NATL ACAD SCI USA, V86, P332, DOI 10.1073/pnas.86.1.332
   BALZARINI J, 1986, INT J CANCER, V37, P451, DOI 10.1002/ijc.2910370318
   BALZARINI J, 1992, ANTIMICROB AGENTS CH, V36, P1073, DOI 10.1128/AAC.36.5.1073                                                           
   BALZARINI J, 1991, P NATL ACAD SCI USA, V88, P4961, DOI 10.1073/pnas.88.11.4961
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   BLUMENSTEIN JJ, 1989, BIOCHEM BIOPH RES CO, V163, P980, DOI 10.1016/0006-291X(89)92318-8
   BONE R, 1991, J AM CHEM SOC, V113, P9382, DOI 10.1021/ja00024a061
   BOWMAN MC, 1983, J ANAL TOXICOL, V7, P55, DOI 10.1093/jat/7.1.55                                                              
   BREINIG MC, 1980, ANIONIC POLYM DRUGS, P211
   BRIGHTY DW, 1991, P NATL ACAD SCI USA, V88, P7802, DOI 10.1073/pnas.88.17.7802
   BRODER S, 1985, LANCET, V2, P627
   BUSSO M, 1991, AIDS, V5, P1425, DOI 10.1097/00002030-199112000-00003
   CALLAHAN LN, 1991, J VIROL, V65, P1543
   CAMARASA MJ, 1992, J MED CHEM, V35, P2721, DOI 10.1021/jm00093a002
   CARDIN AD, 1991, J BIOL CHEM, V266, P13355
   CHEN S, 1992, BIOCHEMISTRY-US, V89, P5872
   CLANTON DJ, 1992, J ACQ IMMUN DEF SYND, V5, P771
   COHEN JS, 1991, ANTIVIR RES, V16, P121, DOI 10.1016/0166-3542(91)90019-N
   COHEN JS, 1991, PHARMACOL THERAPEUT, V52, P211, DOI 10.1016/0163-7258(91)90009-B                                                    
   COOK PD, 1991, ANTI-CANCER DRUG DES, V6, P585
   CRABBE MJC, 1991, AIDS RES HUM RETROV, V7, P261
   DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574                                                         
   DEBOUCK C, 1992, AIDS RES HUM RETROV, V8, P153, DOI 10.1089/aid.1992.8.153
   DEBYSER Z, 1992, J BIOL CHEM, V267, P11769
   DECLERCQ E, 1991, BIOCHEM PHARMACOL, V42, P963, DOI 10.1016/0006-2952(91)90276-B                                                    
   DECLERCQ E, 1979, CANCER LETT, V8, P9, DOI 10.1016/0304-3835(79)90017-X                                                    
   DECLERCQ E, 1992, AIDS RES HUM RETROV, V8, P119, DOI 10.1089/aid.1992.8.119                                                          
   DEDERA D, 1991, J VIROL, V65, P6129
   DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0
   DEGOLS G, 1992, ANTIVIR RES, V17, P279, DOI 10.1016/0166-3542(92)90023-X
   DESJARLAIS RL, 1990, P NATL ACAD SCI USA, V87, P6644, DOI 10.1073/pnas.87.17.6644                                                         
   DESOMER P, 1968, J VIROL, V2, P886
   DUEWEKE TJ, 1992, J BIOL CHEM, V267, P27
   DUNCAN R, 1992, ANTI-CANCER DRUG, V3, P175, DOI 10.1097/00001813-199206000-00001
   Fischer A, 1939, P SOC EXP BIOL MED, V42, P81
   FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0
   FITZGIBBON JE, 1992, ANTIMICROB AGENTS CH, V36, P153, DOI 10.1128/AAC.36.1.153                                                            
   FLEET GWJ, 1988, FEBS LETT, V237, P128, DOI 10.1016/0014-5793(88)80185-6
   FLEXNER C, 1991, ANTIMICROB AGENTS CH, V35, P2544, DOI 10.1128/AAC.35.12.2544                                                          
   FREEMAN HS, 1987, DYES PIGMENTS, V8, P417, DOI 10.1016/0143-7208(87)85034-9                                                    
   GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936
   GHOSH MK, 1992, PROG NUCLEIC ACID RE, V42, P79, DOI 10.1016/S0079-6603(08)60574-7                                                   
   GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863
   GROB PM, 1992, AIDS RES HUM RETROV, V8, P145, DOI 10.1089/aid.1992.8.145
   GRUTERS RA, 1987, NATURE, V330, P74, DOI 10.1038/330074a0
   GUSTAFSON KR, 1989, J NATL CANCER I, V81, P1254, DOI 10.1093/jnci/81.16.1254                                                         
   HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969
   HARTMAN NR, 1990, AIDS RES HUM RETROV, V6, P805, DOI 10.1089/aid.1990.6.805                                                          
   HILDRETH JEK, 1989, SCIENCE, V244, P1075, DOI 10.1126/science.2543075
   HOSOYA M, 1991, ANTIMICROB AGENTS CH, V35, P2515, DOI 10.1128/AAC.35.12.2515                                                          
   HSU MC, 1991, SCIENCE, V254, P1799, DOI 10.1126/science.1763331                                                         
   HUFF JR, 1991, J MED CHEM, V34, P2305, DOI 10.1021/jm00112a001
   HUSSEY RE, 1988, NATURE, V331, P78, DOI 10.1038/331078a0
   JENTSCH KD, 1987, J GEN VIROL, V68, P2183, DOI 10.1099/0022-1317-68-8-2183
   KAHN M, 1991, J MED CHEM, V34, P3395, DOI 10.1021/jm00116a009
   KAPLAN LD, 1987, AM J MED, V82, P615, DOI 10.1016/0002-9343(87)90108-2
   KARPAS A, 1988, P NATL ACAD SCI USA, V85, P9229, DOI 10.1073/pnas.85.23.9229
   KEMPF DJ, 1990, J MED CHEM, V33, P2687, DOI 10.1021/jm00172a002
   KINCHINGTON D, 1992, ANTIVIR RES, V17, P53, DOI 10.1016/0166-3542(92)90090-R
   KLUNDER JM, 1992, J MED CHEM, V35, P1887, DOI 10.1021/jm00088a027                                                             
   KONIG H, 1989, ANTIMICROB AGENTS CH, V33, P2109, DOI 10.1128/AAC.33.12.2109                                                          
   KOZLOWSKI MR, 1991, BRAIN RES, V553, P300, DOI 10.1016/0006-8993(91)90838-M
   KUCERA LS, 1990, AIDS RES HUM RETROV, V6, P491, DOI 10.1089/aid.1990.6.491
   KUKLA MJ, 1991, J MED CHEM, V34, P3187, DOI 10.1021/jm00115a007
   KUNTZ ID, 1992, SCIENCE, V257, P1078, DOI 10.1126/science.257.5073.1078
   LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383
   LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983
   LARSEN AK, 1986, P NATL ACAD SCI USA, V83, P2964, DOI 10.1073/pnas.83.9.2964
   LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563
   LI TY, 1992, J ORG CHEM, V57, P3449, DOI 10.1021/jo00038a039
   LIN TS, 1989, ANTIMICROB AGENTS CH, V33, P2149, DOI 10.1128/AAC.33.12.2149                                                          
   LINGHAM RB, 1992, J ANTIBIOT, V45, P686, DOI 10.7164/antibiotics.45.686                                                      
   MACGREGOR IR, 1984, THROMB HAEMOSTASIS, V51, P321
   LORENTSEN KJ, 1989, ANN INTERN MED, V111, P561, DOI 10.7326/0003-4819-111-7-561
   MARTIN JA, 1992, ANTIVIR RES, V17, P265, DOI 10.1016/0166-3542(92)90022-W
   MCGUIGAN C, 1992, ANTIVIR RES, V17, P197, DOI 10.1016/0166-3542(92)90041-3
   MEIJER DKF, 1992, ANTIVIR RES, V18, P215, DOI 10.1016/0166-3542(92)90058-D
   MELLORS JW, 1992, MOL PHARMACOL, V41, P446
   MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568                                                         
   MICHAEL WR, 1968, TOXICOL APPL PHARM, V12, P473, DOI 10.1016/0041-008X(68)90154-3
   MILTON RCD, 1992, SCIENCE, V256, P1445, DOI 10.1126/science.1604320
   MITCHELL LLW, 1992, BIOCHEMISTRY-US, V31, P7707, DOI 10.1021/bi00148a035
   MITSUYA H, 1984, SCIENCE, V226, P172, DOI 10.1126/science.6091268                                                         
   MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273
   MOELLING K, 1990, FEBS LETT, V261, P373, DOI 10.1016/0014-5793(90)80595-A
   MOELLING K, 1989, J VIROL, V63, P5489
   MOHAN P, 1990, AIDS, V4, P821, DOI 10.1097/00002030-199008000-00021
   MOHAN P, 1992, ANTIVIR RES, V18, P139, DOI 10.1016/0166-3542(92)90034-3
   MOHAN P, 1990, LIFE SCI, V47, P993, DOI 10.1016/0024-3205(90)90471-3
   MOHAN P, 1991, J MED CHEM, V34, P212, DOI 10.1021/jm00105a033
   MOHAN P, 1992, PHARM RES-DORDR, V9, P703, DOI 10.1023/A:1015882901078                                                         
   MOHAN P, 1991, BIOCHEM PHARMACOL, V41, P642, DOI 10.1016/0006-2952(91)90641-H                                                    
   Mohan P, 1991, Drug Des Discov, V8, P69
   MUI PW, 1992, J MED CHEM, V35, P201, DOI 10.1021/jm00079a029
   MULLIGAN MJ, 1990, AIDS RES HUM RETROV, V6, P707, DOI 10.1089/aid.1990.6.707
   NAESENS L, 1989, EUR J CLIN MICROBIOL, V8, P1043, DOI 10.1007/BF01975167
   NEURATH AR, 1992, ANTIVIR CHEM CHEMOTH, V3, P55, DOI 10.1177/095632029200300108                                                      
   NEYTS J, 1992, VIROLOGY, V189, P48, DOI 10.1016/0042-6822(92)90680-N
   NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210
   OHKI K, 1991, J ACQ IMMUN DEF SYND, V4, P1233
   OSWALD M, 1991, FEBS LETT, V292, P298, DOI 10.1016/0014-5793(91)80888-A
   OTTENBRITE RM, 1980, ANIONIC POLYM DRUGS, P1
   PANTALEO G, 1991, EUR J IMMUNOL, V21, P1771, DOI 10.1002/eji.1830210730                                                          
   PARISH CR, 1990, J IMMUNOL, V145, P1188
   PARKER KA, 1992, J ORG CHEM, V57, P97, DOI 10.1021/jo00027a019
   PATIL AD, 1992, J NAT PROD, V55, P1170, DOI 10.1021/np50087a002
   PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0
   PEAKMAN M, 1992, J INFECT DIS, V165, P799, DOI 10.1093/infdis/165.5.799                                                        
   PEREZPEREZ MJ, 1992, J MED CHEM, V35, P2988, DOI 10.1021/jm00094a009
   PERNO CF, 1990, J EXP MED, V171, P1043, DOI 10.1084/jem.171.4.1043                                                          
   PERNO CF, 1992, ANTIVIR RES, V17, P289, DOI 10.1016/0166-3542(92)90024-Y
   PETERS M, 1991, AIDS, V5, P1534, DOI 10.1097/00002030-199112000-00021
   RATNER L, 1992, AIDS RES HUM RETROV, V8, P165, DOI 10.1089/aid.1992.8.165
   RAUSCH DM, 1992, BIOCHEM PHARMACOL, V43, P1785, DOI 10.1016/0006-2952(92)90711-Q
   RICHMAN D, 1991, ANTIMICROB AGENTS CH, V35, P305, DOI 10.1128/AAC.35.2.305                                                            
   RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241
   ROEDERER M, 1992, AIDS RES HUM RETROV, V8, P209, DOI 10.1089/aid.1992.8.209
   ROMERO DL, 1991, P NATL ACAD SCI USA, V88, P8806, DOI 10.1073/pnas.88.19.8806                                                         
   ROOKE R, 1991, ANTIMICROB AGENTS CH, V35, P988, DOI 10.1128/AAC.35.5.988                                                            
   ROSEN CA, 1992, AIDS RES HUM RETROV, V8, P175, DOI 10.1089/aid.1992.8.175                                                          
   SAARI WS, 1991, J MED CHEM, V34, P2922, DOI 10.1021/jm00113a036
   SCHINAZI RF, 1992, ANTIMICROB AGENTS CH, V36, P2432, DOI 10.1128/AAC.36.11.2432                                                          
   SCHINAZI RF, 1990, ANTIVIR RES, V13, P265, DOI 10.1016/0166-3542(90)90071-E
   SCHOLS D, 1990, VIROLOGY, V175, P556, DOI 10.1016/0042-6822(90)90440-3
   SCHOLS D, 1991, J ACQ IMMUN DEF SYND, V4, P677
   SHIH CK, 1991, P NATL ACAD SCI USA, V88, P9878, DOI 10.1073/pnas.88.21.9878
   SKOOG MT, 1992, MED RES REV, V12, P27, DOI 10.1002/med.2610120103
   SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514
   SPINKS A, 1948, BIOCHEM J, V42, P109, DOI 10.1042/bj0420109                                                               
   STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788                                                         
   SUZUKI H, 1989, AGR BIOL CHEM TOKYO, V53, P3369, DOI 10.1080/00021369.1989.10869842                                                  
   TAN GT, 1992, J MED CHEM, V35, P4846, DOI 10.1021/jm00104a010
   TAN GT, 1993, IN PRESS BIOCH BIOPH
   TANAKA H, 1991, J MED CHEM, V34, P349, DOI 10.1021/jm00105a055
   TATENO M, 1989, P NATL ACAD SCI USA, V86, P4287, DOI 10.1073/pnas.86.11.4287
   THIRIART C, 1988, AIDS, V2, P345, DOI 10.1097/00002030-198810000-00003
   TOMASSELLI AG, 1991, J BIOL CHEM, V266, P14548
   TRAUNECKER A, 1988, NATURE, V331, P84, DOI 10.1038/331084a0
   UHLMANN E, 1990, CHEM REV, V90, P543, DOI 10.1021/cr00102a001                                                             
   VANROEY P, 1989, P NATL ACAD SCI USA, V86, P3929
   VERMOTDESROCHES C, 1991, MOL IMMUNOL, V28, P1095, DOI 10.1016/0161-5890(91)90024-E
   WEAVER JL, 1992, ANTIVIR CHEM CHEMOTH, V3, P147, DOI 10.1177/095632029200300303                                                      
   WELLS CL, 1990, J ACQ IMMUN DEF SYND, V3, P361
   WHITE EL, 1991, ANTIVIR RES, V16, P257
   WINDSOR E, 1964, AM J MED, V37, P408, DOI 10.1016/0002-9343(64)90197-4
   YATES PC, 1991, STRUCT CHEM, V2, P611, DOI 10.1007/BF00676822
   ZHANG ZY, 1991, J BIOL CHEM, V266, P15591
NR 160
TC 15
Z9 15
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0272-4391
EI 1098-2299
J9 DRUG DEVELOP RES
JI Drug Dev. Res.
PD MAY
PY 1993
VL 29
IS 1
BP 1
EP 17
DI 10.1002/ddr.430290102                                                   
          
PG 17
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LC006
UT WOS:A1993LC00600001
DA 2018-01-05
ER

PT J
AU GHOSH, AK
   MCKEE, SP
   THOMPSON, WJ
   DARKE, PL
   ZUGAY, JC
AF GHOSH, AK
   MCKEE, SP
   THOMPSON, WJ
   DARKE, PL
   ZUGAY, JC
TI POTENT HIV-1 PROTEASE INHIBITORS - STEREOSELECTIVE SYNTHESIS OF A
   DIPEPTIDE MIMIC
SO JOURNAL OF ORGANIC CHEMISTRY
LA English
DT Article
ID STEREOCONTROLLED SYNTHESIS; CRYSTAL-STRUCTURE; ISOSTERES; LACTONES; AIDS
AB The synthesis of a differentially protected dipeptide mimic 10 in enantiomerically pure form is described. The key step involves the epimerization of the C-2 center of the lactone 4, hydrolysis and protection of the resulting hydroxy acid, followed by Curtius rearrangement to introduce the urethane functionality. The scope and versatility of this isostere has been demonstrated by its conversion to potent HIV-1 protease inhibitors with nanomolar potencies.  Also, established through the synthesis of compound 13 and 14, the 3S hydroxyl configuration of the dipeptide isostere 1 is the preferred configuration for its potency. The present synthesis is efficient and provides an access to other dipeptide mimics with a great deal of structural diversity.
RP GHOSH, AK (reprint author), MERCK RES LABS,DEPT MED CHEM & MOLEC BIOL,W POINT,PA 19486, USA.
CR BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   CHENERA B, 1991, BIOORG MED CHEM LETT, V1, P219, DOI 10.1016/S0960-894X(00)80256-5
   ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122
   EVANS BE, 1985, J ORG CHEM, V50, P4615, DOI 10.1021/jo00223a037
   FRAY AH, 1986, J ORG CHEM, V51, P4828, DOI 10.1021/jo00375a014
   GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936
   GHOSH AK, 1991, TETRAHEDRON LETT, V32, P5729
   GHOSH AK, 1991, J ORG CHEM, V56, P6500, DOI 10.1021/jo00023a009
   GRIECO PA, 1977, J ORG CHEM, V42, P1717, DOI 10.1021/jo00430a010                                                             
   GRIECO PA, 1974, J ORG CHEM, V39, P120, DOI 10.1021/jo00915a036                                                             
   GRUNEWALD GL, 1988, J ORG CHEM, V53, P4021, DOI 10.1021/jo00252a026
   HAMADA Y, 1989, J AM CHEM SOC, V111, P669, DOI 10.1021/ja00184a041
   HEIMBACH JC, 1989, BIOCHEM BIOPH RES CO, V164, P955, DOI 10.1016/0006-291X(89)91762-2
   HUFF JR, 1991, J MED CHEM, V34, P2305, DOI 10.1021/jm00112a001
   JOUIN P, 1989, J ORG CHEM, V54, P617, DOI 10.1021/jo00264a022                                                             
   KEMPF DJ, 1992, J ORG CHEM, V57, P5692, DOI 10.1021/jo00047a023                                                             
   KEMPF DJ, 1990, J MED CHEM, V33, P2687, DOI 10.1021/jm00172a002
   KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686
   LEE KK, 1969, CHEM PHARM BULL, V17, P2540
   MAIBAUM J, 1988, J ORG CHEM, V53, P869, DOI 10.1021/jo00239a035
   NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0
   NINOMIYA K, 1974, TETRAHEDRON, V30, P2151, DOI 10.1016/S0040-4020(01)97352-1                                                   
   NORBECK DW, 1992, 7TH INT C AIDS 3 STD
   NORBECK DW, 1992, 32ND ICAAC AN
   SAITO S, 1989, TETRAHEDRON LETT, V30, P837, DOI 10.1016/S0040-4039(01)80629-8                                                   
   SAKAITANI M, 1988, TETRAHEDRON LETT, V29, P2983, DOI 10.1016/0040-4039(88)85064-0
   TERASHIMA S, 1969, CHEM PHARM BULL, V17, P2533
   WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279
   SIGAL IS, 1988, Patent No. 337714
   KEMPF DJ, 1992, Patent No. 911194645
NR 30
TC 47
Z9 47
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0022-3263
J9 J ORG CHEM
JI J. Org. Chem.
PD FEB 26
PY 1993
VL 58
IS 5
BP 1025
EP 1029
DI 10.1021/jo00057a011
PG 5
WC Chemistry, Organic
SC Chemistry
GA KN989
UT WOS:A1993KN98900011
DA 2018-01-05
ER

PT J
AU SPONSLER, E
   GELMAN, A
   RAJGURU, S
   TORRES, M
   KOSSOVSKY, N
AF SPONSLER, E
   GELMAN, A
   RAJGURU, S
   TORRES, M
   KOSSOVSKY, N
TI IMMUNOLOGICAL ACTIVITY OF BIOLOGICALLY STRUCTURED HIV GP120 ADSORBED TO
   NANOCRYSTALLINE PARTICULATES IN 3 ANIMAL-MODELS
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 UNIV CALIF LOS ANGELES, MED CTR, LOS ANGELES, CA 90024 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD FEB 23
PY 1993
VL 7
IS 4
BP A709
EP A709
PN 2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA KP975
UT WOS:A1993KP97501095
DA 2018-01-05
ER

PT J
AU BIGLINO, A
   FORNO, B
   POLLONO, AM
   GHIO, P
   ALBERA, C
AF BIGLINO, A
   FORNO, B
   POLLONO, AM
   GHIO, P
   ALBERA, C
TI ALVEOLAR IMMUNE MEDIATORS IN HIV-RELATED PNEUMONIA - DIFFERENT ROLE OF
   IL-2 AND IL-1 IN INDUCING LUNG DAMAGE
SO CHEST
LA English
DT Article
ID HUMAN IMMUNODEFICIENCY VIRUS; NECROSIS FACTOR-ALPHA; LYMPHOCYTES-T;
   HYPERSENSITIVITY PNEUMONITIS; BRONCHOALVEOLAR LAVAGE; SARCOIDOSIS;
   MACROPHAGES; INFECTION; CYTOMEGALOVIRUS; INTERLEUKIN-1
AB In order to elucidate the role played by alveolar cytokines in the pathogenesis of HIV-related lung damage, levels of interleukin (IL) 1 beta, IL-2, TL-6, tumor necrosis factor (TNF)-alpha, and interferon (Ifn) were assessed on supernatant of bronchoalveolar lavage fluid from 30 consecutive HIV-1 seropositive (HIVAb+) patients with clinical and radiologic evidence of pneumonia, from 20 HIV- seronegative (HIVAb-) patients with pulmonary sarcoidosis, and from 10 HIVAb- healthy control subjects. Cytokine levels were expressed as picogram (IL-1, TNF), nanogram (IL-6), and international unit (IL-2, Ifn) per milligram of albumin per deciliter. Total and differential cell counts, cytofluorimetric enumeration of CD3+, CD3+/DR+, CD4+, CD8+, and CD8+/CD16+ cells, as well as microbiologic investigations for opportunistic agents were performed on lavage pellets. HIV-related pneumonia was characterized by higher mean alveolar level of IL-2 (12 +/- 5 IU), and by more elevated mean counts of T cells (109 +/- 16), activated T cells (60 +/- 12), and CD8+ cells (90 +/- 13)/mul if compared with both active sarcoidosis and control subjects, where respective values of 0.2 +/- 0.1 and 0.3 +/- 0.2 IU IL-2/mgAb/dl, of 52 +/- 11 and 7 +/- 2 T cells, of 20 +/- 5 and 1.2 +/- 0.3 activated T cells, and of 11 +/- 2 and 3 +/- 0.6 CD8+ cells per microliter were found. HIV-infected patients with opportunistic lung infections (OIs) showed the highest mean IL-2 level (21 +/- 4 IU), and higher counts of both CD8+ (117 +/- 20) and CD8+/CD16+ (36 +/- 7) cells per microliter if compared with patients without evidence of OIs (respectively, 62 +/- 13 CD8+ and 18 +/- 3 CD8+/CD16+ cells per microliter). By contrast, extremely high IL-1 levels (1,46.3 +/- 760 pg), and IL-2 levels similar to control subjects (3.4 +/- 1.2 IU), were found in the absence of OIs. Different mechanisms depending respectively on IL-2-mediated cytotoxic cell recruitment and activation, or IL-1-mediated tissue injury may account for HIV-related lung damage, depending on the presence or absence of opportunistic agents.
C1 UNIV TURIN,IST MALATTIE INFETT,I-10124 TURIN,ITALY.
   UNIV TURIN,MALATTIE APPARTO RESP CLIN,I-10124 TURIN,ITALY.
RP BIGLINO, A (reprint author), OSPED AMEDEO SAVOIA,CORSO SVIZZERA 164,I-10149 TURIN,ITALY.
CR BERMAN JS, 1990, AM REV RESPIR DIS, V142, P238, DOI 10.1164/ajrccm/142.1.238                                                        
   BIGLINO A, 1991, J ACQ IMMUN DEF SYND, V4, P261
   COX RA, 1990, AIDS RES HUM RETROV, V6, P431, DOI 10.1089/aid.1990.6.431
   DANIELE RP, 1988, IMMUNOLOGY IMMUNOLOG, P303
   GILLIS S, 1978, J IMMUNOL, V120, P2027
   GOLDBLUM SE, 1988, INFECT IMMUN, V56, P2255
   HAMPSON F, 1989, AM J PHYSIOL, V256, pC336
   HUNNINGHAKE GW, 1987, AM REV RESPIR DIS, V135, P66
   ISRAELBIET D, 1991, J IMMUNOL, V147, P490
   KELLEY J, 1990, AM REV RESPIR DIS, V141, P765, DOI 10.1164/ajrccm/141.3.765                                                        
   LECOSSIER D, 1988, AM REV RESPIR DIS, V137, P592, DOI 10.1164/ajrccm/137.3.592                                                        
   MASIH AS, 1991, MODERN PATHOL, V4, P108
   MERRILL JE, 1990, CLIN IMMUNOL IMMUNOP, V54, P174
   MOLINA JM, 1989, J CLIN INVEST, V84, P733, DOI 10.1172/JCI114230                                                               
   RANKIN JA, 1988, CLIN CHEST MED, V9, P387
   RANKIN JA, 1988, CHEST, V94, P155, DOI 10.1378/chest.94.1.155
   ROBINSON BWS, 1985, J CLIN INVEST, V75, P1488, DOI 10.1172/JCI111852
   SCHULTZ DA, 1991, J CLIN LAB ANAL, V5, P69, DOI 10.1002/jcla.1860050113
   SEMENZATO G, 1991, EUR RESPIR J, V4, P94
   SEMENZATO G, 1989, AM REV RESPIR DIS, V139, P1317, DOI 10.1164/ajrccm/139.6.1317                                                       
   SPEICH R, 1989, SCHWEIZ MED WSCHR, V119, P601
   TEIRSTEIN AS, 1988, CLIN CHEST MED, V9, P467
   TRENTIN L, 1990, J IMMUNOL, V145, P2147
   WHITE DA, 1989, AM REV RESPIR DIS, V140, P1763, DOI 10.1164/ajrccm/140.6.1763                                                       
NR 24
TC 7
Z9 7
U1 0
U2 0
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348
SN 0012-3692
J9 CHEST
JI Chest
PD FEB
PY 1993
VL 103
IS 2
BP 439
EP 443
DI 10.1378/chest.103.2.439
PG 5
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA KL712
UT WOS:A1993KL71200026
PM 7679346
DA 2018-01-05
ER

PT J
AU BUCKLE, PE
   DAVIES, RJ
   KINNING, T
   YEUNG, D
   EDWARDS, PR
   POLLARDKNIGHT, D
   LOWE, CR
AF BUCKLE, PE
   DAVIES, RJ
   KINNING, T
   YEUNG, D
   EDWARDS, PR
   POLLARDKNIGHT, D
   LOWE, CR
TI THE RESONANT MIRROR - A NOVEL OPTICAL SENSOR FOR DIRECT SENSING OF
   BIOMOLECULAR INTERACTIONS .2. APPLICATIONS
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE BIOSENSOR; EVANESCENT OPTICAL SENSORS; SURFACE PLASMON RESONANCE;
   OPTICAL WAVE-GUIDES; RESONANT MIRROR SENSOR
ID SURFACE-PLASMON RESONANCE; GRATING COUPLERS; IMMOBILIZATION;
   IMMUNOSENSORS; HIV-1
AB The application of a novel optical evanescent wave sensor, the Resonant Mirror (RM), to the direct study of biological recognition studies is described. In particular, measurement of antigen/antibody and enzyme/substrate/inhibitor interactions in real-time without labelling is detailed. The RM, described in the preceding paper (Cush et al., 1992), detects changes in refractive index and/or thickness occuring within a few hundred nanometers of the sensor surface. Several methods for immobilisation of biomolecules at the sensor surface have been investigated using antibodies and radioactively labelled antigens as model systems. One of the immobilisation techniques involves deposition of carboxymethyl-dextran on the sensor device and subsequent covalent attachment of biomolecules to the gel via their amino groups. With an anti-theophylline antibody, this method resulted in at least 212 femtomoles of active antibody per mm2  of the surface, a surface density equivalent to at least 9 monolayers of antibody.
   Immunoassays performed on the RM with immobilised antibodies resulted in sensitivities in the nM range for the complementary antigens. The specificity and sensitivity of the system was further improved by the use of sandwich or multi-site immunoassays and, by the use of enhancer particles, such as colloidal gold particles. The broader applicability of the RM to studies on molecular interaction studies was demonstrated in an assay for the proteolytic enzyme trypsin and the specific inhibition of enzyme activity by alpha1-anti-trypsin.
C1 FISONS APPL SENSOR TECHNOL,EASTBRIDGE HOUSE,BAR HILL,CAMBRIDGE,ENGLAND.
   UNIV CAMBRIDGE,INST BIOTECHNOL,CAMBRIDGE,ENGLAND.
OI Lowe, Christopher R/0000-0001-5432-9109
CR BRIGHAMBURKE M, 1992, ANAL BIOCHEM, V205, P125, DOI 10.1016/0003-2697(92)90588-X
   CULLEN DC, 1987, BIOSENSORS, V3, P211
   DANIELS PB, 1988, SENSOR ACTUATOR, V15, P11, DOI 10.1016/0250-6874(88)85013-3
   FLANAGAN MT, 1984, ELECTRON LETT, V20, P968, DOI 10.1049/el:19840660                                                             
   GRANZOW R, 1992, BIO-TECHNOL, V10, P390, DOI 10.1038/nbt0492-390                                                             
   KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9                                                    
   LIEDBERG B, 1983, SENSOR ACTUATOR, V4, P299, DOI 10.1016/0250-6874(83)85036-7
   LOFAS S, 1990, J CHEM SOC CHEM COMM, V21, P1526
   LOWE CR, 1989, PHILOS T ROY SOC B, V324, P487, DOI 10.1098/rstb.1989.0062                                                          
   LUKOSZ W, 1991, BIOSENS BIOELECTRON, V6, P227, DOI 10.1016/0956-5663(91)80007-K                                                    
   LUKOSZ W, 1991, BIOSENS BIOELECTRON, V6, P215, DOI 10.1016/0956-5663(91)80006-J                                                    
   MAYO CS, 1989, J IMMUNOL METHODS, V120, P105, DOI 10.1016/0022-1759(89)90295-0
   NELLEN PM, 1988, SENSOR ACTUATOR, V15, P285, DOI 10.1016/0250-6874(88)87017-3                                                    
   OSHANNESSY DJ, 1992, ANAL BIOCHEM, V205, P132, DOI 10.1016/0003-2697(92)90589-Y
   POLLARDKNIGHT D, 1990, ANN BIOL CLIN-PARIS, V48, P642
   SLOPER AN, 1990, SENSOR ACTUAT B-CHEM, V1, P589, DOI 10.1016/0925-4005(90)80279-9                                                    
   SUNDERLAND RM, 1984, CLIN CHEM, V30, P1533
   THOMPSON M, 1991, ANAL CHEM, V63, P393
   VALENTINE RC, 1967, J MOL BIOL, V27, P615, DOI 10.1016/0022-2836(67)90063-0                                                    
   VANCOTT TC, 1992, J IMMUNOL METHODS, V146, P163, DOI 10.1016/0022-1759(92)90225-I                                                    
NR 20
TC 148
Z9 150
U1 1
U2 16
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD, OXON, ENGLAND OX5 1GB
SN 0956-5663
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PY 1993
VL 8
IS 7-8
BP 355
EP 363
DI 10.1016/0956-5663(93)80074-Y
PG 9
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA MP482
UT WOS:A1993MP48200012
DA 2018-01-05
ER

PT J
AU LENARD, J
   RABSON, A
   VANDEROEF, R
AF LENARD, J
   RABSON, A
   VANDEROEF, R
TI PHOTODYNAMIC INACTIVATION OF INFECTIVITY OF HUMAN-IMMUNODEFICIENCY-VIRUS
   AND OTHER ENVELOPED VIRUSES USING HYPERICIN AND ROSE-BENGAL - INHIBITION
   OF FUSION AND SYNCYTIA FORMATION
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE VESICULAR STOMATITIS VIRUS; INFLUENZA VIRUS; SENDAI VIRUS; HEMOLYSIS
ID VESICULAR STOMATITIS-VIRUS; T-CELL CLONE; VIRUCIDAL ACTIVITY; HEMOLYSIS;
   MEMBRANE; PROTEIN; AGENTS; PSEUDOHYPERICIN; MEROCYANINE-540;
   ANTHRAQUINONES
AB The mechanism of the antiviral activity of hypericin was characterized and compared with that of rose bengal. Both compounds inactivate enveloped (but not unenveloped) viruses upon illumination by visible light. Human immunodeficiency and vesicular stomatitis viruses were photodynamically inactivated by both dyes at nanomolar concentrations. Photodynamic inactivation of fusion (hemolysis) by vesicular stomatitis, influenza, and Sendai viruses was induced by both dyes under similar conditions (e.g., I50 = 20-50 nM for vesicular stomatitis virus), suggesting that loss of infectivity resulted from inactivation of fusion. Syncytium formation, between cells activated to express human immunodeficiency virus gp120 on their surfaces and CD4+ cells, was inhibited by illumination in the presence of 1 muM hypericin. Hypericin and rose bengal thus exert similar virucidal effects. Both presumably act by the same mechanism-namely, the inactivation of the viral fusion function by singlet oxygen produced upon illumination. The implications of this photodynamic antiviral action for the potential therapeutic usefulness of both hypericin and rose bengal are discussed.
C1 CTR ADV BIOTECHNOL & MED,DEPT MOLEC GENET & MICROBIOL,PISCATAWAY,NJ 08854.
RP LENARD, J (reprint author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PHYSIOL & BIOPHYS,675 HOES LANE,PISCATAWAY,NJ 08854, USA.
FU NIAID NIH HHS [AI-13002]
CR ANDERSEN DO, 1991, ANTIVIR RES, V16, P185, DOI 10.1016/0166-3542(91)90024-L
   BAILEY CA, 1984, VIROLOGY, V133, P111, DOI 10.1016/0042-6822(84)90429-X
   BARRATT MD, 1982, CHEM-BIOL INTERACT, V38, P215, DOI 10.1016/0009-2797(82)90041-2
   BISACCIA E, 1990, ANN INTERN MED, V113, P270, DOI 10.7326/0003-4819-113-4-270
   Blum HF, 1937, J CELL COMPAR PHYSL, V9, P217, DOI 10.1002/jcp.1030090206                                                          
   Blum H. F., 1941, PHOTODYNAMIC ACTION
   CARPENTER S, 1991, PHOTOCHEM PHOTOBIOL, V53, P169, DOI 10.1111/j.1751-1097.1991.tb03919.x                                              
   CLOUSE KA, 1989, J IMMUNOL, V142, P431
   DURAN N, 1986, PHOTOCHEM PHOTOBIOL, V43, P677, DOI 10.1111/j.1751-1097.1986.tb05646.x
   FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365
   GIULIVI C, 1990, PHOTOCHEM PHOTOBIOL, V52, P745, DOI 10.1111/j.1751-1097.1990.tb08676.x
   GOMORI G, 1955, METHOD ENZYMOL, V1, P138, DOI 10.1016/0076-6879(55)01020-3
   HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081                                                         
   HOROWITZ B, 1991, TRANSFUSION, V31, P58
   HOXIE JA, 1986, SCIENCE, V234, P1123, DOI 10.1126/science.3095925
   HUDSON JB, 1991, ANTIVIR RES, V15, P101, DOI 10.1016/0166-3542(91)90028-P
   KALYANARAMAN B, 1987, P NATL ACAD SCI USA, V84, P2999, DOI 10.1073/pnas.84.9.2999
   KNOX JP, 1985, PLANT CELL ENVIRON, V8, P19, DOI 10.1111/j.1365-3040.1985.tb01204.x
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LAVIE G, 1989, P NATL ACAD SCI USA, V86, P5963, DOI 10.1073/pnas.86.15.5963
   LENARD J, 1982, J GEN VIROL, V62, P353, DOI 10.1099/0022-1317-62-2-353                                                      
   LENARD J, 1990, J VIROL, V64, P3486
   LENARD J, 1981, VIROLOGY, V110, P479, DOI 10.1016/0042-6822(81)90079-9
   MERUELO D, 1988, P NATL ACAD SCI USA, V85, P5230, DOI 10.1073/pnas.85.14.5230
   MILLER DK, 1980, J CELL BIOL, V84, P421, DOI 10.1083/jcb.84.2.421
   NORTH J, 1992, TRANSFUSION, V32, P121, DOI 10.1046/j.1537-2995.1992.32292180139.x
   Pace N, 1941, J AM CHEM SOC, V63, P2570, DOI 10.1021/ja01855a009
   ROAT MI, 1987, ARCH OPHTHALMOL-CHIC, V105, P1415
   SCHINAZI RF, 1990, ANTIVIR RES, V13, P265, DOI 10.1016/0166-3542(90)90071-E
   SIEBER F, 1987, PHOTOCHEM PHOTOBIOL, V46, P707, DOI 10.1111/j.1751-1097.1987.tb04836.x
   TANG J, 1990, ANTIVIR RES, V13, P313, DOI 10.1016/0166-3542(90)90015-Y
   TURNER GS, 1968, J GEN VIROL, V3, P433, DOI 10.1099/0022-1317-3-3-433
   VALENZENO DP, 1982, PHOTOCHEM PHOTOBIOL, V35, P343
   VALENZENO DP, 1987, PHOTOCHEM PHOTOBIOL, V46, P147, DOI 10.1111/j.1751-1097.1987.tb04749.x
   WILLEY RL, 1988, J VIROL, V62, P139
NR 35
TC 186
Z9 191
U1 3
U2 7
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JAN 1
PY 1993
VL 90
IS 1
BP 158
EP 162
DI 10.1073/pnas.90.1.158
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA KF407
UT WOS:A1993KF40700033
PM 7678335
OA gold
DA 2018-01-05
ER

PT J
AU EBERLE, J
   SEIBL, R
AF EBERLE, J
   SEIBL, R
TI A NEW METHOD FOR MEASURING REVERSE-TRANSCRIPTASE ACTIVITY BY ELISA
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE REVERSE TRANSCRIPTASE; ELISA; RETROVIRUS; DNA-POLYMERASE; HIV
ID HUMAN-IMMUNODEFICIENCY-VIRUS; RETROVIRUS; AIDS; PATIENT; CULTURE; ASSAY
AB A new and sensitive assay of reverse transcriptase (RT) activity of retroviruses measures the incorporation of digoxigenin-labelled dUTP in newly synthesized DNA instead of radioactively labelled (H-3- or  P-32-)dTTP. To avoid difficulties associated with separation of non-incorporated nucleotides from the newly synthesized DNA, biotin-labelled dUTP is added to the reaction mixture in very low concentrations. After reverse transcription, the newly synthesized, doubly labelled DNA is immobilized on streptavidin-coated ELISA wells and evaluated photometrically by binding of peroxidase-conjugated anti-digoxigenin-antibodies (sheep) and subsequent colour development with 2,2'-azino-di[3-ethylbenzthiazolin-sulfonate(6)] (ABTS(R)) as substrate. For better standardization, it is suggested that RT activity is given in units (one unit of RT is the amount of enzyme incorporating one nanomole of labelled dNTP in 10 min at 37-degrees-C into an acid precipitable DNA) rather than in cpm (counts per minute). The method is specific and easy to perform.
C1 BOEHRINGER MANNHEIM GMBH,BIOCHEM RES CTR,PENZBERG,GERMANY.
RP EBERLE, J (reprint author), UNIV MUNICH,MAX VON PETTENKOFER INST,HIV LABOR,PETTENKOFERSTR 9A,W-8000 MUNICH 2,GERMANY.
CR BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   BARRESINOUSSI F, 1985, LANCET, V2, P721
   FEORINO P, 1987, J CLIN MICROBIOL, V25, P2344
   HOFFMAN AD, 1985, VIROLOGY, V147, P326, DOI 10.1016/0042-6822(85)90135-7
   KESSLER C, 1990, BIOL CHEM H-S, V371, P917, DOI 10.1515/bchm3.1990.371.2.917                                                    
   KESSLER C, 1991, MOL CELL PROBE, V5, P161, DOI 10.1016/0890-8508(91)90041-H
   LEE M, 1990, 6TH INT C AIDS SAN F, V2, P321
   MUHLEGGER K, 1990, BIOL CHEM H-S, V371, P953, DOI 10.1515/bchm3.1990.371.2.953
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415                                                         
   PORSTMANN T, 1991, J VIROL METHODS, V31, P181, DOI 10.1016/0166-0934(91)90156-T
   SOMOGYI PA, 1990, J VIROL METHODS, V27, P269, DOI 10.1016/0166-0934(90)90095-W
   WU JC, 1988, ANTIMICROB AGENTS CH, V32, P1884
NR 12
TC 61
Z9 62
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
J9 J VIROL METHODS
JI J. Virol. Methods
PD DEC 1
PY 1992
VL 40
IS 3
BP 347
EP 356
DI 10.1016/0166-0934(92)90092-R
PG 10
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA KB458
UT WOS:A1992KB45800010
PM 1282132
DA 2018-01-05
ER

PT J
AU STOWASSER, B
   BUDT, KH
   LI, JQ
   PEYMAN, A
   RUPPERT, D
AF STOWASSER, B
   BUDT, KH
   LI, JQ
   PEYMAN, A
   RUPPERT, D
TI NEW HYBRID TRANSITION-STATE ANALOG INHIBITORS OF HIV PROTEASE WITH
   PERIPHERAL C2-SYMMETRY
SO TETRAHEDRON LETTERS
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; RETROVIRAL PROTEASES; CRYSTAL-STRUCTURE
AB The synthesis of novel hybrid transition state analogs, a combination of phosphinic acid- and hydroxymethylene-type inhibitors of HIV protease, is demonstrated. These nonsymmetrical structures, placed in a peripheric C2-symmetrical environment, inhibit HIV protease in the lower nanomolar range.
RP STOWASSER, B (reprint author), HOECHST AG, PHARMA FORSCHUNG G838, W-6230 FRANKFURT 80, GERMANY.
CR BREIPOHL G, 1989, EPA0373576
   BUDT KH, 1990, EP0435059
   ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122
   FELCHT UH, 1982, METHODEN ORGANISCH E, V2, P123
   GROBELNY D, 1990, BIOCHEM BIOPH RES CO, V169, P1111, DOI 10.1016/0006-291X(90)92010-W
   KEMPF DJ, 1990, J MED CHEM, V33, P2687, DOI 10.1021/jm00172a002
   KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686
   KONIG W, 1990, 21ST P EUR PEPT S, P143
   MISITI D, 1990, TETRAHEDRON LETT, V31, P7359, DOI 10.1016/S0040-4039(00)88567-6                                                   
   MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273
   NAHM S, 1981, TETRAHEDRON LETT, V22, P3815, DOI 10.1016/S0040-4039(01)91316-4                                                   
   NORBECK DW, 1991, ANNU REP MED CHEM, V26, P141
   PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0
   PEYMAN A, IN PRESS TETRAHEDRON
   ROBERTS MM, 1990, RETROVIRAL PROTEASES
   SAMPSON NS, 1988, J ORG CHEM, V53, P4500, DOI 10.1021/jo00254a015
   TOMASSELLI AG, 1991, CHIMICAOGGI     0506
   WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279
NR 18
TC 375
Z9 377
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0040-4039
J9 TETRAHEDRON LETT
JI Tetrahedron Lett.
PD OCT 27
PY 1992
VL 33
IS 44
BP 6625
EP 6628
DI 10.1016/S0040-4039(00)61002-X                                           
          
PG 4
WC Chemistry, Organic
SC Chemistry
GA JV802
UT WOS:A1992JV80200019
DA 2018-01-05
ER

PT J
AU JORDAN, SP
   ZUGAY, J
   DARKE, PL
   KUO, LC
AF JORDAN, SP
   ZUGAY, J
   DARKE, PL
   KUO, LC
TI ACTIVITY AND DIMERIZATION OF HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE AS A
   FUNCTION OF SOLVENT COMPOSITION AND ENZYME CONCENTRATION
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID SYNTHETIC HIV-1 PROTEASE; RETROVIRAL PROTEASES; TYPE-1 PROTEASE;
   INHIBITION; EXPRESSION; DIMER; GAG
AB The activity of human immunodeficiency virus 1 (HIV-1) protease has been examined as a function of solvent composition, incubation time, and enzyme concentration at 37-degrees-C in the pH 4.5-5.5 range. Glycerol and dimethyl sulfoxide inhibit the enzyme, while polyethylene glycol and bovine serum albumin activate the enzyme. When incubated at a concentration of 50-200 nM, the activity of the protease decreases irreversibly with an apparent first-order rate constant of 4-9 x 10(-3) min-1. The presence of 0.1% (w/v) polyethylene glycol or bovine serum albumin in the reaction buffer dramatically stabilizes enzyme activity. In the absence of prolonged incubation of the enzyme at submicromolar concentration, the specific activity of HIV-1 protease in buffers of either high or low ionic strength is constant over the enzyme concentration range of 0.25-5 nM, indicating that dissociation of the dimeric protease, if occurring, can only be governed by a picomolar dissociation constant. Similarly, the variation of the specific activity of HIV-2 protease over the enzyme concentration of 4-85 nM is consistent only with a dimer dissociation constant of less than 10 nM. We conclude that: 1) the assumption of a nondissociating HIV-1 protease is a valid one for kinetic studies of tight-binding inhibitors where nanomolar concentrations of the enzymes are employed; 2) stock protease solutions of submicromolar concentration in the absence of activity-stabilizing compounds may lead to erroneous kinetic data and complicate mechanistic interpretations.
C1 MERCK SHARP & DOHME LTD,DEPT BIOL CHEM,WP26-431,W POINT,PA 19486.
CR BOURINBAIAR AS, 1991, NATURE, V349, P111, DOI 10.1038/349111b0                                                                
   CHENG YSE, 1990, P NATL ACAD SCI USA, V87, P9660, DOI 10.1073/pnas.87.24.9660
   DARKE PL, 1989, J BIOL CHEM, V264, P2307
   DELEAN A, 1978, AM J PHYSIOL, V235, pE97
   DIIANNI CL, 1990, J BIOL CHEM, V265, P17348
   FITZGERALD PMD, 1990, J BIOL CHEM, V265, P14209
   HEIMBACH JC, 1989, BIOCHEM BIOPH RES CO, V164, P955, DOI 10.1016/0006-291X(89)91762-2
   HOLZMAN TF, 1991, J BIOL CHEM, V266, P19217
   HYLAND LJ, 1991, BIOCHEMISTRY-US, V30, P8454, DOI 10.1021/bi00098a024
   JACKS T, 1988, NATURE, V331, P280, DOI 10.1038/331280a0
   KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686
   MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161
   MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486
   MEEK TD, 1990, NATURE, V343, P90, DOI 10.1038/343090a0
   MOORE ML, 1989, BIOCHEM BIOPH RES CO, V159, P420, DOI 10.1016/0006-291X(89)90008-9                                                    
   MYERS G, 1991, HUMAN RETROVIRUSES A
   TOMASSELLI AG, 1990, BIOCHEMISTRY-US, V29, P264, DOI 10.1021/bi00453a036                                                             
   VACCA JP, 1991, J MED CHEM, V34, P1225, DOI 10.1021/jm00107a050
   WASIEWSKI W, 1976, THROMB RES, V8, P881, DOI 10.1016/0049-3848(76)90017-7
   WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279
   ZHANG ZY, 1991, J BIOL CHEM, V266, P15591
NR 21
TC 49
Z9 49
U1 0
U2 1
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 5
PY 1992
VL 267
IS 28
BP 20028
EP 20032
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA JR858
UT WOS:A1992JR85800046
PM 1400318
DA 2018-01-05
ER

PT J
AU LEWERENZ, HJ
   JUNGBLUT, H
   CAMPBELL, SA
   GIERSIG, M
   MULLER, DJ
AF LEWERENZ, HJ
   JUNGBLUT, H
   CAMPBELL, SA
   GIERSIG, M
   MULLER, DJ
TI DIRECT OBSERVATION OF REVERSE TRANSCRIPTASES BY SCANNING TUNNELING
   MICROSCOPY
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID HIGH-RESOLUTION; DNA; POLYMERASE
AB First images on a nanometer scale of reverse transcriptases (RT) of the human immunodeficiency virus (HIV-1) and of the Moloney murine leukemia virus (MuLV) obtained by scanning tunneling microscopy (STM) are reported. The common feature of the observed molecules is a ring-type or horseshoe shape with hole diameters of almost-equal-to 30 angstrom. The STM images are compared with high resolution transmission electron microscopy (TEM) and existing structure predictions. The similarities of the structural data obtained by STM and TEM and their agreement with the structure prediction for the RT of HIV-1 shows the principal possibility to image such biomolecules by STM.
C1 PORTSMOUTH POLYTECH,DEPT CHEM,PORTSMOUTH PO1 2DT,ENGLAND.
RP LEWERENZ, HJ (reprint author), HAHN MEITNER INST KERNFORSCH BERLIN GMBH,BEREICH PHOTOCHEM ENERGIEUMWANDLUNG,GLIENICKER STR 100,W-1000 BERLIN 39,GERMANY.
RI Muller, Daniel/A-5967-2010
OI Muller, Daniel/0000-0003-3075-0665
CR AMREIN M, 1988, SCIENCE, V240, P514, DOI 10.1126/science.3358130                                                         
   BALTIMORE D, 1975, VIRUSES POLYM CANCER, P155
   BARBER AM, 1990, AIDS RES HUM RETROV, V6, P1061, DOI 10.1089/aid.1990.6.1061
   BARO AM, 1985, NATURE, V315, P253, DOI 10.1038/315253a0
   BENDIXEN C, 1990, J VAC SCI TECHNOL A, V8, P703, DOI 10.1116/1.576987                                                                
   FISCHER AG, 1986, SCIENCE, V233, P655
   GALLO RC, 1971, NATURE, V234, P194, DOI 10.1038/234194a0                                                                
   GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817
   GUCKENBERGER R, 1988, ULTRAMICROSCOPY, V25, P111, DOI 10.1016/0304-3991(88)90218-5
   HORBER JKH, 1988, CHEM PHYS LETT, V145, P151, DOI 10.1016/0009-2614(88)80169-6
   HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865
   JUNGBLUT H, 1992, APPL PHYS COMMUN, V11, P31
   JUNGBLUTT H, IN PRESS FARADAY DIS, V94
   KELLER RW, 1990, J VAC SCI TECHNOL A, V8, P706, DOI 10.1116/1.576988
   KESHET E, 1979, J VIROL, V31, P376
   KNOWLES JR, 1991, NATURE, V350, P121, DOI 10.1038/350121a0
   KUNATH W, 1985, ULTRAMICROSCOPY, V16, P123, DOI 10.1016/0304-3991(85)90068-3                                                    
   LEWERENZ HJ, 1981, ACS SYM SER, V146, pC2
   LIN TH, 1991, J BIOL CHEM, V266, P1635
   LLOYD LF, 1991, J MOL BIOL, V217, P119
   Monzack J., 1972, Metallography, V5, P179, DOI 10.1016/0026-0800(72)90054-7
   RESNICK R, 1984, J VIROL, V51, P813
   SELCI S, 1990, J VAC SCI TECHNOL A, V8, P642, DOI 10.1116/1.576362
   SODROSKI J, 1986, NATURE, V322, P470, DOI 10.1038/322470a0
   TEMIN HM, 1974, ENZYMES, P10
   Varmus H., 1987, Scientific American, V257, P48
   WILSON JA, 1969, ADV PHYS, V18, P193, DOI 10.1080/00018736900101307                                                       
   NANOSCOPE, V2
NR 28
TC 7
Z9 7
U1 0
U2 2
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD SEP
PY 1992
VL 8
IS 9
BP 1663
EP 1667
DI 10.1089/aid.1992.8.1663
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA JW296
UT WOS:A1992JW29600017
PM 1280957
DA 2018-01-05
ER

PT J
AU SAWYER, TK
   STAPLES, DJ
   LIU, L
   TOMASSELLI, AG
   HUI, JO
   OCONNELL, K
   SCHOSTAREZ, H
   HESTER, JB
   MOON, J
   HOWE, WJ
   SMITH, CW
   DECAMP, DL
   CRAIK, CS
   DUNN, BM
   LOWTHER, WT
   HARRIS, J
   POORMAN, RA
   WLODAWER, A
   JASKOLSKI, M
   HEINRIKSON, RL
AF SAWYER, TK
   STAPLES, DJ
   LIU, L
   TOMASSELLI, AG
   HUI, JO
   OCONNELL, K
   SCHOSTAREZ, H
   HESTER, JB
   MOON, J
   HOWE, WJ
   SMITH, CW
   DECAMP, DL
   CRAIK, CS
   DUNN, BM
   LOWTHER, WT
   HARRIS, J
   POORMAN, RA
   WLODAWER, A
   JASKOLSKI, M
   HEINRIKSON, RL
TI HIV PROTEASE (HIV PR) INHIBITOR STRUCTURE-ACTIVITY-SELECTIVITY, AND
   ACTIVE-SITE MOLECULAR MODELING OF HIGH-AFFINITY LEU-PSI-[CH(OH)CH2]VAL
   MODIFIED VIRAL AND NONVIRAL SUBSTRATE-ANALOGS
SO INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH
LA English
DT Article
DE ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS; HIV PROTEASE; MOLECULAR
   MODELING; PEPSTATIN; PEPTIDOMIMETIC; STRUCTURE-ACTIVITY
ID DESIGN; POTENT; SPECIFICITY; MATURATION; PROTEINASE; PEPTIDES
AB This report details the structure-activity relationships of the HIV gag substrate analog Val-Ser-Gln-Asn-Leupsi[CH(OH)CH2]Val-Ile-Val(U-85548E), an inhibitor exhibiting subnanomolar affinity towards HIV type-1 aspartic proteinase (HIV-1 PR). Our data show that the P1-P2' tripeptidyl sequence provides the minimal chemical determinant for HIV-1 PR binding. We describe the structure-activity properties of Leupsi[CH(OH)CH2]Val substitution in other peptidyl ligands of nonviral substrate origin (e.g., angiotensinogen, insulin and pepstatin). Furthermore, the aspartic proteinase selectivities of a few key compounds are summarized relative to evaluation against human renin, human pepsin, and the fungal enzyme, rhizopuspepsin. These studies have led to the rational design of nanomolar potent inhibitors of both HIV-1 and HIV-2 PR. Finally, a 2.5 angstrom resolution X-ray crystallographic structure of U-85548E complexed to synthetic HIV-1 PR dimer (Jaskolski et al, Biochemistry 30, 1600 [1991]) provided a 3-D picture of the inhibitor bound to the enzyme active site, and we performed computer-assisted molecular modeling studies to explore the possible binding modes of the above series of Leupsi[CH(OH)CH2]Val substituted HIV-1 PR inhibitors.
C1 UPJOHN CO,UPJOHN LABS,KALAMAZOO,MI 49001.
   NCI,FREDERICK CANC RES & DEV CTR,MACROMOLEC STRUCT LAB,FREDERICK,MD 21701.
   UNIV FLORIDA,DEPT BIOCHEM & MOLEC BIOL,GAINESVILLE,FL 32611.
   UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143.
RP SAWYER, TK (reprint author), WARNER LAMBERT PARKE DAVIS CO,PEPTIDE & PEPTIDOMIMENT CHEM,ANN ARBOR,MI 48106, USA.
FU NCI NIH HHS [N01-CO-74101]; NIDDK NIH HHS [DK 18865]
CR APPELT K, 1991, J MED CHEM, V34, P1925, DOI 10.1021/jm00111a001
   ASHORN P, 1990, P NATL ACAD SCI USA, V87, P7472, DOI 10.1073/pnas.87.19.7472
   DARKE PL, 1988, BIOCHEM BIOPH RES CO, V156, P297, DOI 10.1016/S0006-291X(88)80839-8                                                   
   DUNN BM, 1986, BIOCHEM J, V237, P899, DOI 10.1042/bj2370899                                                               
   FITZGERALD PMD, 1990, J BIOL CHEM, V265
   HUFF JR, 1991, J MED CHEM, V34, P2305, DOI 10.1021/jm00112a001
   JASKOLSKI M, 1991, BIOCHEMISTRY-US, V30, P1600, DOI 10.1021/bi00220a023
   KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6                                                    
   KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686
   LOWTHER WT, 1992, PEPTIDES CHEM STRUCT, P413
   MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486
   MEEK TD, 1990, NATURE, V343, P90, DOI 10.1038/343090a0
   MOON JB, 1991, PROTEINS, V11, P314, DOI 10.1002/prot.340110409
   RICHARDS AD, 1989, FEBS LETT, V253, P214, DOI 10.1016/0014-5793(89)80961-5
   ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354
   SAWYER TK, 1988, J MED CHEM, V31, P18, DOI 10.1021/jm00396a006
   THAISRIVONGS S, 1986, J MED CHEM, V29, P2088, DOI 10.1021/jm00160a049                                                             
   TOMASSELLI AG, 1990, BIOCHEMISTRY-US, V29, P264, DOI 10.1021/bi00453a036                                                             
   TOMASSELLI AG, 1990, J BIOL CHEM, V265, P14675
   TOMASSELLI AG, 1992, STRUCTURE FUNCTION A, P469
   TOMASSELLI AG, 1991, CHEM TODAY       MAY, P6
   VACCA JP, 1991, J MED CHEM, V34, P1225, DOI 10.1021/jm00107a050
   WUTS PGM, 1988, J ORG CHEM, V53, P4503, DOI 10.1021/jo00254a016
NR 23
TC 9
Z9 9
U1 0
U2 0
PU MUNKSGAARD INT PUBL LTD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 0367-8377
J9 INT J PEPT PROT RES
JI Int. J. Pept. Protein Res.
PD SEP-OCT
PY 1992
VL 40
IS 3-4
BP 274
EP 281
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA JX365
UT WOS:A1992JX36500014
PM 1478785
DA 2018-01-05
ER

PT J
AU MOLEMA, G
   JANSEN, RW
   VISSER, J
   MEIJER, DKF
AF MOLEMA, G
   JANSEN, RW
   VISSER, J
   MEIJER, DKF
TI SIMULTANEOUS ANALYSIS OF AZIDOTHYMIDINE AND ITS MONOPHOSPHATE,
   DIPHOSPHATE AND TRIPHOSPHATE DERIVATIVES IN BIOLOGICAL-FLUIDS, TISSUE
   AND CULTURED-CELLS BY A RAPID HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC
   METHOD
SO JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; COLONY-STIMULATING FACTOR; INTRACELLULAR
   METABOLISM; 3'-AZIDO-3'-DEOXYTHYMIDINE; MACROPHAGE; INFECTION; INVITRO;
   3'-AZIDO-2',3'-DIDEOXYTHYMIDINE; PHOSPHORYLATION; 5'-TRIPHOSPHATE
AB A rapid high-performance liquid chromatographic (HPLC) method for the simultaneous analysis of the antiviral drug azidothymidine (AZT), AZT monophosphate, AZT diphosphate and AZT triphosphate, with ultraviolet detection in the nanomolar range, is described. Determination of these compounds in vitro in the human MT-4 lymphocyte cell line did not require a prior extraction, and AZT and its phosphorylated derivatives could be accurately analysed in one HPLC run. However, plasma, bile, liver homogenate and urine samples could not be injected directly into the chromatograph. Therefore, a solid-phase extraction procedure was developed. using azidodideoxyinosine as internal standard. The extractions of the compounds of interest from all but urine samples were reproducible, with recoveries between 65% (AZT triphosphate from plasma) and 100% (AZT from plasma).
RP MOLEMA, G (reprint author), UNIV GRONINGEN,CTR PHARM,DEPT PHARMACOL & THERAPEUT,ANT DEUSINGLAAN 2,9713 AW GRONINGEN,NETHERLANDS.
CR BALZARINI J, 1988, BIOCHEM PHARMACOL, V37, P897, DOI 10.1016/0006-2952(88)90178-5                                                    
   BALZARINI J, 1989, J BIOL CHEM, V264, P6127
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   BIGLINO A, 1991, J ACQ IMMUN DEF SYND, V4, P261
   DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0
   DECLERCQ E, 1991, J ACQ IMMUN DEF SYND, V4, P207
   DHAWAN RK, 1990, BIOCHEM PHARMACOL, V40, P2695, DOI 10.1016/0006-2952(90)90589-D
   FISCHL MA, 1989, AIDS, V3, pS137, DOI 10.1097/00002030-198901001-00021
   FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401                                                     
   FRIDLAND A, 1990, MOL PHARMACOL, V37, P665
   FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333
   GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648
   GENDELMAN HE, 1989, AIDS, V3, P475, DOI 10.1097/00002030-198908000-00001
   HIRSCH MS, 1987, ANTIMICROB AGENTS CH, V31, P839, DOI 10.1128/AAC.31.6.839                                                            
   HIRSCH MS, 1988, J INFECT DIS, V157, P427, DOI 10.1093/infdis/157.3.427                                                        
   KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660                                                         
   MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934
   MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096                                                         
   MOLEMA G, 1990, BIOCHEM PHARMACOL, V40, P2603, DOI 10.1016/0006-2952(90)90577-8
   PERNO CF, 1989, J EXP MED, V169, P933, DOI 10.1084/jem.169.3.933                                                           
   RYLL T, 1991, J CHROMATOGR-BIOMED, V570, P77, DOI 10.1016/0378-4347(91)80202-N                                                    
   SCHMITT MP, 1990, RES VIROLOGY, V141, P143, DOI 10.1016/0923-2516(90)90016-C                                                    
   TOYOSHIMA T, 1991, ANAL BIOCHEM, V196, P302, DOI 10.1016/0003-2697(91)90470-E
   ZIMMERMAN TP, 1987, J BIOL CHEM, V262, P5748
NR 24
TC 22
Z9 23
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-4347
J9 J CHROMATOGR-BIOMED
JI J. Chromatogr.-Biomed. Appl.
PD AUG 7
PY 1992
VL 579
IS 1
BP 107
EP 114
DI 10.1016/0378-4347(92)80368-Z
PG 8
WC Chemistry, Analytical
SC Chemistry
GA JK247
UT WOS:A1992JK24700012
PM 1447336
DA 2018-01-05
ER

PT J
AU NG, M
   BLASCHKE, TF
   ARIAS, AA
   ZARE, RN
AF NG, M
   BLASCHKE, TF
   ARIAS, AA
   ZARE, RN
TI ANALYSIS OF FREE INTRACELLULAR NUCLEOTIDES USING HIGH-PERFORMANCE
   CAPILLARY ELECTROPHORESIS
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID PRESSURE LIQUID-CHROMATOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS; HTLV-III
   INFECTIVITY; AIDS-RELATED COMPLEX; CELLULAR PHARMACOLOGY; ZONE
   ELECTROPHORESIS; INHIBITOR; 2',3'-DIDEOXYINOSINE; NUCLEOSIDES;
   SEPARATION
AB High-performance capillary electrophoresis (HPCE) with UV absorbance detection (254 nm) has been applied for analyzing intracellular free ribonucleotides. The nucleotide profiles obtained from peripheral blood lymphocytes differ from those obtained from Molt4 human leukemic cells. With a 140 mM borate buffer, pH 9.4, a nearly complete profile can be obtained in 25 min. HPCE has comparable resolution to that of high-performance liquid chromatography (HPLC) but is faster in terms of time per sample run (25 min vs 45 min) and requires much less sample (nanoliter range for HPCE vs microliter range for HPLC).
C1 STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305.
   STANFORD UNIV,MED CTR,SCH MED,DIV CLIN PHARMACOL,STANFORD,CA 94305.
RI Zare, Richard/A-8410-2009
OI Blaschke, Terrence/0000-0001-5307-2620
FU NIAID NIH HHS [AI 27762]
CR AHLUWALIA G, 1987, BIOCHEM PHARMACOL, V36, P3797, DOI 10.1016/0006-2952(87)90440-0
   ATKINSON DE, 1968, BIOCHEMISTRY-US, V7, P4030, DOI 10.1021/bi00851a033
   BROWN EG, 1982, ANAL BIOCHEM, V123, P378, DOI 10.1016/0003-2697(82)90461-4
   BUROLLA VP, 1989, AM BIOTECHNOL LAB, V7, P20
   COONEY DA, 1987, BIOCHEM PHARMACOL, V36, P1765, DOI 10.1016/0006-2952(87)90235-8
   COONEY DA, 1986, BIOCHEM PHARMACOL, V35, P2065, DOI 10.1016/0006-2952(86)90571-X
   DOLNIK V, 1989, J CHROMATOGR, V480, P321, DOI 10.1016/S0021-9673(01)84301-6
   FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333
   HAMMER DF, 1988, ANAL BIOCHEM, V169, P300, DOI 10.1016/0003-2697(88)90288-6                                                    
   HO HT, 1989, ANTIMICROB AGENTS CH, V33, P844, DOI 10.1128/AAC.33.6.844                                                            
   HUANG XH, 1990, ANAL CHEM, V62, P2049, DOI 10.1021/ac00217a028
   KAWASAKI H, 1990, MED PEDIATR ONCOL, V18, P131, DOI 10.1002/mpo.2950180209                                                          
   LAMBERT JS, 1990, NEW ENGL J MED, V322, P1333, DOI 10.1056/NEJM199005103221901
   MAESSEN JG, 1988, CLIN CHEM, V34, P1087
   MINOWADA J, 1972, J NATL CANCER I, V49, P891
   NGUYEN AL, 1990, ANAL CHEM, V62, P2490, DOI 10.1021/ac00221a015
   POGOLOTTI AL, 1982, ANAL BIOCHEM, V126, P335, DOI 10.1016/0003-2697(82)90524-3                                                    
   RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402
   SKOOG L, 1970, EUR J BIOCHEM, V17, P202, DOI 10.1111/j.1432-1033.1970.tb01154.x
   STOCCHI V, 1987, ANAL BIOCHEM, V167, P181, DOI 10.1016/0003-2697(87)90150-3
   Stryer L., 1988, BIOCHEMISTRY-US
   TSUDA T, 1988, J HIGH RES CHROMATOG, V11, P721, DOI 10.1002/jhrc.1240111007                                                         
NR 22
TC 55
Z9 56
U1 2
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0003-2700
J9 ANAL CHEM
JI Anal. Chem.
PD AUG 1
PY 1992
VL 64
IS 15
BP 1682
EP 1684
DI 10.1021/ac00039a010
PG 3
WC Chemistry, Analytical
SC Chemistry
GA JF827
UT WOS:A1992JF82700011
PM 1443617
DA 2018-01-05
ER

PT J
AU MOHAN, P
AF MOHAN, P
TI ANTI-AIDS DRUG DEVELOPMENT - CHALLENGES AND STRATEGIES
SO PHARMACEUTICAL RESEARCH
LA English
DT Review
DE ANTI-AIDS AGENTS; HUMAN IMMUNODEFICIENCY VIRUS-1 (HIV-1); DEVELOPMENT;
   INHIBITORS; MECHANISM; SELECTIVITY
ID HUMAN-IMMUNODEFICIENCY-VIRUS; LYMPHADENOPATHY-ASSOCIATED VIRUS;
   RECOMBINANT SOLUBLE CD4; INDUCED SYNCYTIUM FORMATION; VESICULAR
   STOMATITIS-VIRUS; CHRONICALLY INFECTED-CELLS; SYNTHETIC HIV-1 PROTEASE;
   REVERSE-TRANSCRIPTASE; DEXTRAN SULFATE; CRYSTAL-STRUCTURE
AB A myriad of chemical derivatives has been shown to inhibit in vitro replication of the AIDS virus at concentrations that are nontoxic to the host cells. The majority of these agents acts by either (i) inhibiting enzymes such as reverse transcriptase (RT), protease, or glucosidase, (ii) arresting expression of genes or gene products, or (iii) inhibiting viral processes such as giant cell (syncytia) formation or viral binding to the target cell. The nucleoside RT inhibitors are the most widely studied agents at both the preclinical and the clinical levels. Their inability to cure AIDS has stimulated the discovery of several novel nonnucleoside RT inhibitors, possessing varied structures and demonstrating activity at nanomolar concentrations. These agents demonstrate a unique mode of binding to RT and show a high specificity for HIV-1. Protease inhibitors, soluble CD4 derivatives, oligonucleotides, and many anionic derivatives also demonstrate potent anti-HIV-1 activities. These derivatives possess mechanisms of action different to the nucleosides and exhibit selectivity as exemplified by their high in vitro therapeutic indices. This article discusses the structural parameters that govern activity in these agents, the pros and cons regarding the development of these compounds as putative anti-AIDS agents, and the future promise of searching for newer agents directed at novel targets to inhibit the AIDS virus.
RP MOHAN, P (reprint author), UNIV ILLINOIS, COLL PHARM, DEPT MED CHEM & PHARMACOGNOSY MC781, CHICAGO, IL 60680 USA.
CR AGRAWAL S, 1989, P NATL ACAD SCI USA, V86, P7790, DOI 10.1073/pnas.86.20.7790                                                         
   BABA M, 1990, J ACQ IMMUN DEF SYND, V3, P493
   BABA M, 1988, BIOCHEM BIOPH RES CO, V155, P1404, DOI 10.1016/S0006-291X(88)81297-X
   BABA M, 1990, ANTIMICROB AGENTS CH, V34, P134, DOI 10.1128/AAC.34.1.134                                                            
   BABA M, 1988, P NATL ACAD SCI USA, V85, P6132, DOI 10.1073/pnas.85.16.6132                                                         
   BABA M, 1991, P NATL ACAD SCI USA, V88, P2356, DOI 10.1073/pnas.88.6.2356
   BABA M, 1990, ANTIMICROB AGENTS CH, V34, P2358, DOI 10.1128/AAC.34.12.2358                                                          
   BABA M, 1988, ANTIMICROB AGENTS CH, V32, P1742, DOI 10.1128/AAC.32.11.1742                                                          
   BABA M, 1990, J INFECT DIS, V161, P208, DOI 10.1093/infdis/161.2.208                                                        
   BABA M, 1991, 7TH INT C AIDS FLOR
   BABOONIAN C, 1991, BIOCHEM BIOPH RES CO, V179, P17, DOI 10.1016/0006-291X(91)91327-9
   BALZARINI J, 1989, P NATL ACAD SCI USA, V86, P332, DOI 10.1073/pnas.86.1.332
   BALZARINI J, 1986, BIOCHEM BIOPH RES CO, V136, P64, DOI 10.1016/0006-291X(86)90877-6
   BALZARINI J, 1986, INT J CANCER, V37, P451, DOI 10.1002/ijc.2910370318
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   BATTEN PL, 1979, TOXICOL APPL PHARM, V48, pA171
   BOWMAN MC, 1983, J ANAL TOXICOL, V7, P55, DOI 10.1093/jat/7.1.55                                                              
   BRODER S, 1990, ANN INTERN MED, V113, P604, DOI 10.7326/0003-4819-113-8-604
   BRODER S, 1985, LANCET, V2, P627
   BUGELSKI PJ, 1991, J ACQ IMMUN DEF SYND, V4, P923
   BYRN RA, 1990, NATURE, V344, P667, DOI 10.1038/344667a0
   CAMERMAN A, 1987, P NATL ACAD SCI USA, V84, P8239, DOI 10.1073/pnas.84.23.8239
   CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0
   CARDIN AD, 1991, J BIOL CHEM, V266, P13355
   CLAPHAM PR, 1989, NATURE, V337, P368, DOI 10.1038/337368a0
   COHEN JS, 1991, ANTIVIR RES, V16, P121, DOI 10.1016/0166-3542(91)90019-N
   COHEN KA, 1991, J BIOL CHEM, V266, P14670
   CUSHMAN M, 1991, J MED CHEM, V34, P329, DOI 10.1021/jm00105a052
   DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574                                                         
   DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186                                                         
   DECLERCQ E, 1989, J ANTIMICROB CHEMOTH, V23, P35
   DECLERCQ E, 1979, CANCER LETT, V8, P9, DOI 10.1016/0304-3835(79)90017-X                                                    
   DECLERCQ E, 1989, NUCLEOS NUCLEOT, V8, P659, DOI 10.1080/07328318908054206                                                       
   DECLERCQ E, 1991, J ACQ IMMUN DEF SYND, V4, P207
   DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0
   DESJARLAIS RL, 1990, P NATL ACAD SCI USA, V87, P6644, DOI 10.1073/pnas.87.17.6644                                                         
   DREYER GB, 1989, P NATL ACAD SCI USA, V86, P9752, DOI 10.1073/pnas.86.24.9752
   ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122
   FARNSWORTH NR, 1985, B WORLD HEALTH ORGAN, V63, P965
   FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0
   FLEET GWJ, 1988, FEBS LETT, V237, P128, DOI 10.1016/0014-5793(88)80185-6
   FRANK KB, 1991, J BIOL CHEM, V266, P14232
   FREEMAN HS, 1987, DYES PIGMENTS, V8, P417, DOI 10.1016/0143-7208(87)85034-9                                                    
   GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936
   GOBBO VD, 1991, ANTIVIR RES, V16, P65
   GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863
   GRUTERS RA, 1987, NATURE, V330, P74, DOI 10.1038/330074a0
   GUSTAFSON KR, 1989, J NATL CANCER I, V81, P1254, DOI 10.1093/jnci/81.16.1254                                                         
   HARTMAN NR, 1990, AIDS RES HUM RETROV, V6, P805, DOI 10.1089/aid.1990.6.805                                                          
   HASELTINE WA, 1989, J ACQ IMMUN DEF SYND, V2, P311
   HASELTINE WA, 1988, J ACQ IMMUN DEF SYND, V1, P217
   HORWITZ JP, 1964, J ORG CHEM, V29, P2076, DOI 10.1021/jo01030a546                                                             
   HUFF JR, 1991, J MED CHEM, V34, P2305, DOI 10.1021/jm00112a001
   HUSSEY RE, 1988, NATURE, V331, P78, DOI 10.1038/331078a0
   JENTSCH KD, 1987, J GEN VIROL, V68, P2183, DOI 10.1099/0022-1317-68-8-2183
   KAHN JO, 1990, ANN INTERN MED, V112, P254, DOI 10.7326/0003-4819-112-4-
   KAPLAN LD, 1987, AM J MED, V82, P615, DOI 10.1016/0002-9343(87)90108-2
   KARPAS A, 1988, P NATL ACAD SCI USA, V85, P9229, DOI 10.1073/pnas.85.23.9229
   KEMPF DJ, 1990, J MED CHEM, V33, P2687, DOI 10.1021/jm00172a002
   LAPATTO R, 1989, NATURE, V342, P299, DOI 10.1038/342299a0                                                                
   LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383
   LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983
   LEMAITRE M, 1987, P NATL ACAD SCI USA, V84, P648, DOI 10.1073/pnas.84.3.648
   LETSINGER RL, 1989, P NATL ACAD SCI USA, V86, P6553, DOI 10.1073/pnas.86.17.6553
   LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563
   LOONEY DJ, 1990, J ACQ IMMUN DEF SYND, V3, P649
   LORENTSEN KJ, 1989, ANN INTERN MED, V111, P561, DOI 10.7326/0003-4819-111-7-561
   MARQUEZ VE, 1990, J MED CHEM, V33, P978, DOI 10.1021/jm00165a015                                                             
   MATSUKURA M, 1989, P NATL ACAD SCI USA, V86, P4244, DOI 10.1073/pnas.86.11.4244
   MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486
   MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568                                                         
   MICHAEL WR, 1968, TOXICOL APPL PHARM, V12, P473, DOI 10.1016/0041-008X(68)90154-3
   MITSUYA H, 1984, SCIENCE, V226, P172, DOI 10.1126/science.6091268                                                         
   MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273
   MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096                                                         
   MOHAN P, 1991, Antiviral Chemistry and Chemotherapy, V2, P215
   MOHAN P, 1990, LIFE SCI, V47, P993, DOI 10.1016/0024-3205(90)90471-3
   MOHAN P, 1991, J MED CHEM, V34, P212, DOI 10.1021/jm00105a033
   MOHAN P, 1991, BIOCHEM PHARMACOL, V41, P642, DOI 10.1016/0006-2952(91)90641-H                                                    
   Mohan P, 1991, Drug Des Discov, V8, P69
   MOHAN P, IN PRESS ANTIVIRAL R
   MOHAN P, UNPUB
   MONTEFIORI DC, 1989, P NATL ACAD SCI USA, V86, P7191, DOI 10.1073/pnas.86.18.7191
   NAESENS L, 1989, EUR J CLIN MICROBIOL, V8, P1043, DOI 10.1007/BF01975167
   NAKASHIMA H, 1989, ANTIVIR RES, V11, P233, DOI 10.1016/0166-3542(89)90033-8
   NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0
   NUNBERG JH, 1991, J VIROL, V65, P4887
   OSTERTAG W, 1974, P NATL ACAD SCI USA, V71, P4980, DOI 10.1073/pnas.71.12.4980
   OVERTON HA, 1990, VIROLOGY, V179, P508, DOI 10.1016/0042-6822(90)90326-M
   PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0
   PAUWELS R, 1991, 7TH INT C AIDS FLOR
   PERNO CF, 1990, J EXP MED, V171, P1043, DOI 10.1084/jem.171.4.1043                                                          
   POWERS R, 1991, J MOL BIOL, V221, P1081, DOI 10.1016/0022-2836(91)80113-9
   RICHMAN D, 1991, ANTIMICROB AGENTS CH, V35, P305, DOI 10.1128/AAC.35.2.305                                                            
   ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354
   ROEDERER M, 1990, P NATL ACAD SCI USA, V87, P4884, DOI 10.1073/pnas.87.12.4884
   ROMERO DL, 1991, P NATL ACAD SCI USA, V88, P8806, DOI 10.1073/pnas.88.19.8806                                                         
   SARIN PS, 1988, P NATL ACAD SCI USA, V85, P7448, DOI 10.1073/pnas.85.20.7448
   SCHINAZI RF, 1990, ANTIVIR RES, V13, P265, DOI 10.1016/0166-3542(90)90071-E
   SCHOLS D, 1990, VIROLOGY, V175, P556, DOI 10.1016/0042-6822(90)90440-3
   SHIRASAKA T, 1990, P NATL ACAD SCI USA, V87, P9426, DOI 10.1073/pnas.87.23.9426
   SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514
   STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943
   STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788                                                         
   STEIN CA, 1989, AIDS RES HUM RETROV, V5, P639, DOI 10.1089/aid.1989.5.639
   SUZUKI H, 1989, AGR BIOL CHEM TOKYO, V53, P3369, DOI 10.1080/00021369.1989.10869842                                                  
   TAN GT, 1991, J BIOL CHEM, V266, P23529
   TANAKA H, 1991, J MED CHEM, V34, P349, DOI 10.1021/jm00105a055
   TATENO M, 1989, P NATL ACAD SCI USA, V86, P4287, DOI 10.1073/pnas.86.11.4287
   TOMASSELLI AG, 1991, J BIOL CHEM, V266, P14548
   TRAUNECKER A, 1988, NATURE, V331, P84, DOI 10.1038/331084a0
   VANROEY P, 1989, P NATL ACAD SCI USA, V86, P3929
   WILLIAMS RT, 1959, METABOLISM DETOXICAT, P497
   WINCHESTER BG, 1990, BIOCHEM J, V269, P227, DOI 10.1042/bj2690227                                                               
   WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279
   YARCHOAN R, 1986, LANCET, V1, P575
   YARCHOAN R, 1989, PHARMACOL THERAPEUT, V40, P329, DOI 10.1016/0163-7258(89)90083-1
   ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280
NR 118
TC 27
Z9 27
U1 0
U2 4
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD JUN
PY 1992
VL 9
IS 6
BP 703
EP 714
DI 10.1023/A:1015882901078                                                 
          
PG 12
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA HX884
UT WOS:A1992HX88400001
PM 1384026
DA 2018-01-05
ER

PT J
AU MARTIN, SF
   AUSTIN, RE
   OALMANN, CJ
   BAKER, WR
   CONDON, SL
   DELARA, E
   ROSENBERG, SH
   SPINA, KP
   STEIN, HH
   COHEN, J
   KLEINERT, HD
AF MARTIN, SF
   AUSTIN, RE
   OALMANN, CJ
   BAKER, WR
   CONDON, SL
   DELARA, E
   ROSENBERG, SH
   SPINA, KP
   STEIN, HH
   COHEN, J
   KLEINERT, HD
TI 1,2,3-TRISUBSTITUTED CYCLOPROPANES AS CONFORMATIONALLY RESTRICTED
   PEPTIDE ISOSTERES - APPLICATION TO THE DESIGN AND SYNTHESIS OF NOVEL
   RENIN INHIBITORS
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID STABILIZE SECONDARY STRUCTURES; ANGIOTENSIN-CONVERTING ENZYME;
   LACTAM-BRIDGED DIPEPTIDES; TRANSITION-STATE ANALOGS; AMINO-ACID
   DERIVATIVES; X-RAY; ASPARTIC PROTEINASE; HIV-1 PROTEASE; SCISSILE BOND;
   SYSTEM
AB The 1,2,3-trisubstituted cyclopropanes 6 and 7 are the first members of a novel class of isosteric replacements for peptide linkages that are more generally represented by the dipeptide mimics 2 and 3.  These unique peptide surrogates are specifically designed to lock a section of a peptide backbone in an extended beta-strand conformation (phi-angle restriction) while simultaneously enforcing one of two specifically defined orientations for the amino acid side chain (chi(1)-angle restriction).  Methods were first developed for the stereoselective, asymmetric synthesis of the trisubstituted cyclopropanes 15a-d, 18a-d, 22a-d, and 23a-d (Scheme II), by an efficient approach featuring the Rh2(S-MEPY)4 (11) and Rh2(R-MEPY)4 (20) catalyzed cyclization of the allylic diazoacetates 10a-d to give the optically active lactones 12a-d and 21a-d, respectively, in up to greater-than-or-equal-to 94% enantiomeric excess.  Nucleophilic opening of the lactone ring of 12a-d gave the corresponding morpholine amides 14a-d.  By exploiting tactics that allowed for selective epimerization of one of the two functionalized side chains on the cyclopropane nucleus, 14a-d were transformed into the two series of diastereoisomeric morpholine amide carboxylic acids 15a-d and 18a-d.  Epimerization of the morpholine amide group on 14a-d followed by Jones oxidation of the intermediate alcohols gave 15a-d.  Alternatively, initial oxidation of the primary alcohol groups in 14a-d followed by selective, base-catalyzed inversion alpha to the aldehyde function and then Jones oxidation gave the diastereomeric dicarboxylic acid derivatives 18a-d.  In a similar fashion, the enantiomeric lactones 21a-d were converted into the two corresponding enantiomeric series of dicarboxylic acid derivatives 22a-d and 23a-d.  Inhibitors of aspartic proteinases, of which renin is a typical example, are known to bind to the enzyme active site cleft in an extended conformation.  Thus, in order to evaluate the efficacy of 1,2,3-trisubstituted cyclopropanes as rigid replacements of beta-strand secondary structure in pseudopeptidic ligands, 15a-d, 18a-d, 22a-d, and 23a-d were incorporated at the P3 subsite of the potential renin inhibitors 24a-h and 25a-h by coupling with the tripeptide replacement 8.  A significant number of these substances inhibited renin at nanomolar concentrations.  On the basis of this preliminary test, 1,2,3-trisubstituted cyclopropanes do appear to constitute a viable new class of peptide mimics.  Since the stereochemistry at each carbon on the cyclopropane ring may be altered, these novel replacements may also function as stereochemical probes to establish the conformation of pseudopeptide ligands bound to their macromolecular targets.
C1 ABBOTT LABS,DIV PHARMACEUT PROD,ABBOTT PK,IL 60064.
RP MARTIN, SF (reprint author), UNIV TEXAS,DEPT CHEM & BIOCHEM,AUSTIN,TX 78712, USA.
CR ABADZAPATERO C, 1990, IN PRESS SEP P SON A
   BASHA A, 1977, TETRAHEDRON LETT, P4171
   Blankley C. J., 1973, ORG SYNTH, VV, P258
   BLUNDELL TL, 1987, BIOCHEMISTRY-US, V26, P5585, DOI 10.1021/bi00392a001
   BOCK MG, 1987, J MED CHEM, V30, P1853, DOI 10.1021/jm00393a029
   BOLIS G, 1987, J MED CHEM, V30, P1729, DOI 10.1021/jm00393a008
   BROWN CA, 1973, J CHEM SOC CHEM COMM, P553, DOI 10.1039/c39730000553
   COOPER JB, 1989, BIOCHEMISTRY-US, V28, P8596, DOI 10.1021/bi00447a049
   COREY EJ, 1984, TETRAHEDRON LETT, V25, P3559, DOI 10.1016/S0040-4039(01)91075-5
   DOYLE MP, 1991, J AM CHEM SOC, V113, P1423, DOI 10.1021/ja00004a059
   EDE NJ, 1990, TETRAHEDRON LETT, V31, P6071, DOI 10.1016/S0040-4039(00)98031-6
   ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122
   ERNEST I, 1990, TETRAHEDRON LETT, V31, P4011, DOI 10.1016/S0040-4039(00)94485-X
   Farmer P. S., 1980, DRUG DESIGN, V10, P119
   FEIGEL M, 1986, J AM CHEM SOC, V108, P181, DOI 10.1021/ja00261a033
   FESIK SW, 1991, BIOCHEMISTRY-US, V30, P6574, DOI 10.1021/bi00240a030
   FLYNN GA, 1987, J AM CHEM SOC, V109, P7914, DOI 10.1021/ja00259a068                                                             
   FOUNDLING SI, 1987, NATURE, V327, P349, DOI 10.1038/327349a0
   FREIDINGER RM, 1980, SCIENCE, V210, P656, DOI 10.1126/science.7001627
   FREIDINGER RM, 1982, J ORG CHEM, V47, P104, DOI 10.1021/jo00340a023
   GARVEY DS, 1990, J ORG CHEM, V55, P936, DOI 10.1021/jo00290a026
   GLASSMAN HN, 1990, J CARDIOVASC PHARM, V16, pS76, DOI 10.1097/00005344-199016004-00016
   HATCH LF, 1950, J AM CHEM SOC, V72, P5643, DOI 10.1021/ja01168a078                                                             
   HINDS MG, 1991, J MED CHEM, V34, P1777, DOI 10.1021/jm00110a005
   HOLLADAY MW, 1991, J ORG CHEM, V56, P3900, DOI 10.1021/jo00012a022
   HRUBY VJ, 1982, LIFE SCI, V31, P189, DOI 10.1016/0024-3205(82)90578-1
   HRUBY VJ, 1990, BIOCHEM J, V268, P249, DOI 10.1042/bj2680249                                                               
   HSIAO CN, 1990, SYNTHETIC COMMUN, V20, P3507, DOI 10.1080/00397919008051594
   HUTCHINS C, 1991, CRIT REV BIOCHEM MOL, V26, P77, DOI 10.3109/10409239109081721
   JAKOVAC IJ, 1979, J ORG CHEM, V44, P2165, DOI 10.1021/jo01327a028                                                             
   James M.N.G., 1987, BIOL MACROMOL, V3, P413
   JASKOLSKI M, 1991, BIOCHEMISTRY-US, V30, P1600, DOI 10.1021/bi00220a023
   JUPP RA, 1990, BIOCHEM J, V265, P871, DOI 10.1042/bj2650871                                                               
   KAHN M, 1987, HETEROCYCLES, V25, P29, DOI 10.3987/S-1987-01-0029                                                          
   KAHN M, 1986, TETRAHEDRON LETT, V27, P4841, DOI 10.1016/S0040-4039(00)85077-7
   KAHN M, 1989, TETRAHEDRON LETT, V30, P2317, DOI 10.1016/S0040-4039(01)80387-7
   KAHN M, 1988, J AM CHEM SOC, V110, P1638, DOI 10.1021/ja00213a055
   KAZMIERSKI WM, 1991, J AM CHEM SOC, V113, P2275, DOI 10.1021/ja00006a055
   KEMP DS, 1989, J ORG CHEM, V54, P109, DOI 10.1021/jo00262a026
   KEMP DS, 1988, TETRAHEDRON LETT, V29, P4935, DOI 10.1016/S0040-4039(00)80645-0
   KEMP DS, 1982, TETRAHEDRON LETT, V23, P3761, DOI 10.1016/S0040-4039(00)87700-X
   KEMP DS, 1985, J ORG CHEM, V50, P5834, DOI 10.1021/jo00350a077
   KEMP DS, 1988, TETRAHEDRON LETT, V29, P5057, DOI 10.1016/S0040-4039(00)80678-4                                                   
   Kleinert H D, 1991, Adv Pharmacol, V22, P207, DOI 10.1016/S1054-3589(08)60036-8
   KLEINERT HD, 1989, AM J HYPERTENS, V2, P800, DOI 10.1093/ajh/2.10.800                                                            
   Kostka V., 1985, ASPARTIC PROTEINASES
   KRSTENANSKY JL, 1982, BIOCHEM BIOPH RES CO, V109, P1368, DOI 10.1016/0006-291X(82)91928-3
   LULY J R, 1988, Journal of Organic Chemistry, V53, P6108
   LULY Jr, 1988, J MED CHEM, V31, P2264, DOI 10.1021/jm00120a005
   LYNCH VM, 1991, ACTA CRYSTALLOGR C, V7, P1345
   MARTIN SF, 1990, TETRAHEDRON LETT, V31, P4731, DOI 10.1016/S0040-4039(00)97718-9
   MELNICK MJ, 1990, TETRAHEDRON LETT, V31, P961, DOI 10.1016/S0040-4039(00)94403-4
   MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029
   MILLER M, 1990, RETROVIRAL PROTEASES, P93
   NAGAI U, 1985, TETRAHEDRON LETT, V26, P647, DOI 10.1016/S0040-4039(00)89169-8
   NAKAGAWA N, 1984, AGR BIOL CHEM TOKYO, V48, P2505, DOI 10.1080/00021369.1984.10866523                                                  
   OCAIN T D, 1991, Drugs of the Future, V16, P37
   OLSON GL, 1990, J AM CHEM SOC, V112, P323, DOI 10.1021/ja00157a050
   ONDETTI MA, 1982, ANNU REV BIOCHEM, V51, P283, DOI 10.1146/annurev.bi.51.070182.001435
   ONDETTI MA, 1981, J MED CHEM, V24, P355, DOI 10.1021/jm00136a001
   PEACH MJ, 1977, PHYSIOL REV, V57, P313
   PLATTNER JJ, 1988, J MED CHEM, V31, P2277, DOI 10.1021/jm00120a006                                                             
   ROSENBERG SH, 1991, J MED CHEM, V34, P469, DOI 10.1021/jm00105a073
   ROSENBERG SH, 1991, 201ST NAT M AM CHEM
   SHAM HL, 1987, FEBS LETT, V220, P299, DOI 10.1016/0014-5793(87)80834-7
   SHIMAMOTO K, 1991, J ORG CHEM, V56, P4167, DOI 10.1021/jo00013a018                                                             
   Spatola A. F., 1983, CHEM BIOCH AMINO ACI, V7, P267
   STAMMER CH, 1990, TETRAHEDRON, V46, P2231
   STILL WC, 1978, J ORG CHEM, V43, P2923, DOI 10.1021/jo00408a041                                                             
   SUGUNA K, 1987, P NATL ACAD SCI USA, V84, P7009, DOI 10.1073/pnas.84.20.7009
   SWAIN AL, 1990, P NATL ACAD SCI USA, V87, P8805, DOI 10.1073/pnas.87.22.8805
   THAISRIVONGS S, 1988, J MED CHEM, V31, P1369, DOI 10.1021/jm00402a021
   Thaisrivongs S., 1988, DRUG NEWS PERSPECT, V1, P11
   THORSETT ED, 1983, BIOCHEM BIOPH RES CO, V111, P166, DOI 10.1016/S0006-291X(83)80131-4
   TONIOLO C, 1990, INT J PEPT PROT RES, V35, P287, DOI 10.1111/j.1399-3011.1990.tb00052.x                                              
   VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302
   VIG OP, 1983, INDIAN J CHEM B, V22, P919
   WATENPAUGH KD, 1991, 12TH PEPT CHEM BIOL
   WEBER C, 1991, BIOCHEMISTRY-US, V30, P6563, DOI 10.1021/bi00240a029
   WILLIAMS PD, 1991, J MED CHEM, V34, P887, DOI 10.1021/jm00107a004
   WOLF JP, 1989, J ORG CHEM, V54, P3164, DOI 10.1021/jo00274a037
   YU KL, 1988, J MED CHEM, V31, P1430, DOI 10.1021/jm00402a031
   ZYDOWSKY TM, 1988, J ORG CHEM, V53, P5607, DOI 10.1021/jo00259a003
NR 83
TC 91
Z9 91
U1 0
U2 12
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD MAY 15
PY 1992
VL 35
IS 10
BP 1710
EP 1721
DI 10.1021/jm00088a005
PG 12
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA HU927
UT WOS:A1992HU92700005
PM 1588553
DA 2018-01-05
ER

PT J
AU SCHAFER, V
   VONBRIESEN, H
   ANDREESEN, R
   STEFFAN, AM
   ROYER, C
   TROSTER, S
   KREUTER, J
   RUBSAMENWAIGMANN, H
AF SCHAFER, V
   VONBRIESEN, H
   ANDREESEN, R
   STEFFAN, AM
   ROYER, C
   TROSTER, S
   KREUTER, J
   RUBSAMENWAIGMANN, H
TI PHAGOCYTOSIS OF NANOPARTICLES BY HUMAN-IMMUNODEFICIENCY-VIRUS
   (HIV)-INFECTED MACROPHAGES - A POSSIBILITY FOR ANTIVIRAL DRUG TARGETING
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE NANOPARTICLES; HUMAN IMMUNODEFICIENCY VIRUS (HIV); MACROPHAGE; DRUG
   TARGETING; PHAGOCYTOSIS
ID MONOCYTES; SYSTEM; BLOOD; AIDS; RATS
AB Human monocytes/macrophages (MO/MAC) were isolated from peripheral blood and cultivated on hydrophobic Teflon membranes. This culture system is suitable for HIV infection of MO/MAC in vitro. After transfer into 24-well plates the mature macrophages (infected or uninfected) were used for measurements of phagocytosis. The uptake of different, radioactively labeled nanoparticles (NP) made of polyalkylcyanoacrylate, polymethylmethacrylate (PMMA), and human serum albumin (HSA) by the macrophages was determined. In addition, the influence on phagocytosis of size and composition, concentration, and surface of the NP was studied. Further, macrophages of different state of activation were tested. NP made of polyhexylcyanoacrylate (PHCA) or human serum albumin with a diameter of about 200 nm were found most useful for targeting antiviral substances such as azidothymidine to macrophages. Cells infected in vitro with HIV-1D117/III, a monocytotropic HIV isolate from a perinatally infected child, possessed an even higher phagocytotic activity than noninfected cells. Macrophages isolated from HIV-infected patients also showed good incorporation of NP. Thus, the concept of a specific targeting of antiviral substances to macrophages in HIV-infected individuals appears quite promising.
C1 GEORG SPEYER HAUS,CHEMOTHERAPEUT FORSCHUNGSINST,W-6000 FRANKFURT,GERMANY.
   JW GOETHE UNIV,INST PHARMAZEUT TECHNOL,W-6000 FRANKFURT,GERMANY.
   UNIV FREIBURG,MED KLIN,W-7800 FREIBURG,GERMANY.
   UNIV STRASBOURG 1,VIROL LAB,F-67070 STRASBOURG,FRANCE.
CR ANDREESEN R, 1986, BLOOD, V67, P1257
   ANDREESEN R, 1983, J IMMUNOL METHODS, V56, P295, DOI 10.1016/S0022-1759(83)80019-2                                                   
   BURKE DS, 1986, ANN INTERN MED, V105, P968, DOI 10.7326/0003-4819-105-6-968_1
   ESSER R, 1990, PATHOBIOLOGY, V59, P219
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   HOR G, 1986, NUCLEAR MED CLIN ONC
   Ikada Y, 1986, J BIOACT COMPAT POL, V1, P32
   JOHNSTON RB, 1988, NEW ENGL J MED, V318, P747, DOI 10.1056/NEJM198803243181205
   KREUTER J, 1983, PHARM ACTA HELV, V58, P196
   KREUTER J, 1979, J PHARM SCI, V68, P1443, DOI 10.1002/jps.2600681129
   KUHNEL H, 1989, P NATL ACAD SCI USA, V86, P2383, DOI 10.1073/pnas.86.7.2383                                                          
   LEU D, 1984, J PHARM SCI, V73, P1433, DOI 10.1002/jps.2600731028
   LHERM C, 1989, DPHG ANN M, P682
   MARTY JJ, 1978, PHARM ACTA HELV, V53, P17
   MELTZER MS, 1990, IMMUNOL TODAY, V11, P217, DOI 10.1016/0167-5699(90)90086-O                                                    
   MUNZ DL, 1981, PROGR RADIOPHARMACOL, V2, P261
   ROY S, 1988, J LEUKOCYTE BIOL, V43, P91
   RUBSAMENWAIGMANN H, 1989, LANCET, V2, P1155
   RUBSAMENWAIGMANN H, 1986, J MED VIROL, V19, P335, DOI 10.1002/jmv.1890190406
   SCHEIBENBOGEN C, 1989, Experimental Cell Biology, V57, P118
   TROSTER SD, 1990, INT J PHARM, V61, P85, DOI 10.1016/0378-5173(90)90047-8
   van Furth R., 1988, INFLAMMATION BASIC P, P281
   VONBRIESEN H, 1990, RES VIROLOGY, V141, P225, DOI 10.1016/0923-2516(90)90025-E
   WASER PG, 1987, INT J PHARM, V39, P213, DOI 10.1016/0378-5173(87)90219-5
   WIDDER K, 1979, J PHARM SCI, V68, P79, DOI 10.1002/jps.2600680124
   KREUTER J, 1987, Patent No. 3774061
   1987, MORBID MORTAL WEE S1, V37, pS3
NR 27
TC 100
Z9 107
U1 2
U2 26
PU PLENUM PUBL CORP
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013
SN 0724-8741
J9 PHARMACEUT RES
JI Pharm. Res.
PD APR
PY 1992
VL 9
IS 4
BP 541
EP 546
DI 10.1023/A:1015852732512
PG 6
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA HM776
UT WOS:A1992HM77600016
PM 1495900
DA 2018-01-05
ER

PT J
AU TANAKA, H
   TAKASHIMA, H
   UBASAWA, M
   SEKIYA, K
   NITTA, I
   BABA, M
   SHIGETA, S
   WALKER, RT
   DECLERCQ, E
   MIYASAKA, T
AF TANAKA, H
   TAKASHIMA, H
   UBASAWA, M
   SEKIYA, K
   NITTA, I
   BABA, M
   SHIGETA, S
   WALKER, RT
   DECLERCQ, E
   MIYASAKA, T
TI STRUCTURE-ACTIVITY-RELATIONSHIPS OF
   1-[(2-HYDROXYETHOXY)METHYL]-6-(PHENYLTHIO)THYMINE ANALOGS - EFFECT OF
   SUBSTITUTIONS AT THE C-6 PHENYL RING AND AT THE C-5 POSITION ON
   ANTI-HIV-1 ACTIVITY
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; PLACEBO-CONTROLLED TRIAL; AIDS-RELATED
   COMPLEX; AZIDOTHYMIDINE AZT; DOUBLE-BLIND; HIV; TOXICITY; URIDINES;
   THERAPY; AGENTS
AB The effect of substitution on the pyrimidine moiety of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)-2-thiothymine (HEPT-S) on anti-HIV-1 activity was investigated by synthesizing a series of 5-methyl-6-(arylthio) and 5-substituted-6-(phenylthio) derivatives.  Preparation of the 5-methyl-6-(arylthio) derivatives was carried out based on either LDA lithiation of 1-[[2-(tert-butyldimethylsiloxy)ethoxy]methyl]thymine (3) and 1-[[2-(tert-butyldimethylsiloxy)ethoxy]methyl]-2-thiothymine (4) followed by reaction with diaryl disulfides or an addition-elimination reaction of 1-[[2-(tert-butyldimethylsiloxy)ethoxy]methyl]-6-(phenylsulfinyl)thymine (31) with aromatic thiols.  Preparation of the 5-substituted-6-(phenylthio) derivatives was carried out based on either C-5 lithiation of the 1-[[2-(tert-butyldimethylsiloxy)ethoxy]methyl]-6-(phenylthio)uracil (41) with LTMP or the LDA lithiation of 5-alkyl-1-[[2-(tert-butyldimethylsiloxy)ethoxy]methyl]-2-thiouracil derivatives 45-47.  Substitution at the meta position of the C-6-(phenylthio) ring by the methyl group improved the original anti-HIV-1 activity of HEPT, and introduction of two m-methyl groups to the phenylthio ring further potentiated the activity [EC50:  6-[(3,5-dimethylphenyl)thio]-1-[(2-hydroxyethoxy)methyl]thymine (28), 0.26-mu-M; 6-[(3,5-dimethylphenyl)thio]-1-[(2-hydroxyethoxy)methyl]-2-thiothymine (30), 0.22-mu-M].  When the 5-methyl group was replaced by an ethyl or an isopropyl group, the anti-HIV-1 activity of HEPT was also improved remarkably [EC50:  5-ethyl-1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)-2-thiouracil (48), 0.11-mu-M; 5-isopropyl-1-[(2-hydroxyethoxy)-methyl]-6-(phenylthio)-2-thiouracil (50), 0.059-mu-M; 5-ethyl-1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)-2-thiouracil (54), 0.12-mu-M; 5-isopropyl-1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)-2-thiouracil (56), 0.063-mu-M].  6-[(3,5-Dimethylphenyl)thio]-5-ethyl-1-[(2-hydroxyethoxy)methyl]thymine derivatives 51 and 57 and 6-[(3,5-dimethylphenyl)thio]-5-isopropyl-1-[(2-hydroxyethoxy)methyl]thymine derivatives 52 and 58 inhibited the replication of HIV-1 in the nanomolar concentration range.
C1 SHOWA UNIV,SCH PHARMACEUT SCI,HATANODAI 1-5-8,SHINAGAWA KU,TOKYO 142,JAPAN.
   FUKUSHIMA MED SCH,FUKUSHIMA 96012,JAPAN.
   UNIV BIRMINGHAM,DEPT CHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.
   CATHOLIC UNIV LEUVEN,REGA INST MED RES,B-3000 LOUVAIN,BELGIUM.
   MITSUBISHI KASEI CORP,RES CTR,YOKOHAMA 227,JAPAN.
RI Baba, Masanori/G-3867-2011
CR ANDERSON GW, 1964, J AM CHEM SOC, V86, P1839, DOI 10.1021/ja01063a037                                                             
   BABA M, 1991, P NATL ACAD SCI USA, V88, P2356, DOI 10.1073/pnas.88.6.2356
   BABA M, 1990, ANTIMICROB AGENTS CH, V34, P2358, DOI 10.1128/AAC.34.12.2358                                                          
   BABA M, 1989, BIOCHEM BIOPH RES CO, V165, P1375, DOI 10.1016/0006-291X(89)92756-3
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   BASNAK I, 1979, COLLECT CZECH CHEM C, V44, P2426, DOI 10.1135/cccc19792426                                                            
   DECLERCQ E, 1989, ANTIVIR RES, V12, P1, DOI 10.1016/0166-3542(89)90064-8                                                    
   FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401                                                     
   GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936
   Johnson TB, 1931, J AM CHEM SOC, V53, P1989, DOI 10.1021/ja01356a057                                                             
   KIM YH, 1988, CHEM LETT, P1045, DOI 10.1246/cl.1988.1045                                                            
   LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383
   MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273
   MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096                                                         
   MIYASAKA T, 1989, J MED CHEM, V32, P2507, DOI 10.1021/jm00132a002                                                             
   PAUWELS R, 1987, J VIROL METHODS, V16, P171, DOI 10.1016/0166-0934(87)90002-4
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402
   SIEGL WO, 1977, J ORG CHEM, V42, P3442, DOI 10.1021/jo00441a028                                                             
   TANAKA H, 1986, TETRAHEDRON, V42, P4187, DOI 10.1016/S0040-4020(01)87642-0
   TANAKA H, 1991, J MED CHEM, V34, P1394, DOI 10.1021/jm00108a023
   TANAKA H, 1983, CHEM PHARM BULL, V31, P2164
   TANAKA H, 1982, TETRAHEDRON, V38, P2635, DOI 10.1016/0040-4020(82)80016-1
   TANAKA H, 1991, J MED CHEM, V34, P349, DOI 10.1021/jm00105a055
   YARCHOAN R, 1989, SCIENCE, V245, P412, DOI 10.1126/science.2502840                                                         
NR 25
TC 170
Z9 175
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD JAN 24
PY 1992
VL 35
IS 2
BP 337
EP 345
DI 10.1021/jm00080a020
PG 9
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA HB382
UT WOS:A1992HB38200020
PM 1732552
DA 2018-01-05
ER

PT B
AU KREUTER, J
   VONBRIESEN, H
   RUBSAMENWAIGMANN, H
   SCHAFER, V
AF KREUTER, J
   VONBRIESEN, H
   RUBSAMENWAIGMANN, H
   SCHAFER, V
GP ASSOC PHARM GALENIQUE IND
TI PHAGOCYTOSIS OF NANOPARTICLES BY HIV-INFECTED AND UNINFECTED HUMAN
   MACROPHAGES
SO 6TH INTERNATIONAL CONFERENCE ON PHARMACEUTICAL TECHNOLOGY, VOLS 1-5
LA English
DT Proceedings Paper
CT 6TH INTERNATIONAL CONF ON PHARMACEUTICAL TECHNOLOGY
CY JUN 02-04, 1992
CL PARIS, FRANCE
SP CNRS, CONSEIL NATL ORDRE PHARMACIENS, FEDERAT INT PHARM, CONTROLLED RELEASE SOC, SWEDISH ACAD PHARM SCI, ARBEITSGEMEINSCH PHARM VERFAHRENSTECH, ASSOC FRANCOPHONE ENSEIGNMENTS PHARM GALENIQUE, ASSOC CADRES IND PHARM
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ASSOC PHARMACIE GALENIQUE INDUSTRIELLE
PI CHATENAY MALABRY
PA CHATENAY MALABRY
PY 1992
BP 34
EP 41
PG 8
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA BX82V
UT WOS:A1992BX82V00206
DA 2018-01-05
ER

PT J
AU ROSENTHAL, PJ
   WOLLISH, WS
   PALMER, JT
   RASNICK, D
AF ROSENTHAL, PJ
   WOLLISH, WS
   PALMER, JT
   RASNICK, D
TI ANTIMALARIAL EFFECTS OF PEPTIDE INHIBITORS OF A PLASMODIUM-FALCIPARUM
   CYSTEINE PROTEINASE
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
DE CHEMOTHERAPY; HEMOGLOBIN; MALARIA; PROTEASE; PROTEINASE INHIBITOR
ID CATHEPSIN-B; HIV-1 PROTEASE; MALARIA; CHLOROQUINE; RESISTANCE;
   RESURGENCE; DESIGN
AB We previously identified a Plasmodium falciparum trophozoite cysteine proteinase (TCP) and hypothesized that it is required for the degradation of host hemoglobin by intraerythrocytic malaria parasites. To test this hypothesis and to evaluate TCP as a chemotherapeutic target, we examined the antimalarial effects of a panel of peptide fluoromethyl ketone proteinase inhibitors. For each inhibitor, effectiveness at inhibiting the activity of TCP correlated with effectiveness at both blocking hemoglobin degradation and killing cultured parasites. Benzyloxycarbonyl (Z)-Phe-Arg-CH2F, the most potent inhibitor, inhibited TCP at picomolar concentrations and blocked hemoglobin degradation and killed parasites at nanomolar concentrations. Micromolar concentrations of the inhibitor were nontoxic to cultured mammalian cells. These results support the hypothesis that TCP is a necessary hemoglobinase and suggest that it is a promising chemotherapeutic target.
C1 SAN FRANCISCO GEN HOSP,DEPT MED,SAN FRANCISCO,CA 94110.
   PROTOTEK INC,DUBLIN,CA 94568.
RP ROSENTHAL, PJ (reprint author), UNIV CALIF SAN FRANCISCO,BOX 0811,SAN FRANCISCO,CA 94143, USA.
FU NIAID NIH HHS [AI-00870]
CR ANGLIKER H, 1988, BIOCHEM J, V256, P481, DOI 10.1042/bj2560481                                                               
   BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535
   BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001                                             
   Bruce-Chwatt LJ, 1986, CHEMOTHERAPY MALARIA
   CABANTCHIK ZI, 1989, BLOOD, V74, P1464
   DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6
   GEARY TG, 1983, J PARASITOL, V69, P97, DOI 10.2307/3281283                                                                 
   KOSTIS JB, 1987, ANGIOTENSIN CONVERTI, P19
   KROGSTAD DJ, 1987, NEW ENGL J MED, V317, P542
   MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486
   MEEK TD, 1990, NATURE, V343, P90, DOI 10.1038/343090a0
   MORAN JS, 1989, JAMA-J AM MED ASSOC, V262, P245, DOI 10.1001/jama.262.2.245
   ONDETTI MA, 1977, SCIENCE, V196, P441, DOI 10.1126/science.191908                                                          
   RASNICK D, 1985, ANAL BIOCHEM, V149, P461, DOI 10.1016/0003-2697(85)90598-6
   RAUBER P, 1986, BIOCHEM J, V239, P633, DOI 10.1042/bj2390633                                                               
   Rich D. H., 1986, PROTEINASE INHIBITOR
   ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354
   ROCKETT KA, 1990, FEBS LETT, V259, P257, DOI 10.1016/0014-5793(90)80022-B                                                    
   ROSENTHAL PJ, 1989, MOL BIOCHEM PARASIT, V35, P177, DOI 10.1016/0166-6851(89)90120-5
   ROSENTHAL PJ, 1988, J CLIN INVEST, V82, P1560, DOI 10.1172/JCI113766
   ROSENTHAL PJ, 1987, J EXP MED, V166, P816, DOI 10.1084/jem.166.3.816
   Salvesen G., 1989, PROTEOLYTIC ENZYMES, P83
   SEGLEN PO, 1983, METHOD ENZYMOL, V96, P737
   SHERMAN IW, 1979, MICROBIOL REV, V43, P453
   SMITH RE, 1988, ANTICANCER RES, V8, P525
   VANNOORDEN CJF, 1988, J RHEUMATOL, V15, P1525
   WALSH JA, 1989, ANN NY ACAD SCI, V569, P1, DOI 10.1111/j.1749-6632.1989.tb27354.x
   WYLER DJ, 1983, NEW ENGL J MED, V308, P934, DOI 10.1056/NEJM198304213081605                                                     
   WYLER DJ, 1983, NEW ENGL J MED, V308, P875, DOI 10.1056/NEJM198304143081505                                                     
NR 29
TC 162
Z9 162
U1 0
U2 6
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 222 E 70TH STREET, NEW YORK, NY 10021
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD NOV
PY 1991
VL 88
IS 5
BP 1467
EP 1472
DI 10.1172/JCI115456
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA GN727
UT WOS:A1991GN72700006
PM 1939639
OA gold
DA 2018-01-05
ER

PT J
AU KO, WH
   WONG, CC
   YEUNG, HW
   YUNG, MH
   SHAW, PC
   TAM, SC
AF KO, WH
   WONG, CC
   YEUNG, HW
   YUNG, MH
   SHAW, PC
   TAM, SC
TI INCREASING THE PLASMA HALF-LIFE OF TRICHOSANTHIN BY COUPLING TO DEXTRAN
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
ID RIBOSOME-INACTIVATING PROTEINS; MOLECULAR-WEIGHT; ROOT TUBERS;
   ALPHA-MOMORCHARIN; BETA-MOMORCHARIN; KIRILOWII; ABORTIFACIENT;
   CARBOHYDRATE; HEMOGLOBIN; INHIBITION
AB Trichosanthin (TCS) is a plant protein which has a wide spectrum of pharmacological activities. It was demonstrated recently that this compound suppressed the replication of human immunodeficiency virus (HIV-1) in vitro. The mechanism of action is believed to be inhibition of protein synthesis. Trichosanthin is a low molecular weight protein which is expected to be easily filtered and eliminated through the kidney. To minimize renal loss, the molecular size of trichosanthin can be increased by coupling to dextran. The larger complex will not undergo glomerular filtration and therefore renal loss can be prevented. This study investigates the kidney's role in trichosanthin elimination and the beneficial effect afforded by coupling to dextran in prolonging plasma half-life. For this purpose, a radioimmunoassay has been developed to determine the concentration of TCS in plasma and urine. The sensitivity of this assay is in the nanogram range. Trichosanthin was coupled to dextran T40 by a dialdehyde method and successful coupling was confirmed by gel filtration chromatography. The complex retained specific binding to trichosanthin antibodies with decreased affinity which can be partially reversed after incubation with dextranase; an enzyme that digested dextran. The pharmacokinetics of intravenously administered trichosanthin (0.75 mg/kg) was compared between two groups of rats with normal and impaired renal function (bilateral renal arterial ligation). Rats with ligation showed a decrease in plasma clearance from 4780 +/- 570 to 220 +/- 20-mu-L/min and an increase in the mean residence time from 9 +/- 1 to 145 +/- 16 min. Despite the several-fold difference in these parameters, recovery of trichosanthin from normal rat urine was only 0.38 +/- 0.05%. This value can be increased by using higher injection doses. The data indicate that the kidney is an important organ for the elimination of trichosanthin. When the dextran-trichosanthin complex was injected into normal rats trichosanthin activity was not detected in the urine. All the pharmacokinetic parameters suggest that the dextran-trichosanthin complex stayed longer in the body and maintained a much higher plasma concentration than trichosanthin.
C1 CHINESE UNIV HONG KONG,DEPT PHYSIOL,SHA TIN,HONG KONG.
   CHINESE UNIV HONG KONG,DEPT BIOCHEM,SHA TIN,HONG KONG.
CR BERNARD A, 1988, KIDNEY INT, V34, P175, DOI 10.1038/ki.1988.163                                                             
   BLUMENSTEIN J, 1978, BLOOD SUBSTITUTES PL, P205
   BRIGOTTI M, 1989, BIOCHEM J, V257, P723, DOI 10.1042/bj2570723                                                               
   BYERS V, AIDS, V4, P1189
   CHENG KF, 1982, OBSTET GYNECOL, V59, P494
   CHOW TP, 1990, J BIOL CHEM, V265, P8665
   COJOCEL C, 1981, PFLUG ARCH EUR J PHY, V390, P211, DOI 10.1007/BF00658263                                                              
   CUNNINGTON PG, 1981, BIOCHEM J, V193, P261, DOI 10.1042/bj1930261                                                               
   ENDO Y, 1987, J BIOL CHEM, V262, P5908
   ENDO Y, 1988, EUR J BIOCHEM, V171, P45, DOI 10.1111/j.1432-1033.1988.tb13756.x
   KING TP, 1975, ARCH BIOCHEM BIOPHYS, V169, P464
   KUBOTA S, 1986, BIOCHIM BIOPHYS ACTA, V871, P101, DOI 10.1016/0167-4838(86)90138-X                                                    
   MARSHALL JJ, 1977, FEBS LETT, V83, P249, DOI 10.1016/0014-5793(77)81015-6                                                    
   MCGRATH MS, 1989, P NATL ACAD SCI USA, V86, P2844, DOI 10.1073/pnas.86.8.2844
   MELTON RG, 1987, BIOCHEM PHARMACOL, V36, P105, DOI 10.1016/0006-2952(87)90387-X
   MOGENSEN CE, 1977, SCAND J CLIN LAB INV, V37, P477, DOI 10.3109/00365517709101835
   PAN KZ, 1985, ADV CHINESE MED MATE, P297
   SAMBROOK J, 1989, MOL CLONING LAB MANU, pCH12
   SEPPALA I, 1989, J IMMUNOL, V143, P1259
   Stripe F., 1988, NUCL ACIDS, V16, P1349
   TAM SC, 1978, CAN J BIOCHEM CELL B, V56, P981, DOI 10.1139/o78-153                                                                 
   TAM SC, 1976, P NATL ACAD SCI USA, V73, P2128, DOI 10.1073/pnas.73.6.2128                                                          
   TAMHANE AC, 1977, COMMUN STAT A-THEOR, V6, P15, DOI 10.1080/03610927708827466                                                       
   TSAO SW, 1986, TOXICON, V24, P831, DOI 10.1016/0041-0101(86)90108-X
   WALDMANN TA, 1972, J CLIN INVEST, V51, P2162, DOI 10.1172/JCI107023
   WANG Y, 1986, PURE APPL CHEM, V58, P789, DOI 10.1351/pac198658050789                                                         
   WANG Y, 1985, ADV CHINESE MED MATE, P289
   YEUNG HW, 1988, INT J PEPT PROT RES, V31, P265
   YEUNG HW, 1986, INT J PEPT PROT RES, V27, P325
   YEUNG HW, 1987, IMMUNOPHARM IMMUNOT, V9, P25, DOI 10.3109/08923978709035200
   ZHANG XJ, 1986, NATURE, V321, P477
NR 31
TC 16
Z9 16
U1 1
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0006-2952
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD OCT 9
PY 1991
VL 42
IS 9
BP 1721
EP 1728
DI 10.1016/0006-2952(91)90508-3
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA GL973
UT WOS:A1991GL97300011
PM 1718284
DA 2018-01-05
ER

PT J
AU FARBER, EM
   COHEN, EN
   TROZAK, DJ
   WILKINSON, DI
AF FARBER, EM
   COHEN, EN
   TROZAK, DJ
   WILKINSON, DI
TI PEPTIDE-T IMPROVES PSORIASIS WHEN INFUSED INTO LESIONS IN NANOGRAM
   AMOUNTS
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Article
ID VASOACTIVE INTESTINAL POLYPEPTIDE; RECEPTOR-BINDING; HIV RECEPTOR; AIDS;
   INFECTIVITY; VIP
AB In each of 14 patients, two small but comparable psoriatic lesions were infused for 2 weeks with either saline or a saline solution of peptide T (as its analog D-ala1-peptide T amide) at 10(-7) mol/L with Alzet osmotic pumps worn extracorporeally.  During infusion, lesions were photographed and scored for clinical features of psoriasis on a 9-point scale.  After another 7 days, biopsy specimens were taken from the infused sites, and sections were scored for features of psoriasis on a 19-point scale.  The differences between means for data from saline- and peptide T-infused lesions were evaluated statistically.  Peptide T-infused lesions improved clinically; scores decreased from a mean of 4.35 initially to 1.57 at biopsy, whereas control lesions changed from 4.43 to 3.57 (p < 0.01 for 1.57 vs 3.57).  Histologic scores were also significantly different (5.28 for peptide T vs 10.00 for controls, 0.05 > p > 0.02).  This study provides evidence that intralesionally infused peptide T demonstrates some clearing effect in psoriasis.
C1 PSORIASIS RES INST,600 TOWN & COUNTRY VILLAGE,PALO ALTO,CA 94301.
CR BRIDGE TP, 1989, LANCET, V2, P226
   DUVIC M, 1987, LANCET, V2, P627
   HAEGERSTRAND A, 1989, P NATL ACAD SCI USA, V86, P5993, DOI 10.1073/pnas.86.15.5993
   MAHONEY SE, 1990, J INVEST DERMATOL, V94, P552
   Marcusson J A, 1989, Acta Derm Venereol Suppl (Stockh), V146, P117
   MARSCUSSON JA, 1989, ACTA DERM-VENER    S, V69, P86
   MOORE TC, 1988, IMMUNOPHARMACOLOGY, V16, P181, DOI 10.1016/0162-3109(88)90006-9
   PERT CB, 1988, PSYCHOPHARMACOL BULL, V24, P315
   PERT CB, 1986, P NATL ACAD SCI USA, V83, P9254, DOI 10.1073/pnas.83.23.9254
   PERT CB, 1986, CLIN NEUROPHARMACOL, V9, pS198
   PINCELLI C, 1990, J INVEST DERMATOL, V94, P566
   RABIER M, 1991, J INVEST DERMATOL, V96, P628
   RUFF M R, 1989, Drugs of the Future, V14, P1049
   RUFF MR, 1987, FEBS LETT, V211, P17, DOI 10.1016/0014-5793(87)81265-6
   RUFF MR, 1987, LANCET, V2, P751
   SMITH CC, 1988, DRUG DEVELOP RES, V15, P371, DOI 10.1002/ddr.430150404
   WELLS KH, 1990, J AM ACAD DERMATOL, V22, P1175, DOI 10.1016/0190-9622(90)70161-A                                                    
   WETTERBERG L, 1987, LANCET, V1, P159
NR 18
TC 42
Z9 42
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0190-9622
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD OCT
PY 1991
VL 25
IS 4
BP 658
EP 664
DI 10.1016/0190-9622(91)70249-2
PG 7
WC Dermatology
SC Dermatology
GA GJ168
UT WOS:A1991GJ16800009
PM 1791224
DA 2018-01-05
ER

PT J
AU LIPTON, SA
AF LIPTON, SA
TI CALCIUM-CHANNEL ANTAGONISTS AND HUMAN-IMMUNODEFICIENCY-VIRUS COAT
   PROTEIN-MEDIATED NEURONAL INJURY
SO ANNALS OF NEUROLOGY
LA English
DT Note
ID AIDS DEMENTIA COMPLEX; ENVELOPE GLYCOPROTEIN; NERVOUS-SYSTEM;
   GANGLION-CELLS; HIV-1; NEUROTOXICITY; INFECTION; PREVENTION; ANTIBODIES;
   BRAIN
AB Recent evidence in vitro has suggested that neuronal injury observed in the acquired immunodeficiency syndrome dementia complex may depend, at least in part, on toxic effects of the human immunodeficiency virus type 1 envelope protein, gp120. This laboratory previously reported that members of the dihydropyridine class of calcium channel antagonists, nimodipine and nifedipine, greatly attenuate the rise in intracellular calcium engendered by gp 120 and prevent subsequent neuronal injury. The relatively low (nanomolar) concentrations of dihydropyridines that were effective suggested that their action might be exerted at the level of the L-type of voltage-dependent calcium channels. In the present study, I tested members of the three other major classes of Ca2+ channel antagonist drugs to determine if they too could prevent neurotoxicity induced by gp 120. At the maximal dose that did not cause neuronal damage in and of itself, a diphenylalkylamine piperazine derivative (flunarizine, 10-mu-M) was the most effective, a phenylalkylamine (verapamil, 100-mu-M) was possibly effective, whereas a benzothiazepine (diltiazem, 1-mu-M) was ineffectual in protecting rat retinal ganglion cells from gp 120-induced toxicity in vitro. To explain these results, previous work has shown that the various classes of Ca2+ channel antagonists may exhibit differential potency in blocking voltage-dependent Ca2+ current in neurons, with dihydropyridines and flunarizine being the most potent at neuronal calcium channels. Moreover, these channels on mammalian central neurons are relatively insensitive to agents such as verapamil and diltiazem compared with other cell types like muscle. The low micromolar concentrations necessary for potency of flunarizine is in keeping with that predicted by binding and electrophysiological studies for block of voltage-dependent calcium channels. Other mechanisms of neuroprotection by flunarizine from gp120, however, cannot be totally excluded.
C1 BETH ISRAEL HOSP,DEPT NEUROL,BOSTON,MA 02215.
   BRIGHAM & WOMENS HOSP,DEPT NEUROL,BOSTON,MA 02115.
   MASSACHUSETTS GEN HOSP,DEPT NEUROL,BOSTON,MA 02114.
   HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115.
RP LIPTON, SA (reprint author), CHILDRENS HOSP MED CTR,DEPT NEUROL,CELLULAR & MOLEC NEUROSCI LAB,BOSTON,MA 02115, USA.
FU NINDS NIH HHS [NS07264]; NEI NIH HHS [EY05477, EY09024]
CR BERMAN PW, 1985, SCIENCE, V227, P1490, DOI 10.1126/science.2983428                                                         
   BRENNEMAN DE, 1988, NATURE, V335, P639, DOI 10.1038/335639a0
   CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6                                                    
   DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646
   FOX AP, 1987, J PHYSIOL-LONDON, V394, P149, DOI 10.1113/jphysiol.1987.sp016864                                                  
   GIULIAN D, 1990, SCIENCE, V250, P1593, DOI 10.1126/science.2148832
   GODFRAIND T, 1986, PHARMACOL REV, V38, P321
   GREENBERG DA, 1987, ANN NEUROL, V21, P317, DOI 10.1002/ana.410210402
   HAHN JS, 1988, P NATL ACAD SCI USA, V85, P6556, DOI 10.1073/pnas.85.17.6556
   HO DD, 1989, ANN INTERN MED, V111, P400, DOI 10.7326/0003-4819-111-5-400
   KAISER PK, 1990, NEUROLOGY, V40, P1757, DOI 10.1212/WNL.40.11.1757                                                          
   KETZLER S, 1990, ACTA NEUROPATHOL, V80, P92, DOI 10.1007/BF00294228                                                              
   KORNFELD H, 1988, NATURE, V335, P445, DOI 10.1038/335445a0
   LASKY LA, 1986, SCIENCE, V233, P209, DOI 10.1126/science.3014647
   LEIFER D, 1984, SCIENCE, V224, P303, DOI 10.1126/science.6143400                                                         
   LIN JW, 1990, P NATL ACAD SCI USA, V87, P4538, DOI 10.1073/pnas.87.12.4538
   LIPTON S A, 1990, Society for Neuroscience Abstracts, V16, P289
   LIPTON SA, 1987, J PHYSIOL-LONDON, V385, P361, DOI 10.1113/jphysiol.1987.sp016497                                                  
   LIPTON SA, 1991, IN PRESS ADV PHARM
   LIPTON SA, 1991, IN PRESS NEURON
   OFFERMANN J T, 1990, Society for Neuroscience Abstracts, V16, P191
   PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272
   ROBEY WG, 1986, P NATL ACAD SCI USA, V83, P7023, DOI 10.1073/pnas.83.18.7023
   SUCHER NJ, 1991, IN PRESS BRAIN RES
   WEISS JH, 1990, SCIENCE, V247, P1474, DOI 10.1126/science.2157282
   YAARI Y, 1987, SCIENCE, V235, P680, DOI 10.1126/science.2433765
   ZERNIG G, 1990, TRENDS PHARMACOL SCI, V11, P38, DOI 10.1016/0165-6147(90)90040-F
NR 27
TC 55
Z9 55
U1 0
U2 2
PU LITTLE BROWN CO
PI BOSTON
PA 34 BEACON STREET, BOSTON, MA 02108-1493
SN 0364-5134
J9 ANN NEUROL
JI Ann. Neurol.
PD JUL
PY 1991
VL 30
IS 1
BP 110
EP 114
DI 10.1002/ana.410300121
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA FV102
UT WOS:A1991FV10200019
PM 1656845
DA 2018-01-05
ER

PT J
AU TAN, CK
   CIVIL, R
   MIAN, AM
   SO, AG
   DOWNEY, KM
AF TAN, CK
   CIVIL, R
   MIAN, AM
   SO, AG
   DOWNEY, KM
TI INHIBITION OF THE RNASE H ACTIVITY OF HIV REVERSE-TRANSCRIPTASE BY
   AZIDOTHYMIDYLATE
SO BIOCHEMISTRY
LA English
DT Article
ID 5' EXONUCLEASE ACTIVITY; AIDS-RELATED COMPLEX;
   3'-AZIDO-3'-DEOXYTHYMIDINE TRIPHOSPHATE; DNA-POLYMERASE; ZIDOVUDINE AZT;
   MUTAGENESIS; SENSITIVITY; MECHANISM; MUTATIONS; THERAPY
AB The effects of AZTMP and other nucleoside 5'-monophosphates on the RNA-dependent DNA polymerase and RNase H activities of a recombinant HIV reverse transcriptase have been investigated.  Both activities are sensitive to inhibition by millimolar concentrations of AZTMP with MgCl2 as divalent cation activator.  Substitution of Mn2+ for Mg2+ markedly potentiates the inhibition of RNase H activity by AZTMP, reducing the IC50 from 5 to 0.05 mM.  In contrast, Mn2+ does not alter the sensitivity of the RNA-dependent DNA polymerase activity to inhibition by AZTMP.  The inhibition of RNase H activity by AZTMP can be reversed by increasing concentrations of the substrate poly(A)/poly(dT), suggesting that AZTMP may compete with the substrate for binding at the active site of RNase H.  Other nucleoside 5'-monophosphates do not inhibit RNase H in the presence of Mg2+.  However, in the presence of Mn2+, deoxy- and dideoxynucleoside 5'-monophosphates that are complementary to the DNA strand of the heteroduplex substrate are somewhat inhibitory.  The RNA-dependent DNA polymerase activity is a slightly inhibited by AZTMP and ddTMP in either Mg2+ or Mn2+, and substitution of Mn2+ for Mg2+ results in inhibition by ddAMP as well.  Naturally occurring ribo- or deoxyribonucleoside 5'-monophosphates are not inhibitory at concentrations up to 5 mM.  Since AZTTP/inhibits the RNA-dependent DNA polymerase activity of HIV reverse transcriptase at nanomolar concentrations, it is unlikely that the inhibition of this activity by AZTMP plays a significant role in the antiviral effect of AZT.  However, the inhibition of the RNase H activity by AZTMP, which can reach millimolar concentrations in vivo, may account for part of the sensitivity of the virus to AZT.
C1 UNIV MIAMI,SCH MED,DEPT MED,MIAMI,FL 33101.
   UNIV MIAMI,SCH MED,DEPT ONCOL,MIAMI,FL 33101.
   UNIV MIAMI,SCH MED,DEPT BIOCHEM MOLEC BIOL,MIAMI,FL 33101.
FU NIAID NIH HHS [U01-AI25696]
CR BERKOWER I, 1973, J BIOL CHEM, V248, P5914
   BYRNES JJ, 1976, BIOCHEMISTRY-US, V15, P2817, DOI 10.1021/bi00658a018
   CHENG YC, 1987, J BIOL CHEM, V262, P2187
   DEIBEL MR, 1990, AIDS RES HUM RETROV, V6, P329, DOI 10.1089/aid.1990.6.329
   ELDEIRY WS, 1984, P NATL ACAD SCI-BIOL, V81, P7378, DOI 10.1073/pnas.81.23.7378                                                         
   FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401                                                     
   FURMAN PA, 1988, AM J MED, V85, P176
   FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333
   KANAYA S, 1983, J BIOL CHEM, V258, P1276
   LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803
   LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0
   LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383
   LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983
   MITSUYA H, 1987, NATURE, V325, P773, DOI 10.1038/325773a0
   MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096                                                         
   QUE BG, 1978, BIOCHEMISTRY-US, V17, P1603, DOI 10.1021/bi00602a004
   SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5
   STARNES MC, 1989, J BIOL CHEM, V264, P7073
   STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P1972, DOI 10.1128/AAC.31.12.1972                                                          
   TAN CK, 1991, BIOCHEMISTRY-US, V30, P2651, DOI 10.1021/bi00224a013
   VRANG L, 1987, ANTIVIR RES, V7, P139, DOI 10.1016/0166-3542(87)90002-7
   YARCHOAN R, 1989, NEW ENGL J MED, V321, P726
   YARCHOAN R, 1986, LANCET, V1, P575
   YOSHIKAWA M, 1967, TETRAHEDRON LETT, P5065
NR 24
TC 55
Z9 55
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD MAY 21
PY 1991
VL 30
IS 20
BP 4831
EP 4835
DI 10.1021/bi00234a001
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA FM712
UT WOS:A1991FM71200001
PM 1709809
DA 2018-01-05
ER

PT J
AU STIENEKER, F
   KREUTER, J
   LOWER, J
AF STIENEKER, F
   KREUTER, J
   LOWER, J
TI HIGH ANTIBODY-TITERS IN MICE WITH POLYMETHYLMETHACRYLATE NANOPARTICLES
   AS ADJUVANT FOR HIV VACCINES
SO AIDS
LA English
DT Article
DE AIDS; HIV VACCINE; NANOPARTICLES AS ADJUVANT; POLYMETHYLMETHACRYLATE
ID PARTICULATE POLYMERIC ADJUVANTS; GLYCOPROTEIN GP120; CHIMPANZEES; VIRUS;
   RECOMBINANT; INFECTION
AB The aim of the present study was to determine the effect of polymethylmethacrylate (PMMA) nanoparticles as adjuvants for an HIV-2 whole-virus vaccine in mice.  The data clearly revealed that PMMA nanoparticles induced 10-100-fold higher antibody titres than aluminium hydroxide or an aqueous vaccine control preparation as measured by enzyme-linked immunosorbent assay.  Moreover, the high antibody titres obtained with PMMA as adjuvant appeared to be stable for between 10 and 20 weeks after immunization.  In contrast, the titres of the control preparations, fluid or aluminium hydroxide formulations, decreased after 10 weeks.
C1 UNIV FRANKFURT,INST PHARMAZEUT TECHNOL,GEORG VOIGT STR 16,W-6000 FRANKFURT,GERMANY.
   BUNDESAMT SERA & IMPFSTOFFE,PAUL EHRLICH INST,LANGEN,GERMANY.
CR ALLISON AC, 1986, J IMMUNOL METHODS, V95, P157, DOI 10.1016/0022-1759(86)90402-3
   ARTHUR LO, 1987, P NATL ACAD SCI USA, V84, P8583, DOI 10.1073/pnas.84.23.8583
   BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0
   CARBANELA ME, 1972, J BONE JT SURG, V54, P278
   CHANH TC, 1988, CELL IMMUNOL, V111, P77, DOI 10.1016/0008-8749(88)90052-4                                                    
   Charnley J., 1970, ACRYLIC CEMENT ORTHO
   CIANCIOLO GJ, 1985, SCIENCE, V230, P453, DOI 10.1126/science.2996136
   FALK W, 1975, KUNSTSTOFFHANDBUCH P, P851
   HU SL, 1987, NATURE, V328, P721, DOI 10.1038/328721a0
   KIKUKAWA R, 1986, J VIROL, V57, P1159
   KREUTER J, 1976, EXP CELL BIOL, V44, P12
   KREUTER J, 1976, INFECT IMMUN, V13, P204
   KREUTER J, 1988, VACCINE, V6, P253, DOI 10.1016/0264-410X(88)90220-4                                                    
   KREUTER J, 1981, J PHARM SCI, V70, P367, DOI 10.1002/jps.2600700406                                                          
   KREUTER J, 1978, INFECT IMMUN, V19, P667
   KREUTER J, 1986, VACCINE, V4, P125, DOI 10.1016/0264-410X(86)90051-4
   KURTH R, 1984, MUNCHEN MED WOCHEN, V126, P1363
   KURTH R, 1985, BEDEUTUNG MENSCHLICH, P23
   NOTHDURFT H, 1955, NATURWISSENSCHAFTEN, V42, P106, DOI 10.1007/BF00617260                                                              
   OTTEL H, 1963, ULLMANS ENCY TECHNIS, V14, P302
   PYLE SW, 1989, VACCINE, V7, P465, DOI 10.1016/0264-410X(89)90164-3
   RASKOVA H, 1967, S SER IMMUNOBIOL STR, V6, P115
   RIDDLE EH, 1954, MONOMERIC ACRYLIC ES, P15
   SAXINGER C, 1983, LAB INVEST, V49, P371
   STINSON NE, 1965, BRIT J EXP PATHOL, V46, P135
   STINSON NE, 1964, BRIT J EXP PATHOL, V45, P21
   TESSMAR K, METHODEN ORGANISCHEN, V14, P1037
NR 27
TC 26
Z9 30
U1 0
U2 10
PU RAPID SCIENCE PUBLISHERS
PI LONDON
PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH
SN 0269-9370
J9 AIDS
JI Aids
PD APR
PY 1991
VL 5
IS 4
BP 431
EP 435
DI 10.1097/00002030-199104000-00012                                        
          
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA FL461
UT WOS:A1991FL46100012
PM 2059385
DA 2018-01-05
ER

PT J
AU GORNY, MK
   XU, JY
   GIANAKAKOS, V
   KARWOWSKA, S
   WILLIAMS, C
   SHEPPARD, HW
   HANSON, CV
   ZOLLAPAZNER, S
AF GORNY, MK
   XU, JY
   GIANAKAKOS, V
   KARWOWSKA, S
   WILLIAMS, C
   SHEPPARD, HW
   HANSON, CV
   ZOLLAPAZNER, S
TI PRODUCTION OF SITE-SELECTED NEUTRALIZING HUMAN MONOCLONAL-ANTIBODIES
   AGAINST THE 3RD VARIABLE DOMAIN OF THE HUMAN-IMMUNODEFICIENCY-VIRUS
   TYPE-1 ENVELOPE GLYCOPROTEIN
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE ACQUIRED IMMUNODEFICIENCY SYNDROME; LYMPHOBLASTOID LINES;
   HETEROHYBRIDOMA
ID CD4 RECEPTOR; GP120; HIV; PROTEIN; EPITOPES; ENHANCEMENT; GENERATION;
   ANTIGEN; CELLS; ASSAY
AB Cell lines secreting IgG1 human monoclonal antibodies (mAbs) to the envelope glycoprotein, gp120, of human immunodeficiency virus (HIV) have been produced by transformation of peripheral blood cells from HIV-infected individuals and by fusion of transformed cells to a human-mouse heteromyeloma cell line (SHM-D33).  Two human mAbs were site-selected by means of a 23-mer synthetic peptide spanning a portion of the third variable domain of gp120 from the MN strain of HIV.  The two heterohybridomas produce three times more IgG than do their parent lymphoblastoid cell lines.  The specificities of these mAbs have been mapped to sequences near the tip of the disulfide loop of the gp120 third variable domain, Lys-Arg-Ile-His-Ile and His-Ile-Gly-Pro-Gly-Arg, respectively.  The mAbs have dissociation constants of 3.7 X 10(-6) M and 8.3 X 10(-7) M, neutralize HIV(MN) in vitro at nanogram levels, and bear the characteristics of antibodies associated with protective immunity in vivo.
C1 NYU MED CTR,DEPT PATHOL,550 1ST AVE,NEW YORK,NY 10016.
   CALIF DEPT HLTH SERV,VIRAL & RICKETTSIAL DIS LAB,BERKELEY,CA 94704.
   VET AFFAIRS MED CTR,NEW YORK,NY 10010.
FU NIAID NIH HHS [AI 82693, AI 72658]
CR AMADORI A, 1989, AIDS RES HUM RETROV, V5, P73, DOI 10.1089/aid.1989.5.73                                                           
   BANAPOUR B, 1987, J IMMUNOL, V139, P4027
   CHANH TC, 1986, EMBO J, V5, P3065
   DALGLEISH AG, 1988, VIROLOGY, V165, P209, DOI 10.1016/0042-6822(88)90674-5
   DESGRANGES C, 1988, LANCET, V1, P935
   DEVASH Y, 1990, AIDS RES HUM RETROV, V6, P307, DOI 10.1089/aid.1990.6.307                                                          
   DEVASH Y, 1990, P NATL ACAD SCI USA, V87, P3445, DOI 10.1073/pnas.87.9.3445
   EMINI EA, 1990, J VIROL, V64, P3674
   EVANS LA, 1988, J IMMUNOL, V140, P941
   FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4                                                    
   GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998
   GOEDERT JJ, 1989, LANCET, V2, P1351
   GORNY M, 1989, PROGR AIDS PATHOLOGY, P181
   GORNY MK, 1989, P NATL ACAD SCI USA, V86, P1624, DOI 10.1073/pnas.86.5.1624
   GOUDSMIT J, 1990, VACCINES 90, P291
   GOUDSMIT J, 1988, AIDS, V2, P157
   GRUNOW R, 1988, J IMMUNOL METHODS, V106, P257, DOI 10.1016/0022-1759(88)90206-2
   HALE G, 1988, LANCET, V2, P1394
   HANSON CV, 1990, J CLIN MICROBIOL, V28, P2030
   HO DD, 1987, J VIROL, V61, P2024
   HO DD, 1988, SCIENCE, V239, P1021, DOI 10.1126/science.2830667                                                         
   HOMSY J, 1989, SCIENCE, V244, P1357, DOI 10.1126/science.2786647
   HUSSAIN KA, 1987, J VIROL, V61, P2956
   JACKSON GG, 1988, LANCET, V2, P647
   JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768                                                         
   KARPAS A, 1990, P NATL ACAD SCI USA, V87, P7613, DOI 10.1073/pnas.87.19.7613
   KARPAS A, 1988, P NATL ACAD SCI USA, V85, P9234, DOI 10.1073/pnas.85.23.9234
   KHAZAELI MB, 1989, J IMMUNOL METHODS, V117, P175, DOI 10.1016/0022-1759(89)90138-5
   LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685                                                         
   LARSSON A, 1987, MOL IMMUNOL, V24, P569, DOI 10.1016/0161-5890(87)90037-X
   LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1
   LINSLEY PS, 1988, J VIROL, V62, P3695
   MANDEL B, 1985, IMMUNOCHEMISTRY VIRU, P53
   MATSUDA S, 1989, SCAND J IMMUNOL, V30, P425, DOI 10.1111/j.1365-3083.1989.tb02446.x                                              
   MODROW S, 1987, J VIROL, V61, P570
   MYERS G, 1990, HUMAN RETROVIRUSES A
   OHLIN M, 1989, IMMUNOLOGY, V68, P325
   PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1758
   PAPSIDERO LD, 1989, J VIROL, V63, P267
   PINTER A, 1988, J IMMUNOL METHODS, V112, P235, DOI 10.1016/0022-1759(88)90363-8
   PRINCE AM, 1990, VACCINES 90, P347
   REITZ MS, 1988, CELL, V54, P57, DOI 10.1016/0092-8674(88)90179-1                                                    
   ROBINSON JE, 1990, AIDS RES HUM RETROV, V6, P567, DOI 10.1089/aid.1990.6.567                                                          
   ROBINSON WE, 1990, P NATL ACAD SCI USA, V87, P3185, DOI 10.1073/pnas.87.8.3185
   ROBINSON WE, 1988, LANCET, V1, P790
   ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055
   RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198
   SARIN PS, 1986, SCIENCE, V232, P1135, DOI 10.1126/science.3010464
   SCOTT CF, 1990, P NATL ACAD SCI USA, V87, P8597, DOI 10.1073/pnas.87.21.8597
   SPEAR GT, 1990, J VIROL, V64, P5869
   STEPHENS PE, 1990, NATURE, V343, P219, DOI 10.1038/343219b0                                                                
   SUGANO T, 1988, BIOCHEM BIOPH RES CO, V155, P1105, DOI 10.1016/S0006-291X(88)81254-3
   SUN NC, 1989, J VIROL, V63, P3579
   THOMAS EK, 1988, AIDS, V2, P25, DOI 10.1097/00002030-198802000-00004
   TILL MA, 1989, P NATL ACAD SCI USA, V86, P1987, DOI 10.1073/pnas.86.6.1987
   TYLER DS, 1990, J IMMUNOL, V145, P3276
NR 56
TC 163
Z9 163
U1 0
U2 0
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR
PY 1991
VL 88
IS 8
BP 3238
EP 3242
DI 10.1073/pnas.88.8.3238
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FG913
UT WOS:A1991FG91300057
PM 2014246
OA gold
DA 2018-01-05
ER

PT J
AU BOTO, WMO
   BROWN, L
   CHREST, J
   ADLER, WH
AF BOTO, WMO
   BROWN, L
   CHREST, J
   ADLER, WH
TI DISTINCT MODULATORY EFFECTS OF BRYOSTATIN-1 AND STAUROSPORINE ON THE
   BIOSYNTHESIS AND EXPRESSION OF THE HIV RECEPTOR PROTEIN (CD4) BY T-CELLS
SO CELL REGULATION
LA English
DT Article
ID HUMAN IMMUNODEFICIENCY VIRUS; TUMOR PROMOTERS; RIBONUCLEIC-ACID; PHORBOL
   ESTERS; HTLV-III/LAV; KINASE-C; INFECTIVITY; BINDING; ANTIGEN; FUSION
AB A family of structurally related macrocyclic lactones, bryostatins, have recently been shown to display several intriguing pharmacologic properties.  Bryostatins are biosynthetic products of bryozoa phyllum of marine animals.  To extend the analyses of the biological activities of these highly unusual biosynthetic animal products, we have examined the effect of bryostatin 1 (bryo-1) on the steady-state expression of the human immunodeficiency virus receptor, CD4, by normal peripheral blood T lymphocytes.  Incubation of the cells with 5 nM bryo-1 caused a substantial loss of CD4 from the cell surface, as analyzed by flow cytometry using anti-CD4 monoclonal antibody.  The modulation of CD4 expression by bryo-1 was not due to a cytotoxicity effect:  in the culture conditions where it modulated CD4, bryo-1 also stimulated the expression of the interleukin 2 gene, as indicated by northern blot hybridization.  In addition, incubation of the lymphocytes with nanomolar amounts of protein kinase C antagonist, staurosporine, resulted in the inhibition of the bryo-1-induced modulation of CD4 expression.  The results of radioimmunoprecipitation analysis of detergent lysates of [S-35] methionine-labeled lymphocytes strongly suggest that bryo-1 inhibits the glycosylation and expression of CD4 in a manner similar to that of tunicamycin.
C1 ADDICT RES & TREATMENT CORP,BROOKLYN,NY 11201.
   NIA,CLIN IMMUNOL SECT,BALTIMORE,MD 21224.
RP BOTO, WMO (reprint author), CUNY CITY COLL,DEPT BIOL,NEW YORK,NY 10031, USA.
FU NCRR NIH HHS [RR03060-04]
CR BERKOW RL, 1985, BIOCHEM BIOPH RES CO, V131, P1109, DOI 10.1016/0006-291X(85)90205-0
   BLUE ML, 1989, J IMMUNOL, V142, P374
   BOTO WMO, 1984, J IMMUNOL, V133, P981
   CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005
   FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274                                                         
   FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9
   GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025                                                             
   HENNINGS H, 1987, CANCER RES, V47, P6006
   HESS AA, 1988, J IMMUNOL, V140, P433
   HOXIE JA, 1986, J IMMUNOL, V137, P1194
   ISAKOV N, 1987, J IMMUNOL, V138, P3100
   JAMESON BA, 1988, SCIENCE, V240, P1335, DOI 10.1126/science.2453925
   JEFFREY AM, 1986, P NATL ACAD SCI USA, V83, P241, DOI 10.1073/pnas.83.2.241
   KIKKAWA U, 1985, CANCER CELLS, V1, P239
   KOGA Y, 1990, J IMMUNOL, V144, P94
   KONIG R, 1988, J BIOL CHEM, V263, P9502
   KRAFT AS, 1986, P NATL ACAD SCI USA, V83, P1334, DOI 10.1073/pnas.83.5.1334
   LEMEUR M, 1981, CELL, V23, P561, DOI 10.1016/0092-8674(81)90152-5
   LIFSON JD, 1988, SCIENCE, V241, P712, DOI 10.1126/science.2969619
   LIFSON JD, 1986, NATURE, V323, P725, DOI 10.1038/323725a0
   LIFSON JD, 1986, SCIENCE, V232, P1123, DOI 10.1126/science.3010463
   MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8
   MAY WS, 1987, P NATL ACAD SCI USA, V84, P8483, DOI 10.1073/pnas.84.23.8483
   MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934
   PETTIT GR, 1984, J AM CHEM SOC, V106, P6768, DOI 10.1021/ja00334a050
   PETTIT GR, 1982, J AM CHEM SOC, V104, P6846, DOI 10.1021/ja00388a092                                                             
   SAKSENA RK, 1988, J IMMUNOL, V141, P1782
   SCHOLS D, 1989, P NATL ACAD SCI USA, V86, P3322, DOI 10.1073/pnas.86.9.3322
   SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514
   SMITH JB, 1985, BIOCHEM BIOPH RES CO, V132, P939, DOI 10.1016/0006-291X(85)91898-4                                                    
   STEIN BS, 1987, CELL, V49, P659, DOI 10.1016/0092-8674(87)90542-3
   TRENN G, 1988, J IMMUNOL, V140, P433
NR 32
TC 16
Z9 17
U1 4
U2 7
PU AMER SOC CELL BIOL
PI BETHESDA
PA PUBL OFFICE 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 1044-2030
J9 CELL REGUL
PD FEB
PY 1991
VL 2
IS 2
BP 95
EP 103
PG 9
WC Cell Biology
SC Cell Biology
GA EZ581
UT WOS:A1991EZ58100002
PM 1863603
DA 2018-01-05
ER

PT J
AU SCHATZL, H
   GELDERBLOM, HR
   NITSCHKO, H
   VONDERHELM, K
AF SCHATZL, H
   GELDERBLOM, HR
   NITSCHKO, H
   VONDERHELM, K
TI ANALYSIS OF NONINFECTIOUS HIV PARTICLES PRODUCED IN PRESENCE OF HIV
   PROTEINASE-INHIBITOR
SO ARCHIVES OF VIROLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEASE INHIBITOR; VIRAL INFECTIVITY;
   PEPSTATIN-A; MATURATION; MORPHOLOGY; DESIGN
AB Newly developed substrate analogue peptidomimetics are able to inhibit the human immunodeficiency virus, HIV-1 proteinase at nanomolar concentration.  In HIV infected cell culture they exhibit antiviral activity.  We have analyzed the non-infectious HIV particles produced in chronically HIV infected cell culture in presence of one of these inhibitors. The total production of virus particles was not substantially reduced in drug treated cultures, compared to non-inhibited control cultures, but the infectivity of these virus particles was reduced about 100 fold. The processing of gag and gag-pol protein precursor was inhibited; only borderline activity of reverse transcriptase (RT) could be detected in these particles and they contained nonprocessed gag precursor protein.
   Thin section electron microscopy of inhibitor-treated, HIV-infected cells revealed reduced viral cytopathogenicity and both inhibition of particle assembly and incomplete maturation of the particles formed. The HIV particles produced in the presence of the proteinase inhibitor were studded with envelope glycoprotein knobs and often comprised multiple budding regions, but were morphologically immature.
C1 UNIV MUNICH,MAX VONPETTENKOFER INST,PETTENKOFER STR 9A,W-8000 MUNICH 2,GERMANY.
   BUNDESGESUNDHEITSAMT,ROBERT KOCH INST,W-1000 BERLIN 33,GERMANY.
RI Schatzl, Hermann/G-4958-2011
CR ASHORN P, 1990, P NATL ACAD SCI USA, V87, P7472, DOI 10.1073/pnas.87.19.7472
   CLAVEL F, 1990, J VIROL, V64, P5230
   COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402
   ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122
   GELDERBLOM HR, 1987, VIROLOGY, V156, P171, DOI 10.1016/0042-6822(87)90449-1
   GELDERBLOM HR, 1989, ARCH VIROL, V106, P1, DOI 10.1007/BF01311033
   GELDERBLOM HR, 1990, RETROVIRAL PROTEASES, P159
   HANSEN J, 1988, EMBO J, V7, P1785
   HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401
   KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686
   KRAUSSLICH HG, 1988, J VIROL, V62, P4393
   KRAUSSLICH HG, 1989, VIRAL PROTEINASES TA
   MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486
   MEEK TD, 1990, NATURE, V343, P90, DOI 10.1038/343090a0
   PENG C, 1989, J VIROL, V63, P2550
   ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354
   SCHNEIDER J, 1988, CELL, V54, P363, DOI 10.1016/0092-8674(88)90199-7
   SEELMEIER S, 1988, P NATL ACAD SCI USA, V85, P6612, DOI 10.1073/pnas.85.18.6612
   STEWART L, 1990, J VIROL, V64, P5076
   VONDERHELM K, 1989, FEBS LETT, V247, P349, DOI 10.1016/0014-5793(89)81368-7                                                    
NR 20
TC 45
Z9 45
U1 0
U2 0
PU SPRINGER-VERLAG WIEN
PI VIENNA
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA
SN 0304-8608
J9 ARCH VIROL
JI Arch. Virol.
PY 1991
VL 120
IS 1-2
BP 71
EP 81
DI 10.1007/BF01310950
PG 11
WC Virology
SC Virology
GA GH907
UT WOS:A1991GH90700006
PM 1929879
DA 2018-01-05
ER

PT J
AU NITSCHKO, H
   SCHATZL, H
   GELDERBLOM, HR
   OSWALD, M
   VONDERHELM, K
AF NITSCHKO, H
   SCHATZL, H
   GELDERBLOM, HR
   OSWALD, M
   VONDERHELM, K
TI INHIBITION OF THE RETROVIRAL HIV-PROTEINASE IMPAIRS MATURATION TO
   INFECTIOUS HUMAN-IMMUNODEFICIENCY-VIRUS (HIV)
SO BIOMEDICA BIOCHIMICA ACTA
LA English
DT Article; Proceedings Paper
CT 8TH CONF ON PROTEOLYSIS ( ICOP MEETING )
CY OCT 14-18, 1990
CL WILDBAD KREUTH, GERMANY
SP SONDERFORSCHUNGSBEREICH, CIBA GEIGY, GRUNENTHAL, PLANTORGAN WERK, SANOFI PHARMA, SCHERING, FOND CHEM IND
ID PROTEASE INHIBITOR; PEPSTATIN-A; TYPE-1; CLEAVAGE; DESIGN
AB Newly developed inhibitors block the aspartic-type retroviral proteinase of the human immunodeficiency virus (HIV) at nanomolar concentration. The viral proteinase is responsible for the processing of viral encoded proteins. Applied to HIV infected cell culture, these inhibitors exhibit antiviral effects. The detailed analysis of these antiviral effects demonstrated that the synthesis of viral particles is only minimally decreased while the rate of infectious HIV particles is substantially reduced. The lack of infectivity is due to a failure in particle maturation which again is caused by the inhibition of the viral proteinase.
C1 ROBERT KOCH INST,W-1000 BERLIN 65,GERMANY.
RP NITSCHKO, H (reprint author), UNIV MUNICH,MAX VON PETTENKOFER INST,W-8000 MUNICH 2,GERMANY.
RI Schatzl, Hermann/G-4958-2011
CR COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402
   CRAWFORD S, 1985, J VIROL, V53, P899
   ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122
   HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401
   KATOH I, 1985, VIROLOGY, V145, P280, DOI 10.1016/0042-6822(85)90161-8                                                    
   KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686
   KRAUSSLICH HG, 1989, VIRAL PROTEINASES TA
   LOEB DD, 1989, J VIROL, V63, P111
   MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486
   MEEK TD, 1990, NATURE, V343, P90, DOI 10.1038/343090a0
   MOUS J, 1988, J VIROL, V62, P1433
   PEARL LH, 1987, NATURE, V328, P482, DOI 10.1038/328482b0                                                                
   ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354
   SCHATZL H, 1991, ARCH VIROL, V120, P425
   SEELMEIER S, 1988, P NATL ACAD SCI USA, V85, P6612, DOI 10.1073/pnas.85.18.6612
   SHOEMAN RL, 1990, P NATL ACAD SCI USA, V87, P6336, DOI 10.1073/pnas.87.16.6336
   VONDERHELM K, 1989, FEBS LETT, V247, P349, DOI 10.1016/0014-5793(89)81368-7                                                    
   VONDERHELM K, 1977, P NATL ACAD SCI USA, V74, P911
   WALLIN M, 1990, J GEN VIROL, V71, P1985, DOI 10.1099/0022-1317-71-9-1985
   YOSHINAKA Y, 1977, CELL, V12, P709, DOI 10.1016/0092-8674(77)90271-9
NR 20
TC 0
Z9 0
U1 0
U2 0
PU AKADEMIE VERLAG GMBH
PI BERLIN
PA MUHLENSTRASSE 33-34, D-13187 BERLIN, GERMANY
SN 0232-766X
J9 BIOMED BIOCHIM ACTA
PY 1991
VL 50
IS 4-6
BP 655
EP 658
PG 4
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA GN426
UT WOS:A1991GN42600051
PM 1801738
DA 2018-01-05
ER

PT J
AU HANSEN, JES
   NIELSEN, C
   VESTERGAARD, BF
AF HANSEN, JES
   NIELSEN, C
   VESTERGAARD, BF
TI INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS-1 (HIV-1) AND HERPES-SIMPLEX
   VIRUS-1 (HSV-1) INFECTIVITY WITH A BROAD RANGE OF LECTINS
SO SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID ENVELOPE GLYCOPROTEIN GP120; HTLV-III/LAV; CELL-FUSION;
   OLIGOSACCHARIDES; BINDING; TYPE-1; GLYCOSYLATION; CARBOHYDRATE;
   ANTIBODIES; ADSORPTION
AB Five lectins with specificity for N- and O-linked oligosaccharides were examined for inhibition of HIV-1 and HSV-1 infectivity in vitro. HIV-1 isolate HTLV(III)B was preincubated with lectin and subsequently inoculated onto MT-4 cells. Lectins specific for N-linked oligosaccharides blocked HIV infection in nanomolar-micromolar concentrations, but no anti-HIV effect was found with the lectin HPA, mainly reacting with O-linked oligosaccharides. HSV-1 infectivity was measured in a plaque reduction assay using Vero cells, and while both N- and O-linked oligosaccharide -specific lectins inhibited HSV-1 infection, the most potent inhibition was found with the lectin HPA. These results indicate that lectins may have a broad antiviral effect on enveloped viruses only limited by types of oligosaccharides present on individual viruses.
C1 STATENS SERUM INST,DEPT VIROL,DK-2300 COPENHAGEN,DENMARK.
RP HANSEN, JES (reprint author), HVIDOVRE UNIV HOSP,DEPT INFECT DIS 144,DK-2650 HVIDOVRE,DENMARK.
CR CAMPADELLIFIUME G, 1982, J VIROL, V43, P1061
   DATEMA R, 1987, PHARMACOL THERAPEUT, V33, P221, DOI 10.1016/0163-7258(87)90066-0
   FULLER AO, 1985, J VIROL, V55, P475
   GEYER H, 1988, J BIOL CHEM, V263, P11760
   HAMMAR L, 1989, AIDS RES HUM RETROV, V5, P495, DOI 10.1089/aid.1989.5.495
   HANSEN JES, 1990, J VIROL, V64, P2833
   HANSEN JES, 1989, AIDS, V3, P635, DOI 10.1097/00002030-198910000-00003                                                
   HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081                                                         
   ITO M, 1974, J VIROL, V13, P1312
   LERHOJ J, 1965, SCIENCE, V149, P633
   LIFSON JD, 1986, NATURE, V323, P725, DOI 10.1038/323725a0
   LUNDSTROM M, 1987, VIROLOGY, V161, P385, DOI 10.1016/0042-6822(87)90131-0
   MATTHEWS TJ, 1987, P NATL ACAD SCI USA, V84, P5424, DOI 10.1073/pnas.84.15.5424                                                         
   MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934
   MIZUOCHI T, 1990, J BIOL CHEM, V265, P8519
   NIELSEN CM, 1987, LANCET, V1, P566
   OLOFSSON S, 1990, J GEN VIROL, V71, P889, DOI 10.1099/0022-1317-71-4-889                                                      
   OLOFSSON S, 1981, ARCH VIROL, V70, P321, DOI 10.1007/BF01320247
   OLOFSSON S, 1983, J GEN VIROL, V64, P2735, DOI 10.1099/0022-1317-64-12-2735
   POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935
   ROBINSON WE, 1987, AIDS RES HUM RETROV, V3, P265, DOI 10.1089/aid.1987.3.265
   SVENNERHOLM B, 1982, J GEN VIROL, V63, P343, DOI 10.1099/0022-1317-63-2-343                                                      
   VESTERGA.BF, 1972, CANCER, V30, P68, DOI 10.1002/1097-0142(197207)30:1<68::AID-CNCR2820300111>3.0.CO;2-0
   VESTERGAARD BF, 1973, ACTA PATH MICRO IM B, VB 81, P808
   WENSKE EA, 1982, J VIROL, V44, P241
NR 25
TC 13
Z9 13
U1 0
U2 0
PU SCANDINAVIAN UNIVERSITY PRESS
PI OSLO
PA PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO,
   NORWAY
SN 0036-5548
J9 SCAND J INFECT DIS
JI Scand. J. Infect. Dis.
PY 1991
VL 23
IS 4
BP 425
EP 430
DI 10.3109/00365549109075090                                               
          
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA GE309
UT WOS:A1991GE30900005
PM 1659737
DA 2018-01-05
ER

EF